PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Prigge, ST; Kolhekar, AS; Eipper, BA; Mains, RE; Amzel, LM				Prigge, ST; Kolhekar, AS; Eipper, BA; Mains, RE; Amzel, LM			Amidation of bioactive peptides: The structure of peptidylglycine alpha-hydroxylating monooxygenase	SCIENCE			English	Article							DOPAMINE-BETA-HYDROXYLASE; ENZYME-BOUND COPPER; MACROMOLECULAR STRUCTURES; PROTEIN; SITE; STEREOCHEMISTRY; IDENTIFICATION; BIOSYNTHESIS; INTERMEDIATE; SPECTROSCOPY	Many neuropeptides and peptide hormones require amidation at the carboxyl terminus for activity. Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the amidation of these diverse physiological regulators. The amino-terminal domain of the bifunctional PAM protein is a peptidylglycine alpha-hydroxylating monooxygenase (PHM) with two coppers that cycle through cupric and cuprous oxidation states. The anomalous signal of the endogenous coppers was used to determine the structure of the catalytic core of oxidized rat PHM with and without bound peptide substrate. These structures strongly suggest that the PHM reaction proceeds via activation of substrate by a copper-bound oxygen species. The mechanistic and structural insight gained from the PHM structures can be directly extended to dopamine beta-monooxygenase.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Prigge, Sean/GVS-9197-2022	Prigge, Sean/0000-0001-9684-1733; Amzel, L. Mario/0000-0002-0129-9572	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R56DK032949, R37DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32949] Funding Source: Medline; NIGMS NIH HHS [GM44692] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BATTERSBY AR, 1976, J CHEM SOC PERK T 1, P1056, DOI 10.1039/p19760001056; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; EVANS SV, 1993, J MOL GRAPHICS, V11, P268; FITZPATRICK PF, 1986, J BIOL CHEM, V261, P4510; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; Grimmelikhuijzen CJP, 1996, INT REV CYTOL, V167, P37, DOI 10.1016/S0074-7696(08)61345-5; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P4541, DOI 10.1021/bi00471a006; KIZER JS, 1986, ENDOCRINOLOGY, V118, P2262, DOI 10.1210/endo-118-6-2262; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; MERKLER DJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P93, DOI 10.1006/abbi.1995.1140; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; MILLER SM, 1985, BIOCHEMISTRY-US, V24, P2114, DOI 10.1021/bi00330a004; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; NEWTON MD, 1997, J ELECTROANAL CHEM, V5025, P1; NOGUCHI M, 1992, BIOCHEM J, V283, P883, DOI 10.1042/bj2830883; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PING DS, 1992, J AM CHEM SOC, V114, P3998, DOI 10.1021/ja00036a071; RAMER SE, 1988, J AM CHEM SOC, V110, P8526, DOI 10.1021/ja00233a032; REEDY BJ, 1994, J AM CHEM SOC, V116, P1924, DOI 10.1021/ja00084a037; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; SUZUKI K, 1993, EUR J BIOCHEM, V213, P93, DOI 10.1111/j.1432-1033.1993.tb17738.x; Yonekura H, 1996, BIOCHEM BIOPH RES CO, V218, P495, DOI 10.1006/bbrc.1996.0088; ZABRISKIE TM, 1991, J CHEM SOC CHEM COMM, P571, DOI 10.1039/c39910000571	40	291	293	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1300	1305		10.1126/science.278.5341.1300	http://dx.doi.org/10.1126/science.278.5341.1300			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360928				2022-12-24	WOS:A1997YG04300047
J	Johnston, C				Johnston, C			Cervical adenocarcinoma in situ: a persistent clinical dilemma	LANCET			English	Editorial Material							UTERINE CERVIX; IN-SITU; INSITU; CONIZATION; MANAGEMENT				Johnston, C (corresponding author), UNIV MICHIGAN,MED CTR,DEPT OBSTET & GYNAECOL,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.							AYER B, 1987, ACTA CYTOL, V31, P397; BERTRAND M, 1987, AM J OBSTET GYNECOL, V157, P21, DOI 10.1016/S0002-9378(87)80338-1; CULLIMORE JE, 1992, BRIT J OBSTET GYNAEC, V99, P314, DOI 10.1111/j.1471-0528.1992.tb13730.x; Denehy TR, 1997, OBSTET GYNECOL, V90, P1, DOI 10.1016/S0029-7844(97)00122-1; HOPKINS MP, 1988, OBSTET GYNECOL, V71, P842; IM DD, 1995, GYNECOL ONCOL, V59, P179; MUNTZ HG, 1992, OBSTET GYNECOL, V80, P935; NICKLIN JL, 1991, AUST NZ J OBSTET GYN, V31, P179, DOI 10.1111/j.1479-828X.1991.tb01814.x; POYNOR EA, 1995, GYNECOL ONCOL, V57, P158, DOI 10.1006/gyno.1995.1118; WILDRICH T, 1996, GYNECOL ONCOL, V61, P304	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1337	1338		10.1016/S0140-6736(05)65129-X	http://dx.doi.org/10.1016/S0140-6736(05)65129-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365443				2022-12-24	WOS:A1997YE87200003
J	Skov, L; Clemmensen, O; Baadsgaard, O				Skov, L; Clemmensen, O; Baadsgaard, O			Thin cutaneous malignant melanoma and the MIN terminology	LANCET			English	Editorial Material							CRITERIA		ODENSE UNIV HOSP,DEPT DERMATOL,DK-5000 ODENSE,DENMARK	University of Southern Denmark; Odense University Hospital	Skov, L (corresponding author), UNIV COPENHAGEN,GENTOFTE HOSP,DEPT DERMATOL,DK-2900 HELLERUP,DENMARK.		Skov, Lone/W-3575-2018	Skov, Lone/0000-0002-4784-9680				Cook MG, 1996, HISTOPATHOLOGY, V28, P497, DOI 10.1046/j.1365-2559.1996.d01-464.x; *CRC MEL PATH PAN, 1997, J CLIN PATHOL, V50, P202; DEWIT PEJ, 1993, EUR J CANCER, V29A, P831, DOI 10.1016/S0959-8049(05)80419-8; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; HASTRUP N, 1994, HISTOPATHOLOGY, V24, P503; THORN M, 1994, BRIT J CANCER, V70, P743, DOI 10.1038/bjc.1994.388	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1264	1265		10.1016/S0140-6736(05)62469-5	http://dx.doi.org/10.1016/S0140-6736(05)62469-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357402				2022-12-24	WOS:A1997YD68900004
J	Marques, G; Musacchio, M; Shimell, MJ; WunnenbergStapleton, K; Cho, KWY; OConnor, MB				Marques, G; Musacchio, M; Shimell, MJ; WunnenbergStapleton, K; Cho, KWY; OConnor, MB			Production of a DPP activity gradient in the early Drosophila embryo through the opposing actions of the SOG and TLD proteins	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-1; TGF-BETA FAMILY; PROCOLLAGEN C-PROTEINASE; SHORT GASTRULATION GENE; DORSAL-VENTRAL PATTERN; XENOPUS CHORDIN; ASTACIN FAMILY; GROWTH-FACTOR; TOLLOID GENE; CELL FATES	During early Drosophila embryogenesis, several zygotic gene products act to establish a posttranscriptional activity gradient of the morphogen DPP. Among these molecules, Tolloid, a putative metalloprotease related to BMP-1, enhances DPP function, while SOG, an ortholog of the Xenopus organizer Chordin, inhibits DPP function. Using epistasis tests and a Xenopus secondary axis induction assay, we show that TLD negates the inhibitory effects of SOG/CHD on DPP/BMP-type ligands. In transient transfection assays, we demonstrate that TLD cleaves SOG and that cleavage is stimulated by DPP. We propose that formation of the embryonic DPP activity gradient involves the opposing effects of SOG inhibiting DPP and TLD processing SOG to release DPP from the inhibitory complex.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92697; UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities			O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054704, K04GM000599] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01158] Funding Source: Medline; NIGMS NIH HHS [GM00599, GM54704] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CHERBAS L, 1994, METHOD CELL BIOL, V44, P161, DOI 10.1016/S0091-679X(08)60912-7; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GELBART WM, 1989, DEVELOPMENT, V107, P65; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1995, NATURE, V376, P520, DOI 10.1038/376520a0; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Hoffmann FM, 1991, CURR OPIN CELL BIOL, V3, P947, DOI 10.1016/0955-0674(91)90112-C; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Marques G., 1997, ASTACINS STRUCTURE F, P191; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NGUYEN T, 1994, DEV BIOL, V166, P569, DOI 10.1006/dbio.1994.1338; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; PIROTTA V, 1986, DROSOPHILA PRACTICAL, P83; RAY RP, 1991, DEVELOPMENT, V113, P35; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	52	297	311	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					417	426		10.1016/S0092-8674(00)80425-0	http://dx.doi.org/10.1016/S0092-8674(00)80425-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363950	Bronze			2022-12-24	WOS:A1997YD94100015
J	Piccolo, S; Agius, E; Lu, B; Goodman, S; Dale, L; DeRobertis, EM				Piccolo, S; Agius, E; Lu, B; Goodman, S; Dale, L; DeRobertis, EM			Cleavage of chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann organizer activity	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; DORSAL-VENTRAL PATTERN; DROSOPHILA EMBRYO; SHORT GASTRULATION; XENOPUS EMBRYO; GENE; BMP-4; INDUCTION; RECEPTOR	The Xolloid secreted metalloprotease, a tolloid-related protein, was found to cleave Chordin and Chordin/ BMP-4 complexes at two specific sites in biochemical experiments. Xolloid mRNA blocks secondary axes caused by chordin, but not by noggin, follistatin, or dominant-negative BMP receptor, mRNA injection. Xolloid-treated Chordin protein was unable to antagonize BMP activity. Furthermore, Xolloid digestion released biologically active BMPs from Chordin/BMP inactive complexes. Injection of dominant-negative Xolloid mRNA indicated that the in vivo function of Xolloid is to limit the extent of Spemann's organizer field. We propose that Xolloid regulates organizer function by a novel proteolytic mechanism involving a double inhibition pathway required to pattern the dorsoventral axis: XOLL inverted left perpendicular CHD inverted inverted perpendicular BMPs --> BMPR.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of London; University College London			Dale, Leslie/C-6709-2008; agius, Eric/AHC-9705-2022	Agius, Eric/0000-0003-2123-9283; De Robertis, Edward/0000-0002-7843-1869; PICCOLO, STEFANO/0000-0002-2037-0004	NICHD NIH HHS [R37 HD021502-13, R37 HD021502, R37 HD21502-11] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DALE L, 1992, DEVELOPMENT, V115, P573; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Dosch R, 1997, DEVELOPMENT, V124, P2325; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; GOODMAN S, 1997, IN PRESS DEV BIOL; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; JONES CM, 1992, DEVELOPMENT, V115, P639; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Lin JJ, 1997, DEV GROWTH DIFFER, V39, P43; MAENO M, 1993, GENE, V134, P257, DOI 10.1016/0378-1119(93)90103-A; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Suzuki A, 1997, BIOCHEM BIOPH RES CO, V232, P153, DOI 10.1006/bbrc.1997.6219; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Takahara K, 1996, GENOMICS, V34, P157, DOI 10.1006/geno.1996.0260; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	45	332	348	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					407	416		10.1016/S0092-8674(00)80424-9	http://dx.doi.org/10.1016/S0092-8674(00)80424-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363949	Green Accepted, Bronze			2022-12-24	WOS:A1997YD94100014
J	Grotta, J				Grotta, J			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA - The best current option for most patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TISSUE-PLASMINOGEN-ACTIVATOR; URGENT THERAPY; MINUTES				Grotta, J (corresponding author), UNIV TEXAS,SCH MED,DEPT NEUROL,6431 FANNIN,SUITE 7044,HOUSTON,TX 77030, USA.		Grotta, James/AAH-7423-2021					Adams HP, 1996, CIRCULATION, V94, P1167, DOI 10.1161/01.CIR.94.5.1167; [Anonymous], 1996, NEUROLOGY, V47, P835; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1993, THROMBOLYTIC THERAPY, V2, P59; DONMAN GA, 1995, LANCET, V345, P578; *EUR COOP AC STROK, 1995, JAMA-J AM MED ASSOC, V274, P1017; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; *MULT AC STROK TRI, 1996, NEW ENGL J MED, V335, P145; *MULT AC STROK TRI, 1995, LANCET, V346, P1509; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581	13	42	42	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1310	1313						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345085				2022-12-24	WOS:A1997YC92000013
J	Clark, F; Azen, SP; Zemke, R; Jackson, J; Carlson, M; Mandel, D; Hay, J; Josephson, K; Cherry, B; Hessel, C; Palmer, J; Lipson, L				Clark, F; Azen, SP; Zemke, R; Jackson, J; Carlson, M; Mandel, D; Hay, J; Josephson, K; Cherry, B; Hessel, C; Palmer, J; Lipson, L			Occupational therapy for independent-living older adults - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH SURVEY SF-36; QUALITY-OF-LIFE; SATISFACTION; PERFORMANCE; POPULATION; MACARTHUR; VALIDITY; OUTCOMES; SCIENCE; SERVICE	Context.-Preventive health programs may mitigate against the health risks of older adulthood. Objective.-To evaluate the effectiveness of preventive occupational therapy (OT) services specifically tailored for multiethnic, independent-living older adults. Design.-A randomized controlled trial. Setting.-Two government subsidized apartment complexes for independent-living older adults. Subjects.-A total of 361 culturally diverse volunteers aged 60 years or older. Intervention.-An OT group, a social activity control group, and a nontreatment control group, The period of treatment was 9 months. Main Outcome Measures.-A battery of self-administered questionnaires designed to measure physical and social function, self-rated health, life satisfaction, and depressive symptoms, Results.-Benefit attributable to OT treatment was found for the quality of interaction scale on the Functional Status Questionnaire (P=.03), Life Satisfaction Index-Z (P=.03), Medical Outcomes Study Health Perception Survey (P=.05), and for 7 of 8 scales on the RAND 36-item Health Status Survey, Short Form: bodily pain (P=.03), physical functioning (P=.008), role limitations attributable to health problems (P=.02), vitality (P=.004), social functioning (P=.05), role limitations attributable to emotional problems (P=.05), and general mental health (P=.02). Conclusions.-Significant benefits for the OT preventive treatment group were found across various health, function, and quality-of-life domains. Because the control groups tended to decline over the study interval, our results suggest that preventive health programs based on OT may mitigate against the health risks of older adulthood.	UNIV SO CALIF,SCH MED,STAT CONSULTAT & RES CTR,DEPT PREVENT MED,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH PHARM,DEPT PHARMACEUT ECON & POLICY,LOS ANGELES,CA 90089; UNIV SO CALIF,SCH MED,DEPT MED,DIV GERIATR MED,LOS ANGELES,CA 90033	University of Southern California; University of Southern California; University of Southern California	Clark, F (corresponding author), UNIV SO CALIF,DEPT OCCUPAT SCI & OCCUPAT THERAPY,1540 ALCAZAR,CHP 133,LOS ANGELES,CA 90033, USA.			Jackson, Jeanne/0000-0001-5290-7382	NATIONAL INSTITUTE ON AGING [R01AG011810] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG11810] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACHELDER JM, 1993, AM J OCCUP THER, V48, P73; BERKMAN LF, 1993, J CLIN EPIDEMIOL, V46, P1129, DOI 10.1016/0895-4356(93)90112-E; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; Carlson M, 1996, AM J OCCUP THER, V50, P89, DOI 10.5014/ajot.50.2.89; CLARK F, 1993, AM J OCCUP THER, V47, P1067, DOI 10.5014/ajot.47.12.1067; Clark F, 1996, AM J OCCUP THER, V50, P99, DOI 10.5014/ajot.50.2.99; Clark F., 1993, WILLARD SPACKMANS OC, P44; CLARK FA, 1991, AM J OCCUP THER, V45, P300, DOI 10.5014/ajot.45.4.300; Cohen J, 1987, STAT POWER ANAL BEHA; CRIMMINS EM, 1994, DEMOGRAPHY, V31, P159, DOI 10.2307/2061913; EBRAHIM S, 1995, SOC SCI MED, V41, P1383, DOI 10.1016/0277-9536(95)00116-O; Fisher BJ, 1995, INT J AGING HUM DEV, V41, P239, DOI 10.2190/HA9X-H48D-9GYB-85XW; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Gatz M, 1995, EMERGING ISSUES IN MENTAL HEALTH AND AGING, pR15; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HOPKINS HL, 1993, WILLARD SPACKMANS OC; Jackson J, 1996, OCCUPATIONAL SCI EVO; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; LARSON KO, 1996, ROTE ROLE OCCUPATION; LARUE A, 1979, J GERONTOL, V34, P687, DOI 10.1093/geronj/34.5.687; LEVINE RE, 1992, AM J OCCUP THER, V47, P147; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MURRELL SA, 1989, PSYCHOL AGING, V4, P166; ORY MG, 1994, SOC INDIC RES, V33, P89, DOI 10.1007/BF01078959; Pearlin LI, 1995, EMERGING ISSUES IN MENTAL HEALTH AND AGING, P97, DOI 10.1037/10179-004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Townsend E, 1996, OCCUP THER J RES, V16, P179, DOI 10.1177/153944929601600303; U. S. Bureau of the Census, 1996, STAT ABSTR US; *US BUR CENS, 1992, PUBL US BUR CENS; VERBRUGGE LM, 1993, SOC SCI MED, V38, P1; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOOD V, 1969, J GERONTOL, V24, P465, DOI 10.1093/geronj/24.4.465; YERXA E J, 1989, Occupational Therapy in Health Care, V6, P1; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zemke R., 1996, OCCUPATIONAL SCI EVO; [No title captured]	42	395	398	0	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1321	1326		10.1001/jama.278.16.1321	http://dx.doi.org/10.1001/jama.278.16.1321			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343462				2022-12-24	WOS:A1997YA90500032
J	Lima, CD; Klein, MG; Hendrickson, WA				Lima, CD; Klein, MG; Hendrickson, WA			Structure-based analysis of catalysis and substrate definition in the HIT protein family	SCIENCE			English	Article							X-RAY STRUCTURE; TRANSITION-STATE ANALOG; NEUTRON-DIFFRACTION; CRYSTAL-STRUCTURES; URIDINE VANADATE; IDENTIFICATION; COMPLEX; URIDYLYLTRANSFERASE; PHOSPHOHISTIDINE; DICTYOSTELIUM	The histidine triad (HIT) protein family is among the most ubiquitous and highly conserved in nature, but a biological activity has not yet been identified for any member of the HIT family. Fragile histidine triad protein (FHIT) and protein kinase C interacting protein (PKCI) were used in a structure-based approach to elucidate characteristics of in vivo ligands and reactions. Crystallographic structures of ape, substrate analog, pentacovalent transition-state analog, and product slates of both enzymes reveal a catalytic mechanism and define substrate characteristics required for catalysis, thus unifying the HIT family as nucleotidyl hydrolases, transferases, or both. The approach described here may be useful in identifying structure-function relations between protein families identified through genomics.	HERBERT IRVING CANC CTR, NEW YORK, NY 10032 USA; INST HUMAN NUTR, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Lima, CD (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOL BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.			Lima, Christopher/0000-0002-9163-6092	NCI NIH HHS [T32CA09503] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FEINSTEINJAFFE I, 1985, ORGANOMETALLICS, V4, P1189, DOI 10.1021/om00126a009; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; Holm L, 1997, STRUCTURE, V5, P165, DOI 10.1016/S0969-2126(97)00176-7; Holm L, 1997, TRENDS BIOCHEM SCI, V22, P116, DOI 10.1016/S0968-0004(97)01021-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; LIMA CD, 1996, P NATL ACAD SCI USA, V93, P5355; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILKIS SJ, 1983, J BIOL CHEM, V258, P6135; ROBINSON AK, 1993, BIOCHIM BIOPHYS ACTA, V1161, P139, DOI 10.1016/0167-4838(93)90207-8; ROBINSON K, 1994, BIOCHEM J, V304, P662, DOI 10.1042/bj3040662; ROSE ZB, 1982, METHOD ENZYMOL, V87, P42; SERAPHIN B, 1992, J DNA SEQUENCING MAP, V3, P177; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; THRALL SH, 1983, BIOCHEMISTRY-US, V32, P1803; Tse-Dinh Y.-C., 1980, J BIOL CHEM, V255, P5560; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677; WEI YF, 1991, METHOD ENZYMOL, V200, P388; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WESTBROOK ML, 1996, P IUCR COMPUTING SCH; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; Zhang M, 1997, BIOCHEMISTRY-US, V36, P15, DOI 10.1021/bi961804n	34	190	197	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					286	290		10.1126/science.278.5336.286	http://dx.doi.org/10.1126/science.278.5336.286			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323207				2022-12-24	WOS:A1997YA56400044
J	Moody, DB; Reinhold, BB; Guy, MR; Beckman, EM; Frederique, DE; Furlong, ST; Ye, S; Reinhold, VN; Sieling, PA; Modlin, RL; Besra, GS; Porcelli, SA				Moody, DB; Reinhold, BB; Guy, MR; Beckman, EM; Frederique, DE; Furlong, ST; Ye, S; Reinhold, VN; Sieling, PA; Modlin, RL; Besra, GS; Porcelli, SA			Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells	SCIENCE			English	Article							MYCOLIC ACIDS; CD1 FAMILY; MYCOBACTERIUM; IDENTIFICATION; RESTRICTS; GENES	The human CD1b protein presents lipid antigens to T cells, but the molecular mechanism is unknown. Identification of mycobacterial glucose monomycolate (GMM) as a CD1b-presented glycolipid allowed determination of the structural requirements for its recognition by T cells. Presentation of GMM to CD1b-restricted T cells was not affected by substantial variations in its lipid tails, but was extremely sensitive to chemical alterations in its carbohydrate or other polar substituents. These findings support the view that the recently demonstrated hydrophobic CD1 groove binds the acyl chains of lipid antigens relatively nonspecifically, thereby positioning the hydrophilic components for highly specific interactions with T cell antigen receptors.	BRIGHAM & WOMENS HOSP,DIV RHEUMATOL IMMUNOL & ALLERGY,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BOSTON UNIV,SCH MED,MASS SPECTROMETRY UNIT,BOSTON,MA 02118; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523; UNIV CALIF LOS ANGELES,SCH MED,DIV DERMATOL,LOS ANGELES,CA 90033; UNIV CALIF LOS ANGELES,SCH MED,DEPT IMMUNOL & MICROBIOL,LOS ANGELES,CA 90033	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; Colorado State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X; Besra, Gurdyal/0000-0002-5605-0395	NCRR NIH HHS [RR10888] Funding Source: Medline; NIAMS NIH HHS [AR01988] Funding Source: Medline; NIGMS NIH HHS [GM54045] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001988] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12737; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1969, EUR J BIOCHEM, V13, P117; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; DATTA AK, 1991, CARBOHYD RES, V218, P95, DOI 10.1016/0008-6215(91)84089-W; EADS J, 1993, J BIOL CHEM, V268, P26375; KANEDA K, 1988, J GEN MICROBIOL, V134, P2213; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; NATSUHARA Y, 1990, CANCER IMMUNOL IMMUN, V31, P99, DOI 10.1007/BF01742373; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	20	376	379	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					283	286		10.1126/science.278.5336.283	http://dx.doi.org/10.1126/science.278.5336.283			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323206				2022-12-24	WOS:A1997YA56400043
J	Andersen, SSL; Ashford, AJ; Tournebize, R; Gavet, O; Sobel, A; Hyman, AA; Karsenti, E				Andersen, SSL; Ashford, AJ; Tournebize, R; Gavet, O; Sobel, A; Hyman, AA; Karsenti, E			Mitotic chromatin regulates phosphorylation of Stathmin/Op18	NATURE			English	Article							MICROTUBULE DYNAMICS; EGG EXTRACTS; CELL CYCLE; PROTEIN; XENOPUS; CHROMOSOMES; KINASE; ONCOPROTEIN-18; ORGANIZATION; PHOSPHATASE	Meiotic and mitotic spindles are required for the even segregation of duplicated chromosomes to the two daughter cells. The mechanism of spindle assembly is not fully understood, but two have been proposed that are not mutually exclusive(1-3). The 'search and capture' model suggests that dynamic microtubules become progressively captured and stabilized by the kinetochores on chromosomes, leading to spindle assembly(3,4). The 'local stabilization' model proposes that chromosomes change the state of the cytoplasm around them, making it more favourable to microtubule polymerization(2,5-9). It has been shown(10,11) that Stathmin/Op18 inhibits microtubule polymerization in vitro by interaction with tubulin(12), and that overexpression in tissue culture cells of non-phosphorylatable mutants of Stathmin/Op18 prevents the assembly of mitotic spindles(13). We have used Xenopus egg extracts and magnetic chromatin beads(14) to show that mitotic chromatin induces phosphorylation of Stathmin/Op18. We have also shown the Stathmin/Op18 is one of the factors regulated by mitotic chromatin that governs preferential microtubule growth around chromosomes during spindle assembly.	EUROPEAN MOL BIOL LAB,CELL BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY; INSERM,U440,F-75005 PARIS,FRANCE	European Molecular Biology Laboratory (EMBL); Institut National de la Sante et de la Recherche Medicale (Inserm)			Andersen, Søren S. L./O-1915-2017; Tournebize, Regis/K-7847-2018; Hyman, Tony/F-1923-2011; Hyman, Anthony A/B-3917-2017	Andersen, Søren S. L./0000-0002-3625-1640; Tournebize, Regis/0000-0003-3718-3130; Hyman, Anthony A/0000-0003-3664-154X				ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; Belmont L, 1996, TRENDS BIOCHEM SCI, V21, P197, DOI 10.1016/S0968-0004(96)80013-2; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; CURMI PA, IN PRESS J BIOL CHEM; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FELIX MA, 1994, CELL CYCLE PRACTICAL, P253; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MAREK LF, 1978, CHROMOSOMA, V68, P367, DOI 10.1007/BF00327171; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MASSON D, 1995, J CELL BIOL, V131, P1015, DOI 10.1083/jcb.131.4.1015; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; SAMANTA A, 1995, P NATL ACAD SCI USA, V92, P6582, DOI 10.1073/pnas.92.14.6582; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; TOURNEBIZE R, IN PRESS EMBO J; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1997, CURR OPIN CELL BIOL, V9, P37, DOI 10.1016/S0955-0674(97)80149-4; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	30	112	115	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					640	643		10.1038/39382	http://dx.doi.org/10.1038/39382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335509				2022-12-24	WOS:A1997YA00800069
J	Aparicio, OM; Weinstein, DM; Bell, SP				Aparicio, OM; Weinstein, DM; Bell, SP			Components and dynamics of DNA replication complexes in S-cerevisiae: Redistribution of MCM proteins and Cdc45p during S phase	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; MINICHROMOSOME MAINTENANCE; CHROMOSOMAL REPLICATION; POLYMERASE-EPSILON; CDC6 PROTEIN; ARS ELEMENTS; XENOPUS; INITIATION	In S. cerevisiae, the chromatin structure of DNA replication origins changes as cells become competent for DNA replication, suggesting that G1 phase-specific association of replication factors with origin DNA regulates entry into S phase. We demonstrate that ORC, Cdc45p, and MCM proteins are components of prereplication complexes (pre-RC). The MOM-origin association is dependent upon ORC and Cdc6p. During S phase, MCM proteins and Cdc45p dissociate from origin DNA and associate with nonorigin DNA with similar kinetics as DNA Polymerase a, which is present at DNA replication forks. Our results identify protein components of the pre-RC and a novel replication complex appearing at the G1/S transition (the RC), and suggest that after initiation MCM proteins and Cdc45p move with eukaryotic replication forks.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)				Bell, Stephen/0000-0002-2876-610X; Aparicio, Oscar/0000-0002-5591-0277	NIGMS NIH HHS [GM52339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1992, DNA REPLICATION, P931; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DUTTA A, 1997, IN PRESS ANN REV CEL, V13; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MAINE GT, 1984, GENETICS, V106, P365; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MOIR D, 1982, GENETICS, V100, P547; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NEWLON CS, 1991, GENETICS, V129, P343; NEWLON CS, 1991, GENETICS, V130, P235; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Shcherbakova PV, 1996, GENETICS, V142, P717; SIKORSKI RS, 1989, GENETICS, V122, P19; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHU JG, 1992, MOL CELL BIOL, V12, P4733, DOI 10.1128/MCB.12.10.4733; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	50	624	634	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					59	69		10.1016/S0092-8674(01)80009-X	http://dx.doi.org/10.1016/S0092-8674(01)80009-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335335	Bronze			2022-12-24	WOS:A1997XZ80900009
J	Michaelis, C; Ciosk, R; Nasmyth, K				Michaelis, C; Ciosk, R; Nasmyth, K			Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids	CELL			English	Article							STRAND-BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; DNA-REPLICATION; FISSION YEAST; TOPOISOMERASE-II; BUDDING YEAST; GENE; CONDENSATION; COMPLEX	Cohesion between sister chromatids opposes the splitting force exerted by microtubules, and loss of this cohesion is responsible for the subsequent separation of sister chromatids during anaphase. We describe three chromosmal proteins that prevent premature separation of sister chromatids in yeast. Two, Smc1p and Smc3p, are members of the SMC family, which are putative ATPases with coiled-coil domains. A third protein, which we call Scc1p, binds to chromosomes during S phase, dissociates from them at the metaphase-to-anaphase transition, and is degraded by the anaphase promoting complex. Association of Scc1p with chromatin depends on Smc1p. Proteins homologous to Scclp exist in a variety of eukaryotic organisms including humans. A common cohesion apparatus might be used by all eukaryotic cells during both mitosis and meiosis.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Ciosk, Rafal/L-7327-2013	Nasmyth, Kim/0000-0001-7030-4403; Ciosk, Rafal/0000-0003-2234-6216				AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BERENS C, 1992, J BIOL CHEM, V267, P1945; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Callan H.G, 1986, LAMPBRUSH CHROMOSOME; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLOWAY SL, 1993, CELL, V73, P13093; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOSHLAND D, 1987, SCIENCE, V238, P1713, DOI 10.1126/science.3317838; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; McKay MJ, 1996, GENOMICS, V36, P305, DOI 10.1006/geno.1996.0466; MOLNAR M, 1995, GENETICS, V141, P61; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Rose M, 1990, LAB COURSE MANUAL ME; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIBBENS RV, 1993, J CELL BIOL, V80, P674; SPENCER F, 1990, GENETICS, V124, P237; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; YAMADA H, 1994, YEAST, V10, P883, DOI 10.1002/yea.320100704; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	41	1146	1165	2	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					35	45		10.1016/S0092-8674(01)80007-6	http://dx.doi.org/10.1016/S0092-8674(01)80007-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335333	Bronze			2022-12-24	WOS:A1997XZ80900007
J	Varnum, MD; Zagotta, WN				Varnum, MD; Zagotta, WN			Interdomain interactions underlying activation of cyclic nucleotide-gated channels	SCIENCE			English	Article							CATION CHANNEL; FUNCTIONAL EXPRESSION; SUBUNIT INTERACTIONS; MOLECULAR MECHANISM; POTASSIUM CHANNEL; COMPLEMENTARY-DNA; MODULATION; SHAKER; GENE; CALMODULIN	Cyclic nucleotide-gated (CNG) ion channels are multimeric proteins that activate in response to the binding of cyclic nucleotide to intracellular domains. Here, an intramolecular protein-protein interaction between the amino-terminal domain and the carboxylterminal ligand-binding domain of the rat olfactory CNG channel was shown to exert an autoexcitatory effect on channel activation. Calcium-calmodulin, which modulates CNG channel activity during odorant adaptation, blocked this interaction. A specific deletion within the amino-terminal domain disrupted the interdomain interaction in vitro and altered the gating properties and calmodulin sensitivity of expressed channels. Thus, the amino-terminal domain may promote channel opening by directly interacting with the carboxyl-terminal gating machinery; calmodulin regulates channel activity by targeting this interaction.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [R01EY010329] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010329, EY 10329] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Finn J. T., 1995, Biophysical Journal, V68, pA253; Fodor AA, 1997, J GEN PHYSIOL, V109, P3, DOI 10.1085/jgp.109.1.3; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; Gordon SE, 1996, BIOCHEMISTRY-US, V35, P3994, DOI 10.1021/bi952607b; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GORDON SE, 1995, NEURON, V14, P177; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; Grunwald M. E., 1997, Biophysical Journal, V72, pA335; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SHEN NV, 1993, NEURON, V11, P67; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; VARNUM MD, UNPUB; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTT AWN, 1996, ANN REV NEUROSCI, V19, P235; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	35	125	128	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					110	113		10.1126/science.278.5335.110	http://dx.doi.org/10.1126/science.278.5335.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311913				2022-12-24	WOS:A1997XZ12400049
J	Spraggon, G; Everse, SJ; Doolittle, RF				Spraggon, G; Everse, SJ; Doolittle, RF			Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin	NATURE			English	Article							ELECTRON-MICROSCOPY; GAMMA-CHAIN; PLASMINOGEN-ACTIVATOR; POLYMERIZATION; IDENTIFICATION; LOCALIZATION; SITES; REQUIREMENTS; ASSOCIATION; MOLECULES	In blood coagulation, units of the protein fibrinogen pack together to form a fibrin clot, but a crystal structure for fibrinogen is needed to understand how this is achieved. The structure of a cove fragment (fragment D) from human fibrinogen has now been determined to 2.9 Angstrom resolution. The 86K three-chained structure consists of a coiled-coil region and two homologous globular entities oriented at approximately 130 degrees to each other, Additionally, the covalently bound dimer of fragment D, known as 'doubte-D', was isolated from human fibrin, crystallized in the presence of a Gly-Pro-Arg-Pro-amide peptide ligand, which simulates the donor polymerization site, and its structure solved by molecular replacement with the model of fragment D.	UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bailey K, 1943, NATURE, V151, P716, DOI 10.1038/151716a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; COHEN C, 1961, J POLYM SCI, V49, P144; DANG CV, 1985, J BIOL CHEM, V260, P9713; DONAHUE JP, 1994, P NATL ACAD SCI USA, V91, P12178, DOI 10.1073/pnas.91.25.12178; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P1563, DOI 10.1002/pro.5560011204; DOOLITTLE RF, 1977, BIOCHEMISTRY-US, V16, P1710, DOI 10.1021/bi00627a029; EBERT RF, 1994, 1994 INDEX VARIANT H; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; FU YP, 1995, GENOMICS, V30, P71, DOI 10.1006/geno.1995.0010; FUREY W, IN PRESS METHODS ENZ; Gerloff DL, 1997, PROTEINS, V27, P279; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUDRYCLERGEON G, 1974, PATHOL BIOL, V22, P47; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, NEWSLETT PROTEIN CRY, V31, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIHALYI E, 1963, BIOCHIM BIOPHYS ACTA, V67, P90; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MOSESSON MW, 1995, J CLIN INVEST, V96, P1053, DOI 10.1172/JCI118091; MOSESSON MW, 1995, J STRUCT BIOL, V115, P88, DOI 10.1006/jsbi.1995.1033; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIEUWENHUIZEN W, 1983, BIOCHIM BIOPHYS ACTA, V748, P86, DOI 10.1016/0167-4838(83)90030-4; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; PIZZO SV, 1973, J BIOL CHEM, V248, P4574; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHIELEN WJG, 1991, BIOCHEM J, V276, P655, DOI 10.1042/bj2760655; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	50	371	397	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					455	462		10.1038/38947	http://dx.doi.org/10.1038/38947			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333233				2022-12-24	WOS:A1997XY90900045
J	Chowienczyk, P; Ritter, J				Chowienczyk, P; Ritter, J			Arginine: NO more than a simple aminoacid?	LANCET			English	Editorial Material							NITRIC-OXIDE; HYPERCHOLESTEROLEMIC PATIENTS				Chowienczyk, P (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,LONDON SE1 7EH,ENGLAND.			Chowienczyk, Phil/0000-0003-4507-038X				BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; CASINO PR, 1994, J AM COLL CARDIOL, V23, P844, DOI 10.1016/0735-1097(94)90628-9; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; MACALLISTER RJ, 1994, BRIT J PHARMACOL, V112, P43, DOI 10.1111/j.1476-5381.1994.tb13026.x; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510	10	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					901	902		10.1016/S0140-6736(05)63263-1	http://dx.doi.org/10.1016/S0140-6736(05)63263-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314865				2022-12-24	WOS:A1997XY67200005
J	Hautamaki, RD; Kobayashi, DK; Senior, RM; Shapiro, SD				Hautamaki, RD; Kobayashi, DK; Senior, RM; Shapiro, SD			Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice	SCIENCE			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; 1ST 2 CENTURIES; FUTURE-RESEARCH; METALLOPROTEINASES; METALLOELASTASE; EXPRESSION; LOCALIZATION; SUGGESTIONS; HAMSTERS; CLONING	To determine which proteinases are responsible for the lung destruction characteristic of pulmonary emphysema, macrophage elastase-deficient (MME-/-) mice were subjected to cigarette smoke. In contrast to wild-type mice, MME-/- mice did not have increased numbers of macrophages in their lungs and did not develop emphysema in response to long-term exposure to cigarette smoke. Smoke-exposed MME-/- mice that received monthly intratracheal instillations of monocyte chemoattractant protein-1 showed accumulation of alveolar macrophages but did not develop air space enlargement. Thus, macrophage elastase is probably sufficient for the development of emphysema that results from chronic inhalation of cigarette smoke.	WASHINGTON UNIV, SCH MED, BAMES JEWISH HOSP, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, BAMES JEWISH HOSP, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)								BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHAPMAN HA, 1994, AM J RESP CRIT CARE, V150, pS155, DOI 10.1164/ajrccm/150.6_Pt_2.S155; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DUNNILL M. S., 1962, THORAX, V17, P320, DOI 10.1136/thx.17.4.320; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; HAUTAMAKI RD, UNPUB; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; MERCHANT RK, 1992, AM REV RESPIR DIS, V146, P448, DOI 10.1164/ajrccm/146.2.448; NAGAI A, 1994, AM J RESP CRIT CARE, V150, P1411, DOI 10.1164/ajrccm.150.5.7952569; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1334, DOI 10.1164/ajrccm/146.5_Pt_1.1334; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1615, DOI 10.1164/ajrccm/146.6.1615; *US CDC, 1996, US NATL CENT HLTH ST, V44, P1; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WRIGHT JL, 1990, AM REV RESPIR DIS, V142, P1422, DOI 10.1164/ajrccm/142.6_Pt_1.1422	29	1101	1158	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					2002	2004		10.1126/science.277.5334.2002	http://dx.doi.org/10.1126/science.277.5334.2002			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302297				2022-12-24	WOS:A1997XX84900047
J	Stark, H; Rodnina, MV; RinkeAppel, J; Brimacombe, R; Wintermeyer, W; vanHeel, M				Stark, H; Rodnina, MV; RinkeAppel, J; Brimacombe, R; Wintermeyer, W; vanHeel, M			Visualization of elongation factor Tu on the Escherichia coli ribosome	NATURE			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR EF-TU; CRYSTAL-STRUCTURE; PROTEIN-SYNTHESIS; TERNARY COMPLEX; GTP HYDROLYSIS; CROSS-LINKING; BINDING; REGION; SITE	The delivery of a specific amino acid to the translating ribosome is fundamental to protein synthesis. The binding of aminoacyl-transfer RNA to the ribosome is catalysed by the elongation factor Tu (EF-Tu). The elongation factor the aminoacyl-tRNA and GTP form a stable 'ternary' complex that binds to the ribosome. We have used electron cryomicroscopy and angular reconstitution(1) to visualize directly the kirromycin-stalled ternary complex in the A site of the 70S ribosome of Escherichia coli. Electron cryomicroscopy had previously given detailed ribosomal structures at 25 and 23 Angstrom (refs 2, 3) resolution, and was used to determine the position of tRNAs on the ribosome(4,5). In particular, the structures' of pre-translocational (tRNAs in A and P sites) and post-translocational ribosomes (P and E sites occupied) were both visualized at a resolution of similar to 20 Angstrom. Our three-dimensional reconstruction at 18 Angstrom resolution shows the ternary complex spanning the inter-subunit space with the acceptor domain of the tRNA reaching into the decoding centre. Domain I (the G domain) of the EF-Tu is bound both to the L7/L12 stalk and to the 50S body underneath the stalk, whereas domain 2 is oriented towards the S12 region on the 30S subunit.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; MAX PLANCK GESELL,FRITZ HABER INST,D-14195 BERLIN,GERMANY; UNIV WITTEN HERDECKE,INST MOL BIOL,D-58448 WITTEN,GERMANY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY	Imperial College London; Max Planck Society; Fritz Haber Institute of the Max Planck Society; Witten Herdecke University; Max Planck Society			Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Holger, Stark/0000-0002-6161-1118				Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Dey D, 1995, BIOCHIMIE, V77, P925, DOI 10.1016/0300-9084(95)80003-4; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MUELLER F, IN PRESS J MOL BIOL; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; SANTER UV, 1995, RNA, V1, P89; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANRYK DI, 1995, NUCLEIC ACIDS RES, V23, P3563, DOI 10.1093/nar/23.17.3563; WOLF H, 1977, EUR J BIOCHEM, V75, P67, DOI 10.1111/j.1432-1033.1977.tb11504.x	31	313	317	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					403	406		10.1038/38770	http://dx.doi.org/10.1038/38770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311785				2022-12-24	WOS:A1997XX67500058
J	Adams, MA; Dolan, P				Adams, MA; Dolan, P			Could sudden increases in physical activity cause degeneration of intervertebral discs?	LANCET			English	Article							LUMBAR SPINE; EXERCISE; STRENGTH; PAIN	Epidemiological studies link high repetitive loading of the lower back with degeneration of intervertebral discs, and experiments on cadaver spines confirm that repetitive mechanical loading can disrupt the lumbar discs in a manner characteristic of ''degeneration''. But why do living discs not just strengthen in response to this stimulus, as other musculo-skeletal tissues do? Our hypothesis proposes that the low metabolic rate of lumbar discs (the largest avascular structures in the body) prevents them from keeping pace with adaptive remodelling changes in adjacent tissues, so that large and abrupt increases in a person's level of physical activity may leave the lumbar discs the weak link in a strengthening and heavily loaded spine. Recent laboratory investigations support the hypothesis, but clinical evidence Is required to relate recent disc degeneration with recent increases in physical activity, and so test the hypothesis.			Adams, MA (corresponding author), UNIV BRISTOL, DEPT ANAT, SOUTHWELL ST, BRISTOL BS2 8EJ, AVON, ENGLAND.		Adams, Michael A/C-9875-2009	Adams, Michael A/0000-0003-0435-8651; Dolan, Patricia/0000-0001-8561-675X				ADAMS MA, 1982, SPINE, V7, P184, DOI 10.1097/00007632-198205000-00002; ADAMS MA, 1985, SPINE, V10, P524, DOI 10.1097/00007632-198507000-00006; ADAMS MA, 1994, CLIN BIOMECH, V9, P5, DOI 10.1016/0268-0033(94)90052-3; ADAMS MA, 1995, INT SOC STUD LUMB SP; Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; BAYLISS MT, 1988, SPINE, V13, P972, DOI 10.1097/00007632-198809000-00003; Boos N, 1995, SPINE, V20, P2613, DOI 10.1097/00007632-199512150-00002; DOLAN P, 1994, J BIOMECH, V27, P1237, DOI 10.1016/0021-9290(94)90277-1; GRANHED H, 1987, SPINE, V12, P146, DOI 10.1097/00007632-198703000-00010; Green T P, 1993, Eur Spine J, V2, P209, DOI 10.1007/BF00299448; Ishihara H, 1996, J APPL PHYSIOL, V80, P839, DOI 10.1152/jappl.1996.80.3.839; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; KELSEY J L, 1984, Journal of Orthopaedic Research, V2, P61, DOI 10.1002/jor.1100020110; LANYON LE, 1982, J BIOMECH, V15, P141, DOI 10.1016/0021-9290(82)90246-9; MAROUDAS A, 1975, J ANAT, V120, P113; McNally D.S., 1996, BONE JOINT SURG BR, V78, P965, DOI [10.1302/0301-620X.78B6.0780965, DOI 10.1302/0301-620X.78B6.0780965]; MOFFETT JAK, 1993, INT J NURS STUD, V30, P197, DOI 10.1016/0020-7489(93)90031-O; MONETA GB, 1994, SPINE, V19, P1968, DOI 10.1097/00007632-199409000-00018; NEUMANN P, 1993, SPINE, V18, P637, DOI 10.1097/00007632-199304000-00017; OSTI OL, 1990, SPINE, V15, P762, DOI 10.1097/00007632-199008010-00005; PORTER RW, 1989, SPINE, V14, P201, DOI 10.1097/00007632-198902000-00009; VASCONCELOS D, 1973, EPILEPSIA, V14, P323, DOI 10.1111/j.1528-1157.1973.tb03967.x; VIDEMAN T, 1995, SPINE, V20, P699, DOI 10.1097/00007632-199503150-00011	23	35	37	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	1997	350	9079					734	735		10.1016/S0140-6736(97)03021-3	http://dx.doi.org/10.1016/S0140-6736(97)03021-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291918				2022-12-24	WOS:A1997XU97700045
J	Lo, HJ; Kohler, JR; DiDomenico, B; Loebenberg, D; Cacciapuoti, A; Fink, GR				Lo, HJ; Kohler, JR; DiDomenico, B; Loebenberg, D; Cacciapuoti, A; Fink, GR			Nonfilamentous C-albicans mutants are avirulent	CELL			English	Article							CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; FILAMENTOUS GROWTH; HYPHAL FORMATION; GENE; PROTEIN; YEAST; HOMOLOG; MORPHOGENESIS	Candida albicans and Saccharomyces cerevisiae switch from a yeast to a filamentous form. In Saccharomyces, this switch is controlled by two regulatory proteins, Ste12p and Phd1p. Single-mutant strains, ste 12/ste12 or phd1/phd1, are partially defective, whereas the sfe12/ste12 phd1/phd1 double mutant is completely defective in filamentous growth and is noninvasive. The equivalent cph1/cph1 efg1/efg1 double mutant in Candida (Cph1p is the Ste12p homolog and Efg1p is the Phd1p homolog) is also defective in filamentous growth, unable to form hyphae or pseudohyphae in response to many stimuli, including serum or macrophages. This Candida cph1/cph1 efg1/efg1 double mutant, locked in the yeast form, is avirulent in a mouse model.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; CHILDRENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA; SCHERING PLOUGH RES INST, KENILWORTH, NJ 07033 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Merck & Company; Schering-Plough Research Institute			Lo, Hsiu-Jung/B-2658-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010, R01GM040266] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI009236] Funding Source: Medline; NIGMS NIH HHS [GM40266, GM35010] Funding Source: Medline; PHS HHS [F32A109236] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; BOONE C, 1991, J BACTERIOL, V173, P6859, DOI 10.1128/jb.173.21.6859-6864.1991; BULLOCK WE, 1990, PRINCIPLES PRACTICE, P2340; CACCIAPUOTI A, 1992, ANTIMICROB AGENTS CH, V36, P64, DOI 10.1128/AAC.36.1.64; CANNON RD, 1992, MOL GEN GENET, V235, P453, DOI 10.1007/BF00279393; CHAPMAN SW, 1990, PRINCIPLES PRACTICE, P2353; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DABROWA N, 1981, J GEN MICROBIOL, V127, P391; DIAMOND RD, 1990, PRINCIPLES PRACTICE, P2331; Diener AC, 1996, GENETICS, V143, P769; EDWARDS JE, 1990, PRINCIPLES PRACTICE, P1943; FONZI WA, 1993, GENETICS, V134, P717; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; LIU HP, 1995, SCIENCE, V267, P17; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; ODDS FC, 1985, CRC CR REV MICROBIOL, V12, P45, DOI 10.3109/10408418509104425; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SHEPHERD MG, 1980, CAN J MICROBIOL, V26, P21, DOI 10.1139/m80-004; Sherman F., 1986, METHODS YEAST GENETI; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982	29	1418	1472	1	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					939	949		10.1016/S0092-8674(00)80358-X	http://dx.doi.org/10.1016/S0092-8674(00)80358-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298905	Bronze			2022-12-24	WOS:A1997XV56300014
J	Henningsen, U; Schliwa, M				Henningsen, U; Schliwa, M			Reversal in the direction of movement of a molecular motor	NATURE			English	Article							MICROTUBULE MOTOR; CRYSTAL-STRUCTURE; NCD PROTEIN; KINESIN; DROSOPHILA; DOMAINS; SEGREGATION	Kinesin and non-claret disjunctional (ncd) are molecular motors of the kinesin superfamily that move in opposite directions along microtubules. The molecular basis underlying the direction of movement is unclear, although it is thought to be an intrinsic property of the motor domain, a conserved region about 330 amino acids in length(1-3). The motor domain is found at the amino terminus in conventional kinesins, but at the carboxy terminus in ncd(4,5). Here we report on a chimaera composed of the motor domain of the minus-end-directed kinesin of Neurospora crassa(6). The bacterially expressed fusion protein was tested in motility assays using polarity-marked microtubules(7). Surprisingly, the chimaera moved towards the plus end, demonstrating that the polarity of force generation of the ncd motor domain has been reversed. This finding indicates that the domain organization, particularly the position of the motor domain, is of fundamental importance for the polarity of force production. It also demonstrates that the direction of microtubule movement is not controlled solely by the motor domain(8).	UNIV MUNICH, ADOLF BUTENANDT INST ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich								AMAL I, 1996, CURR BIOL, V6, P1265; Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HYMAN AA, 1991, J CELL SCI, P125; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MARKS DL, 1994, J CELL SCI, V107, P2417; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TABOR S, 1990, CURRENT PROTOCOLS MO; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	22	182	184	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					93	96		10.1038/38022	http://dx.doi.org/10.1038/38022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288974				2022-12-24	WOS:A1997XU59600052
J	Liu, RH; Orgel, LE				Liu, RH; Orgel, LE			Oxidative acylation using thioacids	NATURE			English	Article							CONDENSATION	Several important prebiotic reactions, including the coupling of amino acids into polypeptides by the formation of amide linkages, involve acylation. Theae reactions present a challenge to the understanding of prebiotic synthesis. Condensation reactions relying on dehydrating agents are either inefficient in aqueous solution(1,2) or require strongly acidic conditions and high temperatures(3). Activated amino acids such as thioester derivatives have therefore been suggested as likely substrates for prebiotic peptide synthesis(4-7). Here we propose a closely related route to amide bond formation involving oxidative acylation by thioacids. We find that phenylalanine, leucine and phenylphosphate are acylated efficiently in aqueous solution by thioacetic acid and oxidizing agent, From a prebiotic point of view, oxidative acylation has the advantage of proceeding efficiently in solution and under mild conditions. We anticipate that oxidative acylation should prove to be a general method for activating carboxylic acids, including amino acids.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute								BRATERMAN PS, 1983, NATURE, V303, P163, DOI 10.1038/303163a0; BUTLER EA, 1958, ANAL CHEM, V30, P1379, DOI 10.1021/ac60140a027; Cefola M., 1962, TALANTA, V9, P537, DOI DOI 10.1016/0039-9140(62)80125-8; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; de Duve C, 1991, BLUEPRINT CELL NATUR; FERRIS J P, 1987, P29; HAWKER JR, 1981, J MOL EVOL, V17, P285, DOI 10.1007/BF01795750; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; Liu CF, 1996, TETRAHEDRON LETT, V37, P933, DOI 10.1016/0040-4039(95)02394-1; ROSENTHAL D, 1957, J AM CHEM SOC, V79, P2684, DOI 10.1021/ja01568a007; SHEEHAN JC, 1952, J AM CHEM SOC, V74, P4726, DOI 10.1021/ja01138a528; SMITH PAS, 1965, CHEM OPEN CHAIN ORGA, P165; WEBER AL, 1981, J MOL EVOL, V18, P24, DOI 10.1007/BF01733208; WEBER AL, 1979, J MOL EVOL, V13, P193, DOI 10.1007/BF01739479; Whittet DCB, 1997, ORIGINS LIFE EVOL B, V27, P249, DOI 10.1023/A:1006534500363; WIELAND T, 1988, ROOTS OF MODERN BIOCHEMISTRY, P213	18	71	73	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					52	54		10.1038/37944	http://dx.doi.org/10.1038/37944			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288964				2022-12-24	WOS:A1997XU59600040
J	Grady, RM; Teng, HB; Nichol, MC; Cunningham, JC; Wilkinson, RS; Sanes, JR				Grady, RM; Teng, HB; Nichol, MC; Cunningham, JC; Wilkinson, RS; Sanes, JR			Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy	CELL			English	Article							MDX MOUSE MUSCLE; NEUROMUSCULAR-JUNCTION; GLYCOPROTEIN COMPLEX; AGRIN RECEPTOR; PROTEIN; FIBERS; CELLS; REGENERATION; LOCALIZATION; ASSOCIATION	Dystrophin is a cytoskeletal protein of muscle fibers; its toss in humans leads to Duchenne muscular dystrophy, an inevitably fatal wasting of skeletal and cardiac muscle. mdx mice also lack dystrophin, but are only mildly dystrophic. Utrophin, a homolog of dystrophin, is confined to the postsynaptic membrane at skeletal neuromuscular junctions and has been implicated in synaptic development. However, mice lacking utrophin show only subtle neuromuscular defects. Here, we asked whether the mild phenotypes of the two single mutants reflect compensation between the two proteins. Synaptic development was qualitatively normal in double mutants, but dystrophy was severe and closely resembled that seen in Duchenne. Thus, utrophin attenuates the effects of dystrophin deficiency, and the double mutant may provide a useful model for studies of pathogenesis and therapy.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Grady, RM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110, USA.		Wilkinson, Robert/F-5408-2012					AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BELL CD, 1968, J NEUROL SCI, V7, P529, DOI 10.1016/0022-510X(68)90058-0; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRIDGES LR, 1986, J NEUROL SCI, V72, P147, DOI 10.1016/0022-510X(86)90003-1; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; DECONINCK AE, 1997, IN PRESS CELL, V90, P717; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; DIMARIO JX, 1991, DEV BIOL, V148, P314, DOI 10.1016/0012-1606(91)90340-9; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Engel AG, 1994, MYOLOGY, P1769; Engel AG, 1994, MYOLOGY, pP1133; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANKEL KA, 1976, HUM PATHOL, V7, P375, DOI 10.1016/S0046-8177(76)80053-6; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; LICHTMAN JW, 1987, J PHYSIOL-LONDON, V393, P355, DOI 10.1113/jphysiol.1987.sp016827; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; MASTAGLIA FL, 1975, J NEUROL SCI, V25, P227, DOI 10.1016/0022-510X(75)90143-4; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; MENKE A, 1995, J CELL SCI, V108, P727; Mora M, 1996, DEV BRAIN RES, V91, P70, DOI 10.1016/0165-3806(95)00169-7; MUKOYAMA M, 1987, J NEUROL SCI, V81, P155, DOI 10.1016/0022-510X(87)90092-X; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; ODA T, 1993, J PEDIATR ORTHOPED, V13, P478, DOI 10.1097/01241398-199307000-00012; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PETROF BJ, 1993, AM J PHYSIOL, V265, pC834; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; Quinlivan RM, 1996, NEUROMUSCULAR DISORD, V6, P237, DOI 10.1016/0960-8966(96)00007-7; REISER PJ, 1988, DEV BIOL, V129, P400, DOI 10.1016/0012-1606(88)90387-9; REZVANI M, 1995, J APPL PHYSIOL, V78, P961, DOI 10.1152/jappl.1995.78.3.961; SANES JR, 1995, DEV BIOL, V6, P163; SARTORE S, 1982, NATURE, V298, P294, DOI 10.1038/298294a0; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; THIMAN N, 1991, J CELL BIOL, V115, P1695; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WAKAI S, 1988, J NEUROL SCI, V84, P167, DOI 10.1016/0022-510X(88)90122-0; WILKINSON RS, 1992, J PHYSIOL-LONDON, V448, P413, DOI 10.1113/jphysiol.1992.sp019049	63	516	530	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					729	738		10.1016/S0092-8674(00)80533-4	http://dx.doi.org/10.1016/S0092-8674(00)80533-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288752	Bronze			2022-12-24	WOS:A1997XT06600016
J	Bennett, AM; Tonks, NK				Bennett, AM; Tonks, NK			Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CYCLIN D1; MYOGENIC DIFFERENTIATION; MYOD FAMILY; FACTOR-BETA; EXPRESSION; INHIBITION; MYOBLASTS; CELLS; RAS	The signal transduction pathway or pathways linking extracellular signals to myogenesis are poorly defined. Upon mitogen withdrawal from C2C12 myoblasts, the mitogen-activated protein kinase (MAPK) p42Erk2 is inactivated concomitant with up-regulation of muscle-specific genes, Overexpression of MAPK phosphatase-1 (MKP-1) inhibited p42Erk2 activity and was sufficient to relieve the inhibitory effects of mitogens on muscle-specific gene expression. Later during myogenesis, endogenous expression of MKP-1 decreased. MKP-1 overexpression during differentiation prevented myotube formation despite appropriate expression of myosin heavy chain, This indicates that muscle-specific gene expression is necessary but not sufficient to commit differentiated myocytes to myotubes and suggests a function for the MAPKs during the early and late stages of skeletal muscle differentiation.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory				Bennett, Anton/0000-0001-5187-7599				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BENNETT AJ, UNPUB; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KONG YF, 1995, MOL CELL BIOL, V15, P5205; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	29	298	307	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1288	1291		10.1126/science.278.5341.1288	http://dx.doi.org/10.1126/science.278.5341.1288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360925				2022-12-24	WOS:A1997YG04300044
J	Parker, D				Parker, D			Health effects of child labour	LANCET			English	Editorial Material											Parker, D (corresponding author), MINNESOTA DEPT HLTH,POB 9441,MINNEAPOLIS,MN 55440, USA.							ASTHANA S, 1995, SOC SCI MED, V40, P177, DOI 10.1016/0277-9536(94)E0066-2; Harvey PJ, 1994, TRADING AWAY FUTURE; ISLAM MA, 1994, EUR J CLIN NUTR, V48, P416; PARKER DL, 1997, STOLEN DREAMS PORTRA; RAJU T N K, 1989, Indian Journal of Pediatrics, V56, P193, DOI 10.1007/BF02726606; SAIYED HN, 1995, INDIAN J MED RES, V102, P138	6	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1395	1396		10.1016/S0140-6736(05)65169-0	http://dx.doi.org/10.1016/S0140-6736(05)65169-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365469				2022-12-24	WOS:A1997YE87200051
J	Scott, K; Sun, YM; Beckingham, K; Zuker, CS				Scott, K; Sun, YM; Beckingham, K; Zuker, CS			Calmodulin regulation of Drosophila light-activated channels and receptor function mediates termination of the light response in vivo	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; PHOTORECEPTOR CELL; INDUCED PHOSPHORYLATION; PROTEIN-KINASE; PHOSRESTIN-I; TRP; GENE; PHOTOTRANSDUCTION; ARRESTIN; CA2+	Calmodulin (CAM) participates in a variety of intracellular transduction processes by modulating signaling molecules in response to calcium changes. We report the characterization of Drosophila Cam mutants and the role of CAM in photoreceptor cell function. Contrary to current models of excitation and TRP channel function, we demonstrate that the transient phenotype of trp mutants can be explained by CAM regulation of the TRPL channel rather than by the loss of a store-operated conductance leading to depletion of the internal stores. We also analyzed light responses in a variety of mutant and transgenic backgrounds and demonstrate the importance of calmodulin in mediating calcium-dependent negative regulation of phototransduction. Our results show that CAM coordinates termination of the light response by modulating receptor and ion channel activity.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; RICE UNIV,DEPT BIOCHEM,HOUSTON,TX 77005; RICE UNIV,DEPT CELL BIOL,HOUSTON,TX 77005	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rice University; Rice University								Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; Arnon A, 1997, SCIENCE, V275, P1119, DOI 10.1126/science.275.5303.1119; Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1988, MOL ASPECTS CELLULAR; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DOYLE KE, 1990, J MOL BIOL, V213, P599, DOI 10.1016/S0022-2836(05)80245-1; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1993, P ROY SOC B-BIOL SCI, V252, P223, DOI 10.1098/rspb.1993.0069; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Heiman RG, 1996, P NATL ACAD SCI USA, V93, P2420, DOI 10.1073/pnas.93.6.2420; Hofstee CA, 1996, VISUAL NEUROSCI, V13, P897, DOI 10.1017/S0952523800009147; Kahn ES, 1997, J NEUROCHEM, V68, P169; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; Maniatis T., 1982, MOL CLONING; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; Minke B, 1996, CURR OPIN NEUROBIOL, V6, P459, DOI 10.1016/S0959-4388(96)80050-X; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PETERSEN CH, 1995, BIOCHEM J, V311, P31; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PORTER JA, 1995, EMBO J, V14, P4450, DOI 10.1002/j.1460-2075.1995.tb00124.x; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU T, 1993, DEVELOPMENT, V117, P1223; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335; YEANDLE S, 1957, STUDIES SLOW POTENTI; YOSHIOKA T, 1983, BIOCHEM BIOPH RES CO, V111, P567, DOI 10.1016/0006-291X(83)90344-3; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	59	167	169	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					375	383		10.1016/S0092-8674(00)80421-3	http://dx.doi.org/10.1016/S0092-8674(00)80421-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363946	Bronze			2022-12-24	WOS:A1997YD94100011
J	Woronicz, JD; Gao, X; Cao, Z; Rothe, M; Goeddel, DV				Woronicz, JD; Gao, X; Cao, Z; Rothe, M; Goeddel, DV			I kappa B kinase-beta: NF-kappa B activation and complex formation with I kappa B kinase-alpha and NIK	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; RECEPTOR; FAMILY	Activation of the transcription factor nuclear factor kappa B (NF-kappa B) by inflammatory cytokines requires the successive action or NF-kappa B-inducing kinase (NIK) and I kappa B kinase-alpha (IKK-alpha). A widely expressed protein kinase was identified that is 52 percent identical to IKK-alpha. I kappa B kinase-beta (IKK-beta) activated NF-kappa B when overexpressed and phosphorylated serine residues 32 and 36 of I kappa B-alpha and serines 19 and 23 of I kappa B-beta. The activity of IKK-beta was stimulated by tumor necrosis factor and interleukin-1 treatment. IKK-alpha and IKK-beta formed heterodimers that interacted with NIK. Overexpression of a catalytically inactive form of IKK-beta blocked cytokine-induced NF-kappa B activation. Thus, an active I kappa B kinase complex may require three distinct protein kinases.	TULARIK, S SAN FRANCISCO, CA 94080 USA									Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CONNELLY MA, 1995, CELL MOL BIOL RES, V41, P5437; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gao X., UNPUB; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG J, IN PRESS P NATL ACAD; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOCK BA, 1995, GENOMICS, V27, P348, DOI 10.1006/geno.1995.1054; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WORONICZ JD, UNPUB	22	1054	1119	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					866	869		10.1126/science.278.5339.866	http://dx.doi.org/10.1126/science.278.5339.866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346485				2022-12-24	WOS:A1997YD47900047
J	McIntire, SL; Reimer, RJ; Schuske, K; Edwards, RH; Jorgensen, EM				McIntire, SL; Reimer, RJ; Schuske, K; Edwards, RH; Jorgensen, EM			Identification and characterization of the vesicular GABA transporter	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; BRAIN SYNAPTIC VESICLES; CAENORHABDITIS-ELEGANS; C-ELEGANS; ACETYLCHOLINE TRANSPORTER; MONOAMINE TRANSPORTER; ACTIVE-TRANSPORT; GLUTAMATE UPTAKE; RAT-BRAIN; EXPRESSION	Synaptic transmission involves the regulated exocytosis of vesicles filled with neurotransmitter. Classical transmitters are synthesized in the cytoplasm, and so must be transported into synaptic vesicles. Although the vesicular transporters for monoamines and acetylcholine have been identified, the proteins responsible for packaging the primary inhibitory and excitatory transmitters, gamma-aminobutyric acid (GABA) and glutamate remain unknown(1,2) Studies in the nematode Caenorhabditis elegans have implicated the gene unc-47 in the release of GABA(3). Here we show that the sequence of unc-47 predicts a protein with ten transmembrane domains, that the gene is expressed by GABA neurons, and that the protein colocalizes,vith synaptic vesicles. Further, a rat homologue of unc-47 is expressed by central GABA neurons and confers vesicular GABA transport in transfected cells with kinetics and substrate specificity similar to those previously reported for synaptic vesicles from the brain. Comparison of this vesicular GABA transporter (VGAT) with a vesicular transporter for monoamines shows that there are differences in the bioenergetic dependence of transport, and these presumably account for the differences in structure. Thus VGAT is the first of a new family of neurotransmitter transporters.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL,GRAD PROGRAM CELL BIOL & BIOMED SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Utah System of Higher Education; University of Utah								ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BRENNER S, 1974, GENETICS, V77, P71; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CARLSON MD, 1989, J NEUROCHEM, V53, P1889, DOI 10.1111/j.1471-4159.1989.tb09258.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHRISTENSEN H, 1991, EUR J PHARM-MOLEC PH, V207, P73, DOI 10.1016/S0922-4106(05)80040-9; CLARK SG, 1994, GENETICS, V137, P987; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FERGUSON EL, 1985, GENETICS, V110, P17; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; FYKSE EM, 1988, J NEUROCHEM, V50, P1237, DOI 10.1111/j.1471-4159.1988.tb10599.x; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KISH PE, 1989, P NATL ACAD SCI USA, V86, P3877, DOI 10.1073/pnas.86.10.3877; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; NAITO S, 1983, J BIOL CHEM, V258, P696; NONET MI, IN PRESS J NEUROSCI; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; SASSOON D, 1993, GUIDE TECHNIQUES MOU, P384; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	30	649	671	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					870	876		10.1038/39908	http://dx.doi.org/10.1038/39908			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349821				2022-12-24	WOS:A1997YC14800062
J	Sisk, JE; Moskowitz, AJ; Whang, W; Lin, JD; Fedson, DS; McBean, AM; Plouffe, JF; Cetron, MS; Butler, JC				Sisk, JE; Moskowitz, AJ; Whang, W; Lin, JD; Fedson, DS; McBean, AM; Plouffe, JF; Cetron, MS; Butler, JC			Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; TENTATIVE GUIDELINES; ECONOMIC EVALUATIONS; RISK; EFFICACY; COUNTY; IMMUNIZATION; POPULATION; INFLUENZA; DISEASE	Context.-Clinical, epidemiologic, and policy considerations support updating the cost-effectiveness of pneumococcal vaccination for elderly people and targeting the evaluation only to prevention of pneumococcal bacteremia. Objective.-To assess the implications for medical costs and health effects of vaccination against pneumococcal bacteremia in elderly people. Design.-Cost-effectiveness analysis of pneumococcal vaccination compared with no vaccination, from a societal perspective. Setting and Participants.-The elderly population aged 65 years and older in the United States in 3 geographic areas: metropolitan Atlanta, Ga; Franklin County, Ohio; and Monroe County, New York. Main Outcome Measures.-Incremental medical costs and health effects, expressed in quality-adjusted life-years per person vaccinated. Results.-Vaccination was cost saving, ie, it both reduced medical expenses and improved health, for all age groups and geographic areas analyzed in the base case, For people aged 65 years and older, vaccination saved $8.27 and gained 1.21 quality-adjusted days of life per person vaccinated, Vaccination of the 23 million elderly people unvaccinated in 1993 would have gained about 78 000 years of healthy life and saved $194 million, In univariate sensitivity analysis, the results remained cost saving except for doubling vaccination costs, including future medical costs of survivors, and lowering vaccination effectiveness, With assumptions most unfavorable to vaccination, cost per quality-adjusted life-year ranged from $35 822 for ages 65 to 74 years to $598 487 for ages 85 years and older. In probabilistic sensitivity analysis, probability intervals were more narrow, with less than 5% probability that the ratio for ages 85 years and older would exceed $100 000. Conclusions.-Pneumococcal vaccination saves costs in the prevention of bacteremia alone and is greatly underused among the elderly population, on both health and economic grounds. These results support recent recommendations of the Advisory Committee on Immunization Practices and public and private efforts under way to improve vaccination rates.	SUNY STONY BROOK, STONY BROOK, NY 11794 USA; PASTEUR MERIEUX MSD, LYON, FRANCE; UNIV MINNESOTA, MINNEAPOLIS, MN USA; OHIO STATE UNIV, COLUMBUS, OH 43210 USA; CTR DIS CONTROL & PREVENT, ATLANTA, GA USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Sanofi-Aventis; Sanofi France; University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; Centers for Disease Control & Prevention - USA	Sisk, JE (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, DIV HLTH POLICY & MANAGEMENT, 600 W 168TH ST, 6TH FLOOR, NEW YORK, NY 10032 USA.		Whang, William/AAE-3853-2019	Moskowitz, Alan/0000-0002-4412-9450				*ACP TASK FORC AD, 1994, GUID AD IMM, P107; AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CAMPBELL JF, 1989, HAWAII MED J, V48, P517; *CDC, 1984, MMWR-MORBID MORTAL W, V33, P273; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P506; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CHIANG CL, 1991, ANNU REV PUBL HEALTH, V12, P281, DOI 10.1146/annurev.pu.12.050191.001433; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; ERICKSON P, 1995, STAT NOTES, V7, P1; FARR BM, 1995, ARCH INTERN MED, V155, P2336, DOI 10.1001/archinte.155.21.2336; Fedson D S, 1992, Clin Geriatr Med, V8, P183; FEDSON D S, 1990, Journal of the American Medical Association, V264, P1117, DOI 10.1001/jama.264.9.1117; Fedson D S, 1993, Semin Respir Infect, V8, P285; FEDSON DS, 1994, ARCH INTERN MED, V154, P2531, DOI 10.1001/archinte.154.22.2531; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P113; Fedson DS, 1994, VACCINES, P517; FORRESTER HL, 1987, AM J MED, V83, P425, DOI 10.1016/0002-9343(87)90751-0; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; Gold MR, 1996, COST EFFECTIVENESS H; GYORKOS TW, 1994, CAN J PUBLIC HEALTH, V85, pS14; HILLIER FS, 1974, OPER RES, P620; HIRSCHMANN JV, 1994, ARCH INTERN MED, V154, P373, DOI 10.1001/archinte.154.4.373; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; KEELER EB, 1983, MANAGE SCI, V29, P300, DOI 10.1287/mnsc.29.3.300; LASCHOBER MA, 1996, HLTH HLTH CARE MED P, P44; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MCBEAN AM, 1991, ARCH INTERN MED, V151, P2009, DOI 10.1001/archinte.151.10.2009; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PLOUFFE JF, 1994, J CLIN MICROBIOL, V32, P1606, DOI 10.1128/JCM.32.6.1606-1607.1994; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; RIDDIOUGH M A, 1983, Journal of the American Medical Association, V249, P3189, DOI 10.1001/jama.249.23.3189; Schoenbaum S C, 1993, HMO Pract, V7, P5; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMBERKOFF MS, 1994, SEMIN RESPIR INFECT, V8, P294; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; SISK JE, 1986, ANN INTERN MED, V104, P78; *US C OFF TECHN AS, 1990, COSTS EFF COL CANC S; *US C OFF TECHN AS, 1990, COSTS EFF CERV CANC; *US COUNC EC ADV, 1997, EC REP PRES, P365; *US PHS, 1991, HLTH PEOPL 2000 NAT; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WILLEMS JS, 1980, NEW ENGL J MED, V303, P553, DOI 10.1056/NEJM198009043031004; WILLEMS JS, 1981, J INFECT DIS, V144, P486, DOI 10.1093/infdis/144.5.486; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616	52	267	276	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1333	1339		10.1001/jama.278.16.1333	http://dx.doi.org/10.1001/jama.278.16.1333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343464				2022-12-24	WOS:A1997YA90500034
J	Chen, WR; Midtgaard, J; Shepherd, GM				Chen, WR; Midtgaard, J; Shepherd, GM			Forward and backward propagation of dendritic impulses and their synaptic control in mitral cells	SCIENCE			English	Article							RAT OLFACTORY-BULB; PYRAMIDAL NEURONS; ACTION-POTENTIALS; INITIATION; RECORDINGS; SLICES; CA2+	The site of impulse initiation is crucial for the integrative actions of mammalian central neurons, but this question is currently controversial. Some recent studies support classical evidence that the impulse always arises in the soma-axon hillock region, with back-propagation through excitable dendrites, whereas others indicate that the dendrites are sufficiently excitable to initiate impulses that propagate forward along the dendrite to the soma-axon hillock. This issue has been addressed in the olfactory mitral cell, in which excitatory synaptic input is restricted to the distal tuft of a single primary dendrite. In rat olfactory bulb slices, dual whole cell recordings were made at or near the soma and from distal sites on the primary dendrite. The results show that the impulse can be initiated in either the soma-axon hillock or in the distal primary dendrite, and that the initiation site is controlled physiologically by the excitatory synaptic inputs to the distal tuft and inhibitory synaptic inputs near the soma.	UNIV COPENHAGEN,DEPT MED PHYSIOL,DK-2200 COPENHAGEN N,DENMARK	University of Copenhagen	Chen, WR (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510, USA.							BENARDO LS, 1982, J NEUROSCI, V2, P1614; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CALLAWAY JC, 1995, J NEUROSCI, V15, P2777; CHANG HT, 1952, COLD SPRING HARB SYM, V17, P189, DOI 10.1101/SQB.1952.017.01.019; Chen W., UNPUB; Chen WR, 1997, BRAIN RES, V745, P189, DOI 10.1016/S0006-8993(96)01150-X; CRAGG BG, 1955, J PHYSIOL-LONDON, V129, P608, DOI 10.1113/jphysiol.1955.sp005382; DEFELIPE J, 1992, PROG NEUROBIOL, V39, P563, DOI 10.1016/0301-0082(92)90015-7; Ennis M, 1996, NEUROREPORT, V7, P989, DOI 10.1097/00001756-199604100-00007; HAMILTON KA, 1989, BRAIN RES, V338, P181; HAUSSER M, 1995, NEURON, V15, P637, DOI 10.1016/0896-6273(95)90152-3; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; HUGUENARD JR, 1989, P NATL ACAD SCI USA, V86, P2473, DOI 10.1073/pnas.86.7.2473; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; KAUER JS, 1974, J PHYSIOL-LONDON, V243, P695, DOI 10.1113/jphysiol.1974.sp010772; LEVETEAU J, 1965, SCIENCE, V175, P170; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MORI K, 1982, J NEUROSCI, V2, P497; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORI K, 1975, BRAIN RES, V100, P685, DOI 10.1016/0006-8993(75)90170-5; Nickell WT, 1996, BRAIN RES BULL, V39, P57, DOI 10.1016/0361-9230(95)02042-X; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; RALL W, 1966, EXP NEUROL, V14, P44, DOI 10.1016/0014-4886(66)90023-9; REGEHR WG, 1994, CURR BIOL, V4, P436, DOI 10.1016/S0960-9822(00)00096-8; SCOTT JW, 1987, NEUROBIOLOGY TASTE S, P151; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; SHEPHERD GM, 1977, HDB PHYSL          1, V1, P945; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRUSTON N, 1995, SCIENCE, V268, P297, DOI 10.1126/science.7716524; Stuart G, 1997, TRENDS NEUROSCI, V20, P125, DOI 10.1016/S0166-2236(96)10075-8; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; TURNER RW, 1991, J NEUROSCI, V11, P2270; WELLIS DP, 1987, CHEM SENSES, V12, P707	38	195	204	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					463	467		10.1126/science.278.5337.463	http://dx.doi.org/10.1126/science.278.5337.463			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334305				2022-12-24	WOS:A1997YB35500045
J	Ellegren, H; Lindgren, G; Primmer, CR; Moller, AP				Ellegren, H; Lindgren, G; Primmer, CR; Moller, AP			Fitness loss and germline mutations in barn swallows breeding in Chernobyl	NATURE			English	Article							HIRUNDO-RUSTICA; MISMATCH REPAIR; DNA; RADIATION; EVOLUTION; ACCIDENT	The severe nuclear accident at Chernobyl in 1986 resulted in the worst reported accidental exposure of radioactive material to free-living organisms(1). Short-term effects on human populations inhabiting polluted areas include increased incidence of thyroid cancer(2), infant leukaemia(3), and congenital malformations in newborns(4). Two recent studies(5,6) have reported, although with some controversy(7,8), that germline mutation rates were increased in humans and voles living close to Chernobyl, but little is known about the viability of the organisms affected(9). Here we report an increased frequency of partial albinism, a morphological aberration associated with a loss of fitness, among barn swallows, Hirundo rustica, breeding close to Chernobyl. Heritability estimates indicate that mutations causing albinism were at least partly of germline origin. Furthermore, evidence for an increased germline mutation rate was obtained from segregation analysis at two hypervariable microsatellite loci, indicating that mutation events in barn swallows from Chernobyl were two-to tenfold higher than in birds from control areas in Ukraine and Italy.	UNIV PARIS 06,CNRS,URA 258,ECOL LAB,F-75252 PARIS 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Ellegren, H (corresponding author), SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,BOX 597,S-75124 UPPSALA,SWEDEN.		Moller, Anders/O-6665-2016; Primmer, Craig R/B-8179-2008	Moller, Anders/0000-0003-3739-4675; Primmer, Craig R/0000-0002-3687-8435				ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; Baker RJ, 1996, NATURE, V380, P707, DOI 10.1038/380707a0; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Dubrova YE, 1996, NATURE, V383, P226, DOI 10.1038/383226b0; Dyck J., 1985, DICT BIRDS, P472; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; HANOTTE O, 1994, MOL ECOL, V3, P529, DOI 10.1111/j.1365-294X.1994.tb00133.x; Hillis DM, 1996, NATURE, V380, P665, DOI 10.1038/380665a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MOLLER AP, 1993, P ROY SOC B-BIOL SCI, V252, P51, DOI 10.1098/rspb.1993.0045; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petridou E, 1996, NATURE, V382, P352, DOI 10.1038/382352a0; Primmer CR, 1996, NAT GENET, V13, P391, DOI 10.1038/ng0896-391; Primmer CR, 1996, HEREDITAS, V124, P281, DOI 10.1111/j.1601-5223.1996.00281.x; PRIMMER CR, 1995, MOL ECOL, V4, P493, DOI 10.1111/j.1365-294X.1995.tb00243.x; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Saino N, 1997, EVOLUTION, V51, P562, DOI 10.1111/j.1558-5646.1997.tb02443.x; Satoh C, 1996, NATURE, V383, P226, DOI 10.1038/383226a0; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; [No title captured]	23	195	213	0	103	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					593	596		10.1038/39303	http://dx.doi.org/10.1038/39303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335497				2022-12-24	WOS:A1997YA00800057
J	Rodriguez, I; Basler, K				Rodriguez, I; Basler, K			Control of compartmental affinity boundaries by hedgehog	NATURE			English	Article							DROSOPHILA IMAGINAL DISKS; PROTEIN KINASE-A; SIGNAL-TRANSDUCTION; ENGRAILED GENE; PATTERN; EXPRESSION; ENCODES	In Drosophila, each segmental primordium is subdivided into two cell populations, the anterior (A) and posterior (P) compartments by the selective activity of the transcription factor Engrailed (En) in P cells(1-4). Under En control, P cells secrete, but cannot respond to, the signalling protein Hedgehog (Hh)(5-7). In contrast, and by default, A cells are programmed to respond to Hh by expressing other signalling molecules, such as Decapentaplegic (Dpp) and Wingless (Wg), which organize growth and patterning in both compartments(5,7-9). Cells of the A and P compartments do not intermix, apparently as a consequence of their having distinct cell affinities that cause them to maximize contact with cells of the same compartment, while minimizing contact with cells from the other compartment(10). This failure to mix has previously been ascribed to an autonomous and direct role for En in specifying a P, as opposed to an A, cell affinity(3,11-13). However, an alternative hypothesis is that Hh secreted by P cells induces A cells to acquire a distinct cell affinity, ensuring that a stable 'affinity boundary' forms wherever P and A cells meet, Here we show that the affinity boundary that segregates A and P cells into adjacent but immiscible cell populations is to a large extent a consequence of local Hh signalling, rather than a reflection of an intrinsic affinity difference between A and P cells.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich			Rodriguez, Isabel/J-2636-2017	Rodriguez, Isabel/0000-0002-7322-4756; Basler, Konrad/0000-0003-3534-1529				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; Lawrence P.A., 1986, P229; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; XU T, 1993, DEVELOPMENT, V117, P1223; ZECCA M, 1995, DEVELOPMENT, V121, P2265	31	112	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	1997	389	6651					614	618		10.1038/39343	http://dx.doi.org/10.1038/39343			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335503				2022-12-24	WOS:A1997YA00800063
J	Varmus, H; Satcher, D				Varmus, H; Satcher, D			Ethical complexities of conducting research in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CTR DIS CONTROL & PREVENT,ATLANTA,GA 30329	Centers for Disease Control & Prevention - USA	Varmus, H (corresponding author), NIH,BETHESDA,MD 20892, USA.							Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; *NAT COMM PROT HUM, 1988, 887809 GPO; *US DEP HHS, 1997, COND CLIN TRIALS MAT; *WHO, 1994, REC M MOTH TO INF TR; *WORLD MED ASS DEC, 1996, 18 WORLD MED ASS HEL	6	243	250	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					1003	1005		10.1056/NEJM199710023371411	http://dx.doi.org/10.1056/NEJM199710023371411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309109				2022-12-24	WOS:A1997XY42300011
J	Mihic, SJ; Ye, Q; Wick, MJ; Koltchine, VV; Krasowski, MD; Finn, SE; Mascia, MP; Valenzuela, CF; Hanson, KK; Greenblatt, EP; Harris, RA; Harrison, NL				Mihic, SJ; Ye, Q; Wick, MJ; Koltchine, VV; Krasowski, MD; Finn, SE; Mascia, MP; Valenzuela, CF; Hanson, KK; Greenblatt, EP; Harris, RA; Harrison, NL			Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors	NATURE			English	Article							ACID TYPE-A; LONG-CHAIN ALCOHOLS; GENERAL-ANESTHETICS; CURRENTS; PROPOFOL; INHIBITION; MODULATION	Volatile anaesthetics have historically been considered to act in a nonspecific manner on the central nervous system(1,2). More recent studies, however, have revealed that the receptors for inhibitory neurotransmitters such as gamma-aminobutyric acid (GABA) and glycine are sensitive to clinically relevant concentrations of inhaled anaesthetics(3). The function of GABAA and glycine receptors is enhanced by a number of anaesthetics(4-9) and alcohols(10-12), whereas activity of the related(13) GABA rho 1 receptor is reduced(14). We have used this difference in pharmacology to investigate the molecular basis for modulation of these receptors by anaesthetics and alcohols. By using chimaeric receptor constructs, we have identified a region of 45 amino-acid residues that is both necessary and sufficient for the enhancement of receptor function. Within this region, two specific amino-acid residues in transmembrane domains 2 and 3 are critical for allosteric modulation of both GABA(A) and glycine receptors by alcohols and two volatile anaesthetics. These observations support the idea that anaesthetics exert a specific effect on these ion-channel proteins, and allow fbr the future testing of specific hypotheses of the action of anaesthetics.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Alcohol Res Ctr, Denver, CO 80262 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Denver Veteran Adm Med Ctr, Alcoholism Res Ctr, Denver, CO 80220 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Chicago; University of Chicago; University of Pennsylvania	Mihic, SJ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.		Krasowski, Matthew D/ABA-8590-2020	Krasowski, Matthew D/0000-0003-0856-8402; Hanson, Kirsten/0000-0002-0154-0979				DildyMayfield JE, 1996, BRIT J PHARMACOL, V118, P378, DOI 10.1111/j.1476-5381.1996.tb15413.x; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; JANOFF AS, 1981, BIOCHIM BIOPHYS ACTA, V649, P125, DOI 10.1016/0005-2736(81)90017-1; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LYON RC, 1981, J PHARMACOL EXP THER, V218, P669; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SANNA E, 1995, MOL PHARMACOL, V47, P213; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SHOENBORN BP, 1967, NATURE, V214, P1120; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Yu DH, 1996, MOL PHARMACOL, V50, P1010; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	27	1034	1056	6	82	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 25	1997	389	6649					385	389		10.1038/38738	http://dx.doi.org/10.1038/38738			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311780				2022-12-24	WOS:A1997XX67500053
J	TunstallPedoe, H; Woodward, M; Tavendale, R; Brook, RA; McCluskey, MK				TunstallPedoe, H; Woodward, M; Tavendale, R; Brook, RA; McCluskey, MK			Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; MYOCARDIAL-INFARCTION; LIFE-STYLE; ALCOHOL-CONSUMPTION; PLASMA-FIBRINOGEN; PASSIVE SMOKING; SERUM COTININE; BLOOD-PRESSURE; CASE-FATALITY; MORTALITY	Objective: To compare prediction by 27 different factors in men and women of coronary heart disease events, coronary deaths, and deaths from all causes. Design: Cohort study. Setting: Scottish population study. Subjects: In 1984-7 random sampling of residents aged 40-59 produced 11 629 men and women who generated survey clinic questionnaires, examination findings, and blood and urine specimens. Main outcome measures: Subsequent death, coronary artery surgery, and myocardial infarction. Risks were calculated for each category of factor or fifth of continuous variables. 27 factors were ranked by descending age adjusted hazard ratio of the top to bottom class in each factor, by sex and end point. Results: Follow up averaged; 7.6 years, during which the 5754 men had 404 coronary events, 159 coronary deaths, and 383 deaths and the 5875 women 177, 47, and 208 respectively The rankings for factors for the three end points were mainly similar in men and women, although hazard ratios were often higher in women. Classical risk factors ranked better for predicting coronary risk than newer ones. Yet strong prediction of coronary risk was no guarantee of significant prediction of all cause mortality. Findings included an anomalous coronary protective role for type A behaviour in women; raised plasma fibrinogen as a strong predictor of all end points; and an unexpectedly powerful protective relation of dietary potassium to all cause mortality. Conclusions: These initial unifactorial rankings and comparisons must be interpreted with caution until potential interaction, confounding, and problems of measurement and causation are further explored.			TunstallPedoe, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.		Woodward, Mark/D-8492-2015; Woodward, Mark/L-6817-2017	Woodward, Mark/0000-0001-9800-5296				BORTNER RW, 1969, J CHRON DIS, V22, P87, DOI 10.1016/0021-9681(69)90061-7; Collett D, 1994, MODELLING SURVIVAL D; CROMBIE I, 1990, HLTH ED J, V49, P71; CROMBIE IK, 1990, BRIT HEART J, V64, P199; CROMBIE IK, 1989, STATISTICIAN, V38, P25; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KNOX SS, 1993, J PSYCHOSOM RES, P709; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; LEE AJ, 1993, BRIT HEART J, V69, P338; LEE AJ, 1993, BRIT J HAEMATOL, V83, P616, DOI 10.1111/j.1365-2141.1993.tb04699.x; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; Morrison C, 1997, BMJ-BRIT MED J, V314, P541, DOI 10.1136/bmj.314.7080.541; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; Prineas R., 1982, MINNESOTA CODE MANUA; RICHEDWARDS JW, 1995, AM J EPIDEMIOL, V142, P909, DOI 10.1093/oxfordjournals.aje.a117738; ROSE G, 1980, LANCET, V1, P523; Rose G, 1982, CARDIOVASCULAR SURVE; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SMITH CB, 1992, EUR J CLIN NUTR, V46, P75; SMITH CB, 1992, EUR J CLIN NUTR, V46, P85; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1990, BRIT HEART J, V64, P295; SWEETNAM PM, 1994, CIRCULATION, V90, P769, DOI 10.1161/01.CIR.90.2.769; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; TUNSTALLPEDOE H, 1995, J EPIDEMIOL COMMUN H, V49, P139, DOI 10.1136/jech.49.2.139; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, 1991, J CLIN EPIDEMIOL, V44, P1411, DOI 10.1016/0895-4356(91)90102-F; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; *WHO, 1996, WORLD HLTH STAT ANN; *WHO MONICA PROJ, 1989, WORLD HLTH STAT ANN, P27; WHO MONICA Project, 1990, MONICA MAN; WOODWARD M, 1990, STATISTICIAN, V39, P319, DOI 10.2307/2349049; WOODWARD M, 1993, ADDICTION, V88, P821, DOI 10.1111/j.1360-0443.1993.tb02096.x; WOODWARD M, 1991, J CLIN EPIDEMIOL, V44, P1405, DOI 10.1016/0895-4356(91)90101-E; WOODWARD M, 1992, PREV MED, V21, P136, DOI 10.1016/0091-7435(92)90013-8; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103	49	258	262	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					722	729		10.1136/bmj.315.7110.722	http://dx.doi.org/10.1136/bmj.315.7110.722			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314758	Green Published			2022-12-24	WOS:A1997XX67400024
J	Strickberger, SA; Man, KC; Daoud, EG; Goyal, R; Brinkman, K; Knight, BP; Weiss, R; Bahu, M; Morady, F				Strickberger, SA; Man, KC; Daoud, EG; Goyal, R; Brinkman, K; Knight, BP; Weiss, R; Bahu, M; Morady, F			Adenosine-induced atrial arrhythmia: A prospective analysis	ANNALS OF INTERNAL MEDICINE			English	Article						atrial fibrillation; adenosine; tachycardia, supraventricular; electrophysiology; Wolff-Parkinson-White syndrome	PARKINSON-WHITE SYNDROME; INTRAVENOUS ADENOSINE; COMPLEX TACHYCARDIA; ACCESSORY PATHWAY; HEART-RATE; FIBRILLATION; FLUTTER; DIAGNOSIS; CONDUCTION; POTASSIUM	Background: Adenosine is considered safe and effective for paroxysmal supraventricular tachycardia (PSVT), but anecdotal experience suggests that adenosine can precipitate atrial arrhythmias. Objectives: To determine the frequency and mechanisms of adenosine-induced atrial arrhythmias. Setting: Clinical electrophysiology laboratory at a university medical center. Design: Prospective observational study. Patients: 200 consecutive patients with PSVT undergoing an electrophysiology procedure. Intervention: During PSVT, 12 mg of adenosine was administered centrally through the femoral vein. Measurements: Frequency of adenosine-induced atrial fibrillation. Results: Paroxysmal supraventricular tachycardia terminated after adenosine administration in 198 patients (99% [95% CI, 96% to 100%]). Adenosine led to atrial fibrillation (n = 22) or atrial fibrillation and atrial flutter (n = 2) in 24 patients (12% [CI, 7.5% to 16.5%]). An atrial premature complex occurred in all 24 patients who developed atrial fibrillation, atrial flutter, or both and in 102 of the 176 patients (58%) who did not (P < 0.001). The mean (+/-SD) time from the preceding atrial complex to the atrial premature complex was shorter when an atria[ arrhythmia occurred, and the mean ratio of this interval to the preceding atrial cycle length was also lower when atrial fibrillation developed (0.37 +/- 0.16 compared with 0.49 +/- 0.16; P = 0.002). Conclusions: The incidence of atrial fibrillation induced by 12 mg of adenosine administered through the femoral vein was 12%. Fibrillation seems to be associated with a ''long-short'' atrial sequence. If the mechanism of PSVT is unknown and the Wolff-Parkinson-White syndrome is possible, administration of adenosine should be limited to medical facilities that have emergency resuscitation equipment.			Strickberger, SA (corresponding author), UNIV MICHIGAN, MED CTR, 1500 E MED CTR DR, BOX 0022, ANN ARBOR, MI 48109 USA.							BELARDINELLI L, 1983, AM J PHYSIOL, V244, pH734, DOI 10.1152/ajpheart.1983.244.5.H734; BIAGGIONI I, 1986, LIFE SCI, V39, P2229, DOI 10.1016/0024-3205(86)90401-7; BRODSKY MA, 1995, AM HEART J, V130, P564, DOI 10.1016/0002-8703(95)90367-4; CONTI JB, 1995, AM J CARDIOL, V75, P952, DOI 10.1016/S0002-9149(99)80698-5; Cosio FG, 1996, J CARDIOVASC ELECTR, V7, P60, DOI 10.1111/j.1540-8167.1996.tb00461.x; DIMARCO JP, 1990, ANN INTERN MED, V113, P104, DOI 10.7326/0003-4819-113-2-104; DOMANOVITS H, 1994, EUR HEART J, V15, P589, DOI 10.1093/oxfordjournals.eurheartj.a060553; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2199; EXNER DV, 1995, ANN INTERN MED, V122, P351, DOI 10.7326/0003-4819-122-5-199503010-00005; FEDIDA D, 1989, AM J PHYSIOL, V256, pH1500, DOI 10.1152/ajpheart.1989.256.5.H1500; *FUJ US INC MEDC R, 1996, PACK INS AD; GARRATT CJ, 1994, AM J CARDIOL, V74, P401, DOI 10.1016/0002-9149(94)90415-4; GARRATT CJ, 1990, AM J CARDIOL, V65, P868, DOI 10.1016/0002-9149(90)91428-9; GARRATT CJ, 1991, CIRCULATION, V84, P1962, DOI 10.1161/01.CIR.84.5.1962; GRIFFITH MJ, 1988, LANCET, V1, P672; Herbert ME, 1997, ANN EMERG MED, V29, P172, DOI 10.1016/S0196-0644(97)70324-X; JOHNSON EA, 1956, NATURE, V178, P1174, DOI 10.1038/1781174a0; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P181; Kim IB, 1996, CIRCULATION, V94, P2961, DOI 10.1161/01.CIR.94.11.2961; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; Lerman BB, 1996, J CARDIOVASC ELECTR, V7, P559, DOI 10.1111/j.1540-8167.1996.tb00563.x; LI HGG, 1994, J AM COLL CARDIOL, V24, P728, DOI 10.1016/0735-1097(94)90021-3; LOPEZ JA, 1994, TEX HEART I J, V21, P130; MORADY F, 1988, J AM COLL CARDIOL, V11, P1235, DOI 10.1016/0735-1097(88)90287-2; NUNAIN SO, 1992, CARDIOVASC RES, V26, P939, DOI 10.1093/cvr/26.10.939; ONUNAIN S, 1993, AM J CARDIOL, V71, P248, DOI 10.1016/0002-9149(93)90748-2; RANKIN AC, 1993, BRIT HEART J, V69, P263; RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395; Silverman AJ, 1996, AM J EMERG MED, V14, P300, DOI 10.1016/S0735-6757(96)90182-5; SLADE AKB, 1993, BRIT HEART J, V70, P91; SMEETS JLRM, 1986, CIRC RES, V58, P96, DOI 10.1161/01.RES.58.1.96; Smith JR, 1997, PACE, V20, P743, DOI 10.1111/j.1540-8159.1997.tb03897.x; TEBBENJOHANNS J, 1995, PACE, V18, P743, DOI 10.1111/j.1540-8159.1995.tb04673.x; WALKER KW, 1995, PACE, V18, P441, DOI 10.1111/j.1540-8159.1995.tb02543.x; WELLS JL, 1978, PACE, V1, P426, DOI 10.1111/j.1540-8159.1978.tb03504.x; WEST GA, 1985, PFLUG ARCH EUR J PHY, V403, P75, DOI 10.1007/BF00583285; WHALLEY DW, 1995, PACE, V18, P1556, DOI 10.1111/j.1540-8159.1995.tb06742.x; WIENER N, 1946, Arch Inst Cardiol Mex, V16, P205	39	71	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					417	422		10.7326/0003-4819-127-6-199709150-00001	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312997				2022-12-24	WOS:A1997XV77900001
J	Zuckerman, E; Zuckerman, T; Levine, AM; Douer, D; Gutekunst, K; Mizokami, M; Qian, DG; Velankar, M; Nathwani, BN; Fong, TL				Zuckerman, E; Zuckerman, T; Levine, AM; Douer, D; Gutekunst, K; Mizokami, M; Qian, DG; Velankar, M; Nathwani, BN; Fong, TL			Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma	ANNALS OF INTERNAL MEDICINE			English	Article							ESSENTIAL MIXED CRYOGLOBULINEMIA; NON-A; LYMPHOPROLIFERATIVE DISORDERS; PERIPHERAL-BLOOD; UNITED-STATES; RISK-FACTORS; HCV; ASSAY; DONORS; RNA	Background: Several studies from Europe have reported a high prevalence (9% to 32%) of chronic hepatitis C virus (HCV) infection in patients with B-cell non-Hodgkin lymphoma. It has been suggested that HCV plays a role in the pathogenesis of B-cell non-Hodgkin lymphoma. Objective: To determine the prevalence of HCV infection in patients with B-cell lymphoma in the United States. Design: Controlled, cross-sectional analysis. Setting: University medical center. Patients: 120 patients with B-cell lymphoma (78% were Hispanic, 9% were black, 7% were Asian, and 6% were white), 154 patients with other malignant hematologic conditions (control group 1), and 114 patients with nonmalignant conditions (control group 2). Measurements: Samples were tested for antibodies to HCV by enzyme-linked immunosorbent assay. Hepatitis C virus RNA was detected by reverse-transcription polymerase chain reaction. Genotyping for HCV was done with genotype-specific primers from the HCV core region. Results: infection with HCV was detected in 26 patients (22% [95% CI, 15% to 30%]) with B-cell lymphoma compared with 7 of 154 patients (4.5%) in control group 1 and 6 of 114 patients (5%) in control group 2 (P < 0.001). Risk factors for HCV infection were present in 15 patients (60%) with B-cell lymphoma and occurred a median of 15 years before diagnosis of lymphoma. Monocytoid B-cell lymphoma was the most common type of lymphoma found in HCV-positive patients (23% compared with 7% in HCV-negative patients) (P = 0.034). Conclusions: The prevalence of HCV infection was higher in patients with B-cell non-Hodgkin lymphoma than in controls. The possible role of HCV in the pathogenesis of B-cell lymphoma warrants further investigation.	UNIV SO CALIF, SCH MED, DIV HEMATOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; ROCHE MOL SYST, SOMERVILLE, NJ 08876 USA; NAGOYA CITY UNIV, SCH MED, NAGOYA, AICHI 467, JAPAN	University of Southern California; University of Southern California; Roche Holding; Nagoya City University								AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COGLIATTI SB, 1990, J CLIN PATHOL, V43, P619, DOI 10.1136/jcp.43.8.619; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; ELLIS M, 1995, EUR J CLIN INVEST, V25, P833, DOI 10.1111/j.1365-2362.1995.tb01692.x; FERRI C, 1993, EUR J CLIN INVEST, V23, P399, DOI 10.1111/j.1365-2362.1993.tb00782.x; FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x; FERRI C, 1993, BLOOD, V82, P3701; FRANZIN F, 1995, BRIT J HAEMATOL, V90, P548, DOI 10.1111/j.1365-2141.1995.tb05582.x; Hanley J, 1996, LANCET, V347, P1339, DOI 10.1016/S0140-6736(96)90991-5; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lau JYN, 1996, ANN INTERN MED, V124, P868, DOI 10.7326/0003-4819-124-10-199605150-00002; McColl MD, 1996, BRIT J HAEMATOL, V92, P771; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MONTALTO G, 1995, HEPATOLOGY, V22, P1409; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; MONTEVRDE A, 1994, P M HCV CRYOGLOBULIN, P34; MUSSINI C, 1995, BLOOD, V85, P1144, DOI 10.1182/blood.V85.4.1144.bloodjournal8541144; NATHWANI BN, 1992, HUM PATHOL, V23, P1061, DOI 10.1016/0046-8177(92)90270-D; NATHWANI BN, 1992, NEOPLASTIC HEMATOPAT, P555; NGAN BY, 1991, HUM PATHOL, V22, P409, DOI 10.1016/0046-8177(91)90125-9; NOLTE FS, 1995, J CLIN MICROBIOL, V33, P1775, DOI 10.1128/JCM.33.7.1775-1778.1995; Ohno T, 1997, J CLIN MICROBIOL, V35, P201, DOI 10.1128/JCM.35.1.201-207.1997; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; Pioltelli P, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91328-8; PORTER DD, 1986, PROG MED VIROL, V33, P42; ROSENBERG SA, 1982, CANCER, V49, P2112; SANTINI GF, 1993, BLOOD, V82, P2932; SAXENA S, 1995, LAB MED, V26, P682, DOI 10.1093/labmed/26.10.682; SHEIBANI K, 1988, CANCER, V62, P1531, DOI 10.1002/1097-0142(19881015)62:8<1531::AID-CNCR2820620814>3.0.CO;2-A; SHEIBANI K, 1986, AM J PATHOL, V124, P310; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; Zein NN, 1996, ANN INTERN MED, V125, P634, DOI 10.7326/0003-4819-125-8-199610150-00002; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	39	348	352	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					423	428		10.7326/0003-4819-127-6-199709150-00002	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9312998				2022-12-24	WOS:A1997XV77900002
J	Moore, M; Onorato, IM; McCray, E; Castro, KG				Moore, M; Onorato, IM; McCray, E; Castro, KG			Trends in drug-resistant tuberculosis in the United States, 1993-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION	Context.-With the resurgence of tuberculosis (TB) disease in the late 1980s and early 1990s in the United States, multidrug-resistant (MDR) TB emerged as a serious challenge to TB control. In response, the Centers for Disease Control and Prevention in 1993 added drug susceptibility test results to the information collected for the national surveillance system to monitor trends in drug resistance. Objective.-To determine the extent of drug-resistant tuberculosis (TB) in the United States. Design.-Descriptive analysis or TB surveillance data. Study Population.-Patients reported to the national TB surveillance system as confirmed TB cases with culture-positive disease from 1993 through 1996 by the 50 states, New York City, and the District of Columbia (DC). Main Outcome Measure.-Percentage of case patients with culture-positive disease whose isolates are resistant to specific anti-TB drugs. Results.-Overall resistance to at least isoniazid was 8.4%; rifampin, 3.0%; both isoniazid and rifampin (ie, MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol hydrochloride, 2.2%. Rates of resistance were significantly higher for case patients with a prior TB episode. Among those without prior TB, isoniazid resistance of 4% or more was found in 41 states, New York City, and DC. A total of 1457 MDR TB cases were reported from 42 states, New York City, and DC; however, 38% were reported from New York City. Rates of isoniazid and streptomycin resistance were higher for cases among US-born compared with foreign-born patients, but rates of rifampin resistance and MDR TB were similar. Among US-born patients, resistance to first-line drugs, particularly rifampin mono-resistance, was significantly higher among those with human immunodeficiency virus (HIV) infection. Conclusions.-Compared with recent US surveys in 1991 and 1992, isoniazid resistance has remained relatively stable. In addition, the percentage of MDR TB has decreased, although the national trend was significantly influenced by the marked decrease in New York City. Foreign-born and HIV-positive patients and those with prior TB have higher rates of resistance. The widespread extent of isoniazid resistance confirms the need for drug susceptibility testing to guide optimal treatment of patients with culture-positive disease.			Moore, M (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-10,ATLANTA,GA 30333, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; Bloch AB, 1996, PUBLIC HEALTH REP, V111, P26; BLOCH AB, 1994, AM LUNG ASS AM THOR; Bradford WZ, 1996, LANCET, V348, P928, DOI 10.1016/S0140-6736(96)03027-9; BURWEN DR, 1995, ARCH INTERN MED, V155, P1281, DOI 10.1001/archinte.155.12.1281; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P521; *CDC, 1981, MMWR-MORBID MORTAL W, V30, P273; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P587; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; DOSTER B, 1976, AM REV RESPIR DIS, V113, P419; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FRIEDEN TB, 1993, NEW ENGL J MED, V528, P521; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; LASZLO A, 1994, B WORLD HEALTH ORGAN, V72, P603; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1995, AM J RESP CRIT CARE, V152, P1067, DOI 10.1164/ajrccm.152.3.7663785; RIDZON R, 1996, AM J RESP CRIT CARE, V153, pA493; RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; WHITNEY CG, 1996, AM J RESP CRIT CARE, V153, pA492	28	129	132	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					833	837		10.1001/jama.278.10.833	http://dx.doi.org/10.1001/jama.278.10.833			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293991				2022-12-24	WOS:A1997XU55200038
J	Matsunami, H; Buck, LB				Matsunami, H; Buck, LB			A multigene family encoding a diverse array of putative pheromone receptors in mammals	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; OLFACTORY EPITHELIUM; VOMERONASAL SYSTEM; ODORANT RECEPTORS; GENE-EXPRESSION; NEURONS; ORGANIZATION; TRANSDUCTION; INFORMATION; PROTEINS	The vomeronasal organ of mammals is an olfactory sensory structure that detects pheromones. It contains two subsets of sensory neurons that differentially express G alpha(o) and G alpha(i2). By comparing gene expression in single neurons, we identified a novel multigene family that codes for a diverse array of candidate pheromone receptors (VRs) expressed by the G alpha(o)(+) subset. Different VRs are expressed by different neurons, but those neurons are interspersed, suggesting a distributed mode of sensory coding. Chromosome mapping experiments suggest an evolutionary connection between genes encoding VRs and receptors for volatile odorants. However, a dramatically different structure for VRs and the existence of variant VR mRNA forms indicate that there are diverse strategies to detect functionally distinct sensory stimuli.			Matsunami, H (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; BRADY G, 1993, METHOD ENZYMOL, V225, P611; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUCK LB, 1987, CELL, V51, P127, DOI 10.1016/0092-8674(87)90017-1; BUCK LB, 1995, CELL, V83, P349, DOI 10.1016/0092-8674(95)90110-8; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Jia CP, 1996, BRAIN RES, V719, P117, DOI 10.1016/0006-8993(96)00110-2; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RONNETT GV, 1992, TRENDS NEUROSCI, V15, P508, DOI 10.1016/0166-2236(92)90104-G; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Segaloff D L, 1992, Oxf Rev Reprod Biol, V14, P141; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SINGER AG, 1991, J STEROID BIOCHEM, V39, P627, DOI 10.1016/0960-0760(91)90261-3; Sorensen PW, 1996, CHEM SENSES, V21, P245, DOI 10.1093/chemse/21.2.245; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vogt R.G., 1987, P385; WILSON EO, 1963, SCI AM, V208, P100, DOI 10.1038/scientificamerican0563-100; Wu YM, 1996, BIOCHEM BIOPH RES CO, V220, P900, DOI 10.1006/bbrc.1996.0503; Wysocki C.J., 1987, P125	55	550	569	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					775	784		10.1016/S0092-8674(00)80537-1	http://dx.doi.org/10.1016/S0092-8674(00)80537-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288756	Bronze			2022-12-24	WOS:A1997XT06600020
J	Spitzer, NC; Sejnowski, TJ				Spitzer, NC; Sejnowski, TJ			Computational biology - Biological information processing: Bits of progress	SCIENCE			English	Editorial Material							MECHANISM		UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	University of California System; University of California San Diego; Howard Hughes Medical Institute; Salk Institute	Spitzer, NC (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Sejnowski, Terrence/AAV-5558-2021	Spitzer, Nicholas/0000-0002-3523-1103				ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bezrukov SM, 1997, NATURE, V385, P319, DOI 10.1038/385319a0; BRABANT G, 1997, INT C BIOL INF PROC; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hartwell L, 1997, NATURE, V387, P855, DOI 10.1038/43072; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Prank K, 1996, BIOPHYS J, V70, P2540, DOI 10.1016/S0006-3495(96)79825-9; REINITZ J, 1995, MECH DEVELOP, V49, P133, DOI 10.1016/0925-4773(94)00310-J; Rieke F., 1997, SPIKES EXPLORING NEU	15	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1060	1061		10.1126/science.277.5329.1060	http://dx.doi.org/10.1126/science.277.5329.1060			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9289851				2022-12-24	WOS:A1997XT03300023
J	DiPrisco, GV; Pearlstein, E; Robitaille, R; Dubuc, R				DiPrisco, GV; Pearlstein, E; Robitaille, R; Dubuc, R			Role of sensory-evoked NMDA plateau potentials in the initiation of locomotion	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; RETICULOSPINAL NEURONS; BRAIN-STEM; SPINAL-CORD; MEMBRANE-PROPERTIES; FICTIVE LOCOMOTION; SEA LAMPREY; ACTIVATION; RECEPTORS; NETWORK	Reticulospinal (RS) neurons constitute the main descending motor system of lampreys. This study reports an natural conditions whereby N-methyl-D-aspartate (NMDA)-mediated plateau potentials were elicited and associated with the onset of locomotion. Reticulospinal neurons responded in a linear fashion to mild skin stimulation. With stronger stimuli, large depolarizing plateaus with spiking activity were elicited and were accompanied by swimming movements, Calcium imaging revealed sustained intracellular calcium rise upon sensory stimulation. Blocking NMDA receptors on RS neurons prevented the plateau potentials as well as the associated rise in intracellular calcium. Thus, the activation of NMDA receptors mediates a switch from sensory-reception mode to a motor command mode in RS neurons.	UNIV QUEBEC, DEPT KINANTHROPOL, MONTREAL, PQ H3C 3P8, CANADA; UNIV MONTREAL, DEPT PHYSIOL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA	University of Quebec; University of Quebec Montreal; Universite de Montreal			Pearlstein, Edouard/P-4616-2016	Pearlstein, Edouard/0000-0001-9405-5667; Robitaille, Richard/0000-0001-6628-0146				BOWERMAN RF, 1976, COMP BIOCHEM PHYS A, V54, P1, DOI 10.1016/S0300-9629(76)80061-8; BRODIN L, 1985, BRAIN RES, V360, P139, DOI 10.1016/0006-8993(85)91229-6; BRODIN L, 1988, ARCH ITAL BIOL, V126, P317; Brodin L, 1990, PREPARATIONS VERTEBR, P103; BUCHANAN JT, 1987, BRAIN RES, V408, P321, DOI 10.1016/0006-8993(87)90397-0; CAZALETS JR, 1992, J PHYSIOL-LONDON, V455, P187, DOI 10.1113/jphysiol.1992.sp019296; CURRIE SN, 1983, BRAIN RES, V279, P238, DOI 10.1016/0006-8993(83)90183-X; DAVIS WJ, 1976, IDENTIFIED NEURONS B, P293; DELIAGINA TG, 1993, EXP BRAIN RES, V95, P421; DELIAGINA TG, 1995, J EXP BIOL, V198, P2581; DIPRISCO GV, 1995, BRAIN RES, V695, P76, DOI 10.1016/0006-8993(95)00936-K; DOUGLAS JR, 1993, J NEUROSCI, V13, P990; Drew T, 1996, EXP BRAIN RES, V111, P153; DUBUC R, 1993, J COMP NEUROL, V327, P251, DOI 10.1002/cne.903270207; DUBUC R, 1993, J COMP NEUROL, V327, P260, DOI 10.1002/cne.903270208; EATON RC, 1991, BRAIN BEHAV EVOLUT, V37, P272, DOI 10.1159/000114365; Frost WN, 1996, P NATL ACAD SCI USA, V93, P422, DOI 10.1073/pnas.93.1.422; GILLETTE R, 1978, SCIENCE, V199, P798, DOI 10.1126/science.622571; Grillner S, 1988, Adv Neurol, V47, P425; GRILLNER S, 1991, ANNU REV NEUROSCI, V14, P169, DOI 10.1146/annurev.neuro.14.1.169; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; HAGEVIK A, 1994, BRAIN RES, V636, P147, DOI 10.1016/0006-8993(94)90190-2; Hirschfeld H, 1997, J VESTIBUL RES-EQUIL, V7, P265, DOI 10.1016/S0957-4271(96)00180-2; KASICKI S, 1989, BRAIN RES, V484, P203, DOI 10.1016/0006-8993(89)90363-6; KOYAMA H, 1987, J COMP NEUROL, V264, P437, DOI 10.1002/cne.902640402; KUPFERMANN I, 1978, BEHAV BRAIN SCI, V1, P3, DOI 10.1017/S0140525X00059057; LETHBRIDGE RC, 1982, BIOL LAMPREYS, V3, P377; MCCLELLAN AD, 1984, BRAIN RES, V300, P357, DOI 10.1016/0006-8993(84)90846-1; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; MILNER KL, 1988, BRAIN RES, V452, P273, DOI 10.1016/0006-8993(88)90031-5; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; Nelson S B, 1992, Curr Opin Neurobiol, V2, P484, DOI 10.1016/0959-4388(92)90184-M; NIEUWENHUYS R, 1972, J COMP NEUROL, V145, P165, DOI 10.1002/cne.901450204; ODONOVAN MJ, 1993, J NEUROSCI METH, V46, P91, DOI 10.1016/0165-0270(93)90145-H; OHTA Y, 1989, J NEUROPHYSIOL, V62, P1079, DOI 10.1152/jn.1989.62.5.1079; OMalley DM, 1996, NEURON, V17, P1145, DOI 10.1016/S0896-6273(00)80246-9; ORLOVSKY GN, 1992, EXP BRAIN RES, V90, P479; PETERSON BW, 1971, BRAIN RES, V27, P373, DOI 10.1016/0006-8993(71)90264-2; RONAN M, 1989, J COMP NEUROL, V281, P54, DOI 10.1002/cne.902810106; Rossignol S, 1996, HDB PHYSL SECTION 12, P173; Rossignol SLJ, 1988, NEURAL CONTROL RHYTH, P201; ROVAINEN CM, 1967, J NEUROPHYSIOL, V30, P1000, DOI 10.1152/jn.1967.30.5.1000; ROVAINEN CM, 1982, BIOL LAMPREYS, P1; SALT TE, 1986, NATURE, V322, P263, DOI 10.1038/322263a0; SHIMAMURA M, 1983, BRAIN RES, V260, P27, DOI 10.1016/0006-8993(83)90761-8; SILLAR KT, 1994, EUR J MORPHOL, V32, P185; SIROTA M, 1995, CAN J PHYSL PHARM, V73; SWAIN GP, 1993, J COMP NEUROL, V336, P194, DOI 10.1002/cne.903360204; WALLEN P, 1987, J NEUROSCI, V7, P2745; WICKELGREN WO, 1977, J PHYSIOL-LONDON, V270, P89, DOI 10.1113/jphysiol.1977.sp011940; WIERSMA CAG, 1964, COMP BIOCHEM PHYSIOL, V12, P509, DOI 10.1016/0010-406X(64)90153-7; Zompa IC, 1996, BRAIN RES, V718, P221, DOI 10.1016/0006-8993(96)00131-X	52	107	107	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1122	1125		10.1126/science.278.5340.1122	http://dx.doi.org/10.1126/science.278.5340.1122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353193				2022-12-24	WOS:A1997YE65200052
J	OScalaidhe, SP; Wilson, FAW; GoldmanRakic, PS				OScalaidhe, SP; Wilson, FAW; GoldmanRakic, PS			Areal segregation of face-processing neurons in prefrontal cortex	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; RHESUS-MONKEY; VISUAL PATHWAYS; MACAQUE MONKEY; UNIT-ACTIVITY; FRONTAL-LOBE; PARIETAL; MEMORY; ORGANIZATION; SUBDIVISIONS	A central issue in cognitive neuroscience concerns the functional architecture of the prefrontal cortex and the degree to which it is organized by sensory domain. To examine this issue, multiple areas of the macaque monkey prefrontal cortex were mapped for selective responses to visual stimuli that are prototypical of the brain's object vision pathway-pictorial representations of faces. Prefrontal neurons not only selectively process information related to the identity of faces but, importantly, such neurons are localized to a remarkably restricted area. These findings suggest that the prefrontal cortex is functionally compartmentalized with respect to the nature of its inputs.			OScalaidhe, SP (corresponding author), YALE UNIV,SCH MED,NEUROBIOL SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038546, R37MH038546, P50MH044866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH44866, MH38546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; BARBAS H, 1985, NEUROSCIENCE, V15, P619, DOI 10.1016/0306-4522(85)90064-8; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BATES JF, 1995, SOC NEUR ABSTR, V21, P1054; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; Bullier J, 1996, BEHAV BRAIN RES, V76, P89, DOI 10.1016/0166-4328(95)00182-4; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; COURTNEY SM, 1996, CEREB CORTEX, V6, P1047; DESIMONE R, 1979, BRAIN RES, V178, P363, DOI 10.1016/0006-8993(79)90699-1; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1994, J NEUROSCI, V14, P6171; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; GOLDMAN PS, 1970, EXP NEUROL, V27, P291, DOI 10.1016/0014-4886(70)90222-0; GROSS CG, 1962, EXP NEUROL, V5, P453, DOI 10.1016/0014-4886(62)90057-2; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; JACOBSON S, 1977, BRAIN RES, V132, P209, DOI 10.1016/0006-8993(77)90417-6; KAWAMURA K, 1984, Neuroscience Research, V1, P89, DOI 10.1016/S0168-0102(84)80007-3; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; MACPHERSON JM, 1979, BRAIN RES, V175, P183, DOI 10.1016/0006-8993(79)90530-4; McCarthy G, 1996, CEREB CORTEX, V6, P600, DOI 10.1093/cercor/6.4.600; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; MISHKIN M, 1978, BRAIN RES, V143, P313, DOI 10.1016/0006-8993(78)90571-1; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; OWEN AM, 1997, TRNEDS COGN NEUROSCI, V4, P123; PASSINGHAM R, 1975, BRAIN RES, V92, P89, DOI 10.1016/0006-8993(75)90529-6; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PIGAREV IN, 1979, NEUROSCI LETT, V12, P207, DOI 10.1016/0304-3940(79)96063-4; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; ROBINSON CJ, 1980, J COMP NEUROL, V192, P69, DOI 10.1002/cne.901920105; RODMAN HR, 1993, J NEUROPHYSIOL, V70, P1115, DOI 10.1152/jn.1993.70.3.1115; RODMAN HR, 1994, CEREB CORTEX, V5, P484; ROLLS ET, 1986, EXP BRAIN RES, V65, P38; SARY G, 1993, SCIENCE, V260, P995, DOI 10.1126/science.8493538; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; Sereno A. B., 1997, Society for Neuroscience Abstracts, V23, P302; Sereno A. B., 1995, Society for Neuroscience Abstracts, V21, P282; SUZUKI H, 1983, EXP BRAIN RES, V53, P47; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; WEBSTER MJ, 1994, CEREB CORTEX, V5, P470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	45	256	258	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1135	1138		10.1126/science.278.5340.1135	http://dx.doi.org/10.1126/science.278.5340.1135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353197				2022-12-24	WOS:A1997YE65200056
J	Burt, RA				Burt, RA			The Supreme Court speaks - Not assisted suicide but a constitutional right to palliative care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Burt, RA (corresponding author), YALE UNIV,SCH LAW,NEW HAVEN,CT 06520, USA.							Cherny N I, 1994, J Palliat Care, V10, P31; *INST MED, 1997, APPR DEATH IMPR CAR, P10; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; Pisano DJ, 1996, J LAW MED ETHICS, V24, P310, DOI 10.1111/j.1748-720X.1996.tb01872.x; Portenoy RK, 1996, J LAW MED ETHICS, V24, P296, DOI 10.1111/j.1748-720X.1996.tb01871.x	5	125	125	3	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1234	1236		10.1056/NEJM199710233371712	http://dx.doi.org/10.1056/NEJM199710233371712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9337388				2022-12-24	WOS:A1997YB71800012
J	Lim, H; Paria, BC; Das, SK; Dinchuk, JE; Langenbach, R; Trzaskos, JM; Dey, SK				Lim, H; Paria, BC; Das, SK; Dinchuk, JE; Langenbach, R; Trzaskos, JM; Dey, SK			Multiple female reproductive failures in cyclooxygenase 2-deficient mice	CELL			English	Article							DECIDUAL CELL REACTION; MOUSE UTERUS; SELECTIVE-INHIBITION; BLASTOCYST IMPLANTATION; PREOVULATORY FOLLICLES; OVARIAN-STEROIDS; GENE DISRUPTION; H SYNTHASE-1; EXPRESSION; RAT	Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins (PGs) and exists in two isoforms, COX-1 and COX-2. In spite of long-standing speculation, definitive roles of PGs in various events of early pregnancy remain elusive. We demonstrate herein that the targeted disruption of COX-2, but not COX-1, in mice produces multiple failures in female reproductive processes that include ovulation, fertilization, implantation, and decidualization. Using multiple approaches, we conclude that these defects are the direct result of target organ-specific COX-2 deficiency but are not the result of deficiency of pituitary gonadotropins or ovarian steroid hormones, or reduced responsiveness of the target organs to their respective hormones.	UNIV KANSAS, MED CTR, DEPT MOL & INTEGRAT PHYSIOL, KANSAS CITY, KS 66160 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; NIEHS, LAB EXPT CARCINOGENESIS & MUTAGENESIS, RES TRIANGLE PK, NC 27709 USA	University of Kansas; University of Kansas Medical Center; DuPont; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X	NICHD NIH HHS [HD 12304, HD 33994, HD 29968] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD029968, R01HD012304, R37HD012304] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Benson GV, 1996, DEVELOPMENT, V122, P2687; Chakraborty I, 1996, J MOL ENDOCRINOL, V16, P107, DOI 10.1677/jme.0.0160107; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DAS SK, 1994, DEVELOPMENT, V120, P1071; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; Dey SK, 1996, REPROD ENDOCRINOLOGY, V1, P421; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; EPPIG JJ, 1991, BIOESSAYS, V13, P569, DOI 10.1002/bies.950131105; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; KENNEDY TG, 1985, BIOL REPROD, V33, P140, DOI 10.1095/biolreprod33.1.140; KENNEDY TG, 1983, BIOL REPROD, V29, P1069, DOI 10.1095/biolreprod29.5.1069; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIM H, 1997, IN PRESS ENDOCRINOLO; MCMASTER MT, 1993, J REPROD FERTIL, V99, P561, DOI 10.1530/jrf.0.0990561; MCMASTER MT, 1992, MOL ENDOCRINOL, V6, P101, DOI 10.1210/me.6.1.101; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; PETERSON JW, 1996, MOL CELL BIOL, V64, P2137; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PINTO DJ, 1995, MED CHEM RES, V5, P394; PSYCHOYOS A, 1973, HDB PHYSL, P187; RANKIN JC, 1977, BIOL REPROD, V17, P549, DOI 10.1095/biolreprod17.4.549; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; SATOKATA I, 1995, NATURE, V374, P460, DOI 10.1038/374460a0; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TSAFRIRI A, 1996, REPROD ENDOCRINOLOGY, P235; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WHITTEN WK, 1968, J REPROD FERTIL, V17, P399, DOI 10.1530/jrf.0.0170399; WORDINGER RJ, 1986, J REPROD FERTIL, V77, P471, DOI 10.1530/jrf.0.0770471; Yang ZM, 1997, BIOL REPROD, V56, P368, DOI 10.1095/biolreprod56.2.368; YOSHINAG.K, 1966, J REPROD FERTIL, V12, P593, DOI 10.1530/jrf.0.0120593	54	1141	1188	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					197	208		10.1016/S0092-8674(00)80402-X	http://dx.doi.org/10.1016/S0092-8674(00)80402-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346237				2022-12-24	WOS:A1997YC35000007
J	Boshoff, C; Endo, Y; Collins, PD; Takeuchi, Y; Reeves, JD; Schweickart, VL; Siani, MA; Sasaki, T; Williams, TJ; Gray, PW; Moore, PS; Chang, Y; Weiss, RA				Boshoff, C; Endo, Y; Collins, PD; Takeuchi, Y; Reeves, JD; Schweickart, VL; Siani, MA; Sasaki, T; Williams, TJ; Gray, PW; Moore, PS; Chang, Y; Weiss, RA			Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; MULTICENTRIC CASTLEMANS DISEASE; KAPOSIS-SARCOMA; DNA-SEQUENCES; TAT PROTEIN; MOLECULAR-CLONING; GROWTH-FACTOR; C CHEMOKINE; CELLS; INFECTION	Unique among known human herpesviruses, Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) encodes chemokine-like proteins (vMIP-I and VMIP-II). VMIP-II was shown to block infection of human immunodeficiency virus-type 1 (HIV-1) on a CD4-positive cell line expressing CCR3 and to a lesser extent on one expressing CCR5, whereas both vMIP-I and VMIP-II partially inhibited HIV infection of peripheral blood mononuclear cells. Like eotaxin, VMIP-II activated and chemoattracted human eosinophils by way of CCR3. vMIP-I and VMIP-II, but not cellular MIP-1 alpha or RANTES, were highly angiogenic in the chorioallantoic assay, suggesting a possible pathogenic role in Kaposi's sarcoma.	KANAZAWA UNIV,DEPT EXPT THERAPEUT,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEV CTR MOL TARGET DRUGS,CANC RES INST,KANAZAWA,ISHIKAWA 920,JAPAN; NATL HEART & LUNG INST,IMPERIAL COLL SCH MED,DEPT APPL PHARMACOL,LONDON SW3 6LY,ENGLAND; ICOS,BOTHELL,WA 98021; GRYPHON SCI,SAN FRANCISCO,CA 94080; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL & EPIDEMIOL,NEW YORK,NY 10032	Kanazawa University; Kanazawa University; Imperial College London; Icos Corporation; Columbia University	Boshoff, C (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND.		Chang, Yuan/F-4146-2011; Reeves, Jacqueline/I-5379-2012; Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011; ENDO, Yoshio/D-8428-2015	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; ENDO, Yoshio/0000-0003-0785-2006	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67391] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Angiolillo AL, 1996, ANN NY ACAD SCI, V795, P158, DOI 10.1111/j.1749-6632.1996.tb52664.x; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P761; BOSHOFF C, UNPUB; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Chadburn A, 1997, CANCER-AM CANCER SOC, V80, P788, DOI 10.1002/(SICI)1097-0142(19970815)80:4&lt;788::AID-CNCR18&gt;3.0.CO;2-P; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Danesi R, 1997, CLIN CANCER RES, V3, P265; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DUPIN N, 1995, NEW ENGL J MED, V333, P798; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gessain A, 1996, BLOOD, V87, P414; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KNIGHTON D, 1977, BRIT J CANCER, V35, P347, DOI 10.1038/bjc.1977.49; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MCKNIGHT A, 1994, VIROLOGY, V201, P8, DOI 10.1006/viro.1994.1260; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOSER B, 1993, J BIOL CHEM, V268, P7125; Murphy PM, 1997, NATURE, V385, P296, DOI 10.1038/385296a0; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OIKAWA T, 1991, CANCER LETT, V59, P57, DOI 10.1016/0304-3835(91)90136-6; ORENSTEIN JM, 1997, J ACQ IMMUN DEF SYND, V11, P735; PARRAVICINI C, IN PRES AM J PATHOL; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; WAHMAN A, 1991, EPIDEMIOL REV, V13, P178, DOI 10.1093/oxfordjournals.epirev.a036068; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; YOSHIZAKI K, 1989, BLOOD, V74, P1360	59	395	423	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					290	294		10.1126/science.278.5336.290	http://dx.doi.org/10.1126/science.278.5336.290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323208				2022-12-24	WOS:A1997YA56400045
J	Howard, J				Howard, J			Molecular motors: structural adaptations to cellular functions	NATURE			English	Review							MICROTUBULE-ACTIVATED ATPASE; SINGLE KINESIN MOLECULES; SKINNED MUSCLE-FIBERS; MYOSIN POWER STROKE; ACTIN-FILAMENTS; CONTRACTING MUSCLE; IN-VITRO; SMOOTH-MUSCLE; ADP RELEASE; CRYOELECTRON MICROSCOPY	Molecular motors are protein machines whose directed movement along cytoskeletal filaments is driven by ATP hydrolysis. Eukaryotic cells contain motors that help to transport organelles to their correct cellular locations and to establish and alter cellular morphology during cell locomotion and division. The best-studied motors, myosin from skeletal muscle and conventional kinesin from brain, are remarkably similar in structure, yet have very different functions. These differences can be understood in terms of the 'duty ratio', the fraction of the time that a motor Is attached to its filament. Differences in duty ratio can explain the diversity of structures, speeds and oligomerization states of members of the large kinesin, myosin and dynein families of motors.			Howard, J (corresponding author), UNIV WASHINGTON, DEPT PHYSIOL & BIOPHYS, BOX 357290, SEATTLE, WA 98195 USA.		Howard, Jonathon/D-4229-2011; Howard, Jonathon/J-7492-2016	Howard, Jonathon/0000-0003-0086-1196; Howard, Jonathon/0000-0003-0086-1196				Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; Bahler M, 1996, CURR OPIN CELL BIOL, V8, P18, DOI 10.1016/S0955-0674(96)80043-3; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BLOCK SM, 1995, NATURE, V378, P132, DOI 10.1038/378132a0; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRENNEN C, 1977, ANNU REV FLUID MECH, V9, P339, DOI 10.1146/annurev.fl.09.010177.002011; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHEN YD, 1993, P NATL ACAD SCI USA, V90, P5148, DOI 10.1073/pnas.90.11.5148; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; CREVEL IMT, IN PRESS J MOL BIOL; DILLON PF, 1982, CIRC RES, V50, P799, DOI 10.1161/01.RES.50.6.799; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FERENCZI MA, 1984, J PHYSIOL-LONDON, V350, P519, DOI 10.1113/jphysiol.1984.sp015216; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FORD LE, 1985, J PHYSIOL-LONDON, V361, P131, DOI 10.1113/jphysiol.1985.sp015637; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GIBBONS BH, 1994, MOL BIOL CELL, V5, P57, DOI 10.1091/mbc.5.1.57; GILLESPIE PG, 1995, CURR OPIN NEUROBIOL, V5, P449, DOI 10.1016/0959-4388(95)80004-2; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hamasaki T, 1995, BIOPHYS J, V69, P2569, DOI 10.1016/S0006-3495(95)80128-1; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Hille B., 1992, IONIC CHANNELS EXCIT; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Huxley AF, 1996, J MUSCLE RES CELL M, V17, P507, DOI 10.1007/BF00123366; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1994, BIOPHYS J, V67, P2411, DOI 10.1016/S0006-3495(94)80728-3; HUXLEY HE, 1965, SCI AM, V213, P18, DOI 10.1038/scientificamerican1265-18; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KOJIMA H, 1994, P NATL ACAD SCI USA, V91, P12962, DOI 10.1073/pnas.91.26.12962; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; MOLLOY JE, 1995, BIOPHYS J, V68, pS298; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RIVOLTA MN, 1995, BBA-BIOENERGETICS, V1232, P1, DOI 10.1016/0005-2728(95)00107-1; SANGER JM, 1990, CELL MOTIL CYTOSKE S, V2; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Suzuki N, 1996, BIOPHYS J, V70, P401, DOI 10.1016/S0006-3495(96)79583-8; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; WADE RH, 1993, J STRUCT BIOL, V110, P1, DOI 10.1006/jsbi.1993.1001; WAKABAYASHI K, 1994, BIOPHYS J, V67, P2422, DOI 10.1016/S0006-3495(94)80729-5; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; YOKOTA E, 1994, J CELL SCI, V107, P353; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	88	435	438	2	111	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 9	1997	389	6651					561	567		10.1038/39247	http://dx.doi.org/10.1038/39247			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335494				2022-12-24	WOS:A1997YA00800048
J	Taddei, F; Hayakawa, H; Bouton, MF; Cirinesi, AM; Matic, I; Sekiguchi, M; Radman, M				Taddei, F; Hayakawa, H; Bouton, MF; Cirinesi, AM; Matic, I; Sekiguchi, M; Radman, M			Counteraction by MutT protein of transcriptional errors caused by oxidative damage	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; MUTATIONS; CLONING; CDNA; SUBSTITUTIONS; TRANSLATION; REPLICATION; ELIMINATION	Oxidized guanine (8-oxo-7,8-dihydroguanine; 8-oxo-G) is a potent mutagen because of its ambiguous pairing with cytosine and adenine. The Escherichia coli MutT protein specifically hydrolyzes both 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) and 8-oxo-guanosine triphosphate (8-oxo-rGTP), which are otherwise incorporated in DNA and RNA opposite template A. In vivo, this cleaning of the nucleotide pools decreases both DNA replication and transcription errors. The effect of mutT mutation on transcription fidelity was shown to depend on oxidative metabolism Such control of transcriptional fidelity by the ubiquitous MutT function has implications for evolution of RNA-based life, phenotypic expression, adaptive mutagenesis, and functional maintenance of nondividing cells.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN; FUKUOKA DENT COLL,DEPT BIOL,FUKUOKA 81401,JAPAN; INST JACQUES MONOD,F-75251 PARIS 05,FRANCE	Kyushu University; Fukuoka Dental College (FDC); UDICE-French Research Universities; Universite Paris Cite			; Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0002-7034-4365; Radman, Miroslav/0000-0003-0216-3148				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES BA, 1995, NATURE, V375, P741, DOI 10.1038/375741a0; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; CUPPLES CG, 1988, GENETICS, V120, P637; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; Galitski T, 1996, GENETICS, V143, P645; GALLANT J, 1979, MECH AGEING DEV, V10, P27, DOI 10.1016/0047-6374(79)90068-X; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; HAYAKAWA H, 1997, UNPUB; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Miller J.H., 1972, EXPT MOL GENETICS; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NINIO J, 1991, BIOCHIMIE, V73, P1517, DOI 10.1016/0300-9084(91)90186-5; NINIO J, 1991, GENETICS, V129, P957; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; RADMAN M, 1973, PHYSICOCHEMICAL PROP, V3, P161; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; TADDEI F, UNPUB; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	29	244	250	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					128	130		10.1126/science.278.5335.128	http://dx.doi.org/10.1126/science.278.5335.128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311918				2022-12-24	WOS:A1997XZ12400054
J	Yu, SP; Yeh, CH; Sensi, SL; Gwag, BJ; Canzoniero, LMT; Farhangrazi, ZS; Ying, HS; Tian, M; Dugan, LL; Choi, DW				Yu, SP; Yeh, CH; Sensi, SL; Gwag, BJ; Canzoniero, LMT; Farhangrazi, ZS; Ying, HS; Tian, M; Dugan, LL; Choi, DW			Mediation of neuronal apoptosis by enhancement of outward potassium current	SCIENCE			English	Article							IONOPHORE-INDUCED APOPTOSIS; CEREBELLAR GRANULE CELLS; RAT CORTICAL-NEURONS; INTRACELLULAR CALCIUM; K+-CHANNELS; HIPPOCAMPAL-NEURONS; DNA FRAGMENTATION; NERVOUS-SYSTEM; LYMPHOCYTE-T; CA2+ INFLUX	Apoptosis of mouse neocortical neurons induced by serum deprivation or by staurosporine was associated with an early enhancement of delayed rectifier (I-K) current and loss of total intracellular K+. This I-K augmentation was not seen in neurons undergoing excitotoxic necrosis or in older neurons resistant to staurosporine-induced apoptosis. Attenuating outward K+ current with tetraethylammonium or elevated extracellular K+, but not blockers of Ca2+, Cl-, or other K+ channels, reduced apoptosis, even if associated increases in intracellular Ca2+ concentration were prevented. Furthermore, exposure to the K+ ionophore valinomycin or the K+-channel opener cromakalim induced apoptosis. Enhanced K+ efflux may mediate certain forms of neuronal apoptosis.	WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR STUDY NERVOUS SYST INJURY, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Sensi, Stefano L./J-3164-2016; Sensi, Stefano L./O-1335-2019	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; CANZONIERO, Lorella Maria Teresa/0000-0003-2255-5341	PHS HHS [30337] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams P R, 1986, Adv Neurol, V44, P137; ALLBRITTON NL, 1988, J EXP MED, V167, P514, DOI 10.1084/jem.167.2.514; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; BEHRENS MI, UNPUB; BENNETT MR, 1979, BRAIN RES, V173, P549, DOI 10.1016/0006-8993(79)90250-6; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COLLINS F, 1991, J NEUROSCI, V11, P2582; CONE CD, 1976, SCIENCE, V192, P155, DOI 10.1126/science.56781; DECKERS CLP, 1993, EXP CELL RES, V208, P362, DOI 10.1006/excr.1993.1257; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; deLuca A, 1996, J NEUROSCI, V16, P4174; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ENOKIDO Y, 1993, NEUROSCIENCE, V57, P965, DOI 10.1016/0306-4522(93)90041-D; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HILLE B, 1967, J GEN PHYSIOL, V50, P1287, DOI 10.1085/jgp.50.5.1287; JOHNSON EM, 1992, EXP NEUROL, V115, P163, DOI 10.1016/0014-4886(92)90242-I; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KONISHI T, 1989, J PHYSIOL-LONDON, V411, P115, DOI 10.1113/jphysiol.1989.sp017564; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAMPE PA, 1995, J NEUROBIOL, V26, P205, DOI 10.1002/neu.480260205; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCDONALD JW, IN PRESS BRAIN RES; MURRELL RD, 1993, EUR J NEUROSCI, V5, P1261, DOI 10.1111/j.1460-9568.1993.tb00911.x; NEHER E, 1972, PFLUG ARCH EUR J PHY, V336, P87, DOI 10.1007/BF00592924; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; POLITI DMT, 1989, EUR J PHARMACOL, V168, P7, DOI 10.1016/0014-2999(89)90626-2; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Rose Kamala, 1993, P46; ROUZAIREDUBOIS B, 1991, CELL SIGNAL, V3, P333, DOI 10.1016/0898-6568(91)90062-Y; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SANCHEZ DY, 1992, J GEN PHYSIOL, V100, P217, DOI 10.1085/jgp.100.2.217; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UCKER DS, 1991, NEW BIOL, V3, P103; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x	51	515	551	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					114	117		10.1126/science.278.5335.114	http://dx.doi.org/10.1126/science.278.5335.114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311914				2022-12-24	WOS:A1997XZ12400050
J	Valdivia, RH; Falkow, S				Valdivia, RH; Falkow, S			Fluorescence-based isolation of bacterial genes expressed within host cells	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM VIRULENCE; ESCHERICHIA-COLI; IDENTIFICATION; SELECTION; SECRETION; MACROPHAGES; AVIRULENT; PROTEINS; MUTANTS; SURVIVE	A selection strategy was devised to identify bacterial genes preferentially expressed when a bacterium associates with its host cell. Fourteen Salmonella typhimurium genes, which were under the control of at least four independent regulatory circuits, were identified to be selectively induced in host macrophages. Four genes encode virulence factors, including a component of a type III secretory apparatus. This selection methodology should be generally applicable to the identification of genes from pathogenic organisms that are induced upon association with host cells or tissues.			Valdivia, RH (corresponding author), STANFORD UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, STANFORD, CA 94305 USA.		Valdivia, Raphael/R-5377-2019	Valdivia, Raphael/0000-0003-0961-073X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26195] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAOUI A, 1992, J BACTERIOL, V174, P7661, DOI 10.1128/JB.174.23.7661-7669.1992; ALLAOUI A, 1995, MOL MICROBIOL, V18, P343, DOI 10.1111/j.1365-2958.1995.mmi_18020343.x; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DELPORTILLO FG, 1992, MOL MICROBIOL, V6, P3289; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GULIG PA, 1987, INFECT IMMUN, V55, P2891, DOI 10.1128/IAI.55.12.2891-2901.1987; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; GULIG PA, 1996, ESCHERICHIA COLI SAL, V2, P2774; Hensel M, 1997, MOL MICROBIOL, V24, P155, DOI 10.1046/j.1365-2958.1997.3271699.x; HORWITZ MA, 1987, J EXP MED, V166, P1310, DOI 10.1084/jem.166.5.1310; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Mahan MJ, 1996, ESCHERICHIA COLI SAL, P2803; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; RHEN M, 1988, MICROB PATHOGENESIS, V5, P275, DOI 10.1016/0882-4010(88)90100-3; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; VALDIVIA RH, UNPUB; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16	33	488	515	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					2007	2011		10.1126/science.277.5334.2007	http://dx.doi.org/10.1126/science.277.5334.2007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302299				2022-12-24	WOS:A1997XX84900049
J	Seretakis, D; Lagiou, P; Lipworth, L; Signorello, LB; Rothman, KJ; Trichopoulos, D				Seretakis, D; Lagiou, P; Lipworth, L; Signorello, LB; Rothman, KJ; Trichopoulos, D			Changing seasonality of mortality from coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR MORTALITY; TEMPERATURE; DECLINE	Context.-Coronary heart disease is the major cause of mortality in the United States. Factors associated with coronary risk are important to identify, Coronary mortality is greater during the winter months. Objective.-To investigate whether declining coronary mortality has been accompanied by a change in the seasonal pattern and to investigate the hypothesis that diminishing exposures to environmental cold and heat have affected the seasonal pattern. Design.-We used published data on coronary mortality by year to evaluate the time trend in the seasonal pattern, We fit a sine curve to the monthly frequency of deaths in each year and examined the trend over time in the ratio of the peak to the trough of the curve. Setting.-We used monthly coronary deaths in the United States from 1937 through 1991. Deaths by cause and month were not available by geographic area within the United States, but we were able to examine total monthly deaths in 2 regions with contrasting climates, New England and the South. Outcome Measures.-We used the yearly peak-to-trough ratio as our primary outcome and assessed its trend over time by linear regression, We also depicted the time trends using polynomial smoothing. Results.-The peak-to-trough ratio diminished by about 2% per year until around 1970, when the trend reversed. In New England, the decline was steeper than in the South, as measured from all deaths. Conclusion.-Seasonal patterns in coronary mortality in the United States have changed with time, These changes are compatible with the gradual expansion of adequate heating and the subsequent increased use of air-conditioning. Microclimatic influences on coronary mortality could explain in part the socioeconomic gradient of cardiovascular mortality.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BOSTON UNIV, MED CTR, DEPT EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, MED CTR, SECT PREVENT MED, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University				Rothman, Kenneth/0000-0003-2398-1705				EDWARDS JH, 1961, ANN HUM GENET, V25, P83, DOI 10.1111/j.1469-1809.1961.tb01501.x; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; KATSOUYANNI K, 1988, LANCET, V2, P573; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; LLOYD OL, 1995, BRIT MED J, V310, P467, DOI 10.1136/bmj.310.6977.467; MARMOT MG, 1986, LANCET, V2, P274; *NAT CTR HLTH STAT, 1937, VIT STAT US; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; U. S. Bureau of the Census, 1996, STAT ABSTR US; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029	12	92	96	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1012	1014		10.1001/jama.278.12.1012	http://dx.doi.org/10.1001/jama.278.12.1012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307350				2022-12-24	WOS:A1997XX01200033
J	Engel, MH; Macko, SA				Engel, MH; Macko, SA			Isotopic evidence for extraterrestrial non-racemic amino acids in the Murchison meteorite	NATURE			English	Article							ORGANIC-MOLECULES; MASS-SPECTROMETRY; CARBON; LIFE; HYDROCARBONS; ENANTIOMERS; EARTH; CHIRALITY; DELIVERY; ORIGINS	Many amino acids contain an asymmetric centre, occurring as laevorotatory, L, or dextrorotatory, D, compounds. It is generally assumed that abiotic synthesis of amino acids on the early Earth resulted in racemic mixtures (L-and D-enantiomers in equal abundance). But the origin of life required, owing to conformational constraints, the almost exclusive selection of either L-or D-enantiomers(1,2), and the question of why living-systems on the Earth consist of L-enantiomers rather than D-enantiomers is unresolved(3). A substantial fraction of the organic compounds on the early Earth may have been derived from comet and meteorite impacts(4-6). It has been reported previously that amino acids in the Murchison meteorite exhibit an excess of L-enantiomers(7), raising the possibility that a similar excess was present in the initial inventory of organic compounds on the Earth. The stable carbon isotope compositions of individual amino acids in Murchison support an extraterrestrial origin(8)-rather than a terrestrial overprint of biological amino acids-although reservations have persisted (see, for example, ref. 9). Here we show that individual amino-acid enantiomers from Murchison are enriched in N-15 relative to their terrestrial counterparts, so confirming an extraterrestrial source for an L-enantiomer excess in the Solar System that may predate the origin of life on the Earth.	UNIV VIRGINIA, DEPT ENVIRONM SCI, CHARLOTTESVILLE, VA 22903 USA	University of Virginia	Engel, MH (corresponding author), UNIV OKLAHOMA, SCH GEOL & GEOPHYS, NORMAN, OK 73019 USA.		Macko, Stephen/K-4588-2015					BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; COHEN J, 1995, SCIENCE, V267, P1265, DOI 10.1126/science.7871419; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; ENGEL MH, 1994, P NATL ACAD SCI USA, V91, P10475, DOI 10.1073/pnas.91.22.10475; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; ENGEL MH, 1990, NATURE, V348, P47, DOI 10.1038/348047a0; ENGEL MH, 1993, ORGANIC GEOCHEMISTRY, P685; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; Fogel M.L., 1993, ORGANIC GEOCHEMISTRY, P73, DOI DOI 10.1007/978-1-4615-2890-6_3; GILMOUR I, 1992, METEORITICS, V27, P224; GOLDANSKII VI, 1991, NATURE, V352, P114, DOI 10.1038/352114a0; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; HARE PE, 1985, CHEM BIOCH AMINO ACI, P415; HOPPE P, 1995, GEOCHIM COSMOCHIM AC, V59, P4029, DOI 10.1016/0016-7037(95)00280-D; KIEFFER HH, 1992, MARS, P1; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; Macko SA, 1997, ANAL CHEM, V69, P926, DOI 10.1021/ac960956l; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MERRITT DA, 1994, J AM SOC MASS SPECTR, V5, P387, DOI 10.1016/1044-0305(94)85054-2; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; ORO J, 1961, NATURE, V190, P389, DOI 10.1038/190389a0; PIZZARELLO S, 1994, GEOCHIM COSMOCHIM AC, V58, P5579, DOI 10.1016/0016-7037(94)90251-8; PIZZARELLO S, 1991, GEOCHIM COSMOCHIM AC, V55, P905, DOI 10.1016/0016-7037(91)90350-E; SHOCK EL, 1990, GEOCHIM COSMOCHIM AC, V54, P3159, DOI 10.1016/0016-7037(90)90131-4; SILFER JA, 1991, ANAL CHEM, V63, P370, DOI 10.1021/ac00004a014; SILFER JA, 1994, ORG GEOCHEM, V21, P603, DOI 10.1016/0146-6380(94)90006-X; SILFER JA, 1991, THESIS U OKLAHOMA; VALLENTYNE JR, 1964, GEOCHIM COSMOCHIM AC, V28, P157, DOI 10.1016/0016-7037(64)90147-4; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	32	386	391	4	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					265	268		10.1038/38460	http://dx.doi.org/10.1038/38460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305838				2022-12-24	WOS:A1997XW77200041
J	Polyak, K; Xia, Y; Zweier, JL; Kinzler, KW; Vogelstein, B				Polyak, K; Xia, Y; Zweier, JL; Kinzler, KW; Vogelstein, B			A model for p53-induced apoptosis	NATURE			English	Article							CELL-DEATH; GENE; P53; IDENTIFICATION; EXPRESSION	The inactivation of the p53 gene in a large proportion of human cancers has inspired an intense search for the encoded protein's physiological and biological properties. Expression of p53 induces either a stable growth arrest or programmed cell death (apoptosis). In human colorectal cancers, the growth arrest is dependent on the transcriptional induction of the protein p21(WAF1/CIP1) (ref. 1), but the mechanisms underlying the development of p53-dependent apoptosis are largely unknown(2). As the most well documented biochemical property of p53 is its ability to activate transcription of genes, we examined in detail the transcripts induced by p53 expression before the onset of apoptosis. Of 7,202 transcripts identified, only 14 (0.19%) were found to be markedly increased in p53-expressing cells compared with control cells. Strikingly, many of these genes were predicted to encode proteins that could generate or respond to oxidative stress, including one that is implicated in apoptosis in plant meristems, These observations stimulated additional biochemical and pharmacological experiments suggesting that p53 results in apoptosis through a three-step process: (1) the transcriptional induction of redox-related genes; (2) the formation of reactive oxygen species; and (3) the oxidative degradation of mitochondrial components, culminating in cell death.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University			Pillay, Nischalan/F-9536-2012					BOREK C, 1987, British Journal of Cancer, V55, P74; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; HAYWARD DC, 1993, P NATL ACAD SCI USA, V90, P2979, DOI 10.1073/pnas.90.7.2979; HOLLAND PC, 1973, J BIOL CHEM, V248, P6050; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KREOMER G, 1997, IMMUNOL TODAY, V18, P45; Lehar SM, 1996, ONCOGENE, V12, P1181; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAO PV, 1992, J BIOL CHEM, V267, P96; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAMM I, 1978, ADV VIRUS RES, V22, P188; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WALDMAN T, 1995, CANCER RES, V55, P5187; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	29	2174	2274	3	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					300	305		10.1038/38525	http://dx.doi.org/10.1038/38525			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305847				2022-12-24	WOS:A1997XW77200052
J	Feeney, M; Clegg, A; Winwood, P; Snook, J				Feeney, M; Clegg, A; Winwood, P; Snook, J			A case-control study of measles vaccination and inflammatory bowel disease	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; RISK FACTOR; VIRUS; INFECTION; ABSENCE	Background The cause of inflammatory bowel disease (IBD) remains to be established. Evidence has linked measles infection in early childhood with the subsequent risk of developing IBD, particularly Crohn's disease. A cohort study raised the possibility that immunisation with live attenuated measles vaccine, which induces active immunity to measles infection, might also predispose to the later development of IBD, provoking concerns about the safety of the vaccine. Method We report a case-control study of 140 patients with IBD (including 83 with Crohn's disease) born in or after 1968, and 280 controls matched for age, sex acid general practitioner (GP) area, designed to assess the influence of measles vaccination on later development of IBD. Documentary evidence of childhood vaccination history was sought from GP and community health records. Findings Crude measles vaccination rates were 56.4% in patients with IBD and 57.1% among controls. Matched odds ratios for measles vaccination were 1.08 (95% CI in patients with Crohn's disease, 0.84 in patients with ulcerative colitis, and 0.97 (0.64-1.47) in all patients with IBD. Interpretation These findings provide no support for the hypothesis that measles vaccination in childhood predisposes to the later development of either IBD overall or Crohn's disease in particular.	POOLE HOSP,DEPT GASTROENTEROL,POOLE BH15 2JB,DORSET,ENGLAND; ROYAL BOURNEMOUTH HOSP,DEPT GASTROENTEROL,BOURNEMOUTH,DORSET,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND	Poole Hospital; University of York - UK			Snook, Jonathon/AAK-3541-2020					BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; BAXTER T, 1995, LANCET, V345, P1363; Breslow N, 1980, STATISTICAL METHODS, V32; CALMAN KC, 1995, COMMUNICATION   0428; Cosgrove M, 1996, ARCH DIS CHILD, V74, P460, DOI 10.1136/adc.74.5.460; *DEP HLTH STAT DIV, KORN DAT VACC IMM; Ekbom A, 1996, LANCET, V348, P515, DOI 10.1016/S0140-6736(96)04429-7; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; FARRINGTON P, 1995, LANCET, V345, P1362, DOI 10.1016/S0140-6736(95)92559-7; GENT AE, 1994, LANCET, V343, P766, DOI 10.1016/S0140-6736(94)91841-4; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; Haga Y, 1996, GUT, V38, P211, DOI 10.1136/gut.38.2.211; HERMONTAYLOR JM, 1995, LANCET, V345, P922, DOI 10.1016/S0140-6736(95)90033-0; Hills, 1993, STAT MODELS EPIDEMIO; IIZUKA M, 1995, LANCET, V345, P199; Jones P, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61184-1; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; MACDONALD TT, 1995, LANCET, V345, P1363; MILLER C, 1987, BRIT MED J, V295, P22, DOI 10.1136/bmj.295.6589.22; PATRIARCA PA, 1995, LANCET, V345, P1062, DOI 10.1016/S0140-6736(95)90810-2; RIIS P, 1990, INFLAMMATORY BOWEL D; ROTHMANN K, 1986, MODERN EPIDEMIOLOGY; SALISBURY DM, 1996, IMMUNISATION INFECT, P125; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; THAYER WR, 1990, INFLAMMATORY BOWEL D; THOMPSON NP, 1995, EUR J GASTROEN HEPAT, V7, P385; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Thompson NP, 1996, LANCET, V347, P263, DOI 10.1016/S0140-6736(96)90438-9; Wickramaratne P J, 1995, Stat Methods Med Res, V4, P311, DOI 10.1177/096228029500400404	29	83	84	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					764	766		10.1016/S0140-6736(97)03192-9	http://dx.doi.org/10.1016/S0140-6736(97)03192-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297995				2022-12-24	WOS:A1997XW28200010
J	Chen, X; Weisberg, E; Fridmacher, V; Watanabe, M; Naco, G; Whitman, M				Chen, X; Weisberg, E; Fridmacher, V; Watanabe, M; Naco, G; Whitman, M			Smad4 and FAST-1 in the assembly of activin-responsive factor	NATURE			English	Article							MESODERM INDUCTION; MAD PROTEINS; BETA; RECEPTORS; FAMILY	Members of the TGF-beta superfamily of signalling molecules work by activating transmembrane receptors with phosphorylating activity (serine-threonine kinase receptors)(1); these in turn phosphorylate and activate(2) SMADs(3,4), a class of signal transducers. Activins are growth factors that act primarily through Smad2(5-7), possibly in partnership with Smad4, which forms heteromeric complexes with different ligand-specific SMADs after activation(8,9). In frog embryos, Smad2 participates in an activin-responsive factor (ARF), which then binds to a promoter element of the Mix.2 gene(10). The principal DNA-binding component of ARF is FAST-1 (ref. 11), a transcription factor with a novel winged-helix structure. We now report that Smad4 is present in ARF, and that FAST-1, Smad4 and Smad2 co-immunoprecipitate in a ligand-regulated fashion. We have mapped the site of interaction between FAST-1 and Smad2/Smad4 to a novel carboxyterminal domain of FAST-1, and find that overexpression of this domain specifically inhibits activin signalling. In a yeast two-hybrid assay,the FAST-1 carboxy terminus interacts with Smad2 but not Smad4. Deletion mutants of the FAST-1 carboxy terminus that still participate in ligand-regulated Smad2 binding no longer associated with Smad4 or ARF. These results indicate that Smad4 stabilizes a ligand-stimulated Smad2-FAST-1 complex as an active DNA-binding factor.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								Bartel P. L., 1993, CELLULAR INTERACTION, P153; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	17	484	500	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					85	89		10.1038/38008	http://dx.doi.org/10.1038/38008			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288972				2022-12-24	WOS:A1997XU59600050
J	GomisRuth, FX; Maskos, K; Betz, M; Bergner, A; Huber, R; Suzuki, K; Yoshida, N; Nagase, H; Brew, K; Bourenkov, GP; Bartunik, H; Bode, W				GomisRuth, FX; Maskos, K; Betz, M; Bergner, A; Huber, R; Suzuki, K; Yoshida, N; Nagase, H; Brew, K; Bourenkov, GP; Bartunik, H; Bode, W			Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1	NATURE			English	Article							HUMAN-TISSUE INHIBITOR; CATALYTIC DOMAIN; TERMINAL DOMAIN; 3-DIMENSIONAL STRUCTURE; COLLAGENASES; HYDROXAMATE; SUPERFAMILY; ACTIVATION; ASTACINS; PROTEIN	Matrix metalloproteinases (MMPs) are zinc endopeptidases that are required for the degradation of extracellular matrix components during normal embryo development, morphogenesis and tissue remodelling(1). Their proteolytic activities are precisely regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs)(1-5). Disruption of this balance results in diseases such as arthritis, atherosclerosis, tumour growth and metastasis(1,2). Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1. TIMP-1, a 184-residue protein(5), has the shape of an elongated, contiguous wedge. With its long edge, consisting of five different chain regions, it occupies the entire length of the active-site cleft of MMP-3. The central disulphide-linked segments Cys 1-Thr 2-Cys 3-Val 4 and Ser 68-Val 69 bind to either side of the catalytic zinc. Cys 1 bidentally coordinates this zinc, and the Thr-2 side chain extends into the large specificity pocket of MMP-3. This unusual architecture of the interface between MMP-3 and TIMP-1 suggests new possibilities for designing TIMP variants and synthetic MMP inhibitors with potential therapeutic applications.	MAX PLANCK INST BIOCHEM,ABT STRUKTURFORSCH,D-82152 MARTINSRIED,GERMANY; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101; DESY,AG PROT DYNAM MPG ASMB,D-22603 HAMBURG,GERMANY	Max Planck Society; University of Kansas; University of Kansas Medical Center; University of Miami; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009; Bourenkov, Gleb P/C-7794-2017	Brew, Keith/0000-0003-1306-1032; Bourenkov, Gleb P/0000-0002-2617-5920; Bergner, Andreas/0000-0002-5843-4325; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; Brunger AT, 1991, CURR OPIN STRUC BIOL, V1, P1016, DOI 10.1016/0959-440X(91)90100-8; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V31; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nagase H, 1996, ZINC METALLOPROTEASE, P153; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1996, DENZO FILM PROCESSIN; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; ROUSSEL A, 1989, TURBO FRODO SILICON; STOCKER W, 1995, PROTEIN SCI, V4, P823; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK E, 1994, AM J RESP CRIT CARE, V150, P5165; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; [No title captured]	30	480	495	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					77	81		10.1038/37995	http://dx.doi.org/10.1038/37995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288970				2022-12-24	WOS:A1997XU59600048
J	Herrada, G; Dulac, C				Herrada, G; Dulac, C			A novel family of putative pheromone receptors in mammals with a topographically organized and sexually dimorphic distribution	CELL			English	Article							ACCESSORY OLFACTORY-BULB; VOMERONASAL SYSTEM; DIFFERENTIAL LOCALIZATION; CA2+-SENSING RECEPTOR; GLUTAMATE RECEPTOR; G-PROTEINS; EXPRESSION; EPITHELIUM; RAT; BINDING	Mammals have retained two functionally and anatomically independent collections of olfactory neurons located in the main olfactory epithelium and in the vomeronasal organ (VNO). Pheromones activate the VNO in order to elicit fixed action behaviors and neuroendocrine changes involved in animal reproduction and aggression. Differential screening of cDNA libraries constructed from individual rat VNO neurons has led to the isolation of a novel family of similar to 100 genes encoding seven transmembrane receptors with sequence similarity with Ca2+-sensing and metabotropic glutamate receptors. These genes are likely to encode a novel family of pheromone receptors. Patterns of receptor gene expression suggest that the VNO is organized into discrete and sexually dimorphic functional units that may permit segregation of pheromone signals leading to specific arrays of behaviors and neuroendocrine responses.			Herrada, G (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOL BIOL,CAMBRIDGE,MA 02138, USA.			Dulac, Catherine/0000-0001-5024-5418				Berghard A, 1996, J NEUROSCI, V16, P909; Berliner DL, 1996, J STEROID BIOCHEM, V58, P259, DOI 10.1016/0960-0760(96)00062-3; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Humphrey T, 1940, J COMP NEUROL, V73, P431, DOI 10.1002/cne.900730305; ICHIKAWA M, 1994, DEV BRAIN RES, V78, P1, DOI 10.1016/0165-3806(94)90002-7; IMAMURA K, 1985, BRAIN RES, V328, P362, DOI 10.1016/0006-8993(85)91050-9; JACOBSON L, 1811, ANN MUS HIST NAT PAR, V18, P412; JIANG XC, 1990, J BIOL CHEM, V265, P8736; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIMAN ER, 1996, NEUROBIOLOGY, V6, P487; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; MENZIES RA, 1992, PHYSIOL BEHAV, V52, P741, DOI 10.1016/0031-9384(92)90408-T; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1987, BRAIN RES, V408, P215, DOI 10.1016/0006-8993(87)90375-1; MURPHY MR, 1970, SCIENCE, V167, P302, DOI 10.1126/science.167.3916.302; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Rasmussen LEL, 1996, NATURE, V379, P684, DOI 10.1038/379684a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHINOHARA H, 1992, ACTA ANAT, V144, P167; SINGER AG, 1986, J BIOL CHEM, V261, P3323; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4348; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILSON E, 1963, PHEROMONES SCI AM, V5, P2; WYSOCKI CJ, 1989, NEURAL CONTROL REPRO, P545	47	559	581	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					763	773		10.1016/S0092-8674(00)80536-X	http://dx.doi.org/10.1016/S0092-8674(00)80536-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288755	Bronze			2022-12-24	WOS:A1997XT06600019
J	David, RJ; Collins, JW				David, RJ; Collins, JW			Differing birth weight among infants of US-born blacks, African-born blacks, and US-born whites	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; PRETERM DELIVERY; RACIAL-DIFFERENCES; WOMEN; PREGNANCY; MORTALITY; HEALTH; RACE; OUTCOMES; AGE	Background In the United States, the birth weights of infants of black women are lower than those of infants of white women. The extent to which the lower birth weights among blacks are related to social or genetic factors is unclear. Methods We used vital records for 1980 through 1995 from Illinois to determine the distribution of birth weights among infants born to three groups of women - U.S.-born blacks, African-born blacks, and U.S.-born whites. Results The mean birth weight of 44,046 infants of U.S.-born white women was 3446 g, that of 3135 infants of African-born black women was 3333 g, and that of 43,322 infants of U.S.-born black women was 3089 g. The incidence of low birth weight (weight less than 2500 g) was 13.2 percent among infants of U.S.-born black women and 7.1 percent among infants of African-born black women, as compared with 4.3 percent among infants of U.S, born white women (relative risks, 3.1 and 1.6, respectively). Among the women at lowest risk (those 20 to 39 years old, with 12 years of education for themselves and their spouses, early prenatal care, gravida 2 or 3, and no previous fetal loss), the rate of low birth weight in infants of African-born black women (3.6 percent) was closer to the rate in infants of U.S, born white women (2.4 percent), and the rate in infants of U.S.-born black women remained high (7.5 percent). Conclusions The birth-weight patterns of infants of African-born black women and U.S.-born white women are more closely related to one another than to the birth weights of infants of U.S.-born black women. (C) 1997, Massachusetts Medical Society.	UNIV ILLINOIS,SCH MED,DEPT PEDIAT,CHICAGO,IL; CHILDRENS MEM HOSP,DIV NEONATOL,CHICAGO,IL 60614; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University	David, RJ (corresponding author), COOK CTY CHILDRENS HOSP,DIV NEONATOL,700 S WOOD ST,CHICAGO,IL 60612, USA.							ADAMS J, 1973, SCIENCE, V180, P1137, DOI 10.1126/science.180.4091.1137; AMINI SB, 1994, OBSTET GYNECOL, V83, P342; *BUR CENS, 1993, CP215 BUR CENS; CABRAL H, 1990, AM J PUBLIC HEALTH, V80, P70, DOI 10.2105/AJPH.80.1.70; CHAKRABORTY R, 1991, Ethnicity and Disease, V1, P245; COLLINS JW, 1990, AM J PUBLIC HEALTH, V80, P679, DOI 10.2105/AJPH.80.6.679; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; DAVID R J, 1991, Ethnicity and Disease, V1, P236; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FOX SH, 1994, AM J EPIDEMIOL, V139, P1008, DOI 10.1093/oxfordjournals.aje.a116940; Friedman Daniel J., 1993, Ethnicity and Disease, V3, P255; Geronimus Arline T., 1992, Ethnicity and Disease, V2, P207; GLASS B, 1953, AM J HUM GENET, V5, P11; GOLDENBERG RL, 1991, OBSTET GYNECOL, V78, P782; HULSEY TC, 1991, AM J OBSTET GYNECOL, V164, P1299, DOI 10.1016/0002-9378(91)90703-T; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; KLEINMAN JC, 1991, AM J DIS CHILD, V145, P194, DOI 10.1001/archpedi.1991.02160020086023; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; LITTLE RE, 1987, AM J HUM GENET, V40, P512; MAGNUS P, 1984, CLIN GENET, V26, P289; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; NAYLOR AF, 1967, ANN HUM GENET, V31, P71, DOI 10.1111/j.1469-1809.1967.tb02021.x; Oliver Roland, 1988, SHORT HIST AFRICA; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; REED TE, 1969, SCIENCE, V165, P762, DOI 10.1126/science.165.3895.762; ROWLEY DL, 1993, AM J PREV MED, V9, P1; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHEEHAN TJ, 1995, NEW ENGL J MED, V333, P386; VALANIS BM, 1979, SOC BIOL, V26, P189; WASSE H, 1994, AM J PUBLIC HEALTH, V84, P1505, DOI 10.2105/AJPH.84.9.1505; WILCOX A, 1990, J PEDIATR-US, V116, P7, DOI 10.1016/S0022-3476(05)81638-5; WILCOX AJ, 1983, INT J EPIDEMIOL, V12, P314, DOI 10.1093/ije/12.3.314; Wildschut H I, 1991, Paediatr Perinat Epidemiol, V5, P363, DOI 10.1111/j.1365-3016.1991.tb00722.x; Witzig R, 1996, ANN INTERN MED, V125, P675, DOI 10.7326/0003-4819-125-8-199610150-00008	37	335	341	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1209	1214		10.1056/NEJM199710233371706	http://dx.doi.org/10.1056/NEJM199710233371706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337381				2022-12-24	WOS:A1997YB71800006
J	Duhamel, JR; Bremmer, F; BenHamed, S; Graf, W				Duhamel, JR; Bremmer, F; BenHamed, S; Graf, W			Spatial invariance of visual receptive fields in parietal cortex neurons	NATURE			English	Article							RESPONSE PROPERTIES; MACAQUE MONKEY; AREA MT; SPACE; CONNECTIONS; MOVEMENT; MEMORY; GAZE	Spatial information is conveyed to the primary visual cortex in retinal coordinates, Movement trajectory programming, however, requires a transformation from this sensory frame of reference into a frame appropriate for the selected part of the body, such as the eye, head or arms(1-4). To achieve this transformation, visual information must be combined with information from other sources: for instance, the location of an object of interest can be defined with respect to the observer's head if the position of the eyes in the orbit is known and is added to the object's retinal coordinates, Here we show that in a subdivision of the monkey parietal lobe, the ventral intraparietal area (VIP), the activity of visual neurons is modulated by eye-position signals, as in many other areas of the cortical visual system(5-10). We find that individual receptive fields of a population of VIP neurons are organized along-a continuum, from eye to head coordinates, In the latter case, neurons encode the azimuth and/or elevation of a visual stimulus, independently of the direction in which the eyes are looking, thus representing spatial locations explicitly in at least a head-centred frame of reference.	RUHR UNIV BOCHUM,DEPT ZOOL & NEUROBIOL,D-44780 BOCHUM,GERMANY	Ruhr University Bochum	Duhamel, JR (corresponding author), COLL FRANCE,CNRS,LAB PHYSIOL PERCEPT & ACT,11 PL MARCELIN BERTELOT,F-75005 PARIS,FRANCE.		Duhamel, Jean-René/M-4723-2017; Ben Hamed, Suliann/O-6070-2014; Bremmer, Frank/F-3268-2012	Duhamel, Jean-René/0000-0003-0210-1027; Ben Hamed, Suliann/0000-0003-1510-7284; Bremmer, Frank/0000-0003-1597-7407				ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; Bernstein N.A., 1967, COORDINATION REGULAT; BOUSSAOUD D, 1993, EXP BRAIN RES, V91, P202; Bremmer F, 1997, J NEUROPHYSIOL, V77, P944, DOI 10.1152/jn.1997.77.2.944; BREMMER F, 1997, CONTRIBUTION PARIETA, P619; Colby CL, 1996, COGNITIVE BRAIN RES, V5, P105, DOI 10.1016/S0926-6410(96)00046-8; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P487; Duhamel J.-R, 1991, BRAIN SPACE; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; DUHAMEL JR, IN PRESS J NEUROPHYS; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; GALLETTI C, 1989, J NEUROSCI, V9, P1112; Galletti C, 1995, EUR J NEUROSCI, V7, P2486, DOI 10.1111/j.1460-9568.1995.tb01047.x; GALLETTI C, 1993, EXP BRAIN RES, V96, P221; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; HYVARINEN J, 1981, BRAIN RES, V206, P287, DOI 10.1016/0006-8993(81)90533-3; LEWIS JW, 1996, SOC NEUR ABSTR, V22; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MATELLI M, 1994, SOC NEUR ABSTR, V20; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; SOECHTING JF, 1989, J NEUROPHYSIOL, V62, P582, DOI 10.1152/jn.1989.62.2.582; TANNE J, 1996, SOC NEUR ABSTR, V22; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	29	428	431	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					845	848		10.1038/39865	http://dx.doi.org/10.1038/39865			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349815				2022-12-24	WOS:A1997YC14800056
J	Papavasiliou, F; Casellas, R; Suh, HY; Qin, XF; Besmer, E; Pelanda, R; Nemazee, D; Rajewsky, K; Nussenzweig, MC				Papavasiliou, F; Casellas, R; Suh, HY; Qin, XF; Besmer, E; Pelanda, R; Nemazee, D; Rajewsky, K; Nussenzweig, MC			V(D)J recombination in mature B cells: A mechanism for altering antibody responses	SCIENCE			English	Article							HEAVY-CHAIN GENE; GERMINAL-CENTERS; ALLELIC EXCLUSION; TRANSGENIC MICE; IMMUNE-RESPONSE; MATURATION; RAG-1; REARRANGEMENT; LYMPHOCYTES; GENERATION	The clonal selection theory states that B lymphocytes producing high-affinity immunoglobulins are selected from a pool of cells undergoing antibody gene mutation. Somatic hypermutation is a well-documented mechanism for achieving diversification of immune responses in mature B cells. Antibody genes were also found to be modified in such cells in germinal centers by recombination of the variable (V), diversity (D), and joining (J) segments. The ability to alter immunoglobulin expression by V(D)J recombination in the selective environment of the germinal center may be an additional mechanism for inactivation or diversification of immune responses.	ROCKEFELLER UNIV,MOL IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; INST IMMUNOL,D-79108 FREIBURG,GERMANY; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLOGNE,GENET INST,WAYERTAL,GERMANY	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; National Jewish Health; University of Cologne			Nussenzweig, Michel/AAE-7292-2019	QIN, FRANK XIAOFENG/0000-0002-5395-0304; Rajewsky, Klaus/0000-0002-6633-6370	NIAID NIH HHS [R01 AI033608, AI33890] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033890, R01AI033608, R29AI033890] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BURNET FM, 1959, CLONAL SELECTION THE; CASELLAS R, UNPUB; CEBRA JJ, 1966, J EXP MED, V123, P547, DOI 10.1084/jem.123.3.547; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hikida M, 1997, J IMMUNOL, V158, P2509; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; LOZANO F, 1993, NATURE, V363, P271, DOI 10.1038/363271a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1994, IMMUNOL REV, V137, P173, DOI 10.1111/j.1600-065X.1994.tb00664.x; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PEARSE M, 1988, P NATL ACAD SCI USA, V85, P6082, DOI 10.1073/pnas.85.16.6082; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P825; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	44	208	213	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					298	301		10.1126/science.278.5336.298	http://dx.doi.org/10.1126/science.278.5336.298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323210				2022-12-24	WOS:A1997YA56400047
J	Sames, D; Chen, XT; Danishefsky, SJ				Sames, D; Chen, XT; Danishefsky, SJ			Convergent total synthesis of a tumour-associated mucin motif	NATURE			English	Article							GLYCOSYL PHOSPHITES; OLIGOSACCHARIDES; CELLS; CARBOHYDRATE; RECOGNITION; LEUKOSIALIN; PHOSPHATES; VACCINES; ANTIGENS; GLYCANS	Synthetic glycoconjugates that mimic cell-surface tumour antigens (glycolipids or glycoproteins with unusual carbohydrate structural motifs) have been shown to trigger humoral responses in murine and human immune systems(1-3). This raises the exciting possibility of inducing active immunity with fully synthetic carbohydrate vaccines, particularly if vaccine compounds can be synthesized that resemble the surface environment of transformed cells even more closely. Glycopeptides seem particularly suitable for this purpose. In contrast to most glycolipids and the carbohydrates themselves, glycopeptides bind to major histocompatibility complex molecules, and, in favourable cases, can stimulate T cells and lead to the expression of receptors that recognize the carbohydrate part of a glycopeptide with high specificity(4-8). The preparation of glycopeptides and glycoproteins remains, however, a difficult challenge(9-12): earlier synthesis methods have been inefficient, and established cloning approaches that allow engineering of global glycopatterns produce only heterogeneous glycoproteins(13). Here we report an efficient strategy of the synthesis of tumour-associated mucin glycopeptides with clustered trisaccharide glycodomains corresponding to the (2,6)-sialyl T antigen. Our approach involves construction of the complete glycodomain in the first stage, followed by convergent coupling to amino acid residues and subsequent incorporation of the glycosyl amino acid units into a peptide chain. This general strategy allows the assembly of molecules in which selected glycoforms can be incorporated at any desired position of the peptide chain. The resultant fully synthetic O-linked glycopeptide clusters are the closest homogeneous mimics of cell-surface mucins at present available, and so are promising compounds for the development of anticancer vaccines.	MEM SLOAN KETTERING CANC CTR,BIOORGAN CHEM LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027	Memorial Sloan Kettering Cancer Center; Columbia University								Bill RM, 1996, CHEM BIOL, V3, P145, DOI 10.1016/S1074-5521(96)90255-0; BILODEAU MT, 1996, ANGEW CHEM INT EDIT, V35, P1381; Carlstedt I, 1997, BIOCHEM SOC T, V25, P214, DOI 10.1042/bst0250214; DECK B, 1995, J IMMUNOL, V155, P1074; Elofsson M, 1997, TETRAHEDRON, V53, P369, DOI 10.1016/S0040-4020(96)00992-1; FINN OJ, 1995, IMMUNOL REV, V145, P61, DOI 10.1111/j.1600-065X.1995.tb00077.x; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; IIJIMA H, 1989, CARBOHYD RES, V186, P95, DOI 10.1016/0008-6215(89)84008-X; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JENSON T, 1997, J IMMUNOL, P3769; JIANG JJ, 1994, SYNTHETIC COMMUN, V24, P187, DOI 10.1080/00397919408013818; KONDO H, 1994, J ORG CHEM, V59, P864, DOI 10.1021/jo00083a032; KUNZ H, 1997, GLYCOPEPTIDES RELATE, P23; Liebe B, 1997, ANGEW CHEM INT EDIT, V36, P618, DOI 10.1002/anie.199706181; MARTIN TJ, 1993, GLYCOCONJUGATE J, V10, P16, DOI 10.1007/BF00731182; MOURITSEN S, 1994, EUR J IMMUNOL, V24, P1066, DOI 10.1002/eji.1830240509; NAKAHARA Y, 1994, ACS SYM SER, V560, P249; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; Paulsen H, 1997, J CHEM SOC PERK T 1, P281, DOI 10.1039/a604123j; PAULSEN H, 1988, LIEBIGS ANN CHEM, P75; Qui D., 1997, TETRAHEDRON LETT, V38, P45; Ragupathi G, 1997, ANGEW CHEM INT EDIT, V36, P125, DOI 10.1002/anie.199701251; SAITOH O, 1991, CANCER RES, V51, P2854; SCHMIDT RR, 1994, ADV CARBOHYD CHEM BI, V50, P84; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SIM MM, 1993, J AM CHEM SOC, V115, P2260, DOI 10.1021/ja00059a023; SZABO L, 1995, CARBOHYD RES, V274, P11, DOI 10.1016/0008-6215(95)00016-M; TOYOKUNI T, 1995, CHEM SOC REV, V24, P231, DOI 10.1039/cs9952400231; TSUDA T, 1996, J CHEM SOC CHEM COMM, P2779; Witte K, 1997, J AM CHEM SOC, V119, P2114, DOI 10.1021/ja961846z	31	102	105	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					587	591		10.1038/39292	http://dx.doi.org/10.1038/39292			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335496				2022-12-24	WOS:A1997YA00800055
J	Vallet, V; Chraibi, A; Gaeggeler, HP; Horisberger, JD; Rossier, BC				Vallet, V; Chraibi, A; Gaeggeler, HP; Horisberger, JD; Rossier, BC			An epithelial serine protease activates the amiloride-sensitive sodium channel	NATURE			English	Article							TOAD URINARY-BLADDER; SUBUNITS; CELLS; MUTATIONS	Sodium balance, and ultimately blood pressure and extracellular fluid volume, is maintained by precise regulation of the activity of the epithelial sodium channel (ENaC)(1-3). In a Xenopus kidney epithelial cell Line (A6), exposure of the apical membrane to the protease inhibitor aprotinin reduces transepithelial sodium transport. Sodium-channel activity can be restored by subsequent exposure to the nonspecific protease trypsin. Using A6 cells and a functional complementation assay to detect increases in ENaC activity, we have cloned a 329-residue protein belonging to the serine protease family. We show that coexpression of this protein with ENaC in Xenopus oocytes increases the activity of the sodium channel by two- to threefold. This channel-activating protease (CAP1) is expressed in kidney, gut, lung, skin and ovary. Sequence analysis predicts that CAP1 is a secreted and/or glycosylphosphatidylinositol-anchored protein: ENaC activity would thus be regulated by the activity of a protease expressed at the surface of the same cell. This previously undiscovered mechanism for autocrine regulation may apply to other ion channels, in particular to members of the ENaC family that are present in neurons and epithelial cells.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND	University of Lausanne			Horisberger, Jean-Daniel/A-2538-2009					CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHRAIBI A, UNPUB J GEN PHYSL; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANDLER JS, 1979, P NATL ACAD SCI USA, V76, P4151, DOI 10.1073/pnas.76.8.4151; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; LEWIS SA, 1991, J MEMBRANE BIOL, V122, P77, DOI 10.1007/BF01872741; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; ORCE GG, 1980, AM J PHYSIOL, V239, pF459, DOI 10.1152/ajprenal.1980.239.5.F459; PUOTI A, 1995, AM J PHYSIOL, V38, pC188; ROSSIER BC, 1997, J AM SOC NEPHROL, V9, P980; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483	18	424	432	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					607	610		10.1038/39329	http://dx.doi.org/10.1038/39329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335501				2022-12-24	WOS:A1997YA00800061
J	Bruce, ME; Will, RG; Ironside, JW; McConnell, I; Drummond, D; Suttie, A; McCardle, L; Chree, A; Hope, J; Birkett, C; Cousens, S; Fraser, H; Bostock, CJ				Bruce, ME; Will, RG; Ironside, JW; McConnell, I; Drummond, D; Suttie, A; McCardle, L; Chree, A; Hope, J; Birkett, C; Cousens, S; Fraser, H; Bostock, CJ			Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; SCRAPIE INCUBATION; DIFFERENT STRAINS; RODENTS; LINES; SHEEP	There are many strains of the agents that cause transmissible spongiform encephalopathies (TSEs) or 'prion' diseases, These strains are distinguishable by their disease characteristics in experimentally infected animals, in particular the incubation periods and neuropathology they produce in panels of inbred mouse strains(1-4). We have shown that the strain of agent from cattle affected by bovine spongiform encephalopathy (BSE) produces a characteristic pattern of disease in mice that is retained after experimental passage through a variety of intermediate species(5-7). This BSE 'signature' has also been identified in transmissions to mice of TSEs of domestic cats and two exotic species of ruminant(6,8), providing the first direct evidence for the accidental spread of a TSE between species, Twenty cases of a clinically and pathologically atypical form of Creutzfeldt-Jakob disease (CJD), referred to as 'new variant' CJD (vCJD)(9), have been recognized in unusually young people in the United Kingdom, and a further case has been reported in France(10). This has raised serious concerns that BSE may have spread to humans, putatively by dietary exposure, Here we report the interim results of transmissions of sporadic CJD and VJD to mice, Our data provide strong evidence that the same agent strain is involved in both BSE and vCJD.	WESTERN GEN HOSP,NATL CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; INST ANIM HLTH,NEWBURY RG20 7NN,BERKS,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND	University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; University of London; London School of Hygiene & Tropical Medicine	Bruce, ME (corresponding author), INST ANIM HLTH,BBSRC MRC NEUROPATHOGENESIS UNIT,W MAINS RD,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND.		Hope, James/C-4966-2011	Ironside, James/0000-0001-5869-2108				Bell JE, 1997, NEUROPATH APPL NEURO, V23, P26, DOI 10.1111/j.1365-2990.1997.tb01182.x; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; FARQUHAR CF, 1994, TRANSMISSIBLE SPONGI, P301; Foster JD, 1996, VET REC, V138, P546, DOI 10.1136/vr.138.22.546; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; FRASER H, 1994, VET REC, V134, P449, DOI 10.1136/vr.134.17.449; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; Fraser H, 1996, BRAIN PATHOL, V6, P89, DOI 10.1111/j.1750-3639.1996.tb00788.x; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; Hill AF, 1997, LANCET, V350, P188, DOI 10.1016/S0140-6736(05)62356-2; Kirkwood B., 1988, BR K ESSENTIALS MED; Mardia K. V., 1979, MULTIVARIATE ANAL; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; Tateishi J, 1996, SEMIN VIROL, V7, P175, DOI 10.1006/smvy.1996.0022; TATEISHI J, 1979, ANN NEUROL, V5, P581, DOI 10.1002/ana.410050616; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	28	1586	1630	1	104	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					498	501		10.1038/39057	http://dx.doi.org/10.1038/39057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333239				2022-12-24	WOS:A1997XY90900057
J	Novacek, MJ; Rougier, GW; Wible, JR; McKenna, MC; Dashzeveg, D; Horovitz, I				Novacek, MJ; Rougier, GW; Wible, JR; McKenna, MC; Dashzeveg, D; Horovitz, I			Epipubic bones in eutherian mammals from the late Cretaceous of Mongolia	NATURE			English	Article							FLAMING CLIFFS; DINOSAUR	An important transformation in the evolution of mammals was the loss of the epipubic bones. These are elements projecting anteriorly from the pelvic girdle into the abdominal region in a variety of Mesozoic mammals, related tritylodonts, marsupials and monotremes but not in living eutherian (placental) mammals(1-3). Here we describe a new eutherian from the Late Cretaceous period of Mongolia, and report the first record of epipubic bones in two distinct eutherian lineages. The presence of epipubic bones and other primitive features suggests that these groups occupy a basal position in the Eutheria. It has been argued that the epipubic bones support the pouch in living mammals(1,3,4), but epipubic bones have since been related to locomotion and suspension of the litter mass of several attached, lactating offspring(5). The loss of the epipubic bones in eutherians can be related to the evolution of prolonged gestation, which would not require prolonged external attachment of altricial young. Thus the occurrence of epipubic bones in two Cretaceous eutherians suggests that the dramatic modifications connected with typical placental reproduction(3,6,7) may have been later events in the evolution of the Eutheria.	UNIV LOUISVILLE, SCH MED, DEPT ANAT SCI & NEUROBIOL, LOUISVILLE, KY 40292 USA; MONGOLIAN ACAD SCI, INST GEOL, ULAANBAATAR, MONGOLIA	University of Louisville; Mongolian Academy of Sciences	Novacek, MJ (corresponding author), AMER MUSEUM NAT HIST, DEPT VERTEBRATE PALEONTOL, NEW YORK, NY 10024 USA.							DASHZEVEG D, 1995, NATURE, V374, P446, DOI 10.1038/374446a0; FOURIE S, 1962, NAVORSINGE NASIONALE, V2, P7; GREGORY WILLIAM K., 1926, AMER MUS NOVITATES, V225, P1; JELLISON WL, 1945, J MAMMAL, V26, P146, DOI 10.2307/1375090; KIELAN-JAWOROWSKA Z, 1975, Palaeontologia Polonica, V33, P5; Kielan-Jaworowska Z, 1981, PALAEONTOLOGIA POLON, V42, P25; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSK.Z, 1977, PALAEONTOL POL, V37, P55; KIELANJAWOROWSKA Z, 1975, NATURE, V255, P698, DOI 10.1038/255698a0; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; LECHE W, 1891, BIOL FOREN FORHANDL, V3, P120; LILLEGRAVEN JA, 1987, BIOL J LINN SOC, V32, P281, DOI 10.1111/j.1095-8312.1987.tb00434.x; Lilligraven J. A., 1969, Paleontological Contributions University of Kansas, VNo. 50, P1; MACPHEE RDE, 1993, MAMMAL PHYLOGENY : PLACENTALS, P13; MARSHALL LG, 1979, ZOOL J LINN SOC-LOND, V66, P369, DOI 10.1111/j.1096-3642.1979.tb01914.x; McKenna MC., 1975, PHYLOGENY PRIMATES, P21, DOI [DOI 10.1007/978-1-4684-2166-8_2, 10.1007/978-1-4684-2166-8_2]; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; NORELL MA, 1994, SCIENCE, V266, P779, DOI 10.1126/science.266.5186.779; NOVACEK MJ, 1986, B AM MUS NAT HIST, V183, P1; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; NOVACEK MJ, 1994, SCI AM, V271, P60, DOI 10.1038/scientificamerican1294-60; Reig O.A., 1987, P1; RENFREE MB, 1993, MAMMAL PHYLOGENY, P4; ROUGIER G. W., 1993, THESIS U BUENOS AIRE; Springer Mark S., 1997, P129; Tyndale-Biscoe CH., 1987, REPROD PHYSL MARSUPI; VAUGHN PETER PAUL, 1956, JOUR ELISHA MITCHELL SCI SOC, V72, P243; WHITE TD, 1989, J THEOR BIOL, V139, P343, DOI 10.1016/S0022-5193(89)80213-9	29	92	97	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					483	486		10.1038/39020	http://dx.doi.org/10.1038/39020			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333234				2022-12-24	WOS:A1997XY90900052
J	Solomon, CG; Willett, WC; Carey, VJ; RichEdwards, J; Hunter, DJ; Colditz, GA; Stampfer, MJ; Speizer, FE; Spiegelman, D; Manson, JE				Solomon, CG; Willett, WC; Carey, VJ; RichEdwards, J; Hunter, DJ; Colditz, GA; Stampfer, MJ; Speizer, FE; Spiegelman, D; Manson, JE			A prospective study of pregravid determinants of gestational diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; PHYSICAL-ACTIVITY; INSULIN-SECRETION; CIGARETTE-SMOKING; RISK-FACTORS; WEIGHT-GAIN; WOMEN; PREVALENCE; POPULATION; CRITERIA	Context.-Gestational diabetes mellitus (GDM) affects 3% to 5% of pregnancies. Knowledge of risk factors for GDM is needed to identify possible preventive strategies. Objective.-To assess whether recognized determinants of non-insulin-dependent diabetes mellitus also may be markers for increased risk of GDM. Design.-Prospective cohort study. Setting.-The Nurses' Health Study II, which involves female US nurses aged 25 to 42 years at entry. Participants.-The analyses included 14 613 women without previous GDM or other known diabetes who reported a singleton pregnancy between 1990 and 1994. Of these women, 722 (4.9%) reported a new diagnosis of GDM. Main Outcome Measure: Self-report of GDM, validated by medical record review in a subset. Results.-In multivariate analyses including age, pregravid body mass index (BMI), and other GDM risk factors, the risk for GDM increased significantly with increasing maternal age (P for trend, <.01) and family history of diabetes mellitus (relative risk, 1.68; 95% confidence interval [CI], 1.39-2.04). Relative risks for GDM were 2.13 (95% CI, 1.65-2.74) for pregravid BMI of 25 to 29.9 kg/m(2) and 2.90 (95% CI, 2.15-3.91) for BMI of 30 kg/m(2) or more (vs BMI of <20 kg/m(2)). Risk for GDM increased with greater weight gain in early adulthood, and it also increased among nonwhite women. Pregravid current smokers had a relative risk for GDM of 1.43 (95% CI, 1.14-1.80), and pregravid vigorous exercise was associated with a nonsignificant reduction in GDM risk. Conclusions.-Advanced maternal age, family history of diabetes mellitus, nonwhite ethnicity, higher BMI, weight gain in early adulthood, and cigarette smoking predict increased GDM risk. These observations may facilitate the identification of women at particular risk for GDM and suggest potential strategies for reducing this risk even before a woman becomes pregnant, such as avoiding substantial weight gain and smoking.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV GEN MED,SECT CLIN EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, ENDOCRINE HYPERTENS DIV, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT MATERNAL & CHILD HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Solomon, CG (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA050385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50385] Funding Source: Medline; NIDDK NIH HHS [DK-36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAULIEU MD, 1992, CAN MED ASSOC J, V147, P435; BELL DSH, 1990, DIABETES CARE, V13, P1196, DOI 10.2337/diacare.13.11.1196; BERKOWITZ GS, 1992, AM J EPIDEMIOL, V135, P965, DOI 10.1093/oxfordjournals.aje.a116408; BUNG P, 1991, DIABETES, V40, P182, DOI 10.2337/diab.40.2.S182; CHARLES MA, 1993, DIABETES CARE, V16, P593, DOI 10.2337/diacare.16.4.593; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COX NJ, 1994, DIABETES, V43, P166, DOI 10.2337/diab.43.1.166; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; DOOLEY SL, 1991, INT J GYNECOL OBSTET, V35, P13, DOI 10.1016/0020-7292(91)90057-C; DORNHORST A, 1992, DIABETIC MED, V9, P820, DOI 10.1111/j.1464-5491.1992.tb01900.x; GOLDMAN JA, 1967, ISRAEL J MED SCI, V3, P561; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; HARRIS MI, 1991, DIABETES CARE, V14, P639, DOI 10.2337/diacare.14.7.639; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Kanders B., 1991, CONNS CURRENT THERAP, P524; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P93, DOI 10.1016/S0002-9378(11)90676-0; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUHL C, 1991, DIABETES, V40, P18, DOI 10.2337/diab.40.2.S18; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MARTIN AO, 1985, AM J OBSTET GYNECOL, V151, P471, DOI 10.1016/0002-9378(85)90272-8; METZGER BE, 1993, DIABETES CARE, V16, P1598, DOI 10.2337/diacare.16.12.1598; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1982, JAMA-J AM MED ASSOC, V248, P949, DOI 10.1001/jama.248.8.949; OSULLIVAN JB, 1984, CARBOHYD METABOL, P174; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; SIMMONS D, 1995, J INTERN MED, V237, P315, DOI 10.1111/j.1365-2796.1995.tb01181.x; Solomon CG, 1996, DIABETES CARE, V19, P12, DOI 10.2337/diacare.19.1.12; THOMAS F, 1994, DIABETES, V43, P63, DOI 10.2337/diabetes.43.1.63; TROY LM, 1995, INT J OBESITY, V19, P570; VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	36	536	545	1	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1078	1083		10.1001/jama.278.13.1078	http://dx.doi.org/10.1001/jama.278.13.1078			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315766				2022-12-24	WOS:A1997XX30300031
J	Baylin, SB				Baylin, SB			Tying it all together: Epigenetics, genetics, cell cycle, and cancer	SCIENCE			English	Editorial Material							DNA-METHYLTRANSFERASE ACTIVITY; EMBRYONIC STEM-CELLS; DE-NOVO METHYLATION; CPG ISLAND; NUCLEAR ANTIGEN; 5-METHYLCYTOSINE CONTENT; DEPENDENT KINASES; REPLICATION; MOUSE; PCNA		DEPT MED,BALTIMORE,MD 21231		Baylin, SB (corresponding author), JOHNS HOPKINS COMPREHENS CANC CTR,BALTIMORE,MD 21231, USA.							Ahuja N, 1997, CANCER RES, V57, P3370; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BAYLIN SB, IN PRESS ADV CANC RE; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FEINBERG AP, 1988, CANCER RES, V48, P1159; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KO IJ, 1996, GENE DEV, V10, P1054; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAIRD PW, 1994, HUM MOL GENET, V3; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092	61	160	169	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1948	1949		10.1126/science.277.5334.1948	http://dx.doi.org/10.1126/science.277.5334.1948			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9333948				2022-12-24	WOS:A1997XX84900028
J	Li, Y; Field, PM; Raisman, G				Li, Y; Field, PM; Raisman, G			Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells	SCIENCE			English	Article							SCHWANN-CELLS; SPINAL-CORD; AXONAL REGENERATION; SENSORY NEURONS; BULB; SYSTEM; GROWTH; MOTOR; MOUSE	The upper cervical corticospinal tract was transected on one side in adult rats. A suspension of ensheathing cells cultured from adult rat olfactory bulb was injected into the lesion site, This induced unbranched, elongative growth of the cut corticospinal axons, The axons grew through the transplant and continued to regenerate into the denervated caudal host tract, Rats with complete transections and no transplanted cells did not use the forepaw on the lesioned side for directed reaching, Rats in which the transplanted cells had formed a continuous bridge across the lesion exhibited directed forepaw reaching on the lesioned side.*			Li, Y (corresponding author), NATL INST MED RES,MRC,NORMAN & SADIE LEE RES CTR,DIV NEUROBIOL,LONDON NW7 1AA,ENGLAND.		Raisman, Geoffrey/B-3215-2009					BARBER PC, 1982, NEUROSCIENCE, V7, P3077, DOI 10.1016/0306-4522(82)90231-7; BARBER PC, 1978, BRAIN RES, V141, P57, DOI 10.1016/0006-8993(78)90616-9; DEVON R, 1992, BRAIN RES, V589, P175; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; KUHLENGEL KR, 1990, J COMP NEUROL, V293, P74, DOI 10.1002/cne.902930107; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LI Y, 1994, J NEUROSCI, V14, P4050; MONTEROMENEI CN, 1992, BRAIN RES, V570, P198, DOI 10.1016/0006-8993(92)90582-T; MOULTON DG, 1974, ANN NY ACAD SCI, V237, P52, DOI 10.1111/j.1749-6632.1974.tb49843.x; NEUBERGER TJ, 1992, J COMP NEUROL, V315, P16, DOI 10.1002/cne.903150103; RAISMAN G, 1985, NEUROSCIENCE, V14, P237, DOI 10.1016/0306-4522(85)90176-9; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; RAMONCUETO A, 1992, NEUROSCIENCE, V47, P213, DOI 10.1016/0306-4522(92)90134-N; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WILSON KCP, 1981, BRAIN RES, V205, P245, DOI 10.1016/0006-8993(81)90336-X; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309	18	720	832	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					2000	2002		10.1126/science.277.5334.2000	http://dx.doi.org/10.1126/science.277.5334.2000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302296				2022-12-24	WOS:A1997XX84900046
J	Gardner, SG; Bingley, PJ; Sawtell, PA; Weeks, S; Gale, EAM; Bell, RAF; Dunger, DB; Mukhtar, A; OMalley, BP; Silk, BR; Smith, EH; Scott, RDM; Latham, PJ; Lakhani, PK; Paton, RC; Ackland, FM; Fox, CJ; Griffin, NK; Matthews, DR; Neil, HAW; Mann, NP; Simpson, HCR; Brown, RS; Knight, AH; Cowen, JM; Pearce, JC; Cheetham, CH; Gallen, IW; Sandler, L; Westcott, T				Gardner, SG; Bingley, PJ; Sawtell, PA; Weeks, S; Gale, EAM; Bell, RAF; Dunger, DB; Mukhtar, A; OMalley, BP; Silk, BR; Smith, EH; Scott, RDM; Latham, PJ; Lakhani, PK; Paton, RC; Ackland, FM; Fox, CJ; Griffin, NK; Matthews, DR; Neil, HAW; Mann, NP; Simpson, HCR; Brown, RS; Knight, AH; Cowen, JM; Pearce, JC; Cheetham, CH; Gallen, IW; Sandler, L; Westcott, T			Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD IDDM; MELLITUS; RISK; EUROPE; ONSET	Objectives: To monitor incidence of insulin dependent diabetes in children in Oxford health region since 1985, and to look for any evidence of disproportionate increase in children aged under 5, Design: Primary ascertainment of cases of childhood diabetes was by prospective registration of all patients with insulin dependent diabetes diagnosed before age 15 years between 1985 and 1996 and resident in Oxford region at time of diagnosis, This was supplemented by examination of centralised hospital discharge records and death certificates, Secondary case ascertainment was by postal surveys of general practitioners in 1987 and 1996, Setting: Area formerly administered by Oxford Regional Health Authority. Subjects: 1037 children presenting with insulin dependent diabetes under age of 15 years, Main outcome measures: Incidence of insulin dependent diabetes in children aged 0-4, 5-9, and 10-14 years during 1985-95, Results: Overall incidence of diabetes in children aged 0-15 was 18.6 cases/100 000/year and showed an annual increase of 4% from 1985 to 1996. This was mainly due to a rapid increase in children aged 0-4 years, in whom there was an annual increase of 11% (95% confidence interval 6% to 15%, P < 0.0001), while the annual increase in those aged 5-9 was 4% (0 to 7%, P = 0.05) and in those aged 10-14 was 1% (-2% to 4%, P = 0.55), Conclusions: Incidence of insulin dependent diabetes in children aged under 5 years has risen markedly in the Oxford region over the past decade, The cause of the increase is unknown, but environmental influences encountered before birth or in early postnatal life are likely to be responsible.	UNIV BRISTOL,SOUTHMEAD HOSP,DEPT MED,BRISTOL BS10 5NB,AVON,ENGLAND; HORTON GEN HOSP,BANBURY,OXON,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; KETTERING DIST HOSP,KETTERING,NORTHANTS,ENGLAND; KING EDWARD VII HOSP,WINDSOR,ENGLAND; MILTON KEYNES DIST GEN HOSP,MILTON KEYNES,BUCKS,ENGLAND; NORTHAMPTON GEN HOSP,NORTHAMPTON,ENGLAND; RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND; ROYAL BERKSHIRE HOSP,READING RG1 5AN,BERKS,ENGLAND; STOKE MANDEVILLE HOSP,AYLESBURY HP21 8AL,BUCKS,ENGLAND; WEXHAM PK HOSP,SLOUGH SL2 4HL,BERKS,ENGLAND; WYCOMBE GEN HOSP,HIGH WYCOMBE,BUCKS,ENGLAND	Southmead Hospital; University of Bristol; University of Oxford; Radcliffe Infirmary; Royal Berkshire Hospital								BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BINGLEY PJ, IN PRESS DIABETES; BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; BLOOM A, 1975, BRIT MED J, V2, P580; BURDEN AC, 1989, DIABETIC MED, V6, P334; DAHLQUIST GG, 1995, DIABETES, V44, P408, DOI 10.2337/diabetes.44.4.408; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; *DIAB EP RES INT G, 1990, DIABETES, V39, P858; Ellis TM, 1996, LANCET, V347, P1464, DOI 10.1016/S0140-6736(96)91690-6; GINSBERGFELLNER F, 1985, REV INFECT DIS, V7, P5170; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; GREEN A, 1985, DIABETOLOGIA, V28, P339; HENDERSON P, 1949, BRIT MED J, V1, P478, DOI 10.1136/bmj.1.4602.478; LEVYMARCHAL C, 1995, DIABETOLOGIA, V38, P823, DOI 10.1007/s001250050359; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PINKNEY JH, 1994, DIABETOLOGIA, V37, P70; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; STAINES A, 1993, DIABETOLOGIA, V36, P1282, DOI 10.1007/BF00400806; TUOMILEHTO J, 1991, DIABETOLOGIA, V34, P282, DOI 10.1007/BF00405089; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; VANDERAUWERA B, 1995, J CLIN ENDOCR METAB, V80, P2567, DOI 10.1210/jc.80.9.2567; WADSWORTH E, 1995, BRIT MED J, V310, P700, DOI 10.1136/bmj.310.6981.700	23	182	187	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					713	717		10.1136/bmj.315.7110.713	http://dx.doi.org/10.1136/bmj.315.7110.713			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314756	Green Published			2022-12-24	WOS:A1997XX67400022
J	Allikmets, R; Shroyer, NF; Singh, N; Seddon, JM; Lewis, RA; Bernstein, PS; Peiffer, A; Zabriskie, NA; Li, YX; Hutchinson, A; Dean, M; Lupski, JR; Leppert, M				Allikmets, R; Shroyer, NF; Singh, N; Seddon, JM; Lewis, RA; Bernstein, PS; Peiffer, A; Zabriskie, NA; Li, YX; Hutchinson, A; Dean, M; Lupski, JR; Leppert, M			Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration	SCIENCE			English	Article							BEAVER DAM EYE; FUNDUS FLAVIMACULATUS; MACULOPATHY; DYSTROPHY; FROG	Age-related macular degeneration (AMD) is the leading cause of severe central visual impairment among the elderly and is associated both with environmental factors such as smoking and with genetic factors. Here, 167 unrelated AMD patients were screened for alterations in ABCR, a gene that encodes a retinal rod photoreceptor protein and is defective in Stargardt disease, a common hereditary form of macular dystrophy. Thirteen different AMD-associated alterations, both deletions and amino acid substitutions, were found in one allele of ABCR in 26 patients (16%). Identification of ABCR alterations will permit presymptomatic testing of high-risk individuals and may lead to earlier diagnosis of AMD and to new strategies for prevention and therapy.	NCI, LAB GENOM DIVERS, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NCI, INTRAMURAL RES SUPPORT PROGRAM, SAIC FREDERICK, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; UNIV UTAH, DEPT HUMAN GENET, ECCLED INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02114 USA; BAYLOR COLL MED, DEPT OPHTHALMOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV UTAH, MORAN EYE CTR, DEPT OPHTHALMOL, SALT LAKE CITY, UT 84132 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Utah System of Higher Education; University of Utah			Allikmets, Rando/ABD-4533-2021; Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; 				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALLIKMETS R, UNPUB; ANDERSON KL, 1995, AM J HUM GENET, V57, P1351; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060; EGAN KM, 1993, PRINCIPLES PRACTICES, P109; Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054; FISHMAN GA, 1976, ARCH OPHTHALMOL-CHIC, V94, P2061, DOI 10.1001/archopht.1976.03910040721003; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; GERBER S, 1995, AM J HUM GENET, V56, P396; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; MartinezMir A, 1997, GENOMICS, V40, P142, DOI 10.1006/geno.1996.4528; *NAT EYE I, 1992, AG REL EYE DIS STUD; National Advisory Eye Council (U.S.), 1993, NIH PUBL; PAPERMASTER DS, 1976, EXP EYE RES, V23, P105, DOI 10.1016/0014-4835(76)90194-9; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; SHUSTER TA, 1988, EXP EYE RES, V46, P475, DOI 10.1016/S0014-4835(88)80005-8; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SZUTS EZ, 1985, BIOCHEMISTRY-US, V24, P4176, DOI 10.1021/bi00336a054; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352	25	700	736	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1805	1807		10.1126/science.277.5333.1805	http://dx.doi.org/10.1126/science.277.5333.1805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295268	Green Submitted			2022-12-24	WOS:A1997XX29800042
J	Nelson, JC; Saven, JG; Moore, JS; Wolynes, PG				Nelson, JC; Saven, JG; Moore, JS; Wolynes, PG			Solvophobically driven folding of nonbiological oligomers	SCIENCE			English	Article							SECONDARY STRUCTURE; PHENYLACETYLENE MACROCYCLES; MOLECULAR MECHANICS; HELIX-COIL; PRINCIPLES; ALANINE; CRYSTAL; DESIGN	In solution, biopolymers commonly fold into well-defined three-dimensional structures, but only recently has analogous behavior been explored in synthetic chain molecules. An aromatic hydrocarbon backbone is described that spontaneously acquires a stable helical conformation having a large cavity. The chain does not form intramolecular hydrogen bonds, and solvophobic interactions drive the folding transition, which is sensitive to chain length, solvent quality, and temperature.	UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT MAT SCI & ENGN,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,URBANA,IL 61801; UNIV ILLINOIS,SCH CHEM SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NCRR NIH HHS [PHS 1 S10 RR10444-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l; BIXON M, 1963, BIOPOLYMERS, V1, P419, DOI 10.1002/bip.360010503; BLOOMFIELD VA, 1974, PHYSICAL CHEM NUCLEI; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Cantor C.R., 1980, BIOPHYS CHEM; Creighton T.E., 1993, PROTEINS; DADO GP, 1994, J AM CHEM SOC, V116, P1054, DOI 10.1021/ja00082a029; DILL KA, 1995, PROTEIN SCI, V4, P561; DOLGIKH DA, 1996, MOL BIOL, V30, P1149; GO N, 1968, P NATL ACAD SCI USA, V59, P1030, DOI 10.1073/pnas.59.4.1030; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; Hamuro Y, 1996, J AM CHEM SOC, V118, P7529, DOI 10.1021/ja9539857; Honig B, 1996, FOLD DES, V1, pR17, DOI 10.1016/S1359-0278(96)00005-3; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LOKEY RS, 1995, NATURE, V375, P303; LUTHEYSCHULTEN Z, 1995, J PHYS CHEM-US, V99, P2177, DOI 10.1021/j100007a057; MIRNY LA, 1996, FOLDING DESIGN, V1, P221; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nelson JC, 1996, J ORG CHEM, V61, P8160, DOI 10.1021/jo961250u; OKUYAMA K, 1984, J PHYS CHEM-US, V88, P1711, DOI 10.1021/j150653a010; PADMANABHAN S, 1994, J MOL BIOL, V241, P706, DOI 10.1006/jmbi.1994.1545; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; Perkins S. J., 1982, BIOL MAGN RESON, V4, P193; POLAND D, 1970, THEORY HELIXCOLL TRA; Privalov Peter L., 1992, P83; Saven JG, 1996, J MOL BIOL, V257, P199, DOI 10.1006/jmbi.1996.0156; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Seebach D, 1996, HELV CHIM ACTA, V79, P2043, DOI 10.1002/hlca.19960790802; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; STILL WC, 1996, MACROMODEL, V5; VENKATAC.CM, 1969, ANNU REV BIOCHEM, V38, P45, DOI 10.1146/annurev.bi.38.070169.000401; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; YANG AS, 1995, J MOL BIOL, V252, P351, DOI 10.1006/jmbi.1995.0502; ZHANG JS, 1994, J AM CHEM SOC, V116, P4227, DOI 10.1021/ja00089a012	41	734	740	1	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1793	1796		10.1126/science.277.5333.1793	http://dx.doi.org/10.1126/science.277.5333.1793			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295264				2022-12-24	WOS:A1997XX29800038
J	Sleat, DE; Donnelly, RJ; Lackland, H; Liu, CG; Sohar, I; Pullarkat, RK; Lobel, P				Sleat, DE; Donnelly, RJ; Lackland, H; Liu, CG; Sohar, I; Pullarkat, RK; Lobel, P			Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis	SCIENCE			English	Article							MITOCHONDRIAL ATP SYNTHASE; SUBUNIT-C; GENE; GLYCOPROTEINS; THIOESTERASE; INHIBITORS; EXPRESSION; SEQUENCE; ENZYMES; DISEASE	Classical late-infantile neuronal ceroid lipofuscinosis (LINCL) is a fatal neurodegenerative disease whose defective gene has remained elusive. A molecular basis for LINCL was determined with an approach applicable to other lysosomal storage diseases. When the mannose 6-phosphate modification of newly synthesized lysosomal enzymes was used as an affinity marker, a single protein was identified that is absent in LINCL. Sequence comparisons suggest that this protein is a pepstatin-insensitive lysosomal peptidase, and a corresponding enzymatic activity was deficient in LINCL autopsy specimens. Mutations in the gene encoding this protein were identified in LINCL patients but not in normal controls.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT LAB MED & PATHOL,NEWARK,NJ 07103; NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Institute for Basic Research in Developmental Disabilities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45992] Funding Source: Medline; NINDS NIH HHS [NS30147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOUSTANY RM, 1996, HDB CLIN NEUROLOGY, V66, P671; DE BERNARDO S, 1974, ARCH BIOCHEM BIOPHYS, V163, P390, DOI 10.1016/0003-9861(74)90490-1; Ezaki J, 1996, J NEUROCHEM, V67, P1677, DOI 10.1046/j.1471-4159.1996.67041677.x; *INT BATT DIS CONS, 1995, CELL, V82, P949; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; IVY GO, 1992, AM J MED GENET, V42, P555, DOI 10.1002/ajmg.1320420427; KORNFELD S, 1995, METABOLIC MOL BASES, V2; Oda K, 1996, J BIOCHEM, V120, P564; ODA K, 1994, J BIOL CHEM, V269, P26518; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PALMER DN, 1989, J BIOL CHEM, V264, P5736; RIDER JA, 1992, AM J MED GENET, V42, P519, DOI 10.1002/ajmg.1320420419; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1997, BIOCHEM J, V324, P33, DOI 10.1042/bj3240033; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; SLEAT DE, UNPUB; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	19	453	466	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1802	1805		10.1126/science.277.5333.1802	http://dx.doi.org/10.1126/science.277.5333.1802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295267				2022-12-24	WOS:A1997XX29800041
J	Kraaijeveld, AR; Godfray, HCJ				Kraaijeveld, AR; Godfray, HCJ			Trade-off between parasitoid resistance and larval competitive ability in Drosophila melanogaster	NATURE			English	Article							ENCAPSULATION ABILITY; ASOBARA-TABIDA; SELECTION; WASP	The extent to which an organism is selected to invest in defences against pathogens and parasites depends on the advantages that ensue should infection occur, but also on the, costs of maintaining defences in the absence of infection. the presence of heritable variation in resistance suggests that costs exist, but we know very little about the nature or magnitude of these costs in natural populations of animals(1). A powerful technique for identifying trade-offs between fitness components is the study of correlated responses to artificial selection(2,3). We have selected Drosophila melanogaster for improved resistance against an endoparasitoid, Asobara tabida. Endoparasitoids are insects whose larvae develop internally within the body of other insects, eventually killing them, although their hosts can sometimes survive attack by mounting a cellular immune response(4-6). We found that reduced larval competitive ability in unparasitized D. melanogaster is a correlated response to artificial selection for improved resistance against A. tabida. The strength of selection for competitive ability and parasitoid resistance is likely to vary temporally and spatially, which may explain the observed heritable variation in resistance.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,NERC,CTR POPULAT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Imperial College London								ATKINSON WD, 1979, J ANIM ECOL, V48, P91, DOI 10.2307/4102; CARTON Y, 1991, ACTA OECOL, V12, P89; CARTON Y, 1985, DEV COMP IMMUNOL, V9, P211, DOI 10.1016/0145-305X(85)90112-0; Godfray HCJ, 1994, PARASITOIDS BEHAV EV, DOI [10.1515/9780691207025, DOI 10.1515/9780691207025]; Gupta AP, 1985, COMPREHENSIVE INSECT, P85; HENTER HJ, 1995, EVOLUTION, V49, P427, DOI [10.2307/2410267, 10.1111/j.1558-5646.1995.tb02275.x]; Hughes K, 1996, J INSECT BEHAV, V9, P477, DOI 10.1007/BF02214024; KRAAIJEVELD AR, 1995, EVOL ECOL, V9, P10, DOI 10.1007/BF01237692; KRAAIJEVELD AR, 1994, ECOL ENTOMOL, V19, P221, DOI 10.1111/j.1365-2311.1994.tb00413.x; LEWONTIN RC, 1955, EVOLUTION, V9, P27, DOI 10.2307/2405355; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; Read A. F., 1995, P450, DOI 10.1017/CBO9780511629396.018; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Salt G., 1970, CELLULAR DEFENCE REA; SANTOS M, 1992, HEREDITY, V69, P489, DOI 10.1038/hdy.1992.163; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335	17	562	571	1	216	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					278	280		10.1038/38483	http://dx.doi.org/10.1038/38483			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305840				2022-12-24	WOS:A1997XW77200045
J	Lurie, P; Wolfe, SM				Lurie, P; Wolfe, SM			Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ZIDOVUDINE TREATMENT; CLINICAL RESEARCH; HIV-INFECTION; INFANT; TYPE-1; ETHICS				Lurie, P (corresponding author), PUBL CITIZENS HLTH RES GRP,WASHINGTON,DC 20009, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; ANNAS G, 1997, BOSTON GLOBE    0518, pC1; Bishop WP, 1996, S AFR MED J, V86, P458; BRENNAN TA, 1994, COMMUNICATION   1228; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper E., 1996, P57; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; HALSEY NA, 1997, COMMUNICATION   0506; HEIMLICH HJ, 1996, 11 INT C AIDS VANC J; LALLEMANT M, 1995, ZDV COURSE PREVENT P; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MACHIN D, 1987, STAT TABLES DESIGN C, P35; *NIH, 1997, DRAFT TALK POINTS RE; ROUZIOUX C, 1993, AIDS, V7, pS49, DOI 10.1097/00002030-199311002-00011; Scarlatti G, 1996, LANCET, V348, P863, DOI 10.1016/S0140-6736(95)11030-5; SIMONDS RJ, 1996, 11 INT C AIDS VANC C; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; VARMUS H, 1997, TESTIMONY SUBCOMMITT; VARMUS H, 1996, M ADV COMM DIR NIH D; *WHO, 1994, REC M MOTH INF TRANS; WIKTOR SZ, RANDOMIZED PLACEBO B; World Health Organization, 1993, INT ETH GUID BIOM RE	25	457	474	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					853	856		10.1056/NEJM199709183371212	http://dx.doi.org/10.1056/NEJM199709183371212			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9295246				2022-12-24	WOS:A1997XW28300012
J	Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H				Aboussouan, LS; Khan, SU; Meeker, DP; Stelmach, K; Mitsumoto, H			Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis	ANNALS OF INTERNAL MEDICINE			English	Article							NASAL VENTILATION; NATURAL-HISTORY; PREDICTION; DISEASE	Background: Noninvasive positive-pressure ventilation may benefit patients with amyotrophic lateral sclerosis and respiratory insufficiency. Objective: To determine 1) whether patients tolerant of noninvasive positive-pressure ventilation have better survival than intolerant patients and 2) whether bulbar symptoms account for intolerance of noninvasive positive-pressure ventilation. Design: Observational cohort study. Setting: Tertiary care referral center. Patients: 39 patients with amyotrophic lateral sclerosis who were treated with noninvasive positive-pressure ventilation. Intervention: Noninvasive positive-pressure ventilation was started for patients with new orthopnea, new hypercapnia, or both. Patients were divided into two groups: those tolerant of and those intolerant of noninvasive positive-pressure ventilation. Results: The risk for death from onset of respiratory insufficiency was higher for intolerant patients than for tolerant patients. (relative risk, 3.1 [95% CI, 1.8 to 9.6]). Moderate or severe bulbar symptoms were more prevalent among intolerant patients than among tolerant patients (67% compared with 33%; P = 0.04). Conclusions: Among patients with amyotrophic lateral sclerosis, those who are tolerant of noninvasive positive-pressure ventilation have better survival than do those who are intolerant. Bulbar symptoms partially account for intolerance of noninvasive positive-pressure ventilation.	WAYNE STATE UNIV, SCH MED, DETROIT, MI 48201 USA; CLEVELAND CLIN FDN, DEPT PULM & CRIT CARE MED, CLEVELAND, OH 44195 USA; CLEVELAND CLIN FDN, DEPT NEUROL, CLEVELAND, OH 44195 USA	Wayne State University; Cleveland Clinic Foundation; Cleveland Clinic Foundation			Aboussouan, Loutfi/O-2317-2019	Aboussouan, Loutfi/0000-0003-2716-0904				BACH JR, 1993, CHEST, V104, P1553, DOI 10.1378/chest.104.5.1553; BACH JR, 1994, LANCET, V344, P752, DOI 10.1016/S0140-6736(94)92242-X; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BROOKS BR, 1991, ADV NEUROL, V56, P521; CAROSCIO JT, 1987, NEUROL CLIN, V5, P1; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CROWLEY J, 1984, ANNU REV PUBL HEALTH, V5, P385; FALLAT RJ, 1979, ARCH NEUROL-CHICAGO, V36, P74, DOI 10.1001/archneur.1979.00500380044004; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; HILL NS, 1994, CHEST, V105, P337, DOI 10.1378/chest.105.2.337; HILLEL AD, 1989, NEUROEPIDEMIOLOGY, V8, P142, DOI 10.1159/000110176; HOWARD RS, 1989, BRAIN, V112, P1155, DOI 10.1093/brain/112.5.1155; JABLECKI CK, 1989, MUSCLE NERVE, V12, P833, DOI 10.1002/mus.880121008; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Oppenheimer Edward Anthony, 1993, Palliative Medicine, V7, P49; RAPHAEL JC, 1994, LANCET, V343, P1600	16	254	260	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1997	127	6					450	453		10.7326/0003-4819-127-6-199709150-00006	http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV779	9313002				2022-12-24	WOS:A1997XV77900006
J	Hanna, FWF; Scanlon, MF				Hanna, FWF; Scanlon, MF			Hyponatraemia, hypothyroidism, and role of arginine-vasopressin	LANCET			English	Editorial Material							MYXEDEMA; HYPONATREMIA				Hanna, FWF (corresponding author), UNIV WALES HOSP,DEPT DIABET ENDOCRINOL & METAB,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.			hanna, fahmy/0000-0001-5800-1442				ALLON M, 1990, J AM SOC NEPHROL, V1, P205; ARCHAMBEAUDMOUVEROUX F, 1987, ANN MED INTERNE, V138, P114; GILLUM DM, 1997, AM J PHYSIOL, V253, pF170; HOCHBERG Z, 1983, HORM RES, V17, P128, DOI 10.1159/000179687; IWASAKI Y, 1990, J CLIN ENDOCR METAB, V70, P534, DOI 10.1210/jcem-70-2-534; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; KOIDE Y, 1982, ENDOCRINOL JAPON, V29, P363; MCDONOUGH AA, 1988, AM J PHYSIOL, V254, pC323, DOI 10.1152/ajpcell.1988.254.2.C323; Montenegro J, 1996, AM J KIDNEY DIS, V27, P195, DOI 10.1016/S0272-6386(96)90539-9; OJAMAA K, 1993, ANN THORAC SURG, V56, pS61, DOI 10.1016/0003-4975(93)90556-W; Saito T, 1997, J CLIN ENDOCR METAB, V82, P1054, DOI 10.1210/jc.82.4.1054; SKOWSKY WR, 1978, AM J MED, V64, P613, DOI 10.1016/0002-9343(78)90581-8	12	74	80	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					755	756		10.1016/S0140-6736(05)62563-9	http://dx.doi.org/10.1016/S0140-6736(05)62563-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297992				2022-12-24	WOS:A1997XW28200007
J	Tanaka, TU; Knapp, D; Nasmyth, K				Tanaka, TU; Knapp, D; Nasmyth, K			Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; RECOGNITION COMPLEX; S-PHASE; XENOPUS; INITIATION; CHROMATIN; BINDING; KINASE; PHOSPHORYLATION	In eukaryotic cells, firing of DNA replication origins normally does not recur until after M phase. This characteristic is thought to be due to the properties of ''initiation'' proteins like Ore, Cdc6, and Mcms. Using formaldehyde cross-linking, we show that Cdc6p and Mcm7p associate specifically with replication origins during G1 but not during G2 in S. cerevisiae. Mcm7p's association with origins depends on Cdc6p. Ectopic expression of Cdc6p enables it to associate with origins during G2, but this fails to recruit Mcm7p. Our data suggest that the loading of Mcm proteins onto origins is regulated by two mechanisms: first, by Cdc6p occupancy, and second, by S-and M-CDKs, whose activity during S, G2, and M phases prevents Mcm loading.			Tanaka, TU (corresponding author), RES INST MOL PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.		Tanaka, Tomoyuki U/A-4775-2008; Knapp, Dunja/N-2180-2017	Knapp, Dunja/0000-0002-7533-2208; Nasmyth, Kim/0000-0001-7030-4403; Tanaka, Tomoyuki/0000-0002-9886-5947				BLOW JJ, 1996, EUKARYOTIC DNA REPLI, P143; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1996, MOL CELL BIOL, V16, P5081; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; NASMYTH K, 1996, DNA REPLICATION EUKA, P331; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TOYN JH, 1995, MOL CELL BIOL, V15, P5312; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	36	431	437	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					649	660		10.1016/S0092-8674(00)80526-7	http://dx.doi.org/10.1016/S0092-8674(00)80526-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288745	Bronze			2022-12-24	WOS:A1997XT06600009
J	Finzi, D; Hermankova, M; Pierson, T; Carruth, LM; Buck, C; Chaisson, RE; Quinn, TC; Chadwick, K; Margolick, J; Brookmeyer, R; Gallant, J; Markowitz, M; Ho, DD; Richman, DD; Siliciano, RF				Finzi, D; Hermankova, M; Pierson, T; Carruth, LM; Buck, C; Chaisson, RE; Quinn, TC; Chadwick, K; Margolick, J; Brookmeyer, R; Gallant, J; Markowitz, M; Ho, DD; Richman, DD; Siliciano, RF			Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DYNAMICS IN-VIVO; PERIPHERAL-BLOOD; LIFE-SPAN; T-CELL; INFECTION; LYMPHOCYTES; RESISTANCE; PLASMA; INHIBITOR	The hypothesis that quiescent CD4(+) T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4(+) T lymphocytes. The frequency of resting CD4(+) T cells harboring talent HIV-l was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4(+) T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Diego; University of California System; University of California San Diego			Quinn, Thomas/A-2494-2010; Buck, Christopher/G-8358-2017	Buck, Christopher/0000-0003-3165-8094	NIAID NIH HHS [AI28108, AI27670, AI23871] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028108, R01AI023871, R37AI028108, U01AI027670] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; CHUN TW, IN PRESS P NATL ACAD; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; EBERLE J, 1995, AIDS RES HUM RETROV, V11, P671, DOI 10.1089/aid.1995.11.671; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FINZI DD, UNPUB; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; MCLEAN AR, 1995, P NATL ACAD SCI USA, V92, P707; Mellors J. W., 1995, International Antiviral News, V3, P8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATEL SS, 1988, J IMMUNOL, V141, P3726; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PLATAK M, 1993, SCIENCE, V259, P1749; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Stellbrink HJ, 1997, AIDS, V11, P1103, DOI 10.1097/00002030-199709000-00004; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WONG JK, IN PRESS P NATL ACAD	33	2360	2424	4	146	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1295	1300		10.1126/science.278.5341.1295	http://dx.doi.org/10.1126/science.278.5341.1295			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360927				2022-12-24	WOS:A1997YG04300046
J	Lacronique, V; Boureux, A; DellaValle, V; Poirel, H; Quang, CT; Mauchauffe, M; Berthou, C; Lessard, M; Berger, R; Ghysdael, J; Bernard, OA				Lacronique, V; Boureux, A; DellaValle, V; Poirel, H; Quang, CT; Mauchauffe, M; Berthou, C; Lessard, M; Berger, R; Ghysdael, J; Bernard, OA			A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CYTOKINE RECEPTOR SUPERFAMILY; HEMATOPOIETIC-CELLS; TYROSINE KINASE; GENE; TEL; T(12-21); DEFECTS	The Janus family of tyrosine kinases (JAK) plays an essential role in development and in coupling cytokine receptors to downstream intracellular signaling events. A t(9;12)(p24;p13) chromosomal translocation in a T cell childhood acute lymphoblastic leukemia patient was characterized and shown to fuse the 3' portion of JAK2 to the 5' region of TEL, a gene encoding a member of the ETS transcription factor family, The TEL-JAK2 fusion protein includes the catalytic domain of JAK2 and the TEL-specific oligomerization domain, TEL-induced oligomerization of TEL-JAK2 resulted in the constitutive activation of its tyrosine kinase activity and conferred cytokine-independent proliferation to the interleukin-3-dependent Ba/F3 hematopoietic cell line.	INST GENET MOL, INSERM, U301, F-75010 PARIS, FRANCE; INST GENET MOL, CNRS, SD 401 301, F-75010 PARIS, FRANCE; CTR UNIV ORSAY, INST CURIE, SECT RECH, CNRS, UNITE MIXTE RECH 146, F-91405 ORSAY, FRANCE; CTR HOSP REG BREST, HOP MORVAN, LAB CYTOGENET, UNITE HEMATOL, F-29609 BREST, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; CHU Brest; Universite de Bretagne Occidentale			Penard-Lacronique, Virginie/R-1938-2019; Bernard, Olivier A./E-5721-2016; Penard-Lacronique, Virginie/E-5729-2016; QUANG, christine TRAN/G-7508-2016; GHYSDAEL, Jacques/F-3377-2013	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Bernard, Olivier/0000-0002-0463-9747				Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bernard OA, 1996, LEUKEMIA LYMPHOMA, V23, P459, DOI 10.3109/10428199609054854; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MIURA O, 1994, BLOOD, V84, P1501; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; PRITCHARD MA, 1992, MAMM GENOME, V3, P36, DOI 10.1007/BF00355839; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429	25	646	678	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1309	1312		10.1126/science.278.5341.1309	http://dx.doi.org/10.1126/science.278.5341.1309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360930				2022-12-24	WOS:A1997YG04300049
J	Wong, JK; Hezareh, M; Gunthard, HF; Havlir, DV; Ignacio, CC; Spina, CA; Richman, DD				Wong, JK; Hezareh, M; Gunthard, HF; Havlir, DV; Ignacio, CC; Spina, CA; Richman, DD			Recovery of replication-competent HIV despite prolonged suppression of plasma viremia	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR NECROSIS FACTOR; TYPE-1; EXPRESSION; SEQUENCE; PROTEASE	In evaluating current combination drug regimens for treatment of human immunodeficiency virus (HIV) disease, it is important to determine the existence of viral reservoirs. After depletion of CD8 cells from the peripheral blood mononuclear cells (PBMCs) of both patients and normal donors, activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from PBMCs of six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years. Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,TREATMENT CTR,SAN DIEGO,CA 92103; VET AFFAIRS SAN DIEGO HEALTHCARE SYST,SAN DIEGO,CA 92063	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Wong, JK (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		gunthard, huldrych f/F-1724-2011	gunthard, huldrych f/0000-0002-1142-6723	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001361, U01AI027670, U01AI038858] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FREUNDLICH B, 1983, J IMMUNOL METHODS, V62, P31, DOI 10.1016/0022-1759(83)90107-2; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Lech WJ, 1996, J VIROL, V70, P2038, DOI 10.1128/JVI.70.3.2038-2043.1996; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MATSUYAMA T, 1989, AIDS RES HUM RETROV, V5, P139, DOI 10.1089/aid.1989.5.139; Mulder J, 1997, J CLIN MICROBIOL, V35, P1278, DOI 10.1128/JCM.35.5.1278-1280.1997; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Sanchez G, 1997, J VIROL, V71, P2233, DOI 10.1128/JVI.71.3.2233-2240.1997; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1989, IMMUNOLOGY, V66, P628; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	25	1721	1763	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1291	1295		10.1126/science.278.5341.1291	http://dx.doi.org/10.1126/science.278.5341.1291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360926				2022-12-24	WOS:A1997YG04300045
J	Wallace, MR; Chamberlin, CJ; Zerboni, L; Sawyer, MH; Oldfield, EC; Olson, PE; Arvin, AM				Wallace, MR; Chamberlin, CJ; Zerboni, L; Sawyer, MH; Oldfield, EC; Olson, PE; Arvin, AM			Reliability of a history of previous varicella infection in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				ZOSTER VIRUS-INFECTIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDREN; SUSCEPTIBILITY; CHICKENPOX; ANTIBODY; VACCINE; REINFECTION; RESPONSES	Context.-Apparent second episodes of varicella are reported in immunocompetent hosts, but laboratory confirmation of prior immune status has rarely been possible. Objective.-To evaluate adult patients with varicella who claimed to have had previous varicella to determine whether they had true second episodes or primary cases with inaccurate clinical histories. Design.-Adult subjects with varicella who enrolled in an antiviral treatment trial were interviewed about a history of varicella. The clinical course of varicella was documented prospectively in all subjects. Serum samples that predated the acute illness were obtained from the US Navy's central serum storage facility for subjects who reported a previous episode of varicella. These stored samples were tested in parallel by enzyme-linked immunosorbent assay, latex agglutination, and Western blot for IgG antibodies to varicella-zoster virus (VZV), Participants.-Twenty military personnel with varicella and a history of the disease. Setting.-A military hospital in San Diego, Calif. Main Outcome Measure.-Presence or absence of antibodies to VZV. Results.-Twenty (10.8%) of 184 adults with serologically confirmed acute varicella reported a prior history of varicella. The clinical course of these 20 patients did not differ from those with no history of varicella. Serum samples that had been collected a mean of 12.4 months (median, 12 months; range, 3 days to 34 months) before the incident episode were available for 19 subjects. All 19 serum samples lacked IgG antibodies to VZV, Conclusion.-A history of previous varicella infection in adults with varicella may not be reliable. True second episodes of varicella are probably rare in immunocompetent adults.	NAVAL MED CTR, DIV INFECT DIS, DEPT INTERNAL MED, SAN DIEGO, CA 94305 USA; STANFORD UNIV, DEPT PEDIAT, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT INFECT DIS, STANFORD, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT PEDIAT, SAN DIEGO, CA USA	United States Department of Defense; United States Navy; Naval Medical Center San Diego; Stanford University; Stanford University; University of California System; University of California San Diego								ACHESON DWK, 1988, J INFECTION, V16, P193, DOI 10.1016/S0163-4453(88)94122-9; ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; BAXTER JD, 1994, CLIN INFECT DIS, V18, P785, DOI 10.1093/clinids/18.5.785; FELDMAN S, 1987, PEDIATRICS, V80, P465; Gallagher J, 1996, OCCUP MED-OXFORD, V46, P289, DOI 10.1093/occmed/46.4.289; GERSHON AA, 1990, J INFECT DIS, V161, P661, DOI 10.1093/infdis/161.4.661; GERSHON AA, 1981, AM J MED SCI, V282, P12, DOI 10.1097/00000441-198107000-00002; GERSHON AA, 1984, J INFECT DIS, V149, P137, DOI 10.1093/infdis/149.2.137; GERSHON AA, 1995, PEDIATR INFECT DIS J, V14, P742, DOI 10.1097/00006454-199509000-00003; GORDON JE, 1962, AM J MED SCI, V244, P132; GUERVICH I, 1990, INFECT CONT HOSP EP, V11, P510; JUNKER AK, 1994, J MED VIROL, V43, P119, DOI 10.1002/jmv.1890430204; Junker K, 1989, Curr Probl Dermatol, V18, P152; JURA E, 1989, PEDIATR INFECT DIS J, V8, P586, DOI 10.1097/00006454-198909000-00003; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; LOCKSLEY RM, 1985, J INFECT DIS, V152, P1172, DOI 10.1093/infdis/152.6.1172; MARTIN KA, 1994, J INFECT DIS, V170, P991, DOI 10.1093/infdis/170.4.991; MCKINNEY WP, 1989, AM J INFECT CONTROL, V17, P26, DOI 10.1016/S0196-6553(89)80009-4; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; MYERS MG, 1982, PEDIATRICS, V70, P199; PALUMBO PE, 1984, J GEN VIROL, V65, P2141, DOI 10.1099/0022-1317-65-12-2141; ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801; ROTBART HA, 1993, J INFECT DIS, V167, P195, DOI 10.1093/infdis/167.1.195; STEELE RW, 1982, PEDIATRICS, V70, P604; STEINBERG SP, 1991, J CLIN MICROBIOL, V29, P1527, DOI 10.1128/JCM.29.7.1527-1529.1991; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; vonSeidlein L, 1996, J PEDIATR-US, V128, P52, DOI 10.1016/S0022-3476(96)70427-4; Wallace MR, 1996, J INFECT DIS, V174, P249, DOI 10.1093/infdis/174.2.249; WALLACE MR, 1994, SOUTHERN MED J, V87, P74, DOI 10.1097/00007611-199401000-00016; WILLIAMS V, 1974, J INFECT DIS, V130, P669, DOI 10.1093/infdis/130.6.669	31	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1520	1522		10.1001/jama.278.18.1520	http://dx.doi.org/10.1001/jama.278.18.1520			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363973				2022-12-24	WOS:A1997YE44500037
J	Tjandra, N; Bax, A				Tjandra, N; Bax, A			Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium	SCIENCE			English	Article							QUANTITATIVE J-CORRELATION; PHOSPHOLIPID MICELLES; HUMAN UBIQUITIN; PROTEINS; RELAXATION; SPECTROSCOPY; RESOLUTION	In isotropic solution, internuclear dipolar couplings average to zero as a result of rotational diffusion. By dissolving macromolecules in a dilute aqueous nematic discotic liquid-crystalline medium containing widely spaced magnetically oriented particles, a tunable degree of solute alignment with the magnetic field can be created while retaining the high resolution and sensitivity of the regular isotropic nuclear magnetic resonance (NMR) spectrum. Dipolar couplings between H-1-H-1, H-1-C-13, H-1-N-15, and C-13-C-13 pairs in such an oriented macromolecule no longer average to zero, and are readily measured. Distances and angles derived from dipolar couplings in human ubiquitin are in excellent agreement with its crystal structure. The approach promises to improve the accuracy of structures determined by NMR, and extend the size limit.	NIDDKD, CHEM PHYS LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Tjandra, N (corresponding author), NHLBI, BIOPHYS CHEM LAB, NIH, BLDG 10, BETHESDA, MD 20892 USA.							Bax A, 1997, J BIOMOL NMR, V10, P289, DOI 10.1023/A:1018308717741; BODEN N, 1987, J PHYS CHEM-US, V91, P4092, DOI 10.1021/j100299a031; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; Emsley J.W., 1975, NMR SPECTROSCOPY USI; GRIESINGER C, 1986, J CHEM PHYS, V85, P6837, DOI 10.1063/1.451421; Harrison WJ, 1996, FARADAY DISCUSS, V104, P139, DOI 10.1039/fd9960400139; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kung HC, 1995, J MAGN RESON SER B, V109, P323, DOI 10.1006/jmrb.1995.9987; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MacArthur MW, 1996, J MOL BIOL, V264, P1180, DOI 10.1006/jmbi.1996.0705; METZ G, 1995, J AM CHEM SOC, V117, P564, DOI 10.1021/ja00106a078; Ottiger M, 1997, J AM CHEM SOC, V119, P9825, DOI 10.1021/ja971639e; RAM P, 1988, BIOCHIM BIOPHYS ACTA, V940, P289, DOI 10.1016/0005-2736(88)90203-9; SANDERS CR, 1994, PROG NUCL MAG RES SP, V26, P421, DOI 10.1016/0079-6565(94)80012-X; SANDERS CR, 1992, BIOCHEMISTRY-US, V31, P8898, DOI 10.1021/bi00152a029; SAUPE A, 1963, PHYS REV LETT, V11, P462, DOI 10.1103/PhysRevLett.11.462; Tjandra N, 1996, J AM CHEM SOC, V118, P6264, DOI 10.1021/ja960106n; Tjandra N, 1997, J MAGN RESON, V124, P512, DOI 10.1006/jmre.1996.1088; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; Tolman JR, 1996, J MAGN RESON SER B, V112, P245, DOI 10.1006/jmrb.1996.0138; Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Vold RR, 1996, J MAGN RESON SER B, V113, P267, DOI 10.1006/jmrb.1996.0187; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wuthrich K., 1986, NMR PROTEINS NUCL AC; [No title captured]	31	1429	1446	4	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1111	1114		10.1126/science.278.5340.1111	http://dx.doi.org/10.1126/science.278.5340.1111			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353189				2022-12-24	WOS:A1997YE65200048
J	Korth, C; Stierli, B; Streit, P; Moser, M; Schaller, O; Fischer, R; SchulzSchaeffer, W; Kretzschmar, H; Raeber, A; Braun, U; Ehrensperger, F; Hornemann, S; Glockshuber, R; Riek, R; Billeter, M; Wuthrich, K; Oesch, B				Korth, C; Stierli, B; Streit, P; Moser, M; Schaller, O; Fischer, R; SchulzSchaeffer, W; Kretzschmar, H; Raeber, A; Braun, U; Ehrensperger, F; Hornemann, S; Glockshuber, R; Riek, R; Billeter, M; Wuthrich, K; Oesch, B			Prion (PrPSc)-specific epitope defined by a monoclonal antibody	NATURE			English	Article							CREUTZFELDT-JAKOB-DISEASE; SCRAPIE PRION; PROTEIN PRP; MICE; GENE; FORMS	Prions are infectious particles causing transmissible spongiform encephalopathies (TSEs). They consist, at least in part, of an isoform (PrPSc) of the ubiquitous cellular prion protein (PrPC). Conformational differences between PrPC and PrPSc are evident from increased beta-sheet content and protease resistance in PrPSc (refs 1-3). Here we describe a monoclonal antibody, 15B3, that can discriminate between the normal and disease-specific forms of PrP. Such an antibody has been long sought as it should be invaluable far characterizing the infectious particle as well as for diagnosis of TSEs such as bovine spongiform encephalopathy (BSE) or Creutzfeldt-Jakob disease (CJD) in humans. 15B3 specifically precipitates bovine, murine or human PrPSc, but not PrPC, suggesting that it recognizes an epitope common to prions from different species. Using immobilized synthetic peptides, iue mapped three polypeptide segments in PrP as the 15B3 epitope. In the NMR structure of recombinant mouse PrP, segments 2 and 3 of the 15B3 epitope are near neighbours in space, and segment 1 is located in a different part nf the molecule, We discuss models for the PrPSc-specific epitope that ensure close spatial proximity of all three 15B3 segments, either by intermolecular contacts in oligomeric forms of the prion protein or by intramolecular rearrangement.	UNIV ZURICH, BRAIN RES INST, CH-8029 ZURICH, SWITZERLAND; ETH ZURICH, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; UNIV GOTTINGEN, INST NEUROPATHOL, D-37075 GOTTINGEN, GERMANY; UNIV ZURICH, INST NEUROPATHOL, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH, KLIN WIEDERKAUER & PFERDEMED, CH-8057 ZURICH, SWITZERLAND; UNIV ZURICH, INST VET PATHOL, CH-8057 ZURICH, SWITZERLAND; ETH ZURICH, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Gottingen; University of Zurich; University of Zurich; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Korth, C (corresponding author), UNIV ZURICH, PRION AG, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Korth, Carsten/F-7433-2010; Billeter, Martin/A-8293-2010	Riek, Roland/0000-0002-6333-066X				Billeter M, 1997, P NATL ACAD SCI USA, V94, P7281, DOI 10.1073/pnas.94.14.7281; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHANDLER RL, 1961, LANCET, V1, P1378; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Glockshuber R, 1997, TRENDS BIOCHEM SCI, V22, P241, DOI 10.1016/S0968-0004(97)01070-0; GOLDMANN W, 1991, J GEN VIROL, V72, P201, DOI 10.1099/0022-1317-72-1-201; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Kaneko K, 1997, J MOL BIOL, V270, P574, DOI 10.1006/jmbi.1997.1135; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KITAMOTO T, 1989, J GEN VIROL, V70, P3371, DOI 10.1099/0022-1317-70-12-3371; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1994, BIOCHEMISTRY-US, V33, P5926, DOI 10.1021/bi00185a033; PADAN EA, 1985, J BIOL CHEM, V260, P8280; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Warwicker J, 1996, BIOCHEM BIOPH RES CO, V226, P777, DOI 10.1006/bbrc.1996.1428; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201	27	516	566	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					74	77		10.1038/36337	http://dx.doi.org/10.1038/36337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363892				2022-12-24	WOS:A1997YE47700054
J	Sun, XW; Kuhn, L; Ellerbrock, TV; Chiasson, MA; Bush, TJ; Wright, TC				Sun, XW; Kuhn, L; Ellerbrock, TV; Chiasson, MA; Bush, TJ; Wright, TC			Human papillomavirus infection in women infected with the human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CERVICAL INTRAEPITHELIAL NEOPLASIA; CHAIN-REACTION AMPLIFICATION; RISK; DYSPLASIA	Background Among women infected with the human immunodeficiency virus (HIV), there is a high prevalence of human papillomavirus (HPV) infections. However, little is known about the natural history of HPV infections in HIV-seropositive women, and persistent HPV infections may explain the increased risk of cervical squamous intraepithelial lesions and invasive cervical cancer in HIV-seropositive women. Methods A total of 220 HIV-seropositive and 231 HIV-seronegative women in the New York City area were evaluated at two or more semiannual gynecologic examinations that included a Pap test, a test for HPV DNA, and colposcopy. Results HPV DNA was detected at the initial ex amination in 56 percent of the HIV-seropositive and 31 percent of the HIV-seronegative women. After four examinations, the cumulative prevalence of HPV infection was 83 percent in the seropositive women and 62 percent in the seronegative women (P<0.001). Persistent HPV infections were found in 24 percent of the seropositive women but in only 4 percent of the seronegative women (P<0.001). Twenty percent of the seropositive women and 3 percent of the seronegative women had persistent infections with HPV-16-associated viral types (16, 31, 33, 35, or 58) or HPV-18-associated types (18 or 45) (P<0.001), which are most strongly associated with cervical cancer. The detection of HPV DNA in women with previously negative tests was not associated with sexual activity during the interval since the preceding examination. Conclusions HIV-seropositive women have a high rate of persistent HPV infections with the types of HPV that are strongly associated with the development of high-grade squamous intraepithelial lesions and invasive cervical cancer. These persistent infections may explain the increased incidence of squamous intraepithelial lesions in HIV-seropositive women. (C) 1997, Massachusetts Medical Society.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10027; COLUMBIA UNIV,DIV EPIDEMIOL,NEW YORK,NY 10027; CTR DIS CONTROL & PREVENT,NATL CTR HIV STD & TB PREVENT,DIV HIV AIDS PREVENT,ATLANTA,GA; NEW YORK CITY DEPT HLTH,BUR DIS INTERVENT RES,NEW YORK,NY 10013	Columbia University; Columbia University; Columbia University; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene			Manzotti, Grazia/C-5985-2008		PHS HHS [U64/CCU206822] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; Bernard HU, 1996, J INFECT DIS, V173, P516; Chiasson MA, 1997, OBSTET GYNECOL, V89, P690, DOI 10.1016/S0029-7844(97)00069-0; Collett D, 1994, MODELLING SURVIVAL D; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hillemanns P, 1996, AIDS, V10, P1641, DOI 10.1097/00002030-199612000-00008; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; *IIARC, 1995, IARC MON EV CARC RIS, V64; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOULOS JP, 1993, GYNECOL ONCOL, V48, P364, DOI 10.1006/gyno.1993.1064; KREISS JK, 1992, SEX TRANSM DIS, V19, P54, DOI 10.1097/00007435-199201000-00011; LAGA M, 1992, INT J CANCER, V50, P45, DOI 10.1002/ijc.2910500110; LUNGU O, 1992, MOL CELL PROBE, V6, P145, DOI 10.1016/0890-8508(92)90059-7; MANOS MM, 1989, CANCER CEL, V7, P209; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; WILLIAMS AB, 1994, OBSTET GYNECOL, V83, P205; WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591	20	403	421	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1343	1349		10.1056/NEJM199711063371903	http://dx.doi.org/10.1056/NEJM199711063371903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358128				2022-12-24	WOS:A1997YE44600003
J	Fredricks, DN; Relman, DA				Fredricks, DN; Relman, DA			Cultivation of Whipple bacillus: the irony and the ecstasy	LANCET			English	Editorial Material							DISEASE; IDENTIFICATION		STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; VET AFFAIRS PALO ALTO HLTH CARE SYST,PALO ALTO,CA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Fredricks, DN (corresponding author), STANFORD UNIV,MED CTR,DEPT MED,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305, USA.			Fredricks, David/0000-0003-2735-6800; Relman, David A./0000-0001-8331-1354				BEUSCHER HU, 1995, INFECT IMMUN, V63, P1270, DOI 10.1128/IAI.63.4.1270-1277.1995; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; MARACK P, 1994, CELL, V76, P323; Ramzan NN, 1997, ANN INTERN MED, V126, P520, DOI 10.7326/0003-4819-126-7-199704010-00004; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; Schoedon G, 1997, J INFECT DIS, V176, P672, DOI 10.1086/514089; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; TRIER JS, 1965, GASTROENTEROLOGY, V48, P684; Whipple GH, 1907, B JOHNS HOPKINS HOSP, V18, P382; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z	12	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1262	1263		10.1016/S0140-6736(97)22044-1	http://dx.doi.org/10.1016/S0140-6736(97)22044-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357400	Green Submitted			2022-12-24	WOS:A1997YD68900002
J	Fuhlbrigge, RC; Kieffer, JD; Armerding, D; Kupper, TS				Fuhlbrigge, RC; Kieffer, JD; Armerding, D; Kupper, TS			Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells	NATURE			English	Article							P-SELECTIN; LEUKOCYTE ADHESION; FUCOSYL-TRANSFERASE; GLYCOPROTEIN LIGAND; PHYSIOLOGICAL FLOW; MYELOID CELLS; FUCT-VII; RECEPTOR; MOLECULE; BINDING	T cells play a pathogenic role in many inflammatory and certain malignant skin diseases, including psoriasis, atopic and allergic contact dermatitis, and cutaneous T-cell lymphoma(1-6). Memory T cells that infiltrate the skin express a unique skin-homing receptor called cutaneous lymphocyte-associated antigen (CLA), a carbohydrate epitope that facilitates the targeting of T cells to inflamed skin(1,7,8). CLA is defined by both its reactivity with a unique monoclonal antibody, HECA-452, and its activity as a ligand for E-selectin(2,9-11), but the structure of the protein component of CLA has not previously been defined. Here we report that CLA is an inducible carbohydrate modification of P-selectin glycoprotein ligand-1 (PSGL-1), a known surface glycoprotein that is expressed constitutively on all human peripheral-blood T cells, Cultured peripheral-blood T cells can be differentiated into CLA-bearing cells, which bind both E-selectin and P-selectin, or CLA-negative cells, which bind P-selectin but do not bind E-selectin, suggesting that there is independent regulation of selectin-binding phenotypes, We propose that differential post-translational modification of a single cell-surface receptor, PSGL-1, mediated by fucosyltransferase VII, serves as a mechanism for regulating tissue-specific homing of memory T cells.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV DERMATOL,HARVARD SKIN DIS RES CTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Kupper, Thomas/O-4962-2019					ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; BABI LFS, 1995, J IMMUNOL, V154, P1543; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Diacovo TG, 1996, J EXP MED, V183, P1193, DOI 10.1084/jem.183.3.1193; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; JONES DA, 1994, J CLIN INVEST, V94, P2443, DOI 10.1172/JCI117612; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kieffer JD, 1995, BIOCHEM BIOPH RES CO, V217, P466, DOI 10.1006/bbrc.1995.2799; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Lowe John B., 1994, P163; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Pitzalis C, 1996, ARTHRITIS RHEUM, V39, P137, DOI 10.1002/art.1780390118; ROOK AH, 1995, HEMATOL ONCOL CLIN N, V9, P997, DOI 10.1016/S0889-8588(18)30054-6; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Wagers AJ, 1996, BLOOD, V88, P2125, DOI 10.1182/blood.V88.6.2125.bloodjournal8862125	27	421	444	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					978	981		10.1038/40166	http://dx.doi.org/10.1038/40166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353122				2022-12-24	WOS:A1997YD29900058
J	Ikeya, M; Lee, SMK; Johnson, JE; McMahon, AP; Takada, S				Ikeya, M; Lee, SMK; Johnson, JE; McMahon, AP; Takada, S			Wnt signalling required for expansion of neural crest and CNS progenitors	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; VITAL DYE ANALYSIS; MOUSE EMBRYO; CELL-MIGRATION; INT-1 PROTOONCOGENE; EXPRESSION; TRANSFORMATION; HINDBRAIN; PATHWAYS; DOMAINS	Interactions between cells help to elaborate pattern within the vertebrate central nervous system (CNS)(1). The genes Wnt-1 and Wnt-3a, which encode members of the Wnt family of cysteine-rich secreted signals, are coexpressed at the dorsal midline of the developing neural tube, coincident with dorsal patterning(2,3). Each signal is essential for embryonic development, Wnt-1 for midbrain patterning(4,5) and Wnt-3a for formation of the paraxial mesoderm(6), but the absence of a dorsal neural-tube phenotype in each mutant suggests that Wnt signalling may be redundant. Here we demonstrate that in the absence of both Wnt-1 and Wnt-3a there is a marked deficiency in neural crest derivatives, which originate from the dorsal neural tube(7), and a pronounced reduction in dorsolateral neural precursors within the neural tube itself. These phenotypes do not seem to result from a disruption in the mechanisms responsible for establishing normal dorsoventral polarity. Rather, our results are consistent with a model in which local Wnt signalling regulates the expansion of dorsal neural precursors. Given the widespread expression of different Wnt genes in discrete areas of the mammalian neural tube(3), this may represent a general model for the action of Wnt signalling in the developing CNS.	KYOTO UNIV, FAC SCI, CTR MOL & DEV BIOL, SAKYO KU, KYOTO 60601, JAPAN; HARVARD UNIV, BIOLABS, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	Kyoto University; Harvard University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Johnson, Jane/F-8881-2010; McMahon, Andrew P/ABE-7520-2020	Ikeya, Makoto/0000-0002-3930-8032; /0000-0002-8605-2746; Takada, Shinji/0000-0003-4125-6056				Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; Couly G, 1996, DEVELOPMENT, V122, P3393; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Kontges G, 1996, DEVELOPMENT, V122, P3229; Le Douarin N.M., 1982, NEURAL CREST; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MADEN M, 1992, MECH DEVELOP, V37, P13, DOI 10.1016/0925-4773(92)90011-8; MARK M, 1993, DEVELOPMENT, V119, P319; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SERBEDZIJA GN, 1989, DEVELOPMENT, V106, P809; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	30	560	571	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					966	970		10.1038/40146	http://dx.doi.org/10.1038/40146			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353119				2022-12-24	WOS:A1997YD29900055
J	Dahmane, N; Lee, J; Robins, P; Heller, P; Altaba, ARI				Dahmane, N; Lee, J; Robins, P; Heller, P; Altaba, ARI			Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours	NATURE			English	Article							BASAL-CELL CARCINOMAS; HUMAN HOMOLOG; CANDIDATE GENE; EXPRESSION; MUTATIONS; IDENTIFICATION; ONCOGENE; PROTEIN	Sporadic basal cell carcinoma (BCC) is the most common type of malignant cancer in fair-skinned adults. Familial BCCs and a fraction of sporadic BCCs have lost the function of Patched (Ptc), a Sonic hedgehog (Shh) receptor(1-3) that acts negatively on this signalling pathway. Overexpression of Shh can induce BCCs in mice(4). Here we show that ectopic expression of the zinc-finger transcription factor Gli1 in the embryonic frog epidermis results in the development of tumours that express endogenous Gli1. We also show that Shh and the Gli genes are normally expressed in hair follicles, and that human sporadic BCCs consistently express Gli1 but not Shh or Gli3. Because Gli1, but not Gli3, acts as a target and mediator of Shh signalling(5), our results suggest that expression of GLi(1) in basal cells induces BCC formation. Moreover, loss of Ptc or overexpression of Shh cannot be the sole causes of Gli1 induction and sporadic BCC formation, as they do not occur consistently. Thus any mutations leading to the expression of Gli1 in basal cells are predicted to induce CC formation.	NYU,MED CTR,SKIRBALL INST,DEV GENET PROGRAM,NEW YORK,NY 10016; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016	New York University; New York University; New York University				Ruiz i Altaba, Ariel/0000-0003-2292-3933				Ackerman A.B., 1993, NEOPLASMS FOLLICULAR; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; ALTABA ARI, 1995, DEV BIOL, V1270, P299; ALTABA ARI, 1993, ESSENTIAL DEV BIOL P; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GRIMWOOD RE, 1986, J INVEST DERMATOL, V86, P191, DOI 10.1111/1523-1747.ep12284253; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Iseki S, 1996, BIOCHEM BIOPH RES CO, V218, P688, DOI 10.1006/bbrc.1996.0123; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lee J, 1997, DEVELOPMENT, V124, P2537; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; ROBERTS WM, 1989, CANCER RES, V49, P5407; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5048; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; XIAO HG, 1994, PEDIATR NEUROSURG, V20, P178, DOI 10.1159/000120783	29	515	539	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					876	881		10.1038/39918	http://dx.doi.org/10.1038/39918			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349822				2022-12-24	WOS:A1997YC14800063
J	Lowe, SL; Peter, F; Subramaniam, VN; Wong, SH; Hong, WJ				Lowe, SL; Peter, F; Subramaniam, VN; Wong, SH; Hong, WJ			A SNARE involved in protein transport through the Golgi apparatus	NATURE			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; VESICULAR TRANSPORT; FUSION; VESICLES; COMPLEX; ER; BOS1P; YEAST	In eukaryotic cells, the Golgi apparatus receives newly synthesized proteins from the endoplasmic reticulum (ER) and delivers them after covalent modification to their destination in the cell. These proteins move from the inside (cis) face to the plasma-membrane side (trans) of the Golgi, through a stack of cisternae, towards the trans-Golgi network (TGN), but very little is known about how proteins are moved through the Golgi compartments. In a model known as the maturation model, no special transport process was considered necessary, with protein movement along the Golgi being achieved by maturation of the cisternae. Alternatively, proteins could be transported by vesicles or membrane tubules. Although little is known about membrane-tubule-mediated transport, the molecular mechanism for vesicle-mediated transport is quite well understood, occurring through docking of SNAREs on the vesicle with those on the target membrane. We have now identified a protein of relative molecular mass 27K which is associated with the Golgi apparatus. The cytoplasmic domain of this protein or antibodies raised against it quantitatively inhibit transport in vitro from the ER to the trans-Golgi/TGN, acting at a stage between the cis/medial- and the trans-Golgi/TGN. This protein, which behaves like a SNARE and has been named GS27 (for Golgi SNARE of 27K), is identical to membrin, a protein implicated earlier in ER-to-Golgi transport. Our results suggest that protein movement from medial- to the trans-Golgi/TGN depends on SNARE-mediated vesicular transport.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 119076,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Subramaniam, V. Nathan/A-1901-2010; HONG, Wanjin/E-9927-2010	Subramaniam, V. Nathan/0000-0002-4583-7790; 				BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HONG W, 1996, PROTEIN TRAFFICKING; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; Lowe SL, 1996, J CELL SCI, V109, P209; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1992, J CELL BIOL, V119, P1077; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	28	69	73	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					881	884		10.1038/39923	http://dx.doi.org/10.1038/39923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349823				2022-12-24	WOS:A1997YC14800064
J	Sun, FL; Dean, WL; Kelsey, G; Allen, ND; Reik, W				Sun, FL; Dean, WL; Kelsey, G; Allen, ND; Reik, W			Transactivation of Igf2 in a mouse model of Beckwith-Wiedemann syndrome	NATURE			English	Article							GROWTH-FACTOR-II; PERINATAL LETHALITY; TRANSGENIC MICE; GENE; OVERGROWTH; METHYLATION; EXPRESSION; H19; CHROMOSOME-7; MUTATIONS	The gene IGF2, which encodes a fetal insulin-like growth factor, is imprinted, so only one of two parental copies of the gene is expressed, The altered expression of IGF2 has been implicated in Beckwith-Wiedemann syndrome, a human fetal overgrowth syndrome, which is characterized by overgrowth of several organs and an increased risk of developing childhood tumours, We have introduced Igf2 transgenes into the mouse genome by using embryonic stern cells, which leads to transactivation of the endogenous Igf2 gene, The consequent overexpression of Igf2 results in most of the symptoms of Beckwith-Wiedemann syndrome, including prenatal overgrowth, polyhydramnios, fetal and neonatal lethality, disproportionate organ overgrowth including tongue enlargement, and skeletal abnormalities. These phenotypes establish Igf2 overexpression as a key determinant of Beckwith-Wiedemann syndrome.	BABRAHAM INST,DEPT GENET & DEV,LAB DEV GENET & IMPRINTING,CAMBRIDGE CB2 4AT,ENGLAND; BABRAHAM INST,DEPT GENET & DEV,DEV NEUROBIOL LAB,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			Reik, Wolf/I-6794-2012; allen, nick d/A-4336-2010	Reik, Wolf/0000-0003-0216-9881; Dean, Wendy/0000-0001-9441-5044; Allen, Nicholas/0000-0003-4009-186X; Kelsey, Gavin/0000-0002-9762-5634				BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ELLIOTT M, 1994, J MED GENET, V31, P560, DOI 10.1136/jmg.31.7.560; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; Hatada I, 1997, J BIOL CHEM, V272, P9120, DOI 10.1074/jbc.272.14.9120; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HEDBORG F, 1994, AM J PATHOL, V145, P802; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Joyce JA, 1997, HUM MOL GENET, V6, P1543, DOI 10.1093/hmg/6.9.1543; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE JE, 1993, MOL REPROD DEV, V35, P382, DOI 10.1002/mrd.1080350411; LEE JT, 1997, NATURE, V386, P272; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; McLaughlin KJ, 1996, DEVELOPMENT, V122, P265; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; REIK W, 1995, HUM MOL GENET, V4, P2379, DOI 10.1093/hmg/4.12.2379; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Sasaki H, 1996, DNA Res, V3, P331, DOI 10.1093/dnares/3.5.331; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; SLATTER RE, 1994, J MED GENET, V31, P749, DOI 10.1136/jmg.31.10.749; WALTER J, 1996, EPIGENETIC MECHANISM, P1195; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WARD A, 1992, INSULIN LIKE GROWTH, P45; Ward Andrew, 1997, Genes and Function, V1, P25; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	44	251	261	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					809	815		10.1038/39797	http://dx.doi.org/10.1038/39797			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349812				2022-12-24	WOS:A1997YC14800047
J	Cerritelli, ME; Cheng, NQ; Rosenberg, AH; McPherson, CE; Booy, FP; Steven, AC				Cerritelli, ME; Cheng, NQ; Rosenberg, AH; McPherson, CE; Booy, FP; Steven, AC			Encapsidated conformation of bacteriophage T7 DNA	CELL			English	Article							DOUBLE-STRANDED DNA; CRYO-ELECTRON-MICROSCOPY; HERPES-SIMPLEX VIRUS; X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; SIMIAN VIRUS-40; WILD-TYPE; HEADS; ORGANIZATION	The structural organization of encapsidated T7 DNA was investigated by cryo-electron microscopy and image processing. A tail-deletion mutant was found to present two preferred views of phage heads: views along the axis through the capsid vertex where the connector protein resides and via which DNA is packaged; and side views perpendicular to this axis. The resulting images reveal striking patterns of concentric rings in axial views, and punctate arrays in side views. As corroborated by computer modeling, these data establish that the T7 chromosome is spooled around this axis in approximately six coaxial shells in a quasicrystalline packing, possibly guided by the core complex on the inner surface of the connector.	NIAMSD,STRUCT BIOL LAB,NIH,BETHESDA,MD 20892; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); United States Department of Energy (DOE); Brookhaven National Laboratory								ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; AUBREY KL, 1992, BIOCHEMISTRY-US, V31, P11835, DOI 10.1021/bi00162a023; BAKER TS, 1989, BIOPHYS J, V55, P243, DOI 10.1016/S0006-3495(89)82799-7; BAKER TS, 1988, P NATL ACAD SCI USA, V85, P422, DOI 10.1073/pnas.85.2.422; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BLACK LW, 1985, P NATL ACAD SCI USA, V82, P7960, DOI 10.1073/pnas.82.23.7960; BOOY FP, 1985, J MOL BIOL, V184, P667, DOI 10.1016/0022-2836(85)90312-2; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; BOOY FP, 1992, P 50 ANN M EMSA, V1, P452; BOOY FP, 1992, MEMBRANE FUSION, P21; Casjens S., 1988, BACTERIOPHAGES, V1, P16; Cerritelli ME, 1996, J MOL BIOL, V258, P286, DOI 10.1006/jmbi.1996.0250; Cerritelli ME, 1996, J MOL BIOL, V258, P299, DOI 10.1006/jmbi.1996.0251; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; CHUNG YB, 1990, J MOL BIOL, V216, P939, DOI 10.1016/S0022-2836(99)80012-6; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DIERKSEN K, 1995, BIOPHYS J, V68, P1416, DOI 10.1016/S0006-3495(95)80314-0; DONATE LE, 1990, VIROLOGY, V179, P936, DOI 10.1016/0042-6822(90)90172-N; EARNSHAW W, 1976, J MOL BIOL, V104, P387, DOI 10.1016/0022-2836(76)90278-3; EARNSHAW WC, 1979, J MOL BIOL, V134, P575, DOI 10.1016/0022-2836(79)90368-1; EARNSHAW WC, 1978, CELL, V14, P559, DOI 10.1016/0092-8674(78)90242-8; EARNSHAW WC, 1977, NATURE, V268, P598, DOI 10.1038/268598a0; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; Garcia LR, 1996, J BACTERIOL, V178, P6921, DOI 10.1128/jb.178.23.6921-6929.1996; GELLERT M, 1964, J MOL BIOL, V8, P341, DOI 10.1016/S0022-2836(64)80197-2; HARRISON SC, 1983, J MOL BIOL, V171, P577, DOI 10.1016/0022-2836(83)90045-1; HUD NV, 1995, BIOPHYS J, V69, P1355, DOI 10.1016/S0006-3495(95)80002-0; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; KOSTURKO LD, 1979, CELL, V16, P515, DOI 10.1016/0092-8674(79)90026-6; LEPAULT J, 1987, EMBO J, V6, P1507, DOI 10.1002/j.1460-2075.1987.tb02393.x; LEPAULT J, 1985, J MOL BIOL, V182, P431, DOI 10.1016/0022-2836(85)90202-5; Livolant F, 1996, PROG POLYM SCI, V21, P1115, DOI 10.1016/S0079-6700(96)00016-0; MOFFATT BA, 1988, J BACTERIOL, V170, P2095, DOI 10.1128/jb.170.5.2095-2105.1988; MORITA M, 1993, VIROLOGY, V193, P748, DOI 10.1006/viro.1993.1183; NORTH AC, 1961, NATURE, V191, P1242, DOI 10.1038/1911242a0; RICHARDS KE, 1973, J MOL BIOL, V78, P255, DOI 10.1016/0022-2836(73)90114-9; ROEDER GS, 1977, VIROLOGY, V76, P263, DOI 10.1016/0042-6822(77)90302-6; SERWER P, 1986, J MOL BIOL, V190, P509, DOI 10.1016/0022-2836(86)90019-7; SERWER P, 1992, J MOL BIOL, V223, P999, DOI 10.1016/0022-2836(92)90258-L; Serwer P, 1997, J STRUCT BIOL, V120, P32, DOI 10.1006/jsbi.1997.3895; SERWER P, 1976, J MOL BIOL, V107, P271, DOI 10.1016/S0022-2836(76)80005-8; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; Steven A. C., 1986, ELECT MICROSCOPY PRO, P1; Steven AC, 1997, FASEB J, V11, P733, DOI 10.1096/fasebj.11.10.9271358; THOMAS GJ, 1990, J RAMAN SPECTROSC, V21, P569, DOI 10.1002/jrs.1250210908; TRUS BL, 1992, P NATL ACAD SCI USA, V89, P11508, DOI 10.1073/pnas.89.23.11508; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; WIDOM J, 1983, J MOL BIOL, V171, P419, DOI 10.1016/0022-2836(83)90038-4	49	298	302	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					271	280		10.1016/S0092-8674(00)80409-2	http://dx.doi.org/10.1016/S0092-8674(00)80409-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346244	Bronze			2022-12-24	WOS:A1997YC35000014
J	Zandi, E; Rothwarf, DM; Delhase, M; Hayakawa, M; Karin, M				Zandi, E; Rothwarf, DM; Delhase, M; Hayakawa, M; Karin, M			The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation	CELL			English	Article							SITE-SPECIFIC PHOSPHORYLATION; INDUCED APOPTOSIS; CELL-DEATH; PROTEINS; SIGNAL; FAMILY; UBIQUITINATION; DISSOCIATION; PROTEOLYSIS; DEGRADATION	Recently we purified a 900 kDa cytokine-responsive I kappa B kinase complex (IKK) and molecularly cloned one of its subunits, IKK alpha, a serine kinase. We now describe the molecular cloning and characterization of IKK beta, a second subunit of the IKK complex. IKK beta is 50% identical to IKK alpha and like it contains a kinase domain, a leucine zipper, and a helix-loop-helix. Although IKK alpha and IKK beta can undergo homotypic interaction, they also interact with each other and the functional IKK complex contains both subunits. The catalytic activities of both IKK alpha and IKK beta make essential contributions to I kappa B phosphorylation and NF-kappa B activation. While the interactions between IKK alpha and IKK beta may be mediated through their leucine zipper motifs, their helix-loop-helix motifs may be involved in interactions with essential regulatory subunits.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LAB GENE REGULAT & SIGNAL TRANSDUCT,LA JOLLA,CA 92093	University of California System; University of California San Diego			Delhase, Mireille/ABE-5256-2021	Delhase, Mireille/0000-0003-2312-1051	NCI NIH HHS [CA50528] Funding Source: Medline; NIEHS NIH HHS [ES06376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	28	1566	1637	1	43	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					243	252		10.1016/S0092-8674(00)80406-7	http://dx.doi.org/10.1016/S0092-8674(00)80406-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346241	Bronze			2022-12-24	WOS:A1997YC35000011
J	Jack, RS; Fan, XL; Bernheiden, M; Rune, G; Ehlers, M; Weber, A; Kirsch, G; Mentel, R; Furll, B; Freudenberg, M; Schmitz, G; Stelter, F; Schutt, C				Jack, RS; Fan, XL; Bernheiden, M; Rune, G; Ehlers, M; Weber, A; Kirsch, G; Mentel, R; Furll, B; Freudenberg, M; Schmitz, G; Stelter, F; Schutt, C			Lipopolysaccharide-binding protein is required to combat a murine Gram-negative bacterial infection	NATURE			English	Article							FREE-FLOW ISOTACHOPHORESIS; CD14; ENDOTOXIN; MICE; LPS; LIPOPROTEINS; MONOCYTES; RECEPTOR; SHOCK	An invading pathogen must be held in check by the innate immune system until a specific immune response can be mounted. In the case of Gram-negative bacteria, the principal stimulator of the innate immune system is Lipopolysaccharide (LPS), a component of the bacterial outer membrane(1). In vitro, LPS is bound by lipopolysaccharide-binding protein (LBP)(2) and transferred to CD14-the LPS receptor on the macrophage surface(3,4)-or to high-density lipoprotein (HDL) particles(5,6). Transfer to CD14 triggers an inflammatory response which is crucial for keeping an infection under control. Here we investigate how LBP functions in vivo by using LBP-deficient mice. Surprisingly, we find that LBP is not required in vivo for the clearance of LPS from the circulation, but is essential for the rapid induction of an inflammatory response by small amounts of LPS or Gram-negative bacteria and for survival of an intraperitoneal Salmonella infection.	UNIV GREIFSWALD,INST ANAT,D-17489 GREIFSWALD,GERMANY; UNIV GREIFSWALD,NUKL MED KLIN & POLIKLIN,D-17489 GREIFSWALD,GERMANY; UNIV GREIFSWALD,INST MED MIKROBIOL,D-17489 GREIFSWALD,GERMANY; MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY; UNIV KLINIKUM REGENSBURG,KLIN CHEM & LAB MED,D-93042 REGENSBURG,GERMANY	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; University of Regensburg	Jack, RS (corresponding author), UNIV GREIFSWALD,INST IMMUNOL & TRANSFUS MED,SAUERBRUCHSTR,D-17489 GREIFSWALD,GERMANY.			Freudenberg, Marina Alexandra/0000-0001-5894-1805				FREUDENBERG MA, 1991, INFECT IMMUN, V59, P2110, DOI 10.1128/IAI.59.6.2110-2115.1991; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GALLAY P, 1994, P NATL ACAD SCI USA, V91, P7922, DOI 10.1073/pnas.91.17.7922; Grunwald U, 1996, J IMMUNOL, V157, P4119; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; NOWICKA G, 1990, J LIPID RES, V31, P1947; NOWICKA G, 1990, J LIPID RES, V31, P1173; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHMITZ G, 1997, HDB LIPOPROTEIN TEST, P477; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schutt C, 1995, RES IMMUNOL, V146, P339, DOI 10.1016/0923-2494(96)81038-8; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J IMMUNOL, V158, P3925; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025	18	283	297	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					742	745		10.1038/39622	http://dx.doi.org/10.1038/39622			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338787				2022-12-24	WOS:A1997YA95900058
J	Dolan, RJ; Fink, GR; Rolls, E; Booth, M; Holmes, A; Frackowiak, RSJ; Friston, KJ				Dolan, RJ; Fink, GR; Rolls, E; Booth, M; Holmes, A; Frackowiak, RSJ; Friston, KJ			How the brain learns to see objects and faces in an impoverished context	NATURE			English	Article							INFERIOR TEMPORAL CORTEX; SELECTIVE ATTENTION; EXTRASTRIATE CORTEX; RECOGNITION MEMORY; NEURONS	A degraded image of an object or face, which appears meaningless when seen for the first time, is easily recognizable after viewing an undegraded version of the same image(1), The neural mechanisms by which this form of rapid perceptual learning facilitates perception are not well understood. Psychological theory suggests the involvement of systems for processing stimulus attributes, spatial attention and feature binding(2), as well as those involved in visual imagery(3). Here we investigate where and how this rapid perceptual learning is expressed in the human brain by using functional neuroimaging to measure brain activity during exposure to degraded images before and after exposure to the corresponding undegraded versions (Fig. 1), Perceptual learning of faces or objects enhanced the activity of inferior temporal regions known to be involved in face and object recognition respectively(4-6). In addition, both face and object learning led to increased activity in medial and lateral parietal regions that have been implicated in attention(7) and visual imagery(8). We observed a strong coupling between the temporal face area and the medial parietal cortex when, and only when, faces were perceived, This suggests that perceptual learning involves direct interactions between areas involved in face recognition and those involved in spatial attention, feature binding and memory recall.	ROYAL FREE HOSP,SCH MED,ACAD DEPT PSYCHIAT,LONDON NW3,ENGLAND; UNIV OXFORD,DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford	Dolan, RJ (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON W1N 3BG,ENGLAND.		Fink, Gereon R./AFW-9377-2022; Frackowiak, Richard/H-4383-2011; Fink, Gereon R./E-1616-2012; Frackowiak, Richard S/I-1809-2013; Friston, Karl/D-9230-2011	Fink, Gereon R./0000-0002-8230-1856; Frackowiak, Richard/0000-0002-3151-822X; Fink, Gereon R./0000-0002-8230-1856; Friston, Karl/0000-0001-7984-8909; Rolls, Edmund/0000-0003-3025-1292; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Clark VP, 1996, NEUROIMAGE, V4, P1, DOI 10.1006/nimg.1996.0025; DESIMONE R, 1979, BRAIN RES, V178, P363, DOI 10.1016/0006-8993(79)90699-1; Fink GR, 1996, NATURE, V382, P626, DOI 10.1038/382626a0; FLETCHER P, 1995, NEUROIMAGE, V2, P196; FRIEDMANHILL SR, 1995, SCIENCE, V269, P853, DOI 10.1126/science.7638604; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1997, HUM BRAIN MAPP, V5, P133, DOI 10.1002/(SICI)1097-0193(1997)5:2<133::AID-HBM7>3.0.CO;2-4; GROSS CG, 1979, NEUROPSYCHOLOGIA, V17, P215, DOI 10.1016/0028-3932(79)90012-5; GROSS CG, 1972, HDB SENSORY PHYSL, V7, P451; HAXBY JV, 1994, J NEUROSCI, V14, P6336; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; ISHAI A, 1995, SCIENCE, V268, P1772, DOI 10.1126/science.7792605; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kosslyn S. M., 1996, IMAGE BRAIN RESOLUTI; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.neuro.13.1.25; RAMACHANDRAN VS, 1994, ARTFUL EYE, P249; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SAKIA K, 1994, NEUROREPORT, V5, P829; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Talairach J., 1988, COPLANAR STEREOTAXIC; TANAKA K, 1986, J NEUROSCI, V6, P134; Tovee MJ, 1996, NEUROREPORT, V7, P2757, DOI 10.1097/00001756-199611040-00070; TREISMAN A, 1988, Q J EXP PSYCHOL-A, V40, P201, DOI 10.1080/02724988843000104; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549	30	295	296	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					596	599		10.1038/39309	http://dx.doi.org/10.1038/39309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335498	Green Submitted			2022-12-24	WOS:A1997YA00800058
J	Nakao, A; Afrakhte, M; Moren, A; Nakayama, T; Christian, JL; Heuchel, R; Itoh, S; Kawabata, N; Heldin, NE; Heldin, CH; tenDijke, P				Nakao, A; Afrakhte, M; Moren, A; Nakayama, T; Christian, JL; Heuchel, R; Itoh, S; Kawabata, N; Heldin, NE; Heldin, CH; tenDijke, P			Identification of Smad7, a TGF beta-inducible antagonist of TGF-beta signalling	NATURE			English	Article							MESODERM INDUCTION; XENOPUS-EMBRYOS; EXPRESSION; PROTEINS	TGF-beta signals from the membrane to the nucleus through serine. threonine kinase receptors and their downstream effecters, termed SMAD proteins(1). The activated TGF-beta receptor induces phosphorylation of two such proteins, Smad2 and Smad3 (refs 2-6), which form hetero-oligomeric complex(es) with Smad4/DPC4 (refs 5-10) that translocate to the nucleus(2,4,5,7), where they then regulate transcriptional responses(11,12). However, the mechanisms by which the intracellular signals of TGF-beta are switched off are unclear. Here we report the identification of Smad7, which is related to Smad6 (ref. 13). Transfection of Smad7 blocks responses mediated by TGF-beta in mammalian cells, and injection of Smad7 RNA into Xenopus embryos blocks activin/TGF-beta signalling. Smad7 associates stably with the TGF-beta receptor complex, but is not phosphorylated upon TGF-beta stimulation. TGF beta-mediated phosphorylation of Smad2 and Smad3 is inhibited by Smad7, indicating that the antagonistic effect of Smad7 is exerted at this important regulatory step. TGF-beta rapidly induces expression of Smad7 mRNA, suggesting that Smad7 may participate in a negative feedback loop to control TGF-beta responses.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN; OREGON HLTH SCI UNIV,SCH MED,DEPT CELL & DEV BIOL,L215,PORTLAND,OR 97201; JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; JAPAN SOC PROMOT SCI,RES FUTURE PROGRAM,TOSHIMA KU,TOKYO 170,JAPAN	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital; Oregon Health & Science University; Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science			Nakayama, Takuya/J-5812-2015; Heuchel, Rainer/P-7875-2019; Dijke, Peter ten/AAG-4660-2021	Nakayama, Takuya/0000-0002-5531-6710; Heuchel, Rainer/0000-0002-2782-585X; Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730				Afrakhte M, 1996, INT J CANCER, V68, P802; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moon R. T., 1989, TECHNIQUE, V1, P76; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	29	1482	1594	4	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					631	635		10.1038/39369	http://dx.doi.org/10.1038/39369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335507				2022-12-24	WOS:A1997YA00800067
J	Kroman, N; Wohlfahrt, J; Andersen, KW; Mouridsen, HT; Westergaard, T; Melbye, M				Kroman, N; Wohlfahrt, J; Andersen, KW; Mouridsen, HT; Westergaard, T; Melbye, M			Time since childbirth and prognosis in primary breast cancer: population based study	BRITISH MEDICAL JOURNAL			English	Article							FULL TERM PREGNANCY; WOMEN; RISK; INCREASE; BIRTH; AGE	Objective: To investigate whether time since birth of last child was of prognostic importance in Women with primary breast cancer. Design: Retrospective cohort study based on a population based database of breast cancer diagnoses with detailed information on tumour characteristics, treatment regimens, reproductive factors, and vital status. Setting: Denmark. Subjects: 5652 women with primary breast cancer aged 45 years or less at the time of diagnosis. Main outcome measures: 5 and 10 year survival; relative risk of dying. Results: Women diagnosed in the first 2 years after last childbirth had a crude 5 year survival of 58.7% and 10 year survival of 46.1% compared with 78.4% and 66.0% for Women whose last childbirth was more than 2 years before their diagnosis. After adjustment for age, reproductive factors, and stage of disease (tumour size, axillary nodal status, and histological grading), a diagnosis sooner than 2 years since last childbirth was significantly associated with a poor survival (relative risk 1.58, 95% confidence interval 1.24 to 2.02) compared with women who gave birth more than 5 years previously. Further analyses showed that the effect was not modified by age at diagnosis, tumour size, and nodal status. Conclusion: A diagnosis of breast cancer less than 2 years after having given birth is associated with a particularly pool-survival irrespective of the stage of disease at debut. Therefore, a recent pregnancy should be regarded as a negative prognostic factor and should be considered in. counselling these patients and in the decisions regarding adjuvant treatment.	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL RES,DK-2300 COPENHAGEN,DENMARK; CENT HOSP HILLEROD,DEPT SURG A,DK-3400 HILLEROD,DENMARK; RIGSHOSP,DANISH BREAST CANC COOPERAT GRP,DK-2100 COPENHAGEN,DENMARK	Aarhus University; Statens Serum Institut; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen				melbye, mads/0000-0001-8264-6785				ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; BOETANI JCM, 1988, PREV MED, V17, P634; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; Clark R M, 1989, Clin Oncol (R Coll Radiol), V1, P11, DOI 10.1016/S0936-6555(89)80004-4; COX DR, 1972, J R STAT SOC B, V34, P187; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; GRUBBS CJ, 1983, J NATL CANCER I, V71, P625; GUINEE VF, 1994, LANCET, V343, P1587; HART CA, 1988, BAILLIERE CLIN IMMUN, V2, P735; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; MAX MH, 1984, AM SURGEON, V50, P23; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; PETREK JA, 1994, MONOGR NCI, P113; *SAS I, 1992, P229 SAS I STAT; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; STIRRAT GM, 1994, BRIT MED J, V308, P1385, DOI 10.1136/bmj.308.6941.1385; STORM HH, 1991, CANC REGISTRATION PR, P220; TRETLI S, 1988, BRIT J CANCER, V58, P382, DOI 10.1038/bjc.1988.224; VONSCHOULTZ E, 1995, J CLIN ONCOL, V13, P430, DOI 10.1200/JCO.1995.13.2.430; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578	21	72	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					851	855		10.1136/bmj.315.7112.851	http://dx.doi.org/10.1136/bmj.315.7112.851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353505	Green Published			2022-12-24	WOS:A1997YA00700023
J	Hall, TMT; Porter, JA; Young, KE; Koonin, EV; Beachy, PA; Leahy, DJ				Hall, TMT; Porter, JA; Young, KE; Koonin, EV; Beachy, PA; Leahy, DJ			Crystal structure of a hedgehog autoprocessing domain: Homology between hedgehog and self-splicing proteins	CELL			English	Article							TERMINAL CLEAVAGE PRODUCT; SONIC HEDGEHOG; AUTOPROTEOLYTIC CLEAVAGE; CIRCULAR PERMUTATIONS; ANOMALOUS DIFFRACTION; PATTERNING ACTIVITY; XENOPUS-LAEVIS; INDUCTION; ALIGNMENT; SEQUENCE	The similar to 25 kDa carboxy-terminal domain of Drosophila Hedgehog protein (Hh-C) possesses an autoprocessing activity that results in an intramolecular cleavage of full-length Hedgehog protein and covalent attachment of a cholesterol moiety to the newly generated amino-terminal fragment. We have identified a 17 kDa fragment of Hh-C (Hh-C-17) active in the initiation of autoprocessing and report here its crystal structure. The Hh-C-17 structure comprises two homologous subdomains that appear to have arisen from tandem duplication of a primordial gene. Residues in the Hh-C-17 active site have been identified, and their role in Hedgehog autoprocessing probed by site-directed mutagenesis. Aspects of sequence, structure, and reaction mechanism are conserved between Hh-C-17 and the self-splicing regions of inteins, permitting reconstruction of a plausible evolutionary history of Hh-C and the inteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOL BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; NIH, NATL CTR BIOTECHNOL INFORMAT, NATL LIB MED, BETHESDA, MD 20894 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)			Hall, Traci/F-5849-2019	Hall, Traci/0000-0001-6166-3009				Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Burglin TR, 1996, CURR BIOL, V6, P1047, DOI 10.1016/S0960-9822(02)70659-3; BURNCROT DA, 1995, MOL CELL BIOL, V15, P2294; Dalgaard JZ, 1997, J COMPUT BIOL, V4, P193, DOI 10.1089/cmb.1997.4.193; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HEINEMANN U, 1995, TRENDS BIOCHEM SCI, V20, P349, DOI 10.1016/S0968-0004(00)89073-8; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JONES DH, 1992, BIOTECHNIQUES, V12, P528; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P141, DOI 10.1016/S0968-0004(00)88989-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PIETROKOVSKI S, 1997, IN PRESS PROT SCI; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P179, DOI 10.1016/S0968-0004(00)89003-9; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P777, DOI 10.1073/pnas.72.3.777; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x	51	226	235	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					85	97		10.1016/S0092-8674(01)80011-8	http://dx.doi.org/10.1016/S0092-8674(01)80011-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335337	hybrid			2022-12-24	WOS:A1997XZ80900011
J	Kim, U; SanchezVives, MV; McCormick, DA				Kim, U; SanchezVives, MV; McCormick, DA			Functional dynamics of GABAergic inhibition in the thalamus	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; CENTRAL-NERVOUS-SYSTEM; UNDERLYING SYNCHRONIZED OSCILLATIONS; IN-VITRO; POSTSYNAPTIC POTENTIALS; PERIGENICULATE NUCLEUS; ABSENCE SEIZURES; PYRAMIDAL CELLS; ELECTROPHYSIOLOGICAL PROPERTIES; THALAMOCORTICAL OSCILLATIONS	The inhibitory gamma-aminobutyric acid-containing (GABAergic) neurons of the thalamic reticular and perigeniculate nuclei are involved in the generation of normal and abnormal synchronized activity in thalamocortical networks. An important factor controlling the generation of activity in this system is the amplitude and duration of inhibitory postsynaptic potentials (IPSPs) in thalamocortical cells, which depend on the pattern of activity generated in thalamic reticular and perigeniculate cells. Activation of single ferret perigeniculate neurons generated three distinct patterns of GABAergic IPSPs in thalamocortical neurons of the dorsal lateral geniculate nucleus: Low-frequency tonic discharge resulted in small-amplitude IPSPs mediated by GABA(A) receptors, burst firing resulted in large-amplitude GABA(A) IPSPs, and prolonged burst firing activated IPSPs mediated by GABA(A) and GABA(B) receptors. These functional properties of GABAergic inhibition can reconfigure the operations of thalamocortical networks into patterns of activity associated with waking, slow-wave sleep, and generalized seizures.	YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA	Yale University			Sanchez-Vives, Maria/J-8526-2014; Kobelt, Liza/F-5926-2011; McCormick, David A/J-2649-2015	Sanchez-Vives, Maria/0000-0002-8437-9083; McCormick, David A/0000-0002-9803-8335				AVOLI M, 1983, J NEUROPHYSIOL, V50, P819, DOI 10.1152/jn.1983.50.4.819; Bal T, 1996, NEURON, V17, P297, DOI 10.1016/S0896-6273(00)80161-0; BAL T, 1995, J PHYSIOL-LONDON, V483, P641, DOI 10.1113/jphysiol.1995.sp020612; BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; BENARDO LS, 1994, J PHYSIOL-LONDON, V476, P203, DOI 10.1113/jphysiol.1994.sp020124; BERMAN NJ, 1992, PROG BRAIN RES, V90, P443; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUSCH C, 1990, COLD SH Q B, V55, P69; BUZSAKI G, 1991, NEUROSCIENCE, V41, P351, DOI 10.1016/0306-4522(91)90332-I; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CONTRERAS D, 1993, J PHYSIOL-LONDON, V470, P273, DOI 10.1113/jphysiol.1993.sp019858; Cox C. L., 1996, Society for Neuroscience Abstracts, V22, P97; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; CUCCHIARO JB, 1991, J COMP NEUROL, V310, P316, DOI 10.1002/cne.903100304; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; DESTEXHE A, 1995, P NATL ACAD SCI USA, V92, P9515, DOI 10.1073/pnas.92.21.9515; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Jones EG, 1985, THALAMUS; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILES R, 1990, J PHYSIOL-LONDON, V431, P659, DOI 10.1113/jphysiol.1990.sp018353; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OTIS TS, 1992, J NEUROPHYSIOL, V67, P227, DOI 10.1152/jn.1992.67.1.227; Peters A.J, 1985, CEREBRAL CORTEX CELL, V1, DOI [10.1086/414271, DOI 10.1086/414271]; SANCHEZVIVES MV, IN PRESS NEUROSCIENC; SNEAD OC, 1992, EUR J PHARMACOL, V213, P343, DOI 10.1016/0014-2999(92)90623-C; Sodickson DL, 1996, J NEUROSCI, V16, P6374; SOLTESZ I, 1992, PROG BRAIN RES, V90, P151; STERIADE M, 1986, J NEUROSCI, V6, P68; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; THOMPSON SM, 1992, J PHYSIOL-LONDON, V451, P329, DOI 10.1113/jphysiol.1992.sp019167; THOMSON AM, 1988, NEUROSCIENCE, V25, P491, DOI 10.1016/0306-4522(88)90253-9; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; UHLRICH DJ, 1991, J NEUROPHYSIOL, V65, P1528, DOI 10.1152/jn.1991.65.6.1528; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; WARREN RA, 1994, J NEUROPHYSIOL, V72, P1993, DOI 10.1152/jn.1994.72.4.1993	50	259	263	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					130	134		10.1126/science.278.5335.130	http://dx.doi.org/10.1126/science.278.5335.130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311919				2022-12-24	WOS:A1997XZ12400055
J	Xu, J; Dodd, RL; Makino, CL; Simon, MI; Baylor, DA; Chen, J				Xu, J; Dodd, RL; Makino, CL; Simon, MI; Baylor, DA; Chen, J			Prolonged photoresponses in transgenic mouse rods lacking arrestin	NATURE			English	Article							PHOSPHODIESTERASE ACTIVATION; RETINAL RODS; IN-VIVO; RHODOPSIN; PROTEIN; BINDING; PHOTORECEPTORS; INACTIVATION; PHOTOTRANSDUCTION; PHOSPHORYLATION	Arrestins are soluble cytoplasmic proteins that bind to G-protein-coupled receptors, thus switching off activation of the G protein and terminating the signalling pathway that triggers the cellular response(1,2). Although visual arrestin has been shown to quench the catalytic activity of photoexcited, phosphorylated rhodopsin in a reconstituted system(3), its role in the intact rod cell remains unclear because phosphorylation alone reduces the catalytic activity of rhodopsin(4-6). Here we have recorded photocurrents of rods from transgenic mice in which one or both copies of the arrestin gene were disrupted, Photoresponses were unaffected when arrestin expression was halved, indicating that arrestin binding is not rate limiting for recovery of the rod photoresponse, as it is in Drosophila(7,8). With arrestin absent, the flash response displayed a rapid partial recovery followed by a prolonged final phase, This behaviour indicates that an arrestin-independent mechanism initiates the quench of rhodopsin's catalytic activity and that arrestin completes the quench, The intensity dependence of the photoresponse in rods lacking arrestin further suggests that, although arrestin is required for normal signal termination, it does not participate directly in light adaptation.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; CALTECH,DIV BIOL,PASADENA,CA 91125	Stanford University; California Institute of Technology			Makino, Clint Lawrence/H-8428-2019	Makino, Clint Lawrence/0000-0002-6005-9069				ADMUS G, 1997, INVEST OPHTH VIS SCI, V38, P283; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1987, RETINAL PROTEINS, P497; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CONE RA, 1969, NATURE, V221, P820, DOI 10.1038/221820a0; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEE RH, EXP EYE RES, V51, P325; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Palczewski K, 1996, EXP EYE RES, V63, P599, DOI 10.1006/exer.1996.0151; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PENN JS, 1986, EXP EYE RES, V43, P915, DOI 10.1016/0014-4835(86)90070-9; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMIREZSOLIS R, 1993, GUIDE TECHNIQUES MOU, P855; RANGANATHAN R, 1995, CELL, V81, P841, DOI 10.1016/0092-8674(95)90004-7; RAPORT CJ, 1994, INVEST OPHTH VIS SCI, V35, P2932; SCHREMSER JL, 1995, EXP EYE RES, V61, P17, DOI 10.1016/S0014-4835(95)80054-9; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	30	262	264	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					505	509		10.1038/39068	http://dx.doi.org/10.1038/39068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333241				2022-12-24	WOS:A1997XY90900059
J	Neuenschwander, H; Modell, B				Neuenschwander, H; Modell, B			Audit of process of antenatal screening for sickle cell disorders at a north London hospital	BRITISH MEDICAL JOURNAL			English	Article									UCL, SCH MED, WHITTINGTON HOSP, DEPT PRIMARY CARE & POPULAT SCI, LONDON N19 5HT, ENGLAND	University of London; University College London; UCL Medical School					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Modell B, 1997, BRIT MED J, V315, P779, DOI 10.1136/bmj.315.7111.779; MODELL M, 1990, BRIT MED J, V300, P1702, DOI 10.1136/bmj.300.6741.1702; PETROU M, 1992, J MED GENET, V29, P820, DOI 10.1136/jmg.29.11.820; *STAND MED ADV COM, 1994, REPORT WORKING PARTY	4	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					784	785						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345171				2022-12-24	WOS:A1997XY91100021
J	Hoganson, CW; Babcock, GT				Hoganson, CW; Babcock, GT			A metalloradical mechanism for the generation of oxygen from water in photosynthesis	SCIENCE			English	Article							AMINO-ACID-RESIDUES; TYROSINE Y-Z; PHOTOSYSTEM-II; EVOLVING COMPLEX; MANGANESE CLUSTER; D1 POLYPEPTIDE; REDUCED DERIVATIVES; PROTON RELEASE; ACTIVE-SITE; MN CLUSTER	In plants and algae, photosystem II uses light energy to oxidize water to oxygen at a metalloradical site that comprises a tetranuclear manganese cluster and a tyrosyl radical, A model is proposed whereby the tyrosyl radical functions by abstracting hydrogen atoms from substrate water bound as terminal ligands to two of the four manganese ions. Molecular oxygen is produced in the final step in which hydrogen atom transfer and oxygen-oxygen bond formation occur together in a concerted reaction. This mechanism establishes clear analogies between photosynthetic water oxidation and amino acid radical function in other enzymatic reactions.	MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM-37300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babcock G. T., 1995, PHOTOSYNTHESIS LIGHT, V2, P209; Babcock GT, 1997, ACTA CHEM SCAND, V51, P533, DOI 10.3891/acta.chem.scand.51-0533; BABCOCK GT, 1976, FEBS LETT, V61, P286; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; Baldwin MJ, 1996, J AM CHEM SOC, V118, P11325, DOI 10.1021/ja9626906; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BLOMBERG MRA, IN PRESS J AM CHEM S; Bogershausen O, 1996, BER BUNSEN PHYS CHEM, V100, P1987; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P1224, DOI 10.1021/bi00119a036; Britt R.D, 1996, ADV PHOTOSYNTHESIS O; BRUDVIG GW, 1986, P NATL ACAD SCI USA, V83, P4586, DOI 10.1073/pnas.83.13.4586; Caudle MT, 1997, J AM CHEM SOC, V119, P3415, DOI 10.1021/ja9641158; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; Cotton F. A., 1988, ADV INORG CHEM, P707; DAU H, 1995, BIOCHEMISTRY-US, V34, P5274, DOI 10.1021/bi00015a043; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P1, DOI 10.1016/0005-2728(84)90073-2; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; GARDNER KA, 1995, SCIENCE, V269, P1849, DOI 10.1126/science.7569922; GILBERT JA, 1985, J AM CHEM SOC, V107, P3855, DOI 10.1021/ja00299a017; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; GIRERD JJ, 1995, PHOTOSYNTHESIS LIGHT, V2, P217; GREENWOOD NN, 1984, CHEM ELEMENTS, P1228; HADDY A, 1992, BIOCHIM BIOPHYS ACTA, V1099, P25, DOI 10.1016/0304-4173(92)90004-X; HAUMANN M, 1994, BIOCHEMISTRY-US, V33, P864, DOI 10.1021/bi00170a003; Haumann M, 1996, BBA-BIOENERGETICS, V1273, P237, DOI 10.1016/0005-2728(95)00152-2; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P165; HOGANSON CW, 1994, MET IONS BIOL SYST, V30, P77; Hoganson CW, 1995, PHOTOSYNTH RES, V46, P177, DOI 10.1007/BF00020428; Ingold C. K., 1969, STRUCTURE MECHANISM, P457; Karge M, 1997, BIOCHEMISTRY-US, V36, P8904, DOI 10.1021/bi962342g; Karge M, 1996, FEBS LETT, V378, P140, DOI 10.1016/0014-5793(95)01433-0; KERR JA, 1996, HDB CHEM PHYSICS, P9; KHANGULOV S, 1993, BIOCHEMISTRY-US, V32, P4912, DOI 10.1021/bi00069a028; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KOIKE H, 1987, BIOCHIM BIOPHYS ACTA, V893, P524, DOI 10.1016/0005-2728(87)90104-6; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRAMARZ KW, 1994, PROG INORG CHEM, V42, P1, DOI 10.1002/9780470166437.ch1; Kretschmann H, 1996, BBA-BIOENERGETICS, V1274, P1, DOI 10.1016/0005-2728(95)00150-6; KRISHTALIK LI, 1990, BIOELECTROCH BIOENER, V23, P249, DOI 10.1016/0302-4598(90)80014-A; LAVERGNE J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P175, DOI 10.1016/S0005-2728(09)91005-2; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; LINDBERG K, 1993, PHOTOSYNTH RES, V38, P401, DOI 10.1007/BF00046767; LYDAKISSIMANTIR.N, IN PRESS BIOCH BIOPH; LYDAKISSIMANTIR.N, 1995, PHOTOSYNTHESIS LIGHT, V2, P279; MANCHANDA R, 1995, COORDIN CHEM REV, V144, P1, DOI 10.1016/0010-8545(95)01147-H; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MESSINGER J, 1995, PHOTOSYNTHESIS LIGHT, V2, P283; MESSINGER J, IN PRESS BIOCHEMISTR; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; ONO T, 1992, SCIENCE, V258, P1335, DOI 10.1126/science.258.5086.1335; PECORARO VL, 1988, PHOTOCHEM PHOTOBIOL, V48, P249; PECORARO VL, 1992, MANGANESE REDOX ENZY, P197; PROSS A, 1995, THEORETICAL PHYSICAL; RANDALL DW, 1995, J AM CHEM SOC, V117, P11780, DOI 10.1021/ja00152a021; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P86, DOI 10.1021/bi9614287; RENGER G, 1992, FEBS LETT, V299, P28, DOI 10.1016/0014-5793(92)80092-U; RIGGS PJ, 1992, J AM CHEM SOC, V114, P10650, DOI 10.1021/ja00052a079; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; Roelofs TA, 1996, P NATL ACAD SCI USA, V93, P3335, DOI 10.1073/pnas.93.8.3335; ROTZINGER FP, 1987, J AM CHEM SOC, V109, P6619, DOI 10.1021/ja00256a010; Sawyer D. T, 1991, OXYGEN CHEM; SHANK M, 1994, BIOCHEMISTRY-US, V33, P15433, DOI 10.1021/bi00255a025; STERN MK, 1992, MANGANESE REDOX ENZY, P233; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tang XS, 1996, J AM CHEM SOC, V118, P7638, DOI 10.1021/ja9610592; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; TIAN GC, 1994, BIOCHEMISTRY-US, V33, P226, DOI 10.1021/bi00167a030; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; TOMMOS C, IN PRESS ACCT CHEM R; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VINCENT JB, 1987, INORG CHIM A-BIOINOR, V136, pL41, DOI 10.1016/S0020-1693(00)81142-1; Wachter RM, 1996, J AM CHEM SOC, V118, P2782, DOI 10.1021/ja9519896; WALDO GS, 1992, J AM CHEM SOC, V114, P5869, DOI 10.1021/ja00040a064; Wincencjusz H, 1997, BIOCHEMISTRY-US, V36, P3663, DOI 10.1021/bi9626719; Witt HT, 1996, BER BUNSEN PHYS CHEM, V100, P1923, DOI 10.1002/bbpc.19961001202; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; [No title captured]	84	498	505	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1953	1956		10.1126/science.277.5334.1953	http://dx.doi.org/10.1126/science.277.5334.1953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302282				2022-12-24	WOS:A1997XX84900032
J	Kamohara, S; Burcelin, R; Halaas, JL; Friedman, JM; Charron, MJ				Kamohara, S; Burcelin, R; Halaas, JL; Friedman, JM; Charron, MJ			Acute stimulation of glucose metabolism in mice by leptin treatment	NATURE			English	Article							OBESE GENE; RAT HYPOTHALAMUS; MESSENGER-RNA; FOOD-INTAKE; OB PROTEIN; OB/OB MICE; EXPRESSION; INSULIN; RECEPTOR; IDENTIFICATION	Leptin is an adipocyte hormone that functions as an afferent signal in a negative feedback loop regulating body weight(1-4), and acts by interacting with a receptor in the hypothalamus and other tissues(5,6), Leptin treatment has potent effects on lipid metabolism, and leads to a large, specific reduction of adipose tissue mass after several days(1,4). Here we show that leptin also acts acutely to increase glucose metabolism, although studies of leptin's effect on glucose metabolism have typically been confounded by the weight-reducing actions of leptin treatment, which by itself could affect glucose homoeostasis(1-3). We have demonstrated acute in vivo effects of intravenous and intracerebroventricular administrations of leptin on glucose metabolism, A five-hour intravenous infusion of leptin into wild-type mice increased glucose turnover and glucose uptake, but decreased hepatic glycogen content, The plasma levels of insulin and glucose did not change. Similar effects were observed after both intravenous and intracerebroventricular infusion of leptin, suggesting that effects of leptin on glucose metabolism are mediated by the central nervous system (CNS), These data indicate that leptin induces a complex metabolic response with effects on glucose as well as lipid metabolism, This response is unique to leptin, which suggests that new efferent signals emanate from the CNS after leptin treatment.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10021	Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine				Kamohara, Seika/0000-0002-2482-6611				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125; GosteliPeter MA, 1996, BIOCHEM BIOPH RES CO, V221, P521, DOI 10.1006/bbrc.1996.0629; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; LAUTALA P, 1981, ACTA ENDOCRINOL-COP, V98, P481, DOI 10.1530/acta.0.0980481; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEONG SF, 1984, BIOCHEM J, V218, P131, DOI 10.1042/bj2180131; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Massillon D, 1995, AM J PHYSIOL-ENDOC M, V269, pE1037, DOI 10.1152/ajpendo.1995.269.6.E1037; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MILES PDG, 1991, P NATL ACAD SCI USA, V88, P1296, DOI 10.1073/pnas.88.4.1296; NAGAI K, 1988, HORM METAB RES, V20, P37, DOI 10.1055/s-2007-1010743; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Satoh N, 1997, ENDOCRINOLOGY, V138, P947, DOI 10.1210/en.138.3.947; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VRANIC M, 1976, J CLIN INVEST, V57, P245, DOI 10.1172/JCI108275; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185	29	591	613	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					374	377		10.1038/38717	http://dx.doi.org/10.1038/38717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311777				2022-12-24	WOS:A1997XX67500050
J	Williams, PA; Fulop, V; Garman, EF; Saunders, NFW; Ferguson, SJ; Hajdu, J				Williams, PA; Fulop, V; Garman, EF; Saunders, NFW; Ferguson, SJ; Hajdu, J			Haem-ligand switching during catalysis in crystals of a nitrogen-cycle enzyme	NATURE			English	Article							NITRIC-OXIDE; THIOSPHAERA-PANTOTROPHA; ELECTRON-TRANSFER; CYTOCHROME CD(1); HEME-PROTEINS; REDUCTASE; PSEUDOAZURIN; BINDING; PROGRAM	Cytochrome cd(1) nitrite reductase catalyses the conversion of nitrite to nitric oxide in the nitrogen cycle(1,2). The crystal structure of the oxidized enzyme(3,4) shows that the d(1) haem iron of the active site is ligated by His/Tyr side chains, and the c haem iron is ligated by a His/His ligand pair. Here we show that both haems undergo re-ligation during catalysis, Upon reduction, the tyrosine ligand of the d(1) haem is released to allow substrate binding, Concomitantly, a refolding of the cytochrome c domain takes place, resulting in an unexpected change of the c haem iron coordination from His17/His69 to Met106/His69. This step is similar to the last steps in the folding of cytochrome c(5-8). The changes must affect the redox potential of the haems, and suggest a mechanism by which internal electron transfer is regulated, Structures of reaction intermediates show how nitric oxide is formed and expelled from the active-site iron, as well as how both haems return to their starting coordination. These results show how redox energy can be switched into conformational energy within a haem protein.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND; UNIV UPPSALA,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	University of Oxford; University of Oxford; University of Oxford; Uppsala University			Saunders, Neil/B-5325-2010; Fulop, Vilmos/AAZ-7720-2021	Saunders, Neil/0000-0003-2139-6107; Williams, Pamela/0000-0002-1257-2351; Garman, Elspeth/0000-0001-8329-5665	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BERGER H, 1980, BIOCHIM BIOPHYS ACTA, V622, P355, DOI 10.1016/0005-2795(80)90047-1; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; EDWARDS SL, 1988, BIOCHEMISTRY-US, V27, P8074, DOI 10.1021/bi00421a016; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; PETTIGREW GW, 1987, CYTOCHROMES C BIOL A; PETTIGREW GW, 1987, CYTOCHROMES C EVOLUT; Poulos TL, 1996, NAT STRUCT BIOL, V3, P401, DOI 10.1038/nsb0596-401; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WILLIAMS PA, 1996, THESIS OXFORD U; Wittung P, 1996, FEBS LETT, V388, P47, DOI 10.1016/0014-5793(96)00513-3; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51	31	258	262	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					406	412		10.1038/38775	http://dx.doi.org/10.1038/38775			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311786				2022-12-24	WOS:A1997XX67500059
J	Liu, Q; Fischer, U; Wang, F; Dreyfuss, G				Liu, Q; Fischer, U; Wang, F; Dreyfuss, G			The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins	CELL			English	Article							MOTOR-NEURON GENE; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; COILED BODY; MOLECULAR ANALYSIS; CDNA CLONING; SURVIVAL; BINDING; DELETIONS; CAP; IDENTIFICATION	Spinal muscular atrophy (SMA), one of the most common fatal autosomal recessive diseases, is characterized by degeneration of motor neurons and muscular atrophy. The SMA disease gene, termed Survival of Motor Neurons (SMN), is deleted or mutated in over 98% of SMA patients. The function of the SMN protein is unknown. We found that SMN is tightly associated with a novel protein, SIP1, and together they form a specific complex with several spliceosomal snRNP proteins. SMN interacts directly with several of the snRNP Sm core proteins, including B, D1-3, and E. Interestingly, SIP1 has significant sequence similarity with Brr1, a yeast protein critical for snRNP biogenesis. these findings suggest a role for SMN and SIP1 in spliceosomal snRNP biogenesis and function and provide a likely molecular mechanism for the cause of SMA.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			Dreyfuss, Gideon/D-1218-2013; Fischer, Utz/AAT-8422-2020; Fischer, Utz/A-4090-2016	Dreyfuss, Gideon/0000-0001-8129-8774; Fischer, Utz/0000-0002-1465-6591; Fischer, Utz/0000-0002-1465-6591				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BOHMANN K, 1995, J CELL SCI S, V19, P107; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CHANG JG, 1995, AM J HUM GENET, V57, P1503; CHOI YD, 1984, J CELL BIOL, V99, P1997; COBBEN JM, 1995, AM J HUM GENET, V57, P805; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; CZEIZEI A, 1989, J MED GENET, V21, P761; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEENEY RJ, 1989, J BIOL CHEM, V264, P5776; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen E, 1996, AM J HUM GENET, V59, P1057; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HERRMANN H, 1995, EMBO J, V14, P2076; LATCHMAN D S, 1990, New Biologist, V2, P297; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Liu Q, 1996, COLD SPRING HARB SYM, V61, P689; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604	50	522	539	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1013	1021		10.1016/S0092-8674(00)80367-0	http://dx.doi.org/10.1016/S0092-8674(00)80367-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323129	hybrid			2022-12-24	WOS:A1997XX76800007
J	Bjorge, T; Dillner, J; Anttila, T; Engeland, A; Hakulinen, T; Jellum, E; Lehtinen, M; Luostarinen, T; Paavonen, J; Pukkala, E; Sapp, M; Schiller, J; Youngman, L; Thoresen, S				Bjorge, T; Dillner, J; Anttila, T; Engeland, A; Hakulinen, T; Jellum, E; Lehtinen, M; Luostarinen, T; Paavonen, J; Pukkala, E; Sapp, M; Schiller, J; Youngman, L; Thoresen, S			Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers	BRITISH MEDICAL JOURNAL			English	Article							ANAL EPIDERMOID CARCINOMA; SQUAMOUS-CELL CARCINOMA; INTRAEPITHELIAL NEOPLASIA; SERUM ANTIBODIES; UTERINE CERVIX; HPV DNA; TYPE-16; VULVA; INFECTION; EXPERIENCE	Objective: To evaluate the association between infection with the major oncogenic types of human papillomavirus and the risk of developing non-cervical anogenital cancers in a cohort followed up prospectively. Design: Data from two large serum banks to which about 700 000 people had donated serum samples were followed up for a mean of 8 years. People who developed non-cervical anogenital cancers during follow up were identified by registry linkage with the nationwide cancer registries in Finland and Norway Within this cohort a nested case-control study was conducted based on the serological diagnosis of infection with human papillomavirus types 16, 18, and 33. Subjects: 81 cases and 240 controls matched for sex, age, and storage time of serum samples. Main outcome measures: Odds ratios of developing non-cervical anogenital cancers in presence of IgG antibodies to specific micro-organisms. Results: Subjects seropositive far human. papillomavirus type 16 had an increased risk of developing non-cervical anogenital cancers (odds ratio 3.1 (95% confidence interval 1.4 to 6.9)). Subjects seropositive for type 33 also had an increased risk (odds ratio 2.8 (1.0 to 8.3)) but not significantly after adjustment for infection with type 16. Seropositivity for human papillomavirus type 16 was associated with an increased risk of developing vulvar and vaginal. cancers (odds ratio 4.5 (1.1 to 22)) and a strongly increased risk of developing preinvasive vulvar and vaginal lesions (odds ratio infinity (3.8 to infinity)). Seropositivity for human papillomavirus type 18 increased the risk of developing preinvasive lesions (odds ratio 12 (1.2 to 590)). High, but non-significant odds ratios for types 16 and 33 were seen for penile cancers. Conclusions: This study provides prospective seroepidemiological evidence that infection with human papillomavirus type 16 confers an increased risk of developing non-cervical genital cancers, particularly vulvar and vaginal cancers.	KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-17177 STOCKHOLM,SWEDEN; NATL PUBL HLTH INST,FIN-90101 OULU,FINLAND; KAROLINSKA INST,DEPT CANC EPIDEMIOL,S-17177 STOCKHOLM,SWEDEN; NORWEGIAN CANC SOC,JANUS COMM,N-0369 OSLO,NORWAY; NATL PUBL HLTH INST,DEPT INFECT DIS EPIDEMIOL,FIN-00300 HELSINKI,FINLAND; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,FIN-00170 HELSINKI,FINLAND; UNIV HELSINKI HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND; UNIV TAMPERE,TAMPERE SCH PUBL HLTH,FIN-33101 TAMPERE,FINLAND; UNIV MAINZ,DEPT MED MICROBIOL,D-55101 MAINZ,GERMANY; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV OXFORD,CLIN TRIALS SERV UNIT,OXFORD OX2 6HE,ENGLAND	Karolinska Institutet; Finland National Institute for Health & Welfare; Karolinska Institutet; Finland National Institute for Health & Welfare; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; Tampere University; Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford	Bjorge, T (corresponding author), CANC REGISTRY NORWAY,INST EPIDEMIOL CANC RES,N-0310 OSLO,NORWAY.		Engeland, Anders/AAG-7437-2021; Schiller, John/ABK-8287-2022	lehtinen, matti/0000-0002-9481-0535; van Tinteren, Harm/0000-0002-4626-8702; Bjorge, Tone/0000-0002-9096-5257; Paavonen, Jorma/0000-0003-4775-606X; Luostarinen, Tapio/0000-0003-3231-8550				AnderssonEllstrom A, 1996, SEX TRANSM DIS, V23, P234, DOI 10.1097/00007435-199605000-00013; ANDERSSONELLSTROM A, 1994, LANCET, V344, P1435, DOI 10.1016/S0140-6736(94)90601-7; ANSINK AC, 1994, GYNECOL ONCOL, V52, P180, DOI 10.1006/gyno.1994.1028; AYNAUD O, 1994, CANCER, V74, P1762, DOI 10.1002/1097-0142(19940915)74:6<1762::AID-CNCR2820740619>3.0.CO;2-1; BJORGE T, 1995, INT J CANCER, V62, P29, DOI 10.1002/ijc.2910620108; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1990, OBSTET GYNECOL, V75, P859; BRINTON LA, 1990, GYNECOL ONCOL, V38, P49, DOI 10.1016/0090-8258(90)90010-I; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; CHENG G, 1995, J INFECT DIS, V172, P1584, DOI 10.1093/infdis/172.6.1584; Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6; *CYT SOFTW CORP, 1993, LOGX TURB VERS 1 1, V1; Daling J R, 1992, IARC Sci Publ, P223; DILLNER J, 1995, CANCER J - FRANCE, V8, P264; Dillner J, 1996, J INFECT DIS, V173, P1394, DOI 10.1093/infdis/173.6.1394; DILLNER J, 1995, INT J CANCER, V60, P377; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; GRAHAM S, 1979, CANCER, V44, P1870, DOI 10.1002/1097-0142(197911)44:5<1870::AID-CNCR2820440546>3.0.CO;2-E; HEINO P, 1995, J NATL CANCER I, V87, P437, DOI 10.1093/jnci/87.6.437; HORDING U, 1994, GYNECOL ONCOL, V52, P241, DOI 10.1006/gyno.1994.1039; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; JELLUM E, 1995, ENVIRON HEALTH PERSP, V103, P85, DOI 10.2307/3432566; KIRNBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494, DOI 10.1093/jnci/86.7.494; Lehtinen M, 1996, BMJ-BRIT MED J, V312, P537, DOI 10.1136/bmj.312.7030.537; LI JY, 1982, JNCI-J NATL CANCER I, V69, P1063; MEHTA CR, 1995, STAT MED, V14, P2143, DOI 10.1002/sim.4780141908; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MESSING MJ, 1995, OBSTET GYNECOL, V86, P51, DOI 10.1016/0029-7844(95)00101-V; MILDELANGOSCH K, 1995, INT J CANCER, V63, P639, DOI 10.1002/ijc.2910630507; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; Trimble CL, 1996, OBSTET GYNECOL, V87, P59, DOI 10.1016/0029-7844(95)00351-7; WANG SP, 1970, AM J OPHTHALMOL, V70, P367, DOI 10.1016/0002-9394(70)90096-6; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	35	53	56	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					646	649		10.1136/bmj.315.7109.646	http://dx.doi.org/10.1136/bmj.315.7109.646			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310566	Green Published			2022-12-24	WOS:A1997XW69400019
J	Fertleman, CR; Gallagher, A; Rossiter, MA				Fertleman, CR; Gallagher, A; Rossiter, MA			Evaluation of fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences	BRITISH MEDICAL JOURNAL			English	Article									N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND									BLACK J, 1986, LIVING SICKLE CELL D, P112; FRANCEDAWSON M, 1994, NURS STAND, V45, P25; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN	3	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					650	650		10.1136/bmj.315.7109.650	http://dx.doi.org/10.1136/bmj.315.7109.650			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310567	Green Published			2022-12-24	WOS:A1997XW69400020
J	Neilson, JP				Neilson, JP			Assessment of fetal nuchal translucency test for Down's syndrome	LANCET			English	Editorial Material							FIRST-TRIMESTER; GENERAL-POPULATION; MATERNAL AGE; TRISOMY-21; THICKNESS; GESTATION; FETUSES				Neilson, JP (corresponding author), UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							ALFIREVIC Z, 1997, PREGNANCY CHILDBIRTH; Braithwaite JM, 1996, BRIT J OBSTET GYNAEC, V103, P1201, DOI 10.1111/j.1471-0528.1996.tb09629.x; Chaban FK, 1996, PRENATAL DIAG, V16, P537, DOI 10.1002/(SICI)1097-0223(199606)16:6<537::AID-PD911>3.0.CO;2-4; Hyett JA, 1996, ULTRASOUND OBST GYN, V7, P101, DOI 10.1046/j.1469-0705.1996.07020101.x; HYETT JA, 1995, AM J OBSTET GYNECOL, V172, P1411, DOI 10.1016/0002-9378(95)90470-0; Kornman LH, 1996, PRENATAL DIAG, V16, P797, DOI 10.1002/(SICI)1097-0223(199609)16:9<797::AID-PD948>3.3.CO;2-D; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; ROBERTS LJ, 1995, BRIT J OBSTET GYNAEC, V102, P381, DOI 10.1111/j.1471-0528.1995.tb11289.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x; SZABO J, 1990, LANCET, V336, P1133, DOI 10.1016/0140-6736(90)92614-N	10	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					754	755		10.1016/S0140-6736(05)62562-7	http://dx.doi.org/10.1016/S0140-6736(05)62562-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297991				2022-12-24	WOS:A1997XW28200006
J	Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ				Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ			Impact of covert duplicate publication on meta-analysis: a case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTOPERATIVE NAUSEA; INTRAVENOUS ONDANSETRON; REDUNDANT PUBLICATION; MULTIPLE PUBLICATION; CONTROLLED TRIALS; PREVENTION; SURGERY; DROPERIDOL; PLACEBO; QUALITY	Objective: To quantify the impact of duplicate data on estimates of efficacy. Design: Systematic search for published full reports of randomised controlled trials investigating ondansetron's effect on postoperative emesis. Abstracts were not considered. Data sources: Eighty four-trials (11 980 patients receiving ondansetron) published between 1991 and September 1996. Main outcome measures: Percentage of duplicated trials and patient data. Estimation of antiemetic efficacy (prevention of emesis) of the most duplicated ondansetron regimen. Comparison between the efficacy of non-duplicated and duplicated data. Results: Data from nine trials had been published in 14 further reports, duplicating data from 3335 patients receiving ondansetron; none used a clear cross reference. Intravenous ondansetron 4 mg versus placebo was investigated in 16 reports not subject to duplicate publication three reports subject to duplicate publication, and six duplicates of those three reports. The number needed to treat to prevent vomiting within 24 hours was 9.5 (95% confidence interval 6.9 to 15) in the 16 non-duplicated reports and 3.9 (3.3 to 4.8) in the three reports which were duplicated (P < 0.00001). When these 19 were combined the number needed to treat was 6.4 (5.3 to 7.9). When all original and duplicate reports were combined (n = 25) the apparent number needed to treat improved to 4.9 (4.4 to 5.6). Conclusions: By searching systematically we found 17% of published full reports of randomised trials and 28% of the patient data were duplicated. Trials reporting greater treatment effect were significant more likely to be duplicated. Inclusion of duplicated data in meta-analysis led to a 23% overestimation of ondansetron's antiemetic efficacy.	JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Oxford	Tramer, MR (corresponding author), CHURCHILL HOSP, NUFFIELD DEPT ANAESTHET, OXFORD OX3 7LJ, ENGLAND.							ANGELL M, 1989, NEW ENGL J MED, V320, P1212, DOI 10.1056/NEJM198905043201812; [Anonymous], 1979, BMJ-BRIT MED J, V1, P532; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; Calamandrei M, 1994, Cah Anesthesiol, V42, P19; CALAMANDREI M, 1994, MINERVA ANESTESIO S1, V60, P37; Campbell C, 1995, AM J ANESTHESIOL, V22, P81; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; Collini S., 1995, Acta Anaesthesiologica Italica, V46, P49; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAVIS A, 1995, ANAESTH INTENS CARE, V23, P438, DOI 10.1177/0310057X9502300404; DERSHWITZ M, 1992, CLIN PHARMACOL THER, V52, P96, DOI 10.1038/clpt.1992.107; DERSHWITZ M, 1997, AMBULATORY ANESTHESI, P441; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIDONATO A, 1994, MINERVA ANESTHESI S1, V60, P61; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x; GIORGI L, 1994, MINERVA ANESTESIO S1, V60, P73; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HELMERS JH, 1992, EUROPEAN J ANAEST S6, V9, P49; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466; KHALIL SN, 1994, ANESTH ANALG, V79, P845; Kovac A, 1992, Eur J Anaesthesiol Suppl, V6, P37; Kovac AL, 1996, J CLIN ANESTH, V8, P644, DOI 10.1016/S0952-8180(96)00173-0; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V270, P2495, DOI 10.1001/jama.1993.03510200101040; MARKHAM A, 1993, DRUGS, V45, P931, DOI 10.2165/00003495-199345060-00006; MCKENZIE R, 1993, J CLIN ANESTH, V5, P30, DOI 10.1016/0952-8180(93)90084-R; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Melani A. M., 1995, Acta Anaesthesiologica Italica, V46, P37; PAECH MJ, 1995, ANAESTH INTENS CARE, V23, P548, DOI 10.1177/0310057X9502300503; PAXTON LD, 1995, ANAESTHESIA, V50, P403, DOI 10.1111/j.1365-2044.1995.tb05993.x; PEARMAN MH, 1994, ANAESTHESIA, V49, P11, DOI 10.1111/j.1365-2044.1994.tb03577.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; Taddei F., 1995, Acta Anaesthesiologica Italica, V46, P43; Tramer M, 1997, BRIT J ANAESTH, V78, P247, DOI 10.1093/bja/78.3.247; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088; TRAMER MR, IN PRESS ANESTHESIOL; VOLPE N, 1994, DRUG INVEST, V8, P67, DOI 10.1007/BF03257429; VOLPE N, 1994, MINERVA ANESTESIO S1, V60, P121; WATCHA MF, 1995, EUR J ANAESTH, V12, P18; Zideman DA, 1996, MONATSSCHR KINDERH, V144, P727; ZIDEMAN DA, 1994, BRIT MED J, V308, P1349	47	451	455	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	1997	315	7109					635	640		10.1136/bmj.315.7109.635	http://dx.doi.org/10.1136/bmj.315.7109.635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310564	Green Published			2022-12-24	WOS:A1997XW69400017
J	Unger, VM; Hargrave, PA; Baldwin, JM; Schertler, GFX				Unger, VM; Hargrave, PA; Baldwin, JM; Schertler, GFX			Arrangement of rhodopsin transmembrane alpha-helices	NATURE			English	Article							PROJECTION STRUCTURE; BOVINE RHODOPSIN; ACTIVATION; RESOLUTION; RECEPTORS; PROTEIN; TRANSDUCIN; DOMAIN	Rhodopsins(1), the photoreceptors in rod cells, are G-protein-coupled receptors with seven hydrophobic segments containing characteristic conserved sequence patterns that define a large family(2,3). Members of the family are expected to share a conserved transmembrane structure. Direct evidence for the arrangement of seven alpha-helices was obtained from a 9 Angstrom projection map of bovine rhodopsin(4). Structural constraints inferred from a comparison of G-protein-coupled receptor sequences were used to assign the seven hydrophobic stretches in the sequence to features in the projection map(5), A low-resolution three-dimensional structure of bovine rhodopsin(6) and two projection structures of frog rhodopsin(7) confirmed the position of the three least tilted helices, 4, 6 and 7, A more elongated peak of density for helix 5 indicated that it is tilted or bent(6,7), but helices 1, 2 and 3 were not resolved, Here we have used electron micrographs of frozen-hydrated two-dimensional frog rhodopsin crystals to determine the structure of frog rhodopsin, Seven rods of density in the map are used to estimate tilt angles for the seven helices. Density visible on the extracellular side of the membrane suggests a folded domain, Density extends from helix 6 on the intracellular side, and a short connection between helices 1 and 2, and possibly a part of the carboxy terminus, are visible.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610	MRC Laboratory Molecular Biology; State University System of Florida; University of Florida; State University System of Florida; University of Florida			Schertler, Gebhard/M-9512-2014	Schertler, Gebhard F.X./0000-0002-5846-6810				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HAN M, 1995, BIOPHYS CHEM, V56, P23, DOI 10.1016/0301-4622(95)00011-L; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARGRAVE PA, 1993, INT REV CYTOL B, V137, P49; HAVELKA WA, 1995, J MOL BIOL, V247, P726, DOI 10.1006/jmbi.1995.0176; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; THURMOND RL, 1997, P NATL ACAD SCI USA, V94, P1713; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040	26	446	452	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					203	206		10.1038/38316	http://dx.doi.org/10.1038/38316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296501				2022-12-24	WOS:A1997XV75700054
J	Yu, SJM; Conticello, VP; Zhang, GH; Kayser, C; Fournier, MJ; Mason, TL; Tirrell, DA				Yu, SJM; Conticello, VP; Zhang, GH; Kayser, C; Fournier, MJ; Mason, TL; Tirrell, DA			Smectic ordering in solutions and films of a rod-like polymer owing to monodispersity of chain length	NATURE			English	Article							SYSTEM; PHASES	Solutions and melts of stiff ('rod-like') macromolecules often exhibit nematic liquid crystalline phases characterized by orientational, but not positional, molecular order(1,2). Smectic phases, in which macromolecular rods are organized into layers roughly perpendicular to the direction of molecular orientation, are rare, owing at least in part to the polydisperse nature (distribution of chain lengths) of polymers prepared by conventional polymerization processes. Bacterial methods for polypeptide synthesis(3), in which artificial genes encoding the polymer are expressed in bacterial vectors, offer the opportunity to make macromolecules with very well defined chain lengths. Here we show that a monodisperse derivative of poly(gamma-benzyl alpha,L-glutamate) prepared in this way shows smectic ordering in solution and in films. This result suggests that methods for preparing monodisperse polymers might provide access to new smectic phases with layer spacings that are susceptible to precise control on the scale of tens of nanometres.	UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOL BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst			Yu, Michael S/A-3332-2010	Conticello, Vincent/0000-0001-6940-6947				ALBRECHT C, 1993, PROG COLL POL SCI S, V92, P111; BLOCK H, 1993, POLY GAMMA BENZYL L, P135; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; Chen JT, 1996, SCIENCE, V273, P343, DOI 10.1126/science.273.5273.343; Demus D., 1978, TEXTURES LIQUID CRYS; DUKE RW, 1976, J AM CHEM SOC, V98, P3094, DOI 10.1021/ja00427a006; DUPRE DB, 1979, LIQUID CRYSTALS 4TH, P203; FLORY PJ, 1956, PROC R SOC LON SER-A, V234, P73, DOI 10.1098/rspa.1956.0016; KRICHELDORF HR, 1987, ALPHA AMINOACID N CA, P170; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIVOLANT F, 1986, J PHYS-PARIS, V47, P1813, DOI 10.1051/jphys:0198600470100181300; PAPKOV SP, 1984, ADV POLYM SCI, V59, P75; PRESTON J, 1978, LIQUID CRYSTALLINE O, P141; RADZILOWSKI LH, 1994, MACROMOLECULES, V27, P7747, DOI 10.1021/ma00104a033; ROBINSON C, 1957, NATURE, V180, P1183, DOI 10.1038/1801183a0; SAMULSKI ET, 1967, NATURE, V216, P997, DOI 10.1038/216997a0; STROOBANTS A, 1987, PHYS REV A, V36, P2929, DOI 10.1103/PhysRevA.36.2929; STUPP SI, 1993, SCIENCE, V259, P59, DOI 10.1126/science.259.5091.59; WATANABE J, 1993, ORDERING MACROMOLECU, P99; WEE EL, 1990, NATURE, V346, P44; WEN X, 1989, PHYS REV LETT, V63, P2760, DOI 10.1103/PhysRevLett.63.2760; WULFMAN DS, 1988, SYNTHETIC COMMUN, V18, P2349, DOI 10.1080/00397918808082380; ZHANG GH, 1992, MACROMOLECULES, V25, P3601, DOI 10.1021/ma00039a048	23	187	195	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					167	170		10.1038/38254	http://dx.doi.org/10.1038/38254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296493				2022-12-24	WOS:A1997XV75700044
J	Hickman, M; Sutcliffe, H; Sondhi, A; Stimson, GV				Hickman, M; Sutcliffe, H; Sondhi, A; Stimson, GV			Validation of a regional drug misuse database: implications for policy and surveillance of problem drug use in the UK	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Hickman, M (corresponding author), IMPERIAL COLL SCH MED, DEPT SOCIAL SCI & MED, CTR RES DRUGS & HLTH BEHAV, LONDON SW6 1RQ, ENGLAND.		Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X; Sondhi, Arun/0000-0002-4748-5522				CRABBE T, 1995, INT J DRUG POLICY, V6, P31; DONMALL M, 1990, DRUG MISUSE DATABASE; Home Office, 1995, TACKLING DRUGS TOGET; STIMSON GV, 1995, SOC SCI MED, V41, P699, DOI 10.1016/0277-9536(94)00435-V; SUTTON M, 1993, ADDICTION, V88, P455, DOI 10.1111/j.1360-0443.1993.tb02051.x	5	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	1997	315	7108					581	581						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302956				2022-12-24	WOS:A1997XV71700026
J	Zipkin, ID; Kindt, RM; Kenyon, CJ				Zipkin, ID; Kindt, RM; Kenyon, CJ			Role of a new Rho family member in cell migration and axon guidance in C-elegans	CELL			English	Article							GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; CAENORHABDITIS-ELEGANS; SMALL GTPASES; GENE; CDC42; RAC; SEQUENCE; PATHWAY; HOMOLOG	Rho family GTPases are thought to regulate actin-dependent processes, but their functions in vivo are still poorly understood. We have investigated the function of a new, widely expressed Rho family member in C. elegans by analyzing mutations in the endogenous gene. Activated and null alleles all inhibit cell migration, demonstrating that this protein is required for cell migration in vivo. Only a small subset of the migrations inhibited by activating mutations are inhibited by null mutations, suggesting that considerable functional redundancy exists within this system. Our findings support this conclusion and show that mig-2 functions redundantly with another pathway to regulate nuclear migration. Surprisingly, activated alleles also cause misguided axon growth, suggesting that Rho family GTPases may couple guidance cues to process outgrowth.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017924, R01GM037053] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM37053, 5F32GM17924-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; Chen WN, 1996, GENE, V180, P217, DOI 10.1016/S0378-1119(96)00414-3; CHEN WN, 1994, J BIOL CHEM, V269, P32394; CLARK DV, 1995, MOL GEN GENET, V247, P367, DOI 10.1007/BF00293205; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Forrester WC, 1997, DEVELOPMENT, V124, P1831; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Run JQ, 1996, GENETICS, V143, P225; RUVKUN G, 1989, GENETICS, V121, P501; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WILLIAMS BD, 1992, GENETICS, V131, P609	38	212	217	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					883	894		10.1016/S0092-8674(00)80353-0	http://dx.doi.org/10.1016/S0092-8674(00)80353-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298900	Bronze			2022-12-24	WOS:A1997XV56300009
J	Presley, JF; Cole, NB; Schroer, TA; Hirschberg, K; Zaal, KJM; LippincottSchwartz, J				Presley, JF; Cole, NB; Schroer, TA; Hirschberg, K; Zaal, KJM; LippincottSchwartz, J			ER-to-Golgi transport visualized in living cells	NATURE			English	Article							GREEN-FLUORESCENT PROTEIN; ENDOPLASMIC-RETICULUM; VIRAL GLYCOPROTEIN; BETA-COP; COMPLEX; COMPARTMENT; VIRUS; ORGANIZATION; MEMBRANES; SURFACE	Newly synthesized proteins that leave the endoplasmic reticulum (ER) are funnelled through the Golgi complex before being sorted for transport to their different final destinations. Traditional approaches have elucidated the biochemical requirements for such transport(1-3) and have established a role for transport intermediates(4-8). New techniques for tagging proteins fluorescently(9,10) have made it possible to follow the complete life history of single transport intermediates in living cells, including their formation, path and velocity en route to the Golgi complex. We have now visualized ER-to-Golgi transport using the viral. glycoprotein ts045 VSVG tagged with green fluorescent protein (VSVG-GFP). Upon export from the ER, VSVG-GFP became concentrated in many differently shaped, rapidly forming pre-Golgi structures, which translocated inwards towards the Golgi complex along microtubules by using the microtubule minus-end-directed motor complex of dynein/dynactin. No loss of fluorescent material from pre-Golgi structures occurred during their translocation to the Golgi complex and they frequently stretched into tubular shapes. Together, our results indicate that these pre-Golgi carrier structures moving unidirectionally along microtubule tracks are responsible for transporting VSVG-GFP through the cytoplasm to the Golgi complex. This contrasts with the traditional focus on small vesicles as the primary vehicles for ER-to-Golgi transport.	NICHHD, CELL BIOL & METAB BRANCH, NICHHD, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University			Hirschberg, Koret/AAF-4566-2019	Schroer, Trina/0000-0002-5065-1835	NIGMS NIH HHS [R01 GM044589] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Burkhardt J. K., 1995, Molecular Biology of the Cell, V6, p266A; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429	31	940	960	1	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					81	85		10.1038/38001	http://dx.doi.org/10.1038/38001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288971				2022-12-24	WOS:A1997XU59600049
J	Blatchford, O; Davidson, LA; Murray, WR; Blatchford, M; Pell, J				Blatchford, O; Davidson, LA; Murray, WR; Blatchford, M; Pell, J			Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER; HEMORRHAGE; MORTALITY	Objectives: To determine the incidence and case fatality of acute upper gastrointestinal haemorrhage in the west of Scotland and to identify associated factors. Design: Case ascertainment study. Setting: All hospitals treating adults with acute upper gastrointestinal haemorrhage in the west of Scotland. Subjects: 1882 patients aged 15 years and over treated in hospitals for acute upper gastrointestinal haemorrhage during a six month period. Main outcome measures:Incidence of acute upper gastrointestinal haemorrhage per 100 000 population per year, and case fatality. Results: The annual incidence was 172 per 100 000 people aged 15 and over. The annual population mortality was 14.0 per 100 000. Both were higher among elderly people, men, and patients resident in areas of greater social deprivation. Overall case fatality nias 8.2%. This was higher-among those who bled as inpatients after admission for other reasons (42%) and those admitted as tertiary referrals (16%). Factors associated with increased case fatality were age, uraemia, pre-existing malignancy, hepatic failure, hypotension, cardiac failure, and frank haematemesis or a history of syncope at presentation. Social deprivation, sex, and anaemia sere not associated with increased case fatality after adjustment for other factors. Conclusions: The incidence of acute upper gastrointestinal haemorrhage was 67% greater than the highest previously reported incidence in the United Kingdom, which may be partially attributable to the greater social deprivation in the west of Scotland and may be related to the increased prevalence of Helicobacter pylori. Fatality after acute upper gastrointestinal haemorrhage was associated with age, comorbidity, hypotension, and raised blood urea concentrations on admission, Although deprivation tvas associated with Increased incidence, it was not related to the risk of fatality.	ROYAL COLL PHYS & SURG GLASGOW, GLASGOW G2 5RJ, LANARK, SCOTLAND; GLASGOW ROYAL INFIRM NHS, GLASGOW G31 2ER, LANARK, SCOTLAND; EASTERHOUSE HLTH CTR, GLASGOW G34 9HQ, LANARK, SCOTLAND; GREATER GLASGOW HLTH BOARD, DEPT PUBL HLTH, GLASGOW G1 1ET, LANARK, SCOTLAND									ALLAN R, 1976, Q J MED, V45, P533; BROWN RC, 1976, BRIT MED J, V1, P35, DOI 10.1136/bmj.1.6000.35; CLASON AE, 1986, BRIT J SURG, V73, P985, DOI 10.1002/bjs.1800731213; FALAIYE JM, 1978, NIGERIAN MED J, V8, P526; HUNT PS, 1979, BRIT MED J, V1, P1238, DOI 10.1136/bmj.1.6173.1238; JOHNSTON SJ, 1973, BRIT MED J, V3, P655, DOI 10.1136/bmj.3.5882.655; JONES PF, 1973, BRIT MED J, V3, P660, DOI 10.1136/bmj.3.5882.660; KOHLI H S, 1992, Health Bulletin (Edinburgh), V50, P14; LENNARDJONES JE, 1992, J ROY COLL PHYS LOND, V26, P281; MACLEOD IA, 1982, BRIT J SURG, V69, P256, DOI 10.1002/bjs.1800690509; McLoone P., 1994, CARSTAIRS SCORES SCO; MORGAN AG, 1988, SCAND J GASTROENTERO, V23, P51; MORRIS R, 1991, DEPRIVATION HLTH SCO; OHMANN C, 1992, SCAND J GASTROENTERO, V27, P571, DOI 10.3109/00365529209000121; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; *SCOTT HLTH SERV C, 1978, WHAT HAS BEEN HAPP P; *SPSS, 1993, SPSS WIND; VANZANTEN SJOV, 1995, ALIMENT PHARM THERAP, V9, P41; VELLACOTT KD, 1982, BRIT MED J, V284, P548, DOI 10.1136/bmj.284.6315.548; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	22	231	236	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	1997	315	7107					510	514		10.1136/bmj.315.7107.510	http://dx.doi.org/10.1136/bmj.315.7107.510			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329304	Green Published			2022-12-24	WOS:A1997XU50600016
J	Hueber, AO; Zornig, M; Lyon, D; Suda, T; Nagata, S; Evan, GI				Hueber, AO; Zornig, M; Lyon, D; Suda, T; Nagata, S; Evan, GI			Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis	SCIENCE			English	Article							T-CELL HYBRIDOMAS; FAS-LIGAND; IMMUNE EVASION; TUMOR-CELLS; DEATH; BCL-2; FAS/APO-1; PROTEIN; MICE; FIBROBLASTS	Induction of apoptosis by oncogenes like c-myc may be important in restraining the emergence of neoplasia, However, the mechanism by which c-myc induces apoptosis is unknown. CD95 (also termed Fas or APO-I) is a cell surface transmembrane receptor of the tumor necrosis factor receptor family that activates an intrinsic apoptotic suicide program in cells upon binding either its ligand CD95L or antibody, c-myc-induced apoptosis was shown to require interaction on the cell surface between CD95 and its ligand. c-Myc acts downstream of the CD95 receptor by sensitizing cells to the CD95 death signal. Moreover, IGF-I signaling and Bcl-2 suppress c-myc-induced apoptosis by also acting downstream of CD95, These findings link two apoptotic pathways previously thought to be independent and establish the dependency of Myc on CD95 signaling for its killing activity.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN	Cancer Research UK; Osaka University			Nagata, Shigekazu/AAG-3203-2019; Anne-Odile, Hueber/G-4352-2013; Anne-Odile, Hueber/P-9860-2019	Nagata, Shigekazu/0000-0001-9758-8426; Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUEBER AO, UNPUB; ITOH N, 1993, J IMMUNOL, V151, P621; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, UNPUB; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; ZORNIG M, 1995, ONCOGENE, V10, P2397	35	318	324	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1305	1309		10.1126/science.278.5341.1305	http://dx.doi.org/10.1126/science.278.5341.1305			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360929				2022-12-24	WOS:A1997YG04300048
J	Tinetti, ME; Williams, CS				Tinetti, ME; Williams, CS			Falls, injuries due to falls, and the risk of admission to a nursing home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; ELDERLY PEOPLE; OLDER PERSONS; FUNCTIONAL STATUS; COMMUNITY; POPULATION; ADULTS; EFFICACY; CARE; FEAR	Background Falls warrant investigation as a risk factor for nursing home admission because falls are common and are associated with functional disability and because they may be preventable. Methods We conducted a prospective study of a probability sample of 1103 people over 71 years of age who were living in the community. Data on demographic and medical characteristics, use of health care, and cognitive, functional, psychological, and social functioning were obtained at base line and one year later during assessments in the participants' homes. The primary outcome studied was the number of days from the initial assessment to a first longterm admission to a skilled-nursing facility during three years of follow-up, Patients were assigned to four categories during follow-up: those who had no falls, those who had one fall without serious injury, those who had two or more falls without serious injury, and those who had at least one fall causing serious injury. Results A total of 133 participants (12.1 percent) had long-term admissions to nursing homes. In an unadjusted model, the risk of admission increased progressively, as compared with that for the patients with no falls, for those with a single noninjurious fall (relative risk, 4.9; 95 percent confidence interval, 3.2 to 7.5), those with multiple noninjurious falls (relative risk, 8.5; 95 percent confidence interval, 3.4 to 21.2), and those with at least one fall causing serious injury (relative risk, 19.9; 95 percent confidence interval, 12.2 to 32.6). Adjustment for other risk factors lowered these ratios to 3.1 (95 percent confidence interval, 1.9 to 4.9) for one noninjurious fall, 5.5 (95 percent confidence interval, 2.1 to 14.2) for two or more noninjurious falls, and 10.2 (95 percent confidence interval, 5.8 to 17.9) for at least one fall causing serious injury, but the association between falls and admission to a nursing home remained strong and significant. The population attributable risk of long-term admission to a nursing home for these three groups (the proportion of admissions directly attributable to the three categories of falls) was 13 percent, 3 percent, and 10 percent, respectively. Conclusions Among older people living in the community falls are a strong predictor of placement in a skilled-nursing facility; interventions that prevent falls and their sequelae may therefore delay or reduce the frequency of nursing home admissions. (C) 1997, Massachusetts Medical Society.			Tinetti, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.				NIA NIH HHS [R01 AG07447, P60AG10487] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Dunn J E, 1993, J Aging Health, V5, P194, DOI 10.1177/089826439300500203; Foley D J, 1992, J Aging Health, V4, P155, DOI 10.1177/089826439200400201; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREENE VL, 1990, J GERONTOL, V45, pS250, DOI 10.1093/geronj/45.6.S250; HORNBROOK MC, 1994, GERONTOLOGIST, V34, P16, DOI 10.1093/geront/34.1.16; JETTE AM, 1992, GERONTOLOGIST, V32, P634, DOI 10.1093/geront/32.5.634; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KIEL DP, 1991, MED CARE, V29, P221; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LIU K, 1991, MED CARE, V29, P125, DOI 10.1097/00005650-199102000-00005; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MURTAUGH CM, 1990, MED CARE, V28, P952, DOI 10.1097/00005650-199010000-00009; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; OLOUGHLIN JL, 1993, AM J EPIDEMIOL, V137, P342, DOI 10.1093/oxfordjournals.aje.a116681; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; REINSCH S, 1992, GERONTOLOGIST, V32, P450, DOI 10.1093/geront/32.4.450; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Seeman T. E., 1993, J AGING HEALTH, V5, P455, DOI DOI 10.1177/089826439300500403; Spielberger C., 1983, STAI MANUAL; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; WOLINSKY FD, 1993, J GERONTOL, V48, pS93; WOLINSKY FD, 1992, MED CARE, V30, P587, DOI 10.1097/00005650-199207000-00002	37	920	942	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1279	1284		10.1056/NEJM199710303371806	http://dx.doi.org/10.1056/NEJM199710303371806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC920	9345078				2022-12-24	WOS:A1997YC92000006
J	Han, SH; Dillon, SR; Zheng, B; Shimoda, M; Schlissel, MS; Kelsoe, G				Han, SH; Dillon, SR; Zheng, B; Shimoda, M; Schlissel, MS; Kelsoe, G			V(D)J recombinase activity in a subset of germinal center B lymphocytes	SCIENCE			English	Article							PRIMARY IMMUNE-RESPONSE; LIGHT-CHAIN; IN-SITU; RECIPROCAL PARTNERS; GENE REARRANGEMENT; CELLS; MATURATION; SELECTION; MECHANISM; ANTIGEN	Reexpression of the V(D)J recombinase-activating genes RAG1 and RAG2 in germinal center B cells creates the potential for immunoglobulin gene rearrangement and the generation of new antigen receptor specificities. intermediate products of V(D)J recombination are abundant in a subset of germinal center B cells, demonstrating that the kappa immunoglobulin light-chain locus becomes a substrate for renewed V(D)J recombinase activity. This recombinationally active cell compartment contains many heavy-chain VDJ rearrangements that encode low-affinity or nonfunctional antibody. In germinal centers, secondary V(D)J recombination may be induced by diminished binding to antigen ligands, thereby limiting abrupt changes in receptor specificity to B cells that are usually eliminated from the germinal center reaction, This restriction preserves efficient antigen-driven selection in germinal centers while allowing for saltations in the somatic evolution of B cells.	UNIV MARYLAND,SCH MED,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOL & CELL BIOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024335, R01AI040227, R37AI040227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48722] Funding Source: Medline; NIAID NIH HHS [AI40227, AI24335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; CERASOLI D, UNPUB; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; COICO RF, 1983, J IMMUNOL, V131, P2254; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; Cornall RJ, 1995, CURR OPIN IMMUNOL, V7, P804, DOI 10.1016/0952-7915(95)80052-2; COTTER F, 1990, BLOOD, V76, P131; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Han S.-G., UNPUB; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HAN SH, 1995, J IMMUNOL, V155, P556; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; JACOB J, 1993, J EXP MED, V178, P1293, DOI 10.1084/jem.178.4.1293; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; Karasuyama H, 1996, ADV IMMUNOL, V63, P1, DOI 10.1016/S0065-2776(08)60853-6; Kelsoe G, 1995, ADV IMMUNOL, V60, P267, DOI 10.1016/S0065-2776(08)60587-8; Kimoto H, 1997, EUR J IMMUNOL, V27, P268, DOI 10.1002/eji.1830270140; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MILLER C, 1995, J IMMUNOL, V155, P3377; Miller Carla, 1994, Aging Immunology and Infectious Disease, V5, P249; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347	38	252	254	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					301	305		10.1126/science.278.5336.301	http://dx.doi.org/10.1126/science.278.5336.301			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323211				2022-12-24	WOS:A1997YA56400048
J	Shinde, UP; Liu, JJ; Inouye, M				Shinde, UP; Liu, JJ; Inouye, M			Protein memory through altered folding mediated by intramolecular chaperones	NATURE			English	Article							SUBTILISIN BPN'; PRO-SEQUENCE; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PROPEPTIDE; CATALYSIS; PATHWAY; INHIBITION; MECHANISM	The 77-residue propeptide of subtilisin acts as an intramolecular chaperone that organizes the correct folding of its own protease domain, Similar folding mechanisms are used by several prokaryotic and eukaryotic proteins, including prohormone-convertases. Here we show that the intramolecular chaperone of subtilisin facilitates folding by acting as a template for its protease domain, although it does not form part of that domain. Subtilisin E folded by an intramolecular chaperone with an Ile(-48)-to-Val mutation acquires an 'altered' enzymatically active conformation that differs from wild-type subtilisin E. Although both the altered and wild-type subtilisins have identical amino-acid sequences, as determined by amino-terminal sequencing and mass spectrometry, they bind their cognate intramolecular chaperones with 4.5-fold greater affinity than non-cognate intramolecular chaperones, when added in trans. The two subtilisins also have different secondary structures, thermostability and substrate specificities. Our results indicate that an identical polypeptide can fold into an altered conformation through a mutated intramolecular chaperone and maintains memory of the folding process. Such a phenomenon, which we term 'protein memory', map be important in investigations of protein folding.			Shinde, UP (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.							ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BRYAN PN, 1995, INTRAMOLECULAR CHAPE, P85; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KLIBANOV AM, 1995, NATURE, V374, P596, DOI 10.1038/374596a0; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; LEE YC, 1992, FEMS MICROBIOL LETT, V92, P73, DOI 10.1016/0378-1097(92)90544-X; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; LONGSTAFF C, 1990, BIOCHEMISTRY-US, V29, P7339, DOI 10.1021/bi00483a025; MATHEWS BW, 1995, ADV PROTEIN CHEM, V462, P240; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1988, J BIOL CHEM, V263, P11624; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SILEN JL, 1989, NATURE, V341, P362; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WINTHER JR, 1994, J BIOL CHEM, V269, P7006; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	30	131	136	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					520	522		10.1038/39097	http://dx.doi.org/10.1038/39097			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333245				2022-12-24	WOS:A1997XY90900063
J	Tei, H; Okamura, H; Shigeyoshi, Y; Fukuhara, C; Ozawa, R; Hirose, M; Sakaki, Y				Tei, H; Okamura, H; Shigeyoshi, Y; Fukuhara, C; Ozawa, R; Hirose, M; Sakaki, Y			Circadian oscillation of a mammalian homologue of the Drosophila period gene	NATURE			English	Article							SUPRACHIASMATIC NUCLEUS; CLOCK GENE; MELANOGASTER; BEHAVIOR; PROTEIN; PRODUCT; LESIONS; SYSTEM	Many biochemical, physiological and behavioural processes in organisms ranging from microorganisms to vertebrates exhibit circadian rhythms(1). In Drosophila, the gene period (per) is required for the circadian rhythms of locomotor activity and eclosion behaviour(2). Oscillation in the levels of per mRNA and Period (dPer) protein in the fly brain is thought to be responsible for the rhythmicity(3,4). However, no per homologues in animals other than insects have been identified. Here we identify the human and mouse genes (hPER and mPer, respectively) encoding PAS-domain (PAS, a dimerization domain present in Per, Amt and Sim)-containing polypeptides that aro highly homologous to dPer. Besides this structural resemblance, mPer shows autonomous circadian oscillation in its expression in the suprachiasmatic nucleus, which is the primary circadian pacemaker in the mammalian brain(5,6). Clock, a mammalian clock gene encoding a PAS-containing polypeptide(7,8), has now been cloned: it is likely that the Per homologues dimerize with other molecule(s) such as Clock through PAS-PAS interaction in the circadian clock system.	KOBE UNIV, SCH MED, DEPT ANAT & BRAIN SCI, CHUO KU, KOBE, HYOGO 650, JAPAN; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Kobe University; Scripps Research Institute	Tei, H (corresponding author), UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Okamura, Hitoshi/0000-0002-3013-4881				Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Ban Y, 1997, J NEUROSCI, V17, P3920; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COLOT HV, 1988, EMBO J, V7, P3929, DOI 10.1002/j.1460-2075.1988.tb03279.x; EDMUNDS LN, 1988, CELLULAR MOL BASIS B; GILLETTE MU, 1987, BRAIN RES BULL, V19, P135, DOI 10.1016/0361-9230(87)90176-6; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; ITO T, 1993, ELECTROPHORESIS, V14, P278, DOI 10.1002/elps.1150140149; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; SAEZ L, 1988, MOL CELL BIOL, V8, P5378, DOI 10.1128/MCB.8.12.5378; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sambrook J., 1989, MOL CLONING; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; ZERR DM, 1990, J NEUROSCI, V10, P2749	27	641	671	3	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					512	516		10.1038/39086	http://dx.doi.org/10.1038/39086			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333243				2022-12-24	WOS:A1997XY90900061
J	Sagoo, MS; Lagnado, L				Sagoo, MS; Lagnado, L			G-protein deactivation is rate-limiting for shut-off of the phototransduction cascade	NATURE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; LIGHT ADAPTATION; RETINAL RODS; SALAMANDER RODS; CALCIUM-CONCENTRATION; SATURATING FLASHES; RHODOPSIN; KINETICS; TRANSDUCTION	Photoreceptors detect light through a seven-helix receptor (rhodopsin) and heterotrimeric G protein (transducin) coupled to a cyclic GMP phosphodiesterase(1,2). Similar pathways are used to amplify responses to hormones, taste and smell(3-5). The amplification of phototransduction is reduced by a fall in cytoplasmic Ca2+ (refs 6-10), but it is not known how the deactivation of rhodopsin and transducin influence this response and hence the extent and duration of phosphodiesterase activity(11-14). Here we investigate this by recording the electrical response to flashes of light in truncated rod photoreceptors(10). By removing ATP to block the deactivation of rhodopsin by phosphorylation(15), we show that this reaction limits the amplitude of the response and begins within 3.2 s of a flash in a solution containing 1 mu M Ca2+, falling to 0.9 s in a zero-Ca2+ solution. In contrast, the activation and amplitude of the response were unaffected when transducin deactivation by GTP hydrolysis was blocked by replacing GTP with its nonhydrolysable analogue GTP-gamma S-11, demonstrating that there is little GTP hydrolysis occurring over the period in which photoexcited rhodopsin is quenched. The rapid deactivation of rhodopsin is therefore a Ca2+-sensitive step controlling the amplitude of the light response, whereas transducin deactivation is slower and controls recovery.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Sagoo, Mandeep/0000-0003-1530-3824				CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CORSON DW, 1994, VISUAL NEUROSCI, V11, P91, DOI 10.1017/S0952523800011135; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Gold GH, 1997, NATURE, V385, P677, DOI 10.1038/385677a0; GrayKeller MP, 1996, NEURON, V17, P323, DOI 10.1016/S0896-6273(00)80163-4; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; JONES GJ, 1995, J PHYSIOL-LONDON, V487, P441, DOI 10.1113/jphysiol.1995.sp020891; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; Lyubarsky A, 1996, J GEN PHYSIOL, V107, P19, DOI 10.1085/jgp.107.1.19; Matthews HR, 1996, J PHYSIOL-LONDON, V490, P1; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; Murnick JG, 1996, J PHYSIOL-LONDON, V495, P1; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; Nikonov S. S., 1996, Investigative Ophthalmology and Visual Science, V37, pS5; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PEPPERBERG DR, 1994, VISUAL NEUROSCI, V11, P53, DOI 10.1017/S095252380001110X; Sagoo Mandeep S., 1997, Investigative Ophthalmology and Visual Science, V38, pS614; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YOUNGER JP, 1992, INVEST OPHTH VIS SCI, V33, P1104	30	69	69	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					392	395		10.1038/38750	http://dx.doi.org/10.1038/38750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311782				2022-12-24	WOS:A1997XX67500055
J	Nakajima, T; Uchida, C; Anderson, SF; Lee, CG; Hurwitz, J; Parvin, JD; Montminy, M				Nakajima, T; Uchida, C; Anderson, SF; Lee, CG; Hurwitz, J; Parvin, JD; Montminy, M			RNA helicase a mediates association of CBP with RNA polymerase II	CELL			English	Article							TRANSCRIPTION FACTOR CREB; GENE-TRANSCRIPTION; DOSAGE COMPENSATION; DEPENDENT ACTIVATOR; MOLECULAR-CLONING; MALELESS PROTEIN; COACTIVATOR CBP; BINDING PROTEIN; X-CHROMOSOME; COMPLEX	The coactivator CBP has been proposed to stimulate the expression of certain signal-dependent genes via its association with RNA polymerase II complexes. Here we show that complex formation between CBP and RNA polymerase II requires RNA helicase A (RHA), a nuclear DNA/RNA helicase that is related to the Drosophila male dosage compensation factor mle, In transient transfection assays, RHA was found to cooperate with CBP in mediating target gene activation via the CAMP responsive factor CREB. As a mutation in RHA that compromised its helicase activity correspondingly reduced CREB-dependent transcription, we propose that RHA may induce local changes in chromatin structure that promote engagement of the transcriptional apparatus on signal responsive promoters.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV MOL ONCOL,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Memorial Sloan Kettering Cancer Center			Parvin, Jeffrey D/C-8955-2009	jhangiry, parvin/0000-0003-1415-7212	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037828, R01GM053504, R01GM037828] Funding Source: NIH RePORTER; NCI NIH HHS [CA54418] Funding Source: Medline; NIGMS NIH HHS [GM37828, GM53504] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BHATTACHARYA S, 1996, NATURE, V383, P343; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CG, 1993, J BIOL CHEM, V268, P16822; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHANG SS, 1995, J BIOL CHEM, V270, P16422, DOI 10.1074/jbc.270.27.16422	27	455	474	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1107	1112		10.1016/S0092-8674(00)80376-1	http://dx.doi.org/10.1016/S0092-8674(00)80376-1			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323138	Bronze			2022-12-24	WOS:A1997XX76800016
J	Sidrauski, C; Walter, P				Sidrauski, C; Walter, P			The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response	CELL			English	Article							TRANSFER-RNA LIGASE; KAR2 BIP GENE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; 2-5A-DEPENDENT RNASE; YEAST; PATHWAY; OLIGOMERIZATION; PHOSPHORYLATION; INTERFERON	The endoplasmic reticulum (ER) communicates with the nucleus through the unfolded protein response (UPR), which senses accumulation of unfolded proteins in the ER lumen and leads to increased transcription of genes encoding ER-resident chaperones. As a key regulatory step in this signaling pathway, the mRNA encoding the UPR-specific transcription factor Hac1p becomes spliced by a unique mechanism that requires tRNA ligase but not the spliceosome. Splicing is initiated upon activation of Ire1p, a transmembrane kinase that lies in the ER and/or inner nuclear membrane. We show that Ire1p is a bifunctional enzyme: in addition to being a kinase, it is a site-specific endoribonuclease that cleaves HAC1 mRNA specifically at both splice junctions. The addition of purified tRNA ligase completes splicing; we therefore have reconstituted HAC1 mRNA splicing in vitro from purified components.			Sidrauski, C (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Longo, Kenneth A/A-5631-2010					BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; CLARK MW, 1987, J CELL BIOL, V105, P1515, DOI 10.1083/jcb.105.4.1515; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; GREER CL, 1986, MOL CELL BIOL, V6, P635, DOI 10.1128/MCB.6.2.635; GREER CL, 1987, MOL CELL BIOL, V7, P76, DOI 10.1128/MCB.7.1.76; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; Moore M., 1993, RNA WORLD, P303; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; OCONNOR JP, 1991, MOL CELL BIOL, V11, P425, DOI 10.1128/MCB.11.1.425; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; STERN S, 1988, METHOD ENZYMOL, V164, P481; SWEET DJ, 1993, CURR BIOL, V3, P622, DOI 10.1016/0960-9822(93)90014-F; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	33	629	660	0	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1031	1039		10.1016/S0092-8674(00)80369-4	http://dx.doi.org/10.1016/S0092-8674(00)80369-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323131	Bronze			2022-12-24	WOS:A1997XX76800009
J	Dokland, T; McKenna, R; Ilag, LL; Bowman, BR; Incardona, NL; Fane, BA; Rossmann, MG				Dokland, T; McKenna, R; Ilag, LL; Bowman, BR; Incardona, NL; Fane, BA; Rossmann, MG			Structure of a viral procapsid with molecular scaffolding	NATURE			English	Article							FUNCTIONAL IMPLICATIONS; ATOMIC-STRUCTURE; BACTERIOPHAGE-PHI-X174; PHI-X174; PROTEIN; VIRUS; PROHEAD; CAPSIDS	The assembly of a macromolecular structure proceeds along an ordered morphogenetic pathway, and is accomplished by the switching of proteins between discrete conformations as they are added to the nascent assembly(1-3). Scaffolding proteins often play a catalytic role in the assembly process(1,2,4), rather like molecular chaperones(5). Although macromolecular assembly processes are fundamental to all biological systems, they have been characterized most thoroughly in viral systems, such as the icosahedral Escherichia coli bacteriophage Phi X174 (refs 6, 7). The Phi X174 virion contains the proteins F, G, H and J(7,8). assembly, two scaffolding proteins B and D are required for formation of a 108S, 360-Angstrom-diameter procapsid from pentameric precursors containing the F, G and H protein(6,9). The procapsid contains 240 copies of protein D, forming an external scaffold, and 60 copies each of the internal scaffolding protein B, the capsid protein F, and the spike protein G(9,10). Maturation involves packaging of DNA and J proteins and loss of protein B, producing a 132S intermediate(6,7). Subsequent removal of the external scaffold yields the mature virion. Both the F and G proteins have the eight- stranded antiparallel beta-sandwich motifs(8,11) common to many plant and animal viruses(12,13). Here we describe the structure of a procapsid-like particle at 3.5-Angstrom resolution, showing how the scaffolding proteins coordinate assembly of the virus by interactions with the F and G proteins, and showing that the F protein undergoes conformational changes during capsid maturation.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA; UNIV ARKANSAS, DEPT BIOL SCI, FAYETTEVILLE, AR 72701 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Tennessee System; University of Tennessee Health Science Center; University of Arkansas System; University of Arkansas Fayetteville				Dokland, Terje/0000-0001-5655-4123				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Casjens S, 1988, BACTERIOPHAGES, P15; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; EKECHUKWU MC, 1995, GENETICS, V140, P1167; EKECHUKWU MC, 1995, J BACTERIOL, V177, P829, DOI 10.1128/jb.177.3.829-830.1995; FANE BA, 1993, GENETICS, V134, P1003; FARBER MB, 1976, J VIROL, V17, P1027, DOI 10.1128/JVI.17.3.1027-1037.1976; HARRISON SC, 1996, FIELDS VIROLOGY, V1, P59; HAYASHI M, 1978, SINGLE STRANDED DNA, P531; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; ILAG LL, 1995, STRUCTURE, V3, P353, DOI 10.1016/S0969-2126(01)00167-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING J, 1980, BIOL REGUL DEV, V2, P101; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; McKenna R, 1996, J MOL BIOL, V256, P736, DOI 10.1006/jmbi.1996.0121; MCKENNA R, 1994, J MOL BIOL, V237, P517, DOI 10.1006/jmbi.1994.1253; MUKAI R, 1979, P NATL ACAD SCI USA, V76, P4877, DOI 10.1073/pnas.76.10.4877; Osawa F. A. S., 1975, THERMODYNAMICS POLYM; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PRESTON VG, 1994, J GEN VIROL, V75, P2355, DOI 10.1099/0022-1317-75-9-2355; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530	29	117	125	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					308	313		10.1038/38537	http://dx.doi.org/10.1038/38537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305849				2022-12-24	WOS:A1997XW77200054
J	Stoddart, H; Noah, N				Stoddart, H; Noah, N			Usefulness of screening large numbers of contacts for tuberculosis: questionnaire based review	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT EPIDEMIOL & PUBL HLTH,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	Stoddart, H (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.							CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P37, DOI 10.1016/0007-0971(86)90007-0; *JOINT TUB COMM BR, 1994, THORAX, V49, P1193; SCOTT E, 1990, COMMUNICAB DIS REP, V34, P3; SELBY CD, 1989, RESP MED, V83, P353, DOI 10.1016/S0954-6111(89)80212-4; VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R	5	5	5	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					651	651		10.1136/bmj.315.7109.651	http://dx.doi.org/10.1136/bmj.315.7109.651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310568	Green Published			2022-12-24	WOS:A1997XW69400021
J	Offermanns, S; Toombs, CF; Hu, YH; Simon, MI				Offermanns, S; Toombs, CF; Hu, YH; Simon, MI			Defective platelet activation in G alpha(q)-deficient mice	NATURE			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C ISOZYMES; G-PROTEINS; THROMBOXANE A(2); BLOOD-PLATELETS; RECEPTORS; EXPRESSION; C-BETA-2; FAMILY	Platelets are small disc-shaped cell fragments which undergo a rapid transformation when they encounter vascular damage. They become more spherical and extrude pseudopodia, their fibrinogen receptors are activated, causing them to aggregate, they release their granule contents, and eventually form a plug which is responsible for primary haemostasis(1). Activation of platelets is also implicated in the pathogenesis of unstable angina, myocardial infarction and stroke(2,3). Here we show that platelets from mice deficient in the alpha-subunit of the heterotrimeric guanine-nucleotide-binding protein G(q) are unresponsive to a variety of physiological platelet activators. As a result, G alpha(q)-deficient mice have increased bleeding times and are protected from collagen and adrenaline-induced thromboembolism. We conclude that G alpha(q), is essential for the signalling processes used by different platelet activators and that it cannot be replaced by G alpha(i) or the beta gamma subunits of the heterotrimeric G proteins. G alpha(q) may thus be a new target for drugs designed to block the activation of platelets.	CALTECH,DIV BIOL 147 75,PASADENA,CA 91125; AMGEN INC,DEPT PHARMACOL,THOUSAND OAKS,CA 91320	California Institute of Technology; Amgen			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				Banno Y, 1996, J BIOL CHEM, V271, P14989, DOI 10.1074/jbc.271.25.14989; BEARER EL, 1995, CELL MOTIL CYTOSKEL, V30, P50, DOI 10.1002/cm.970300107; BUHL AM, 1995, J BIOL CHEM, V270, P24731; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COLLER BS, 1992, HEART CARDIOVASCULAR, P219; DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAWRENCE WH, 1994, J PHARM SCI, V83, P222, DOI 10.1002/jps.2600830222; Lee SB, 1996, BLOOD, V88, P1684; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, UNPUB NEURON; PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROSENBLUM WI, 1983, THROMB RES, V30, P347, DOI 10.1016/0049-3848(83)90226-8; SAGE SO, 1995, PLATELETS PRACTICAL, P67; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808	30	450	460	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					183	186		10.1038/38284	http://dx.doi.org/10.1038/38284			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296496				2022-12-24	WOS:A1997XV75700049
J	Schmidt, WA; Kraft, HE; Vorpahl, K; Volker, L; GromnicaIhle, EJ				Schmidt, WA; Kraft, HE; Vorpahl, K; Volker, L; GromnicaIhle, EJ			Color duplex ultrasonography in the diagnosis of temporal arteritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GIANT-CELL ARTERITIS; DOPPLER ULTRASOUND FLOW; POLYMYALGIA-RHEUMATICA; CRANIAL ARTERITIS; BIOPSY; SONOGRAPHY; CRITERIA	Background The diagnosis of temporal arteritis usually requires a biopsy of the temporal artery. We examined the usefulness of color duplex ultrasonography in patients suspected of having temporal arteritis. Methods In this prospective study, all patients seen in the departments of rheumatology and ophthalmology from January 1994 to October 1996 who had clinically suspected active temporal arteritis or polymyalgia rheumatica were examined by duplex ultrasonography. The final diagnoses, made according to standard criteria, were temporal arteritis in 30 patients, 21 with biopsy-confirmed disease; polymyalgia rheumatica in 37; and negative histologic findings and a diagnosis other than temporal arteritis or polymyalgia rheumatica in 15. We also studied 30 control patients matched for age and sex to the patients with arteritis. Two ultrasound studies were performed and read before the biopsies; one ultrasonographer was unaware of the clinical information. Results In 22 (73 percent) of the 30 patients with temporal arteritis, ultrasonography showed a dark halo around the lumen of the temporal arteries. The halos disappeared after a mean of 16 days (range, 7 to 56) of treatment with corticosteroids. Twenty four patients (80 percent) had stenoses or occlusions of temporal-artery segments, and 28 patients (93 per cent) had stenoses, occlusions, or a halo. No halos were identified in the 82 patients without temporal arteritis; 6 (7 percent) had stenoses or occlusions. For each of the three types of abnormalities identified by ultrasonography, the interrater agreement was greater than or equal to 95 percent. Conclusions There are characteristic signs of temporal arteritis that can be visualized by color duplex ultrasonography. The most specific sign is a dark halo, which may be due to edema of the artery wall. In patients with typical clinical signs and a halo on ultrasonography, it may be possible to make a diagnosis of temporal arteritis and begin treatment without performing a temporal-artery biopsy. (C) 1997, Massachusetts Medical Society.	KLINIKUM BUCH, DEPT OPHTHALMOL, BERLIN, GERMANY; KLINIKUM BUCH, DEPT PATHOL, BERLIN, GERMANY; KLINIKUM BUCH, DEPT ANGIOL, BERLIN, GERMANY		Schmidt, WA (corresponding author), CLIN RHEUMATOL, ZEPERNICKER STR 1, D-13125 BERLIN, GERMANY.		Schmidt, Wolfgang/W-5599-2019	Schmidt, Wolfgang/0000-0001-7831-8738				ABURN NS, 1993, EYE, V7, P639, DOI 10.1038/eye.1993.147; ASHTONKEY M, 1991, BAILLIERE CLIN RHEUM, V5, P387, DOI 10.1016/S0950-3579(05)80061-5; BARRIER J, 1982, JAMA-J AM MED ASSOC, V248, P2158, DOI 10.1001/jama.248.17.2158; BECKMAN RL, 1990, J CLIN NEURO-OPHTHAL, V10, P304; BIENFANG DC, 1984, AM J OPHTHALMOL, V97, P526, DOI 10.1016/S0002-9394(14)76141-0; BIRD HA, 1979, ANN RHEUM DIS, V38, P434, DOI 10.1136/ard.38.5.434; BUNHOLZL C, 1988, ULTRASCHALL MED, V9, P232; Dany F, 1981, J Mal Vasc, V6, P273; DANY F, 1989, J MAL VASCUL, V14, P104; DAUMANN C, 1989, KLIN MONATSBL AUGENH, V194, P37, DOI 10.1055/s-2008-1046333; DORNBERGER V, 1987, MED WELT, V38, P1302; ELLIOTT PD, 1972, RADIOLOGY, V102, P635; FRIEDMAN G, 1988, ISRAEL J MED SCI, V24, P686; Ghanchi FD, 1996, EYE, V10, P459, DOI 10.1038/eye.1996.101; GILLANDERS LA, 1969, ANN RHEUM DIS, V28, P267, DOI 10.1136/ard.28.3.267; HO AC, 1994, ARCH OPHTHALMOL-CHIC, V112, P938, DOI 10.1001/archopht.1994.01090190086026; HORWITZ HM, 1977, J RHEUMATOL, V4, P76; HUNDER GG, 1972, ARTHRITIS RHEUM, V15, P561, DOI 10.1002/art.1780150602; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; KELLEY JS, 1978, ARCH OPHTHALMOL-CHIC, V96, P845; LIE JT, 1994, J RHEUMATOL, V21, P366; LIE JT, 1994, J RHEUMATOL, V21, P186; LIEB WE, 1992, ACTA OPHTHALMOL, V70, P50; LIOZON F, 1983, PRESSE MED, V12, P2113; LIOZON F, 1986, ANN MED INTERNE, V137, P307; MARANO SR, 1985, NEUROSURGERY, V16, P786, DOI 10.1227/00006123-198506000-00008; MENKES CJ, 1981, NOUV PRESSE MED, V10, P2371; MORGAN GJ, 1978, ARTHRITIS RHEUM, V21, P362, DOI 10.1002/art.1780210312; PUECHAL, 1995, LANCET, V346, P62; PUECHAL X, 1995, LANCET, V345, P1437, DOI 10.1016/S0140-6736(95)92626-7; SALVARANI C, 1994, ARTHRITIS RHEUM, V37, P1621, DOI 10.1002/art.1780371111; SCHMIDT WA, 1995, LANCET, V345, P866, DOI 10.1016/S0140-6736(95)93005-1; SCOTT KR, 1991, OPHTHALMIC SURG LAS, V22, P519; SIEMSSEN SJ, 1987, BRIT J PLAST SURG, V40, P73, DOI 10.1016/0007-1226(87)90015-4; SLAVIN ML, 1986, ARCH OPHTHALMOL-CHIC, V104, P1127; SMALL P, 1991, ARTHRITIS RHEUM, V34, P220, DOI 10.1002/art.1780340215; STEIGERWALT RD, 1994, INT ANGIOL, V13, P286; STOCK AL, 1980, HEAD NECK SURG, V2, P466, DOI 10.1002/hed.2890020604; VINCKIER L, 1989, J MAL VASCUL, V14, P116; VOLLRATHJUNGER C, 1989, KLIN MONATSBL AUGENH, V195, P169, DOI 10.1055/s-2008-1046431; WILLIAMSON TH, 1992, BRIT J OPHTHALMOL, V76, P690, DOI 10.1136/bjo.76.11.690	41	508	515	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1336	1342		10.1056/NEJM199711063371902	http://dx.doi.org/10.1056/NEJM199711063371902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358127				2022-12-24	WOS:A1997YE44600002
J	Shieh, SY; Ikeda, M; Taya, Y; Prives, C				Shieh, SY; Ikeda, M; Taya, Y; Prives, C			DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2	CELL			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA GENE; STRAND-BREAK-REPAIR; WILD-TYPE P53; V(D)J RECOMBINATION; BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE	DNA-damaging agents signal to p53 through as yet unidentified posttranscriptional mechanisms. Here we show that phosphorylation of human p53 at serine 15 occurs after DNA damage and that this leads to reduced interaction of p53 with its negative regulator, the oncoprotein MDM2 in vivo and in vitro. Furthermore, using purified DNA-dependent protein kinase (DNA-PK), we demonstrate that phosphorylation of p53 at serines 15 and 37 impairs the ability of MDM2 to inhibit p53-dependent transactivation. We present evidence that these effects are most likely due to a conformational change induced upon phosphorylation of p53. Our studies provide a plausible mechanism by which the induction of p53 can be modulated by DNA-PK (or other protein kinases with similar specificity) in response to DNA damage.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA; MBL CO LTD, INA LABS, INA, NAGANO 396, JAPAN; NATL CANC CTR, RES INST, CHUO KU, TOKYO 104, JAPAN	Columbia University; National Cancer Center - Japan			qiao, zhixin/I-3408-2012; Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER; NCI NIH HHS [CA58316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bottger V, 1996, ONCOGENE, V13, P2141; CANMAN CE, 1994, CANCER RES, V54, P5054; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1995, ONCOGENE, V11, P609; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Rathmell WK, 1997, CANCER RES, V57, P68; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	63	1685	1719	0	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					325	334		10.1016/S0092-8674(00)80416-X	http://dx.doi.org/10.1016/S0092-8674(00)80416-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363941	hybrid			2022-12-24	WOS:A1997YD94100006
J	Levy, BD; Petasis, NA; Serhan, CN				Levy, BD; Petasis, NA; Serhan, CN			Polyisoprenyl phosphates in intracellular signalling	NATURE			English	Article							CELL-FREE SYSTEM; PRESQUALENE PYROPHOSPHATE; RESPIRATORY BURST; HUMAN-NEUTROPHILS; ACTIVATION; SQUALENE; NADPH; BIOSYNTHESIS; LEUKOCYTES; MECHANISM	In response to environmental stimuli, leukocyte membrane remodelling generates biologically active lipids that can serve as both intra-and extracellular mediators(1). There are several classes of lipids that can mediate inflammatory reactions.(1) We report here on a new intracellular lipid signal that regulates oxygen-radical formation in neutrophils, a key response in microbial killing, inflammation and tissue injury. Screening of neutrophil-derived extracts rich in phosphorylated, non-saponifiable lipids revealed a potent inhibitor of superoxide anion (O-2(-)) production. Structural analysis of biologically active fractions gave four major phosphorylated lipids: most abundant was presqualene diphosphate (PSDP). Upon activation of neutrophil receptors, PSDP and its monophosphate form, presqualene monophosphate (PSMP), undergo rapid remodelling. At submicromolar concentrations, PSDP but not PSMP inhibit O-2(-) production by human neutrophil cell-free oxidase preparations. We prepared PSDP and PSMP by total organic synthesis and matched both the physical properties and biological activity of the neutrophil-derived compounds. Our results indicate that PSDP, a recognized intermediate of cholesterol biosynthesis(2), is present in immune effector cells and is a potent regulator of the cellular response in host defence.	BRIGHAM & WOMENS HOSP, DEPT ANESTHESIA, CTR EXPT THERAPEUT & REPERFUS INJURY, BOSTON, MA 02115 USA; UNIV SO CALIF, DEPT CHEM, LOS ANGELES, CA 90089 USA	Harvard University; Brigham & Women's Hospital; University of Southern California			Petasis, Nicos/B-3162-2009	Petasis, Nicos/0000-0002-8864-4446				ADAIR WL, 1985, METHOD ENZYMOL, V111, P201; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; Bokoch G M, 1994, Curr Opin Hematol, V1, P53; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CHEN PS, 1956, ANAL CHEM, V28, P175; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; EPSTEIN WW, 1970, J BIOL CHEM, V245, P4597; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMEZCAMBRONERO J, 1991, ADV EXP MED BIOL, V314, P35; Jarstfer MB, 1996, J AM CHEM SOC, V118, P13089, DOI 10.1021/ja963308s; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MOOKHTIAR KA, 1994, J BIOL CHEM, V269, P11201; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; POPJAK G, 1969, J BIOL CHEM, V244, P1897; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; ROGERS DH, 1995, J ORG CHEM, V60, P941, DOI 10.1021/jo00109a026; SCHEER A, 1995, BIOCHEMISTRY-US, V34, P4952, DOI 10.1021/bi00015a006; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHECHTER I, 1980, J LIPID RES, V21, P277; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TOU J, 1995, LIPIDS, V30, P373, DOI 10.1007/BF02536294; VANDESSEL GAF, 1993, CRC HDB CHROMATOGRAP, P321; WEISSMANN G, 1980, NEW ENGL J MED, V303, P27	26	54	57	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					985	990		10.1038/40180	http://dx.doi.org/10.1038/40180			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353124				2022-12-24	WOS:A1997YD29900060
J	Izbicki, JR; Hosch, SB; Pichlmeier, U; Rehders, A; Busch, C; Niendorf, A; Passlick, B; Broelsch, CE; Pantel, K				Izbicki, JR; Hosch, SB; Pichlmeier, U; Rehders, A; Busch, C; Niendorf, A; Passlick, B; Broelsch, CE; Pantel, K			Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; BONE-MARROW; FOLLOW-UP; CARCINOMA; MICROMETASTASES; METASTASES; LUNG; ADENOCARCINOMA; ANTIBODIES; TISSUES	Background Current methods of disease staging often fail to detect small numbers of tumor cells in lymph nodes, Metastatic relapse may arise from these few cells. Methods We studied 1308 lymph nodes from 68 patients with esophageal cancer without overt metastases who had undergone radical en bloc esophagectomy. A total of 399 lymph nodes obtained from 68 patients were found to be free of tumor by routine histopathological analysis and were studied further for isolated tumor cells by immunohistochemical analysis with the monoclonal anti-epithelial-cell antibody Ber-EP4. This antibody did not stain lymph nodes from 24 control patients without carcinoma. Results Of the 399 ''tumor free'' lymph nodes, 67 (17 percent), obtained from 42 of the 68 patients, contained Ber-EP4-positive tumor cells. Fifteen of 30 patients who were considered free of lymph-node metastases by histopathological analysis had such cells in their lymph nodes, and 5 of the 15 had small primary tumors. Ber-EP4-positive cells found in ''tumor free'' nodes were independently predictive of significantly reduced relapse-free survival (P = 0.008) and overall survival (P=0.03). They predicted relapse both in patients without nodal metastases (P=0.01) and in those with regional lymph-node involvement (P=0.007). All 12 patients whose lymph nodes were negative on both histopathological and immunohistochemical analysis and who were available for follow-up survived without recurrence. The presence of micrometastatic tumor cells in bone marrow had no additional prognostic value. Conclusions Immunohistochemical examination of lymph nodes may improve the pathological staging of esophageal cancer. (C) 1997, Massachusetts Medical Society.	UNIV HAMBURG,ABT MATH MED,HAMBURG,GERMANY; UNIV HAMBURG,INST PATHOL,D-2000 HAMBURG,GERMANY; UNIV MUNICH,INST IMMUNOL,D-8000 MUNICH,GERMANY	University of Hamburg; University of Hamburg; University of Munich	Izbicki, JR (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,ALLGEMEINCHIRURG ABT,MARTINISTR 52,D-20246 HAMBURG,GERMANY.							ABE S, 1990, J THORAC CARDIOV SUR, V100, P287; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BUSSOLATI G, 1986, BRIT J CANCER, V54, P631, DOI 10.1038/bjc.1986.219; BYRNE J, 1987, EUR J SURG ONCOL, V13, P409; CASSON AG, 1994, ANN THORAC SURG, V58, P1569, DOI 10.1016/0003-4975(94)91986-0; CHEN MYM, 1995, J CLIN GASTROENTEROL, V21, P254, DOI 10.1097/00004836-199510000-00019; CHEN ZL, 1993, JNCI-J NATL CANCER I, V85, P493, DOI 10.1093/jnci/85.6.493; COX DR, 1972, J R STAT SOC B, V34, P187; Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; EARLAM R, 1988, DIS ESOPHAGUS, P11; GOLDMINC M, 1993, BRIT J SURG, V80, P367, DOI 10.1002/bjs.1800800335; HENNESSY TPJ, 1994, WORLD J SURG, V18, P367, DOI 10.1007/BF00316816; Hermanek P, 1992, TNM CLASSIFICATION M; *INT LUDW BREAST C, 1990, LANCET, V335, P1565; Jauch K W, 1992, Eur J Surg Oncol, V18, P553; KASPER M, 1987, EUR J CANCER CLIN ON, V23, P137, DOI 10.1016/0277-5379(87)90007-1; LATZA U, 1990, J CLIN PATHOL, V43, P213, DOI 10.1136/jcp.43.3.213; LERUT T, 1992, ANN SURG, V216, P583, DOI 10.1097/00000658-199211000-00010; LERUT TE, 1994, WORLD J SURG, V18, P379, DOI 10.1007/BF00316818; MARTINI N, 1983, ANN SURG, V198, P386, DOI 10.1097/00000658-198309000-00015; MILLIKAN KW, 1995, ARCH SURG-CHICAGO, V130, P617; MOMBURG F, 1987, CANCER RES, V47, P2883; MORITA M, 1994, SURGERY, V116, P1; OSULLIVAN GC, 1995, GASTROENTEROLOGY, V109, P1535, DOI 10.1016/0016-5085(95)90641-X; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; RAYMOND WA, 1989, PATHOLOGY, V21, P11, DOI 10.3109/00313028909059522; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SIEWERT JR, 1992, CHIRURG, V63, P693; Thorban S, 1996, JNCI-J NATL CANCER I, V88, P1222, DOI 10.1093/jnci/88.17.1222; VOGEL SB, 1995, ANN SURG, V221, P685, DOI 10.1097/00000658-199506000-00008; WATANABE H, 1992, CHIRURG, V63, P689	34	306	333	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1188	1194		10.1056/NEJM199710233371702	http://dx.doi.org/10.1056/NEJM199710233371702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB718	9337377	Bronze			2022-12-24	WOS:A1997YB71800002
J	Cresswell, JL; Barker, DJP; Osmond, C; Egger, P; Phillips, DIW; Fraser, RB				Cresswell, JL; Barker, DJP; Osmond, C; Egger, P; Phillips, DIW; Fraser, RB			Fetal growth, length of gestation, and polycystic ovaries in adult life	LANCET			English	Article							DISEASE; WOMEN; HYPERANDROGENISM; DYSREGULATION; SECRETION; ENDOCRINE; FEATURES; HORMONE	Background Polycystic ovaries are a common disorder associated with menstrual irregularities, subfertility, hirsutism, acne, and a range of endocrine abnormalities, including high concentrations of plasma luteinising hormone (LH) and excessive androgen production. The pathophysiology is not understood. We investigated whether the disorder originates during intrauterine life. Methods We examined 235 women aged 40-42 years who were born in Sheffield, UK. We related the prevalence of polycystic ovaries and the plasma concentrations of gonadotropin hormones and androgens to the women's body size at birth, and the length of gestation. Findings 49 (21%) of the women had polycystic ovaries. We defined two groups of women with the disorder, which correspond to the two groups that commonly present clinically. The first group comprised obese women who were androgenised, with higher than normal concentrations of plasma LH and testosterone. These women had above-average birthweight and were born to overweight mothers. The second group comprised women of normal weight who had high plasma LH, but normal testosterone concentrations. These women were born after term (40 weeks' gestation). Interpretation The two common forms of polycystic ovary syndrome have different origins in intrauterine life. Obese, hirsute women with polycystic ovaries have higher than normal ovarian secretion of androgens that are associated with high birthweight and maternal obesity. Thin women with polycystic ovaries have altered hypothalamic control of LH release resulting from prolonged gestation.	UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, DEPT OBSTET & GYNAECOL, CTR CLIN SCI, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND	University of Southampton; Northern General Hospital; University of Sheffield			fraser, robert b/B-9856-2009	Osmond, Clive/0000-0002-9054-4655				ADAMS J, 1985, LANCET, V2, P1375; BARKER DJP, 1995, LANCET, V345, P1087, DOI 10.1016/S0140-6736(95)90821-8; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P62, DOI 10.1210/endo-68-1-62; BARRACLOUGH C, 1961, ENDOCRINOLOGY, V68, P68, DOI 10.1210/endo-68-1-68; BURGHEN GA, 1980, J CLIN ENDOCR METAB, V50, P113, DOI 10.1210/jcem-50-1-113; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; CONWAY GS, 1992, CLIN ENDOCRINOL, V37, P119, DOI 10.1111/j.1365-2265.1992.tb02295.x; Dunaif Andrea, 1993, P301; EHRMANN DA, 1995, ENDOCR REV, V16, P322, DOI 10.1210/er.16.3.322; ERICKSON GF, 1979, J CLIN ENDOCR METAB, V49, P514, DOI 10.1210/jcem-49-4-514; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; FIORE M, 1988, CLIN CHEM, V34, P1726; FRANKS S, 1985, CLIN OBSTET GYNAECOL, V12, P605; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Gruenwald P, 1974, CIBA F S, V27, P3; HAGUE WM, 1988, CLIN ENDOCRINOL, V29, P593, DOI 10.1111/j.1365-2265.1988.tb03707.x; PASQUALI R, 1993, CLIN ENDOCRINOL, V39, P1, DOI 10.1111/j.1365-2265.1993.tb01744.x; Pfeiffer CA, 1936, AM J ANAT, V58, P195, DOI 10.1002/aja.1000580112; Phillips DIW, 1996, DIABETOLOGIA, V39, P1119; POLSON DW, 1988, LANCET, V1, P870; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	25	163	169	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1131	1135		10.1016/S0140-6736(97)06062-5	http://dx.doi.org/10.1016/S0140-6736(97)06062-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343501				2022-12-24	WOS:A1997YB19900011
J	Feldman, RMR; Correll, CC; Kaplan, KB; Deshaies, RJ				Feldman, RMR; Correll, CC; Kaplan, KB; Deshaies, RJ			A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME; CRYSTAL-STRUCTURE; PROTEIN LIGASE; YEAST; DEGRADATION; PATHWAY	In S. cerevisiae, the G1/S transition requires Cdc4p, Cdc34p, Cdc53p, Skp1p, and the Cln/Cdc28p cyclin-dependent kinase (Cdk). These proteins are thought to promote the proteolytic inactivation of the S-phase Cdk inhibitor Sic1p. We show here that Cdc4p, Cdc53p, and Skp1p assemble into a ubiquitin ligase complex named SCFCdc4p. When mixed together, SCFCdc4p sub- units, E1 enzyme, the E2 enzyme Cdc34p, and ubiquitin are sufficient to reconstitute ubiquitination of Cdk-phosphorylated Sic1p. Phosphorylated Sic1p substrate is specifically targeted for ubiquitination by binding to a Cdc4p/Skp1p subcomplex. Taken together, these data illuminate the molecular basis for the G1/S transition in budding yeast and suggest a general mechanism for phosphorylation-targeted ubiquitination in eukaryotes.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	California Institute of Technology; Massachusetts Institute of Technology (MIT)			Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354	NIGMS NIH HHS [R01 GM52466-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harlow E, 1988, ANTIBODIES LAB MANUA; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HULBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIPREOS E, 1995, 10 INT C EL M SUMM, P83; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, METHOD ENZYMOL, V283, P366; VERMA R, 1997, IN PRESS SCIENCE; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	700	725	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	1997	91	2					221	230		10.1016/S0092-8674(00)80404-3	http://dx.doi.org/10.1016/S0092-8674(00)80404-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346239	Bronze			2022-12-24	WOS:A1997YC35000009
J	WyssCoray, T; Masliah, E; Mallory, M; McConlogue, L; JohnsonWood, K; Lin, C; Mucke, L				WyssCoray, T; Masliah, E; Mallory, M; McConlogue, L; JohnsonWood, K; Lin, C; Mucke, L			Amyloidogenic role of cytokine TGF-beta 1 in transgenic mice and in Alzheimer's disease	NATURE			English	Article							GROWTH-FACTOR-BETA; E EPSILON-4 ALLELE; APOLIPOPROTEIN-E; EXTRACELLULAR-MATRIX; PRECURSOR PROTEIN; HEAD-INJURY; ANGIOPATHY; PLAQUES; DEPOSITION; BRAINS	Deposition of amyloid-beta peptide in the central nervous system is a hallmark of Alzheimer's disease and a possible cause of neurodegeneration(1-3). The factors that initiate or promote deposition of amyloid-beta peptide are not known. The transforming growth factor TGF-beta 1 plays a central role in the response of the brain to injury(4,5), and increased TGF-beta 1 has been found in the central nervous system of patients with Alzheimer's disease(6-8). Here we report that TGF-beta 1 induces amyloid-beta deposition in cerebral blood vessels and meninges of aged transgenic mice overexpressing this cytokine from astrocytes. Co-expression of TGF-beta 1 in transgenic mice overexpressing amyloid-precursor protein, which develop Alzheimer's like patholog(9-11), accelerated the deposition of amyloid-beta peptide. More TGF-beta 1 messenger RNA was present in post-mortem brain tissue of Alzheimer's patients than in controls, the levels correlating strongly with amyloid-beta deposition in the damaged cerebral blood vessels of patients with cerebral amyloid angiopathy, These results indicate that overexpression of TGF-beta 1 may initiate or promote amyloidogenesis in Alzheimer's disease and in experimental models and so may be a risk factor for developing Alzheimer's disease.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,NEUROSCI PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Diego; University of California System; University of California San Diego	WyssCoray, T (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE MOL NEUROBIOL PROGRAM,SAN FRANCISCO,CA 94141, USA.		Wyss-Coray, Tony/AAF-3380-2019	Wyss-Coray, Tony/0000-0001-5893-0831; Mucke, Lennart/0000-0001-6256-9559				CHAO CC, 1994, CLIN DIAGN LAB IMMUN, V1, P109, DOI 10.1128/CDLI.1.1.109-110.1994; FILLIT H, 1995, LAB INVEST, V72, P249; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAAN J, 1994, DEMENTIA, V5, P210, DOI 10.1159/000106725; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; ITOH Y, 1993, J NEUROL SCI, V116, P135, DOI 10.1016/0022-510X(93)90317-R; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Masliah E, 1996, J NEUROSCI, V16, P5795; MASLIAH E, 1992, ANN NEUROL, V32, P321, DOI 10.1002/ana.410320304; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; PERESS NS, 1995, J NEUROPATH EXP NEUR, V54, P802, DOI 10.1097/00005072-199511000-00007; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Terry Robert D., 1994, P179; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WYSSCORAY T, 1995, AM J PATHOL, V147, P53	30	337	353	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					603	606		10.1038/39321	http://dx.doi.org/10.1038/39321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335500				2022-12-24	WOS:A1997YA00800060
J	Cox, GA; Lutz, CM; Yang, CL; Biemesderfer, D; Bronson, RT; Fu, A; Aronson, PS; Noebels, JL; Frankel, WN				Cox, GA; Lutz, CM; Yang, CL; Biemesderfer, D; Bronson, RT; Fu, A; Aronson, PS; Noebels, JL; Frankel, WN			Sodium/hydrogen exchanger gene defect in slow-wave epilepsy mutant mice	CELL			English	Article							RAT NA/H EXCHANGER; NA+/H+ ANTIPORTER; MOLECULAR-CLONING; ABSENCE SEIZURES; PH REGULATION; MOUSE; EXPRESSION; ISOFORM; NHE-1; CELLS	The ''housekeeping'' sodium/hydrogen exchanger, NHE1, mediates the electroneutral 1:1 exchange of Na+ and H+ across the plasma membrane. NHE1 is ubiquitous and is studied extensively for regulation of pH(i), cell volume, and response to growth factors. We describe a spontaneous mouse mutant, slow-wave epilepsy, (swe), with a neurological syndrome including ataxia and a unique epilepsy phenotype consisting of 3/sec absence and tonic-clonic seizures. swe was fine-mapped on Chromosome 4 and identified as a null allele of Nhe1. Mutants show selective neuronal death in the cerebellum and brainstem but otherwise are healthy. This first example of a disease-causing mutation in an Nhe gene provides a new tool for studying the delicate balance of neuroexcitability and cell survival within the CNS.	JACKSON LAB, BAR HARBOR, ME 04609 USA; YALE UNIV, SCH MED, NEW HAVEN, CT 06520 USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA; BAYLOR COLL MED, INST MOL GENET, DEPT NEUROL, DIV NEUROSCI, HOUSTON, TX 77030 USA	Jackson Laboratory; Yale University; Tufts University; United States Department of Agriculture (USDA); Baylor College of Medicine				Noebels, Jeffrey/0000-0002-2887-0839	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031348, R01NS033396, R01NS031348] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31348, NS29702, NS33396] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DJ, 1981, NEUROLOGY, V31, P1175, DOI 10.1212/WNL.31.9.1175; ANDERSON VE, 1991, EPILEPSY RES, P89; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bartolomei F, 1997, EUR NEUROL, V37, P169, DOI 10.1159/000117429; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; DiPasquale E, 1997, J NEUROPHYSIOL, V77, P621, DOI 10.1152/jn.1997.77.2.621; DOOSE H, 1973, EPILEPSIA, V14, P57, DOI 10.1111/j.1528-1157.1973.tb03942.x; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANKEL WN, 1995, MAMM GENOME, V6, P830, DOI 10.1007/BF00292431; HILDEBRANDT F, 1991, BIOCHIM BIOPHYS ACTA, V1129, P105, DOI 10.1016/0167-4781(91)90221-7; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; KAUSHIK N, 1994, MAMM GENOME, V5, P688, DOI 10.1007/BF00426074; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LENNOX WG, 1951, JAMA-J AM MED ASSOC, V146, P529, DOI 10.1001/jama.1951.03670060005002; LOISEAU P, 1995, EPILEPSIA, V36, P1182, DOI 10.1111/j.1528-1157.1995.tb01060.x; Ma E, 1997, NEUROSCIENCE, V79, P591, DOI 10.1016/S0306-4522(96)00674-4; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Maricich SM, 1997, J NEUROSCI, V17, P3675; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Neufeld MY, 1996, MOVEMENT DISORD, V11, P283, DOI 10.1002/mds.870110312; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Noebels JL, 1996, NEURON, V16, P241, DOI 10.1016/S0896-6273(00)80042-2; NOEBELS JL, 1979, SCIENCE, V204, P1334, DOI 10.1126/science.572084; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Ottman R, 1997, AM J HUM GENET, V60, P667; Pasternack M, 1996, NEUROPHARMACOLOGY, V35, P1279, DOI 10.1016/S0028-3908(96)00075-5; PATEL VM, 1987, J CLIN NEUROPHYSIOL, V4, P101, DOI 10.1097/00004691-198704000-00001; Pathak BG, 1996, GENOMICS, V31, P261, DOI 10.1006/geno.1996.0045; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; Pizzonia JH, 1996, J NEUROSCI RES, V44, P191, DOI 10.1002/(SICI)1097-4547(19960415)44:2<191::AID-JNR12>3.0.CO;2-9; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; RUTHERFORD PA, 1997, IN PRESS EXP NEPHROL; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SCHWARTZ WJ, 1978, J COMP NEUROL, V177, P335, DOI 10.1002/cne.901770210; SPRING J, 1994, GENOMICS, V21, P597, DOI 10.1006/geno.1994.1319; STERIADE M, 1995, J NEUROSCI, V15, P623; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; Takahashi KI, 1996, NEUROSCI RES, V24, P109, DOI 10.1016/0168-0102(95)00989-2; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; Tombaugh GC, 1997, J NEUROPHYSIOL, V77, P639, DOI 10.1152/jn.1997.77.2.639; Trapp S, 1996, J PHYSIOL-LONDON, V496, P695, DOI 10.1113/jphysiol.1996.sp021720; TSE CM, 1992, J BIOL CHEM, V267, P9340; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WYLLIE E, 1993, TREATMENT EPILEPSY P	63	227	230	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 3	1997	91	1					139	148		10.1016/S0092-8674(01)80016-7	http://dx.doi.org/10.1016/S0092-8674(01)80016-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335342	hybrid			2022-12-24	WOS:A1997XZ80900016
J	Shibata, H; Toyama, K; Shioya, H; Ito, M; Hirota, M; Hasegawa, S; Matsumoto, H; Takano, H; Akiyama, T; Toyoshima, K; Kanamaru, R; Kanegae, Y; Saito, I; Nakamura, Y; Shiba, K; Noda, H				Shibata, H; Toyama, K; Shioya, H; Ito, M; Hirota, M; Hasegawa, S; Matsumoto, H; Takano, H; Akiyama, T; Toyoshima, K; Kanamaru, R; Kanegae, Y; Saito, I; Nakamura, Y; Shiba, K; Noda, H			Rapid colorectal adenoma formation initiated by conditional targeting of the APC gene	SCIENCE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; MOUSE; MUTATION; TUMORS; CELLS; DELETION; PROTEIN; MICE; FAP	Familial adenomatous polyposis coli (FAP) is a disease characterized by the development of multiple colorectal adenomas, and affected individuals carry germline mutations in the APC gene. With the use of a conditional gene targeting system, a mouse model of FAP was created that circumvents the embryonic lethality of Apc deficiency and directs Apc inactivation specifically to the colorectal epithelium, loxP sites were inserted into the introns around Ape exon 14, and the resultant mutant allele (Apc(580S)) was introduced into the mouse germline. Mice homozygous for Apc0(580S) were normal; however, upon infection of the colorectal region with an adenovirus encoding the Cre recombinase, the mice developed adenomas within 4 weeks, The adenomas showed deletion of Apc exon 14, indicating that the loss of Apc function was caused by Cre-loxP-mediated recombination.	INST CANC RES, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN; JAPAN SCI & TECHNOL CORP, CREST, TOKYO, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN; CTR ADULT DIS, OSAKA 537, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT CLIN ONCOL, SENDAI, MIYAGI 980, JAPAN; UNIV TOKYO, INST MED SCI, MOL GENET LAB, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, MOL MED LAB, MINATO KU, TOKYO 108, JAPAN	Japan Science & Technology Agency (JST); Osaka University; Tohoku University; University of Tokyo; University of Tokyo			hasegawa, sumitaka/A-4020-2012; Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204; Hirota, Morihisa/0000-0001-5682-0911				BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; ICHII S, 1993, ONCOGENE, V8, P2399; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; LUONGO C, 1994, CANCER RES, V54, P5947; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHIBATA H, UNPUB; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TOYAMA K, UNPUB	21	445	455	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					120	123		10.1126/science.278.5335.120	http://dx.doi.org/10.1126/science.278.5335.120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311916				2022-12-24	WOS:A1997XZ12400052
J	Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK				Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK			Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations	SCIENCE			English	Article							IN-VIVO; T-CELLS; ANTIGEN; PEPTIDES; SARCOMAS; IMMUNITY; CANCER; GP96	Immunotherapy of mice with preexisting cancers with heat shock protein preparations derived from autologous cancer resulted in retarded progression of the primary cancer, a reduced metastatic load, and prolongation of life-span. Treatment with heat shock protein preparations derived from cancers other than the autologous cancer did not provide significant protection. Spontaneous cancers (lung cancer and melanoma), chemically induced cancers (fibrosarcoma and colon carcinoma), and an ultraviolet radiation-induced spindle cell cacinoma were tested, and the results support the efficacy of autologous cancer-derived heat shock protein-peptide complexes in immunotherapy of cancers without the need to identify specific tumor antigenic epitopes.	UNIV CONNECTICUT, SCH MED, CTR IMMUNOTHERAPY CANC & INFECT DIS, FARMINGTON, CT 06030 USA	University of Connecticut					NATIONAL CANCER INSTITUTE [R29CA044786, R01CA064394, R01CA044786] Funding Source: NIH RePORTER; NCI NIH HHS [CA64394, CA44786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; BLACHERE NE, 1993, J IMMUNOTHER, V14, P351; BLACHERE NE, IN PRESS J EXP MED; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CHANDAWARKAR RY, UNPUB; DAOU M, 1996, C R I CANC VACCINES; FELDWEG AM, 1995, INT J CANCER, V63, P310, DOI 10.1002/ijc.2910630227; GLOBERSON A, 1964, J NATL CANCER I, V32, P1229, DOI 10.1093/jnci/32.6.1229; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; JANETZKI S, UNPUB; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; PALLADINO MA, 1987, CANCER RES, V47, P5074; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; Peng P, 1997, J IMMUNOL METHODS, V204, P13, DOI 10.1016/S0022-1759(97)00017-3; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; Roman E, 1996, IMMUNOLOGY, V88, P487, DOI 10.1046/j.1365-2567.1996.d01-697.x; Skeen MJ, 1996, J IMMUNOL, V156, P1196; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Srivastava P K, 1996, Semin Immunol, V8, P295, DOI 10.1006/smim.1996.0038; SRIVASTAVA PK, 1984, INT J CANCER, V33, P417, DOI 10.1002/ijc.2910330321; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUGIURA K, 1955, CANCER RES, V15, P38; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Yuui, UNPUB; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391	32	580	739	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					117	120		10.1126/science.278.5335.117	http://dx.doi.org/10.1126/science.278.5335.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311915				2022-12-24	WOS:A1997XZ12400051
J	Steinbach, OC; Wolffe, AP; Rupp, RAW				Steinbach, OC; Wolffe, AP; Rupp, RAW			Somatic linker histones cause loss of mesodermal competence in Xenopus	NATURE			English	Article							GENE-TRANSCRIPTION; MYOD EXPRESSION; EARLY RESPONSE; IN-VIVO; EMBRYOS; INDUCTION; LAEVIS; PROTEIN; CELLS; EMBRYOGENESIS	In Xenopus, cells from the animal hemisphere are competent to form mesodermal tissues from the morula through to the blastula stage(1). Loss of mesodermal competence at early gastrula is programmed cell-autonomously, and occurs even in single cells at the appropriate stage(2). To determine the mechanism by which this occurs, we have been investigating a concomitant, global change in expression of H1 linker histone subtypes. H1 histones are usually considered to be general repressors of transcription(3), but in Xenopus they are increasingly thought to have selective functions in transcriptional regulation(4-6). Xenopus eggs and embryos at stages before the midblastula transition(7) are deficient in histone H1 protein, but contain an oocyte-specific variant called histone B4 or H1M. After the midblastula transition, histone B4 is progressively substituted by three somatic histone H1 variants, and replacement is complete by early neurula(8,9). Here we report that accumulation of somatic H1 protein is rate limiting for the loss of mesodermal competence. This involves selective transcriptional silencing of regulatory genes required for mesodermal differentiation pathways, like muscle, by somatic, but not maternal, H1 protein.	MAX PLANCK GESELL, FRIEDRICH MIESCHER LAB, D-72076 TUBINGEN, GERMANY; NICHHD, MOL EMBRYOL LAB, NIH, BETHESDA, MD 20892 USA	Eberhard Karls University of Tubingen; Max Planck Society; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				rupp, ralph/0000-0002-8068-9957				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1987, DEVELOPMENT, V99, P527; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; DWORKINRASTL E, 1994, DEV BIOL, V161, P425, DOI 10.1006/dbio.1994.1042; FRANK D, 1991, DEVELOPMENT, V113, P1387; GRAINGER RM, 1989, P NATL ACAD SCI USA, V86, P1900, DOI 10.1073/pnas.86.6.1900; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JONES EA, 1987, DEVELOPMENT, V101, P557; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Patterton D, 1996, DEV BIOL, V173, P2, DOI 10.1006/dbio.1996.0002; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; SYMES K, 1987, DEVELOPMENT, V101, P339; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7	29	158	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					395	399		10.1038/38755	http://dx.doi.org/10.1038/38755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311783				2022-12-24	WOS:A1997XX67500056
J	Cohen, LG; Celnik, P; PascualLeone, A; Corwell, B; Faiz, L; Dambrosia, J; Honda, M; Sadato, N; Gerloff, C; Catala, MD; Hallett, M				Cohen, LG; Celnik, P; PascualLeone, A; Corwell, B; Faiz, L; Dambrosia, J; Honda, M; Sadato, N; Gerloff, C; Catala, MD; Hallett, M			Functional relevance of cross-modal plasticity in blind humans	NATURE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; VISUAL-CORTEX; OCCIPITAL CORTEX; COIL SUPPRESSION; PERCEPTION; DISCRIMINATION; ACTIVATION	Functional imaging studies of people who were blind from an early age have revealed that their primary visual cortex can be activated by Braille reading and other tactile discrimination task(1). Other studies have also shown that visual cortical areas can be activated by somatosensory input in blind subjects but not those with sight(2-7). The significance of this cross-modal plasticity is unclear, however, as it is not known whether the visual cortex can process somatosensory information in a functionally relevant way. To address this issue, we used transcranial magnetic stimulation to disrupt the function of different cortical areas in people who were blind from an early age as they identified Braille or embossed Roman letters, Transient stimulation of the occipital (visual) cortex induced errors in both tasks and distorted the tactile perceptions of blind subjects, In contrast, occipital stimu lation had no effect on tactile performance in normal-sighted subjects, whereas similar stimulation is known to disrupt their visual performance. We conclude that blindness from an early age can cause the visual cortex to be recruited to a role in somatosensory processing. We propose that this cross-modal plasticity may account in part for the superior tactile perceptual abilities of blind subjects.	NINCDS,BIOMETRY & FIELD STUDIES BRANCH,NIH,BETHESDA,MD 20892; UNIV BUENOS AIRES,DEPT NEUROL REHABIL,FDN LUCHA ENFERMEDADES NEUROL INFANTILES,RA-1053 BUENOS AIRES,DF,ARGENTINA; BETH ISRAEL DEACONESS MED CTR,LAB MAGNET BRAIN STIMULAT,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV VALENCIA,INST CAJAL,VALENCIA,SPAIN; FUKUI MED SCH,BIOMED IMAGING RES CTR,MATUOKA,FUKUI 91011,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Buenos Aires; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); University of Valencia; University of Fukui	Cohen, LG (corresponding author), NINCDS,HUMAN CORT PHYSIOL UNIT,NIH,BLDG 36,RM 4D04,BETHESDA,MD 20892, USA.		HONDA, Manabu/AAO-1202-2020; Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Sadato, Norihiro/0000-0002-9786-3907				AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; ANDERSON JA, 1972, BIOMETRIKA, V59, P19, DOI 10.2307/2334611; BARKER AT, 1985, LANCET, V1, P1106; BRIDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; CHEN R, IN PRESS ELECTROENCE; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; COHEN LG, 1991, ELECTROEN CLIN NEURO, V81, P366, DOI 10.1016/0168-5597(91)90026-T; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P247, DOI 10.1097/00004691-199605000-00009; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P242, DOI 10.1097/00004691-199605000-00008; HENDERSON DC, 1979, T AM SOC ART INT ORG, V25, P367; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Homser DW, 1989, APPL LOGISTIC REGRES; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Luders H, 1987, SURG TREATMENT EPILE, P297; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PASCUALLEONE A, 1991, NEUROLOGY, V41, P697, DOI 10.1212/WNL.41.5.697; PASCUALLEONE A, 1993, ANN NEUROL, V34, P33, DOI 10.1002/ana.410340108; PascualLeone A, 1996, EXP BRAIN RES, V107, P479; Penfield W., 1959, SPEECH BRAIN MECHANI; Pons T, 1996, NATURE, V380, P479; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Rushton D. N., 1978, Frontiers in Visual Science, P574; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; UHL F, 1991, NEUROSCI LETT, V124, P256, DOI 10.1016/0304-3940(91)90107-5; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7; WASSERMANN EM, IN PRESS ELECTROENCE; [No title captured]	30	650	665	3	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					180	183		10.1038/38278	http://dx.doi.org/10.1038/38278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296495				2022-12-24	WOS:A1997XV75700048
J	Spencer, TE; Jenster, G; Burcin, MM; Allis, CD; Zhou, JX; Mizzen, CA; McKenna, NJ; Onate, SA; Tsai, SY; Tsai, MJ; OMalley, BW				Spencer, TE; Jenster, G; Burcin, MM; Allis, CD; Zhou, JX; Mizzen, CA; McKenna, NJ; Onate, SA; Tsai, SY; Tsai, MJ; OMalley, BW			Steroid receptor coactivator-1 is a histone acetyltransferase	NATURE			English	Article							THYROID-HORMONE RECEPTOR; MMTV PROMOTER; TRANSCRIPTION; ACTIVATION; GENE; CBP; DEACETYLASE; NUCLEOSOME; REGULATOR; COMPLEX	Steroid receptors and coactivator proteins are thought to stimulate gene expression by facilitating the assembly of basal transcription factors into a stable preinitiation complex(1). That is not clear, however, is how these transcription factors gain access to transcriptionally repressed chromatin to modulate the transactivation of specific gene networks in vitro. The available evidence indicates that acetylation of chromatin in vivo is coupled to transcription and that specific histone acetyltransferases (HATs) target histones bound to DNA and overcome the inhibitory effect of chromatin on gene expression(2-4). The steroid-receptor coactivator SRC-1 is a coactivator for many members of the steroid-hormone receptor superfamily of Ligand-inducible transcription factors(5), Here we show that SRC-1 possesses intrinsic histone acetyltransferase activity and that it also interacts with another HAT, p300/CBP-associate factor (PCAF). The HAT activity of SRC-1 maps to its carboxy-terminal region and is primarily specific for histones H3 and H4, Acetylation by SRC-1 and PCAF of histones bound at specific promoters may result from ligand binding to steroid receptors and could be a mechanism by which the activation functions of steroid receptors and associated coactivators enhance formation of a stable preinitiation complex, thereby increasing transcription of specific genes from transcriptionally repressed chromatin templates.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	Baylor College of Medicine; University of Rochester			Spencer, Thomas/AAD-6434-2020	Spencer, Thomas/0000-0003-2815-766X; McKenna, Neil/0000-0001-6689-0104				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; IENSTET G, 1997, P NATL ACAD SCI USA, V94, P7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KINGSTON RE, 1996, GENE DEV, V10, P950; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WONG J, 1997, EMBO J, V11, P3158; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	26	1030	1046	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					194	198		10.1038/38304	http://dx.doi.org/10.1038/38304			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296499				2022-12-24	WOS:A1997XV75700052
J	Ruggiu, M; Speed, R; Taggart, M; McKay, SJ; Kilanowski, F; Saunders, P; Dorin, J; Cooke, HJ				Ruggiu, M; Speed, R; Taggart, M; McKay, SJ; Kilanowski, F; Saunders, P; Dorin, J; Cooke, HJ			The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis	NATURE			English	Article							Y-CHROMOSOME; AUTOSOMAL GENE; ZONA PELLUCIDA; AZOOSPERMIA; HOMOLOG; SPERMATOGENESIS; DELETIONS; CANDIDATE; OOCYTES; HUMANS	RBM and DAZ/SPGY are two families of genes located on the Y chromosome that encode proteins containing RNA-binding motifs, and both have been described as candidate human spermatogenesis genes(1,2). Transmission of deletions from father to son has been observed in the case of DAZ(3-5), but neither gene family has been shown to be essential for spermatogenesis in human males. The DAZ/SPGY genes are particularly amenable to a knockout approach, as they are found on the Y chromosome in Old World primates and apes(6), but in other mammals, they are represented only by an autosomal gene, DAZLA(7-10), which is also present in Old World primates and apes. It has also been shown that a Dazla homologue is essential for spermatogenesis in Drosophila(11). Here we show that Dazla protein is cytoplasmic in male and female germ cells, unlike the nuclear RBM protein(12) Disruption of the Dazla gene leads to loss of germ cells and complete absence of gamete production, demonstrating that Dazla is essential for the differentiation of germ cells.	WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; MRC, REPROD BIOL UNIT, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND	University of Edinburgh			Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380; Ruggiu, Matteo/0000-0002-6404-1210	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1980, P NATL ACAD SCI-BIOL, V77, P1029, DOI 10.1073/pnas.77.2.1029; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Frojdman K, 1993, SERTOLI CELL, P87; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; Niederberger C, 1997, MAMM GENOME, V8, P277, DOI 10.1007/s003359900409; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; Shan ZH, 1996, HUM MOL GENET, V5, P2005, DOI 10.1093/hmg/5.12.2005; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013	17	498	523	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					73	77		10.1038/37987	http://dx.doi.org/10.1038/37987			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288969				2022-12-24	WOS:A1997XU59600047
J	Heyning, JE; Mead, JG				Heyning, JE; Mead, JG			Thermoregulation in the mouths of feeding gray whales	SCIENCE			English	Article							RETE	Vascular structures for heat conservation in the tongue of the gray whale (Eschrichtius robustus) are reported here. Numerous individual countercurrent heat exchangers are found throughout the massive tongue, These converge at the base of the tongue to form a bilateral pair of retia. Temperature measurements from the oral cavity of a live gray whale indicate that more heat may be lost through the blubber layer over the body than through the tongue, despite the fact that the tongue is far more vascularized and has much less insulation, These heal exchangers substantially reduce heat loss when these whales feed in cold waters.	NATL MUSEUM NAT HIST,DIV MAMMALS,WASHINGTON,DC 20560	Smithsonian Institution; Smithsonian National Museum of Natural History	Heyning, JE (corresponding author), NAT HIST MUSEUM LOS ANGELES,SECT VERTEBRATES,900 EXPOSIT BLVD,LOS ANGELES,CA 90007, USA.							BRODIE P, 1985, CAN J ZOOL, V63, P2267, DOI 10.1139/z85-336; CARTE A, 1869, PHILOS T R SOC LONDO, V158, P201; Elsner R., 1974, FUNCTIONAL ANATOMY M, P143; FORD TJ, 1992, NATURE, V359, P680, DOI 10.1038/359680a0; HEYNING JE, 1993, NATURE, V361, P24, DOI 10.1038/361024b0; HOKKANEN JEI, 1990, J THEOR BIOL, V145, P465, DOI 10.1016/S0022-5193(05)80482-5; IRVING L, 1955, J APPL PHYSIOL, V7, P355, DOI 10.1152/jappl.1955.7.4.355; PFEIFFER CJ, 1990, ACTA ANAT, V139, P141; ROMMEL SA, 1992, ANAT RECORD, V232, P150, DOI 10.1002/ar.1092320117; ROMMEL SA, 1993, ANAT REC, V237, P537; RYG M, 1993, J ZOOL, V230, P193, DOI 10.1111/j.1469-7998.1993.tb02682.x; Schmidt-Nielsen K, 1997, ANIMAL PHYSL ADAPTAT; SCHOLANDER P. F., 1958, HVALRADETS SKRIFTER SCI RESULTS MARINE BIOL RES, V44, P1; SCHOLANDER PF, 1955, J APPL PHYSIOL, V8, P279, DOI 10.1152/jappl.1955.8.3.279; SLIJPER EJ, 1936, CAPITA ZOOLOGICA, V617, P1; van Utrecht WL, 1958, ZOOL ANZ, V161, P77	16	21	21	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1138	1139		10.1126/science.278.5340.1138	http://dx.doi.org/10.1126/science.278.5340.1138			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353198				2022-12-24	WOS:A1997YE65200057
J	Nyangulu, DS; Harries, AD; Kangombe, C; Yadidi, AE; Chokani, K; Cullinan, T; Maher, D; Nunn, P; Salaniponi, FM				Nyangulu, DS; Harries, AD; Kangombe, C; Yadidi, AE; Chokani, K; Cullinan, T; Maher, D; Nunn, P; Salaniponi, FM			Tuberculosis in a prison population in Malawi	LANCET			English	Article							NEW-YORK-CITY; ASSOCIATION; INFECTION; SYSTEM	Background Much concern has been expressed about the high prevalence of tuberculosis in prisons in industrialised countries, Since there is almost no information from developing countries, we investigated the rate of pulmonary tuberculosis in a large prison in Malawi. Methods Between May and July, 1996, we carried out an active case-finding survey in Zomba Central Prison, Malawi, through the National Tuberculosis Control Programme. We interviewed prisoners, and those with a cough of at least 1 week's duration were screened by sputum-smear microscopy. If microscopy was negative, prisoners underwent chest radiography. We offered HIV testing, with voluntary consent and counselling before and after tests, to all prisoners, whether positive or negative for pulmonary tuberculosis. Findings 914 (70%) of 1315 prisoners were screened (905 men, nine women; mean age 30 years [SD 11]), 47 (5%) screened prisoners (all men) had pulmonary tuberculosis: 14 were taking antituberculosis treatment and 33 were undiagnosed at the start of the study; 18 were sputum-smear positive and 15 were sputum-smear negative. 16 (73%) of 22 prisoners with previously undiagnosed pulmonary tuberculosis and 30 (75%) of 40 prisoners with cough but no evidence of pulmonary tuberculosis were HIV seropositive, In all prisoners, except one, symptoms of pulmonary tuberculosis had developed after they had entered prison. Interpretation We found a high rate of pulmonary tuberculosis in Zomba Central Prison, which suggests active transmission of tuberculosis. As a result of this study, the National Tuberculosis Control Programme has implemented interventions in eight prisons in Malawi to improve tuberculosis control, including collection of health data, education of prisoners and clinical staff about tuberculosis, active screening of prisoners for pulmonary tuberculosis by sputum-smear microscopy, and active case-finding in the prisons.	MINIST HLTH,NATL TB CONTROL PROGRAMME,LILONGWE,MALAWI; UNIV MALAWI,COLL MED,LILONGWE,MALAWI; ZOMBA CENT PRISON,ZOMBA,MALAWI; WHO,GLOBAL TB PROGRAMME,CH-1211 GENEVA,SWITZERLAND	University of Malawi; World Health Organization				Maher, Dermot/0000-0003-0466-1976				ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; *CDCP, 1989, MMWR-MORBID MORTAL W, V38, P313; CHAVES F, 1993, MED CLIN-BARCELONA, V101, P525; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; Harries A. D., 1994, P241; Harries AD, 1997, T ROY SOC TROP MED H, V91, P416, DOI 10.1016/S0035-9203(97)90262-5; MARTIN V, 1994, TUBERCLE LUNG DIS, V74, P49; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151	11	68	72	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1284	1287		10.1016/S0140-6736(97)05023-X	http://dx.doi.org/10.1016/S0140-6736(97)05023-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357408				2022-12-24	WOS:A1997YD68900010
J	Gordon, M				Gordon, M			Is the best yet to be?	LANCET			English	Article							LIMITS; CARE				Gordon, M (corresponding author), BAYCREST CTR GERIATR CARE,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.							CALLAHAN D, 1994, GERONTOLOGIST, V34, P393, DOI 10.1093/geront/34.3.393; CAMPION EW, 1994, NEW ENGL J MED, V330, P1819, DOI 10.1056/NEJM199406233302509; CASSEL CK, 1992, HEALTH AFFAIR, V11, P87, DOI 10.1377/hlthaff.11.2.87; COHEN GD, 1997, 7 DEADLY MYTHS UNCOV; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; GORDON M, 1993, CAN MED ASSOC J, V148, P393; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; ROSENTHAL J, 1997, NY TIMES        0309, P39; Rowe JW, 1997, GERONTOLOGIST, V37, P433, DOI 10.1093/geront/37.4.433; Scharf S, 1996, DRUG AGING, V9, P399, DOI 10.2165/00002512-199609060-00002; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2354; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; WEINBERGER M, 1993, AM J PUBLIC HEALTH, V83, P338, DOI 10.2105/AJPH.83.3.338; Williams TF, 1997, J AM GERIATR SOC, V45, P244, DOI 10.1111/j.1532-5415.1997.tb04516.x; 1997, NY TIMES        0309	16	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1166	1167		10.1016/S0140-6736(97)05069-1	http://dx.doi.org/10.1016/S0140-6736(97)05069-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343520				2022-12-24	WOS:A1997YB19900048
J	Webb, AK; Hanley, SP				Webb, AK; Hanley, SP			Personal paper: The conflict in transferring a cystic fibrosis specialist service between two hospitals in Manchester	BRITISH MEDICAL JOURNAL			English	Article									N MANCHESTER HLTH AUTHOR,MANCHESTER M8 5RB,LANCS,ENGLAND		Webb, AK (corresponding author), WYTHENSHAWE HOSP,NW LUNG CTR,BRADBURY CYST FIBROSIS UNIT,MANCHESTER M23 9LT,LANCS,ENGLAND.							FORSYTHE M, 1994, BRIT MED J, V308, P151, DOI 10.1136/bmj.308.6922.151; Hughes D, 1995, Health Serv J, V105, P18; ROBSON M, 1992, THORAX, V47, P684, DOI 10.1136/thx.47.9.684; SMITH R, 1992, BRIT MED J, V305, P1308, DOI 10.1136/bmj.305.6865.1308; SMITH R, 1994, BRIT MED J, V309, P1644, DOI 10.1136/bmj.309.6969.1644; WEBB AK, 1994, THORAX, V49, P291, DOI 10.1136/thx.49.4.291	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1009	1011		10.1136/bmj.315.7114.1009	http://dx.doi.org/10.1136/bmj.315.7114.1009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365304	Green Published			2022-12-24	WOS:A1997YC30700031
J	Datta, SR; Dudek, H; Tao, X; Masters, S; Fu, HA; Gotoh, Y; Greenberg, ME				Datta, SR; Dudek, H; Tao, X; Masters, S; Fu, HA; Gotoh, Y; Greenberg, ME			Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery	CELL			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; GROWTH-FACTOR; APOPTOSIS; TRANSDUCTION; INHIBITION; ACTIVATION; MECHANISMS	Growth factors can promote cell survival by activating the phosphatidylinositide-3'-OH kinase and its downstream target, the serine-threonine kinase Akt. However, the mechanism by which Akt functions to promote survival is not understood. We show that growth factor activation of the PI3'K/Akt signaling pathway culminates in the phosphorylation of the BCL-2 family member BAD, thereby suppressing apoptosis and promoting cell survival. Akt phosphorylates BAD in vitro and in vivo, and blocks the BAD-induced death of primary neurons in a site-specific manner. These findings define a mechanism by which growth factors directly inactivate a critical component of the cell-intrinsic death machinery.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM MOL THERAPEUT & TOXICOL,ATLANTA,GA 30322	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Emory University; Emory University			Roszak, Joanna/F-4003-2010	Datta, Sandeep/0000-0002-8068-3862	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053165, R01GM053165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NIGMS NIH HHS [GM53165] Funding Source: Medline; NINDS NIH HHS [NS28829] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BARRES BA, 1993, DEVELOPMENT, V118, P283; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COFFER PJ, 1992, EUR J BIOCHEM, V205, P1217; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GALLI C, 1995, J NEUROSCI, V15, P1172; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miller TM, 1996, J NEUROSCI, V16, P7487; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Vemuri GS, 1996, DEVELOPMENT, V122, P2529; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	57	4772	4951	2	189	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					231	241		10.1016/S0092-8674(00)80405-5	http://dx.doi.org/10.1016/S0092-8674(00)80405-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346240	Bronze			2022-12-24	WOS:A1997YC35000010
J	Wutz, A; Smrzka, OW; Schweifer, N; Schellander, K; Wagner, EF; Barlow, DP				Wutz, A; Smrzka, OW; Schweifer, N; Schellander, K; Wagner, EF; Barlow, DP			Imprinted expression of the Igf2r gene depends on an intronic CpG island	NATURE			English	Article							H19 GENE; METHYLATION; MOUSE; CHROMOSOME; REPLICATION; CREATION; PATTERNS; REGIONS; MICE; DNA	Gametic imprinting is a developmental process that induces parental-specific expression or repression of autosomal and X-chromosome-linked genes(1,2). The mouse Igf2r gene (encoding the receptor for insulin-like growth factor type-2) is imprinted and is expressed from the maternal allele after embryonic implantation(3). We previously proposed that methylation of region 2, a region rich in cytosine-guanine doublets (a 'CpG island') in the second intron of Igf2r, is the imprinting signal that maintains expression of the maternal allele(4). Here we use mouse transgenes to test the role of region 2 and the influence of chromosome location on Igf2r imprinting, Yeast artificial chromosome transgenes successfully reproduced the imprinted methylation and expression pattern of the endogenous Igf2r gene; deletion of region 2 from these transgenes caused a loss of imprinting and restored biallelic Igf2r expression, These results define a primary role for region 2 and a negligible role for chromosomal location in Igf2r imprinting; they also show that methylation imprints can maintain allelic expression, Short transgenes containing only region 2 and yeast artificial chromosome transgenes with an inactive Igf2r promoter do not attract parental-specific methylation. All transgenes showing paternal-specific repression of Igf2r produced an antisense RNA whose transcription was dependent on region 2, The production of an antisense RNA by the repressed parental allele is reminiscent of the imprinting of the Igf2/H19 gene pair(5) and may indicate that expression competition could play a general role in imprinting.	NETHERLANDS CANC INST,NL-1066 CX AMSTERDAM,NETHERLANDS; INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; BOEHRINGER INGELHEIM R&D,A-1121 VIENNA,AUSTRIA; UNIV BONN,D-53115 BONN,GERMANY	Netherlands Cancer Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim; University of Bonn				Wagner, Erwin F/0000-0001-7872-0196				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BICKMORE WA, 1995, J CELL SCI, V108, P2801; BIRD AP, 1993, CURR BIOL, V3, P275, DOI 10.1016/0960-9822(93)90177-P; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Dittrich B, 1996, NAT GENET, V14, P163, DOI 10.1038/ng1096-163; Elson DA, 1997, MOL CELL BIOL, V17, P309, DOI 10.1128/MCB.17.1.309; Hogan B, 1994, MANIPULATING MOUSE E; John RM, 1996, CURR OPIN CELL BIOL, V8, P348, DOI 10.1016/S0955-0674(96)80008-1; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; Leighton PA, 1996, BIOL REPROD, V54, P273, DOI 10.1095/biolreprod54.2.273; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LERCHNER WL, 1996, MECH DEVELOP, V61, P1; LEWIS BC, 1992, GENET ANAL-BIOMOL E, V9, P86, DOI 10.1016/1050-3862(92)90003-N; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; PALDI A, 1995, CURR BIOL, V5, P1030, DOI 10.1016/S0960-9822(95)00207-7; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; Saitoh S, 1996, P NATL ACAD SCI USA, V93, P7811, DOI 10.1073/pnas.93.15.7811; Sambrook J., 1989, MOL CLONING LABORATO, P743; Schweifer N, 1997, GENOMICS, V43, P285, DOI 10.1006/geno.1997.4816; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373	27	478	494	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					745	749		10.1038/39631	http://dx.doi.org/10.1038/39631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338788				2022-12-24	WOS:A1997YA95900059
J	Annas, GJ				Annas, GJ			The bell tolls for a constitutional right to physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; *NY STAT TASK FORC, 1997, DEATH IS SOUGHT ASS; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785	4	16	16	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1098	1103		10.1056/NEJM199710093371523	http://dx.doi.org/10.1056/NEJM199710093371523			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321541	Green Published			2022-12-24	WOS:A1997XZ84400032
J	deMuizon, C; Cifelli, RL; Paz, RC				deMuizon, C; Cifelli, RL; Paz, RC			The origin of the dog-like borhyaenoid marsupials of South America	NATURE			English	Article							MAMMALS	Dog-like marsupials (superfamily Borhyaenoidea) were the largest predacious mammals during the Tertiary period in South America(1). They are critical to our understanding of marsupial origin, phylogeny and palaeobiogeography because they have been related to various marsupial lineages of several continents: didelphoids(2) (mainly New World, but also Europe, Asia and Africa), pediomyrid(3), stagodontids(4) (North America), dasyuroids(5) (Australia) and deltatheroidans(6) (predominantly Asian). These relationships, based mainly on dental morphology, have been discussed and rejected several times(2,3,7,8). Here we report the discovery of exceptionally well preserved skulls and skeletons, referrable to the didelphoid Andinodelphys, which shed new light on the phylogenetic and palaeobiogeographic origin of dog-like marsupials. The skulls of Mayulestes (boryhyaenoid)(9), Andinodelphys and Pucadelphys (didelphoids)(10,11) from the early Palaeocene epoch of Bolivia are the oldest known for American marsupials. Comparison of their basicranial anatomy suggests that dog-like marsupials are closely related to an early didelphimorphian radiation in South America, rather than to Asiatic (deltatheroidan), North American (stagodontid), or Australian(dasyuroid) lineages.	UNIV OKLAHOMA,OKLAHOMA MUSEUM NAT HIST,NORMAN,OK 73019; UNIV MAYOR SAN SIMON,MUSEO ARQUEOL,COCHABAMBA,BOLIVIA	University of Oklahoma System; University of Oklahoma - Norman	deMuizon, C (corresponding author), MUSEUM NATL HIST NAT,CNRS,URA 12,PALEONTOL LAB,8 RUE BUFFON,F-75005 PARIS,FRANCE.		De Muizon, Christian/Q-7986-2019; De Muizon, Christian/P-4335-2017	De Muizon, Christian/0000-0002-1247-8867; De Muizon, Christian/0000-0002-1247-8867				Aplin K.P., 1987, pxv; Archer M., 1982, P397; Archer M., 1976, Australian J Zool, VNo. 39, P1; BONAPARTE JF, 1990, NATL GEOGR RES, V6, P63; Cifelli R.L., 1990, Journal of Vertebrate Paleontology, V10, P295; CIFELLI RL, 1993, P NATL ACAD SCI USA, V90, P9413, DOI 10.1073/pnas.90.20.9413; CIFELLI RL, 1993, MAMMAL PHYLOGENY, P205; CIFELLI RL, IN PRESS J PALEONTOL; CIFELLI RL, IN PRESS J MAMM EVOL; Clemens W.A., 1986, CONTRIBUTIONS GEOLOG, V3, P55, DOI DOI 10.2113/GSR0CKY.24.SPECIAL_; Clemens W.A., 1966, U CALIFORNIA PUBLICA, V62, P1; De Muizon Christian, 1993, Annales de Paleontologie, V79, P233; DEMUIZON C, 1994, NATURE, V370, P208, DOI 10.1038/370208a0; DEMUIZON C, IN PRESS GEODIVERSIT; DEMUIZON C, 1992, REV TECN YAC PETROL, V12, P393; Fox R.C., 1987, P161; FOX RC, 1979, J PALEONTOL, V53, P733; Fox Richard C., 1995, P247; HOFFSTETTER R, 1972, CR ACAD SCI D NAT, V274, P2635; MARSHALL L G, 1978, University of California Publications in Geological Sciences, V117, P1; Marshall L.G., 1980, P345; Marshall Larry G., 1995, Memoires du Museum National d'Histoire Naturelle, V165, P21; MARSHALL LG, 1992, LETHAIA, V25, P361, DOI 10.1111/j.1502-3931.1992.tb01639.x; MARSHALL LG, 1988, NATL GEOGR RES, V4, P23; MARSHALL LG, 1977, SYST ZOOL, V26, P410, DOI 10.2307/2412796; MARSHALL LG, 1990, CURRENT MAMMALOGY, P343; MATTHEW WD, 1916, B AM MUS NAT HIST, V35, P447; Simpson G. G., 1980, CURIOUS HIST S AM MA; Szalay FS, 1996, J VERTEBR PALEONTOL, V16, P474, DOI 10.1080/02724634.1996.10011335; SZALAY FS, 1994, EVOLUTIONARY HIST PR	30	53	55	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					486	489		10.1038/39029	http://dx.doi.org/10.1038/39029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333235				2022-12-24	WOS:A1997XY90900053
J	Agerton, T; Valway, S; Gore, B; Pozsik, C; Plikaytis, B; Woodley, C; Onorato, I				Agerton, T; Valway, S; Gore, B; Pozsik, C; Plikaytis, B; Woodley, C; Onorato, I			Transmission of a highly drug-resistant strain (strain W1) of Mycobacterium tuberculosis - Community outbreak and nosocomial transmission via a contaminated bronchoscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION	Context.-Nosocomial transmission of multidrug-resistant tuberculosis (MDR TB) has been reported primarily in New York State and has generally been presumed to occur via respiratory aerosols. Objective.-To assess nosocomial transmission of MDR TB. In 1995, 8 patients with MDR TB were identified in South Carolina; all were resistant to 7 drugs and had matching DNA fingerprints (strain W1). Community links were identified for 5 patients (Patients 1-5). However, no links were identified for the other 3 patients (Patients 6-8) except being hospitalized at the same hospital as 1 community patient. Design.-Outbreak investigation. Setting.-Community and hospital. Patients.-Eight patients whose MDR TB isolates had DNA fingerprint patterns matching strain W1. Main Outcome Measures.-Clinical characteristics of patients with strain W1 Mycobacterium tuberculosis isolates. Results.-Patient 5 (community patient) and Patient 8, diagnosed April 1995 and November 1995, respectively, had clinical courses consistent with MDR TB, with smear-positive and culture-positive specimens and cavitary lesions on chest radiograph; both died of MDR TB less than 1 month after diagnosis. Patients 6 and 7 (diagnosed May 1995) each had 1 positive culture for MDR TB; specimens were collected during bronchoscopy. Patient 6 had a skin test conversion after bronchoscopy. Neither Patient 6 nor Patient 7 had a clinical course consistent with MDR TB, neither was treated for MDR TB, and both are alive and well. No evidence of laboratory contamination of specimens, transmission on inpatient wards, or contact among patients was found. All 4 received bronchoscopies in May 1995; Patients 6, 7, and 8 had bronchoscopies 1, 12, and 17 days, respectively, after Patient 5. Observations revealed that bronchoscope cleaning was inadequate, and the bronchoscope was never immersed in disinfectant. Conclusions.-Inadequate cleaning and disinfection of the bronchoscope after the procedure performed on Patient 5 led to subsequent false-positive cultures in Patients 6 and 7 and transmission of infection to Patient 6 and active MDR TB to Patient 8.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV PROGRAM,EPIDEM PROGRAM OFF,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV HIV STD TB LAB RES,NATL CTR INFECT DIS,ATLANTA,GA 30333; S CAROLINA DEPT HLTH & ENVIRONM CONTROL,COLUMBIA,SC 29201	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Agerton, T (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-10,ATLANTA,GA 30333, USA.							*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BENNETT SN, 1994, AM J RESP CRIT CARE, V150, P245, DOI 10.1164/ajrccm.150.1.8025757; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P675; *CDCP, 1994, COR CURR TUB WHAT CL; COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; FITCH LE, 1991, J HOSP INFECT, V17, P322, DOI 10.1016/0195-6701(91)90287-I; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GUBLER JGH, 1992, CHEST, V101, P1245, DOI 10.1378/chest.101.5.1245; HUSEN L, 1971, CHEST, V60, P540, DOI 10.1378/chest.60.6.540; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; JEREB JA, 1995, ARCH INTERN MED, V155, P854, DOI 10.1001/archinte.155.8.854; KENT DC, 1967, ARCH ENVIRON HEALTH, V14, P580, DOI 10.1080/00039896.1967.10664795; MARTIN MA, 1994, AM J INFECT CONTROL, V22, P19, DOI 10.1016/0196-6553(94)90087-6; NELSON KE, 1983, AM REV RESPIR DIS, V127, P97, DOI 10.1164/arrd.1983.127.1.97; NICHOLSON G, 1995, J HOSP INFECT, V29, P257, DOI 10.1016/0195-6701(95)90272-4; PRIGOGINE T, 1988, J HOSP INFECT, V11, P93, DOI 10.1016/0195-6701(88)90047-3; SCHMIDEK HH, 1967, CAN MED ASSOC J, V97, P178; TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767, DOI 10.1128/JCM.31.4.767-770.1993; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; WHEELER PW, 1989, J INFECT DIS, V159, P954, DOI 10.1093/infdis/159.5.954; World Health Organization, 1977, INT CLASS DIS	25	126	131	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1073	1077		10.1001/jama.278.13.1073	http://dx.doi.org/10.1001/jama.278.13.1073			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315765				2022-12-24	WOS:A1997XX30300030
J	Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF				Patrick, DL; Pearlman, RA; Starks, HE; Cain, KC; Cole, WG; Uhlmann, RF			Validation of preferences for life-sustaining treatment: Implications for advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article						advance directives; life support care; health status; treatment outcomes	STATES WORSE; DIRECTIVES; ATTITUDES; STABILITY; CHOICES; QUALITY; VALUES; DEATH	Background: Treatment preferences established before life-threatening illness occurs may differ from actual decisions because of changes in preferences or poor understanding of the link between prospective preferences and outcomes. Objective: To evaluate the validity of prospective treatment preferences by examining their concordance with ratings of health states. Design: Survey of seven cohorts of persons with diverse health status. Home-and hospital-based interviews were conducted at baseline and at 6, 18, and 30 months. Setting: The greater Seattle area. Participants: Younger and older well adults; persons with chronic conditions, terminal cancer, or AIDS; stroke survivors; and nursing home residents. Measurements: Concordance between six treatment preferences and five health state ratings (on a seven-point scale) was assessed by using logistic regression to measure the increase in odds of treatment refusal for each one-point change in health state ratings. Preferences were considered concordant if treatments were refused in health states rated as worse than death and were accepted in health states rated as better than death. Reasons for discordance were elicited at the final interview. Results: The probability of refusal of prospective treatment was strongly related to health state ratings. Odds ratios ranged from 1.7 to 1.9 (P < 0.001) for every treatment. When patients were shown their discordant preferences, they had a coherent explanation or changed their health state rating or treatment preference to make the two concordant. Conclusions: Prospective life-sustaining treatment preferences show high convergent validity. For most persons, treatment preferences are grounded in a consistent belief system. Concordance and discordance between treatment preferences and health state ratings offer clinicians the opportunity to explore patients' Values and reasoning.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Patrick, DL (corresponding author), UNIV WASHINGTON, DEPT HLTH SERV, BOX 357660, SEATTLE, WA 98195 USA.		Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	AHRQ HHS [HS06343] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; DANIS M, 1994, ANN INTERN MED, V120, P567, DOI 10.7326/0003-4819-120-7-199404010-00006; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1994, ARCH INTERN MED, V154, P209, DOI 10.1001/archinte.1994.00420020131014; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; Patrick DL, 1993, HLTH STATUS HLTH POL; Pearlman R. A., 1994, Journal of General Internal Medicine, V9, P97; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; PEARLMAN RA, 1995, PUBLICATION NAT TECH; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; Schonwetter RS, 1996, J AM GERIATR SOC, V44, P954, DOI 10.1111/j.1532-5415.1996.tb01867.x; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; *STAT CORP, 1993, STAT REF MAN; Sutherland H J, 1982, Med Decis Making, V2, P299, DOI 10.1177/0272989X8200200306; Tonelli MR, 1996, CHEST, V110, P816, DOI 10.1378/chest.110.3.816; TORRANCE GW, 1982, VALUES LONG TERM CAR; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	25	88	91	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					509	+		10.7326/0003-4819-127-7-199710010-00002	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY733	9313018				2022-12-24	WOS:A1997XY73300002
J	Zimmerman, RK; Medsger, AR; Ricci, EM; Raymund, M; Mieczkowski, TA; Grufferman, S				Zimmerman, RK; Medsger, AR; Ricci, EM; Raymund, M; Mieczkowski, TA; Grufferman, S			Impact of free vaccine and insurance status on physician referral of children to public vaccine clinics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	30th National Immunization Conference	APR 10-11, 1996	WASHINGTON, DC				IMMUNIZATION PRACTICES; PEDIATRICIANS; CARE	Context.-Concerns about financial barriers to vaccination led to the development of the Vaccines for Children (VFC) program, which provides free vaccines to states for children who are uninsured, Medicaid eligible, or Native American or Native Alaskan. Objective.-To understand the effect of economic factors on physician likelihood of referring children to public vaccine clinics for immunizations and to evaluate the VFC program. Design.-A standardized survey was conducted in 1995 by trained personnel using computer-assisted telephone interviewing. Setting and Participants.-A stratified random sample of family physicians, pediatricians, and general practitioners younger than 65 years who were in office-based practices across the United States. Main Outcome Measures.-Likelihood of referral of a child to a health department for vaccination by child's insurance status and by the physician's receipt of free vaccines. Results.-Of the 1769 physicians with whom an interviewer spoke, 1236 participated, Most respondents (66%) were likely to refer an uninsured child to the health department for vaccination, whereas only 8% were likely to refer a child who had insurance that covers vaccination, The majority (58%) of physicians reported differential referral based on insurance status. Among physicians who received free vaccine supplies from the VFC program or elsewhere, 44% were likely to refer an uninsured child whereas 90% of those not receiving free vaccine were likely to refer the same child (P<.001). In regression analysis, the receipt of free vaccine supplies accounted for 24% of the variance in the likelihood to refer an uninsured child for vaccination. Conclusions.-Physicians receiving free vaccine supplies report being less likely to refer children to public clinics for vaccinations.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT HLTH SERV ADM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zimmerman, RK (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT FAMILY MED & CLIN EPIDEMIOL,M-200 SCAIFE HALL,PITTSBURGH,PA 15261, USA.			Zimmerman, Richard/0000-0001-5941-6092; Santibanez, Tammy A./0000-0002-5784-7427	AHRQ HHS [HS08068] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY L, 1989, DESIGNING CONDUCTING; ARNOLD PJ, 1992, AM J DIS CHILD, V146, P728, DOI 10.1001/archpedi.1992.02160180088023; BORDLEY WC, 1994, PEDIATRICS, V94, P376; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P657; Cochran W. G., 1977, SAMPLING TECHNIQUES; FAIRBROTHER G, IN PRESS ARCH PEDIAT; Hamlin JS, 1996, AM J PUBLIC HEALTH, V86, P1812, DOI 10.2105/AJPH.86.12.1812; HOLTMANN AG, 1996, SUPPLYING VACCINE EC, P153; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; Murphy TV, 1997, PEDIATR INFECT DIS J, V16, P47, DOI 10.1097/00006454-199701000-00011; MURPHY TV, 1995, PEDIATR INFECT DIS J, V15, P561; *NAT VACC ADV COMM, 1991, JAMA-J AM MED ASSOC, V266, P1547; Public Health Service U.S. Department of Health and Human Services, 1991, HLTH PEOPL 2000 NAT; RUCHROSS HS, 1994, PEDIATRICS, V94, P508; *SAS I INC, 1996, SAS SYST WIND COMP P; SCHULTE JM, 1991, PEDIATRICS, V87, P204; Taylor JA, 1997, PEDIATRICS, V99, P209; *US GEN ACC OFF, 1995, VACC CHILDR REEX PRO; Wood DL, 1996, ARCH PEDIAT ADOL MED, V150, P577, DOI 10.1001/archpedi.1996.02170310011001; WRIGHT JA, 1992, AM J DIS CHILD, V146, P1033, DOI 10.1001/archpedi.1992.02160210035016; Zimmerman R K, 1993, Fam Pract Res J, V13, P213; Zimmerman R K, 1995, J Am Board Fam Pract, V8, P270; Zimmerman RK, 1997, AM J PREV MED, V13, P89, DOI 10.1016/S0749-3797(18)30204-6; Zimmerman RK, 1997, ARCH PEDIAT ADOL MED, V151, P657, DOI 10.1001/archpedi.1997.02170440019004	24	40	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					996	1000		10.1001/jama.278.12.996	http://dx.doi.org/10.1001/jama.278.12.996			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307347				2022-12-24	WOS:A1997XX01200030
J	Coste, J; Letrait, M; Carel, JC; Tresca, JP; Chatelain, P; Rochiccioli, P; Louis, J; Chaussain, JL; Job, JC				Coste, J; Letrait, M; Carel, JC; Tresca, JP; Chatelain, P; Rochiccioli, P; Louis, J; Chaussain, JL; Job, JC			Long term results of growth hormone treatment in France in children of short stature: population, register based study	BRITISH MEDICAL JOURNAL			English	Article							FINAL HEIGHT; PUBERTAL DEVELOPMENT; GH DEFICIENCY; THERAPY	Objectives: To describe the growth of children treated with growth hormone and to evaluate the prognostic factors for height at the end of treatment Design: Register based cohort study. Setting: French national register of all children treated with growth hormone. Subjects: 3233 short stature children (3165 of whom were deficient in growth hormone) who were treated with growth hormone (excluding children with Turner's syndrome) and whose treatment started between 1973 and 1989, last data being recorded in December 1993. Main outcome measures: Annual changes in height, and height at the end of treatment. Results: Mean height SD score at the end of treatment, after a mean of 4.3 years, was -2, corresponding to gain in mean height SD score of 1 and to a height SD score of 1.1 below tar-get height Ln all, 923 children prematurely stopped taking growth hormone treatment, mainly because of insufficient response (insufficient growth) or tiredness. Variables that predicted height at the end of treatment were age, target height, aetiology of short stature, use of puberty inhibitors, and type of growth hormone. Conclusions: The outcome of children of short stature with growth hormone deficiency who were treated with growth hormone has been less favourable than initially assumed. Growth hormone treatment has not restored normal growth to these children, The highly demanding nature and high costs of this treatment require an optimised prescription, and this remains to be determined.	HOP COCHIN,INST RECH THERAPEUT,F-75674 PARIS,FRANCE; ASSOC FRANCE HYPOPHYSE,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Coste, J (corresponding author), UNIV PARIS 05,HOP COCHIN,FAC COCHIN,DEPT BIOSTAT & INFORMAT MED,ACHARD 7,F-75674 PARIS 14,FRANCE.		Carel, Jean-Claude/AAZ-7691-2020	Carel, Jean-Claude/0000-0002-0424-6767				ALLEN DB, 1990, J PEDIATR-US, V117, P16, DOI 10.1016/S0022-3476(05)82438-2; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BERGMAN U, 1992, J CLIN EPIDEMIOL, V45, P313, DOI 10.1016/0895-4356(92)90092-2; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BLETHEN SL, 1993, J CLIN ENDOCR METAB, V76, P574, DOI 10.1210/jc.76.3.574; BRAMSWIG J, 1995, HORM RES, V43, P126, DOI 10.1159/000184256; BURNS EC, 1981, CLIN ENDOCRINOL, V14, P587, DOI 10.1111/j.1365-2265.1981.tb02969.x; BURNS EC, 1981, EUR J PEDIATR, V137, P155; CACCIARI E, 1994, J CLIN ENDOCR METAB, V79, P1663, DOI 10.1210/jc.79.6.1663; Carel JC, 1996, J CLIN ENDOCR METAB, V81, P3318, DOI 10.1210/jc.81.9.3318; CHIPMAN JJ, 1995, HORM RES, V43, P129, DOI 10.1159/000184257; COLE T, 1993, KIGS REPORT, V10, P37; FRISCH H, 1995, HORM RES, V43, P132, DOI 10.1159/000184258; GRECO L, 1995, BRIT MED J, V310, P696, DOI 10.1136/bmj.310.6981.696; Greulich WW, 1970, RADIOGRAPHIC ATLAS S; HIBI I, 1989, J CLIN ENDOCR METAB, V69, P221, DOI 10.1210/jcem-69-2-221; HIBI I, 1989, ACTA ENDOCRINOL-COP, V120, P409, DOI 10.1530/acta.0.1200409; Hindmarsh PC, 1996, LANCET, V348, P13, DOI 10.1016/S0140-6736(96)01038-0; JOB JC, 1988, ARCH FR PEDIATR, V45, P169; MAES M, 1994, KABI INT GROWTH STUD, V11, P15; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; PRICE DA, 1994, PROGR GROWTH HORMONE; Ranke MB, 1996, HORM RES, V45, P64, DOI 10.1159/000184851; Ranke MB, 1994, PROGR GROWTH HORMONE; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; *SAS I, 1990, SAS US GUID; Sempe M., 1979, AUXOLOGIE METHODES S; Sempe P., 1971, CROISSANCE MATURATIO; SEVERI F, 1995, HORM RES, V43, P138, DOI 10.1159/000184260; VANDENBROECK J, 1995, J PEDIATR-US, V127, P729, DOI 10.1016/S0022-3476(95)70161-3; VANDENBROECK J, 1988, EUR J PEDIATR, V147, P245, DOI 10.1007/BF00442688	32	68	68	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					708	713		10.1136/bmj.315.7110.708	http://dx.doi.org/10.1136/bmj.315.7110.708			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314755	Green Published			2022-12-24	WOS:A1997XX67400021
J	Price, H				Price, H			Deaths from venous thromboembolism associated with combined oral contraceptives	LANCET			English	Letter											Price, H (corresponding author), HM CORONER,EASTERN DIST GREATER LONDON,CORONERS COURT,LONDON E17 8QP,ENGLAND.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					450	450		10.1016/S0140-6736(05)64187-6	http://dx.doi.org/10.1016/S0140-6736(05)64187-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9289596				2022-12-24	WOS:A1997XQ24800074
J	Nightingale, SL				Nightingale, SL			New requirements for labeling of dietary supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-24	WOS:A1997YC91700005
J	Sidow, A; Bulotsky, MS; Kerrebrock, AW; Bronson, RT; Daly, MJ; Reeve, MP; Hawkins, TL; Birren, BW; Jaenisch, R; Lander, ES				Sidow, A; Bulotsky, MS; Kerrebrock, AW; Bronson, RT; Daly, MJ; Reeve, MP; Hawkins, TL; Birren, BW; Jaenisch, R; Lander, ES			Serrate2 is disrupted in the mouse limb-development mutant syndactylism	NATURE			English	Article							NOTCH LOCUS; DROSOPHILA	The mouse syndactylism (sin) mutation impairs some of the earliest aspects of limb development and leads to subsequent abnormalities in digit formation(1-3). In sin homozygotes, the apical ectodermal ridge (AER) is hyperplastic by embryonic day 10.5, leading to abnormal dorsoventral thickening of the limb bud, subsequent merging of the skeletal condensations that give rise to cartilage and bone in the digits, and eventual fusion of digits. The AER hyperplasia and its effect on early digital patterning distinguish sm from many other syndactylies that result from later failure of cell death in the interdigital areas(4,5). Here we use positional cloning to show that the gene mutated in sm mice encodes the putative Notch ligand Serrate2. The results provide direct evidence that a Notch signalling pathway is involved in the earliest stages of Limb-bud patterning and support the idea that an ancient genetic mechanism underlies both AER formation in vertebrates and wing-margin formation in files(6,7). In addition to cloning the sm gene, we have mapped three modifiers of sm, for which we suggest possible candidate genes.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University			Daly, Mark J/B-2453-2017	Daly, Mark J/0000-0002-0949-8752				Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gruneberg H., 1956, Journal of Genetics, V54, P113, DOI 10.1007/BF02981706; GRUNEBERG H, 1960, GENET RES, V1, P196; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JOHNSON DR, 1969, J EMBRYOL EXP MORPH, V21, P285; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LYON MF, 1996, GENETIC VARIANTS STR; MILAIRE J., 1967, ARCH BIOL, V78, P223; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; *MOUS GEN DAT, 1997, MOUS GEN INF; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; Sambrook J., 1989, MOL CLONING; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; Wilkinson DG, 1992, SITU HYBRIDIZATION P; XU T, 1992, DEVELOPMENT, V115, P913	23	96	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					722	725		10.1038/39587	http://dx.doi.org/10.1038/39587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338782				2022-12-24	WOS:A1997YA95900053
J	Zuger, A; Sharp, VL				Zuger, A; Sharp, VL			'HIV specialists': The time has come	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY-CARE PHYSICIANS; AIDS; EXPERIENCE; INFECTION		ST LUKES ROOSEVELT HOSP,HIV AIDS CTR,NEW YORK,NY 10019; BETH ISRAEL HOSP,HIV COMPREHENS CARE CLIN,NEW YORK,NY; ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10467	Mount Sinai St. Luke's; Mount Sinai West; Yeshiva University; Albert Einstein College of Medicine								*AM COLL PHYS INF, 1994, ANN INTERN MED, V120, P310; *AM SOC INT MED, 1995, REINV MAN CAR; BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KAHN JG, 1995, J ACQ IMMUN DEF SYND, V8, pS53; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; LAURENCE J, 1995, AIDS READER, V5, P110; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PAAUW DS, 1995, JAMA-J AM MED ASSOC, V274, P1380, DOI 10.1001/jama.274.17.1380; SANDE MA, 1994, J INFECT DIS, V169, P1197, DOI 10.1093/infdis/169.6.1197; SCHREIBER TL, 1995, J AM COLL CARDIOL, V26, P577, DOI 10.1016/0735-1097(95)00214-O; Soloway B, 1997, AIDS Clin Care, V9, P37; VERGHESE A, 1993, CLIN INFECT DIS, V16, P459, DOI 10.1093/clind/16.4.459; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILSON IB, 1995, J ACQ IMMUN DEF SYND, V8, pS31	18	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1131	1132		10.1001/jama.278.14.1131	http://dx.doi.org/10.1001/jama.278.14.1131			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326457				2022-12-24	WOS:A1997XY42200002
J	Poole, CJM				Poole, CJM			Hazards of powdered surgical gloves	LANCET			English	Editorial Material							LATEX				Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; *DEP HLTH, 1996, LAT SENS HLTH CAR SE; HAGLUND U, 1997, EUR J SURG S579, V163; Heese A, 1996, HAUTARZT, V47, P817, DOI 10.1007/s001050050514; LAMPE AS, 1988, LANCET, V2, P1140; Newsom SWB, 1997, OCCUP MED-OXFORD, V47, P155, DOI 10.1093/occmed/47.3.155; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					973	974		10.1016/S0140-6736(05)64064-0	http://dx.doi.org/10.1016/S0140-6736(05)64064-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329509				2022-12-24	WOS:A1997XZ71000005
J	Koob, GF; LeMoal, M				Koob, GF; LeMoal, M			Drug abuse: Hedonic homeostatic dysregulation	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; STRESS-INDUCED SENSITIZATION; NUCLEUS-ACCUMBENS; ETHANOL WITHDRAWAL; ALCOHOL DEPENDENCE; EXTRACELLULAR DOPAMINE; MOLECULAR MECHANISMS; COCAINE WITHDRAWAL; RECEPTOR AGONISTS; OPIATE-WITHDRAWAL	Understanding the neurobiological mechanisms of addiction requires an integration of basic neuroscience with social psychology, experimental psychology, and psychiatry. Addition is presented as a cycle of spiralling dysregulation of brain reward systems that progressively increases, resulting in compulsive drug use and a loss of control over drug-taking. Sensitization and counteradaptation are hypothesized to contribute to this hedonic homeostatic dysregulation, and the neurobiological mechanisms involved, such as the mesolimbic dopamine system, opioid peptidergic systems, and brain and hormonal stress systems, are beginning to be characterized. This framework provides a realistic approach to identifying the neurobiological factors that produce vulnerability to addiction and to relapse in individuals with a history of addiction.	UNIV BORDEAUX 2, INSERM, U259, F-33077 BORDEAUX, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Koob, GF (corresponding author), Scripps Res Inst, DEPT NEUROPHARMACOL CVN7, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		LE MOAL, Michel/B-5125-2008		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA006420, P50AA006420, R01AA008459, R37AA008459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004043] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA08459, AA06420] Funding Source: Medline; NIDA NIH HHS [DA04043] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ahlstrom Sydney E., 1972, RELIG HIST AM PEOPLE; ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; Baumeister RF, 1994, LOSING CONTROL WHY P, DOI 10.5860/choice.32-6508; Bergman J., 1990, Behav Pharmacol, V1, P355; Bindra D., 1976, THEORY INTELLIGENT B; Cabib S, 1996, PSYCHOPHARMACOLOGY, V128, P331, DOI 10.1007/s002130050142; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BRAIN RES, V692, P47; Carrera M. R. A., 1995, Society for Neuroscience Abstracts, V21, P725; CARROLL ME, 1989, PSYCHOPHARMACOLOGY, V97, P23, DOI 10.1007/BF00443407; CHEN JP, 1991, NEUROSCI LETT, V129, P136, DOI 10.1016/0304-3940(91)90739-G; CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861; COOLS AR, IN PRESS PHARM BIOCH; CRABBE JC, 1992, TRENDS PHARMACOL SCI, V13, P212, DOI 10.1016/0165-6147(92)90066-F; deFonseca FR, 1997, SCIENCE, V276, P2050, DOI 10.1126/science.276.5321.2050; Deroche V, 1997, J PHARMACOL EXP THER, V281, P1401; DEROCHE V, 1992, BRAIN RES, V598, P343, DOI 10.1016/0006-8993(92)90205-N; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; ENGEL JA, 1992, NOVEL PHARM INTERVEN, P68; EPPINGJORDAN M, 1995, NEUR ABSTR, V21, P719; ETTENBERG A, 1982, PHYSIOL BEHAV, V28, P873, DOI 10.1016/0031-9384(82)90207-4; Gold LH, 1996, BEHAV PHARMACOL, V7, P589; HEIMER L, 1991, ADV EXP MED BIOL, V295, P1; HEINRICHS SC, 1995, BEHAV PHARMACOL, V6, P74; HENRY DJ, 1992, ANN NY ACAD SCI, V654, P88, DOI 10.1111/j.1749-6632.1992.tb25958.x; Heyser C. J., 1995, Society for Neuroscience Abstracts, V21, P1698; HEYSER CJ, IN PRESS NEUROPSYCHO; Himmelsbach CK, 1943, FED PROC, V2, P201; HYYTIA P, 1995, EUR J PHARMACOL, V283, P151, DOI 10.1016/0014-2999(95)00314-B; Institute of Medicine, 1996, PATHW ADD; JAFFE J H, 1990, P522; Johnston JB, 1923, J COMP NEUROL, V35, P337, DOI 10.1002/cne.900350502; JUNG CG, 1969, PSYCHOL ENERGY MEANI, V8; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Koob George F., 1995, P759; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; KOOB GF, 1987, NEUROSCI LETT, V79, P315, DOI 10.1016/0304-3940(87)90451-4; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; KOOB GF, 1993, SEMIN NEUROSCI, V5, P351; KOOB GF, 1987, BRAIN REWARD SYSTEMS, P35; KOOP GF, IN PRESS J PSYCHOPHA; Kreek M.J., 1987, PSYCHOPHARMACOLOGY 3, P1597; LAULIN JP, IN PRESS EUR J PHARM; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17; MARKOU A, 1993, PSYCHOPHARMACOLOGY, V112, P163, DOI 10.1007/BF02244907; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093; MURPHY JM, 1987, PHARMACOL BIOCHEM BE, V26, P389, DOI 10.1016/0091-3057(87)90134-1; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; Piazza PV, 1996, ANNU REV PHARMACOL, V36, P359, DOI 10.1146/annurev.pa.36.040196.002043; Piazza PV, 1996, P NATL ACAD SCI USA, V93, P8716, DOI 10.1073/pnas.93.16.8716; PIAZZA PV, IN PRESS BRAIN RES R; PICH EM, 1995, J NEUROSCI, V15, P5439; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RASSNICK S, 1993, BRAIN RES, V605, P25, DOI 10.1016/0006-8993(93)91352-S; Roberts AJ, 1996, ALCOHOL CLIN EXP RES, V20, P1289, DOI 10.1111/j.1530-0277.1996.tb01125.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Russell M. A. H., 1976, DRUGS DRUG DEPENDENC, P182; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; Schulteis G, 1997, PSYCHOPHARMACOLOGY, V129, P56, DOI 10.1007/s002130050162; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; Schulteis G, 1996, NEUROCHEM RES, V21, P1437, DOI 10.1007/BF02532385; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shippenberg TS, 1996, J PHARMACOL EXP THER, V276, P545; SHIPPENBERG TS, 1992, ANN NY ACAD SCI, V654, P347, DOI 10.1111/j.1749-6632.1992.tb25980.x; Smith Devyn, COMMUNICATION; Solomon R.L, 1977, PSYCHOPATHOLOGY EXPT, P124; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; Spanagel R, 1996, EUR J PHARMACOL, V305, P39, DOI 10.1016/0014-2999(96)00174-4; Sterling P., 1988, HDB LIFE STRESS COGN, P629, DOI DOI 10.1016/0005-7967(90)90076-U; Stewart J., 1987, METHODS ASSESSING RE, P211; Tabakoff B., 1992, SUBSTANCE ABUSE COMP, P152; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; VOLPICELLI JR, 1986, LIFE SCI, V38, P841, DOI 10.1016/0024-3205(86)90601-6; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEISS F, 1992, BRAIN RES, V593, P314, DOI 10.1016/0006-8993(92)91327-B; Weiss F, 1996, J NEUROSCI, V16, P3474; WHITE FJ, 1991, BIOL BASES DRUG TOLE, P153; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; WOOLVERTON WL, 1986, PHARMACOL BIOCHEM BE, V24, P531, DOI 10.1016/0091-3057(86)90553-8; World Health Organization, 1990, INT STAT CLASS DIS R; Zhou Y, 1996, EUR J PHARMACOL, V315, P31, DOI 10.1016/S0014-2999(96)00672-3; Zhou Y, 1996, J PHARMACOL EXP THER, V279, P351	99	1796	1836	5	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					52	58		10.1126/science.278.5335.52	http://dx.doi.org/10.1126/science.278.5335.52			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311926				2022-12-24	WOS:A1997XZ12400031
J	Gordon, GS; Sitnikov, D; Webb, CD; Teleman, A; Straight, A; Losick, R; Murray, AW; Wright, A				Gordon, GS; Sitnikov, D; Webb, CD; Teleman, A; Straight, A; Losick, R; Murray, AW; Wright, A			Chromosome and low copy plasmid segregation in E-coli: Visual evidence for distinct mechanisms	CELL			English	Article							POLAR-CAP FORMATION; ESCHERICHIA-COLI; TN7 TRANSPOSITION; CELL-DIVISION; P1 PLASMID; PROTEIN; BINDING; REPLICATION; EXPRESSION; CLONING	We have investigated DNA segregation in E. coli by inserting multiple lac operator sequences into the chromosome near the origin of replication (oriC), in the hisC gene, a terminus marker, and into plasmids P1 and F. Expression of a GFP-LacI fusion protein allowed visualization of lac operator localization. oriC was shown to be specifically localized at or near the cell poles, and when duplicated, one copy moved to the site of new pole formation near the site of cell division. In contrast, P1 and F localized to the cell center and on duplication appeared to move rapidly to the quarter positions in the cell. Our analysis suggests that different active processes are involved in movement and localization of the chromosome and of the two plasmids during segregation.	TUFTS UNIV,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Tufts University; Harvard University; University of California System; University of California San Francisco			Teleman, Aurelio A/E-6864-2013; Teleman, Aurelio/V-8470-2019	Teleman, Aurelio A/0000-0002-4237-9368; Teleman, Aurelio/0000-0002-4237-9368; Straight, Aaron/0000-0001-5885-7881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038035, R01GM018568, R37GM018568] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38035, GM18568] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; AUSTIN S, 1986, J BACTERIOL, V168, P1010, DOI 10.1128/jb.168.2.1010-1013.1986; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DeBoy RT, 1996, J BACTERIOL, V178, P6184, DOI 10.1128/jb.178.21.6184-6191.1996; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HELMSTETTER CE, 1990, RES MICROBIOL, V141, P30, DOI 10.1016/0923-2508(90)90095-8; HELMSTETTER CE, 1987, J MOL BIOL, V197, P195, DOI 10.1016/0022-2836(87)90118-5; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HIRAGA S, 1993, CURR OPIN GENE DEV, V5, P789; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; LOBNEROLESEN A, 1992, J BACTERIOL, V174, P7883; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; NANNINGA N, 1990, RES MICROBIOL, V141, P103, DOI 10.1016/0923-2508(90)90102-V; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; OGDEN GB, 1986, BACTERIAL CHROMATIN, P45; Pogliano J, 1997, P NATL ACAD SCI USA, V94, P559, DOI 10.1073/pnas.94.2.559; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; ROTHFIELD LI, 1994, CELL, V77, P963, DOI 10.1016/0092-8674(94)90435-9; SCHAECHTER M, 1993, JOHN INN S, P61; Sharpe ME, 1996, MOL MICROBIOL, V21, P501, DOI 10.1111/j.1365-2958.1996.tb02559.x; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Wheeler RT, 1997, CELL, V88, P577, DOI 10.1016/S0092-8674(00)81898-X; WIENTJES FB, 1991, RES MICROBIOL, V142, P333, DOI 10.1016/0923-2508(91)90049-G; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; WILSON K, 1992, SHORT PROTOCOLS MOL; WOLDRINGH CL, 1990, RES MICROBIOL, V141, P39, DOI 10.1016/0923-2508(90)90096-9; WOLDRINGH CL, 1987, J GEN MICROBIOL, V133, P575; Wolkow CA, 1996, GENE DEV, V10, P2145, DOI 10.1101/gad.10.17.2145; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; YANG YX, 1993, INFECT IMMUN, V61, P3907, DOI 10.1128/IAI.61.9.3907-3913.1993	45	311	313	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1113	1121		10.1016/S0092-8674(00)80377-3	http://dx.doi.org/10.1016/S0092-8674(00)80377-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323139	Bronze			2022-12-24	WOS:A1997XX76800017
J	Kimura, Y; Vassylyev, DG; Miyazawa, A; Kidera, A; Matsushima, M; Mitsuoka, K; Murata, K; Hirai, T; Fujiyoshi, Y				Kimura, Y; Vassylyev, DG; Miyazawa, A; Kidera, A; Matsushima, M; Mitsuoka, K; Murata, K; Hirai, T; Fujiyoshi, Y			Surface of bacteriorhodopsin revealed by high-resolution electron crystallography	NATURE			English	Article							PROTON TRANSLOCATION; PURPLE MEMBRANE; HALOBACTERIUM-HALOBIUM; DIFFRACTION PATTERNS; SCHIFF-BASE; LIGHT; PROTEIN	Bacteriorhodopsin is a transmembrane protein that uses light energy, absorbed by its chromophore retinal, to pump protons from the cytoplasm of bacteria such as Halobacterium salinarium into the extracellular space(1,2.) It is made up of seven alpha-helices, and in the bacterium forms natural, two-dimensional crystals called purple membranes. We have analysed these crystals by electron cryo-microscopy to obtain images of bacteriorhodopsin at 3.0 Angstrom resolution. The structure covers nearly all 248 amino acids, including loops outside the membrane, and reveals the distribution of charged residues on both sides of the membrane surface. In addition, analysis of the electron-potential map produced by this method allows the determination of the charge status of these residues. On the extracellular side, four glutamate residues surround the entrance to the proton channel, whereas on the cytoplasmic side, four aspartic acids occur in a plane at the boundary of the hydrophobic-hydrophilic interface. The negative charges produced by these aspartate residues is encircled by areas of positive charge that may facilitate accumulation and lateral movement of protons on this surface.	RAT DRUG DESIGN LAB, MATSUKAWA, FUKUSHIMA 96012, JAPAN; MATSUSHITA ELECT IND CO LTD, INT INST ADV RES, SORAKU, KYOTO 61902, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYOU KU, KYOTO 60601, JAPAN	Kyoto University	Kimura, Y (corresponding author), BIOMOL ENGN RES INST, 6-2-3 FUREUDAI, SUITA, OSAKA 565, JAPAN.		Hirai, Teruhisa/G-2105-2015; Fujiyoshi, Yoshinori/E-5989-2012; Vassylyev, Dmitry/A-9005-2008	Hirai, Teruhisa/0000-0002-2114-8149; Fujiyoshi, Yoshinori/0000-0002-8070-1493; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN J, 1984, ULTRAMICROSCOPY, V14, P319, DOI 10.1016/0304-3991(84)90217-1; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; CESKA TA, 1990, J MOL BIOL, V213, P539, DOI 10.1016/S0022-2836(05)80214-1; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KIMURA Y, 1985, J MEMBRANE BIOL, V85, P225, DOI 10.1007/BF01871517; KUSHWAHA SC, 1976, BIOCHIM BIOPHYS ACTA, V426, P703, DOI 10.1016/0005-2736(76)90135-8; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; SAKATA K, 1992, ULTRAMICROSCOPY, V45, P253, DOI 10.1016/0304-3991(92)90513-J; SEIFF F, 1985, P NATL ACAD SCI USA, V82, P3227, DOI 10.1073/pnas.82.10.3227; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; WILSON AJC, 1995, INT TABLE CRYSTALLOG, VC	23	403	411	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	1997	389	6647					206	211		10.1038/38323	http://dx.doi.org/10.1038/38323			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296502				2022-12-24	WOS:A1997XV75700055
J	Deconinck, AE; Rafael, JA; Skinner, JA; Brown, SC; Potter, AC; Metzinger, L; Watt, DJ; Dickson, JG; Tinsley, JM; Davies, KE				Deconinck, AE; Rafael, JA; Skinner, JA; Brown, SC; Potter, AC; Metzinger, L; Watt, DJ; Dickson, JG; Tinsley, JM; Davies, KE			Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy	CELL			English	Article							SKELETAL-MUSCLE FIBERS; MDX MOUSE; NEUROMUSCULAR-JUNCTION; ACETYLCHOLINE-RECEPTOR; PROTEIN; EXPRESSION; LOCALIZATION; ISOFORMS; MUTATION; BINDING	The absence of dystrophin at the muscle membrane leads to Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease that is inevitably fatal in early adulthood. In contrast, dystrophin-deficient mdx mice appear physically normal despite their underlying muscle pathology. We describe mice deficient for both dystrophin and the dystrophin-related protein utrophin. These mice show many signs typical of DMD in humans: they show severe progressive muscular dystrophy that results in premature death, they have ultrastructural neuromuscular and myotendinous junction abnormalities, and they aberrantly coexpress myosin heavy chain isoforms within a fiber. The data suggest that utrophin and dystrophin have complementing roles in normal functional or developmental pathways in muscle. Detailed study of these mice should provide novel insights into the pathogenesis of DMD and provide an improved model for rapid evaluation of gene therapy strategies.	UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND; UNIV LONDON,SCH BIOL SCI,SURREY TW20 0EX,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	University of Oxford; University of London; Royal Holloway University London; Imperial College London			Metzinger, Laurent/B-1426-2016; Rafael-Fortney, Jill/E-3909-2011; metzinger, laurent/AAY-4634-2021	Metzinger, Laurent/0000-0002-7636-8480; metzinger, laurent/0000-0002-7636-8480; Brown, Sue/0000-0001-8112-933X				Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795; CLERK A, 1993, HISTOCHEM J, V25, P554; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; CULLEN MJ, 1988, ACTA NEUROPATHOL, V77, P69, DOI 10.1007/BF00688245; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; JERUSALEM F, 1974, BRAIN, V97, P123, DOI 10.1093/brain/97.1.123; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; LAW DJ, 1994, J CELL SCI, V107, P1477; LAW DJ, 1995, MUSCLE NERVE, V18, P216, DOI 10.1002/mus.880180211; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; Marini J F, 1991, Neuromuscul Disord, V1, P397, DOI 10.1016/0960-8966(91)90003-B; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; NAGEL A, 1990, MUSCLE NERVE, V13, P742, DOI 10.1002/mus.880130813; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Prakash YS, 1996, J NEUROCYTOL, V25, P88, DOI 10.1007/BF02284788; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SEWRY CA, 1994, NEUROMUSCULAR DISORD, V4, P401, DOI 10.1016/0960-8966(94)90079-5; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Vincent A, 1997, TRENDS NEUROSCI, V20, P15, DOI 10.1016/S0166-2236(96)10066-7; WINDER SJ, 1995, J CELL SCI, V108, P63; YELLIN H, 1967, EXP NEUROL, V19, P92, DOI 10.1016/0014-4886(67)90009-X; [No title captured]	45	574	597	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					717	727		10.1016/S0092-8674(00)80532-2	http://dx.doi.org/10.1016/S0092-8674(00)80532-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288751	Bronze			2022-12-24	WOS:A1997XT06600015
J	Tu, YP; Wang, J; Ross, EM				Tu, YP; Wang, J; Ross, EM			Inhibition of brain G(z) GAP and other RGS proteins by palmitoylation of G protein alpha subunits	SCIENCE			English	Article							BINDING REGULATORY PROTEIN; GTPASE-ACTIVATING PROTEINS; LIPID MODIFICATIONS; MEMBRANE ATTACHMENT; PERTUSSIS TOXIN; AMINO-TERMINUS; BETA-GAMMA; MYRISTOYLATION; RECEPTOR; G(S-ALPHA)	Palmitoylation of the alpha subunit of the guanine nucleotide-binding protein G(z) inhibited by more than 90 percent its response to the guanosine triphosphatase (GTPase)-accelerating activity of G(z) GAP, a G(z)-selective member of the regulators of G-protein signaling (RGS) protein family of GTPase-activating proteins (GAPs). Palmitoylation both decreased the affinity of G(z) GAP for the GTP-bound form of G alpha(z) by at least 90 percent and decreased the maximum rate of GTP hydrolysis. Inhibition was reversed by removal of the palmitoyl group by dithiothreitol. Palmitoylation of G alpha(z) also inhibited its response to the GAP activity of G alpha-interacting protein (GAIP), another RGS protein, and palmitoylation of G alpha(l1) inhibited ils response to RGS4. The extent of inhibition of G(z) GAP, GAIP, RGS4, and RGS10 correlated roughly with their intrinsic GAP activities for the G alpha target used in the assay. Reversible palmitoylation is thus a major determinant of G(z) deactivation after its stimulation by receptors, and may be a general mechanism for prolonging or potentiating G-protein signaling.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030355, R01GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BRANDT DR, 1985, J BIOL CHEM, V260, P266; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FERGUSON KM, 1991, METHOD ENZYMOL, V195, P188; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Galbiati F, 1996, BIOCHEM J, V313, P717, DOI 10.1042/bj3130717; GRASSIE MA, 1994, BIOCHEM J, V302, P913, DOI 10.1042/bj3020913; Hepler J.R., 1997, P NATL ACAD SCI USA, V94, p428; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLIGAN G, 1995, BIOCHEM SOC T, V23, P583, DOI 10.1042/bst0230583; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TU Y, UNPUB; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	39	119	123	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1132	1135		10.1126/science.278.5340.1132	http://dx.doi.org/10.1126/science.278.5340.1132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353196				2022-12-24	WOS:A1997YE65200055
J	Guenther, B; Onrust, R; Sali, A; ODonnell, M; Kuriyan, J				Guenther, B; Onrust, R; Sali, A; ODonnell, M; Kuriyan, J			Crystal structure of the delta' subunit of the cramp-loader complex of E-coli DNA polymerase III	CELL			English	Article							ESCHERICHIA-COLI; ADENYLATE KINASE; PROTEIN COMPLEX; GAMMA-SUBUNIT; ATP SYNTHASE; REPLICATION; HOLOENZYME; RESOLUTION; MECHANISM; TRIPHOSPHATE	The crystal structure of the delta' subunit of the clamp-loader complex of E. coli DNA polymerase III has been determined. Three consecutive domains in the structure are arranged in a C-shaped architecture. The N-terminal domain contains a nonfunctional nucleotide binding site. The catalytic component of the clamp-loader complex is the gamma subunit, which is homologous to delta'. A sequence-structure alignment suggests that nucleotides bind to gamma at an interdomain interface within the inner surface of the ''C.'' Th, alignment is extended to other clamp-loader complexes and to the RuvB family of DNA helicases, and suggests that each of these is assembled from C-shaped components that can open and close the jaws of the ''C'' in response to ATP binding and hydrolysis.	HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Cornell University				O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM54762, GM 38839, GM 45547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054762, R37GM038839, R01GM054762, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; CRONET P, 1995, J MOL BIOL, V249, P654, DOI 10.1006/jmbi.1995.0326; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GUENTHER BD, 1996, THESIS ROCKEFELLER U; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOONIN EV, 1991, P NATL ACAD SCI USA, V88, P10647, DOI 10.1073/pnas.88.23.10647; Kornberg A., 1991, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P594; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOSSAL NG, 1984, BACTERIOPHAGE T, V4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, CURR OPIN STRUC BIOL, V7, P206, DOI 10.1016/S0959-440X(97)80027-9; SANCHEZ R, 1997, IN PRESS PROT STRUCT; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YIN KC, 1986, NUCLEIC ACIDS RES, V14, P6541, DOI 10.1093/nar/14.16.6541; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	54	213	217	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					335	345		10.1016/S0092-8674(00)80417-1	http://dx.doi.org/10.1016/S0092-8674(00)80417-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363942	hybrid			2022-12-24	WOS:A1997YD94100007
J	Weissman, D; Rabin, RL; Arthos, J; Rubbert, A; Dybul, M; Swofford, R; Venkatesan, S; Farber, JM; Fauci, AS				Weissman, D; Rabin, RL; Arthos, J; Rubbert, A; Dybul, M; Swofford, R; Venkatesan, S; Farber, JM; Fauci, AS			Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor	NATURE			English	Article							INFECTION; DISEASE; VACCINE; ENTRY	Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) enter target cells by forming a complex between the viral envelope protein and two cell-surface membrane receptors: CD4 and a 7-span transmembrane chemokine receptor (reviewed in refs 1-3). Isolates of HIV that differ in cellular tropism use different subsets of chemokine receptors as entry cofactors: macrophage-tropic HIVs primarily use CCR5, whereas T-cell-tropic and dual-tropic isolates use CXCR4 (refs 1-3) receptors. HIV-mediated signal transduction through CCR5 is not required for efficient fusion and entry of HIV in vitro(4,5). Here we show that recombinant envelope proteins from macrophage-tropic HIV and SIV induce a signal through CCR5 on CD4(+) T cells and that envelope-mediated signal transduction through CCR5 induces chemotaxis of T cells. This chemotactic response may contribute to the pathogenesis of HIV in vivo by chemo-attracting activated CD4(+) cells to sites of viral replication(1,2). HIV-mediated signalling through CCR5 may also enhance viral replication in vivo by increasing the activation state of target cells. Alternatively, envelope-mediated CCR5 signal transduction may influence viral-associated cytopathicity or apoptosis.	NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,FLO CYTOMETRY UNIT,NIH,BETHESDA,MD 20892; NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Rabin, Ronald/0000-0003-3496-0504				Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Kozak SL, 1997, J VIROL, V71, P873, DOI 10.1128/JVI.71.2.873-882.1997; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972; MORI K, 1993, J VIROL, V67, P2807, DOI 10.1128/JVI.67.5.2807-2814.1993; Mossman SP, 1996, J VIROL, V70, P1953, DOI 10.1128/JVI.70.3.1953-1960.1996; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; OH SK, 1992, J ACQ IMMUN DEF SYND, V5, P251; Oravecz T, 1996, J IMMUNOL, V157, P1329; Taub DD, 1996, J IMMUNOL, V156, P2095; TRIKOLA A, 1996, NATURE, V384, P184; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	18	298	304	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					981	985		10.1038/40173	http://dx.doi.org/10.1038/40173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353123				2022-12-24	WOS:A1997YD29900059
J	Banks, DA; Fossel, M				Banks, DA; Fossel, M			Telomeres, cancer, and aging - Altering the human life span	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL-CYCLE CONTROL; HUMAN-FIBROBLASTS; CAENORHABDITIS-ELEGANS; REPLICATIVE SENESCENCE; HEALTH-CARE; IN-VIVO; LONGEVITY; GENES; POLICY; IMPACT	Population projections of the aging global society and its fiscal and social impact have depended on assumptions regarding the human life span. Until now, the assumption that the maximum human life span is fixed has been justified. Recent advances in cell biology, genetics, and our understanding of the cellular processes that underlie aging, however, have shown that this assumption is invalid in a number of animal models and suggest that this assumption may become invalid for humans as well. In vitro alteration of telomeres affects cellular senescence, and in vivo manipulation of genes and diet can increase maximum life span in animal models if these discoveries are extended to humans. We may soon be able to extend the maximum human life span and postpone or prevent the onset of diseases associated with aging. Such a possibility requires that we recognize a growing uncertainty in any attempt to project international health care costs into the next few decades. The costs may be significantly lower than projections, if life span increases and age-related disabilities are postponed or less severe, or perhaps higher, if life span increases without altering the onset and severity of disability. An appropriate uncertainty regarding the human life span undermines any attempt to accurately predict health costs in the next century.	UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CTR ECON & DEMOG AGING,BERKELEY,CA 94720; MICHIGAN STATE UNIV,COLL HUMAN MED,E LANSING,MI 48824	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Michigan State University; Michigan State University College of Human Medicine					NATIONAL INSTITUTE ON AGING [P20AG012839] Funding Source: NIH RePORTER; NIA NIH HHS [P20-AG-12839] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*ALL AG RES, 1997, 7 DEADL MYTHS UNC FA; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Finch CE, 1990, LONGEVITY SENESCENCE; Fossel M, 1996, REVERSING HUMAN AGIN; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1980, P NATL ACAD SCI-BIOL, V77, P1885, DOI 10.1073/pnas.77.4.1885; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYFLICK L, 1994, WHY WE AGE, P313; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; JAZWINSKI SM, 1997, NAT MAN HLTH CAR C B; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lane MA, 1997, AGE, V20, P45, DOI 10.1007/s11357-997-0004-2; LARSEN PL, 1995, GENETICS, V139, P1567; LE R, 1997, DEMOGRAPHY, V34, P67; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; Lundblad V, 1996, CELL, V87, P369, DOI 10.1016/S0092-8674(00)81358-6; MANTON KG, 1993, J GERONTOL, V48, P11, DOI 10.1093/geronj/48.Special_Issue.11; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Marcand S, 1996, CURR BIOL, V6, P1222, DOI 10.1016/S0960-9822(96)00701-4; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1319, DOI 10.1001/jama.273.17.1319; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; *NIH, 1997, SEARCH SECR AG; OKAMOTO Y, 1992, BRIT MED J, V305, P403, DOI 10.1136/bmj.305.6850.403; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Oshima J, 1996, LANCET, V348, P1106, DOI 10.1016/S0140-6736(05)64456-X; Rao R. Nagaraja, 1996, Current Opinion in Oncology, V8, P516; Sallar AM, 1996, NEW ENGL J MED, V334, P537; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DWE, 1993, HUMAN LONGEVITY AGIN; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stewart C, 1997, NATURE, V385, P769, DOI 10.1038/385769a0; SULLIVAN DF, 1971, HEALTH SERV REP, V86, P347, DOI 10.2307/4594169; U. S. Bureau of the Census, 1996, STAT ABSTR US; US Bureau of the Census, 1995, STAT ABSTR US; VANDEWALLE E, 1990, MILBANK Q, V68, P10, DOI 10.2307/3350174; WEINDRUCH R, 1988, RETARDATION AGING DI; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Winker MA, 1996, JAMA-J AM MED ASSOC, V276, P1758, DOI 10.1001/jama.1996.03540210066037; Wise DA, 1997, DEMOGRAPHY, V34, P83, DOI 10.2307/2061661; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; 1997, BALTIMORE SUN   0805, pB5; 1996, SCIENCE, V274, P1989	59	29	30	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1345	1348		10.1001/jama.278.16.1345	http://dx.doi.org/10.1001/jama.278.16.1345			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343466				2022-12-24	WOS:A1997YA90500036
J	Sonke, GS; Stewart, AW; Beaglehole, R; Jackson, R; White, HD				Sonke, GS; Stewart, AW; Beaglehole, R; Jackson, R; White, HD			Comparison of case fatality in smokers and non-smokers after acute cardiac event	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION		UNIV AUCKLAND,FAC MED & HLTH SCI,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND; GREEN LANE HOSP,DEPT CARDIOL,AUCKLAND 3,NEW ZEALAND	University of Auckland				Jackson, Rod/0000-0001-5914-6934; Sonke, Gabe/0000-0001-8088-9628				BARBASH GI, 1995, J AM COLL CARDIOL, V26, P1222, DOI 10.1016/0735-1097(95)00299-5; Sonke GS, 1996, BRIT MED J, V313, P853; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WHITE HD, 1995, AM J CARDIOL, V75, P278, DOI 10.1016/0002-9149(95)80036-R	4	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					992	993		10.1136/bmj.315.7114.992	http://dx.doi.org/10.1136/bmj.315.7114.992			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365298	Green Published			2022-12-24	WOS:A1997YC30700023
J	Lewis, CE				Lewis, CE			Management of patients with HIV/AIDS - Who should care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY; PHYSICIANS		UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								*CDCP, 1997, HIV AIDS SURV REP, V8, P7; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P826; DiMatteo M R, 1994, JAMA, V271, P83, DOI 10.1001/jama.271.1.79; DiMatteo MR, 1994, JAMA-J AM MED ASSOC, V271, P83; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; HUMMELL HJ, 1970, SOC SCI MED, V3, P597, DOI 10.1016/0037-7856(70)90028-4; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; Kraft SK, 1997, ARCH FAM MED, V6, P29, DOI 10.1001/archfami.6.1.29; Lewis CE, 1996, WESTERN J MED, V164, P415; *US DEP HHS, 1997, FED REG         0619, V62, P33417	11	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1133	1134		10.1001/jama.278.14.1133	http://dx.doi.org/10.1001/jama.278.14.1133			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326458				2022-12-24	WOS:A1997XY42200003
J	Nightingale, SL				Nightingale, SL			Request for public comment on informed consent waiver rule in combat situations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-24	WOS:A1997XX30300007
J	Freitas, AA; Rocha, B				Freitas, AA; Rocha, B			Lymphocyte survival: A Red Queen hypothesis	SCIENCE			English	Editorial Material							CELLULAR COMPETITION; T-CELLS; SELECTION; MICE		INST NECKER,INSERM,U345,F-75015 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Freitas, AA (corresponding author), INST PASTEUR,LAB DYNAM LYPHOCYTAIRES,CNRS,URA 1961,F-75015 PARIS,FRANCE.		freitas, antonio/A-2482-2013	freitas, antonio/0000-0001-6392-7178				Agenes F, 1997, EUR J IMMUNOL, V27, P1801, DOI 10.1002/eji.1830270731; Carroll L., 1872, LOOKING GLASS; Freitas AA, 1996, EUR J IMMUNOL, V26, P2640, DOI 10.1002/eji.1830261115; FREITAS AA, 1995, EUR J IMMUNOL, V25, P1729, DOI 10.1002/eji.1830250636; JERNE NK, 1967, COLD SPRING HARB SYM, V32, P591; KIRBERG J, 1997, IN PRESS J EXP MED; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; McLean AR, 1997, P NATL ACAD SCI USA, V94, P5792, DOI 10.1073/pnas.94.11.5792; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANCHOT C, 1997, IN PRESS J EXP MED; van Valen L., 1973, EVOL THEOR, V1, P1, DOI DOI 10.1038/344864A0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M	16	25	25	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1950	1950		10.1126/science.277.5334.1950	http://dx.doi.org/10.1126/science.277.5334.1950			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9333949				2022-12-24	WOS:A1997XX84900029
J	Li, JH; Xu, M; Zhou, H; Ma, JY; Potter, H				Li, JH; Xu, M; Zhou, H; Ma, JY; Potter, H			Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation	CELL			English	Article							APOLIPOPROTEIN-E; DISEASE GENE; MISSENSE MUTATIONS; DOWNS-SYNDROME; BETA-PROTEIN; IN-VITRO; LAMIN-B; APOPTOSIS; EXPRESSION; SCLERODERMA	Mutations in two related genes, presenilin 1 and 2, account for most early-onset familial Alzheimer's disease. Although structural features indicate that the presenilins are membrane proteins, their function(s) is unknown. We have localized the presenilins to the nuclear membrane, its associated interphase kinetochores, and the centrosomes-all subcellular structures involved in cell cycle regulation and mitosis. The colocalization of the presenilins with kinetochores on the nucleoplasmic surface of the inner nuclear membrane, together with other results, suggests that they may play a role in chromosome organization and segregation, perhaps as kinetochore binding proteins/receptors. We discuss a pathogenic pathway for familial Alzheimer's disease in which defective presenilin function causes chromosome missegregation during mitosis, resulting in apoptosis and/or trisomy 21 mosaicism.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIA NIH HHS [AG08084, AG09665] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009665, R01AG008084] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1996, SCIENCE, V271, P159, DOI 10.1126/science.271.5246.159; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Elder GA, 1996, J NEUROSCI RES, V45, P308; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LeBlanc A, 1995, J NEUROSCI, V15, P7837; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Ma JY, 1996, NEUROBIOL AGING, V17, P773; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Martins RH, 1995, NEUROREPORT, V7, P217, DOI 10.1097/00001756-199512290-00052; MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Mitchell AR, 1996, MUTAT RES-FUND MOL M, V372, P153, DOI 10.1016/S0027-5107(96)00135-2; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; Moussaoui S, 1996, FEBS LETT, V383, P219, DOI 10.1016/0014-5793(96)00250-5; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; POTTER H, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P643; POTTER H, 1991, AM J HUM GENET, V48, P1192; Potter H, 1996, LANCET, V348, P66, DOI 10.1016/S0140-6736(05)64399-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWEBER M, 1985, ANN NY ACAD SCI, V450, P223, DOI 10.1111/j.1749-6632.1985.tb21495.x; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STONE JF, 1995, MUTAT RES-DNAGING G, V338, P107, DOI 10.1016/0921-8734(95)00016-Y; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; Takashima A, 1996, BIOCHEM BIOPH RES CO, V227, P423, DOI 10.1006/bbrc.1996.1523; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; Varmus H., 1993, GENES BIOL CANC; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YE Q, 1994, J BIOL CHEM, V269, P11306; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	71	184	190	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					917	927		10.1016/S0092-8674(00)80356-6	http://dx.doi.org/10.1016/S0092-8674(00)80356-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298903	Bronze			2022-12-24	WOS:A1997XV56300012
J	Kolodkin, AL; Levengood, DV; Rowe, EG; Tai, YT; Giger, RJ; Ginty, DD				Kolodkin, AL; Levengood, DV; Rowe, EG; Tai, YT; Giger, RJ; Ginty, DD			Neuropilin is a Semaphorin III receptor	CELL			English	Article							GROWTH CONE GUIDANCE; NEURONAL RECOGNITION MOLECULE; COLLAPSIN-1 MESSENGER-RNA; CHICK NERVOUS-SYSTEM; SPINAL-CORD; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; AXON GUIDANCE; C-ELEGANS; PROTEIN	The semaphorin family contains a large number of phylogenetically conserved proteins and includes several members that have been shown to function in repulsive axon guidance. Semaphorin III (Sema III) is a secreted protein that in vitro causes neuronal growth cone collapse and chemorepulsion of neurites, and in vivo is required for correct sensory afferent innervation and other aspects of development. The mechanism of Sema III function, however, is unknown. Here, we report that neuropilin, a type I transmembrane protein implicated in aspects of neurodevelopment, is a Sema III receptor. We also describe the identification of neuropilin-2, a related neuropilin family member, and show that neuropilin and neuropilin-2 are expressed in overlapping, yet distinct, populations of neurons in the rat embryonic nervous system.			Kolodkin, AL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; IVAINS JK, 1991, J NEUROSCI, V11, P1597; KAWAKAMI A, 1995, J NEUROBIOL, V29, P1; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4065; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; Puschel AW, 1996, EUR J NEUROSCI, V8, P1317, DOI 10.1111/j.1460-9568.1996.tb01593.x; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SATODA M, 1995, J NEUROSCI, V15, P942; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHEPHERD, 1997, DEVELOPMENT, V124, P1377; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wang LH, 1996, J NEUROSCI, V16, P6197; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	45	957	1004	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					753	762		10.1016/S0092-8674(00)80535-8	http://dx.doi.org/10.1016/S0092-8674(00)80535-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288754	hybrid			2022-12-24	WOS:A1997XT06600018
J	Izurieta, HS; Strebel, PM; Blake, PA				Izurieta, HS; Strebel, PM; Blake, PA			Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTHY-CHILDREN; FOLLOW-UP; CHICKENPOX; CORTICOSTEROIDS; INFECTIONS; EFFICACY; TRIALS	Context.-Because lyophilized varicella vaccine must be stored frozen at -15 degrees C or less (less than or equal to 5 degrees F) and administered within 30 minutes after reconstitution, the potential exists for decreased vaccine effectiveness when the vaccine is used under field conditions. Objectives.-To describe an outbreak of varicella in a child care center and to determine postlicensure effectiveness of varicella vaccine. Design.-Retrospective cohort study. Setting.-A child care center in DeKalb County, Georgia, in 1996. Participants.-Of the 184 children registered in the child care center, 148 were eligible for the study based on absence of history of varicella before January 1, 1996. Main Outcome Measures.-Data on disease status, severity and impact of disease, and risk factors for varicella and for vaccine failure were obtained from parents and their children's pediatricians, Varicella vaccine effectiveness was calculated among children aged 12 months or older (eligible for vaccination) using the cohort method. Results.-The outbreak started on January 17, 1996, and lasted 15 weeks. Of the 148 eligible children, 81 (55%) developed varicella, Cases among children younger than 12 months (n=7) were more severe than cases among older children, Varicella occurred in 9 (14%) of 66 vaccinated children and 72 (88%) of 82 unvaccinated children. Varicella was less severe and resulted in fewer days of absence from the child care center among vaccinated compared with unvaccinated cases. Varicella vaccine effectiveness against all forms of disease was 86% (95% confidence interval [CI], 73%-92%), and against moderate-to-severe varicella disease it was 100% (95% CI, 96%-100%). Vaccinated children with asthma or other reactive airway diseases were 7.1 times more likely to have varicella than were vaccinated children without reactive airway diseases (95% CI, 2.4-21.3). Conclusions.-Varicella vaccine administered under routine conditions in physicians' offices was highly effective in preventing varicella in an outbreak characterized by intense exposure. The role of asthma and other reactive airway diseases as risk factors for varicella disease and vaccine failure deserves to be investigated further.	GEORGIA DEPT HUMAN RESOURCES,DIV PUBL HLTH,ATLANTA,GA									[Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], 1994, WORD PROCESSING DATA; ARBETER AM, 1984, AM J DIS CHILD, V138, P434, DOI 10.1001/archpedi.1984.02140430012004; ASANO Y, 1994, PEDIATRICS, V94, P524; ASANO Y, 1982, BIKEN J, V25, P43; AZBUG MJ, 1993, J PEDIATR, V123, P577; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P912, DOI 10.1111/j.1365-2222.1995.tb00391.x; BRUNELL PA, 1988, PEDIATRICS, V81, P779; CHOONG K, 1995, PEDIATR INFECT DIS J, V14, P809; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COMSTOCK GW, 1990, AM J EPIDEMIOL, V131, P205, DOI 10.1093/oxfordjournals.aje.a115490; DELCLAUX B, 1992, PRESSE MED, V21, P1432; FINGER R, 1994, PUBLIC HEALTH REP, V109, P750; Fleiss JL, 1981, STAT METHODS RATES P; GERSHON A, 1991, REV INFECT DIS S11, V13, P5957; IPSEN J, 1984, SCAND J SOC MED, V12, P121, DOI 10.1177/140349488401200305; JONES SEE, 1995, PEDIATR INFECT DIS J, V14, P404; JUST M, 1985, POSTGRAD MED J, V61, P129; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; KUTTER B, 1991, VACCINE, V9, P643; Lee E.T., 1992, STATISTICAL METHODS; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PREBLUD SR, 1981, PEDIATRICS, V68, P14; REMINGTON RD, 1985, STATISTICS APPLICATI, P187; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; TINKELMAN DG, 1992, PEDIATRICS, V90, P479; WELCH MJ, 1994, J ASTHMA, V31, P43, DOI 10.3109/02770909409056768; Wharton M, 1996, INFECT DIS CLIN N AM, V10, P571, DOI 10.1016/S0891-5520(05)70313-5; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WHITE CJ, 1991, PEDIATRICS, V87, P604	31	117	122	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1495	1499						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE445	9363968				2022-12-24	WOS:A1997YE44500032
J	Nguyen, MT; Camenisch, T; Snouwaert, JN; Hicks, E; Coffman, TM; Anderson, PAW; Malouf, MN; Koller, BH				Nguyen, MT; Camenisch, T; Snouwaert, JN; Hicks, E; Coffman, TM; Anderson, PAW; Malouf, MN; Koller, BH			The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth	NATURE			English	Article							PATENT DUCTUS-ARTERIOSUS; PROSTANOID RECEPTORS; CLOSURE; INDOMETHACIN; CLONING; SUBTYPE; RATS	Survival of newborn placental mammals depends on closure of the ductus arteriosus (DA), an arterial connection in the fetus which directs blood away from the pulmonary circulation and towards the placenta where oxygenation occurs(1). Here we show that morphological changes resulting in closure of the DA in mice are virtually identical to those observed in larger mammals, including humans(2), and that maintenance of the DA in the open, or patent, stare in fetal mice is dependent on prostaglandin synthesis, This requirement is absent in mice lacking the prostaglandin E-2 EP4 receptor (EP4(-/-) mice). In EP4(-/-) mice of the 129 strain, remodelling of the DA fails to occur after birth, resulting in a left-to-right shunt of blood and subseqently in death. This suggests that the neonatal drop in prostaglandin E-2 (refs 3-7) that triggers ductal closure is sensed through the EP4 receptor, In contrast, 5% of EP4(-/-) mice of mixed genetic background survive, and selective breeding of these mice leads to a 21% survival rate, suggesting that alleles at other loci can provide an alternative mechanism for ductal closure.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; DUKE UNIV,DEPT MED,DURHAM,NC 27710; DURHAM VET AFFAIRS MED CTR,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV PEDIAT CARDIOL,DURHAM,NC 27710; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; University of North Carolina; University of North Carolina Chapel Hill				Camenisch, Todd/0000-0002-7797-9822				CHALLIS JRG, 1976, PROSTAGLANDINS, V11, P1041, DOI 10.1016/0090-6980(76)90011-3; CHRISTIANSEN NC, 1975, LANCET, V2, P24; CLYMAN RI, 1987, SEMIN PERINATOL, V11, P64; CLYMAN RI, 1980, J PEDIATR-US, V97, P455, DOI 10.1016/S0022-3476(80)80205-8; CLYMAN RI, 1980, PROSTAGLANDINS, V15, P325; COCEANI F, 1980, SEMIN PERINATOL, V4, P109; COCEANI F, 1994, BIOCHEM PHARMACOL, V48, P1315, DOI 10.1016/0006-2952(94)90552-5; COCEANI F, 1973, CAN J PHYSIOL PHARM, V51, P220, DOI 10.1139/y73-031; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; ELLIOTT RB, 1975, LANCET, V1, P140; ENGELHARDT JF, 1992, J CLIN INVEST, V90, P2598, DOI 10.1172/JCI116155; FRIEDMAN WF, 1976, NEW ENGL J MED, V295, P526, DOI 10.1056/NEJM197609022951003; GERSONY WM, 1986, PEDIATR CLIN N AM, V33, P545; GITTENBERGERDEGROOT AC, 1985, J AM COLL CARDIOL, V6, P394, DOI 10.1016/S0735-1097(85)80178-9; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; HEYMANN MA, 1975, PHYSIOL REV, V55, P62, DOI 10.1152/physrev.1975.55.1.62; HONDA A, 1993, J BIOL CHEM, V268, P7759; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Jager BV, 1942, AM J PATHOL, V18, P595; JARKOVSKA D, 1992, PHYSIOL RES, V41, P323; MITCHELL MD, 1980, J REPROD FERTIL, V58, P283, DOI 10.1530/jrf.0.0580283; MOHN A, 1995, DNA CLONING, V4, P143; MOISE KJ, 1988, NEW ENGL J MED, V319, P327, DOI 10.1056/NEJM198808113190602; MOMMA K, 1987, PEDIATR RES, V22, P567, DOI 10.1203/00006450-198711000-00018; OLLEY PM, 1976, CIRCULATION, V53, P728, DOI 10.1161/01.CIR.53.4.728; PATTERSON DF, 1979, PEDIATR CARDIOL, V2, P45; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; REGAN JW, 1994, MOL PHARMACOL, V46, P213; SHARPE GL, 1975, PROSTAGLANDINS, V9, P585, DOI 10.1016/0090-6980(75)90064-7; SMITH GCS, 1994, J PHARMACOL EXP THER, V271, P390	30	272	279	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					78	81		10.1038/36342	http://dx.doi.org/10.1038/36342			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363893				2022-12-24	WOS:A1997YE47700055
J	Huang, ZP; Hankinson, SE; Colditz, GA; Stampfer, MJ; Hunter, DJ; Manson, JE; Hennekens, CH; Rosner, B; Speizer, FE; Willett, WC				Huang, ZP; Hankinson, SE; Colditz, GA; Stampfer, MJ; Hunter, DJ; Manson, JE; Hennekens, CH; Rosner, B; Speizer, FE; Willett, WC			Dual effects of weight and weight gain on breast cancer risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; POSTMENOPAUSAL WOMEN; RELATIVE WEIGHT; HORMONE LEVELS; HEIGHT; SIZE; ASSOCIATION; ESTROGENS; SURVIVAL; LIFE	Context.-Breast cancer is a major cause of mortality among women. It is important to identify modifiable risk factors for this disease. Objective.-To examine body mass index (BMI) at the age of 18 years and at midlife and adult weight change in relation to breast cancer incidence and mortality. Design.-Cohort study. Setting.-A cohort of 95 256 US female nurses aged 30 to 55 years who were followed up for 16 years. Main Outcome Measure.-Incident and fatal breast cancer. Results.-During 1 203 498 person-years, 2517 incident breast cancers (60% postmenopausal) were documented. Higher current BMI was associated with lower breast cancer incidence before menopause and was minimally associated with incidence after menopause. However, a stronger positive relationship was seen among postmenopausal women who never used hormone replacement (relative risk=1.59 for BMI >31 kg/m(2) vs less than or equal to 20 kg/m(2); 95% confidence interval, 1.09-2.32; P for trend <.001). Higher BMI at the age of 18 years was associated with lower breast cancer incidence both before and after menopause. Weight gain after the age of 18 years was unrelated to breast cancer incidence before menopause, but was positively associated with incidence after menopause. This increased risk with weight gain was limited to women who never used postmenopausal hormones; among these women, the relative risk was 1.99 (95% confidence interval, 1.43-2.76) for weight gain of more than 20 kg vs unchanged weight (P for trend <.001). Current BMI and weight gain were even more strongly associated with fatal postmenopausal breast cancer. In this population, the percentage of postmenopausal breast cancer accounted for by weight gain alone was approximately 16% and by hormone replacement therapy alone was 5%, but when the interaction between these variables was considered, together they accounted for about one third of postmenopausal breast cancers. Conclusions.-Avoiding adult weight gain may contribute importantly to the prevention of breast cancer after menopause, particularly among women who do not use postmenopausal hormones.	HARVARD UNIV, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, CAMBRIDGE, MA 02138 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356, R25CA057711] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356, 5-R25-CA57711-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARDBARBASH R, 1990, CANCER RES, V50, P2152; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BARNESJOSIAH D, 1995, CANCER CAUSE CONTROL, V6, P112, DOI 10.1007/BF00052771; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; DANIELL HW, 1993, BREAST CANCER RES TR, V25, P193, DOI 10.1007/BF00689833; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KUMAR NB, 1995, CANCER-AM CANCER SOC, V76, P243, DOI 10.1002/1097-0142(19950715)76:2<243::AID-CNCR2820760214>3.0.CO;2-R; LEMARCHAND L, 1988, AM J EPIDEMIOL, V128, P137; Lipworth L, 1996, EPIDEMIOLOGY, V7, P96, DOI 10.1097/00001648-199601000-00017; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; NEGRI E, 1988, AM J EPIDEMIOL, V128, P1207, DOI 10.1093/oxfordjournals.aje.a115075; NEWCOMB PA, 1995, EPIDEMIOLOGY, V6, P318, DOI 10.1097/00001648-199505000-00022; PATHAK DR, 1992, AM J EPIDEMIOL, V135, P153, DOI 10.1093/oxfordjournals.aje.a116268; Potischman N, 1996, JNCI-J NATL CANCER I, V88, P756, DOI 10.1093/jnci/88.11.756; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SENIE RT, 1992, ANN INTERN MED, V116, P26, DOI 10.7326/0003-4819-116-1-26; TORNBERG SA, 1994, BRIT J CANCER, V69, P358, DOI 10.1038/bjc.1994.65; TRETLI S, 1990, BRIT J CANCER, V62, P299, DOI 10.1038/bjc.1990.282; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; URSIN G, 1995, EPIDEMIOLOGY, V6, P137, DOI 10.1097/00001648-199503000-00009; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P731, DOI 10.1093/oxfordjournals.aje.a114156; Ziegler RG, 1996, J NATL CANCER I, V88, P650, DOI 10.1093/jnci/88.10.650	27	592	598	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1407	1411		10.1001/jama.278.17.1407	http://dx.doi.org/10.1001/jama.278.17.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355998				2022-12-24	WOS:A1997YC91700026
J	Horton, R				Horton, R			The omnipresent still syndrome	LANCET			English	Article																		GALBRAITH JK, 1994, NEW ENGL J MED, V331, P484; Glasgow-McDowell M A, 1996, N C Med J, V57, P401; SINGER PN, 1997, SELECTED WORKS, P235; Walker A., 1997, AGEING EUROPE; WILLIAMS A, 1997, BMJ-BRIT MED J, V314, P8	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1156	1156		10.1016/S0140-6736(05)63816-0	http://dx.doi.org/10.1016/S0140-6736(05)63816-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343514				2022-12-24	WOS:A1997YB19900042
J	Lye, M				Lye, M			Access to advances in cardiology	LANCET			English	Article							MYOCARDIAL-INFARCTION; DRUG-THERAPY				Lye, M (corresponding author), UNIV LIVERPOOL,UNIV CLIN DEPT,DUNCAN BLDG,LIVERPOOL L69 3GA,MERSEYSIDE,ENGLAND.							Abrahamsson P, 1996, CARDIOL ELDER, V4, P89; ADAMS JN, 1995, BRIT HEART J, V73, P87; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P525; *EUR SEC PREV STUD, 1996, LANCET, V347, P1203; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Fishkind D, 1997, J AM GERIATR SOC, V45, P809, DOI 10.1111/j.1532-5415.1997.tb01506.x; Gottlieb S, 1997, CIRCULATION, V95, P342; Hall AS, 1997, LANCET, V349, P1493, DOI 10.1016/S0140-6736(97)04442-5; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; Krumholz HM, 1997, AM J CARDIOL, V79, P581, DOI 10.1016/S0002-9149(96)00819-3; LYE M, IN PRESS TXB GERIATR; Newman J, 1997, ARCH INTERN MED, V157, P1103; *NHS EX, 1997, EL9741 DEP HLTH NHS; OKEEFFE ST, 1996, HEART FAILURE CLIN P, P47; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Playford DA, 1997, DRUG AGING, V10, P444, DOI 10.2165/00002512-199710060-00005; Ramanathan K, 1996, DRUG AGING, V8, P237, DOI 10.2165/00002512-199608040-00002; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; *TASK FORC WORK GR, 1997, EUR HEART J, V18, P736	20	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1162	1163		10.1016/S0140-6736(97)08414-6	http://dx.doi.org/10.1016/S0140-6736(97)08414-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343518				2022-12-24	WOS:A1997YB19900046
J	Crane, BR; Arvai, AS; Gachhui, R; Wu, CQ; Ghosh, DK; Getzoff, ED; Stuehr, DJ; Tainer, JA				Crane, BR; Arvai, AS; Gachhui, R; Wu, CQ; Ghosh, DK; Getzoff, ED; Stuehr, DJ; Tainer, JA			The structure of nitric oxide synthase oxygenase domain and inhibitor complexes	SCIENCE			English	Article							CYTOCHROME-C PEROXIDASE; L-ARGININE; NO SYNTHASE; PROTEIN; SITE; COORDINATION; REPLACEMENT; REFINEMENT; CATALYSIS; ERRORS	The nitric oxide synthase oxygenase domain (NOSox) oxidizes arginine to synthesize the cellular signal and defensive cytotoxin nitric oxide (NO). Crystal structures determined for cytokine-inducible NOSox reveal an unusual fold and heme environment for stabilization of activated oxygen intermediates key for catalysis. A winged beta sheet engenders a curved alpha-beta domain resembling a baseball catcher's mitt with heme clasped in the palm. The location of exposed hydrophobic residues and the results of mutational analysis place the dimer interface adjacent to the heme-binding pocket. Juxtaposed hydrophobic O-2- and polar L-arginine-binding sites occupied by imidazole and aminoguanidine, respectively, provide a template for designing dual-function inhibitors and imply substrate-assisted catalysis.	CLEVELAND CLIN, DEPT IMMUNOL, CLEVELAND, OH 44106 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL58883] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRANE BR, UNPUB; FUREY W, 1990, AM CRYST ASS M AB PA, V33, P18; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; GHOSH D, UNPUB; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIBBS MR, 1990, J MOL BIOL, V213, P167; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mansuy Daniel, 1995, P537; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Mueller Ernest J., 1995, P83; MURSHUDOV G, 1994, ACTA CRYSTALLOGR D, V50, P760; MURSHUDOV G, 1996, P DAR STUD WEEK, P157; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poulos Thomas L., 1995, P125; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; STUEHR D, 1997, ANN REV PHARM TOXICO, V18, P707; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WOLFF DJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P290, DOI 10.1006/abbi.1995.1040; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	52	318	326	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					425	431		10.1126/science.278.5337.425	http://dx.doi.org/10.1126/science.278.5337.425			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334294				2022-12-24	WOS:A1997YB35500034
J	Mizutani, Y; Kitagawa, T				Mizutani, Y; Kitagawa, T			Direct observation of cooling of heme upon photodissociation of carbonmonoxy myoglobin	SCIENCE			English	Article							RESOLVED RESONANCE-RAMAN; SPERM WHALE MYOGLOBIN; RELAXATION; DYNAMICS; SPECTROSCOPY; STILBENE; ENERGY; LASER; HEMOGLOBIN; PROTEINS	The formation of vibrationally excited heme upon photodissociation of carbonmonoxy myoglobin and its subsequent vibrational energy relaxation was monitored by picosecond anti-Stokes resonance Raman spectroscopy. The anti-Stokes intensity of the nu(4) band showed immediate generation of vibrationally excited hemes and biphasic decay of the excited populations. The best fit to double exponentials gave time constants of 1.9 +/- 0.6 and 16 +/- 9 picoseconds for vibrational population decay and 3.0 +/- 1.0 and 25 +/- 14 picoseconds for temperature relaxation of the photolyzed heme when a Boltzmann distribution was assumed. The decay of the nu(4) anti-Stokes intensity was accompanied by narrowing and frequency upshift of the Stokes counterpart. This direct monitoring of the cooling dynamics of the heme cofactor within the globin matrix allows the characterization of the vibrational energy flow through the protein moiety and to the water bath.	OKAZAKI NATL RES INST,INST MOL SCI,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB)			Mizutani, Yasuhisa/B-3809-2009					ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BAKKER HJ, 1990, NATURE, V347, P745, DOI 10.1038/347745a0; ELSAESSER T, 1991, ANNU REV PHYS CHEM, V42, P83; FRANZEN S, 1995, BIOCHEMISTRY-US, V34, P1224, DOI 10.1021/bi00004a016; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GREENE BI, 1978, P NATL ACAD SCI USA, V75, P5255, DOI 10.1073/pnas.75.11.5255; HENRY ER, 1986, P NATL ACAD SCI USA, V83, P8982, DOI 10.1073/pnas.83.23.8982; KEYES MH, 1971, J AM CHEM SOC, V93, P2035; Kruglik SG, 1997, CHEM PHYS LETT, V266, P283, DOI 10.1016/S0009-2614(97)00008-0; LI M, 1993, J CHEM PHYS, V98, P5499, DOI 10.1063/1.464899; LI P, 1994, BIOPHYS J, V66, P430, DOI 10.1016/S0006-3495(94)80793-3; LIAN TQ, 1994, J PHYS CHEM-US, V98, P11648, DOI 10.1021/j100096a005; Lim MH, 1996, J PHYS CHEM-US, V100, P12043, DOI 10.1021/jp9536458; LINGLE R, 1991, J PHYS CHEM-US, V95, P9320, DOI 10.1021/j100176a053; MARTIN JL, 1983, P NATL ACAD SCI-BIOL, V80, P173, DOI 10.1073/pnas.80.1.173; MATOUSEK P, 1995, CHEM PHYS LETT, V237, P373, DOI 10.1016/0009-2614(95)00324-W; Nakabayashi T, 1997, J PHYS CHEM A, V101, P3494, DOI 10.1021/jp963303h; PETRICH JW, 1987, BIOCHEMISTRY-US, V26, P7914, DOI 10.1021/bi00398a056; PHILLIPS DL, 1993, CHEM PHYS, V175, P1, DOI 10.1016/0301-0104(93)80224-W; RAFTERY D, 1994, J CHEM PHYS, V101, P8572, DOI 10.1063/1.468052; SATO S, 1994, APPL PHYS B-LASERS O, V59, P415, DOI 10.1007/BF01081064; SCHOMACKER KT, 1984, J CHEM PHYS, V80, P4701, DOI 10.1063/1.446535; Schultz SL, 1997, J PHYS CHEM A, V101, P1000, DOI 10.1021/jp962454h; SENSION RJ, 1993, J CHEM PHYS, V98, P6291, DOI 10.1063/1.464824; Simpson MC, 1997, J AM CHEM SOC, V119, P5110, DOI 10.1021/ja961198j	26	226	228	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					443	446		10.1126/science.278.5337.443	http://dx.doi.org/10.1126/science.278.5337.443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334299				2022-12-24	WOS:A1997YB35500039
J	Lowe, CJ; Wray, GA				Lowe, CJ; Wray, GA			Radical alterations in the roles of homeobox genes during echinoderm evolution	NATURE			English	Article							MORPHOLOGY; EXPRESSION; PHYLOGENY; MOLECULES; HOMOLOGY	Echinoderms possess one of the most highly derived body architectures of all metazoan phyla, with radial symmetry, a calcitic endoskeleton, and a water vascular system(1,2). How these dramatic morphological changes evolved has been the subject of extensive speculation and debate(3-5), but remains unresolved. Because echinoderms are closely related to chordates and postdate the protostome/deuterostome divergence(2,3,6,7), they must have evolved from bilaterally symmetrical ancestors(1-6). Here we report the expression domains in echinoderms of three important developmental regulatory genes (distal-less, engrailed and orthodenticle), all of which encode transcription factors that contain a homeodomain(8). Our findings show that the reorganization of body architecture involved extensive changes in the deployment and roles of homeobox genes. These changes include modifications in the symmetry of expression domains and the evolution of several new developmental roles, as well as the loss of roles conserved between arthropods and chordates. Some of these modifications seem to have evolved very early in the history of echinoderms, whereas others probably evolved during the subsequent diversification of adult and larval morphology, These results demonstrate the evolutionary lability of regulatory genes that are widely viewed as conservative.	SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Lowe, Christopher/0000-0002-7789-8643				Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Bolker JA, 1996, BIOESSAYS, V18, P489, DOI 10.1002/bies.950180611; Brusca R.C., 1990, INVERTEBRATES; Dan, 1968, INVERTEBRATE EMBRYOL; DAVID B, IN PRESS P 9 INT ECH; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DICKINSON WJ, 1995, TRENDS GENET, V11, P119, DOI 10.1016/S0168-9525(00)89015-0; DOLECKI GJ, 1988, GENE, V64, P21, DOI 10.1016/0378-1119(88)90477-5; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; GAN L, 1995, DEV BIOL, V167, P517, DOI 10.1006/dbio.1995.1046; HOLLAND ND, 1988, ECHINODERM PHYLOGENY, P13; Holland P.W.H., 1990, Seminars in Developmental Biology, V1, P135; Hyman L.H., 1955, INVERTEBRATES, V4; Jefferies RPS, 1996, ACTA ZOOL-STOCKHOLM, V77, P101, DOI 10.1111/j.1463-6395.1996.tb01256.x; Lacalli TC, 1996, PHILOS T R SOC B, V351, P1737, DOI 10.1098/rstb.1996.0155; MALINDA KM, 1994, DEV BIOL, V164, P562, DOI 10.1006/dbio.1994.1224; NIELSEN C, 1995, ANIMAL EVOLUTIION IN; PANGANIBAN G, 1997, P NATL ACAD SCI USA, V94, P2162; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATEL NH, METHOD CELL BIOL, V44, P446; Raff R.A., 1996, SHAPE LIFE; Sharman AC, 1996, NETH J ZOOL, V46, P47, DOI 10.1163/156854295X00050; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; Smith A. B., 1988, ECHINODERM PHYLOGENY, P85; STRATHMANN MF, 1987, REPROD DEV MARINE IN; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; WEDEEN CJ, 1991, DEVELOPMENT, V113, P805	29	220	226	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					718	721		10.1038/39580	http://dx.doi.org/10.1038/39580			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338781				2022-12-24	WOS:A1997YA95900052
J	Dahiyat, BI; Mayo, SL				Dahiyat, BI; Mayo, SL			De novo protein design: Fully automated sequence selection	SCIENCE			English	Article							AMINO-ACIDS; MACROMOLECULAR STRUCTURES; DISTANCE GEOMETRY; NMR-SPECTROSCOPY; COILED COILS; PROPENSITIES; PEPTIDE; PACKING; POLYPEPTIDE; TRANSITION	The first fully automated design and experimental validation of a novel sequence for an entire protein is described. A computational design algorithm based on physical chemical potential functions and stereochemical constraints was used to screen a combinatorial library of 1.9 x 10(27) possible amino acid sequences for compatibility with the design target, a beta beta alpha protein motif based on the polypeptide backbone structure of a zinc finger domain. A BLAST search shows that the designed sequence, full sequence design 1 (FSD-1), has very low identity to any known protein sequence. The solution structure of FSD-1 was solved by nuclear magnetic resonance spectroscopy and indicates that FSD-1 forms a compact well-ordered structure, which is in excellent agreement with the design target structure, This result demonstrates that computational methods can perform the immense combinatorial search required for protein design, and it suggests that an unbiased and quantitative algorithm can be used in various structural contexts.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125; CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; California Institute of Technology					NIGMS NIH HHS [GM08346] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Betz SF, 1996, BIOCHEMISTRY-US, V35, P6955, DOI 10.1021/bi960095a; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; COHEN FE, 1982, J MOL BIOL, V156, P821, DOI 10.1016/0022-2836(82)90144-9; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511; Dahiyat BI, 1997, P NATL ACAD SCI USA, V94, P10172, DOI 10.1073/pnas.94.19.10172; Dahiyat BI, 1997, PROTEIN SCI, V6, P1333, DOI 10.1002/pro.5560060622; DAHIYAT BI, UNPUB; DeMaeyer M, 1997, FOLD DES, V2, P53; DESJARLAIS JR, 1995, PROTEIN SCI, V4, P2006, DOI 10.1002/pro.5560041006; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; GOLDSTEIN RF, 1994, BIOPHYS J, V66, P1335, DOI 10.1016/S0006-3495(94)80923-3; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HELLINGA HW, 1991, J MOL BIOL, V222, P787, DOI 10.1016/0022-2836(91)90511-4; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JACKSON DY, 1994, SCIENCE, V266, P243, DOI 10.1126/science.7939659; JANIN J, 1980, J MOL BIOL, V143, P95, DOI 10.1016/0022-2836(80)90126-6; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KLEMBA M, 1995, NAT STRUCT BIOL, V2, P368, DOI 10.1038/nsb0595-368; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; Marvin JS, 1997, P NATL ACAD SCI USA, V94, P4366, DOI 10.1073/pnas.94.9.4366; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, COMPUTATIONAL ASPECT; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; Struthers MD, 1996, J AM CHEM SOC, V118, P3073, DOI 10.1021/ja954014u; Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342; Su A, 1997, PROTEIN SCI, V6, P1701, DOI 10.1002/pro.5560060810; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P9808, DOI 10.1021/bi00494a008; Wuthrich K., 1986, NMR PROTEINS NUCL AC	51	888	983	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					82	87		10.1126/science.278.5335.82	http://dx.doi.org/10.1126/science.278.5335.82			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311930				2022-12-24	WOS:A1997XZ12400041
J	Rubinstein, M; Phillips, TJ; Bunzow, JR; Falzone, TL; Dziewczapolski, G; Zhang, G; Fang, Y; Larson, JL; McDougall, JA; Chester, JA; Saez, C; Pugsley, TA; Gershanik, O; Low, MJ; Grandy, DK				Rubinstein, M; Phillips, TJ; Bunzow, JR; Falzone, TL; Dziewczapolski, G; Zhang, G; Fang, Y; Larson, JL; McDougall, JA; Chester, JA; Saez, C; Pugsley, TA; Gershanik, O; Low, MJ; Grandy, DK			Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine	CELL			English	Article							METHYL-D-ASPARTATE; EXTRACELLULAR DOPAMINE; TYROSINE-HYDROXYLASE; NUCLEUS-ACCUMBENS; FUNCTIONAL-CHARACTERIZATION; GLUTAMATE-RECEPTOR; SUBSTANTIA-NIGRA; NOVELTY SEEKING; PRIMATE BRAIN; BASAL GANGLIA	The human dopamine D4 receptor (D4R) has received considerable attention because of its high affinity for the atypical antipsychotic clozapine and the unusually polymorphic nature of its gene. To clarify the in vivo role of the D4R, we produced and analyzed mutant mice (D4R(-/-)) lacking this protein. Although less active in open field tests, D4R(-/-) mice outperformed wildtype mice on the rotarod and displayed locomotor supersensitivity to ethanol, cocaine, and methamphetamine. Biochemical analyses revealed that dopamine synthesis and its conversion to DOPAC were elevated in the dorsal striatum from D4R(-/-) mice. Based on these findings, we propose that the D4R modulates normal, coordinated and drug-stimulated motor behaviors as well as the activity of nigrostriatal dopamine neurons.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BEHAV NEUROSCI,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV BUENOS AIRES,INST INVEST FARMACOL,RA-1053 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,INST INVEST INGN GENET & BIOL MOL,CONICET,RA-1053 BUENOS AIRES,DF,ARGENTINA; UNIV BUENOS AIRES,DEPT QUIM BIOL,FCEYN,RA-1053 BUENOS AIRES,DF,ARGENTINA; DEPT VET AFFAIRS MED CTR,RES SERV,PORTLAND,OR 97201; HOSP UNIV VIRGEN DEL ROCIO,SEVILLE 41013,SPAIN; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES,ANN ARBOR,MI 48105	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System; Virgen del Rocio University Hospital; Pfizer			IBIS, TUMORIGENESIS/P-3506-2015; Falzone, Tomás/W-2528-2019; Sáez, Carmen/B-9468-2015	Sáez, Carmen/0000-0002-8600-0508; Dziewczapolski, Gustavo/0000-0003-1393-485X; Low, Malcolm/0000-0002-9900-3708; Falzone, Tomas/0000-0002-7984-1149	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; Ariano MA, 1997, BRAIN RES, V752, P26, DOI 10.1016/S0006-8993(96)01422-9; ARNT J, 1995, EUR J PHARMACOL, V283, P55, DOI 10.1016/0014-2999(95)00292-S; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; Bergson C, 1995, J NEUROSCI, V15, P7821; BOUVIER C, 1995, EUR J PHARM-MOLEC PH, V290, P11, DOI 10.1016/0922-4106(95)90011-X; CAMP DM, 1994, BRAIN RES, V668, P180, DOI 10.1016/0006-8993(94)90523-1; CARLSSON A, 1975, J NEURAL TRANSM, V40, P99; CARTER CJ, 1982, NEUROPHARMACOLOGY, V21, P379, DOI 10.1016/0028-3908(82)90019-3; CHRISTOFFERSEN CL, 1995, NEUROSCIENCE, V67, P373, DOI 10.1016/0306-4522(95)00047-M; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DAR MS, 1984, J NEURAL TRANSM, V60, P283, DOI 10.1007/BF01249100; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; FADDA F, 1991, ALCOHOL ALCOHOLISM S, V1, P439; FISHBURN CS, 1995, FEBS LETT, V361, P215, DOI 10.1016/0014-5793(95)00168-9; FREED CR, 1985, SCIENCE, V229, P62, DOI 10.1126/science.4012312; Geijer T, 1997, ALCOHOL CLIN EXP RES, V21, P35; GEORGE SR, 1993, BIOCHEM BIOPH RES CO, V196, P107, DOI 10.1006/bbrc.1993.2222; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HORNYKIEWICZ O, 1966, PHARMACOL REV, V18, P925; IMPERATO A, 1986, J PHARMACOL EXP THER, V239, P219; ISHII A, 1991, BIOCHEM BIOPH RES CO, V176, P1051, DOI 10.1016/0006-291X(91)90389-O; Kotler M, 1997, MOL PSYCHIATR, V2, P251, DOI 10.1038/sj.mp.4000248; KRISCH I, 1994, J PHARMACOL EXP THER, V271, P343; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; LINDVALL O, 1983, CHEM NEUROANATOMY, P229; MAISONNEUVE IM, 1990, BRAIN RES, V535, P221, DOI 10.1016/0006-8993(90)91604-F; MEADORWOODRUFF JH, 1994, NEUROPSYCHOPHARMACOL, V10, P239, DOI 10.1038/npp.1994.27; Mrzljak L, 1996, NATURE, V381, P245, DOI 10.1038/381245a0; Muramatsu T, 1996, J MED GENET, V33, P113, DOI 10.1136/jmg.33.2.113; OVERTON P, 1992, J NEURAL TRANSM-PARK, V4, P1, DOI 10.1007/BF02257617; Phillips TJ, 1996, INT REV NEUROBIOL, V39, P243, DOI 10.1016/S0074-7742(08)60669-8; PHILLIPS TJ, 1991, PSYCHOPHARMACOLOGY, V103, P557, DOI 10.1007/BF02244259; PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x; PHILLIPS TJ, 1995, ALCOHOL CLIN EXP RES, V19, P269, DOI 10.1111/j.1530-0277.1995.tb01502.x; Pugsley TA, 1995, J PHARMACOL EXP THER, V275, P1355; RASSNICK S, 1992, PSYCHOPHARMACOLOGY, V109, P92, DOI 10.1007/BF02245485; REYNOLDS GP, 1994, J NEUROCHEM, V63, P1576; RIBEIRO P, 1992, P NATL ACAD SCI USA, V89, P9593, DOI 10.1073/pnas.89.20.9593; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; VANTOL HHM, 1992, NATURE, V358, P149; WADDINGTON JL, 1993, REGULATION UNCONDITI, P51; WEISS F, 1992, J NEUROSCI, V12, P4372; Werner P, 1996, MOL PHARMACOL, V49, P656; WESTERINK BHC, 1992, N-S ARCH PHARMACOL, V345, P523, DOI 10.1007/BF00168943; White FJ, 1996, ANNU REV NEUROSCI, V19, P405, DOI 10.1146/annurev.ne.19.030196.002201; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215; ZORN SH, 1994, EUR J PHARM-MOLEC PH, V269, pR1, DOI 10.1016/0922-4106(94)90047-7	59	391	401	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					991	1001		10.1016/S0092-8674(00)80365-7	http://dx.doi.org/10.1016/S0092-8674(00)80365-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323127	Bronze			2022-12-24	WOS:A1997XX76800005
J	Mumford, DM				Mumford, DM			Thank God I have cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					956	956						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302252				2022-12-24	WOS:A1997XV64000040
J	Burtnick, LD; Koepf, EK; Grimes, J; Jones, EY; Stuart, DI; McLaughlin, PJ; Robinson, RC				Burtnick, LD; Koepf, EK; Grimes, J; Jones, EY; Stuart, DI; McLaughlin, PJ; Robinson, RC			The crystal structure of plasma gelsolin: Implications for actin severing, capping, and nucleation	CELL			English	Article							BINDING DOMAIN; F-ACTIN; PROTEIN; SEQUENCE; FILAMENT; IDENTIFICATION; CALCIUM; VILLIN; AMYLOIDOSIS; DEFINITION	The structure of gelsolin has been determined by crystallography and comprises six structurally related domains that, in a Ca2+-free environment, pack together to form a compact globular structure in which the putative actin-binding sequences are not sufficiently exposed to enable binding to occur. We propose that binding Ca2+ can release the connections that join the N- and C-terminal halves of gelsolin, enabling each half to bind actin relatively independently. Domain shifts are proposed in response to Ca2+ as bases for models of how gelsolin acts to sever, cap, or nucleate F-actin filaments. The structure also invites discussion of polyphosphoinositide binding to segment 2 and suggests how mutation at Asp-187 could initiate a series of events that lead to deposition of amyloid plaques, as observed in victims of familial amyloidosis (Finnish type).	UNIV OXFORD,DEPT BIOCHEM,LAB MOL BIOPHYS,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD CTR MOL SCI,OXFORD OX1 3QU,ENGLAND; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA; UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,MIDLOTHIAN,SCOTLAND	University of Oxford; University of Oxford; University of British Columbia; University of Edinburgh			Jones, Yvonne/J-2293-2016; Robinson, Robert/G-9702-2011; Jones, Yvonne/N-8111-2019	Jones, Yvonne/0000-0002-3834-1893; Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Grimes, Jonathan Mark/0000-0001-9698-0389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; FEINBERG J, 1995, BIOCHEM BIOPH RES CO, V209, P426, DOI 10.1006/bbrc.1995.1520; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HELLWEG T, 1993, BIOPHYS J, V65, P799, DOI 10.1016/S0006-3495(93)81121-4; HERRMANNSDOERFER AJ, 1993, AM J PHYSIOL, V265, pG1071, DOI 10.1152/ajpgi.1993.265.6.G1071; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P508; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARKUS MA, 1994, PROTEIN SCI, V3, P70; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MCGOUGH A, 1995, J STRUCT BIOL, V115, P144, DOI 10.1006/jsbi.1995.1038; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; REID SW, 1993, ARCH BIOCHEM BIOPHYS, V302, P31, DOI 10.1006/abbi.1993.1176; SCHNUCHEL A, 1995, J MOL BIOL, V247, P21, DOI 10.1006/jmbi.1994.0118; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; SUN HQ, 1994, J BIOL CHEM, V269, P9473; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VanTroys M, 1996, FEBS LETT, V397, P191, DOI 10.1016/S0014-5793(96)01086-1; VASCONCELLOS CA, 1993, BLOOD, V82, P3648; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; WEEDS AG, 1993, FEBS LETT, V335, P119, DOI 10.1016/0014-5793(93)80452-Z; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1992, J BIOL CHEM, V267, P14616	50	239	244	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					661	670		10.1016/S0092-8674(00)80527-9	http://dx.doi.org/10.1016/S0092-8674(00)80527-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288746	Bronze			2022-12-24	WOS:A1997XT06600010
J	Fisher, GJ; Wang, ZQ; Datta, SC; Varani, J; Kang, S; Voorhees, JJ				Fisher, GJ; Wang, ZQ; Datta, SC; Varani, J; Kang, S; Voorhees, JJ			Pathophysiology of premature skin aging induced by ultraviolet light	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	57th Annual Meeting of the Society-for-Investigative-Dermatology	MAY 01-08, 1996	WASHINGTON, D.C.	Soc Invest Dermatol, Yonsei Univ, Coll Med, Seoul, Korea			TRETINOIN RETINOIC ACID; COLLAGENASE GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; TISSUE INHIBITOR; PHOTOAGED SKIN; CROSS-LINKING; I COLLAGEN; METALLOPROTEINASES; DEGRADATION; PROMOTER	Background Long-term exposure to ultraviolet irradiation from sunlight causes premature skin aging (photoaging), characterized in part by wrinkles, altered pigmentation, and loss of skin tone. Photoaged skin displays prominent alterations in the collagenous extracellular matrix of connective tissue. We investigated the role of matrix-degrading metalloproteinases, a family of proteolytic enzymes, as mediators of collagen damage in photoaging. Methods We studied 59 whites (33 men and 26 women, ranging in age from 21 to 58 years) with light-to-moderate skin pigmentation, none of whom had current or prior skin disease. Only some of the participants were included in each of the studies. We irradiated their buttock skin with fluorescent ultraviolet lights under standard conditions and obtained skin samples from irradiated and nonirradiated areas by keratome or punch biopsy. in some studies, tretinoin and its vehicle were applied to skin under occlusion 48 hours before ultraviolet irradiation. The expression of matrix metalloproteinases was determined by in situ hybridization, immunohistology, and in situ zymography. Irradiation-induced degradation of skin collagen was measured by radioimmunoassay of soluble cross-linked telopeptides. The protein lever of tissue inhibitor of matrix metalloproteinases type 1 was determined by Western blot analysis. Results A single exposure to ultraviolet irradiation increased the expression of three matrix metalloproteinases - collagenase, a 92-kd gelatinase, and stromelysin - in skin connective tissue and outer skin layers, as compared with nonirradiated skin. The degradation of endogenous type I collagen fibrils was increased by 58 percent in irradiated skin, as compared with nonirradiated skin. Collagenase and gelatinase activity remained maximally elevated (4.4 and 2.3 times, respectively) for seven days with four exposures to ultraviolet irradiation, delivered at two-day intervals, as compared with base-line levels, Pretreatment of skin with tretinoin (all-trans-retinoic acid) inhibited the induction of matrix metalloproteinase proteins and activity (by 70 to 80 percent) in both connective tissue and outer layers of irradiated skin. Ultraviolet irradiation also induced tissue inhibitor of matrix metalloproteinases-1, which regulates the enzyme. Induction of the inhibitor was not affected by tretinoin. Conclusions Multiple exposures to ultraviolet irradiation lead to sustained elevations of matrix metalloproteinases that degrade skin collagen and may contribute to photoaging. Treatment with topical tretinoin inhibits irradiation-induced matrix metalloproteinases but not their endogenous inhibitor. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), UNIV MICHIGAN, SCH MED,DEPT DERMATOL,MED SCI 1,RM 6447, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA.		DATTA, SUBHAS CHANDRA/GRY-6638-2022	Scharffetter-Kochanek, Karin/0000-0002-9655-685X				AUTIO P, 1993, ARCH DERMATOL RES, V285, P322, DOI 10.1007/BF00371831; Bernstein EF, 1996, J AM ACAD DERMATOL, V34, P209, DOI 10.1016/S0190-9622(96)80114-9; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; CALDERONE DC, 1995, J AM ACAD DERMATOL, V32, P1016, DOI 10.1016/0190-9622(95)91342-4; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; ELLIS CN, 1990, J AM ACAD DERMATOL, V23, P629, DOI 10.1016/0190-9622(90)70265-J; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FISHER GJ, 1991, J INVEST DERMATOL, V96, P814; GACK S, 1994, J BIOL CHEM, V269, P10363; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; GILCHREST BA, 1992, BRIT J DERMATOL, V127, P25, DOI 10.1111/j.1365-2133.1992.tb16984.x; GRIFFITHS CEM, 1993, NEW ENGL J MED, V329, P530, DOI 10.1056/NEJM199308193290803; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Kaminer Michael S., 1995, P1; KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445; KAZAMA T, 1988, J INVEST DERMATOL, V91, P560, DOI 10.1111/1523-1747.ep12476939; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; Lavker Robert M., 1995, P123; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; OHKUBO T, 1973, ACTA DERM-VENEREOL, V53, P121; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; RAFAL ES, 1992, NEW ENGL J MED, V326, P368, DOI 10.1056/NEJM199202063260603; RISTELI J, 1993, CLIN CHEM, V39, P635; SATO H, 1993, ONCOGENE, V8, P395; SCHWARTZ E, 1993, PHOTOCHEM PHOTOBIOL, V58, P841, DOI 10.1111/j.1751-1097.1993.tb04981.x; SMITH JG, 1962, J INVEST DERMATOL, V39, P347, DOI 10.1038/jid.1962.122; TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UITTO J, 1993, DERMATOLOGY GEN MED, V1, P299; WARREN R, 1992, J AM ACAD DERMATOL, V26, P558; WARREN R, 1991, J AM ACAD DERMATOL, V25, P751, DOI 10.1016/S0190-9622(08)80964-4; WEINSTOCK MA, 1994, J INVEST DERMATOL, V102, pS4, DOI 10.1111/1523-1747.ep12385720; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; WOOLSON RF, 1987, STATISTICAL METHODS, P314; YAMAUCHI M, 1991, J INVEST DERMATOL, V97, P938	43	979	1048	8	98	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	1997	337	20					1419	1428		10.1056/NEJM199711133372003	http://dx.doi.org/10.1056/NEJM199711133372003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YF253	9358139				2022-12-24	WOS:A1997YF25300003
J	Cook, JG; Bardwell, L; Thorner, J				Cook, JG; Bardwell, L; Thorner, J			Inhibitory and activating functions for MAPK Kss1 in the S-cerevisiae filamentous-growth signalling pathway	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; INVASIVE GROWTH; KINASE CASCADE; CELL; GENE; PHOSPHORYLATION; ELEMENTS; FUS3; STE7	Mitogen-activated protein kinase (MAPK) cascades are conserved signalling modules that regulate responses to diverse extracellular stimuli, developmental cues and environmental stresses (reviewed in refs 1-3). A MAPK is phosphorylated and activated by a MAPK kinase (MAPKK), which is activated by an upstream protein kinase, such as Raf, Mos or a MAPKK kinase. Ste7, a MAPKK in the yeast Saccharomyces cerevisiae, is required for two developmental pathways: mating(4) and invasive (filamentous) growth(5,6). Kss1 and Fus3, the MAPK targets of Ste7, are required for mating(7,8), but their role in invasive growth has been unclear.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Bardwell, Lee/I-8284-2019	THORNER, Jeremy/0000-0002-2583-500X; Bardwell, Lee/0000-0002-2393-8363; Cook, Jeanette/0000-0003-0849-7405				BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; Gavrias V, 1996, MOL MICROBIOL, V19, P1255, DOI 10.1111/j.1365-2958.1996.tb02470.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Sherman F., 1986, METHODS YEAST GENETI; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; ZHOU Z, 1995, MOL CELL BIOL, V13, P2069	24	218	220	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	1997	390	6655					85	88		10.1038/36355	http://dx.doi.org/10.1038/36355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363895				2022-12-24	WOS:A1997YE47700057
J	Frisch, M; Glimelius, B; vandenBrule, AJC; Wohlfahrt, J; Meijer, CJLM; Walboomers, JMM; Goldman, S; Svensson, C; Adami, HO; Melbye, M				Frisch, M; Glimelius, B; vandenBrule, AJC; Wohlfahrt, J; Meijer, CJLM; Walboomers, JMM; Goldman, S; Svensson, C; Adami, HO; Melbye, M			Sexually transmitted infection as a cause of anal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN PAPILLOMAVIRUS DNA; HOMOSEXUAL MEN; INTRAEPITHELIAL NEOPLASIA; CARCINOMA; PREVALENCE; DISEASES; PARALLEL; DENMARK; SMOKING; RISK	Background The incidence of anal cancer has increased in recent decades, particularly among women. To identify underlying risk factors, we conducted a population-based case-control study in Denmark and Sweden. Methods We conducted telephone interviews with 324 women and 93 men in whom invasive or in situ anal cancer was diagnosed between 1991 and 1994, 534 controls with adenocarcinoma of the rectum, and 554 population controls. The interviews covered a wide spectrum of possible risk factors for anal cancer. Odds ratios were calculated by logistic regression. Specimens of anal-cancer tissue and samples of rectal adenocarcinomas were tested for human papillomavirus (HPV) DNA with the polymerase chain reaction. Results Multivariate analysis revealed consistent and statistically significant associations between measures of sexual promiscuity and the risk of anal cancer in both men and women. There was a significant trend toward an association between higher numbers of partners of the opposite sex in women (P<0.001) and men (P<0.05) and strong associations with a variety of venereal diseases. In women, receptive anal intercourse, particularly before the age of 30 years, and venereal infections in the partner were also associated with an increased risk (odds ratios, 3.4 and 2.4, respectively). Fifteen percent of the men with anal cancer reported having had homosexual contact, as compared with none of the controls (P<0.001). Highrisk types of HPV, notably HPV-16, were detected in 84 percent of the anal-cancer specimens examined, whereas all rectal-adenocarcinoma specimens tested were negative for HPV. Conclusions Our study provides strong evidence that a sexually transmitted infection causes anal cancer. The presence of high-risk types of HPV, notably HPV-16 (which is known to cause cancer of the cervix), in the majority of anal-cancer tissue specimens suggests that most anal cancers are potentially preventable. (C) 1997, Massachusetts Medical Society.	UNIV UPPSALA HOSP, DEPT ONCOL, S-75185 UPPSALA, SWEDEN; VRIJE UNIV AMSTERDAM, UNIV HOSP, DEPT PATHOL, SECT MOL PATHOL, AMSTERDAM, NETHERLANDS; ERSTA HOSP, DEPT SURG, STOCKHOLM, SWEDEN; HUDDINGE UNIV HOSP, ONCOL DEPT SO STOCKHOLM, STOCKHOLM, SWEDEN; KAROLINSKA INST, DEPT MED EPIDEMIOL, STOCKHOLM, SWEDEN; HARVARD UNIV, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, HARVARD CTR CANC PREVENT, BOSTON, MA USA	Uppsala University; Uppsala University Hospital; Vrije Universiteit Amsterdam; Ersta Sjukhus; Karolinska Institutet; Karolinska Institutet; Harvard University; Harvard University	Frisch, M (corresponding author), STATENS SERUM INST, DEPT EPIDEMIOL RES, DANISH EPIDEMIOL SCI CTR, DK-2300 COPENHAGEN, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785				Austin D F, 1982, Natl Cancer Inst Monogr, V62, P89; BERAL V, 1974, LANCET, V1, P1037; Binkley George E., 1945, AMER JOUR DIGEST DIS, V12, P46; COOPER HS, 1979, DIS COLON RECTUM, V22, P557, DOI 10.1007/BF02587005; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DALING JR, 1992, AM J EPIDEMIOL, V135, P180, DOI 10.1093/oxfordjournals.aje.a116270; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HIGGINS GD, 1991, CANCER-AM CANCER SOC, V68, P561, DOI 10.1002/1097-0142(19910801)68:3<561::AID-CNCR2820680320>3.0.CO;2-R; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HOLM R, 1994, MODERN PATHOL, V7, P449; HOLMES F, 1988, GASTROENTEROLOGY, V95, P107, DOI 10.1016/0016-5085(88)90297-1; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *IARC, 1995, IARC MON EV CARC RIS, V64; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JUDSON FN, 1980, AM J EPIDEMIOL, V112, P836, DOI 10.1093/oxfordjournals.aje.a113056; LI FP, 1982, LANCET, V2, P391; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; MELBYE M, 1994, AM J EPIDEMIOL, V139, P772, DOI 10.1093/oxfordjournals.aje.a117073; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MUNOZ N, 1989, IARC SCI PUBL, V94, P9; NOFFSINGER AE, 1995, CANCER, V75, P958, DOI 10.1002/1097-0142(19950215)75:4<958::AID-CNCR2820750410>3.0.CO;2-1; PALEFSKY JM, 1991, CANCER RES, V51, P1014; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; SAS INSTITUTE INC., 1996, SAS STAT SOFTW CHANG, p[231, 531]; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1990, J CLIN PATHOL, V43, P133, DOI 10.1136/jcp.43.2.133; SCHOLEFIELD JH, 1991, GUT, V32, P674, DOI 10.1136/gut.32.6.674; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR, P813; World Health Organization, 1976, INT CLASS DIS	34	460	474	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 6	1997	337	19					1350	1358		10.1056/NEJM199711063371904	http://dx.doi.org/10.1056/NEJM199711063371904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE446	9358129				2022-12-24	WOS:A1997YE44600004
J	Nossal, GJV				Nossal, GJV			Host immunobiology and vaccine development	LANCET			English	Article							T-CELLS; IMMUNE-RESPONSES; INVIVO; SUBSETS	As the rules of immunoregulation become clearer, the design of vaccines and adjuvants is becoming more scientific. To understand these rules, the interactions between three kinds of cells need to be grasped. Antigen-presenting cells (APCs) initiate the immunoglobulin cascade. The most important of these are dendritic cells, which must first capture antigen, a process aided by particulate matter, the presence of natural or acquired antibodies, or the capacity to activate complement. Then T cells become activated through conjoint action of processed antigenic peptides and APC surface and secreted molecules. T cells mediate inflammation, develop cytotoxic capacity, and help in antibody formation. Whether cells of type 1 or type 2 predominate influences the direction of both cellular and humoral responses. B cells are then activated, leading to antibody formation and often to better antigen presentation. Both T and B cell memory, embedded in long-lived lymphocyte populations, aid heightened immune reactivity when the antigen is re-encountered. The best vaccines stimulate strong memory.			Nossal, GJV (corresponding author), UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA.							BERCK C, 1991, CELL, V67, P1121; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; CHILLER JM, 1970, P NATL ACAD SCI USA, V65, P551, DOI 10.1073/pnas.65.3.551; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DONNELLY JJ, 1994, J IMMUNOL METHODS, V176, P145, DOI 10.1016/0022-1759(94)90308-5; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GROSS A, 1993, J IMMUNOL, V150, P2112; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; KELSOE G, 1995, IMMUNOL TODAY, V16, P324, DOI 10.1016/0167-5699(95)80146-4; MCKENZIE SJ, 1984, J IMMUNOL, V133, P1818; MILLER JFAP, 1972, INT REV CYTOL, V33, P77, DOI 10.1016/S0074-7696(08)61449-7; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; Nossal G. J. V., 1971, Antigens, lymphoid cells and the immune response.; NOSSAL GJV, 1968, J EXP MED, V128, P839, DOI 10.1084/jem.128.4.839; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; SZAKAL AK, 1989, ANNU REV IMMUNOL, V7, P91, DOI 10.1146/annurev.immunol.7.1.91; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	27	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1316	1319		10.1016/S0140-6736(97)03257-1	http://dx.doi.org/10.1016/S0140-6736(97)03257-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357421				2022-12-24	WOS:A1997YD68900044
J	Pak, DTS; Pflumm, M; Chesnokov, I; Huang, DW; Kellum, R; Marr, J; Romanowski, P; Botchan, MR				Pak, DTS; Pflumm, M; Chesnokov, I; Huang, DW; Kellum, R; Marr, J; Romanowski, P; Botchan, MR			Association of the origin recognition complex with heterochromatin and HP1 in higher eukaryotes	CELL			English	Article							POSITION-EFFECT VARIEGATION; NONHISTONE CHROMOSOMAL PROTEIN; DNA-REPLICATION; DROSOPHILA-MELANOGASTER; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; CHROMATIN STRUCTURE; CELL-CYCLE; YEAST; GENE	The origin recognition complex (ORC) is required to initiate eukaryotic DNA replication and also engages in transcriptional silencing in S. cerevisiae. We observed a striking preferential but not exclusive association of Drosophila ORC2 with heterochromatin on interphase and mitotic chromosomes. HP1, a heterochromatin-localized protein required for position effect variegation (PEV), colocalized with DmORC2 at these sites. Consistent with this localization, intact DmORC and HP1 were found in physical complex. The association was shown biochemically to require the chromodomain and shadow domains of HP1. The amino terminus of DmORC1 contained a strong HP1-binding site, mirroring an interaction found independently in Xenopus by a yeast two-hybrid screen. Finally, heterozygous DmORC2 recessive lethal mutations resulted in a suppression of PEV. These results indicate that ORC may play a widespread role in packaging chromosomal domains through interactions with heterochromatin-organizing factors.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; WELLCOME TRUST & CANC RES CAMPAIGN INST, CAMBRIDGE CB2 1QR, ENGLAND	University of California System; University of California Berkeley; McGill University				Chesnokov, Igor/0000-0002-6659-2913	NCI NIH HHS [CA30490, CA09041] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030490, R37CA030490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3163; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Botchan M, 1996, P NATL ACAD SCI USA, V93, P9997, DOI 10.1073/pnas.93.19.9997; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; EISSENBERG JC, 1992, GENETICS, V131, P345; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; Elgin S.C.R., 1978, P112; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; FOE VE, 1989, DEVELOPMENT, V107, P1; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GATTI M, 1976, CHROMOSOMA, V57, P351, DOI 10.1007/BF00332160; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Harlow E, 1988, ANTIBODIES LAB MANUA; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HENIKOFF S, 1995, CURR TOP MICROBIOL, V197, P193; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLUM R, 1995, J CELL SCI, V108, P1407; KELLUM R, 1995, J CELL SCI, V108, P1419; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOHE AR, 1993, GENETICS, V134, P1149; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; PAK DTS, 1996, THESIS U CALIFORNIA; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PIMPINELLI S, 1976, CHROMOSOMA, V57, P377, DOI 10.1007/BF00332161; PIMPINELLI S, 1985, GENETICS, V109, P721; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHNELL R, 1986, MOL CELL BIOL, V6, P494, DOI 10.1128/MCB.6.2.494; Silver L M, 1978, Methods Cell Biol, V18, P151; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Spofford J. B., 1976, GENET BIOL DROSOPHIL, V1c, P955; SZABAD J, 1982, DEV BIOL, V93, P240, DOI 10.1016/0012-1606(82)90256-1; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676	66	346	348	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					311	323		10.1016/S0092-8674(00)80415-8	http://dx.doi.org/10.1016/S0092-8674(00)80415-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363940	Bronze			2022-12-24	WOS:A1997YD94100005
J	Musey, L; Hughes, J; Schacker, T; Shea, T; Corey, L; McElrath, MJ				Musey, L; Hughes, J; Schacker, T; Shea, T; Corey, L; McElrath, MJ			Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; HIV-1 INFECTION; LYMPHOCYTE ACTIVITY; LIMITING DILUTION; IMMUNE-RESPONSES; VACCINIA VIRUS; GAG; VIREMIA; GENE; INDIVIDUALS	Background Early in human immunodeficiency virus type 1 (HIV-1) infection there is a decline in viral replication that has been attributed to host immunity, but the components of this response, particularly the ability of cytotoxic T lymphocytes to control viral burden and influence the outcome of disease, are poorly understood. Methods We prospectively studied 33 patients with primary HIV-1 infection for HIV-specific activated cytotoxic T lymphocytes and memory cytotoxic T lymphocytes and compared these lymphocyte responses with changes in viral load and clinical status over the subsequent 18 to 24 months. Results Soon after infection, activated HIV-specific cytotoxic T lymphocytes, mediated primarily by CD8+ cells, were detected in 17 of 23 patients (74 percent). Memory cytotoxic T lymphocytes were found in 6 of 6 patients tested (100 percent) during the first three months of infection and in 17 of 21 patients (81 percent) tested during the first six months. The frequencies of memory cytotoxic T lymphocytes varied markedly over time, but overall they declined over the first 6 to 8 months and then stabilized over the next 12 to 18 months. The patients with higher frequencies of Env-specific memory cytotoxic T lymphocytes had a median level of plasma HIV-1 RNA about one third that of the patients with lower frequencies (median number of RNA copies per milliliter, 22,000 vs. 62,000; P=0.006). Patients with low frequencies of Env-specific memory cytotoxic T lymphocytes (or none) in early infection had a more rapid decline to less than 300 CD4+ cells per cubic millimeter (P=0.05). Conclusions In early HIV-1 infection, the induction of memory cytotoxic T lymphocytes, particularly those specific for Env, helps control viral replication and is associated with slower declines in CD4+ cell counts. Host cytolytic effector responses appear to delay the progression of HIV-1 disease. (C) 1997, Massachusetts Medical Society.	FRED HUTCHINSON CANC RES CTR,PROGRAM INFECT DIS,DIV CLIN RES,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, R01AI035605, R37AI035605] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35605, AI 05065, AI 27757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; Cleveland W.S., 1993, STAT METHODS S, P309; CLOUSE KA, 1989, J CLIN MICROBIOL, V27, P2316, DOI 10.1128/JCM.27.10.2316-2323.1989; Dalod M, 1996, AIDS RES HUM RETROV, V12, P497, DOI 10.1089/aid.1996.12.497; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; Efron Bradley., 1994, INTRO BOOTSTRAP; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FLEXNER C, 1988, VIROLOGY, V166, P339, DOI 10.1016/0042-6822(88)90504-1; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Kagi D, 1995, EUR J IMMUNOL, V25, P3256, DOI 10.1002/eji.1830251209; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LAMHAMEDICHERRADI S, 1995, AIDS, V9, P421, DOI 10.1097/00002030-199509050-00002; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MCFARLAND EJ, 1993, J INFECT DIS, V167, P719, DOI 10.1093/infdis/167.3.719; MCFARLAND EJ, 1994, J INFECT DIS, V170, P766, DOI 10.1093/infdis/170.4.766; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Musey L, 1997, J EXP MED, V185, P293, DOI 10.1084/jem.185.2.293; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903; Schacker T, 1997, ANN INTERN MED, V126, P174, DOI 10.7326/0003-4819-126-2-199701150-00024; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SHPAER EG, 1994, AIDS RES HUM RETROV, V10, P1679, DOI 10.1089/aid.1994.10.1679; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; SWAIN SL, 1979, J IMMUNOL, V123, P1062; TASWELL C, 1981, J IMMUNOL, V126, P1614; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537	42	464	492	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1267	1274		10.1056/NEJM199710303371803	http://dx.doi.org/10.1056/NEJM199710303371803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345075				2022-12-24	WOS:A1997YC92000003
J	Uehata, M; Ishizaki, T; Satoh, H; Ono, T; Kawahara, T; Morishita, T; Tamakawa, H; Yamagami, K; Inui, J; Maekawa, M; Narumiya, S				Uehata, M; Ishizaki, T; Satoh, H; Ono, T; Kawahara, T; Morishita, T; Tamakawa, H; Yamagami, K; Inui, J; Maekawa, M; Narumiya, S			Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension	NATURE			English	Article							SERINE/THREONINE KINASE; SIGNAL-TRANSDUCTION; BINDING; PHOSPHATASE; CONTRACTION; INHIBITION; FAMILY; GTPASE; CA-2+; BRAIN	Abnormal smooth-muscle contractility may be a major cause of disease states such as hypertension, and a smooth-muscle relaxant that modulates this process would be useful therapeutically. Smooth-muscle contraction is regulated by the cytosolic Ca2+ concentration and by the Ca2+ sensitivity of myofilaments(1): the former activates myosin light-chain kinase and the latter is achieved partly by inhibition of myosin phosphatase(1-3). The small GTPase Rho and its target, Rho-associated kinase, participate in this latter mechanism in vitro(4-6), but their participation has not been demonstrated in intact muscles. Here we show that a pyridine derivative, Y-27632, selectively inhibits smooth-muscle contraction by inhibiting Ca2+ sensitization. We identified the Y-27632 target as a Rho-associated protein kinase, p160ROCK(7). Y-27632 consistently suppresses Rho-induced, p160ROCK-mediated formation of stress fibres in cultured cells and dramatically corrects hypertension in several hypertensive rat models. Our findings indicate that p160ROCK-mediated Ca2+ sensitization is involved in the pathophysiology of hypertension and suggest that compounds that inhibit this process might be useful therapeutically.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 60601,JAPAN	Kyoto University	Uehata, M (corresponding author), YOSHITOMI PHARMACEUT IND LTD,DISCOVERY RES TOKYO,IRUMA,SAITAMA 358,JAPAN.		Yamagami, Keiji/E-9500-2012					ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BUBIN CS, 1974, METHOD ENZYMOL, V38, P308; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SATOH H, 1984, EUR J PHARMACOL, V97, P321, DOI 10.1016/0014-2999(84)90468-0; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; TAKAYASU M, 1986, J NEUROSURG, V65, P80, DOI 10.3171/jns.1986.65.1.0080; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1	29	2432	2582	1	117	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					990	994		10.1038/40187	http://dx.doi.org/10.1038/40187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353125				2022-12-24	WOS:A1997YD29900061
J	Patterson, C; Rosenthal, C				Patterson, C; Rosenthal, C			Living a little more dangerously	LANCET			English	Article							HEALTH; RISK; DISCOURSE		MCMASTER UNIV,OFF GERONTOL STUDIES,HAMILTON,ON,CANADA	McMaster University	Patterson, C (corresponding author), MCMASTER UNIV,DIV GERIATR MED,HAMILTON,ON L8N 3Z5,CANADA.							*ASS RES SCI ENJ, 1997, WORKSH VAL PLEAS QUE; CONNIDIS I, 1987, AGING CANADA SOCIAL, P451; KAUFMAN SR, 1994, MED ANTHROPOL Q, V8, P430, DOI 10.1525/maq.1994.8.4.02a00060; LAVE LB, 1987, SCIENCE, V236, P291, DOI 10.1126/science.3563509; LUPTON D, 1993, INT J HEALTH SERV, V23, P425, DOI 10.2190/16AY-E2GC-DFLD-51X2; MACMILLAN MS, 1994, J ADV NURS, V29, P249; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Tierney MC, 1997, CAN J AGING, V16, P177, DOI 10.1017/S0714980800014288	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1164	1165		10.1016/S0140-6736(97)08231-7	http://dx.doi.org/10.1016/S0140-6736(97)08231-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB199	9343519				2022-12-24	WOS:A1997YB19900047
J	OssarehNazari, B; Bachelerie, F; Dargemont, C				OssarehNazari, B; Bachelerie, F; Dargemont, C			Evidence for a role of CRM1 in signal-mediated nuclear protein export	SCIENCE			English	Article							ORDER CHROMOSOME STRUCTURE; LOCALIZATION SIGNALS; IMPORT FACTOR; LEPTOMYCIN-B; REV PROTEIN; IDENTIFICATION; YEAST; TRANSPORT; INTERACTS; PATHWAY	Chromosome maintenance region 1 (CRM1), a protein that shares sequence similarities with the karyopherin beta family of proteins involved in nuclear import pathway, was shown to form a complex with the leucine-rich nuclear export signal (NES), This interaction was inhibited by leptomycin B, a drug that prevents the function of the CRM1 protein in yeast, To analyze the role of the CRM1-NES interaction in nuclear export, a transport assay based on semipermeabilized cells was developed. In this system, which reconstituted NES-, cytosol-, and energy-dependent nuclear export, leptomycin B specifically blocked export of NES-containing proteins, Thus, the CRM1 protein could act as a NES receptor involved in nuclear protein export.	INST CURIE,CNRS,UMR 144,F-75248 PARIS 05,FRANCE; INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			BACHELERIE, FRANCOISE/F-8823-2013	BACHELERIE, FRANCOISE/0000-0002-0399-3277				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MELCHIOR F, 1993, J CELL BIOL, V123, P215; MICHAEL WM, 1995, CELL, V83, P415; MICHAEL WM, 1997, EMBO J, V12, P3587; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NISHI K, 1994, J BIOL CHEM, V269, P6320; OSSAREHNAZARI B, UNPUB; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; ROUT M, 1997, LCELL, V89, P715; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	37	616	627	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					141	144		10.1126/science.278.5335.141	http://dx.doi.org/10.1126/science.278.5335.141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311922				2022-12-24	WOS:A1997XZ12400058
J	Albillos, A; Dernick, G; Horstmann, H; Almers, W; deToledo, GA; Lindau, M				Albillos, A; Dernick, G; Horstmann, H; Almers, W; deToledo, GA; Lindau, M			The exocytotic event in chromaffin cells revealed by patch amperometry	NATURE			English	Article							ADRENAL-MEDULLARY CELLS; FUSION PORE; TRANSMITTER RELEASE; TIME-COURSE; SECRETORY GRANULES; SINGLE VESICLES; CATECHOLAMINES; FORMS	In mast cells and granulocytes, exocytosis starts with the formation of a fusion pore(1-3). It has been suggested that neurotransmitters may be released through such a narrow pore without full fusion(4,5). However, owing to the small size of the secretory vesicles containing neurotransmitter, the properties of the fusion pore formed during Ca2+-dependent exocytosis and its role in transmitter release are still unknown, Here we investigate exocytosis of individual chromaffin granules by using cell-attached capacitance measurements(3,6) combined,vith electrochemical detection of catecholamines(7,8), achieved by inserting a carbon-fibre electrode into the patch pipette. This allows the simultaneous determination of the opening of individual fusion pores and of the kinetics of catecholamine release from the same vesicle, We found that the fusion-pore diameter stays at <3 nm for a variable period, which can last for several seconds, before it expands, Transmitter is released much faster through this pore than in mast cells, generating a 'foot' signal(8) which precedes the amperometric spike. Occasionally, the narrow pore forms only transiently and does not expand, allowing complete transmitter release without full fusion of the vesicle with the plasma membrane.	MPI MED RES,DEPT MOL & CELL RES,D-69128 HEIDELBERG,GERMANY; UNIV SEVILLA,DEPT PHYSIOL & BIOPHYS,E-41009 SEVILLE,SPAIN	University of Sevilla			Alvarez de Toledo, Guillermo/I-2888-2015; Lindau, Manfred/ABD-3449-2021; Albillos, Almudena/AAA-9098-2019	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Lindau, Manfred/0000-0002-5722-9557; ALBILLOS, ALMUDENA/0000-0003-3315-9715				ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; BACH G, 1967, QUANTITATIVE METHODS, P23; BAUR JE, 1988, ANAL CHEM, V60, P1268, DOI 10.1021/ac00164a006; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Chen BM, 1997, J NEUROSCI, V17, P904; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow RH, 1996, NEURON, V16, P369, DOI 10.1016/S0896-6273(00)80054-9; Chow Robert H., 1995, P245; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; GASNIER B, 1987, FEBS LETT, V222, P215, DOI 10.1016/0014-5793(87)80222-3; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; JANKOWSKI JA, 1993, J BIOL CHEM, V268, P14694; LOLLIKE K, 1995, J CELL BIOL, V129, P99, DOI 10.1083/jcb.129.1.99; Moser T, 1995, PFLUG ARCH EUR J PHY, V431, P196, DOI 10.1007/BF00410191; NEHER E, 1993, NATURE, V363, P497, DOI 10.1038/363497a0; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; SCHERMAN D, 1988, NEUROSCIENCE, V27, P1029, DOI 10.1016/0306-4522(88)90207-2; SPRUCE AE, 1990, NEURON, V4, P643, DOI 10.1016/0896-6273(90)90192-I; Walker A, 1996, PFLUG ARCH EUR J PHY, V431, P729, DOI 10.1007/s004240050058; Walker A, 1996, PFLUG ARCH EUR J PHY, V432, P885, DOI 10.1007/s004240050212; WIGHTMAN RM, 1995, BIOPHYS J, V68, P383, DOI 10.1016/S0006-3495(95)80199-2; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Zhou Z, 1996, BIOPHYS J, V70, P1543, DOI 10.1016/S0006-3495(96)79718-7; ZIMMERBERG J, 1987, P NATL ACAD SCI USA, V84, P1585, DOI 10.1073/pnas.84.6.1585	30	461	469	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					509	512		10.1038/39081	http://dx.doi.org/10.1038/39081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333242				2022-12-24	WOS:A1997XY90900060
J	Nightingale, SL				Nightingale, SL			New requirement for pediatric data on drug products proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, JAMA-J AM MED ASSOC, V273, P279	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-24	WOS:A1997XX30300008
J	Warner, KE; Slade, J; Sweanor, DT				Warner, KE; Slade, J; Sweanor, DT			The emerging market for long-term nicotine maintenance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTES; TOBACCO; GUM; ADDICTION; SMOKING	In increasing numbers, Americans will seek to satisfy nicotine addictions through the use of novel nicotine-delivery products devoid of several of the poisons that make cigarettes so deadly. In the vanguard are tobacco industry devices that heat tobacco derivatives rather than burn tobacco, and pharmaceutical industry nicotine-replacement products, with nicotine gum and the patch now available over the counter. Ostensibly, these 2 industries have diametrically opposed objectives, the tobacco industry striving to sustain nicotine addictions, the pharmaceutical industry to end them. However, a series of technological, economic, political, regulatory, and social developments augurs a strange-bedfellows competition in which these industries will vie for shares of a new multibillion dollar long-term nicotine-maintenance market. Regulatory options range from encouraging competition to banning all nicotine-delivery devices. A more realistic approach discourages use of the most dangerous products, while making less hazardous products readily available to adults.	UNIV MED & DENT NEW JERSEY, DEPT MED, NEW BRUNSWICK, NJ USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, ST PETERS MED CTR, NEW BRUNSWICK, NJ 08903 USA; NON SMOKERS RIGHTS ASSOC, OTTAWA, ON, CANADA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Warner, KE (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH, DEPT HLTH MANAGEMENT & POLICY, 109 S OBSERV, ANN ARBOR, MI 48109 USA.			Warner, Kenneth/0000-0002-8214-1776				*ASH, 1996, ASH SMOK HLTH RE MAY, P2; Benowitz NL, 1997, J AM COLL CARDIOL, V29, P1422, DOI 10.1016/S0735-1097(97)00079-X; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; BENOWITZ NL, 1996, NIH PUBLICATION, P93; BRODER K, 1990, J NATL CANCER I, V82, P8, DOI 10.1093/jnci/82.1.8; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; CAMPBELL WI, 1994, REGULATION TOBACCO P, P542; Cunningham R, 1995, TOB CONTROL, V4, P80, DOI DOI 10.1136/TC.4.1.80; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DAVIS RM, 1993, TOB CONTROL, V2, P11; Eliasson B, 1996, CIRCULATION, V94, P878, DOI 10.1161/01.CIR.94.5.878; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; GIOVINO GA, 1996, NIH PUBLICATION, P39; Glantz S.A., 1996, CIGARETTE PAPERS; GORI GB, 1978, JAMA-J AM MED ASSOC, V240, P1255; HARRIS JE, 1994, 4803 NBER; HEISHMAN SJ, 1993, DRUG ALCOHOL DEPEN, V34, P11, DOI 10.1016/0376-8716(93)90041-N; Heishman SJ, 1994, EXP CLIN PSYCHOPHARM, V2, P345, DOI 10.1037/1064-1297.2.4.345; HENNINGFIELD JE, 1996, NATL I HLTH PUBLICAT, P113; HILTS PJ, 1994, NY TIMES        1127, P1; Hilts PJ, 1996, SMOKE SCREEN TRUTH T; HILTS PJ, 1994, NY TIMES        1127, P13; HOLBROOK J, 1983, HARRISONS PRINCIPLES, P1303; HUGHES JR, 1995, TOB CONTROL, V4, pS33; HWANG SL, 1996, WALL STREET J   0521; JAMIESON S, 1997, CHARLOTTE OBSER 0317, pE1; JARVIK ME, 1993, NICOTINE ADDICTION P, P245; JIMENEZRUIZ C, 1997, NICOTINE REPLACEMENT; KLUGER R, 1996, ASHES ASHES AM HUNDR; KOZLOWSKI LT, 1996, NAT I HLTH PUBLICATI, P161; Leischow SJ, 1996, AM J HEALTH BEHAV, V20, P364; LEISCHOW SJ, 1996, J ADDICT DIS, V15, P146; LONGO WE, 1995, CANCER RES, V55, P2232; Mahood G., 1995, TOB CONTROL, V4, P10, DOI [10.1136/tc.4.1.10, DOI 10.1136/TC.4.1.10]; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Murray RP, 1996, CHEST, V109, P438, DOI 10.1378/chest.109.2.438; Oster G, 1996, MED CARE, V34, P389, DOI 10.1097/00005650-199605000-00002; PAULY JL, 1995, TOB CONTROL, V4, P261, DOI DOI 10.1136/TC.4.3.261; Puska P., 1995, TOB CONTROL, V4, P231, DOI [DOI 10.1136/TC.4.3.231, 10.1136/tc.4.3.231]; RJ Reynolds Tobacco Co, 1988, CHEM BIOL STUD NEW C; Rodu B., 1995, SMOKERS ONLY SMOKELE; RUSSELL MAH, 1991, BRIT J ADDICT, V86, P653; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; SCHWARTZ J, 1997, WASH POST       0426, pA1; SLADE J, 1989, J PSYCHOACTIVE DRUGS, V21, P281, DOI 10.1080/02791072.1989.10472169; SLADE J, 1993, NICOTINE ADDICTION P, P3; SLADE J, 1992, TOBACCO CONTROL S, V1, pS10; Smith CJ, 1996, MUTAT RES-ENVIR MUTA, V361, P1, DOI 10.1016/S0165-1161(96)90222-8; Steimle S, 1996, J NATL CANCER I, V88, P1341, DOI 10.1093/jnci/88.19.1341; *TOB HLTH PROGR, IN PRESS GUID CONTR; TOMAR SL, 1996, TOB CONTROL, V5, P77; U.S. Department of Health and Human Services, 1990, US DEP HLTH HUM SERV; *US DEP HHS, 1996, FED REGISTER, V61, P44396; *US DEP HHS, 1996, NAT I HLTH PUBL; US Department of Health and Human Services, 1988, US DEP HLTH HUM SERV, VCDC 88-8406; US Department of Health and Human Services National Center for Health Statistics, 1989, US DEP HLTH HUM SERV, V169; WEST R, 1991, BRIT J ADDICT, V86, P485; WILKE M, 1996, ADVERTISING AGE 0819, P10; WILLNER JS, 1983, FAMILY MED, P1662	59	72	73	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1087	1092		10.1001/jama.278.13.1087	http://dx.doi.org/10.1001/jama.278.13.1087			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315768				2022-12-24	WOS:A1997XX30300033
J	Steinhoff, MC; AbdElKhalek, MK; Khallaf, N; Hamza, HS; ElAyadi, A; Orabi, A; Fouad, H; Kamei, M				Steinhoff, MC; AbdElKhalek, MK; Khallaf, N; Hamza, HS; ElAyadi, A; Orabi, A; Fouad, H; Kamei, M			Effectiveness of clinical guidelines for the presumptive treatment of streptococcal pharyngitis in Egyptian children	LANCET			English	Article							RHEUMATIC HEART-DISEASE; DEVELOPING-COUNTRIES; DIAGNOSIS; FEVER; PREVENTION; MANAGEMENT	Background Primary prevention of acute rheumatic fever requires antibiotic treatment of acute streptococcal pharyngitis. In developing countries, clinicians must rely on clinical guidelines for presumptive treatment of streptococcal pharyngitis since bacterial culture and rapid diagnostic tests are not feasible. We evaluated the WHO Acute Respiratory Infection guideline in a large urban paediatric clinic in Egypt. Methods Children between 2 and 13 years of age who had a sore throat and pharyngeal erythema were enrolled in the study. Clinical, historical, and demographic information was recorded and a throat culture for group A P-haemolytic streptococci was done. Sensitivity (% of true-positive throat cultures) and specificity (% of true-negative throat cultures] were calculated for each clinical feature. The effect of various guidelines on correct presumptive treatment for throat-culture status was calculated. Findings Of 451 children with pharyngitis, 107 (24%) had group A beta-haemolytic streptococci on throat culture. A purulent exudate was seen in 22% (99/450) of these children and this sign was 31% sensitive and 81% specific for a positive culture. The WHO Acute Respiratory Infections [ARI) guidelines, which suggest treatment for pharyngeal exudate plus enlarged and tender cervical node, were 12% sensitive and 94% specific; 13/107 children with a positive throat culture would correctly receive antibiotics and 323/344 with a negative throat culture would, correctly, not receive antibiotics. Based on our data we propose a modified guideline whereby exudate or large cervical nodes would indicate antibiotic treatment, and this guideline would be 84% sensitive and 40% specific; 90/107 children with a positive throat culture would correctly receive antibiotics and 138/344 with a negative throat culture would, correctly, not receive antibiotics. Interpretation The WHO ARI clinical guideline has a high specificity but low sensitivity that limits the unnecessary use of antibiotics, but does not treat 88% of children with a positive streptococcal throat culture who are al risk of acute rheumatic fever. A modified guideline may be more useful in this population. Prospective studies of treatment guidelines from many regions are needed to assess their use since the frequency of pharyngitis varies.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; CAIRO UNIV,ABU REESH HOSP,SCH MED,CAIRO,EGYPT; MINIST HLTH CAIRO,CAIRO,EGYPT	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt	Steinhoff, MC (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,624 N BROADWAY,SUITE 125,BALTIMORE,MD 21205, USA.							AGARWAL BL, 1981, LANCET, V2, P910; *AM AC PED COMM IN, 1994, RED BOOK, P430; ARGUEDAS A, 1992, J PEDIATR-US, V121, P569, DOI 10.1016/S0022-3476(05)81146-1; BREESE BB, 1954, J PEDIATR-US, V44, P670, DOI 10.1016/S0022-3476(54)80008-4; CHERAYIL BJ, 1987, TROP PEDIAT, V33, P157; DIPPEL DWJ, 1992, J FAM PRACTICE, V34, P149; EISENBERG MJ, 1993, EUR HEART J, V4, P122; el-Kholy A, 1973, J Med Microbiol, V6, P101; ELKHOLY A, 1980, J INFECT DIS, V141, P759, DOI 10.1093/infdis/141.6.759; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; MAJEED HA, 1993, ANN TROP PAEDIATR, V13, P65, DOI 10.1080/02724936.1993.11747626; MARKOWITZ M, 1991, PEDIATR INFECT DIS J, V10, pS11, DOI 10.1097/00006454-199110001-00003; MARKOWITZ M, 1985, J PEDIATR-US, V106, P545, DOI 10.1016/S0022-3476(85)80069-X; MCLAREN MJ, 1994, ANN INTERN MED, V120, P243, DOI 10.7326/0003-4819-120-3-199402010-00012; *RHEUM FEV COMM AM, 1977, THROAT CULT RAT TREA; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P80; SOROUR AH, 1969, J EGYPT MED ASS S8, V52, P1; TILLERMAN M, 1961, AM J DIS CHILD, V101, P476; WANNAMAKER LW, 1972, AM J DIS CHILD, V124, P352, DOI 10.1001/archpedi.1972.02110150050009; WANNAMAKER LW, 1984, MANAGEMENT PHARYNGIT, P25; *WHO, 1995, B WORLD HEALTH ORGAN, V73, P735; *WHO, 1991, WHOARI905, P41; *WHO, 1994, JOINT WHO ISFC M PRI, P4; 1995, B WORLD HEALTH ORGAN, V73, P583	25	64	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					918	921		10.1016/S0140-6736(97)03317-5	http://dx.doi.org/10.1016/S0140-6736(97)03317-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314870				2022-12-24	WOS:A1997XY67200010
J	Pan, ZZ; Tershner, SA; Fields, HL				Pan, ZZ; Tershner, SA; Fields, HL			Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor	NATURE			English	Article							MORPHINE ANALGESIA; MEDULLARY MU; DEPENDENCE; TOLERANCE; REWARD; PHARMACOLOGY; DYNORPHIN; PEPTIDES; PATHWAYS; MODULATE	The analgesic effect of clinically used exogenous opioids, such as morphine, is mediated primarily through mu-opioid receptors(1-3), but the function of the kappa-receptor in opioid analgesia is unclear. Although kappa-receptor agonists can produce analgesia(4,5), behavioural studies indicate that kappa agonists applied intravenously or locally into the spinal cord antagonize morphine analgesia (see refs 4, 6 for reviews). As morphine, a primary mu agonist(1), also binds to kappa-receptors(7) and the analgesic effectiveness of morphine decreases with repeated use (tolerance), it is important to understand the mechanism for the functional interaction between kappa- and mu-opioid receptors in the central nervous system. Here we present in vitro electrophysiological and in vivo behavioural evidence that activation of the kappa-receptor specifically antagonizes mu-receptor-mediated analgesia. We show that in slice preparations of a rat brainstem nucleus, which is critical for the action of opioids in controlling pain, functional kappa- and mu-receptors are each localized on physiologically different types of neuron. Activation of the kappa-receptor hyperpolarizes neurons that are activated indirectly by the mu-receptor. In rats, kappa-receptor activation in this brainstem nucleus significantly attenuates local mu-receptor-mediated analgesia. Our findings suggest a new cellular mechanism for the potentially ubiquitous opposing interaction between mu- and kappa-opioid receptors and may help in the design of treatments for pain.			Pan, ZZ (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK CTR INTEGRAT NEURSCI,SAN FRANCISCO,CA 94143, USA.		Fields, Howard/ABG-9073-2020					AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BHARGAVA HN, 1994, PHARMACOL REV, V46, P293; Bolanos CA, 1996, EUR J PHARMACOL, V317, P1, DOI 10.1016/S0014-2999(96)00698-X; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; FIELDS HL, 1983, NATURE, V306, P684, DOI 10.1038/306684a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; FUNADA M, 1993, NEUROPHARMACOLOGY, V32, P1315; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRUDT TJ, 1993, P NATL ACAD SCI USA, V90, P11429, DOI 10.1073/pnas.90.23.11429; HOOKE LP, 1995, J PHARMACOL EXP THER, V273, P292; KIEFEL JM, 1993, BRAIN RES, V624, P151, DOI 10.1016/0006-8993(93)90073-V; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MARTIN WR, 1983, PHARMACOL REV, V35, P283; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MILLAN MJ, 1990, TRENDS PHARMACOL SCI, V11, P70, DOI 10.1016/0165-6147(90)90321-X; PAN ZZ, 1990, J PHYSIOL-LONDON, V427, P519, DOI 10.1113/jphysiol.1990.sp018185; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206; Roychowdhury SM, 1996, NEUROSCIENCE, V74, P863, DOI 10.1016/0306-4522(96)00180-7; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	29	134	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					382	385		10.1038/38730	http://dx.doi.org/10.1038/38730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311779				2022-12-24	WOS:A1997XX67500052
J	Rackoff, P; Feldman, T				Rackoff, P; Feldman, T			Total lymphoid irradiation - not for rheumatoid arthritis	LANCET			English	Editorial Material							TERM FOLLOW-UP				Rackoff, P (corresponding author), BETH ISRAEL MED CTR,DIV RHEUMATOL,NEW YORK,NY 10003, USA.			Rackoff, Paula/0000-0002-4669-2116				HUBERT G, 1985, ARTHRITIS RHEUM, V28, P1205; SODEN M, 1989, ARTHRITIS RHEUM, V32, P523, DOI 10.1002/anr.1780320503; TANAY A, 1987, ARTHRITIS RHEUM-US, V30, P1, DOI 10.1002/art.1780300101; TRENTHAM DE, 1987, ARTHRITIS RHEUM, V30, P980, DOI 10.1002/art.1780300904; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; Westhovens R, 1997, ARTHRITIS RHEUM, V40, P426, DOI 10.1002/art.1780400306	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					752	753		10.1016/S0140-6736(97)22037-4	http://dx.doi.org/10.1016/S0140-6736(97)22037-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297989				2022-12-24	WOS:A1997XW28200004
J	Nightingale, SL				Nightingale, SL			Workshop on minimizing medical product errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-24	WOS:A1997YC91700008
J	Matilla, A; Koshy, BT; Cummings, C; Isobe, T; Orr, HT; Zoghbi, HY				Matilla, A; Koshy, BT; Cummings, C; Isobe, T; Orr, HT; Zoghbi, HY			The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1	NATURE			English	Article							EXPRESSION ANALYSIS; TYPE-1; GENE; REPEAT; CONSTRUCTION; CLONING; MATRIX; YEAST; SCA1	Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells(1). SCA1 belongs to a growing group of neurodegenerative disorders caused by expansion of CAG repeats, which encode glutamine(2). Although the proteins containing these repeats are widely expressed, the neurodegeneration in SCA1 and other polyglutamine diseases selectively involves a few neuronal subtypes. The mechanism(s) underlying this neuronal specificity is unknown. Here we show that the cerebellar leucine-rich acidic nuclear protein (LANP)(3) interacts with ataxin-1, the SCA1 gene product. LANP is expressed predominantly in Purkinje cells, the primary site of pathology in SCAT. The interaction between LANP and ataxin-1 is significantly stronger when the number of glutamines is increased. Immunofluorescence studies demonstrate that both LANP and ataxin-1 colocalize in nuclear matrix-associated subnuclear structures. The features of the interaction between ataxin-1 and LANP, their spatial and temporal patterns of expression, and the colocalization studies indicate that cerebellar LANP is involved in the pathogenesis of SCA1.	BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CELL & MOL BIOL PROGRAM,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,TOKYO 158,JAPAN; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,INST HUMAN GENET,MINNEAPOLIS,MN 55455	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Tokyo Metropolitan University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			MATILLA-DUEÑAS, ANTONI/C-7980-2011; Isobe, Toshiaki/Q-9279-2017	MATILLA-DUEÑAS, ANTONI/0000-0002-3514-4181; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X				Banfi S, 1996, HUM MOL GENET, V5, P33, DOI 10.1093/hmg/5.1.33; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARPER JW, 1993, CELL, V75, P805; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; MATILLA A, UNPUB P NATL ACAD SC; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SMITH KE, 1995, FEBS LETT, V357, P86, DOI 10.1016/0014-5793(94)01328-X; WONG YHH, 1987, J NEUROCHEM, V48, P1434, DOI 10.1111/j.1471-4159.1987.tb05682.x; ZOGHBI H, 1985, SEMIN CELL BIOL, V6, P29	22	215	223	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					974	978		10.1038/40159	http://dx.doi.org/10.1038/40159			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353121				2022-12-24	WOS:A1997YD29900057
J	Bonita, R				Bonita, R			Added years, onus or bonus?	LANCET			English	Article											Bonita, R (corresponding author), UNIV AUCKLAND,N SHORE HOSP,FAC MED & HLTH SCI,PRIVATE BAG 93-503,AUCKLAND 1,NEW ZEALAND.							ALVAREZ J, 1995, WORLD HEALTH FORUM, V16, P361; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; Bonita Ruth, 1996, World Health Statistics Quarterly, V49, P134; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MCCALLUM J, 1997, AGEING SOCIAL POLICY; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; ROBINE JM, 1997, REV CLIN GERONTOLOGY, V7, P73; SEN K, 1994, AGEING DEBATES DEMOG; van den Bos GAM, 1995, EUR J PUBLIC HEALTH, V5, P29, DOI DOI 10.1093/EURPUB/5.1.29; [WHO] World Health Organization, 1997, HLTH ENV SUST DEV 5; *WORLD BANK, 1996, HUM DEV REP 1995	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1167	1168		10.1016/S0140-6736(97)08459-6	http://dx.doi.org/10.1016/S0140-6736(97)08459-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343521				2022-12-24	WOS:A1997YB19900049
J	Bonni, A; Sun, Y; NadalVicens, M; Bhatt, A; Frank, DA; Rozovsky, I; Stahl, N; Yancopoulos, GD; Greenberg, ME				Bonni, A; Sun, Y; NadalVicens, M; Bhatt, A; Frank, DA; Rozovsky, I; Stahl, N; Yancopoulos, GD; Greenberg, ME			Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; FIBRILLARY ACIDIC PROTEIN; CEREBRAL-CORTEX; CNTF RECEPTOR; TRANSCRIPTION; CELLS; GENE; GFAP; DIFFERENTIATION; NEUROGENESIS	A mechanism by which members of the ciliary neurotrophic factor (CNTF)-leukemia inhibitory factor cytokine family regulate gliogenesis in the developing mammalian central nervous system was characterized, Activation of the CNTF receptor promoted differentiation of cerebral cortical precursor cells into astrocytes and inhibited differentiation of cortical precursors along a neuronal lineage, Although CNTF stimulated both the Janus kinase-signal transducer and activator of transcription (JAK-STAT) and Ras-mitogen-activated protein kinase signaling pathways in cortical precursor cells, the JAK-STAT signaling pathway selectively enhanced differentiation of these precursors along a glial lineage, These findings suggest that cytokine activation of the JAK-STAT signaling pathway may be a mechanism by which cell fate is controlled during mammalian development.	CHILDRENS HOSP,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,NEUROGERONTOL DIV,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT SCI BIOL,LOS ANGELES,CA 90089; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Southern California; University of Southern California; Regeneron					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43855] Funding Source: Medline; NICHD NIH HHS [NIHP30-HD 18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BESNARD F, 1991, J BIOL CHEM, V266, P18877; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BONNI A, UNPUB; CONDORELLI DF, 1994, J NEUROSCI RES, V39, P694, DOI 10.1002/jnr.490390610; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kahn MA, 1997, J NEUROCHEM, V68, P1413; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Richards LJ, 1996, EUR J NEUROSCI, V8, P291, DOI 10.1111/j.1460-9568.1996.tb01213.x; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Sun Y, 1996, MOL CELL NEUROSCI, V7, P152, DOI 10.1006/mcne.1996.0012; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WALSH C, 1988, SCIENCE, V241, P1342, DOI 10.1126/science.3137660; WARE CB, 1995, DEVELOPMENT, V121, P1283; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Williams BP, 1997, NEURON, V18, P553, DOI 10.1016/S0896-6273(00)80297-4; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; ZIA Z, 1995, J NEUROSCI, V16, P5425	35	809	835	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					477	483		10.1126/science.278.5337.477	http://dx.doi.org/10.1126/science.278.5337.477			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334309				2022-12-24	WOS:A1997YB35500049
J	Brzozowski, AM; Pike, ACW; Dauter, Z; Hubbard, RE; Bonn, T; Engstrom, O; Ohman, L; Greene, GL; Gustafsson, JA; Carlquist, M				Brzozowski, AM; Pike, ACW; Dauter, Z; Hubbard, RE; Bonn, T; Engstrom, O; Ohman, L; Greene, GL; Gustafsson, JA; Carlquist, M			Molecular basis of agonism and antagonism in the oestrogen receptor	NATURE			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; IDENTIFICATION; MECHANISMS; ACTIVATION; COMPLEX; SITES	Oestrogens are involved in the growth, development and homeostasis of a number of tissues(1). The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER)(2). Hormone binding to the ligand-binding domain (LED) of the ER initiates a series of molecular events culminating in the activation or repression of target genes, Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery(3,4). Here we report the crystal structures of the LED of ER in complex with the endogenous oestrogen, 17 beta-oestradiol, and the selective antagonist raloxifene(5), at resolutions of 3.1 and 2.6 Angstrom, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties, Agonist and antagonist bind at the same site within the core of the LED but demonstrate different binding modes, In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LED, providing structural evidence of the mechanism of antagonism.	UNIV YORK, DEPT CHEM, PROT STRUCT GRP, YORK YO1 5DD, N YORKSHIRE, ENGLAND; KARO BIO AB, NOVUM, S-14157 HUDDINGE, SWEDEN; UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; KAROLINSKA INST, S-14186 HUDDINGE, SWEDEN	University of York - UK; Karolinska Institutet; University of Chicago; Karolinska Institutet								Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/edrv-17-6-587; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CIOCCA DR, 1995, ENDOCR REV, V16, P35, DOI 10.1210/er.16.1.35; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Draper MW, 1996, J BONE MINER RES, V11, P835; Ekena K, 1997, J BIOL CHEM, V272, P5069, DOI 10.1074/jbc.272.8.5069; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Grese TA, 1997, J MED CHEM, V40, P146, DOI 10.1021/jm9606352; Hegy GB, 1996, STEROIDS, V61, P367, DOI 10.1016/0039-128X(96)00042-6; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; Laskowski R.A., 1993, J APPL CRYSTALLOGR A, V42, P140; LHorset F, 1996, MOL CELL BIOL, V16, P6029; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAKDEL F, 1993, MOL ENDOCRINOL, V7, P1408, DOI 10.1210/me.7.11.1408; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	29	2741	2837	4	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					753	758		10.1038/39645	http://dx.doi.org/10.1038/39645			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338790				2022-12-24	WOS:A1997YA95900061
J	Vernon, SJ; Coulthard, MG; Lambert, HJ; Keir, MJ; Matthews, JNS				Vernon, SJ; Coulthard, MG; Lambert, HJ; Keir, MJ; Matthews, JNS			New renal scarring in children who at age 3 and 4 years had had normal scans with dimercaptosuccinic acid: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY-TRACT INFECTION; REFLUX; SCARS; UROGRAPHY	Objective: To determine up to what age children remain at risk of developing a new renal scar from a urinary tract infection. Design: Follow up study. Families of children who had normal ultrasound scans and scanning with dimercaptosuccinic acid (DMSA) after referral with a urinary tract infection when aged 3 (209) or 4 (220) were invited to bring the children for repeat scans 2-11 years later. A history of infections since the original scan was obtained for children not having a repeat scan. Setting: Teaching hospital. Subjects: Children from three health districts in whom a normal scan had been obtained at age 3-4 years in 1985-1992 because of a urinary tract infection. Main outcome measure: Frequency of new renal scars in each age group. Results:In each group, about 97% of children either had repeat scanning (over 80%) or were confidently believed by their general practitioner or parent not to have had another urinary infection. The rate of further infections since the original scan was similar in the 3 and 4 year old groups (48/176 (27%) and 55/179 (31%)). Few children in either group known to have had further urinary infections did not have repeat scanning (3/209 (1.4%) and 4/220 (1.8%)). In the 3 year old group, 2.4% (5/209) had one or more new kidney scars at repeat scanning,(one sided 95% confidence interval up to 5.0%), whereas none of the 4 year olds did (one sided 95% confidence interval up to 1.4%). The children who developed scars were all aged under 3.4 years when scanned originally. Conclusions: Children with a urinary tract infection but unscarred kidneys after the third birthday have about a 1 in 40 risk of developing a scar subsequently but after the fourth birthday the risk is either very low or zero. Thus the need for urinary surveillance is much reduced in a large number of children.	ROYAL VICTORIA INFIRM, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; ROYAL VICTORIA INFIRM, DEPT MED PHYS, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT STAT, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK			Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X; Lambert, Heather/0000-0003-4389-4078				AGGARWAL VK, 1991, ARCH DIS CHILD, V66, P1284, DOI 10.1136/adc.66.11.1284; [Anonymous], 1991, J R Coll Physicians Lond, V25, P36; *BIRM REFL STUD GR, 1987, BRIT MED J, V293, P237; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; Brooks D, 1977, J R Coll Gen Pract, V27, P678; Coulthard MG, 1997, BMJ-BRIT MED J, V315, P918; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; HODSON CJ, 1965, BRIT MED J, V2, P191, DOI 10.1136/bmj.2.5455.191; JAKOBSSON B, 1994, ARCH DIS CHILD, V70, P111, DOI 10.1136/adc.70.2.111; MERRICK MV, 1980, BRIT J RADIOL, V53, P544, DOI 10.1259/0007-1285-53-630-544; OLBING H, 1992, J UROLOGY, V148, P1653, DOI 10.1016/S0022-5347(17)36995-1; RANSLEY PG, 1978, BR J RADIOL S, V14; ROLLESTON GL, 1974, ARCH DIS CHILD, V49, P531, DOI 10.1136/adc.49.7.531; SHAH KJ, 1978, ARCH DIS CHILD, V53, P210, DOI 10.1136/adc.53.3.210; SHIMADA K, 1989, International Urology and Nephrology, V21, P153, DOI 10.1007/BF02550803; SMELLIE JM, 1985, BRIT MED J, V290, P1957, DOI 10.1136/bmj.290.6486.1957; VERBER IG, 1989, ARCH DIS CHILD, V64, P1533, DOI 10.1136/adc.64.11.1533; VICKERS D, 1991, LANCET, V338, P767, DOI 10.1016/0140-6736(91)90662-9; WHITEAR P, 1990, BRIT J RADIOL, V63, P438, DOI 10.1259/0007-1285-63-750-438; WINTER AL, 1983, J UROLOGY, V129, P1190, DOI 10.1016/S0022-5347(17)52634-8	21	79	82	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					905	908						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361538				2022-12-24	WOS:A1997YB07300020
J	He, SG; Masland, RH				He, SG; Masland, RH			Retinal direction selectivity after targeted laser ablation of starburst amacrine cells	NATURE			English	Article							GANGLION-CELLS; RABBIT RETINA; CAENORHABDITIS-ELEGANS; MAMMALIAN RETINA; RECEPTIVE-FIELDS; CAT RETINA; ACETYLCHOLINE; IDENTIFICATION; RESPONSES; MECHANISM	Directionally selective retinal ganglion cells respond strongly when a stimulus moves in their preferred direction, but respond little or not at all when it moves in the opposite direction(1,2). This selectivity represents a classic paradigm of computation by neural microcircuits, but its cellular mechanism remains obscure. The directionally selective ganglion cells receive many synapses from a type of amacrine cell termed 'starburst' because of its regularly spaced, evenly radiating dendrites(3,4). Starburst amacrine cells have a synaptic asymmetry that has been proposed as the source of the directional response in the ganglion cells(5,6). Here we report experiments that make this unlikely, and offer an alternative concept of the function of starburst cells. We labelled starburst cells in living retinas, then killed them by targeted laser ablation while recording from individual directionally selective ganglion cells. Ablating starburst cells revealed no asymmetric contribution to the ganglion cell response. Instead of being direction discriminators, the starburst cells appear to potentiate generically the responses of ganglion cells to moving stimuli. The origin of direction selectivity probably lies with another type of amacrine cell.	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute								AMES AI, 1996, J NEUROCHEM, V37, P867; AMTHOR FR, 1993, VISUAL MOTION ITS RO; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P135, DOI 10.1113/jphysiol.1982.sp014104; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; Borg-Graham L.J., 1992, SINGLE NEURON COMPUT, P347; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; COHEN ED, 1995, P NATL ACAD SCI USA, V92, P1127, DOI 10.1073/pnas.92.4.1127; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; GRZYWACZ NM, 1993, J NEUROPHYSIOL, V69, P2188, DOI 10.1152/jn.1993.69.6.2188; HUBA R, 1992, BRAIN RES, V577, P10, DOI 10.1016/0006-8993(92)90531-D; JACOBS GA, 1986, J NEUROSCI, V6, P2298; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; MARCHIAFAVA PL, 1979, VISION RES, V19, P1203, DOI 10.1016/0042-6989(79)90185-8; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MASLAND RH, 1986, TRENDS NEUROSCI, V9, P218, DOI 10.1016/0166-2236(86)90062-7; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P79, DOI 10.1098/rspb.1984.0084; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; SCHMIDT M, 1987, J NEUROPHYSIOL, V58, P997, DOI 10.1152/jn.1987.58.5.997; Strettoi E, 1996, P NATL ACAD SCI USA, V93, P14906, DOI 10.1073/pnas.93.25.14906; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TAUCHI M, 1984, PROC R SOC SER B-BIO, V223, P101, DOI 10.1098/rspb.1984.0085; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; VANEY DI, 1991, PROG RETIN RES, V9, P1; VARDI N, 1989, J COMP NEUROL, V288, P601, DOI 10.1002/cne.902880407; YANG G, 1994, J NEUROSCI, V14, P5267	29	118	123	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					378	382		10.1038/38723	http://dx.doi.org/10.1038/38723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311778				2022-12-24	WOS:A1997XX67500051
J	Parker, L				Parker, L			Causes of testicular cancer	LANCET			English	Editorial Material							TRAUMA				Parker, L (corresponding author), UNIV NEWCASTLE UPON TYNE,SIR JAMES SPENCE INST CHILD HLTH,DEPT EPIDEMIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			PARKER, LOUISE/0000-0002-5188-8113				Buetow SA, 1995, EPIDEMIOL REV, V17, P433, DOI 10.1093/oxfordjournals.epirev.a036202; Greaves MF, 1996, LEUKEMIA, V10, P372; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JENSEN TK, 1995, CLIN CHEM, V41, P1896; STONE JM, 1991, CANCER, V68, P211, DOI 10.1002/1097-0142(19910701)68:1<211::AID-CNCR2820680139>3.0.CO;2-Q; SWERDLOW AJ, 1988, BRIT J UROL, V61, P518, DOI 10.1111/j.1464-410X.1988.tb05094.x; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507; WEISS L, 1990, J FORENSIC SCI, V35, P614	8	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					827	828		10.1016/S0140-6736(05)62028-4	http://dx.doi.org/10.1016/S0140-6736(05)62028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310598				2022-12-24	WOS:A1997XX40100006
J	Stade, K; Ford, CS; Guthrie, C; Weis, K				Stade, K; Ford, CS; Guthrie, C; Weis, K			Exportin 1 (Crm1p) is an essential nuclear export factor	CELL			English	Article							ORDER CHROMOSOME STRUCTURE; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; FISSION YEAST; PORE COMPLEX; HNRNP A1; NUCLEOCYTOPLASMIC TRANSPORT; SCHIZOSACCHAROMYCES-POMBE; POLY(A)(+) RNA	Nuclear protein export is mediated by nuclear export signals (NESs), but the mechanisms governing this transport process are not well understood. Using a novel protein export assay in S. cerevisiae, we identify CRM1 as an essential mediator of nuclear protein export in yeast. Crm1p shows homology to importin beta-like transport factors and is able to specifically interact with both the NES motif and the Ran GTPase. A mutation in the shuttling protein Crm1p affects not only protein export, but also mRNA export, indicating that these pathways are tightly coupled in S. cerevisiae. The presented data are consistent with the conclusion that Crm1p is a carrier for the NES-mediated protein export pathway. We propose CRM1 be renamed exportin 1 (XPO1).	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Cole CN, 1997, SEMIN CELL DEV BIOL, V8, P71, DOI 10.1006/scdb.1996.0124; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; MELCHIOR F, 1994, J CELL BIOL, V124, P217; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nehrbass U, 1996, J CELL BIOL, V133, P1153, DOI 10.1083/jcb.133.6.1153; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; TURI TG, 1994, J BIOL CHEM, V269, P24229; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Zabel U, 1996, J CELL BIOL, V133, P1141, DOI 10.1083/jcb.133.6.1141; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	61	932	942	0	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1041	1050		10.1016/S0092-8674(00)80370-0	http://dx.doi.org/10.1016/S0092-8674(00)80370-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323132	Bronze			2022-12-24	WOS:A1997XX76800010
J	Fan, QR; Mosyak, L; Winter, CC; Wagtmann, N; Long, EO; Wiley, DC				Fan, QR; Mosyak, L; Winter, CC; Wagtmann, N; Long, EO; Wiley, DC			Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; HUMAN GROWTH-HORMONE; HUMAN TISSUE FACTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; HUMAN CD4; COMPLEX; BINDING; 2.8-ANGSTROM; MOLECULE	Abnormal cells deficient in class I major histocompatibility complex (MHC) expression are lysed by a class of lymphocytes called natural killer (NK) cells(1). This lysis provides a defence against pathogens and tumour cells that downregulate MHC expression to avoid an MHC-restricted, T-cell immune response. Normal cells escape lysis because their MHC molecules are recognized by NK-cell inhibitory receptors, which inhibit lysis(2). Several such inhibitory receptor families have been described in humans and mice (reviewed in Ief. 2). In the human killer-cell inhibitory receptor family, individual p58 members are specific for a subset of class I human leukocyte antigen (HLA)-C molecules. The human p58 natural killer-cell inhibitory receptor done 42 recognizes HLA-Cw4, -Cw2 and -Cw6, but not HLA-Cw3, -Cw2, -Cw7 or -Cw8, which are recognized by p58 killer-cell inhibitor receptor clone 43 (ref. 3). We have determined the X-ray structure of the p58 NK-cell inhibitory receptor clone 42 at 1.7-Angstrom resolution. The structure has tandem immunoglobulin-like domains positioned at an acute, 60-degree angle. Loops on the outside of the elbow between the domains form a binding site projected away from the NK-cell surface. The topology of the domains and their arrangement relative to each other reveal a relationship to the haematopoietic receptor family, with implications for the signalling mechanism in NK cells.	NIAID, IMMUNOGENET LAB, NIH, ROCKVILLE, MD 20852 USA; HARVARD UNIV, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Howard Hughes Medical Institute			Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fan QR, 1996, P NATL ACAD SCI USA, V93, P7178, DOI 10.1073/pnas.93.14.7178; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LJUGGREN HG, 1990, IMMUNOL TODAY, V11, P237; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Winter CC, 1997, J IMMUNOL, V158, P4026	31	148	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					96	100		10.1038/38028	http://dx.doi.org/10.1038/38028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288975				2022-12-24	WOS:A1997XU59600053
J	Tarasow, TM; Tarasow, SL; Eaton, BE				Tarasow, TM; Tarasow, SL; Eaton, BE			RNA-catalysed carbon-carbon bond formation	NATURE			English	Article							LEWIS-ACID CATALYSIS; DIELS-ALDER REACTION; PORPHYRIN METALATION; RIBOZYMES; WORLD; EVOLUTION; WATER	The 'RNA world' hypothesis(1-3), which assumes that the chemical processes that led to the appearance of life were carried out by RNA molecules, has stimulated interest in catalytic reactions involving oligonucleotides such as catalytic RNA (ribozymes)(4). Naturally occurring ribozymes have, for example, been shown to efficiently catalyse the formation and cleavage of nucleic-acid phosphodiester bonds(4-8), and this narrow range of RNA-catalysed reactions has been subsequently expanded by in vitro selection methods to include ester(9) and amide(10,24) bond formation S(N)2 reactions and porphyrin metallations(11,12). Carbon-carbon bond formation and the creation of asymmetric centres are both of great importance biochemically, but have not yet been accomplished by RNA catalysis, A widely used reaction that creates two new carbon-carbon bonds and up to four stereo-centres is the Diels-Alder cycloaddition, which occurs between a 1,3-butadiene and an alkene. Here we report the successful application of in vitro selection to isolate pyridine-modified RNA molecules that catalyse a Diels-Alder cycloaddition, We find that the RNA molecules accelerate the reaction rate by a factor of up to 800 relative to the uncatalysed reaction.	NEXSTAR PHARMACEUT INC,BOULDER,CO 80301									BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; Conn MM, 1996, J AM CHEM SOC, V118, P7012, DOI 10.1021/ja961249c; Cotton F. A., 1988, ADV INORGANIC CHEM; Dewey TM, 1996, NUCLEOS NUCLEOT, V15, P1611, DOI 10.1080/07328319608002461; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P644; Joyce GF, 1996, CURR BIOL, V6, P965, DOI 10.1016/S0960-9822(02)00640-1; JOYCE GF, 1991, NEW BIOL, V3, P399; JOYCE GF, 1996, CHEM BIOL, V3, P405; KAZAKOV SA, 1996, T BIOORG BIOL CHEM, P244; KUMAR PKR, 1995, FASEB J, V9, P1183, DOI 10.1096/fasebj.9.12.7672511; Li YF, 1996, NAT STRUCT BIOL, V3, P743, DOI 10.1038/nsb0996-743; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MORRIS KN, 1994, P NATL ACAD SCI USA, V91, P13028, DOI 10.1073/pnas.91.26.13028; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; OTTO S, 1995, TETRAHEDRON LETT, V36, P2645, DOI 10.1016/0040-4039(95)00304-U; Otto S, 1996, J AM CHEM SOC, V118, P7702, DOI 10.1021/ja960318k; Pomerantz SC, 1997, J AM CHEM SOC, V119, P3861, DOI 10.1021/ja963875f; Tarasow TM, 1997, BIOCONJUGATE CHEM, V8, P89, DOI 10.1021/bc960082+; WIEGAND TW, IN PRESS CHEM BIOL; Williams J W, 1979, Methods Enzymol, V63, P437	24	300	322	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					54	57		10.1038/37950	http://dx.doi.org/10.1038/37950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288965				2022-12-24	WOS:A1997XU59600041
J	Lynch, ED; Lee, MK; Morrow, JE; Welcsh, PL; Leon, PE; King, MC				Lynch, ED; Lee, MK; Morrow, JE; Welcsh, PL; Leon, PE; King, MC			Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the Drosophila gene diaphanous	SCIENCE			English	Article							LIMB DEFORMITY LOCUS; ACTIN-FILAMENTS; FORMINS; TRANSCRIPTS	The gene responsible for autosomal dominant, fully penetrant, nonsyndromic sensorineural progressive hearing loss in a large Costa Rican kindred was previously localized to chromosome 5q31 and named DFNA1. Deafness in the family is associated with a protein-truncating mutation in a human homolog of the Drosophila gene diaphanous. The truncation is caused by a single nucleotide substitution in a splice donor, leading to a four-base pair insertion in messenger RNA and a frameshift, The diaphanous protein is a profilin ligand and target of Rho that regulates polymerization of actin, the major component of the cytoskeleton of hair cells of the inner ear.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV COSTA RICA, SCH MED, SAN JOSE, COSTA RICA; UNIV COSTA RICA, CTR RES CELLULAR & MOL BIOL, SAN JOSE, COSTA RICA	University of Washington; University of Washington Seattle; Universidad Costa Rica; Universidad Costa Rica	Lynch, ED (corresponding author), UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA.			King, Mary-Claire/0000-0001-9426-1743	NIDCD NIH HHS [R01-DC01076] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001076] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Banfi S, 1997, HUM MOL GENET, V6, P1745, DOI 10.1093/hmg/6.10.1745; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FLOCK A, 1977, J CELL BIOL, V75, P339, DOI 10.1083/jcb.75.2.339; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; GORLIN RJ, 1995, OXFORD MONOGRAPHS ME, V28, P1; ITOH M, 1982, HEARING RES, V6, P277, DOI 10.1016/0378-5955(82)90060-0; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lee M., UNPUB; LEON PE, 1981, AM J HUM GENET, V33, P209; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; LIU XZ, IN PRESS NATURE GENE; LYNCH ED, UNPUB; MAAS RL, 1991, AM J HUM GENET, V48, P687; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Sambrook J., 1989, MOL CLONING; Steel KP, 1996, CURR OPIN NEUROBIOL, V6, P520, DOI 10.1016/S0959-4388(96)80059-6; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TILNEY LG, 1982, HEARING RES, V7, P181, DOI 10.1016/0378-5955(82)90013-2; Tyson J, 1996, HUM MOL GENET, V5, P2055, DOI 10.1093/hmg/5.12.2055; VOGT TF, 1993, P NATL ACAD SCI USA, V90, P5554, DOI 10.1073/pnas.90.12.5554; Wang CC, 1997, GENOMICS, V39, P303, DOI 10.1006/geno.1996.4519; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; WynshawBoris A, 1997, MOL MED, V3, P372, DOI 10.1007/BF03401684; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	39	305	332	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 14	1997	278	5341					1315	1318		10.1126/science.278.5341.1315	http://dx.doi.org/10.1126/science.278.5341.1315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360932				2022-12-24	WOS:A1997YG04300051
J	Clarke, VRJ; Ballyk, BA; Hoo, KH; Mandelzys, A; Pellizzari, A; Bath, CP; Thomas, J; Sharpe, EF; Davies, CH; Ornstein, PL; Schoepp, DD; Kamboj, RK; Collingridge, GL; Lodge, D; Bleakman, D				Clarke, VRJ; Ballyk, BA; Hoo, KH; Mandelzys, A; Pellizzari, A; Bath, CP; Thomas, J; Sharpe, EF; Davies, CH; Ornstein, PL; Schoepp, DD; Kamboj, RK; Collingridge, GL; Lodge, D; Bleakman, D			A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission	NATURE			English	Article							INDUCED EPILEPTIFORM ACTIVITY; AMINO-ACID RECEPTORS; KAINIC ACID; GLUTAMATE RECEPTORS; RAT HIPPOCAMPUS; NERVOUS-SYSTEM; AMPA RECEPTORS; NEURONS; DESENSITIZATION; PHARMACOLOGY	The principal excitatory neurotransmitter in the vertebrate central nervous system, L-glutamate, acts on three classes of ionotripic glutamate receptors, named after the agonists AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxalole-4-propionic acid),NMDA (N-methyl-D-aspartate) and kainate(1). The development of selective pharmacological agents has led to a detailed understanding of the physiological and pathological roles of AMPA and NMDA receptors(2-8). in contrast, the lack of selective kainate receptor ligands has greatly hindered progress in understanding the roles of kainate receptors(9,10). Here we describe the effects of a potent and selective agonist, ATPA ((RS)-2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propanoic acid) and a selective antagonist, LY294486 ((3SR, 4aRS, 6SR, 8aRS)-6-((((1H-tetrazol-5-yl) methyl)oxy)methyl)-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylic acid), of the GluR5 subtype of kainate receptor(11). We have used these agents to show that kainate receptors, comprised of or containing GluR5 subunits, regulate synaptic inhibition in the hippocampus, an action that could contribute to the epileptogenic effects of kainate(12-17).	ELI LILLY & CO, LILLY RES CTR LTD, WINDLESHAM GU20 6PH, SURREY, ENGLAND; UNIV BRISTOL, DEPT ANAT, BRISTOL BS8 1TD, AVON, ENGLAND; ALLELIX BIOPHARMACEUT, MISSISSAUGA, ON L4V 1V7, CANADA; UNIV EDINBURGH, DEPT PHARMACOL, EDINBURGH EH8 9JZ, MIDLOTHIAN, SCOTLAND; ELI LILLY & CO, LILLY CORP CTR, INDIANAPOLIS, IN 46285 USA	Eli Lilly; University of Bristol; University of Edinburgh; Eli Lilly			Collingridge, Graham L/C-4605-2015; Ornstein, Paul/E-4212-2016; collingridge, graham/AAI-8362-2020	Collingridge, Graham L/0000-0002-9572-5359; Ornstein, Paul/0000-0002-4335-1877; Clarke, Vernon/0000-0002-6154-6555	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Bleakman D, 1996, MOL PHARMACOL, V49, P581; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAVIES CH, 1993, NEUROPHARMACOLOGY, V32, P1071, DOI 10.1016/0028-3908(93)90073-C; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; FELDMEYER D, 1994, CURR BIOL, V4, P82, DOI 10.1016/S0960-9822(00)00021-X; FISHER RS, 1984, J NEUROSCI, V4, P1312; Fletcher EJ, 1996, PHARMACOL THERAPEUT, V70, P65, DOI 10.1016/0163-7258(96)00014-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KEHL SJ, 1984, NEUROSCIENCE, V11, P111, DOI 10.1016/0306-4522(84)90217-3; KORCZAK B, 1995, RECEPTOR CHANNEL, V3, P41; KROGSGAARDLARSE.P, 1994, EXCITATORY AMINO ACI, P34; LAURIDSEN J, 1985, J MED CHEM, V28, P668, DOI 10.1021/jm50001a022; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Partin KM, 1996, MOL PHARMACOL, V49, P142; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SLOVITER RS, 1981, NEUROPHARMACOLOGY, V20, P1003, DOI 10.1016/0028-3908(81)90088-5; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WILDING TJ, 1995, MOL PHARMACOL, V47, P582	30	362	372	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					599	603		10.1038/39315	http://dx.doi.org/10.1038/39315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335499				2022-12-24	WOS:A1997YA00800059
J	Sheardown, SA; Duthie, SM; Johnston, CM; Newall, AET; Formstone, EJ; Arkell, RM; Nesterova, TB; Alghisi, GC; Rastan, S; Brockdorff, N				Sheardown, SA; Duthie, SM; Johnston, CM; Newall, AET; Formstone, EJ; Arkell, RM; Nesterova, TB; Alghisi, GC; Rastan, S; Brockdorff, N			Stabilization of Xist RNA mediates initiation of X chromosome inactivation	CELL			English	Article							MOUSE EMBRYOS; CONTROLLING ELEMENTS; LINKED GENES; FEMALE MOUSE; EXPRESSION; STABILITY; CELLS; DIFFERENTIATION; METHYLATION; EUKARYOTES	The onset of X inactivation is preceded by a marked increase in the level of Xist RNA. Here we demonstrate that increased stability of Xist RNA is the primary determinant of developmental up-regulation. Unstable transcript is produced by both alleles in XX ES cells and in XX embryos prior to the onset of random X inactivation. Following differentiation, transcription of unstable RNA from the active X chromosome allele continues for a period following stabilization and accumulation of transcript on the inactive X allele. We discuss the implications of these findings in terms of models for the initiation of random and imprinted X inactivation.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,X INACTIVAT GRP,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CTR CLIN SCI,EMBRYOL GRP,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London			arkell, ruth m/D-1525-2009; Arkell, Ruth/AAR-8471-2021	arkell, ruth m/0000-0002-6213-7323; Arkell, Ruth/0000-0002-6213-7323; Nesterova, Tatyana/0000-0001-7740-4386; Brockdorff, Neil/0000-0003-4838-2653				BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BEDDINGTON R, 1987, P43; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1994, NATURE, V368, P154, DOI 10.1038/368154a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BUZIN CH, 1994, DEVELOPMENT, V120, P3529; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1969, GENET RES, V14, P223, DOI 10.1017/S0016672300002068; CHEW LJ, 1994, MOL ENDOCRINOL, V8, P603, DOI 10.1210/me.8.5.603; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; DREWS U, 1974, CELL, V1, P3, DOI 10.1016/0092-8674(74)90148-2; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hogan B, 1994, MANIPULATING MOUSE E; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MCBURNEY MW, 1980, CELL, V21, P357, DOI 10.1016/0092-8674(80)90472-9; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RACK KA, 1994, HUM MOL GENET, V3, P1053, DOI 10.1093/hmg/3.7.1053; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1982, J EMBRYOL EXP MORPH, V71, P11; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RUSSELL LB, 1965, GENETICS, V52, P470; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SHEARDOWN SA, 1997, IN PRESS GENE; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; TAKAGI N, 1982, CHROMOSOMA, V85, P275, DOI 10.1007/BF00294971; WEBB S, 1992, GENET RES, V59, P205, DOI 10.1017/S0016672300030494; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	52	217	223	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					99	107		10.1016/S0092-8674(01)80012-X	http://dx.doi.org/10.1016/S0092-8674(01)80012-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335338	Bronze			2022-12-24	WOS:A1997XZ80900012
J	vonBulow, GU; Bram, RJ				vonBulow, GU; Bram, RJ			NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily	SCIENCE			English	Article							DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; KAPPA-B; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; APOPTOSIS; BINDING; LIGAND; FAMILY; GENE	Activation of the nuclear factor of activated T cells transcription factor (NF-AT) is a key event underlying lymphocyte action. The CAML (calcium-modulator and cyclophilin ligand) protein is a coinducer of NF-AT activation when overexpressed in Jurkat T cells. A member of the tumor necrosis factor receptor superfamily was isolated by Virtue of its affinity for CAML. Cross-linking of this lymphocyte-specific protein, designated TACl (transmembrane activator and CAML-interactor), on the surface of transfected Jurkat cells with TACl-specific antibodies led to activation of the transcription factors NF-AT, AP-1, acid NF kappa B. TACl-induced activation of NF-AT was specifically blocked by a dominant-negative CAML mutant, thus implicating CAML as a signaling intermediate.	ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Beltinger CP, 1996, GENOMICS, V35, P94, DOI 10.1006/geno.1996.0327; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CAMERINI D, 1991, J IMMUNOL, V147, P3165; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; HOLLOWAY MP, UNPUB; JAIN J, 1993, NATURE, V35, P352; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; VONBULOW GU, UNPUB; WILSONRAWLS J, 1994, VIROLOGY, V201, P66, DOI 10.1006/viro.1994.1266	32	296	341	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					138	141		10.1126/science.278.5335.138	http://dx.doi.org/10.1126/science.278.5335.138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311921				2022-12-24	WOS:A1997XZ12400057
J	Sallusto, F; Mackay, CR; Lanzavecchia, A				Sallusto, F; Mackay, CR; Lanzavecchia, A			Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells	SCIENCE			English	Article							EOSINOPHIL CHEMOATTRACTANT; FUNCTIONAL-PROPERTIES; MOLECULAR-CLONING; PHENOTYPE; ASTHMA; INTERLEUKIN-4; INFLAMMATION; ACTIVATION; MECHANISM; ANTIGEN	There is growing evidence that T helper cell subsets (T(H)1 and T(H)2) can be differentially recruited to promote different types of inflammatory reactions. Murine T(H)1 but not T(H)2 cells are recruited through P-and E-selectin into inflamed tissues, where they induce delayed-type hypersensitivity reactions. The human eotaxin-receptor CCR3, originally described on eosinophils and basophils, was also found to be expressed by T(H)2 cells. An antibody to CCR3 was used to isolate T cells from peripheral blood that give rise to T(H)2-polarized cell lines and to identify T(H)2 cells derived from naive T cells in vitro. Eotaxin stimulated increases in intracellular calcium and chemotaxis of CCR3(+) T cells. The attraction of T(H)2 cells by eotaxin could represent a key mechanism in allergic reactions, because it promotes the allergen-driven production of interleukin-4 and interleukin-5 necessary to activate basophils and eosinophils.	LEUKOSITE INC,CAMBRIDGE,MA 02142		Sallusto, F (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340				Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; FORRSMANN U, 1997, J EXP MED, V185, P2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GERBER BO, UNPUB; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lichtman AH, 1997, CURR BIOL, V7, P242; MACKAY CR, UNPUB; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAD S, 1994, J IMMUNOL, V153, P3514; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SALLUSTO F, UNPUB; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SOMASSE T, 1996, J EXP MED, V184, P473; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; UGUCCIONI MG, IN PRESS J CLIN INVE; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577	36	890	920	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					2005	2007		10.1126/science.277.5334.2005	http://dx.doi.org/10.1126/science.277.5334.2005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302298				2022-12-24	WOS:A1997XX84900048
J	Lesburg, CA; Zhai, GZ; Cane, DE; Christianson, DW				Lesburg, CA; Zhai, GZ; Cane, DE; Christianson, DW			Crystal structure of pentalenene synthase: Mechanistic insights on terpenoid cyclization reactions in biology	SCIENCE			English	Article							SESQUITERPENE CYCLASES; FARNESYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; BIOSYNTHESIS; STEREOCHEMISTRY; PURIFICATION; DIPHOSPHATE; STRATEGY; PROTEINS; PATHWAY	The crystal structure of pentalenene synthase at 2.6 angstrom resolution reveals critical active site features responsible for the cyclization of farnesyl diphosphate into the tricyclic hydrocarbon pentalenene. Metal-triggered substrate ionization initiates catalysis, and the alpha-barrel active site serves as a template to channel and stabilize the conformations of reactive carbocation intermediates through a complex cyclization cascade. The core active site structure of the enzyme may be preserved among the greater family of terpenoid synthases, possibly implying divergence from a common ancestral synthase to satisfy biological requirements for increasingly diverse natural products.	UNIV PENN, DEPT CHEM, ROY & DIANA VAGELOS LABS, PHILADELPHIA, PA 19104 USA; BROWN UNIV, DEPT CHEM, PROVIDENCE, RI 02912 USA	University of Pennsylvania; Brown University								ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Back KW, 1996, P NATL ACAD SCI USA, V93, P6841, DOI 10.1073/pnas.93.13.6841; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1991, PHILOS T ROY SOC B, V332, P123, DOI 10.1098/rstb.1991.0040; CANE DE, 1984, BIOORG CHEM, V12, P312, DOI 10.1016/0045-2068(84)90013-0; CANE DE, 1994, CAN J CHEM, V72, P118, DOI 10.1139/v94-019; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; Cane DE, 1996, J AM CHEM SOC, V118, P1563, DOI 10.1021/ja953751n; CANE DE, 1990, J AM CHEM SOC, V112, P4513, DOI 10.1021/ja00167a059; CHAYET L, 1984, BIOORG CHEM, V12, P329, DOI 10.1016/0045-2068(84)90014-2; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; Corey EJ, 1996, J AM CHEM SOC, V118, P11982, DOI 10.1021/ja9632926; COREY EJ, 1995, J AM CHEM SOC, V117, P11819, DOI 10.1021/ja00152a030; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; Dolara P, 1996, NATURE, V379, P29, DOI 10.1038/379029a0; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESBURG CA, 1995, PROTEIN SCI, V4, P2436, DOI 10.1002/pro.5560041124; LESBURG CA, UNPUB; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHIE CA, 1991, J ROY SOC MED, V84, P602; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nyborg J., 1977, ROTATION METHOD CRYS, P139; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLINY, 1969, NATURALIS HIST; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; RUZICKA L., 1963, PURE AND APPL CHEM, V6, P493, DOI 10.1351/pac196306040493; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018	44	335	353	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1820	1824		10.1126/science.277.5333.1820	http://dx.doi.org/10.1126/science.277.5333.1820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295272				2022-12-24	WOS:A1997XX29800046
J	Masson, GS; Busettini, C; Miles, FA				Masson, GS; Busettini, C; Miles, FA			Vergence eye movements in response to binocular disparity without depth perception	NATURE			English	Article							VIEWING DISTANCE; VISUAL-CORTEX; MONKEY; DEPENDENCE; MECHANISMS; STEREOPSIS; MOTION	Primates use vergence eye movements to align their two eyes on the same object and can correct misalignments by sensing the difference in the positions of the two retinal images of the object (binocular disparity). When large random-dot patterns are viewed dichoptically and small binocular misalignments are suddenly imposed (disparity steps), corrective vergence eye movements are elicited at ultrashort latencies(1,2). Here we show that the same steps applied to dense anticorrelated patterns, in which each black dot in one eye is matched to a white dot in the other eye, initiate vergence responses that are very similar, except that they are in the opposite direction. This sensitivity to the disparity of anticorrelated patterns is shared by many disparity-selective neurons in cortical area V1 (ref. 3), despite the fact that human subjects fail to perceive depth in such stimuli(4,5). These data indicate that the vergence eye movements initiated at ultrashort latencies result solely from locally matched binocular features, and derive their visual input from an early stage of cortical processing before the level at which depth percepts are elaborated.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892; CNRS,CTR RECH NEUROSCI COGNIT,F-13402 MARSEILLE,FRANCE	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Centre National de la Recherche Scientifique (CNRS)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				BISHOP PO, 1986, VISION RES, V26, P1587, DOI 10.1016/0042-6989(86)90177-X; Busettini C, 1996, J NEUROPHYSIOL, V75, P1392, DOI 10.1152/jn.1996.75.4.1392; BUSETTINI C, 1994, EXP BRAIN RES, V100, P484, DOI 10.1007/BF02738407; Busettini C., 1994, Society for Neuroscience Abstracts, V20, P1403; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; Collewijn H, 1990, Rev Oculomot Res, V4, P213; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; CUMMING BG, 1986, J NEUROPHYSIOL, V55, P896, DOI 10.1152/jn.1986.55.5.896; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; JUDGE SJ, 1991, VISION VISUAL DYSFUN, V8, P157; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; MITCHELL DE, 1970, VISION RES, V10, P145, DOI 10.1016/0042-6989(70)90112-4; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; Parker A. J., 1996, Investigative Ophthalmology and Visual Science, V37, pS424; POGGIO GF, 1995, CEREB CORTEX, V5, P193, DOI 10.1093/cercor/5.3.193; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; QIAN N, 1994, NEURAL COMPUT, V6, P390, DOI 10.1162/neco.1994.6.3.390; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P339, DOI 10.1113/jphysiol.1961.sp006812; REGAN D, 1986, INVEST OPHTH VIS SCI, V27, P584; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; WESTHEIMER G, 1969, VISION RES, V9, P749, DOI 10.1016/0042-6989(69)90012-1	21	175	178	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					283	286		10.1038/38496	http://dx.doi.org/10.1038/38496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305842				2022-12-24	WOS:A1997XW77200047
J	Somasundaram, K; Zhang, HB; Zeng, YX; Houvras, Y; Peng, Y; Zhang, HX; Wu, GS; Licht, JD; Weber, BL; ElDeiry, WS				Somasundaram, K; Zhang, HB; Zeng, YX; Houvras, Y; Peng, Y; Zhang, HX; Wu, GS; Licht, JD; Weber, BL; ElDeiry, WS			Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21(WAF1/CiP1)	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; CANCER-CELLS; HUMAN BREAST; GENE BRCA1; EXPRESSION; MOUSE	Much of the predisposition to hereditary breast and ovarian cancer has been attributed to inherited defects in the BRCA1 tumour-suppressor gene(1-3). The nuclear protein BRCA1 has the properties of a transcription factor(4-7), and can interact with the recombination and repair protein pAD51 (ref. 8), Young women with germline alterations in BRCA1 develop breast cancer at rates 100-fold higher than the general population(3), and BRCA1-null mice die before day 8 of development(9,10). However, the mechanisms of BRCA1-mediated growth regulation and tumour suppression remain unknown, Here we show that BRCA1 transactivates expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in a p53-independent manner, and that BRCA1 inhibits cell-cycle progression into the S-phase following its transfection into human cancer cells, BRCA1 does not inhibit S-phase progression in p21(-/-) cells, unlike p21(+/+) cells, and tumour-associated, transactivation-deficient mutants of BRCA1 are defective in both transactivation of p21 and cell-cycle inhibition, These data suggest that one mechanism by which BRCA1 contributes to cell-cycle arrest and growth suppression is through the induction of p21.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,LAB MOL ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CANC,PHILADELPHIA,PA 19104; CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			El-Deiry, Wafik/AAJ-6080-2020; Licht, Jonathan/L-4239-2019	El-Deiry, Wafik/0000-0002-9577-8266; Licht, Jonathan/0000-0002-3942-1369; Houvras, Yariv/0000-0003-0751-3215				Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WALDMAN T, 1995, CANCER RES, V55, P5187; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG W, 1995, CANCER RES, V55, P668	25	461	484	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					187	190		10.1038/38291	http://dx.doi.org/10.1038/38291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296497				2022-12-24	WOS:A1997XV75700050
J	Canagarajah, BJ; Khokhlatchev, A; Cobb, MH; Goldsmith, EJ				Canagarajah, BJ; Khokhlatchev, A; Cobb, MH; Goldsmith, EJ			Activation mechanism of the MAP kinase ERK2 by dual phosphorylation	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; GROWTH-FACTOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; DOMAIN; IDENTIFICATION; SPECIFICITY; INSULIN	The structure of the active form of the MAP kinase ERK2 has been solved, phosphorylated on a threonine and a tyrosine residue within the phosphorylation lip. The lip is refolded, bringing the phosphothreonine and phosphotyrosine into alignment with surface arginine-rich binding sites. Conformational changes occur in the lip and neighboring structures, including the P+1 site, the MAP kinase insertion, the C-terminal extension, and helix C. Domain rotation and remodeling of the proline-directed P+1 specificity pocket account for the activation. The conformation of the P+1 pocket is similar to a second proline-directed kinase, CDK2-CyclinA, thus permitting the origin of this specificity to be defined. Conformational changes outside the lip provide loci at which the state of phosphorylation can be felt by other cellular components.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046993] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46993] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENG P, 1992, SCIENCE, V257, P1404; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Goldsmith EJ, 1996, FASEB J, V10, P702, DOI 10.1096/fasebj.10.7.8635687; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1993, O VERSION 5 9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	75	605	620	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					859	869		10.1016/S0092-8674(00)80351-7	http://dx.doi.org/10.1016/S0092-8674(00)80351-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298898	Bronze			2022-12-24	WOS:A1997XV56300007
J	Collins, MM; Ransohoff, DF; Barry, MJ				Collins, MM; Ransohoff, DF; Barry, MJ			Early detection of prostate cancer - Serendipity strikes again	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med			DIGITAL RECTAL EXAMINATION; FECAL OCCULT BLOOD; COLORECTAL-CANCER; ANTIGEN; ADENOCARCINOMA; DIAGNOSIS; STAGE-T1C; BIOPSIES; VOLUME; TRIAL	An underappreciated characteristic of prostate cancer screening is that it may detect some prostate cancers solely by serendipity or chance, Serendipity, previously described in the detection of colonic neoplasms, could affect prostate cancer detection when a screening test result is abnormal for reasons other than the presence of prostate cancer, but prostate cancer is coincidentally detected during the subsequent evaluation of the abnormal screening result. We reviewed published articles about prostate cancer screening, searching for evidence of serendipity. We defined serendipity in digital rectal examination (DRE) screening as the discovery of a prostate cancer by the random biopsy of an area of the prostate gland other than the palpable suspicious area that prompted the biopsy. We defined serendipity in prostate-specific antigen (PSA) screening as the discovery of a prostate cancer by the random biopsy of a nonpalpable (stage T1c) prostate cancer less than 1.0 cm(3) in volume, since tumors less than 1.0 cm(3) are generally too small to cause elevated PSA levels. We found that serendipity may be responsible for the detection of more than one quarter of apparently DRE-detected prostate cancers and up to one quarter of apparently PSA-detected cancers. Additionally, serendipity played a larger role in the detection of smaller tumors that are common but of uncertain clinical significance. We conclude that serendipity-detected prostate cancers contribute to an overestimation of the true information value of DRE and PSA screening. Whether serendipity is advantageous in prostate cancer screening depends on the as yet uncertain outcomes for men with smaller prostate cancers. However, given our estimates of the potential magnitude of the impact of serendipity, the currently popular DRE- and PSA-based screening strategy may not be optimal. If smaller prostate cancers are important, then we are not finding enough; if they are unimportant, then we are finding too many that we may feel compelled to treat aggressively.	MASSACHUSETTS GEN HOSP, MED SERV, DIV GEN MED, MED PRACTICES EVALUAT CTR, BOSTON, MA 02114 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC USA; UNIV N CAROLINA, DEPT EPIDEMIOL, CHAPEL HILL, NC USA	Harvard University; Massachusetts General Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					AHRQ HHS [HS 08397] Funding Source: Medline; BHP HRSA HHS [5T32PE11001-08] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		BARRY MJ, 1995, UROLOGY, V46, P2, DOI 10.1016/S0090-4295(99)80151-4; BARRY MJ, 1995, ACP J CLUB, V123, P19; BILLEBAUD T, 1992, EUR UROL, V21, P6; BRAWN PN, 1991, CANCER, V68, P1592, DOI 10.1002/1097-0142(19911001)68:7<1592::AID-CNCR2820680721>3.0.CO;2-M; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; COLEY CM, 1995, UROLOGY, V46, P125, DOI 10.1016/S0090-4295(99)80181-2; Dugan JA, 1996, JAMA-J AM MED ASSOC, V275, P288, DOI 10.1001/jama.275.4.288; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; Eskew LA, 1997, J UROLOGY, V157, P199, DOI 10.1016/S0022-5347(01)65322-9; FLANIGAN RC, 1994, J UROLOGY, V152, P1506, DOI 10.1016/S0022-5347(17)32457-6; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Geary ES, 1996, J UROLOGY, V156, P1056, DOI 10.1016/S0022-5347(01)65701-X; GOHAGAN JK, 1994, J UROLOGY, V152, P1905, DOI 10.1016/S0022-5347(17)32412-6; Harmon Taz, 1997, Journal of Urology, V157, P365; Humphrey PA, 1996, J UROLOGY, V155, P816, DOI 10.1016/S0022-5347(01)66316-X; Karakiewicz PI, 1996, UROLOGY, V48, P747, DOI 10.1016/S0090-4295(96)00230-0; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; Levine Michael A., 1997, Journal of Urology, V157, P64; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1993, UROL CLIN N AM, V20, P687; OHORI M, 1994, CANCER-AM CANCER SOC, V74, P104, DOI 10.1002/1097-0142(19940701)74:1<104::AID-CNCR2820740119>3.0.CO;2-5; PROROK P, 1994, CAN J ONCOL S, V4, P102; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RICHIE JP, 1993, UROLOGY, V42, P365, DOI 10.1016/0090-4295(93)90359-I; SCALETSCKY R, 1994, J UROLOGY, V152, P129, DOI 10.1016/S0022-5347(17)32834-3; SCARDINO PT, 1992, HUM PATHOL, V23, P211, DOI 10.1016/0046-8177(92)90102-9; Schroder F H, 1994, Can J Oncol, V4 Suppl 1, P102; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; Vashi Apoorva E., 1997, Journal of Urology, V157, P365; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107	34	44	44	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	1997	278	18					1516	1519		10.1001/jama.1997.03550180066039	http://dx.doi.org/10.1001/jama.1997.03550180066039			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YE445	9363972				2022-12-24	WOS:A1997YE44500036
J	Bootman, MD; Berridge, MJ; Lipp, P				Bootman, MD; Berridge, MJ; Lipp, P			Cooking with calcium: The recipes for composing global signals from elementary events	CELL			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; HELA-CELLS; XENOPUS OOCYTES; GATED CHANNELS; CYTOSOLIC CA2+; MODULATION; RECEPTORS; PATTERNS	Recent studies have suggested that global intracellular Ca2+ signals arise from the summation and coordination of subcellular elementary release events (e.g., ''Ca2+ puffs''), although the modes of recruitment of such signals are unknown. In order to understand how cells utilize elementary Ca2+ release events, we imaged Ca2+ transients evoked through the phosphoinositide pathway in HeLa cells using confocal microscopy. During the pacemaker phase leading to the global Ca2+ signal, elementary Ca2+ release events were recruited in (1) frequency, (2) amplitude, and (3) spatial domains. Since each digital elementary event contributes to a small change of the analog cytosolic Ca2+ concentration, the net effect of the advancement in the three domains is to drive the ambient Ca2+ concentration toward a threshold where the signal becomes regenerative, resulting in a global Ca2+ wave.	BABRAHAM INST, MOL SIGNALLING LAB, CAMBRIDGE CB2 4AT, ENGLAND; UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge			Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; Bootman MD, 1996, CELL CALCIUM, V20, P97, DOI 10.1016/S0143-4160(96)90099-8; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Lipp P, 1997, J PHYSIOL-LONDON, V502, P1, DOI 10.1111/j.1469-7793.1997.001bl.x; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Reber BFX, 1996, PFLUG ARCH EUR J PHY, V432, P893, DOI 10.1007/s004240050213; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; WOJCIKIEWICZ RJH, 1993, J EXP BIOL, V184, P145; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538	28	316	320	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					367	373		10.1016/S0092-8674(00)80420-1	http://dx.doi.org/10.1016/S0092-8674(00)80420-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363945	Bronze			2022-12-24	WOS:A1997YD94100010
J	Hunter, DJ; Hankinson, SE; Laden, F; Colditz, GA; Manson, JE; Willett, WC; Speizer, FE; Wolff, MS				Hunter, DJ; Hankinson, SE; Laden, F; Colditz, GA; Manson, JE; Willett, WC; Speizer, FE; Wolff, MS			Plasma organochlorine levels and the risk of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DICHLORODIPHENYL DICHLOROETHENE DDE; POLYCHLORINATED-BIPHENYLS PCBS; BLOOD-LEVELS; HUMAN-MILK; SERUM; WOMEN; PESTICIDES; ESTROGENS; RESIDUES; LACTATION	Background Exposure to ''environmental estrogens'' such as organochlorines in pesticides and industrial chemicals has been proposed as a cause of increasing rates of breast cancer. Several studies have reported higher blood levels of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE) and polychlorinated biphenyls (PCBs) in patients with breast cancer than in controls. Methods We measured plasma levels of DDE and PCBs prospectively among 240 women who gave a blood sample in 1989 or 1990 and who were subsequently given a diagnosis of breast cancer before June 1, 1992. We compared these levels with those measured in matched control women in whom breast cancer did not develop. Data on DDE were available for 236 pairs, and data on PCBs were available for 230 pairs. Results The median level of DDE was lower among case patients than among controls (4.71 vs, 5.35 parts per billion, P = 0.14), as was the median level of PCBs (4.49 vs. 4.68 parts per billion, P = 0.72), The multivariate relative risk of breast cancer for women in the highest quintile of exposure as compared with women in the lowest quintile was 0.72 for DDE (95 percent confidence interval, 0.37 to 1.40) and 0.66 for PCBs (95 percent confidence interval, 0.32 to 1.37). Exposure to high levels of both DDE and PCBs was associated with a nonsignificantly lower risk of breast cancer (relative risk for women in the highest quintiles of both DDE and PCBs as compared with women in the lowest, 0.43; 95 percent confidence interval, 0.13 to 1.44). Conclusions Our data do not support the hypothesis that exposure to 2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane (DDT) and PCBs increases the risk of breast cancer. (C) 1997, Massachusetts Medical Society.	HARVARD UNIV, SCH MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD CTR CANC PREVENT, BOSTON, MA USA; MT SINAI HOSP, DIV ENVIRONM & OCCUPAT MED, NEW YORK, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Icahn School of Medicine at Mount Sinai	Hunter, DJ (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 181 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [U01CA062984, R01CA049449, U01CA049449, R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356, CA49449, U01 CA/ES62984] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSON LF, 1994, J NATL CANCER I, V86, P576, DOI 10.1093/jnci/86.8.576; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BERGERON JM, 1994, ENVIRON HEALTH PERSP, V102, P780, DOI 10.2307/3432139; BRESLOW NE, 1980, IARC SCI PUBL, V32, P249; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; DEWAILLY E, 1994, J NATL CANCER I, V86, P232, DOI 10.1093/jnci/86.3.232; FALCK F, 1992, ARCH ENVIRON HEALTH, V47, P143; Gammon MD, 1996, CANCER EPIDEM BIOMAR, V5, P467; Gammon MD, 1997, CANCER EPIDEM BIOMAR, V6, P327; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; KRIEGER N, 1994, JNCI-J NATL CANCER I, V86, P589, DOI 10.1093/jnci/86.8.589; KUTZ FW, 1991, REV ENVIRON CONTAM T, V120, P1; Laden F, 1997, CANCER EPIDEM BIOMAR, V6, P333; LONG GL, 1983, ANAL CHEM, V55, pA712, DOI 10.1021/ac00258a001; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; ROBISON AK, 1985, TOXICOL LETT, V27, P109, DOI 10.1016/0378-4274(85)90127-4; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P172, DOI 10.2105/AJPH.76.2.172; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P551; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SAVAGE EP, 1981, AM J EPIDEMIOL, V113, P413, DOI 10.1093/oxfordjournals.aje.a113109; SCRIBNER JD, 1981, CARCINOGENESIS, V2, P1235, DOI 10.1093/carcin/2.12.1235; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.1289/ehp.95103s7113; vantVeer P, 1997, BMJ-BRIT MED J, V315, P81, DOI 10.1136/bmj.315.7100.81; WASSERMANN M, 1976, B ENVIRON CONTAM TOX, V15, P478, DOI 10.1007/BF01685076; WIEMEYER SN, 1984, ARCH ENVIRON CON TOX, V13, P529, DOI 10.1007/BF01056332; WOLFF MS, 1993, JNCI-J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WOLFF MS, 1995, ENVIRON HEALTH PERSP, V103, P141, DOI 10.2307/3432524; WOLFF MS, 1992, ENVIRON RES, V59, P202, DOI 10.1016/S0013-9351(05)80240-3; WOLFF MS, 1991, B ENVIRON CONTAM TOX, V47, P499, DOI 10.1007/BF01700936	33	278	284	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1253	1258		10.1056/NEJM199710303371801	http://dx.doi.org/10.1056/NEJM199710303371801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345073	Bronze			2022-12-24	WOS:A1997YC92000001
J	Condic, ML; Letourneau, PC				Condic, ML; Letourneau, PC			Ligand-induced changes in integrin expression regulate neuronal adhesion and neurite outgrowth	NATURE			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTORS; SENSORY NEURONS; GROWTH CONES; IN-VITRO; FIBRONECTIN; SUBUNIT; CHICK; LOCOMOTION; MIGRATION	Receptors of the integrin family are expressed by every cell type and are the primary means by which cells interact with the extracellular matrix. The control of integrin expression affects a wide range of developmental and cellular processes, including the regulation of gene expression, cell adhesion, cell morphogenesis and cell migration(1-3). Here we show that the concentration of substratum-bound ligand (laminin) post-translationally regulates the amount of receptor (alpha(6) beta(1) integrin) expressed on the surface of sensory neurons. When ligand availability is low, surface amounts of receptor increase, whereas integrin RNA and total integrin protein decrease. Ligand concentration determines surface levels of integrin by altering the rate at which receptor is removed from the cell surface. Furthermore, increased expression of integrin at the cell surface is associated with increased neuronal cell adhesion and neurite outgrowth, These results indicate that integrin regulation maintains neuronal growth-cone motility over a broad range of ligand concentrations, allowing axons to invade different tissues during development and regeneration.	UNIV MINNESOTA, DEPT CELL BIOL & NEUROANAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Condic, ML (corresponding author), UNIV UTAH, SCH MED, DEPT ANAT & NEUROBIOL, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.		Letourneau, Paul C/A-6764-2009					ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BUETTNER HM, 1991, DEV BIOL, V145, P266, DOI 10.1016/0012-1606(91)90125-M; CAI J, 1995, CELL, V83, P693; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DUBAND JL, 1991, J CELL SCI, V98, P517; GAIETTA G, 1994, J CELL SCI, V107, P3339; GOMEZ TM, 1994, J NEUROSCI, V14, P5959; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/jcb.98.4.1474; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; VEKEMAN S, 1993, FEBS LETT, V327, P207, DOI 10.1016/0014-5793(93)80171-P; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; WEAVER CD, 1995, J NEUROSCI, V15, P5275	29	156	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					852	856		10.1038/39878	http://dx.doi.org/10.1038/39878			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349817				2022-12-24	WOS:A1997YC14800058
J	Butler, RN				Butler, RN			Living longer, contributing longer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MT SINAI MED CTR,INT LONGEV CTR US,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai								BASS SA, 1996, GENERATIONS      SPR, P29; FAIRLIE H, 1988, NEW REPUBLIC, V198, P19; HARTOOTYAN RA, 1996, ENCY GERONTOLOGY, V2, P613; *IND SECT, 1996, GIV VOL US; *LINK HOUS, 1997, AGING TODAY, V18, P11; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593	6	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1372	1373		10.1001/jama.278.16.1372	http://dx.doi.org/10.1001/jama.278.16.1372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343470				2022-12-24	WOS:A1997YA90500040
J	Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL				Phillips, CD; Sloane, PD; Hawes, C; Koch, G; Han, J; Spry, K; Dunteman, G; Williams, RL			Effects of residence in Alzheimer disease special care units on functional outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; NURSING-HOME; DEMENTIA; IMPACT; PREDICTORS; STATE; MDS	Context.-Alzheimer disease special care units (SCUs) in nursing homes are increasingly prevalent, but little is known about their effects on residents' outcomes. Objective.-To analyze the effect of SCU residence on the rates at which residents decline in functional status. Design.-A cohort of nursing home residents assessed at multiple points during about 1 year. Facility staff completed all assessments using the Minimum Data Set for Nursing Home Resident Assessment and Care Screening (MDS). Setting.-Medicare-or Medicaid-certified nursing facilities. Patients or Other Participants.-All nursing home residents in 1993 and early 1994 in Kansas, Maine, Mississippi, and South Dakota. Serial MDS assessments of 77 337 residents in more than 800 facilities, including 1228 residents in 48 facilities with SCUs. Main Outcome Measures.-Decline in locomotion, transferring, toileting, eating, dressing, and a summary activities of daily living index; decline in urinary and bowel continence; and significant weight loss. Results.-No statistically significant difference was observed in the speed of decline for residents in SCUs and traditional units in any of the 9 outcomes. Residents were matched on a variety of characteristics, and subgroup analyses were performed. In none did we observe a pattern of better outcomes among SCU residents. Conclusions.-Although SCUs may have provided unmeasured benefits to families and residents, it does not appear that those benefits included any slowing in the rates of functional decline experienced by individuals with dementia.	UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC; RES TRIANGLE INST,DIV STAT RES,RES TRIANGLE PK,NC 27709; RES TRIANGLE INST,PROGRAM AGING & LONG TERM CARE,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Research Triangle Institute; Research Triangle Institute	Phillips, CD (corresponding author), MENORAH PK CTR AGING,MYERS RES INST,BEACHWOOD,OH 44122, USA.				NIA NIH HHS [5-U01-AG10313-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG010313] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON WE, 1994, GERONTOLOGIST, V34, P775, DOI 10.1093/geront/34.6.775; *ADV PAN ALZH DIS, 1991, DHHS PUBL; Allison P., 1982, SOCIOL METHODOL, V13, P61, DOI [10.2307/270718, DOI 10.2307/270718]; *ALZH DIS REL DIS, 1992, GUID DIGN GOALS SPEC; BanaszakHoll J, 1996, HEALTH SERV RES, V31, P97; BENSON DM, 1987, J AM GERIATR SOC, V35, P319, DOI 10.1111/j.1532-5415.1987.tb04638.x; BOLING K, 1991, DEMENTIA UNITS LONG, P3; BRAUN BI, 1991, J AM GERIATR SOC, V39, P329, DOI 10.1111/j.1532-5415.1991.tb02896.x; CHAFETZ P K, 1991, Clinical Gerontologist, V11, P19, DOI 10.1300/J018v11n01_03; CLEARY TA, 1988, GERONTOLOGIST, V28, P511, DOI 10.1093/geront/28.4.511; GOLD DT, 1991, GERONTOLOGIST, V31, P467, DOI 10.1093/geront/31.4.467; GRANT LA, 1995, J AM GERIATR SOC, V43, P569, DOI 10.1111/j.1532-5415.1995.tb06108.x; GREEN CR, 1993, J AM GERIATR SOC, V41, P654, DOI 10.1111/j.1532-5415.1993.tb06740.x; Greene J A, 1985, J Tenn Med Assoc, V78, P559; HARDWICK S, 1994, STATES 1994 PROFILES; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; HAWES C, 1997, FAMILY MEMBERS VIEWS; HEINEMANN GD, 1985, RES AGING, V7, P363, DOI 10.1177/0164027585007003003; HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982; HOLMES D, 1990, GERONTOLOGIST, V30, P178, DOI 10.1093/geront/30.2.178; HURLEY AC, 1992, RES NURS HEALTH, V15, P369, DOI 10.1002/nur.4770150506; *I MED COMM NURS H, 1986, IMPR QUAL NURS HOM; *JOINT COMM ACCR H, 1993, STAND SURV PROT DEM; MATHEW L, 1988, AM J ALZHEIMERS CARE, V3, P16; MEHR DR, 1995, GERONTOLOGIST, V35, P179, DOI 10.1093/geront/35.2.179; MOR V, 1996, GENERATIONS, V19, P24; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS JN, 1991, RESIDENT ASSESSMENT; NORRISBAKER C, IN PRESS MEASURING E; *OFF TECHN ASS, 1992, PUBL OFF TECHN ASS; *OFF TECHN ASS, 1987, OTABA323; OHTA RJ, 1988, GERONTOLOGIST, V28, P803, DOI 10.1093/geront/28.6.803; PHILLIPS CD, IN PRESS ALZHEIMERS; RITER RN, 1992, GERONTOLOGIST, V32, P184, DOI 10.1093/geront/32.2.184; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rovner BW, 1996, J AM GERIATR SOC, V44, P7, DOI 10.1111/j.1532-5415.1996.tb05631.x; Shah BV, 1996, SUDAAN USERS MANUAL; SLOANE PD, 1991, JAMA-J AM MED ASSOC, V265, P1278, DOI 10.1001/jama.265.10.1278; SLOANE PD, 1995, GERONTOLOGIST, V35, P103, DOI 10.1093/geront/35.1.103; STARK AJ, 1995, GERONTOLOGIST, V35, P648, DOI 10.1093/geront/35.5.648; SWANSON EA, 1993, ARCH PSYCHIATR NURS, V5, P292; WELLS Y, 1987, AUST NZ J PSYCHIAT, V21, P524, DOI 10.3109/00048678709158920; ZINN JS, 1994, GERONTOLOGIST, V34, P371, DOI 10.1093/geront/34.3.371	44	58	58	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 22	1997	278	16					1340	1344		10.1001/jama.278.16.1340	http://dx.doi.org/10.1001/jama.278.16.1340			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YA905	9343465				2022-12-24	WOS:A1997YA90500035
J	Giwercman, A; Thomsen, JK; Hertz, J; Berthelsen, JG; Jensen, V; Meinecke, B; Thormann, L; Storm, HH; Skakkebaek, NE				Giwercman, A; Thomsen, JK; Hertz, J; Berthelsen, JG; Jensen, V; Meinecke, B; Thormann, L; Storm, HH; Skakkebaek, NE			Prevalence of carcinoma in situ of the testis in 207 oligozoospermic men from infertile couples: prospective study of testicular biopsies	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; INSITU; MANAGEMENT; NEOPLASIA	Objective: To investigate the prevalence of carcinoma in situ of the testis in a group of oligozoospermic men from infertile couples. Design: A consecutive group of oligozoospermic men from infertile couples were offered bilateral testicular biopsy. The observed prevalence of carcinoma in situ was compared with the expected prevalence of testicular cancer in a corresponding age matched population of Danish men, assuming all untreated cases of carcinoma in situ progress to tumour stage, This calculation was based on data from the Danish Cancer Registry. Subjects: 207 men aged 18-50 years who had sperm density below 10 million/ml in two samples within the previous 2 years or sperm density below 20 million/ml in two samples within the previous 2 years and a history of cryptorchidism or one or two atrophic testicles (orchidometer volume less than 15 cm(3)), or both. Interventions: Bilateral testicular biopsies. Main outcome measures: Carcinoma in situ in the biopsy specimen. Results: No case of carcinoma in situ was found among the 207 men, The expected number in a normal age matched population of corresponding size was 0.8. Conclusion: There is no increase in risk of carcinoma in situ of the testis in moderately oligozoospermic men of couples referred because of infertility.	UNIV COPENHAGEN,HERLEV HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; UNIV COPENHAGEN,GENTOFTE HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; CENT HOSP HILLEROD,DEPT OBSTET & GYNAECOL,DK-3400 HILLEROD,DENMARK; UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT OBSTET & GYNAECOL,COPENHAGEN,DENMARK; DANISH CANC SOC,DIV CANC EPIDEMIOL,DANISH CANC REGISTRY,COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Danish Cancer Society	Giwercman, A (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT GROWTH & REPROD,SECT 5064,DK-2100 COPENHAGEN,DENMARK.			Storm, Hans/0000-0001-7223-8198				BERTHELSEN JG, 1982, BRIT MED J, V285, P1683, DOI 10.1136/bmj.285.6356.1683; BERTHELSEN JG, 1981, SCAND J UROL NEPHROL, V15, P165, DOI 10.3109/00365598109179596; BETTOCCHI C, 1994, J ANDROL, V15, pS14; BRUUN E, 1987, INT J ANDROL, V10, P199, DOI 10.1111/j.1365-2605.1987.tb00184.x; CHEMES HE, 1995, J ANDROL S, pP24; Dieckmann KP, 1996, J CLIN ONCOL, V14, P3126, DOI 10.1200/JCO.1996.14.12.3126; DIECKMANN KP, 1993, J CANC RES CLIN ONCO, V119, P1; GIWERCMAN A, 1987, INT J ANDROL, V10, P173, DOI 10.1111/j.1365-2605.1987.tb00180.x; GIWERCMAN A, 1993, EUR UROL, V23, P104; MULLER J, 1987, INT J ANDROL, V10, P147, DOI 10.1111/j.1365-2605.1987.tb00176.x; MUMPEROW E, 1992, UROL INT, V48, P162, DOI 10.1159/000282322; NUESCHBACHMANN IH, 1977, SCHWEIZ MED WSCHR, V107, P795; PRYOR JP, 1983, BRIT J UROL, V55, P780, DOI 10.1111/j.1464-410X.1983.tb03425.x; ROWLEY MJ, 1966, FERTIL STERIL, V17, P177; SCHUTTE B, 1988, C SCHIRREN S ADV AND, P188; SKAKKEBAEK NE, 1978, HISTOPATHOLOGY, V2, P157, DOI 10.1111/j.1365-2559.1978.tb01706.x; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; WEST AB, 1985, J UROLOGY, V133, P107, DOI 10.1016/S0022-5347(17)48810-0	19	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					989	991		10.1136/bmj.315.7114.989	http://dx.doi.org/10.1136/bmj.315.7114.989			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC307	9365296	Green Published			2022-12-24	WOS:A1997YC30700021
J	McKenna, G; Schousboe, M; Paltridge, G				McKenna, G; Schousboe, M; Paltridge, G			Lesson of the week - Subjective change in ejaculate as symptom of infection with Schistosoma haematobium in travellers	BRITISH MEDICAL JOURNAL			English	Article									CANTERBURY HLTH,SEX HLTH CTR,CHRISTCHURCH,NEW ZEALAND; CANTERBURY HLTH,CANTERBURY HLTH LABS,CHRISTCHURCH,NEW ZEALAND	Canterbury Health Laboratories								CORACHAN M, 1994, AM J TROP MED HYG, V50, P580, DOI 10.4269/ajtmh.1994.50.580; GELFAND M, 1970, AM J TROP MED HYG, V19, P779, DOI 10.4269/ajtmh.1970.19.779; McKenna G, 1996, AUST NZ J MED, V26, P226, DOI 10.1111/j.1445-5994.1996.tb00888.x; NAIDOO P, 1992, VENEREOLOGY, V5, P97; 1993, MMWR-MORBID MORTAL W, V42, P565	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 18	1997	315	7114					1000	1001		10.1136/bmj.315.7114.1000	http://dx.doi.org/10.1136/bmj.315.7114.1000			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YC307	9365301	Green Published			2022-12-24	WOS:A1997YC30700028
J	Verma, R; Annan, RS; Huddleston, MJ; Carr, SA; Reynard, G; Deshaies, RJ				Verma, R; Annan, RS; Huddleston, MJ; Carr, SA; Reynard, G; Deshaies, RJ			Phosphorylation of Sic1p by G(1) Cdk required for its degradation and entry into S phase	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; SELECTIVE DETECTION; MASS-SPECTROMETRY; G1 CYCLINS; START; PHOSPHOPEPTIDES; TRANSITION; PATHWAY; FAMILY	G(1) cyclin-dependent kinase (Cdk)-triggered degradation of the S-phase Cdk inhibitor Sic1p has been implicated in the transition from G(1) to S phase in the cell cycle of budding yeast. A multidimensional electrospray mass spectrometry technique was used to map G(1) Cdk phosphorylation sites in Sic1p both in vitro and in vivo. A Sic1p mutant lacking three Cdk phosphorylation sites did not serve as a substrate for Cdc34p-dependent ubiquitination in vitro, was stable in vivo, and blocked DNA replication. Moreover, purified phosphoSic1p was ubiquitinated in cyclin-depleted G(1) extract, indicating that a primary function of G(1) cyclins is to tag Sic1p for destruction. These data suggest a molecular model of how phosphorylation and proteolysis cooperate to bring about the G(1)/S transition in budding yeast.	SMITHKLINE BEECHAM PHARMACEUT,MASS SPECTROMETRY RES LAB,KING OF PRUSSIA,PA 19406	GlaxoSmithKline	Verma, R (corresponding author), CALTECH,DIV BIOL,BOX 156-29,PASADENA,CA 91125, USA.		Deshaies, Raymond/B-8354-2014; Carr, Steven A./AAH-8366-2019	Deshaies, Raymond/0000-0002-3671-9354; 	NIGMS NIH HHS [R01 GM52466-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FELDMAN RMR, IN PRESS CELL; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; HENCHOZ S, IN PRESS GENES DEV; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Mathias N, 1996, MOL CELL BIOL, V16, P6634; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; REYNARD GJ, UNPUB; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SKOWYRA D, IN PRESS CELL; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Verma R, 1997, METHOD ENZYMOL, V283, P366; Verma R. P., UNPUB; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	28	390	399	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					455	460		10.1126/science.278.5337.455	http://dx.doi.org/10.1126/science.278.5337.455			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334303				2022-12-24	WOS:A1997YB35500043
J	McCord, TB; Carlson, RW; Smythe, WD; Hansen, GB; Clark, RN; Hibbitts, CA; Fanale, FP; Granahan, JC; Segura, M; Matson, DL; Johnson, TV; Martin, PD				McCord, TB; Carlson, RW; Smythe, WD; Hansen, GB; Clark, RN; Hibbitts, CA; Fanale, FP; Granahan, JC; Segura, M; Matson, DL; Johnson, TV; Martin, PD			Organics and other molecules in the surfaces of Callisto and Ganymede	SCIENCE			English	Article							GALILEAN SATELLITES; REFLECTANCE SPECTRUM; INTERNAL STRUCTURE; OPTICAL-CONSTANTS; CARBON-DIOXIDE; ICE ANALOGS; MU-M; FROST	Five absorption features are reported at wavelengths of 3.4, 3.88, 4.05, 4.25, and 4.57 micrometers in the surface materials of the Galilean satellites Callisto and Ganymede from analysis of reflectance spectra returned by the Galileo mission near-infrared mapping spectrometer. Candidate materials include CO2, organic materials (such as tholins containing C=N and C-H), SO2, and compounds containing an SH-functional group; CO2, SO2, and perhaps cyanogen [(CN)(2)] may be present within the surface material itself as collections of a few molecules each. The spectra indicate that the primary surface constituents are water ice and hydrated minerals.	CALTECH,JET PROP LAB,PASADENA,CA 91109; US GEOL SURVEY,DENVER,CO 80225; SCI & TECHNOL INT INC,HONOLULU,HI	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey	McCord, TB (corresponding author), UNIV HAWAII,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822, USA.		Hibbitts, Charles/B-7787-2016	Hibbitts, Charles/0000-0001-9089-4391				Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; Anderson JD, 1997, NATURE, V387, P264, DOI 10.1038/387264a0; ANDERSON JD, 1997, NATURE, V276, P1236; Bishop JL, 1997, METEORIT PLANET SCI, V32, pA14; BLAKE D, 1991, SCIENCE, V254, P548, DOI 10.1126/science.11538372; CALVIN WM, 1991, ICARUS, V89, P305, DOI 10.1016/0019-1035(91)90180-2; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Calvin WM, 1996, GEOPHYS RES LETT, V23, P673, DOI 10.1029/96GL00450; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; Clark R. N., 1986, SATELLITES, P437; CLARK RN, UNPUB USGS DIGITAL S; Colthup N. B., 1990, INTRO INFRARED RAMAN; CRUIKSHANK DP, 1991, ICARUS, V94, P345, DOI 10.1016/0019-1035(91)90233-J; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; FALK M, 1987, J CHEM PHYS, V86, P560, DOI 10.1063/1.452307; FANALE FP, 1979, NATURE, V280, P761, DOI 10.1038/280761a0; Farmer V. C., 1974, INFRARED SPECTRA MIN; FARRELL EF, 1967, AM MINERAL, V52, P380; FINK U, 1973, ASTROPHYS J, V179, pL155, DOI 10.1086/181139; FINK UWE, 1975, ICARUS, V24, P411, DOI 10.1016/0019-1035(75)90058-5; Goody R.M., 1989, ATMOSPHERIC RAD, P67; HOBBS PV, 1974, ICE PHYSICS; IRVINE WM, 1968, ICARUS, V8, P324, DOI 10.1016/0019-1035(68)90083-3; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; MCCORD TB, 1997, T AM GEOPHYS UNION, V78, pS202; MCCORD TB, 1996, B AM ASTRON SOC, V28, P1138; MCCORD TB, 1996, T AM GEOPHYS UNION, V77, pF445; MCDONALD GD, 1991, ICARUS, V94, P354, DOI 10.1016/0019-1035(91)90234-K; Noll KS, 1997, GEOPHYS RES LETT, V24, P1139, DOI 10.1029/97GL00876; Noll KS, 1996, SCIENCE, V273, P341, DOI 10.1126/science.273.5273.341; Notesco G, 1997, ICARUS, V126, P336, DOI 10.1006/icar.1996.5654; OCKMAN N, 1958, ADV PHYS, V7, P199, DOI 10.1080/00018735800101227; PIERSON RH, 1956, ANAL CHEM, V28, P1218, DOI 10.1021/ac60116a002; PILCHER CB, 1972, SCIENCE, V178, P1087, DOI 10.1126/science.178.4065.1087; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; ROUSH TL, 1990, ICARUS, V86, P355, DOI 10.1016/0019-1035(90)90225-X; SALISBURY JW, 1991, INFRARED SPECTRA MIN; SANDFORD SA, 1988, ICARUS, V76, P201, DOI 10.1016/0019-1035(88)90069-3; SANDFORD SA, 1990, ASTROPHYS J, V355, P357, DOI 10.1086/168770; Sill G. T., 1982, SATELLITES JUPITER, P174; SMYTHE WD, 1979, NATURE, V280, P766, DOI 10.1038/280766a0; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; Swayze G., 1993, B AM ASTRON SOC, V25, P1033; WARREN SG, 1986, APPL OPTICS, V25, P2650, DOI 10.1364/AO.25.002650; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WATSON K, 1963, ICARUS, V1, P361; Whittet DCB, 1996, ASTRON ASTROPHYS, V315, pL357; Wilkening L. L, 1982, IAU C 61 COMET DISCO, P85; WOOD DL, 1967, J CHEM PHYS, V47, P2220, DOI 10.1063/1.1703295; [No title captured]; 1996, SCIENCE, V274, P377	54	138	140	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					271	275		10.1126/science.278.5336.271	http://dx.doi.org/10.1126/science.278.5336.271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323203				2022-12-24	WOS:A1997YA56400040
J	Kretzschmar, M; Doody, J; Massague, J				Kretzschmar, M; Doody, J; Massague, J			Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1	NATURE			English	Article							MAD-RELATED PROTEIN; GROWTH-FACTOR-BETA; SIGNALING PATHWAYS; TRANSDUCTION; SPECIFICITY; RECEPTORS; DPC4	The growth factor TGF-beta, bone morphogenetic proteins (BMPs) and related factors regulate cell proliferation, differentiation and apoptosis, controlling the development and maintenance of most tissues(1,2). Their signals are transmitted through the phosphorylation of the tumour-suppressor SMAD proteins by receptor protein serine/threonine kinases (RS/TKs)(3-10), leading to the nuclear accumulation(5,9,11,12) and transcriptional activity of SMAD proteins(6,12,13). Here we report that Smad1, which mediates BMP signals, is also a target of mitogenic growth-factor signalling through epidermal growth factor and hepatocyte growth factor receptor protein tyrosine kinases (RTKs). Phosphorylation occurs at specific serines within the region linking the inhibitory and effector domains of Smad1, and is catalysed by the Erk family of mitogen-activated protein kinases. In contrast to the BMP-stimulated phosphorylation of Smad1, which affects carboxy-terminal serines and induces nuclear accumulation of Smad1(6), Erk-mediated phosphorylation specifically inhibits the nuclear accumulation of Smad1. Thus, Smad1 receives opposing regulatory inputs through RTKs and RS/TKs, and it is this balance that determines the level of Smad1 activity in the nucleus, and so possibly the role of Smad1 in the control of cell fate.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BERNIER SM, 1992, J CELL PHYSIOL, V152, P317, DOI 10.1002/jcp.1041520213; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Ganan Y, 1996, DEVELOPMENT, V122, P2349; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	34	748	775	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					618	622		10.1038/39348	http://dx.doi.org/10.1038/39348			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335504				2022-12-24	WOS:A1997YA00800064
J	Labarrere, CA; Nelson, DR; Faulk, WP				Labarrere, CA; Nelson, DR; Faulk, WP			Endothelial activation and development of coronary artery disease in transplanted human hearts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN CARDIAC ALLOGRAFTS; TISSUE-PLASMINOGEN-ACTIVATOR; ADHESION MOLECULE EXPRESSION; ANTIENDOTHELIAL ANTIBODIES; VASCULAR IMMUNOPATHOLOGY; PROCOAGULANT ACTIVITY; CHRONIC REJECTION; MOUSE HEARTS; RECIPIENTS; CELLS	Context.-The development of coronary artery disease in heart transplants is often associated with graft failure, Early detection of allografts prone to develop this disease is essential to institute new therapeutic approaches that could prolong allograft function. Objective.-To determine if early activation of arterial/arteriolar endothelium predicts the development of coronary artery disease, graft failure, or both in transplanted human hearts. Design.-Prospective cohort study. Setting.-Heart Transplant Center. Participants.-A total of 121 consecutive adult cardiac allograft recipients who received transplants between 1988 and 1995 and were followed up through 1996. Main Outcome Measures.-Development of coronary artery disease and graft failure, Methods.-Immunocytochemistry was performed on serial endomyocardial biopsy specimens to evaluate endothelial activation markers (intercellular adhesion molecule-1 and histocompatibility antigen HLA-DR) in arteries and arterioles. The presence and progression of coronary artery disease was evaluated by annual coronary angiograms with side-by-side comparisons, Results.-None of the 121 donor hearts showed arterial/arteriolar endothelial activation before transplantation. Arterial/arteriolar endothelial activation was present in 78 and absent in 43 of 121 allografts during the first 3 months after transplantation. The time of appearance and the proportion of biopsy specimens showing endothelial activation during these first 3 months were significantly associated with the risk of developing coronary artery disease, the progression of the disease, and the time required to develop the disease (P<.001). Significantly more patients with arterial/arteriolar endothelial activation died or received a second transplant (P<.001). Conclusions.-Activation of arterial/arteriolar endothelium in transplanted human hearts predicts development of coronary artery disease and increased risk of graft failure.	METHODIST RES INST, CLARIAN HLTH, CTR HLTH SERV RES, INDIANAPOLIS, IN 46202 USA; RILEY HOSP, INDIANAPOLIS, IN USA	Indiana University System; James Whitcomb Riley Hospital Children	Labarrere, CA (corresponding author), METHODIST RES INST, CLARIAN HLTH, CTR REPROD & TRANSPLANTAT IMMUNOL, 1701 N SENATE BLVD, INDIANAPOLIS, IN 46202 USA.			Nelson, David/0000-0002-3240-0725				ADAMS DH, 1993, IMMUNOL REV, V134, P5, DOI 10.1111/j.1600-065X.1993.tb00637.x; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Billingham M E, 1990, J Heart Transplant, V9, P587; BRISCOE DM, 1995, TRANSPLANTATION, V59, P204, DOI 10.1097/00007890-199501270-00009; CRISP SJ, 1994, J HEART LUNG TRANSPL, V13, P81; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; FAULK WP, 1989, SEMIN THROMB HEMOST, V15, P88, DOI 10.1055/s-2007-1002691; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, P219; FAULK WP, 1995, TRANSPLANT P, V27, P1944; FAULK WP, 1993, J HEART LUNG TRANSPL, V12, pS125; FAULK WP, 1994, SEMIN HEMATOL, V31, P26; FAULK WP, 1992, ARCH PATHOL LAB MED, V116, P1337; FAULK WP, 1994, MAJOR PROBL PATHOL, V30, P49; Gag SZ, 1996, J AM COLL CARDIOL, V28, P673, DOI 10.1016/0735-1097(96)00201-X; GAO SZ, 1994, J HEART LUNG TRANSPL, V13, P1119; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; KARNOVSKY MJ, 1994, CLIN TRANSPLANT, V8, P308; LABARRERE CA, 1993, TRANSPLANTATION, V55, P1056, DOI 10.1097/00007890-199305000-00021; LABARRERE CA, 1994, CIRCULATION, V89, P1599, DOI 10.1161/01.CIR.89.4.1599; LABARRERE CA, 1995, NEW ENGL J MED, V333, P1111, DOI 10.1056/NEJM199510263331704; LABARRERE CA, 1995, TRANSPLANT P, V27, P1941; LABARRERE CA, 1995, TRANSPLANT P, V27, P1939; LABARRERE CA, 1994, AM J OBSTET GYNECOL, V171, P165, DOI 10.1016/0002-9378(94)90464-2; MEHRA MR, 1995, J AM COLL CARDIOL, V26, P1537, DOI 10.1016/0735-1097(95)00357-6; MILLER LW, 1995, TRANSPLANT REV, V9, P77; POBER JS, 1988, AM J PATHOL, V133, P426; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POSTON RN, 1992, AM J PATHOL, V140, P665; ROSE EA, 1992, J HEART LUNG TRANSPL, V11, pS120; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; RUSSELL PS, 1994, J IMMUNOL, V152, P5135; RUSSELL PS, 1994, AM J PATHOL, V144, P260; SALOMON RN, 1991, AM J PATHOL, V138, P791; SCHOEN JF, 1994, ROBBINS PATHOLOGIC B, P467; SCHROEDER JS, 1991, NEW ENGL J MED, V324, P1805, DOI 10.1056/NEJM199106203242509; STOVIN PGI, 1993, J HEART LUNG TRANSPL, V12, P110; TANIO JW, 1994, CIRCULATION, V89, P1760, DOI 10.1161/01.CIR.89.4.1760; TAYLOR PM, 1992, TRANSPLANTATION, V54, P451, DOI 10.1097/00007890-199209000-00013; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; VERSTRAETE M, 1992, THROMBOSIS CARDIOVAS, P175; WOJTA J, 1993, THROMB HAEMOSTASIS, V70, P469	45	90	93	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1169	1175		10.1001/jama.278.14.1169	http://dx.doi.org/10.1001/jama.278.14.1169			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326477				2022-12-24	WOS:A1997XY42200035
J	Poon, CS; Merrill, CK				Poon, CS; Merrill, CK			Decrease of cardiac chaos in congestive heart failure	NATURE			English	Article							LOW-DIMENSIONAL CHAOS; NONLINEAR DYNAMICS; RATE-VARIABILITY; TIME-SERIES; FIBRILLATION; TURBULENCE; CARDIOLOGY	The electrical properties of the mammalian heart undergo many complex transitions In normal and diseased states(1-7). It has been proposed that the normal heartbeat may display complex nonlinear dynamics, including deterministic chaos(8,9), and that such cardiac chaos may be a useful physiological marker for the diagnosis(10-12) and management(13,14) of certain heart trouble, However, it is not clear whether the heartbeat series of healthy and diseased hearts are chaotic or stochastic(15-17), or whether cardiac chaos represents normal or abnormal behaviour's. Here we have used a highly sensitive technique, which is robust to random noise, to detect chaos(19). We analysed the electrocardiograms from a group of healthy subjects and those with severe congestive heart failure (CHF), a clinical condition associated with a high risk of sudden death. The short-term variations of beat-to-beat interval exhibited strongly and consistently chaotic behaviour in all healthy subjects, but were frequently interrupted by periods of seemingly non-chaotic fluctuations in patients with CHE Chaotic dynamics in the CHF data, even when discernible, exhibited a high degree of random variability over time, suggesting a weaker form of chaos. These findings suggest that cardiac chaos is prevalent in healthy heart, and a decrease in such chaos may be indicative of CHF.			Poon, CS (corresponding author), MIT, HARVARD MIT DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA.							Barahona M, 1996, NATURE, V381, P215, DOI 10.1038/381215a0; CASOLO G, 1989, AM J CARDIOL, V64, P1162, DOI 10.1016/0002-9149(89)90871-0; CHIALVO DR, 1987, NATURE, V330, P749, DOI 10.1038/330749a0; CHIALVO DR, 1990, NATURE, V343, P653, DOI 10.1038/343653a0; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; DENTON TA, 1990, AM HEART J, V120, P1419, DOI 10.1016/0002-8703(90)90258-Y; GARFINKEL A, 1995, TRENDS CARDIOVAS MED, V5, P76, DOI 10.1016/1050-1738(94)00083-2; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; Glass L, 1996, PHYS TODAY, V49, P40, DOI 10.1063/1.881510; GLASS L, 1990, J CARDIOVASC ELECTR, V1, P481; Goldberger AL, 1996, LANCET, V347, P1312, DOI 10.1016/S0140-6736(96)90948-4; GOLDBERGER AL, 1988, EXPERIENTIA, V44, P983, DOI 10.1007/BF01939894; GOLDBERGER AL, 1991, NEWS PHYSIOL SCI, V6, P87, DOI 10.1152/physiologyonline.1991.6.2.87; GREBOGI C, 1984, PHYSICA D, V13, P261, DOI 10.1016/0167-2789(84)90282-3; Ivanov PC, 1996, NATURE, V383, P323, DOI 10.1038/383323a0; JALIFE J, 1990, ANN NY ACAD SCI, P591; KANTERS JK, 1994, J CARDIOVASC ELECTR, V5, P591, DOI 10.1111/j.1540-8167.1994.tb01300.x; KAPLAN DT, 1990, CIRC RES, V67, P886, DOI 10.1161/01.RES.67.4.886; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; POMEAU Y, 1980, COMMUN MATH PHYS, V74, P189, DOI 10.1007/BF01197757; SKINNER JE, 1990, BIO-TECHNOL, V8, P1018, DOI 10.1038/nbt1190-1018; SKINNER JE, 1993, AM HEART J, V125, P731, DOI 10.1016/0002-8703(93)90165-6; SMITH JM, 1984, P NATL ACAD SCI-BIOL, V81, P233, DOI 10.1073/pnas.81.1.233; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608; Turcott RG, 1996, ANN BIOMED ENG, V24, P269, DOI 10.1007/BF02667355; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648	26	251	266	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					492	495		10.1038/39043	http://dx.doi.org/10.1038/39043			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333237				2022-12-24	WOS:A1997XY90900055
J	Suwa, G; Asfaw, B; Beyene, Y; White, TD; Katoh, S; Nagaoka, S; Nakaya, H; Uzawa, K; Renne, P; WoldeGabriel, G				Suwa, G; Asfaw, B; Beyene, Y; White, TD; Katoh, S; Nagaoka, S; Nakaya, H; Uzawa, K; Renne, P; WoldeGabriel, G			The first skull of Australopithecus boisei	NATURE			English	Article							LAKE TURKANA; EARLY HOMINID; KENYA; HOMO; EVOLUTION; ETHIOPIA; REGION; EAST; WEST	Australopithecus boisei was first described from a cranium recovered in 1959 from Olduvai Gorge, Tanzania(1,2). This and subsequent finds, mostly from Kenya's Turkana basin(3-5), resulted in its characterization as a specialized Australopithecus species with a hyper-robust masticatory apparatus(2,4,6). A distinct A. boisei facial morphology has been emphasized to differentiate robust Australopithecus lineages from East and South Africa(6). A preference for closed and/or wet habitats has been hypothesizes. Here we report some new A. boisei specimens, including the taxon's first cranium and associated mandible, from Konso, Ethiopia These fossils extend the known geographical range of A. boisei. They provide clear evidence for the coexistence of A. boisei and Homo erectus within a predominantly dry grassland environment. The A. boisei specimens from Konso demonstrate considerable morphological variation within the species. The unexpected combination of cranial and facial features of this skull cautions against the excessive taxonomic splitting of early hominids based on morphological detail documented in small and/or geographically restricted samples.	RIFT VALLEY RES SERV,ADDIS ABABA,ETHIOPIA; MINIST INFORMAT & CULTURE,DEPT ARCHAEOL & ANTHROPOL,CRCCH,ADDIS ABABA,ETHIOPIA; UNIV CALIF BERKELEY,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720; HYOGO MUSEUM HIMAN & NAT ACTIV,DIV EARTH SCI,SANDA,HYOGO 66913,JAPAN; NAGASAKI UNIV,DEPT GEOG,NAGASAKI 852,JAPAN; KAGAWA UNIV,DEPT EARTH SCI,TAKAMATSU,KAGAWA 852,JAPAN; BERKELEY GEOCHRONOL CTR,BERKELEY,CA 94709; LOS ALAMOS NATL LAB,EES1 D462,LOS ALAMOS,NM 87545	University of California System; University of California Berkeley; Nagasaki University; Kagawa University; Berkeley Geochronolgy Center; United States Department of Energy (DOE); Los Alamos National Laboratory	Suwa, G (corresponding author), UNIV TOKYO,DEPT SCI BIOL,BUNKYO KU,TOKYO 113,JAPAN.			Renne, Paul/0000-0003-1769-5235				Albrecht Gene H., 1993, P123; [Anonymous], 1987, SCI GEOL B; ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; BROWN B, 1993, AM J PHYS ANTHROPOL, V91, P137, DOI 10.1002/ajpa.1330910202; Brunet M, 1996, CR ACAD SCI II A, V322, P907; CARNEY J, 1971, NATURE, V230, P509, DOI 10.1038/230509a0; DUBRUL EL, 1977, AM J PHYS ANTHROPOL, V47, P305, DOI 10.1002/ajpa.1330470211; GOWLETT JAJ, 1981, NATURE, V294, P125, DOI 10.1038/294125a0; HARRIS JM, 1983, KOOBI FORA RES PROJE, V2; HARRIS JM, 1991, KOOBI FORA RES PROJE, V3; Holloway R L, 1983, Hum Neurobiol, V2, P105; Kimbel W.H., 1988, P259; Kimbel WH, 1997, AM J PHYS ANTHROPOL, V103, P235, DOI 10.1002/(SICI)1096-8644(199706)103:2<235::AID-AJPA8>3.3.CO;2-V; LEAKEY LSB, 1959, NATURE, V184, P491, DOI 10.1038/184491a0; LEAKEY LSB, 1964, NATURE, V202, P5, DOI 10.1038/202005a0; LEAKEY MG, 1978, KOOBI FORA RES PROJE, V1; LEAKEY REF, 1988, AM J PHYS ANTHROPOL, V76, P1, DOI 10.1002/ajpa.1330760102; MCCOLLUM MA, 1993, J HUM EVOL, V24, P87, DOI 10.1006/jhev.1993.1009; Rak Y., 1983, AUSTRALOPITHECINE FA, DOI [10.1016/B978-0-12-576280-9.50006-7, DOI 10.1016/B978-0-12-576280-9.50006-7]; RIGHTMIRE GP, 1993, AM J PHYS ANTHROPOL, V90, P1, DOI 10.1002/ajpa.1330900102; SCHRENK F, 1993, NATURE, V365, P833, DOI 10.1038/365833a0; Shipman P., 1988, P343; Suwa G, 1996, AM J PHYS ANTHROPOL, V101, P247, DOI 10.1002/(SICI)1096-8644(199610)101:2<247::AID-AJPA9>3.0.CO;2-Z; Tobias P.V, 1967, OLDUVAI GORGE, V2; UCHIDA A, 1996, PEABODY MUSEUM B, V4; WALKER A, 1986, NATURE, V322, P517, DOI 10.1038/322517a0; WOLDEGABRIEL G, 1994, NATURE, V371, P330, DOI 10.1038/371330a0; WOOD B, 1994, AM J PHYS ANTHROPOL, V95, P117, DOI 10.1002/ajpa.1330950202; WOOD B, 1992, NATURE, V355, P783, DOI 10.1038/355783a0; Wood B. A., 1991, HOMINID CRANIAL REMA, V4	30	80	82	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					489	492		10.1038/39037	http://dx.doi.org/10.1038/39037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XY909	9333236				2022-12-24	WOS:A1997XY90900054
J	Nightingale, SL				Nightingale, SL			Implanted brain stimulator approved to control tremors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-24	WOS:A1997XX30300009
J	Mostad, SB; Overbaugh, J; DeVange, DM; Welch, MJ; Chohan, B; Mandaliya, K; Nyange, P; Martin, HL; NdinyaAchola, J; Bwayo, JJ; Kreiss, JK				Mostad, SB; Overbaugh, J; DeVange, DM; Welch, MJ; Chohan, B; Mandaliya, K; Nyange, P; Martin, HL; NdinyaAchola, J; Bwayo, JJ; Kreiss, JK			Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina	LANCET			English	Article							LONG TERMINAL REPEAT; IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUALLY-TRANSMITTED DISEASES; CERVICOVAGINAL SECRETIONS; BACTERIAL VAGINOSIS; WOMEN; TRANSMISSION; DNA; ASSOCIATION; LYMPHOCYTES	Background Factors that influence shedding of HIV-1 infected cells in cervical and vaginal secretions may be important determinants of sexual and vertical transmission of the virus. We investigated whether hormonal contraceptive use, vitamin A deficiency, and other variables were risk factors for cervical and vaginal shedding of HIV-infected cells. Methods Between December, 1994, and April, 1996, women who attended a municipal sexually transmitted diseases (STDs) clinic in Mombasa, Kenya, and had previously tested positive for HIV-1, were invited to take part in our cross-sectional study. Cervical and vaginal secretions from 318 women were evaluated for the presence of HIV-1 infected cells by PCR amplification of gag DNA sequences. Findings HIV-1 infected cells were detected in 51% of endocervical and 14% of vaginal-swab specimens. Both cervical and vaginal shedding of HIV-1 infected cells were highly associated with CD4 lymphocyte depletion (p=0.0000) and p=0.003, respectively). After adjustment for CD4 count, cervical proviral shedding was significantly associated with use of depot medroxyprogesterone acetate (odds ratio 2.9, 95% CI 1.5-5.7), and with use of low-dose and high-dose oral contraceptive pills (3.8, 1.4-9.9 and 12.3, 1.5-101, respectively), Vitamin A deficiency was highly predictive of vaginal HIV-1 DNA shedding. After adjustment for CD4 count, severe vitamin A deficiency, moderate deficiency, and low normal vitamin A status were associated with 12.9, 8.0, and 4.9-fold increased odds of vaginal shedding, respectively. Gonococcal cervicitis (3.1, 1.1-9.8) and vaginal candidiasis (2.6, 1.2-5.4) were also correlated with significant increases in HIV-1 DNA detection, but Chlamydia trachomatis and Trichomonas vaginalis were not. Interpretation Our study documents several novel correlates of HIV-1 shedding in cervical and vaginal secretions, most notably hormonal contraceptive use and vitamin A deficiency. These factors may be important determinants of sexual or vertical transmission of HIV-1 and are of public health importance because they are easily modified by simple interventions.	UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; COAST PROV GEN HOSP,MOMBASA,KENYA; UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Nairobi	Mostad, SB (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,IARTP,BOX 359909,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039996, R01AI038518, R37AI038518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38518, AI 39996] Funding Source: Medline; NIDDK NIH HHS [DK35816] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amatayakul Kosin, 1994, P363; [Anonymous], 1992, BMJ, V304, P809; BRENNER PF, 1977, AM J OBSTET GYNECOL, V129, P133, DOI 10.1016/0002-9378(77)90733-5; CAROL W, 1992, EXP CLIN ENDOCRINOL, V99, P12, DOI 10.1055/s-0029-1211124; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; CORMACK D, 1987, HAMS HISTOLOGY, P638; EFRON JJ, 1996, JAMA-J AM MED ASSOC, V275, P36; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; FURTH PA, 1990, AIDS RES HUM RETROV, V6, P553, DOI 10.1089/aid.1990.6.553; GHOSH D, 1992, J VIROL, V66, P586, DOI 10.1128/JVI.66.1.586-590.1992; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GROSSMAN CJ, 1984, ENDOCR REV, V5, P435, DOI 10.1210/edrv-5-3-435; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; John GC, 1997, J INFECT DIS, V175, P57, DOI 10.1093/infdis/175.1.57; KOLESNITCHENKO V, 1992, AIDS RES HUM RETROV, V8, P1977, DOI 10.1089/aid.1992.8.1977; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; LANDAY A, 1993, AIDS, V7, P1565, DOI 10.1097/00002030-199312000-00004; MISHELL DR, 1972, AM J OBSTET GYNECOL, V114, P923, DOI 10.1016/0002-9378(72)90098-1; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P200; Schuurs A. H. W. M., 1994, P379; SEMBA RD, 1994, CLIN INFECT DIS, V19, P489, DOI 10.1093/clinids/19.3.489; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; SOMMER A, 1996, VITAMIN A DEFICIENCY; Speroff L, 1996, CLIN GUIDE CONTRACEP, P25; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; VANDEPERRE P, 1988, GENITOURIN MED, V64, P30; WOFSY CB, 1986, LANCET, V1, P527; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	36	249	254	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					922	927		10.1016/S0140-6736(97)04240-2	http://dx.doi.org/10.1016/S0140-6736(97)04240-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314871				2022-12-24	WOS:A1997XY67200011
J	Wylie, PAL; Stevens, D; Drake, W; Stuart, J; Cartwright, K				Wylie, PAL; Stevens, D; Drake, W; Stuart, J; Cartwright, K			Epidemiology and clinical management of meningococcal disease in west Gloucestershire: retrospective, population based study	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; OUTBREAK; MENINGITIS; PENICILLIN	Objective: To study changes in the epidemiology and management of meningococcal disease in one health district during a period of high local incidence of disease. Design: Prospective case ascertainment and data collection over 14 years, with retrospective analysis of cases. Setting: West Gloucestershire (population 320 000). Subjects: Residents developing meningococcal disease between 1 January 1982 and 31 December 1995. Results: 252 cases of invasive meningococcal disease were identified, of which 102 (40%) were officially notified and 191 (76%) were confirmed by culture from a deep site. The observed disease incidence of 5.6/100 000/year was about 2.7 times the national incidence (as measured by either statutory notifications or reference laboratory reports). The period 1983-90 was characterised by a prolonged localised outbreak due to serogroup B serotype 15 sulphonamide resistant (B15R) strains. General practitioners gave benzylpenicillin before hospital admission to 18% of patients who presented with meningococcal disease in the first half of the study period and to 40% who presented in the second half. The overall case fatality rate was 6.7% (17/252). Four deaths were directly or indirectly related to lumbar puncture. Of 120 patients whose lumbar puncture yielded meningococci, nine (8%) showed no abnormality on initial examination. Conclusions: Neither laboratory records nor formal notifications alone can give an accurate estimate of the incidence of meningococcal disease. Because of the dangers of lumbar puncture, the frequency of misleading negative initial findings, and the advent of new diagnostic techniques, the need for samples of cerebrospinal fluid should be critically questioned in each case of suspected meningococcal disease.	GLOUCESTERSHIRE ROYAL HOSP,DEPT PAEDIAT,GLOUCESTER GL1 3NN,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,PUBL HLTH LAB,GLOUCESTER GL1 3NN,ENGLAND	Gloucestershire Royal Hospital; Gloucestershire Royal Hospital								*ADV LIF SUPP GROU, 1993, ADV PAED LIF SUPP PR; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT KAV, 1991, EPIDEMIOL INFECT, V106, P133, DOI 10.1017/S0950268800056491; CARTWRIGHT KAV, 1986, LANCET, V2, P558; CARTWRIGHT KAV, 1989, J CLIN PATHOL, V42, P634, DOI 10.1136/jcp.42.6.634; DAVIES LA, 1989, COMMUNITY MED, V11, P239; *DEP HLTH SOC SEC, 1988, PLCMO882 DHHS; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; Jones D M, 1995, Commun Dis Rep CDR Rev, V5, pR125; Jones D M, 1993, Commun Dis Rep CDR Rev, V3, pR129; JONES DM, 1993, J INFECTION, V27, P83, DOI 10.1016/0163-4453(93)93978-D; Laxton C E, 1994, Commun Dis Rep CDR Rev, V4, pR85; NADEL S, 1995, MENINGOCOCCAL DIS, P207; Newcombe J, 1996, J CLIN MICROBIOL, V34, P1637, DOI 10.1128/JCM.34.7.1637-1640.1996; NI HL, 1992, LANCET, V340, P1432, DOI 10.1016/0140-6736(92)92622-M; PELTOLA H, 1993, LANCET, V342, P509, DOI 10.1016/0140-6736(93)91642-Y; PELTOLA H, 1982, LANCET, V2, P595; POOLMAN JT, 1986, LANCET, V2, P555; *RES COMM BSSI, 1995, J INFECTION, V30, P89; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; SAMUELSSON S, 1992, EPIDEMIOL INFECT, V108, P19, DOI 10.1017/S0950268800049463; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; WEIHE P, 1988, SCAND J INFECT DIS, V20, P291, DOI 10.3109/00365548809032454; Woodward C M, 1995, Commun Dis Rep CDR Rev, V5, pR135	25	58	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					774	779						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345169	Green Published			2022-12-24	WOS:A1997XY91100019
J	Koljak, R; Boutaud, O; Shieh, BH; Samel, N; Brash, AR				Koljak, R; Boutaud, O; Shieh, BH; Samel, N; Brash, AR			Identification of a naturally occurring peroxidase-lipoxygenase fusion protein	SCIENCE			English	Article							CORAL PLEXAURA-HOMOMALLA; ALLENE OXIDE SYNTHASE; MOLECULAR-CLONING; ACID; BIOSYNTHESIS; PURIFICATION; EICOSANOIDS; PROSTANOIDS; CATALASE; PATHWAY	A distant relative of catalase that is specialized for metabolism of a fatty acid hydroperoxide was identified. This heme peroxidase occurs in coral as part of a fusion protein, the other component of which is a lipoxygenase that forms the hydroperoxide substrate, The end product is an unstable epoxide (an allene oxide) that is a potential precursor of prostaglandin-like molecules. These results extend the known chemistry of catalase-like proteins and reveal a distinct type of enzymatic construct involved in the metabolism of polyunsaturated fatty acids.	VANDERBILT UNIV, MED CTR, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; INST CHEM, DEPT BIOORGAN CHEM, EE-0026 TALLINN, ESTONIA	Vanderbilt University			Samel, Nigulas/A-1420-2019		FIC NIH HHS [TW00404] Funding Source: Medline; NIGMS NIH HHS [GM49502] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049502] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BJ, 1985, J AM CHEM SOC, V107, P2976, DOI 10.1021/ja00296a026; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, 1991, J BIOL CHEM, V266, P22926; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; Crombie L, 1991, J CHEM SOC P1, V1, P581; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Gerwick WH, 1996, LIPIDS, V31, P1215, DOI 10.1007/BF02587906; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Hamberg M, 1996, ACTA CHEM SCAND, V50, P219, DOI 10.3891/acta.chem.scand.50-0219; HAMBERG M, 1989, J AM OIL CHEM SOC, V66, P1445, DOI 10.1007/BF02661968; KIKUCHI H, 1982, TETRAHEDRON LETT, V23, P5171, DOI 10.1016/S0040-4039(00)85788-3; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; Peterson Julian A., 1995, P151; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; VALNSHTEIN BK, 1981, NATURE, V293, P411; Wang Y, 1995, Adv Pharmacol, V34, P71; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185; WEINHEIMER AJ, 1974, PROSTAGLANDINS PLEXA, P17	29	100	102	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					1994	1996		10.1126/science.277.5334.1994	http://dx.doi.org/10.1126/science.277.5334.1994			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302294				2022-12-24	WOS:A1997XX84900044
J	Jarrett, RJ				Jarrett, RJ			Should we screen for gestational diabetes?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE-TOLERANCE; PREGNANCY; MELLITUS; NIDDM; WOMEN											ALES KL, 1989, LANCET, V1, P1187; *AM COLL OBST GYN, 1994, MAN DIAB MELL PREGN; Barker DJP, 1992, FETAL INFANT ORIGINS; Coustan DR, 1996, JAMA-J AM MED ASSOC, V275, P1199, DOI 10.1001/jama.275.15.1199; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Gabbe SG, 1989, CARBOHYD METABOL, VIV, P309; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goldenberg RL, 1996, JAMA-J AM MED ASSOC, V275, P1127, DOI 10.1001/jama.275.14.1127; HANSON U, 1990, DIABETOLOGIA, V33, P100, DOI 10.1007/BF00401047; JARRETT RJ, 1993, BMJ-BRIT MED J, V306, P37, DOI 10.1136/bmj.306.6869.37; MOLSTEDPEDERSEN L, 1989, CARBOHYD METABOL, V4, P277; NELSONPIERCY C, 1994, DIABETIC MED, V11, P493, DOI 10.1111/j.1464-5491.1994.tb00313.x; OSULLIVAN JB, 1964, DIABETES, V13, P278; ROBERTS RN, 1993, DIABETIC MED, V10, P438, DOI 10.1111/j.1464-5491.1993.tb00095.x; SAMANTA A, 1989, DIABETES RES CLIN PR, V7, P127, DOI 10.1016/0168-8227(89)90103-4; TOWNER D, 1995, DIABETES CARE, V18, P1446, DOI 10.2337/diacare.18.11.1446; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18	18	33	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	1997	315	7110					736	737		10.1136/bmj.315.7110.736	http://dx.doi.org/10.1136/bmj.315.7110.736			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314761	Green Published			2022-12-24	WOS:A1997XX67400027
J	Kovall, R; Matthews, BW				Kovall, R; Matthews, BW			Toroidal structure of lambda-exonuclease	SCIENCE			English	Article							BREAK REPAIR MODEL; CRYSTAL-STRUCTURE; PHAGE-LAMBDA; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; GENETIC RECOMBINATION; ECORV ENDONUCLEASE; PVUII ENDONUCLEASE; BETA PROTEIN; RED PATHWAY	Structure determination at 2.4 angstrom resolution shows that lambda-exonuclease consists of three subunits that form a toroid. The central channel is funnel shaped, tapering from an inner diameter of about 30 angstroms at the wider end to 15 angstroms at the narrow end. This is adequate to accommodate the DNA substrate and thus provides a structural basis for the ability of the enzyme to sequentially hydrolyze thousands of nucleotides in a highly processive manner, The results also suggest the locations of the active sites and the constraints that limit cleavage to a single strand.	UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of Oregon	Kovall, R (corresponding author), UNIV OREGON, HOWARD HUGHES MED INST, INST MOL BIOL, EUGENE, OR 97403 USA.		Kovall, Rhett/A-3106-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020066, R37GM020066] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20066] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CARTER DM, 1971, J BIOL CHEM, V246, P2502; CASSUTO E, 1971, P NATL ACAD SCI USA, V68, P1639, DOI 10.1073/pnas.68.7.1639; CASSUTO E, 1971, NATURE-NEW BIOL, V229, P13, DOI 10.1038/newbio229013a0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KLEE CB, 1968, J BIOL CHEM, V243, P923; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Linn S.M., 1993, NUCLEASES; LITTLE JW, 1967, J BIOL CHEM, V242, P672; LITTLE JW, 1967, J BIOL CHEM, V242, P679; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OTWINOWSKI Z, 1991, DARESBURY STUDY WEEK, P80; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; STAHL FW, 1985, J MOL BIOL, V181, P199, DOI 10.1016/0022-2836(85)90085-3; STAHL FW, 1985, J GENET, V64, P31; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKAHASHI N, 1990, P NATL ACAD SCI USA, V87, P2790, DOI 10.1073/pnas.87.7.2790; THALER DS, 1987, J MOL BIOL, V195, P75, DOI 10.1016/0022-2836(87)90328-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANOOSTRUM J, 1985, ARCH BIOCHEM BIOPHYS, V243, P332, DOI 10.1016/0003-9861(85)90510-7; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	46	174	219	4	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1824	1827		10.1126/science.277.5333.1824	http://dx.doi.org/10.1126/science.277.5333.1824			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295273				2022-12-24	WOS:A1997XX29800047
J	Scales, SJ; Pepperkok, R; Kreis, TE				Scales, SJ; Pepperkok, R; Kreis, TE			Visualization of ER-to-Golgi transport in living cells reveals a sequential mode of action for COPII and COPI	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; BETA-COP; INTERMEDIATE COMPARTMENT; COATED VESICLES; BREFELDIN-A; SECRETORY PATHWAY; MEMBRANE GLYCOPROTEIN; MONOCLONAL-ANTIBODY; VIRAL GLYCOPROTEIN	Exocytic transport from the endoplasmic reticulum (ER) to the Golgi complex has been visualized in living cells using a chimera of the temperature-sensitive glycoprotein of vesicular stomatitis virus and green fluorescent protein (ts-G-GFP(ct)). Upon shifting to permissive temperature, ts-G-GFP(ct) concentrates into COPII-positive structures close to the ER, which then build up to form an intermediate compartment or transport complex, containing ERGIC-53 and the KDEL receptor, where COPII is replaced by COPI. These structures appear heterogenous and move in a microtubule-dependent manner toward the Golgi complex. Our results suggest a sequential mode of COPII and COPI action and indicate that the transport complexes are ER-to-Golgi transport intermediates from which COPI may be involved in recycling material to the ER.	UNIV GENEVA,DEPT CELL BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283; Pepperkok, Rainer/0000-0002-9762-3583				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P553; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAWANO JI, 1994, J HISTOCHEM CYTOCHEM, V42, P363, DOI 10.1177/42.3.8308253; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1994, J CELL BIOL, V124, P55; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Scheel J, 1997, J CELL BIOL, V137, P319, DOI 10.1083/jcb.137.2.319; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; WHITNEY JA, 1995, CELL, V83, P703	71	417	427	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1137	1148		10.1016/S0092-8674(00)80379-7	http://dx.doi.org/10.1016/S0092-8674(00)80379-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323141	Bronze			2022-12-24	WOS:A1997XX76800019
J	Schwacha, A; Kleckner, N				Schwacha, A; Kleckner, N			Interhomolog bias during meiotic recombination: Meiotic functions promote a highly differentiated interhomolog-only pathway	CELL			English	Article							DOUBLE-STRAND BREAK; SYNAPTONEMAL COMPLEX-FORMATION; SISTER-CHROMATID EXCHANGE; SACCHAROMYCES-CEREVISIAE; RAD51 PROTEIN; CHROMOSOME SYNAPSIS; RECA HOMOLOGS; YEAST MEIOSIS; HOT-SPOT; DNA	Meiotic recombination occurs preferentially between homologous nonsister chromatids rather than between sisters, opposite to the bias of mitotic recombinational repair. We have examined formation of joint molecule recombination intermediates (JMs) between homologs and between sisters in yeast strains lacking the meiotic chromosomal protein Red1, the meiotic recA homolog Dmc1, and/or mitotic recA homolog(s), Rad51, Rad55, and Rad57. Mutant phenotypes imply that most meiotic recombination occurs via an interhomolog-only pathway along which interhomolog bias is established early, prior to or during double strand break (DSB) formation, and then enforced, just at the time when DSBs initiate JM formation. A parallel, less differentiated pathway yields intersister and, probably, a few interhomolog events. Coordinate action of mitotic recA homologs as one functional unit, two functions of RED1, and an interhomolog interaction function of DMC1 are also revealed.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1997, P NATL ACAD SCI USA, V94, P6868, DOI 10.1073/pnas.94.13.6868; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; Bullard SA, 1996, P NATL ACAD SCI USA, V93, P13054, DOI 10.1073/pnas.93.23.13054; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; GAME JC, 1989, GENETICS, V123, P695; Gilbertson LA, 1996, GENETICS, V144, P27; HABER JE, 1984, GENETICS, V106, P185; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; HEYER WD, 1994, EXPERIENTIA, V50, P223, DOI 10.1007/BF01924005; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON JA, 1985, GENETICS, V109, P303; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; KADYK LC, 1992, GENETICS, V132, P387; KENNEY S, 1996, GENES CELLS, V1, P475; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LIN FL, 1984, MOL CELL BIOL, V4, P1020, DOI 10.1128/MCB.4.6.1020; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MaoDraayer Y, 1996, GENETICS, V144, P71; NASSIF N, 1994, MOL CELL BIOL, V14, P1613, DOI 10.1128/MCB.14.3.1613; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Petes TD, 1995, ADV GENET, V33, P41, DOI 10.1016/S0065-2660(08)60330-2; PORTER SE, 1993, GENETICS, V134, P5; Rocco V, 1996, GENES CELLS, V1, P645, DOI 10.1046/j.1365-2443.1996.00256.x; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SCHWACHA A, 1996, THESIS HARVARD U CAM; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SUN H, 1991, MOL CELL BIOL, V11, P6328, DOI 10.1128/MCB.11.12.6328; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; ZENVIRTH D, 1997, IN PRESS GENES CELLS	48	356	362	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1123	1135		10.1016/S0092-8674(00)80378-5	http://dx.doi.org/10.1016/S0092-8674(00)80378-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323140	Bronze			2022-12-24	WOS:A1997XX76800018
J	Takeyama, K; Kitanaka, S; Sato, T; Kobori, M; Yanagisawa, J; Kato, S				Takeyama, K; Kitanaka, S; Sato, T; Kobori, M; Yanagisawa, J; Kato, S			25-hydroxyvitamin D-3 1 alpha-hydroxylase and vitamin D synthesis	SCIENCE			English	Article							D ENDOCRINE SYSTEM; GENE-EXPRESSION; D METABOLISM; CALCIFEROL METABOLISM; PARATHYROID-HORMONE; MESSENGER-RNA; RAT; KIDNEY; 24-HYDROXYLASE; 1,25-DIHYDROXYVITAMIN-D3	Renal 25-hydroxyvitamin D-3 1 alpha-hydroxylase [1 alpha(OH)ase] catalyzes metabolic activation of 25-hydroxyvitamin D-3 into 1 alpha,25-dihydroxyvitamin D-3 [1 alpha,25(OH)(2)D-3], an active form of vitamin D, and is inhibited by 1 alpha,25(OH)(2)D-3. 1 alpha(OH)ase, which was cloned from the kidney of mice lacking the vitamin D receptor (VDR-/- mice), is a member of the P450 family of enzymes (P450(VD1 alpha)). Expression of 1 alpha(OH)ase was suppressed by 1 alpha,25(OH)(2)D-3 in VDR+/+ and VDR+/- mice but not in VDR-/- mice. These results indicate that the negative feedback regulation of active vitamin D synthesis is mediated by 1 alpha(OH)ase through liganded VDR.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; JAPAN SCI & TECHNOL, CREST, KAWAGUCHI, SAITAMA 332, JAPAN; YAMANOUCHI PHARMACEUT CO LTD, INST DRUG DISCOVERY RES, MOL MED LABS, TSUKUBA, IBARAKI 305, JAPAN	University of Tokyo; Japan Science & Technology Agency (JST); Astellas Pharmaceuticals								ADAMS JS, 1985, J CLIN ENDOCR METAB, V60, P960, DOI 10.1210/jcem-60-5-960; AXEN E, 1995, FEBS LETT, V375, P277, DOI 10.1016/0014-5793(95)01226-5; BALSAN S, 1991, NESTLE NUTR WORKS SE, V21, P155; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKMAN MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P535, DOI 10.1006/abbi.1995.1328; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BURGOSTRINIDAD M, 1992, J BIOL CHEM, V267, P3498; COLSTON KW, 1973, BIOCHEM J, V134, P817, DOI 10.1042/bj1340817; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DeLuca H F, 1986, Adv Exp Med Biol, V196, P361; DILWORTH FJ, 1995, J BIOL CHEM, V270, P16766, DOI 10.1074/jbc.270.28.16766; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; FRASER DR, 1973, NATURE-NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0; FREDERICK MA, 1995, CURRENT PROTOCOLS MO; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GRAY TK, 1979, SCIENCE, V204, P1311, DOI 10.1126/science.451538; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HENRY HL, 1974, J BIOL CHEM, V249, P7584; HENRY HL, 1992, J CELL BIOCHEM, V49, P4, DOI 10.1002/jcb.240490103; HENRY HL, 1974, J BIOL CHEM, V249, P7529; HOWARD GA, 1981, J BIOL CHEM, V256, P7738; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; ITOH S, 1995, BBA-GENE STRUCT EXPR, V1264, P26, DOI 10.1016/0167-4781(95)00147-9; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KAWASHIMA H, 1981, NATURE, V291, P327, DOI 10.1038/291327a0; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MANO H, 1994, J BIOL CHEM, V269, P1591; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MAWER EB, 1994, J CLIN ENDOCR METAB, V79, P554, DOI 10.1210/jc.79.2.554; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; Sakaki T, 1996, J BIOL CHEM, V271, P26209, DOI 10.1074/jbc.271.42.26209; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; TONG HS, 1994, J BONE MINER RES, V9, P577; TURNER RT, 1980, P NATL ACAD SCI-BIOL, V77, P5720, DOI 10.1073/pnas.77.10.5720; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Wakino S, 1996, GERONTOLOGY, V42, P67; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WARNER M, 1982, J BIOL CHEM, V257, P2995; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	55	406	426	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1827	1830		10.1126/science.277.5333.1827	http://dx.doi.org/10.1126/science.277.5333.1827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295274				2022-12-24	WOS:A1997XX29800048
J	Ulrich, HD; Mundroff, E; Santarsiero, BD; Driggers, EM; Stevens, RC; Schultz, PG				Ulrich, HD; Mundroff, E; Santarsiero, BD; Driggers, EM; Stevens, RC; Schultz, PG			The interplay between binding energy and catalysis in the evolution of a catalytic antibody	NATURE			English	Article							OXY-COPE REARRANGEMENT; IMMUNE-RESPONSE; GERM-LINE; DIVERSITY; MECHANISM; GENES; VL; VH	Antibody catalysis(1) provides an opportunity to examine the evolution of binding energy and its relation to catalytic function in a system that has many parallels with natural enzymes. Here we report such a study involving an antibody AZ-28 that catalyses an oxy-Cope rearrangement, a pericyclic reaction that belongs to a well studied and widely used class of reactions in organic chemistry(2). Immunization with transition state analogue 1 results in a germline-encoded antibody that catalyses the rearrangement of hexadiene 2 to aldehyde 3 with a rate approaching that of a related pericyclic reaction catalysed by the enzyme chorismate mutase(3). Affinity maturation gives antibody AZ-28, which has six amino acid substitutions, one of which results in a decrease in catalytic rate. To understand the relationship between binding and catalytic rate in this system we characterized a series of active-site mutants and determined the three-dimensional crystal structure of the complex of AZ-28 with the transition state analogue. This analysis indicates that the activation energy depends on a complex balance of several, stereoelectronic effects which are controlled by an extensive network of binding interactions in the active site, Thus in this instance the combinatorial diversity of the immune system provided both an efficient catalyst far a reaction where no enzyme is known, as well as an opportunity to explore the mechanisms and evolution of biological catalysis.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV MAT SCI, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley			Santarsiero, Bernard D/N-9249-2018; Stevens, Raymond/K-7272-2015	Santarsiero, Bernard D/0000-0002-9032-9699; Stevens, Raymond/0000-0002-4522-8725; Ulrich, Helle D./0000-0003-0431-2223				AKOLKAR PN, 1987, J IMMUNOL, V138, P4472; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BRAISTED AC, 1994, J AM CHEM SOC, V116, P2211, DOI 10.1021/ja00084a098; BRUNGER AT, 1996, X PLOR VERSION 3 851; DEWAR MJS, 1977, J AM CHEM SOC, V99, P4417, DOI 10.1021/ja00455a034; DOERING WVE, 1962, TETRAHEDRON, V18, P67; DRIGGERS EM, UNPUB J AM CHEM SOC; GAJEWSKI JJ, 1991, J AM CHEM SOC, V113, P967, DOI 10.1021/ja00003a033; GAJEWSKI JJ, 1980, ACCOUNTS CHEM RES, V13, P142, DOI 10.1021/ar50149a003; Haldane JBS, 1930, ENZYMES; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; NAHMIAS C, 1988, J IMMUNOL, V140, P1304; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PECH M, 1981, NATURE, V291, P668, DOI 10.1038/291668a0; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; STEIGERWALD ML, 1979, J AM CHEM SOC, V101, P1994, DOI 10.1021/ja00502a011; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; ULRICH H, 1996, THESIS U CALIFORNIA; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Ulrich HD, 1996, ACTA CHEM SCAND, V50, P328, DOI 10.3891/acta.chem.scand.50-0328; ULRICH HD, UNPUB J MOL BIOL; Woodward R. B., 1970, CONSERVATION ORBITAL	33	76	77	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					271	275		10.1038/38470	http://dx.doi.org/10.1038/38470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305839				2022-12-24	WOS:A1997XW77200043
J	Leirs, H; Stenseth, NC; Nichols, JD; Hines, JE; Verhagen, R; Verheyen, W				Leirs, H; Stenseth, NC; Nichols, JD; Hines, JE; Verhagen, R; Verheyen, W			Stochastic seasonality and nonlinear density-dependent factors regulate population size in an African rodent	NATURE			English	Article							CAPTURE-RECAPTURE; TANZANIA; SURVIVAL; CYCLES; MODELS; RATS	Ecology has long been troubled by the controversy over how populations are regulated(1,2). Some ecologists focus on the role of environmental effects, whereas others argue that density-dependent feedback mechanisms are central(3-6). The relative importance of both processes is still hotly debated, but clear examples of both processes acting in the same population are rare(7,8). Key-factor analysis (regression of population changes on possible causal factors) and time-series analysis are often used to investigate the presence of density dependence, but such approaches may be biased and provide no information on actual demographic rates(9,10). Here we report on both density-dependent and density-independent effects in a murid rodent pest species, the multimammute rat Mastomys natalensis (Smith, 1834), using statistical capture-recapture models, Both effects occur simultaneously, but we also demonstrate that they do not affect all demographic rates in the same way. We have incorporated the obtained estimates of demographic rates in a population dynamics model and show that the observed dynamics are affected by stabilizing nonlinear density-dependent components coupled with strong deterministic and stochastic seasonal components.	UNIV OSLO,DEPT BIOL,DIV ZOOL,N-0316 OSLO,NORWAY; NATL BIOL SERV,PATUXENT WILDLIFE RES CTR,LAUREL,MD 20708; UNIV ANTWERP,RIJKSUNIV CTR ANTWERP,DEPT BIOL,B-2020 ANTWERP,BELGIUM	University of Oslo; University of Antwerp	Leirs, H (corresponding author), DANISH PEST INFESTAT LAB,SKOVBRYNET 14,DK-2800 LYNGBY,DENMARK.		Leirs, Herwig/B-8197-2008; Stenseth, Nils Chr./G-5212-2016	Leirs, Herwig/0000-0002-7612-5024; Stenseth, Nils Chr./0000-0002-1591-5399				Andrewartha H.G., 1954, DISTRIBUTION ABUNDAN; BROWNIE C, 1993, BIOMETRICS, V49, P1173, DOI 10.2307/2532259; COHEN JE, 1995, NATURE, V378, P610, DOI 10.1038/378610a0; Ebenman B., 1988, SIZE STRUCTURED POPU; GRANJON L, 1994, POL ECOL STUD, V30, P343; GRENFELL BT, 1992, NATURE, V355, P823, DOI 10.1038/355823a0; HINES JE, 1994, MSSURVTV USERS MANUA; HORNFELDT B, 1994, ECOLOGY, V75, P791, DOI 10.2307/1941735; HUBERT B, 1982, REV ECOL, V35, P73; ITO Y, 1972, OECOLOGIA, V10, P347, DOI 10.1007/BF00345737; KENDALL WL, 1992, WILDLIFE 2001 : POPULATIONS, P31; Krebs C.J., 1999, ECOLOGICAL METHODOLO; Kuno E., 1971, Researches Popul Ecol Kyoto Univ, V13, P28, DOI 10.1007/BF02522011; Lebreton J.-D., 1991, BIRD POPULATION STUD, P105; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; LEIRS H, 1994, J TROP ECOL, V10, P55, DOI 10.1017/S0266467400007719; Leirs H, 1996, J APPL ECOL, V33, P937, DOI 10.2307/2404675; LEIRS H, 1993, OIKOS, V68, P53, DOI 10.2307/3545308; NICHOLS JD, 1984, ACTA THERIOL, V29, P357, DOI 10.4098/AT.arch.84-35; Nicholson AJ, 1933, J ANIM ECOL, V2, P132, DOI 10.2307/954; OSTFELD RS, 1995, ECOLOGY, V76, P521, DOI 10.2307/1941210; OSTFELD RS, 1993, NATURE, V366, P259, DOI 10.1038/366259a0; Pollock K. H., 1982, J WILDLIFE MANAGE, V46, P757, DOI DOI 10.2307/3808568; POLLOCK KH, 1981, BIOMETRICS, V37, P521, DOI 10.2307/2530565; Putman RJ, 1996, MAMMAL REV, V26, P81, DOI 10.1111/j.1365-2907.1996.tb00148.x; Saitoh T, 1997, J ANIM ECOL, V66, P14, DOI 10.2307/5960; SUGIHARA G, 1995, NATURE, V378, P559, DOI 10.1038/378559a0; White A, 1996, P ROY SOC B-BIOL SCI, V263, P1731, DOI 10.1098/rspb.1996.0253; WOLDA H, 1993, OECOLOGIA, V95, P581, DOI 10.1007/BF00317444; [No title captured]	30	244	249	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					176	180		10.1038/38271	http://dx.doi.org/10.1038/38271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296494				2022-12-24	WOS:A1997XV75700047
J	Case, RB; Pierce, DW; HomBooher, N; Hart, CL; Vale, RD				Case, RB; Pierce, DW; HomBooher, N; Hart, CL; Vale, RD			The directional preference of kinesin motors is specified by an element outside of the motor catalytic domain	CELL			English	Article							DIRECTED MICROTUBULE MOTOR; STIMULATED ATP HYDROLYSIS; CRYSTAL-STRUCTURE; DIMERIC KINESIN; NCD PROTEIN; HEAVY-CHAIN; MOVEMENT; DROSOPHILA; MOLECULES; SEGREGATION	Members of the kinesin superfamily share a similar motor catalytic domain yet move either toward the plus end (e.g., conventional kinesin) or the minus end (e.g., Ncd) of microtubules. The structural features that determine the polarity of movement have remained enigmatic. Here, we show that kinesin's catalytic domain (316 residues) in a dimeric construct (560 residues) can be replaced with the catalytic domain of Ncd and that the resultant motor moves in the kinesin direction. We also demonstrate that this chimera does not move processively over many tubulin subunits, which is similar to Ncd but differs from the highly processive motion of conventional kinesin. These findings reveal that the catalytic domain contributes to motor processivity but does not control the polarity of movement. We propose that a region adjacent to the catalytic domain serves as a mechanical transducer that determines directionality.										Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1995, PROTEIN PROFILE, V2, P1112; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GIBBONS IR, 1979, J BIOL CHEM, V254, P187; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; HYMAN AA, 1991, J CELL SCI S, V14, P125; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; Morii H, 1997, BIOCHEMISTRY-US, V36, P1933, DOI 10.1021/bi962392l; MORRIS RL, 1997, IN PRESS J CELL BIOL; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; Pierce DW, 1997, NATURE, V388, P338, DOI 10.1038/41009; PIERCE DW, 1997, IN PRESS METH ENZYMO; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1993, NATURE, V361, P115, DOI 10.1038/361115a0; Tripet B, 1997, J BIOL CHEM, V272, P8946; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	46	283	286	2	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					959	966		10.1016/S0092-8674(00)80360-8	http://dx.doi.org/10.1016/S0092-8674(00)80360-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298907	Bronze			2022-12-24	WOS:A1997XV56300016
J	Thorpe, CJ; Schlesinger, A; Carter, JC; Bowerman, B				Thorpe, CJ; Schlesinger, A; Carter, JC; Bowerman, B			Wnt signaling polarizes an early C-elegans blastomere to distinguish endoderm from mesoderm	CELL			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS; MATERNAL GENES; EMBRYOS; GLP-1; PROTEIN; AXES; GUT; IDENTIFICATION; ESTABLISHMENT	A polarizing signal induces endoderm production by a 4-cell stage blastomere in C. elegans called EMS. We identified 16 mutations in five genes, mom-1 through mom-5, required for EMS to produce endoderm. mom-1, mom-2, and mom-3 are required in the signaling cell, P-2, while mom-4 is required in EMS. P-2 signaling downregulates an HMG domain protein, POP-1, in one EMS daughter. The sequence of mom-2 predicts that it encodes a member of the Wnt family of secreted glycoproteins, which in other systems activate HMG domain proteins. Defective mitotic spindle orientations in mom mutant embryos indicate that Wnt signaling influences cytoskeletal polarity in blastomeres throughout the early embryo.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NICHD NIH HHS [HD07348] Funding Source: Medline; NIGMS NIH HHS [GM07413, GM49869] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; DU SJ, 1995, MOL CELL BIOL, V15, P2625; EDGAR LG, 1995, CAENORHABDITIS ELEGA, P303; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Hird SN, 1996, DEVELOPMENT, V122, P1303; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUTTER H, 1994, DEVELOPMENT, V120, P2051; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Shelton CA, 1996, DEVELOPMENT, V122, P2043; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	43	409	425	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					695	705		10.1016/S0092-8674(00)80530-9	http://dx.doi.org/10.1016/S0092-8674(00)80530-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288749	Bronze			2022-12-24	WOS:A1997XT06600013
J	Ibba, M; Morgan, S; Curnow, AW; Pridmore, DR; Vothknecht, UC; Gardner, W; Lin, W; Woese, CR; Soll, D				Ibba, M; Morgan, S; Curnow, AW; Pridmore, DR; Vothknecht, UC; Gardner, W; Lin, W; Woese, CR; Soll, D			A euryarchaeal Lysyl-tRNA synthetase: Resemblance to class I synthetases	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; SEQUENCE; RECOGNITION; GENE; ARCHAEA; GENOME	The sequencing of euryarchaeal genomes has suggested that the essential protein lysyl-transfer RNA (tRNA) synthetase (LysRS) is absent from such organisms. However, a single 62-kilodalton protein with canonical LysRS activity was purified from Methanococcus maripaludis, and the gene that encodes this protein was cloned, The predicted amino acid sequence of M. maripaludis LysRS is similar to open reading frames of unassigned function in both Methanobacterium thermoautotrophicum and Methanococcus jannaschii but is unrelated to canonical LysRS proteins reported in eubacteria, eukaryotes, and the crenarchaeote Sulfolobus solfataricus. The presence of amino acid motifs characteristic of the Rossmann dinucleotide-binding domain identifies M. maripaludis LysRS as a class I aminoacyl-tRNA synthetase, in contrast to the known examples of this enzyme, which are class II synthetases, These data question the concept that the classification of aminoacyl-tRNA synthetases does not vary throughout living systems.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT MOL CELLULAR & DEV BIOL,NEW HAVEN,CT 06511; HAMILTON COLL,DEPT BIOL,CLINTON,NY 13323; NESTLE RES CTR,CH-1000 LAUSANNE,SWITZERLAND; UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602	Yale University; Yale University; Hamilton College; Nestle SA; University System of Georgia; University of Georgia			Vothknecht, Ute C/F-4678-2014	Vothknecht, Ute C/0000-0002-8930-0127				Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bjork Glenn R., 1995, P165; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHEN JS, 1994, J BACTERIOL, V176, P2699, DOI 10.1128/JB.176.9.2699-2705.1994; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FREIST W, 1995, BIOL CHEM H-S, V376, P451; Grayling RA, 1996, FEMS MICROBIOL REV, V18, P203; Hong KW, 1996, EMBO J, V15, P1983, DOI 10.1002/j.1460-2075.1996.tb00549.x; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; NAGEL GM, 1995, J MOL EVOL, V40, P487; Neher R., 1963, J CHROMATOGR, V12, P329; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; Ouzounis CA, 1996, J MOL EVOL, V42, P234, DOI 10.1007/BF02198849; Sensen CW, 1996, MOL MICROBIOL, V22, P175, DOI 10.1111/j.1365-2958.1996.tb02666.x; SMITH D, IN PRESS J BACTERIOL; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWANSON R, COMMUNICATION; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WATANABE K, 1994, NUCLEIC ACIDS RES, V22, P79, DOI 10.1093/nar/22.1.79; Watanabe Kimitsuna, 1995, P225	27	178	184	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1119	1122		10.1126/science.278.5340.1119	http://dx.doi.org/10.1126/science.278.5340.1119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353192				2022-12-24	WOS:A1997YE65200051
J	Stopfer, M; Bhagavan, S; Smith, BH; Laurent, G				Stopfer, M; Bhagavan, S; Smith, BH; Laurent, G			Impaired odour discrimination on desynchronization of odour-encoding neural assemblies	NATURE			English	Article							APIS-MELLIFERA; OLFACTORY NETWORK; OSCILLATIONS; HONEYBEE; CORTEX; ODORS; BULB	Stimulus-evoked oscillatory synchronization of neural assemblies has been described in the olfactory(1-5) and visual(6-8) systems of several vertebrates and invertebrates. In locusts, information about odour identity is contained in the timing of action potentials in an oscillatory population response(9-11), suggesting that oscillations may reflect a common reference far messages encoded in time, Although the stimulus-evoked oscillatory phenomenon is reliable, its roles in sensation, perception, memory formation and pattern recognition remain to be demonstrated-a task requiring a behavioural paradigm, Using honeybees, we now demonstrate that odour encoding involves, as it does in locusts, the oscillatory synchronization of assemblies of projection neurons and that this synchronization is also selectively abolished by picrotoxin, an antagonist of the GABA(A) (gamma-aminobutyric acid) receptor. By using a behavioural leaning paradigm, we show that picrotoxin-induced desynchronization impairs the discrimination of molecularly similar odorants, but not that of dissimilar odorants, It appears, therefore, that oscillatory synchronization of neuronal assemblies is functionally relevant, and essential for fine sensory discrimination This suggests that oscillatory synchronization and the kind of temporal encoding it affords provide an additional dimension by which the brain could segment spatially overlapping stimulus representations.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; OHIO STATE UNIV, DEPT ENTOMOL, COLUMBUS, OH 43210 USA	California Institute of Technology; University System of Ohio; Ohio State University			Laurent, Gilles/A-4583-2012	Laurent, Gilles/0000-0002-2296-114X; Stopfer, Mark/0000-0001-9200-1884				Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; Bhagavan S, 1997, PHYSIOL BEHAV, V61, P107, DOI 10.1016/S0031-9384(96)00357-5; BITTERMAN ME, 1983, J COMP PSYCHOL, V97, P107, DOI 10.1037/0735-7036.97.2.107; DELANEY KR, 1994, P NATL ACAD SCI USA, V91, P669, DOI 10.1073/pnas.91.2.669; GELPERIN A, 1990, NATURE, V345, P437, DOI 10.1038/345437a0; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; GRAY CM, 1988, EXP BRAIN RES, V69, P378; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; Kuwabara M., 1957, Journal of the Faculty of Science Hokkaido University Zoology, V13, P458; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Laurent G, 1996, TRENDS NEUROSCI, V19, P489, DOI 10.1016/S0166-2236(96)10054-0; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MACMILLAN CS, 1987, J COMP PHYSIOL A, V160, P359, DOI 10.1007/BF00613025; MAUELSHAGEN J, 1993, J NEUROPHYSIOL, V69, P609, DOI 10.1152/jn.1993.69.2.609; Menzel R., 1983, P206; MENZEL R, 1988, NATO ASI SERIES H, V19, P335; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NEUENSCHWANDER S, 1993, EUR J NEUROSCI, V5, P870, DOI 10.1111/j.1460-9568.1993.tb00939.x; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; Smith BH, 1997, BEHAV NEUROSCI, V111, P57; SMITH BH, 1989, J INSECT PHYSIOL, V35, P369, DOI 10.1016/0022-1910(89)90110-8; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; YOKOI M, 1995, P NATL ACAD SCI USA, V92, P3371, DOI 10.1073/pnas.92.8.3371	26	692	703	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					70	74		10.1038/36335	http://dx.doi.org/10.1038/36335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363891				2022-12-24	WOS:A1997YE47700053
J	Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN				Dickerson, RR; Kondragunta, S; Stenchikov, G; Civerolo, KL; Doddridge, BG; Holben, BN			The impact of aerosols on solar ultraviolet radiation and photochemical smog	SCIENCE			English	Article							NITROGEN-DIOXIDE PHOTOLYSIS; SKY BRIGHTNESS MEASUREMENTS; EASTERN-UNITED-STATES; AIR-POLLUTION; ACTINIC FLUX; ATMOSPHERE; OZONE; TROPOSPHERE; SCATTERING; CLOUDS	Photochemical smog, or ground-level ozone, has been the most recalcitrant of air pollution problems, but reductions in emissions of sulfur and hydrocarbons may yield unanticipated benefits in air quality. While sulfate and some organic aerosol particles scatter solar radiation back into space and can cool Earth's surface, they also change the actinic flux of ultraviolet (UV) radiation. Observations and numerical models show that UV-scattering particles in the boundary layer accelerate photochemical reactions and smog production, but UV-absorbing aerosols such as mineral dust and soot inhibit smog production. Results could have major implications for the control of air pollution.	NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20742	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Dickerson, RR (corresponding author), UNIV MARYLAND,DEPT METEOROL,COLLEGE PK,MD 20742, USA.		Dickerson, Russell/ABB-1512-2020; Kondragunta, Shobha/F-5601-2010; Stenchikov, Georgiy/AAA-4371-2022; Georgiy, Stenchikov/J-8569-2013; Dickerson, Russell R/F-2857-2010	Dickerson, Russell/0000-0003-0206-3083; Kondragunta, Shobha/0000-0001-8593-8046; Dickerson, Russell R/0000-0003-0206-3083; Stenchikov, Georgiy Lvovich/0000-0001-9033-4925				Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; BLACKBURN TE, 1992, J GEOPHYS RES-ATMOS, V97, P10109, DOI 10.1029/92JD00504; Blindauer C, 1996, J ATMOS CHEM, V24, P1, DOI 10.1007/BF00053820; BRUEHL C, 1989, GEOPHYS RES LETT, V16, P703; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; CIVEROLO KL, 1996, THESIS U MARYLAND CO; DENTENER FJ, 1993, J GEOPHYS RES-ATMOS, V98, P7149, DOI 10.1029/92JD02979; DICKERSON RR, 1982, J GEOPHYS RES-OCEANS, V87, P4933, DOI 10.1029/JC087iC07p04933; FinlaysonPitts BJ, 1997, SCIENCE, V276, P1045, DOI 10.1126/science.276.5315.1045; Flowers EC, 1969, J APPL METEOROL, V8, P955, DOI [10.1175/1520-0450(1969)0082.0.CO;2, DOI 10.1175/1520-0450(1969)0082.0.CO;2]; FRASER RS, 1985, IEEE J GEOSCI REM GE, V23, P525; Hauglustaine DA, 1996, GEOPHYS RES LETT, V23, P2609, DOI 10.1029/96GL02474; Herman JR, 1997, J GEOPHYS RES-ATMOS, V102, P16911, DOI 10.1029/96JD03680; HOLBEN BN, 1997, 6 INT S PHYS MEAS SI, P75; HUSAR RB, 1981, ATMOS ENVIRON, V15, P1919, DOI 10.1016/0004-6981(81)90226-2; HUSAR RB, 1993, ENVIRON SCI TECHNOL, V27, P12, DOI 10.1021/es00038a001; KAUFMAN YJ, 1986, J ATMOS SCI, V43, P1135, DOI 10.1175/1520-0469(1986)043<1135:FEFMOT>2.0.CO;2; KAUFMAN YJ, 1983, J CLIM APPL METEOROL, V22, P1694, DOI 10.1175/1520-0450(1983)022<1694:LEBADS>2.0.CO;2; KAUFMAN YJ, 1994, J GEOPHYS RES-ATMOS, V99, P10341, DOI 10.1029/94JD00229; KELLEY P, 1995, GEOPHYS RES LETT, V22, P2621, DOI 10.1029/95GL02563; KIEHL JT, 1993, SCIENCE, V260, P311, DOI 10.1126/science.260.5106.311; KONDRAGUNTA S, 1997, THESIS U MARYLAND CO; Lary DJ, 1997, J GEOPHYS RES-ATMOS, V102, P3671, DOI 10.1029/96JD02969; LELIEVELD J, 1990, NATURE, V343, P277; Liang JY, 1997, J GEOPHYS RES-ATMOS, V102, P5993, DOI 10.1029/96JD02957; LIU S, 1901, GEOPHYS RES LETT, V18, P2265; Lu Y, 1996, CHEMOSPHERE, V32, P739, DOI 10.1016/0045-6535(96)00028-8; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; Meng Z, 1997, SCIENCE, V277, P116, DOI 10.1126/science.277.5322.116; Naja M, 1996, GEOPHYS RES LETT, V23, P81, DOI 10.1029/95GL03589; Nakajima T, 1996, APPL OPTICS, V35, P2672, DOI 10.1364/AO.35.002672; *NASA, 1994, CHEM KIN PHOT DAT US; National Academy of Sciences, 1991, RETH OZ PROBL URB RE; Odum JR, 1997, SCIENCE, V276, P96, DOI 10.1126/science.276.5309.96; PETERSON JT, 1976, ATMOS ENVIRON, V10, P459, DOI 10.1016/0004-6981(76)90026-3; PETERSON JT, 1981, J APPL METEOROL, V20, P229, DOI 10.1175/1520-0450(1981)020<0229:ATOCNC>2.0.CO;2; PETERSON JT, 1977, ATMOS ENVIRON, V11, P689, DOI 10.1016/0004-6981(77)90177-9; PIELKE RA, 1992, METEOROL ATMOS PHYS, V49, P69, DOI 10.1007/BF01025401; Ravishankara AR, 1997, SCIENCE, V276, P1058, DOI 10.1126/science.276.5315.1058; Remer LA, 1997, J GEOPHYS RES-ATMOS, V102, P16849, DOI 10.1029/96JD01932; Rhoads KP, 1997, J GEOPHYS RES-ATMOS, V102, P18981, DOI 10.1029/97JD01078; RUGGABER A, 1994, J ATMOS CHEM, V18, P171, DOI 10.1007/BF00696813; RYAN W, IN PRESS J AIR WASTE; SEINFELD JH, 1989, SCIENCE, V243, P745, DOI 10.1126/science.243.4892.745; Shetter RE, 1996, J GEOPHYS RES-ATMOS, V101, P14631, DOI 10.1029/96JD00211; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; Systems Applications International (SAI), 1995, US GUID VAR GRID URB; *US EPA, 1996, EPA454R96005; US-EPA, 1991, EPA450491013; VARSHNEY CK, 1992, ATMOS ENVIRON B-URB, V26, P291, DOI 10.1016/0957-1272(92)90004-C; Walcek CJ, 1997, ATMOS ENVIRON, V31, P1221, DOI 10.1016/S1352-2310(96)00257-9; WISCOMBE WJ, 1980, APPL OPTICS, V19, P1505, DOI 10.1364/AO.19.001505; ZAFONTE L, 1977, ENVIRON SCI TECHNOL, V11, P483, DOI 10.1021/es60128a006	54	417	460	16	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					827	830		10.1126/science.278.5339.827	http://dx.doi.org/10.1126/science.278.5339.827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346474				2022-12-24	WOS:A1997YD47900036
J	Gamble, TR; Yoo, SH; Vajdos, FF; vonSchwedler, UK; Worthylake, DK; Wang, H; McCutcheon, JP; Sundquist, WI; Hill, CP				Gamble, TR; Yoo, SH; Vajdos, FF; vonSchwedler, UK; Worthylake, DK; Wang, H; McCutcheon, JP; Sundquist, WI; Hill, CP			Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MAJOR HOMOLOGY REGION; RETROVIRAL GAG PROTEINS; CYCLOPHILIN-A; VIRION MORPHOGENESIS; PARTICLE FORMATION; ASSOCIATION; STEPS	The carboxyl-terminal domain, residues 146 to 231, of the human immunodeficiency virus-1 (HIV-1) capsid protein [CA(146-231)] is required for capsid dimerization and viral assembly. This domain contains a stretch of 20 residues, called the major homology region (MHR), which is conserved across retroviruses and is essential for viral assembly, maturation, and infectivity. The crystal structures of CA(146-231) and CA(151-231) reveal that the globular domain is composed of four helices and an extended aminoterminal strand. CA(146-231) dimerizes through parallel packing of helix 2 across a dyad. The MHR is distinct from the dimer interface and instead forms an intricate hydrogen-bonding network that interconnects strand 1 and helices 1 and 2. Alignment of the CA(146-231) dimer with the crystal structure of the capsid amino-terminal domain provides a model for the intact protein and extends models for assembly of the central conical core of HIV-1.	UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah				McCutcheon, John/0000-0002-5489-6039	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043036, R01AI040333] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI40333, R01 AI43036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNER AT, 1996, X PLOR VERSION 3 843; Clish CB, 1996, FEBS LETT, V378, P43, DOI 10.1016/0014-5793(95)01419-5; CRAVEN RC, 1995, J VIROL, V69, P4213, DOI 10.1128/JVI.69.7.4213-4227.1995; DORFMAN T, 1994, J VIROL, V68, P8180, DOI 10.1128/JVI.68.12.8180-8187.1994; FRANKE EK, 1994, J VIROL, V68, P5300, DOI 10.1128/JVI.68.8.5300-5305.1994; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; GELDERBLOM HR, 1992, MEMBRANE INTERACTION, P33; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; GOFF S, 1981, J VIROL, V38, P238; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KRAUSSLICH HG, 1996, CURRENT TOPICS IMMUN, V214; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAMMANO F, 1994, J VIROL, V68, P4927, DOI 10.1128/JVI.68.8.4927-4936.1994; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Orlinsky KJ, 1996, J VIROL, V70, P3440, DOI 10.1128/JVI.70.6.3440-3448.1996; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reicin AS, 1996, J VIROL, V70, P8645, DOI 10.1128/JVI.70.12.8645-8652.1996; ROSE S, 1992, PROTEINS, V13, P112, DOI 10.1002/prot.340130204; ROY O, 1996, VIROLOGY, V220, P530; STRAMBIODECASTILLIA C, 1992, J VIROL, V66, P7021, DOI 10.1128/JVI.66.12.7021-7032.1992; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swingler S, 1997, J VIROL, V71, P4372, DOI 10.1128/JVI.71.6.4372-4377.1997; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; VONPOBLOTZKI A, 1993, VIROLOGY, V193, P981, DOI 10.1006/viro.1993.1210; VONSCHWEDLER U, UNPUB; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zhang WH, 1996, J GEN VIROL, V77, P743, DOI 10.1099/0022-1317-77-4-743	36	507	518	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					849	853		10.1126/science.278.5339.849	http://dx.doi.org/10.1126/science.278.5339.849			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346481				2022-12-24	WOS:A1997YD47900043
J	Muller, CW; Herrmann, BG				Muller, CW; Herrmann, BG			Crystallographic structure of the T domain DNA complex of the Brachyury transcription factor	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING PROTEIN; GENE; DROSOPHILA; ALIGNMENT	The mouse Brachyury (T) gene is the prototype of a growing family of so-called T-box genes which encode transcriptional regulators and have been identified in a variety of invertebrates and vertebrates, including humans(1-6). Mutations in Brachyury and other T-box genes result in drastic embryonic phenotypes, indicating that T-box gene products are essential in tissue specification, morphogenesis and organogenesis(7-11). The T-box encodes a DNA-binding domain of about 180 amino-acid residues, the T domain(12). Here we report the X-ray structure of ther domain from Xenopus laevis in complex with a 24-nucleotide palindromic DNA duplex. We show that the protein is bound as a dimer, interacting with the major and the minor grooves of the DNA. A new type of specific DNA contact is seen, in which a carboxy-terminal helix is deeply embedded into an enlarged minor groove without bending the DNA. Hydrophobic interactions and an unusual main-chain carbonyl contact to a guanine account for sequence-specific recognition in the minor groove by this helix. Thus the structure of this T domain complex with DNA reveals a new way in which a protein can recognize DNA.	MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY	Max Planck Society	Muller, CW (corresponding author), EUROPEAN MOL BIOL LAB, GRENOBLE OUTSTN, ILL BP 156, F-38042 GRENOBLE 9, FRANCE.		Müller, Christoph W/I-7420-2012; Pillay, Nischalan/F-9536-2012	Müller, Christoph W/0000-0003-2176-8337; 				Agulnik SI, 1996, GENETICS, V144, P249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIEDERICHS K, 1995, PROTEINS, V23, P187, DOI 10.1002/prot.340230208; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Herrmann Bernhard G., 1995, Seminars in Developmental Biology, V6, P385, DOI 10.1016/S1044-5781(06)80002-2; Holland PWH, 1995, DEVELOPMENT, V121, P4283; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; Knezevic V, 1997, DEVELOPMENT, V124, P411; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Li QY, 1997, NAT GENET, V15, P21; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Schulte-Merker S., 1995, Seminars in Developmental Biology, V6, P411, DOI 10.1016/S1044-5781(06)80005-8; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	30	257	260	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					884	888		10.1038/39929	http://dx.doi.org/10.1038/39929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349824				2022-12-24	WOS:A1997YC14800065
J	Rankin, AC				Rankin, AC			Non-sedating antihistamines and cardiac arrhythmia	LANCET			English	Editorial Material							DE-POINTES; TERFENADINE; INTERVAL				Rankin, AC (corresponding author), ROYAL INFIRM,DEPT CARDIOL,GLASGOW G31 2ER,LANARK,SCOTLAND.							HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; LINDQUIST EIR, 1997, LANCET, V39, P1322; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Pratt CM, 1996, AM HEART J, V131, P472, DOI 10.1016/S0002-8703(96)90525-6; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; RAMPE D, 1993, MOL PHARMACOL, V44, P1240; SALATA JJ, 1995, CIRC RES, V76, P110, DOI 10.1161/01.RES.76.1.110; TAN HL, 1995, ANN INTERN MED, V122, P701, DOI 10.7326/0003-4819-122-9-199505010-00009; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313	11	23	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1115	1116		10.1016/S0140-6736(05)63783-X	http://dx.doi.org/10.1016/S0140-6736(05)63783-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343494				2022-12-24	WOS:A1997YB19900003
J	Barnes, PF; Yang, ZH; PrestonMartin, S; Pogoda, JM; Jones, BE; Otaya, M; Eisenach, KD; Knowles, L; Harvey, S; Cave, MD				Barnes, PF; Yang, ZH; PrestonMartin, S; Pogoda, JM; Jones, BE; Otaya, M; Eisenach, KD; Knowles, L; Harvey, S; Cave, MD			Tuberculosis transmission in central Los Angeles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; HOMELESS MEN; SHELTER; EPIDEMIOLOGY; OUTBREAK; PTBN12	Context.-Recent studies suggest that many tuberculosis cases in urban areas result from recent transmission. Delineation of the epidemiologic links between patients is important to optimize strategies to reduce tuberculosis transmission. Objective.-To identify epidemiologic links among recently infected urban patients with tuberculosis. Design.-Prospective evaluation of patients with tuberculosis. Setting.-Central Los Angeles, Calif. Patients.-A total of 162 patients who had culture-proven tuberculosis, Interventions.-Patients were prospectively interviewed to identify their contacts and whereabouts. The IS6110-based and pTBN12-based restriction fragment length polymorphism analyses were performed on Mycobacterium tuberculosis isolates. Patients whose isolates had identical or closely related restriction fragment length polymorphism patterns were considered a cluster. Unconditional logistic regression was used to identify independent predictors of clustering. Main Outcome Measures.-Relationship of clinical and epidemiologic variables to clustering, Results.-A total of 96 (59%) of 162 patients were in 8 clusters, Only 2 of the 96 clustered patients named others in the cluster as contacts, The degree of homelessness was an independent predictor of clustering, Compared with nonclustered patients, patients in 6 clusters were significantly more likely to have spent time at 3 shelters and other locations when at least 1 patient in the cluster was contagious, and these locations were independent predictors of clustering. Among nonhomeless persons, clustered patients were significantly more likely than nonclustered patients to have used daytime services at 3 shelters, Conclusions.-(1) Traditional contact investigation does not reliably identify patients infected with the same M tuberculosis strain, and (2) locations at which the homeless congregate are important sites of tuberculosis transmission for homeless and nonhomeless persons. Measures that reduce tuberculosis transmission should be based on locations rather than on personal contacts.	UNIV SO CALIF, SCH MED, DEPT MED, DIV INFECT DIS, LOS ANGELES, CA 90089 USA; UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90089 USA; LOS ANGELES CTY PUBL HLTH LAB, LOS ANGELES, CA USA; CTY LOS ANGELES DEPT HLTH SERV TB CONTROL PROGRAM, LOS ANGELES, CA USA; STATOLOGY, TRUCKEE, CA USA; UNIV ARKANSAS MED SCI, DEPT PATHOL, LITTLE ROCK, AR 72205 USA; UNIV ARKANSAS MED SCI, DEPT ANAT, LITTLE ROCK, AR 72205 USA; JOHN L MCCLELLAN MEM VET ADM MED CTR, MED RES SERV, LITTLE ROCK, AR USA	University of Southern California; University of Southern California; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035222, R01AI035265] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35222, AI35265] Funding Source: Medline; PHS HHS [CCU901877] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1992, MMWR Recomm Rep, V41, P13; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P869; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; ROST K, 1993, MED CARE, V31, P189, DOI 10.1097/00005650-199303000-00001; SAS Institute INC, 1988, SAS STAT US GUID REL; SEGALMAURER S, 1994, CLIN INFECT DIS, V19, P299, DOI 10.1093/clinids/19.2.299; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VANSOOLINGEN D, 1993, J CLIN MICROBIOL, V31, P1987, DOI 10.1128/JCM.31.8.1987-1995.1993; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; YANG ZH, 1995, J CLIN MICROBIOL, V33, P1064, DOI 10.1128/JCM.33.5.1064-1069.1995	24	171	177	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	1997	278	14					1159	1163		10.1001/jama.278.14.1159	http://dx.doi.org/10.1001/jama.278.14.1159			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY422	9326475				2022-12-24	WOS:A1997XY42200033
J	Forsen, T; Eriksson, JG; Tuomilehto, J; Teramo, K; Osmond, C; Barker, DJP				Forsen, T; Eriksson, JG; Tuomilehto, J; Teramo, K; Osmond, C; Barker, DJP			Mother's weight in pregnancy and coronary heart disease in a cohort of Finnish men: Follow up study	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; FETAL; BIRTH; INSULIN; NUTRITION; THINNESS; GROWTH	Objective: To determine whether restricted growth in utero is associated with an increased risk of coronary heart disease among men in Finland, where rates of the disease are among the highest in the world. Design: Follow up study. Setting: Helsinki, Finland. Subjects: 3302 men born in Helsinki University Central Hospital during 1924-33 who went to school in the city of Helsinki and were resident in Finland in 1971. Main outcome measures: Standardised mortality ratios for coronary heart disease. Results: Men who were thin at birth, with low placental weight, had high death rates from coronary heart disease. Men whose mothers had a high body mass index in pregnancy also had high death rates. In a multivariate analysis the hazard ratio for coronary heart disease was 1.37 (95% confidence interval 1.20 to 1.57) (P < 0.0001) for every standard deviation decrease in ponderal index at birth and 1.24 (1.10 to 1.39) (P = 0.0004) for every standard deviation increase in mother's body mass index. The effect of mother's body mass index was restricted to mothers of below average stature. Conclusion: These findings suggest a new explanation for the epidemics of coronary heart disease that accompany Westernisation. Chronically malnourished women are short and light and their babies tend to be thin. The immediate effect of improved nutrition is that women become fat, which seems to increase the risk of coronary heart disease in the next generation. With continued improvements in nutrition, women become taller and heavier; their babies are adequately nourished; and maternal fatness no longer increases the risk of coronary heart disease, which therefore declines.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,DIABET & GENET EPIDEMIOL UNIT,FIN-00300 HELSINKI,FINLAND; UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND	University of Southampton; Finland National Institute for Health & Welfare; University of Helsinki; Helsinki University Central Hospital				Osmond, Clive/0000-0002-9054-4655				Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; GODFREY KM, IN PRESS BR J OBSTET; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hales CN, 1996, BIOCHEM SOC T, V24, P341, DOI 10.1042/bst0240341; Keys A, 1966, Acta Med Scand Suppl, V460, P1; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Law CM, 1996, J HYPERTENS, V14, P935; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; SALOMAA V, 1992, AM J EPIDEMIOL, V136, P1303, DOI 10.1093/oxfordjournals.aje.a116442; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; YLIAHO T, 1991, TEHTAALAINEN HELSING	17	285	294	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 4	1997	315	7112					837	840		10.1136/bmj.315.7112.837	http://dx.doi.org/10.1136/bmj.315.7112.837			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353502	Green Published			2022-12-24	WOS:A1997YA00700019
J	Fornerod, M; Ohno, M; Yoshida, M; Mattaj, IW				Fornerod, M; Ohno, M; Yoshida, M; Mattaj, IW			CRM1 is an export receptor for leucine-rich nuclear export signals	CELL			English	Article							BINDING PROTEIN COMPLEX; ORDER CHROMOSOME STRUCTURE; REV ACTIVATION DOMAIN; U-SNRNA EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; HNRNP A1; REGULATORY PROTEINS; LEPTOMYCIN-B; TRANSFER-RNA; HIV REV	CRM1 is distantly related to receptors that mediate nuclear protein import and was previously shown to interact with the nuclear pore complex. Overexpression of CRM1 in Xenopus oocytes stimulates Rev and U snRNA export from the nucleus. Conversely, leptomycin B, a cytotoxin that is shown to bind to CRM1 protein, specifically inhibits the nuclear export of Rev and U snRNAs. In vitro, CRM1 forms a leptomycin B-sensitive complex involving cooperative binding of both RanGTP and the nuclear export signal (NES) from either the Rev or PKI proteins. We conclude that CRM1 is an export receptor for leucine-rich nuclear export signals and discuss a model for the role of RanGTP in CRM1 function and in nuclear export in general.	EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV TOKYO, DEPT BIOTECHNOL, TOKYO 113, JAPAN	European Molecular Biology Laboratory (EMBL); University of Tokyo			Fornerod, Maarten/A-7503-2010; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Fornerod, Maarten/0000-0002-6166-3030; Mattaj, Iain/0000-0002-5537-8284				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; CESTARI IN, 1993, BIOTECHNIQUES, V14, P404; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1996, ONCOGENE, V13, P1801; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fridell RA, 1997, J CELL SCI, V110, P1325; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; POKRYWKA NJ, 1995, J BIOL CHEM, V270, P3619, DOI 10.1074/jbc.270.8.3619; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stutz F, 1996, MOL CELL BIOL, V16, P7144; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	63	1677	1707	0	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1051	1060		10.1016/S0092-8674(00)80371-2	http://dx.doi.org/10.1016/S0092-8674(00)80371-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323133	Bronze			2022-12-24	WOS:A1997XX76800011
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Primary target	SCIENCE			English	Article																		Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Dieken ES, 1996, NAT GENET, V12, P174, DOI 10.1038/ng0296-174; Gardner RL, 1997, INT J DEV BIOL, V41, P235	3	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1848	1848		10.1126/science.277.5333.1848	http://dx.doi.org/10.1126/science.277.5333.1848			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324771				2022-12-24	WOS:A1997XX29800053
J	Yamauchi, T; Ueki, K; Tobe, K; Tamemoto, H; Sekine, N; Wada, M; Honjo, M; Takahashi, M; Takahashi, T; Hirai, H; Tushima, T; Akanuma, Y; Fujita, T; Komuro, I; Yazaki, Y; Kadowaki, T				Yamauchi, T; Ueki, K; Tobe, K; Tamemoto, H; Sekine, N; Wada, M; Honjo, M; Takahashi, M; Takahashi, T; Hirai, H; Tushima, T; Akanuma, Y; Fujita, T; Komuro, I; Yazaki, Y; Kadowaki, T			Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone	NATURE			English	Article							C-FOS PROMOTER; INTERFERON-GAMMA; BINDING-SITES; INTACT-CELLS; ACTIVATION; SUBSTRATE-1; MICE; SHC; TRANSCRIPTION; ASSOCIATION	When growth hormone binds to its receptor, which belongs to the cytokine receptor superfamily(1), it activates the Janus kinase Jak2(2) which has tyrosine-kinase activity and initiates an activation of several key intracellular proteins (for example, mitogen-activated protein (MAP) kinases(3-6)) that eventually execute the biological actions induced by growth hormone, including the expression of particular genes. In contrast to receptors that themselves have tyrosine kinase activity, the signalling pathways leading to MAP kinase activation(7,8) that are triggered by growth hormone are poorly understood, but appear to be mediated by the proteins GrB2 and Shc(9). We now show that growth hormone stimulates tyrosine phosphorylation of the receptor for epidermal growth factor (EGFR) and its association with Grb2 and at the same time stimulates MAP kinase activity in liver, an important target tissue of growth hormone, Expression of EGFR and its mutants revealed that growth-hormone-induced activation of MAP kinase and expression of the transcription factor c-fos requires phosphorylation of tyrosines on EGFR, but not its own intrinsic tyrosine-kinase activity, Moreover, tyrosine at residue 1,068 of the EGFR is proposed to be one of the principal phosphorylation sires and Grb2-binding sites stimulated by growth hormone via Jak2. Our results indicate that the role of EGFR in signalling by growth hormone is to be phosphorylated by Jak2, thereby providing docking sites for Grb2 and activating MAP kinases and gene expression, independently of the intrinsic tyrosine kinase activity of EGFR. This may represent a novel cross-talk pathway between the cytokine receptor superfamily and growth factor receptor.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 4,TOKYO 112,JAPAN; MITSUI TOATSU CHEM CO LTD,LIFE SCI LABS,MOBARA 297,JAPAN; UNIV TOKYO,DEPT VET PHYSIOL,TOKYO 113,JAPAN; TOKYO WOMENS MED COLL,DEPT INTERNAL MED 2,TOKYO 162,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Tokyo Women's Medical University; Asahi Life Foundation				Takahashi, Tokiharu/0000-0002-5785-8660				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; FRANK SJ, 1995, J BIOL CHEM, V270, P14765; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MeunierDurimort C, 1996, EUR J BIOCHEM, V237, P660, DOI 10.1111/j.1432-1033.1996.0660p.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sekine N, 1996, ENDOCRINOLOGY, V137, P1841, DOI 10.1210/en.137.5.1841; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	30	244	252	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					91	96		10.1038/36369	http://dx.doi.org/10.1038/36369			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363897				2022-12-24	WOS:A1997YE47700059
J	Nightingale, SL				Nightingale, SL			Education program for reducing risks with unpasteurized juices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-24	WOS:A1997YC91700007
J	LaMendola, NP; Bever, TG				LaMendola, NP; Bever, TG			Peripheral and cerebral asymmetries in the rat	SCIENCE			English	Article							TOPOGRAPHICAL DISORIENTATION; POSTERIOR PARIETAL; UNILATERAL REMOVAL; SPATIAL DEFICITS; CORTEX LESIONS; VIBRISSAE; SYSTEM; MEMORY; DISCRIMINATION; LATERALIZATION	Rats learn a novel foraging pattern better with their right-side whiskers than with their left-side whiskers, They also learn better with the left cerebral hemisphere than with the right hemisphere. Rotating an already learned maze relative to the external environment most strongly reduces right-whisker performance; starting an already learned maze at a different location most strongly reduces left-whisker performance. These results suggest that the right-periphery-left-hemisphere system accesses a map-like representation of the foraging problem, whereas the left-periphery-right-hemisphere system accesses a rote path. Thus, as in humans, functional asymmetries in rats can be elicited by both peripheral and cortical manipulation, and each hemisphere makes qualitatively distinct contributions to a complex natural behavior.	UNIV ARIZONA, PROGRAM COGNIT SCI, TUCSON, AZ 85721 USA; UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85721 USA	University of Arizona; University of Arizona								ADELSTEIN A, 1991, BEHAV NEUROSCI, V105, P459, DOI 10.1037/0735-7044.105.3.459; AHL AS, 1986, VET RES COMMUN, V10, P245, DOI 10.1007/BF02213989; AMMASSARITEULE M, 1985, BEHAV BRAIN RES, V17, P9, DOI 10.1016/0166-4328(85)90003-8; BANICH M, 1997, NEUROPSYCHOLOGY NEUR, pCH6; BEVER TG, 1970, MECH LANGUAGE DEV, P186; Bianki V. L., 1988, RIGHT LEFT HEMISPHER; Bradshaw JL., 1993, EVOLUTION LATERAL AS; Brown Halle D., 1995, P77; Burcham K. J., 1996, Society for Neuroscience Abstracts, V22, P682; CASTELLANO MA, 1989, BEHAV NEUROSCI, V103, P46, DOI 10.1037/0735-7044.103.1.46; Cohen NJ, 1993, MEMORY AMNESIA HIPPO; COLLINS RL, 1968, J HERED, V59, P9, DOI 10.1093/oxfordjournals.jhered.a107656; CORWIN JV, 1994, BEHAV BRAIN RES, V61, P79, DOI 10.1016/0166-4328(94)90010-8; COWELL PE, IN PRESS LATERALITY; CROWNE DP, 1992, BEHAV NEUROSCI, V106, P808, DOI 10.1037/0735-7044.106.5.808; De Renzi E., 1982, DISORDERS SPACE EXPL; DIMATTIA BV, 1988, BEHAV NEUROSCI, V102, P397, DOI 10.1037/0735-7044.102.3.397; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; FRANCO L, 1977, NEUROPSYCHOLOGIA, V15, P107, DOI 10.1016/0028-3932(77)90120-8; Gallistel CR, 1996, J EXP BIOL, V199, P211; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; GUICROBLES E, 1989, BEHAV BRAIN RES, V31, P285, DOI 10.1016/0166-4328(89)90011-9; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; HEFFNER HE, 1986, J NEUROPHYSIOL, V56, P683, DOI 10.1152/jn.1986.56.3.683; HUSTON JP, 1986, EXP NEUROL, V93, P380, DOI 10.1016/0014-4886(86)90198-6; HUTSON KA, 1986, J NEUROPHYSIOL, V56, P1196, DOI 10.1152/jn.1986.56.4.1196; JACOBS RA, 1991, COGNITIVE SCI, V15, P219, DOI 10.1207/s15516709cog1502_2; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KESNER RP, 1989, BEHAV NEUROSCI, V103, P956, DOI 10.1037/0735-7044.103.5.956; KIMURA D, 1973, SCI AM, V228, P70, DOI 10.1038/scientificamerican0373-70; KING VR, 1992, BEHAV BRAIN RES, V50, P53; Kinsbourne M., 1975, ATTENTION PERFORM, VV, P81; KOLB B, 1984, BEHAV NEUROSCI, V98, P44, DOI 10.1037/0735-7044.98.1.44; Kolb B., 1990, CEREBRAL CORTEX RAT, P437; KOROLEVA VI, 1993, NEUROSCI LETT, V149, P153, DOI 10.1016/0304-3940(93)90759-E; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEVY J, 1969, NATURE, V224, P614, DOI 10.1038/224614a0; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MCNAUGHTON BL, 1991, J COGNITIVE NEUROSCI, V3, P192, DOI 10.1162/jocn.1991.3.2.190; MEHTA Z, 1991, CORTEX, V27, P153, DOI 10.1016/S0010-9452(13)80121-9; MILANI H, 1989, BEHAV NEUROSCI, V103, P1067, DOI 10.1037/0735-7044.103.5.1067; MILNER B, 1965, NEUROPSYCHOLOGIA, V3, P317, DOI 10.1016/0028-3932(65)90005-9; NOTTEBOHM F, 1976, J COMP PHYSIOL, V108, P171, DOI 10.1007/BF02169047; O'Keefe J, 1991, Hippocampus, V1, P230, DOI 10.1002/hipo.450010303; O'Keefe J., 1978, HIPPOCAMPUS SPATIAL; OLTON DS, 1977, SCI AM, V236, P82, DOI 10.1038/scientificamerican0677-82; RATCLIFF G, 1973, J NEUROL NEUROSUR PS, V36, P448, DOI 10.1136/jnnp.36.3.448; SCHIFFMA.HR, 1970, ANIM BEHAV, V18, P290, DOI 10.1016/S0003-3472(70)80040-9; SHERMAN GF, 1985, CEREBRAL LATERALIZAT, P89; THOR DH, 1973, PSYCHOL REP, V33, P815, DOI 10.2466/pr0.1973.33.3.815; VINCENT SB, 1912, BEHAV MONOGR, V9, P1; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; ZIMMERBERG B, 1974, SCIENCE, V185, P623, DOI 10.1126/science.185.4151.623	54	60	60	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 17	1997	278	5337					483	486		10.1126/science.278.5337.483	http://dx.doi.org/10.1126/science.278.5337.483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YB355	9334310				2022-12-24	WOS:A1997YB35500050
J	Wong, FL; Boice, JD; Abramson, DH; Tarone, RE; Kleinerman, RA; Stovall, M; Goldman, MB; Seddon, JM; Tarbell, N; Fraumeni, JF; Li, FP				Wong, FL; Boice, JD; Abramson, DH; Tarone, RE; Kleinerman, RA; Stovall, M; Goldman, MB; Seddon, JM; Tarbell, N; Fraumeni, JF; Li, FP			Cancer incidence after retinoblastoma - Radiation dose and sarcoma risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOFT-TISSUE SARCOMAS; BILATERAL RETINOBLASTOMA; HEREDITARY RETINOBLASTOMA; TRILATERAL RETINOBLASTOMA; SURVIVORS; TUMORS; RADIOTHERAPY; NEOPLASMS; CARCINOMAS; MORTALITY	Context.-There is a substantial risk of a second cancer for persons with hereditary retinoblastoma, which is enhanced by radiotherapy. Objective.-To examine long-term risk of new primary cancers in survivors of childhood retinoblastoma and quantify the role of radiotherapy in sarcoma development. Design.-Cohort incidence study of patients with retinoblastoma followed for a median of 20 years, and nested case-control study of a radiation dose-response relationship for bone and soft tissue sarcomas. Setting/Participants.-A total of 1604 patients with retinoblastoma who survived at least 1 year after diagnosis, identified from hospital records in Massachusetts and New York during 1914 to 1984. Results.-Incidence of subsequent cancers was statistically significantly elevated only in the 961 patients with hereditary retinoblastoma, in whom 190 cancers were diagnosed, vs 6.3 expected in the general population (relative risk [RR], 30 [95% confidence interval, 26-47]), Cumulative incidence (+/-SE) of a second cancer at 50 years after diagnosis was 51.0% (+/-6.2%) for hereditary retinoblastoma, and 5.0% (+/-3.0%) for nonhereditary retinoblastoma. All 114 sarcomas of diverse histologic types occurred in patients with hereditary retinoblastoma. For soft tissue sarcomas, the RRs showed a stepwise increase at all dose categories, and were statistically significant at 10 to 29.9 Gy and 30 to 59.9 Gy. A radiation risk for all sarcomas combined was evident at doses above 5 Gy, rising to 10.7-fold at doses of 60 Gy or greater (P<.05). Conclusions.-Genetic predisposition has a substantial impact on risk of subsequent cancers in retinoblastoma patients, which is further increased by radiation treatment. A radiation dose-response relationship is demonstrated for all sarcomas and, for the first time in humans, for soft tissue sarcomas. Retinoblastoma patients should be examined for new cancers and followed into later life to determine whether their extraordinary cancer risk extends to common cancers of adulthood.	NCI, DIV CANC EPIDEMIOL & GENET, NIH, ROCKVILLE, MD 20892 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX USA; NEW YORK HOSP, CORNELL MED CTR, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DEPT OPHTHALMOL, BOSTON, MA USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital				Kleinerman, Ruth/0000-0001-7415-2478	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP085604] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-85604, N02-CP-33013] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; [Anonymous], 1986, Natl Cancer Inst Monogr, V70, P1; BADER JL, 1982, CANCER GENET CYTOGEN, V5, P203, DOI 10.1016/0165-4608(82)90026-7; BOICE JD, 1985, NATL CANCER I MONOGR, V68, P1; DAVIS FG, 1989, CANCER RES, V49, P6130; DERKINDEREN DJ, 1987, OPHTHALMIC PAED GEN, V8, P23, DOI 10.3109/13816818709028511; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FOLBERG R, 1983, ARCH OPHTHALMOL-CHIC, V101, P1562; FRANCOIS J, 1980, OPHTHALMOLOGICA, V181, P93, DOI 10.1159/000309033; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hawkins MM, 1996, J NATL CANCER I, V88, P270, DOI 10.1093/jnci/88.5.270; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN EA, 1992, CANCER-AM CANCER SOC, V70, P423, DOI 10.1002/1097-0142(19920715)70:2<423::AID-CNCR2820700209>3.0.CO;2-B; KNUDSON AG, 1978, SEMIN ONCOL, V5, P57; Kony SJ, 1997, LANCET, V350, P91, DOI 10.1016/S0140-6736(97)01116-1; LASKIN WB, 1988, CANCER-AM CANCER SOC, V62, P2330, DOI 10.1002/1097-0142(19881201)62:11<2330::AID-CNCR2820621113>3.0.CO;2-2; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; Moll AC, 1996, INT J CANCER, V67, P515, DOI 10.1002/(SICI)1097-0215(19960807)67:4<515::AID-IJC9>3.0.CO;2-V; MONSON RR, 1969, COMPUT BIOMED RES, V105, P529; PESIN SR, 1989, AM J OPHTHALMOL, V107, P121, DOI 10.1016/0002-9394(89)90209-2; PRESTON DL, 1991, EPICURE USERS GUIDE; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; ROBINSON E, 1988, JNCI-J NATL CANCER I, V80, P233, DOI 10.1093/jnci/80.4.233; RUKA W, 1991, EUR J SURG ONCOL, V17, P585; SCHIFTER S, 1983, CANCER, V51, P1746, DOI 10.1002/1097-0142(19830501)51:9<1746::AID-CNCR2820510930>3.0.CO;2-G; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002; *UN SCI COMM EFF A, 1994, 1994 UN SCI COMM EFF, VE; *WHO, 1976, ICD O INT CLASSIFICA; WINTHER J, 1988, CANCER, V62, P1458, DOI 10.1002/1097-0142(19881001)62:7<1458::AID-CNCR2820620735>3.0.CO;2-2; XU HJ, 1991, CANCER RES, V51, P2735; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P70	38	462	473	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1262	1267		10.1001/jama.278.15.1262	http://dx.doi.org/10.1001/jama.278.15.1262			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333268				2022-12-24	WOS:A1997XZ70900032
J	Hansen, SK; Takada, S; Jacobson, RH; Lis, JT; Tjian, R				Hansen, SK; Takada, S; Jacobson, RH; Lis, JT; Tjian, R			Transcription properties of a cell type-specific TATA-binding protein, TRF	CELL			English	Article							RNA-POLYMERASE-II; ALCOHOL-DEHYDROGENASE GENE; DIRECT BASAL TRANSCRIPTION; RICH ACTIVATION MOTIF; CRYSTAL-STRUCTURE; DNA-BINDING; FUNCTIONAL-ANALYSIS; DROSOPHILA; COMPLEX; PROMOTER	Eukaryotic cells are thought to contain a single TATA-binding protein (TBP) that directs transcription by cellular RNA polymerases. Here we report a cell type-specific TBP-related factor (TRF) that can form a stable TRF/IIA/IIB TATA DNA complex and substitute for TBP in directing RNA polymerase II transcription in vitro. Transfection studies reveal that TRF can differentially mediate activation by some enhancer proteins but not others. Like TBP, TRF forms a stable complex containing multiple novel subunits, nTAFs. Antibody staining of embryos and polytene chromosomes reveals cell type-specific expression and gene-selective properties consistent with the shaker/male sterile phenotype of trf mutants. These findings suggest TRF is a homolog of TBP that functions to direct tissue-and gene-specific transcription.	CORNELL UNIV,BIOCHEM SECT,ITHACA,NY 14853	Cornell University	Hansen, SK (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.				NATIONAL CANCER INSTITUTE [R01CA025417, R37CA025417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER; NCI NIH HHS [CA25417] Funding Source: Medline; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PAPAZIAN DM, 1988, ANNU REV PHYSIOL, V50, P379; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PASCAL E, 1992, THESIS U CALIFORNIA; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Shopland LS, 1996, CHROMOSOMA, V105, P158, DOI 10.1007/BF02509497; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wang X, 1997, P NATL ACAD SCI USA, V94, P433, DOI 10.1073/pnas.94.2.433; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	50	149	153	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					71	83		10.1016/S0092-8674(01)80010-6	http://dx.doi.org/10.1016/S0092-8674(01)80010-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335336	hybrid			2022-12-24	WOS:A1997XZ80900010
J	Inouye, C; Dhillon, N; Thorner, J				Inouye, C; Dhillon, N; Thorner, J			Ste5 RING-H2 domain: Role in Ste4-promoted oligomerization for yeast pheromone signaling	SCIENCE			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTEIN-PROTEIN INTERACTIONS; MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; SCHISTOSOMA-JAPONICUM; 2-HYBRID SYSTEM; FINGER DOMAIN; DIMERIZATION; BRCA1	Ste5 is a scaffold for the mitogen-activated protein kinase (MAPK) cascade components in a yeast pheromone response pathway. Ste5 also associates with Ste4, the beta subunit of a heterotrimeric guanine nucleotide-binding protein, potentially linking receptor activation to stimulation of the MAPK cascade, A RING-H2 motif at the Ste5 amino terminus is apparently essential for function because Ste5(C177S) and Ste5(C177A C180A) mutants did not rescue the mating defect of a ste5 Delta cell. In vitro Ste5(C177A C180A) bound each component of the MAPK cascade, but not Ste4, Unlike wild-type Ste5, the mutant did not appear to oligomerize; however, when fused to a heterologous dimerization domain (glutathione S-transferase), the chimeric protein restored mating in an ste5 Delta cell and an ste4 Delta ste5 Delta double mutant. Thus, the RING-H2 domain mediates Ste4-Ste5 interaction, which is a prerequisite for Ste5-Ste5 self-association and signaling.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; Bienstock RJ, 1996, CANCER RES, V56, P2539; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CHOI KY, 1994, CELL, V78, P499; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INOUYE C, IN PRESS GENETICS; INOUYE C, UNPUB; Johannsson O, 1996, AM J HUM GENET, V58, P441; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; MCTIGUE MA, 1995, PROTEINS, V22, P55, DOI 10.1002/prot.340220108; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; PRINTEN JA, 1994, GENETICS, V138, P609; Riley LG, 1996, PROTEIN ENG, V9, P223, DOI 10.1093/protein/9.2.223; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sherman F., 1986, METHODS YEAST GENETI; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864	37	139	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					103	106		10.1126/science.278.5335.103	http://dx.doi.org/10.1126/science.278.5335.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311911				2022-12-24	WOS:A1997XZ12400047
J	Nesse, RM; Berridge, KC				Nesse, RM; Berridge, KC			Psychoactive drug use in evolutionary perspective	SCIENCE			English	Article							SENSITIZATION; ADDICTION; RECEPTORS	Pure psychoactive drugs and direct routes of administration are evolutionarily novel features of our environment. They are inherently pathogenic because they bypass adaptive information processing systems and act directly on ancient brain mechanisms that control emotion and behavior. Drugs that induce positive emotions give a false signal of a fitness benefit. This signal hijacks incentive mechanisms of ''liking'' and ''wanting,'' and can result in continued use of drugs that no longer bring pleasure. Drugs that block negative emotions can impair useful defenses, although there are several reasons why their use is often safe nonetheless. A deeper understanding of the evolutionary origins and functions of the emotions and their neural mechanisms is needed as a basis Tor decisions about the use of psychoactive drugs.	UNIV MICHIGAN, INST SOCIAL RES, ANN ARBOR, MI 48106 USA; UNIV MICHIGAN, DEPT PSYCHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nesse, RM (corresponding author), UNIV MICHIGAN, DEPT PSYCHIAT, 5057 ISR, POB 1248, ANN ARBOR, MI 48106 USA.		Berridge, Kent C/C-1525-2009	Berridge, Kent C/0000-0002-6031-2626; Nesse, Randolph/0000-0003-1768-0949				Barlow DH, 1991, PSYCHOL INQ, V2, P97; BARRINGTON EJW, 1982, BRIT MED BULL, V38, P227, DOI 10.1093/oxfordjournals.bmb.a071765; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BERNTSON GG, 1993, ANN NY ACAD SCI, V702, P75, DOI 10.1111/j.1749-6632.1993.tb17243.x; Berridge KC, 1996, NEUROSCI BIOBEHAV R, V20, P1, DOI 10.1016/0149-7634(95)00033-B; BERRIDGE KC, IN PRESS UNDERSTANDI; Bloom Floyd E., 1995, P1063; Buss DM, 1996, PSYCHOL SCI, V7, P373, DOI 10.1111/j.1467-9280.1996.tb00392.x; Butler A. B., 1996, COMP VERTEBRATE NEUR, DOI DOI 10.1002/0471733849.CH19; DUPONT HL, 1973, JAMA-J AM MED ASSOC, V226, P1525, DOI 10.1001/jama.226.13.1525; EATON SB, 1985, NEW ENGL J MED, V312, P283, DOI 10.1056/NEJM198501313120505; Frank Robert H., 1988, PASSIONS REASON STRA; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; GAZZANIGA MS, 1987, INTEGRATED MIND; GELPERIN A, 1986, TRENDS NEUROSCI, V9, P323, DOI 10.1016/0166-2236(86)90098-6; Gilbert P., 1992, DEPRESSION EVOLUTION; GRAY JA, 1987, FEAR STRESS; HOEBEL BG, 1988, STEVENS HDB EXPT PSY, V1, P547; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KEFTNER D, 1996, COGNITION EMOTION, V10, P155; KETELAAR T, IN PRESS PERSONALITY; KETELAAR T, UNPUB; Kluger MJ., 1979, FEVER ITS BIOL EVOLU; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; LeDoux J. E., 1996, EMOTIONAL BRAIN; Li X, 1996, J MOL EVOL, V43, P179, DOI 10.1007/BF02338825; MARKS IM, 1994, ETHOL SOCIOBIOL, V15, P247, DOI 10.1016/0162-3095(94)90002-7; MCGUIRE MT, 1997, DARWINIAN PSYCHIAT; MURPHY ST, 1993, J PERS SOC PSYCHOL, V64, P723, DOI 10.1037/0022-3514.64.5.723; Nesse R M, 1990, Hum Nat, V1, P261, DOI 10.1007/BF02733986; NESSE RM, 1994, ETHOL SOCIOBIOL, V15, P339, DOI 10.1016/0162-3095(94)90007-8; Nesse RM, 1995, WHY WE GET SICK NEW; NESSE RM, 1991, PSYCHOLOQUY, V2; PEROUTKA SJ, 1994, NEUROCHEM INT, V25, P533, DOI 10.1016/0197-0186(94)90151-1; Pomerleau CS, 1997, ADDICTION, V92, P397; Pribbenow B, 1996, NEUROBIOL LEARN MEM, V66, P109, DOI 10.1006/nlme.1996.0052; PRICE J, 1994, BRIT J PSYCHIAT, V164, P309, DOI 10.1192/bjp.164.3.309; RIJDA NH, 1994, NATURE EMOTION, P59; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Shizgal P, 1997, CURR OPIN NEUROBIOL, V7, P198, DOI 10.1016/S0959-4388(97)80008-6; SMITH M, 1986, ADV HUM GENET, V15, P249; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; TOOBY J, 1990, ETHOL SOCIOBIOL, V11, P375, DOI 10.1016/0162-3095(90)90017-Z; Walker RJ, 1996, PARASITOLOGY, V113, pS3, DOI 10.1017/S0031182000077878; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WILLIAMS GC, 1991, Q REV BIOL, V66, P1, DOI 10.1086/417048; Wilson E.O., 1975, P1; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; ZAJONC RB, 1985, SCIENCE, V228, P15, DOI 10.1126/science.3883492; [No title captured]	50	226	228	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					63	66		10.1126/science.278.5335.63	http://dx.doi.org/10.1126/science.278.5335.63			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311928				2022-12-24	WOS:A1997XZ12400033
J	Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC				Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC			The effect of Medicare's payment system for rehabilitation hospitals on length of stay, charges, and total payments	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Medicare's system for the payment of rehabilitation hospitals is based on limits derived from a hospital's average allowable charges per patient discharged during a base year. Thereafter, payments are capped, but hospitals receive incentive payments if charges per patient are reduced in succeeding years. We hypothesized that per-patient charges would increase during the base year and then decrease in subsequent years. Hospitals would thus have higher reimbursement limits and receive incentive payments for reducing their charges. Methods We analyzed Medicare claims data for 190,921 discharges from 69 rehabilitation hospitals from 1987 through 1994. We compared total charges, length of stay, and interim payments before, during, and alter each hospital's base year. Results After we controlled for inflation and temporal and seasonal trends, mean charges per patient discharged increased from $25,131 for patients discharged before the base year to $32,167 for patients discharged in the base year (a 28 percent increase, P<0.001) and the mean length of stay increased from 22.1 to 26.7 days (a 21 percent increase, P<0.001). After the base year, mean charges decreased to $29,307 (a 9 percent decrease) and the mean length of stay decreased to 24.0 days (a 10 percent decrease) (P<0.001 for both comparisons). Analysis of data on patients according to diagnosis-for example, spinal cord injury, brain injury, stroke, amputation or deformity, hip fracture, and arthritis or other joint disorders-showed similar findings for each, with increases in charges and length of stay in the base year, followed by small reductions thereafter For-profit hospitals had greater increases than nonprofit hospitals in their per-patient charges (mean increase, $7,434 vs. $2,929; P<0.001) and length of slay (mean increase, 4.6 vs. 2.3 days, P<0.001) during the base year. Conclusions Although Medicare's reimbursement system far rehabilitation hospitals put an upper limit on total payments, its design was associated with substantial extra costs, including significantly increased payments to hospitals and doctors and increased numbers of hospital days for the average patient. (C) 1997, Massachusetts Medical Society.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chan, L (corresponding author), HLTH CARE FINANCING ADM,DIV CLIN STAND & QUAL,REG 10,MS-RX 40,2201 6TH AVE,SEATTLE,WA 98121, USA.							ALTMAN DG, 1991, PRACTICAL STAT MED R, P194; ARNOLD S, 1992, C9205 PROSP PAYM ASS, P16; *BUR LAB STAT, 1996, CPI DET REP DAT MARC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CROMWELL J, 1990, TEFRA PSYCH HOSP UNI; Davis L M, 1993, Adv Health Econ Health Serv Res, V14, P87; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Guterman S, 1988, Health Care Financ Rev, V9, P67; HARADA N, 1993, INQUIRY-J HEALTH CAR, V30, P54; HARROW B, 1990, IMPACT ANAL TEFRA SY; *HLTH CAR FIN ADM, 1994, MED PROV REIMB MAN 1, P30; *HLTH CAR FIN ADM, 1995, REG OFF MAN MED, pI25; HOSEK S, 1986, R3424HCFA RAND, P1; HSIA DC, 1990, NEW ENGL J MED, V322, P1540; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Langenbrunner J C, 1989, Health Care Financ Rev, V10, P91; *PROSP PAYM ASS CO, 1996, REP REC C MARCH 1 19; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Searle S.R., 1992, VARIANCE COMPONENTS, P168; 1993, FED REGISTER, V58, P63820	21	71	71	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					978	985		10.1056/NEJM199710023371406	http://dx.doi.org/10.1056/NEJM199710023371406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309104				2022-12-24	WOS:A1997XY42300006
J	Poland, GA				Poland, GA			Lessons from the influenza vaccine recall of 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ELDERLY PEOPLE; COST-EFFECTIVENESS; IMMUNIZATION; EFFICACY				Poland, GA (corresponding author), MAYO CLIN & MAYO FDN, MAYO VACCINE RES GRP, 601 B GUGGENHEIM BLDG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1100; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P601; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1987, J CLIN MICROBIOL, V25, P1763, DOI 10.1128/JCM.25.9.1763-1765.1987; Gross PA, 1996, CLIN DIAGN LAB IMMUN, V3, P361, DOI 10.1128/CDLI.3.3.361-362.1996; GROSS PA, 1988, J AM GERIATR SOC, V36, P209, DOI 10.1111/j.1532-5415.1988.tb01802.x; Hilleman MR, 1996, JAMA-J AM MED ASSOC, V275, P241, DOI 10.1001/jama.275.3.241; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; KILBOURNE ED, 1994, VACCINES, P565; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; *NAT VACC ADV COMM, 1994, AD IMM; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; U.S. Department of Health and Human Services Office of Disease Pre- vention and Health Promotion, 1990, HLTH PEOPL 2000	17	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1022	1023		10.1001/jama.278.12.1022	http://dx.doi.org/10.1001/jama.278.12.1022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307353				2022-12-24	WOS:A1997XX01200036
J	Compston, JE				Compston, JE			Designer oestrogens: fact or fantasy?	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN; RISK; RALOXIFENE				Compston, JE (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Compston JE, 1997, DRUGS, V53, P727, DOI 10.2165/00003495-199753050-00001; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DELMAS PD, IN PRESS P ENDOCR SO; Draper MW, 1996, J BONE MINER RES, V11, P835; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	11	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					676	677		10.1016/S0140-6736(97)22036-2	http://dx.doi.org/10.1016/S0140-6736(97)22036-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291896				2022-12-24	WOS:A1997XU97700002
J	Jones, CM; Taylor, GO; Whittle, JG; Evans, D; Trotter, DP				Jones, CM; Taylor, GO; Whittle, JG; Evans, D; Trotter, DP			Water fluoridation, tooth decay in 5 year olds, and social deprivation measured by the Jarman score: analysis of data from British dental surveys	BRITISH MEDICAL JOURNAL			English	Article							CARIES EXPERIENCE; AREAS; CHILDREN; IDENTIFICATION; DENTITION	Objective: To examine the effect of water fluoridation, both artificial and natural, on dental decay, after socioeconomic deprivation was controlled for. Design: Ecological study based on results from the NHS dental surveys in 5 year olds in 1991-2 and 1993-4 and Jarman underprivileged area scores from the 1991 census. Setting: Electoral wards in three areas: Hartlepool (naturally fluoridated), Newcastle and North Tyneside (fluoridated), and Salford and Trafford (non-fluoridated). Subjects: 5 year old children (n = 10 004). Intervention: Water fluoridation (artificial and occurring naturally). Main outcome measure: Ward tooth decay score (score on the ''decayed, missing, and filled tooth index'' for each electoral ward). Results: Multiple linear regression showed a significant interaction between Jarman score for ward, mean number of teeth affected by decay, and both types of water fluoridation. This confirms that the more deprived an area, the greater benefit derived from fluoridation whether natural or artificial (R-2 = 0.84, P < 0.001), At a Jarman score of zero (national mean score) there was a predicted 44% reduction in decay in fluoridated areas, increasing to a 54% reduction in wards with a Jarman score of 40 (very deprived). The area with natural fluoridation (at a level of 1.2 parts per million-higher than levels in artificially fluoridated areas) had a 66% reduction in decay, with a 74% reduction in wards with a Jarman score of 40. Conclusion: Tooth decay is confirmed as a disease associated with social deprivation, and the more socially deprived areas benefit more from fluoridation. Widespread water fluoridation is urgently needed to reduce the ''dental health divide'' by improving the dental health of the poorer people in Britain.	WESHAM PK HOSP,N W DENT PUBL HLTH,PRESTON PR4 3AL,LANCS,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND									BEAL JF, 1990, PREVENTION DENT DIS; BLAND M, 1993, INTRO MED STAT, P148; *BRIT FLUOR SOC, 1996, ONE MILL WAT FLUOR D; CARMICHAEL CL, 1989, BRIT DENT J, V167, P57, DOI 10.1038/sj.bdj.4806919; Ellwood R P, 1995, Community Dent Health, V12, P18; Ellwood RP, 1996, COMMUNITY DENT ORAL, V24, P1, DOI 10.1111/j.1600-0528.1996.tb00802.x; EVANS RW, 1984, COMMUNITY DENT ORAL, V12, P5, DOI 10.1111/j.1600-0528.1984.tb01401.x; HAUSEN H, 1982, COMMUNITY DENT ORAL, V10, P33, DOI 10.1111/j.1600-0528.1982.tb00357.x; HAUSEN H, 1981, COMMUNITY DENT ORAL, V9, P289, DOI 10.1111/j.1600-0528.1981.tb00348.x; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; Jarman B., 1984, BRIT MED J, V289, P587; NAYLOR MN, 1990, PREVENTION DENT DIS; NEWBRUN E, 1989, J PUBLIC HEALTH DENT, V49, P279, DOI 10.1111/j.1752-7325.1989.tb02086.x; Pitts N B, 1995, Community Dent Health, V12, P52; PITTS NB, 1997, COMMUNITY DENT HL S1, V14, pS6; PITTS NB, 1994, COMMUNITY DENT HLTH, V11, P45; Provart S J, 1995, Community Dent Health, V12, P200; Provart S J, 1995, Community Dent Health, V12, P138; Slade GD, 1996, COMMUNITY DENT ORAL, V24, P89, DOI 10.1111/j.1600-0528.1996.tb00822.x; TAYLOR GO, 1995, BRIT DENT J, V178, P47, DOI 10.1038/sj.bdj.4808644; WINTER GB, 1990, ARCH ORAL BIOL, V35, pS1, DOI 10.1016/0003-9969(90)90124-S	21	56	62	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					514	517		10.1136/bmj.315.7107.514	http://dx.doi.org/10.1136/bmj.315.7107.514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329305	Green Published			2022-12-24	WOS:A1997XU50600017
J	Sigrist, SJ; Lehner, CF				Sigrist, SJ; Lehner, CF			Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles	CELL			English	Article							S-PHASE; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; DNA-REPLICATION; PROTEIN-KINASE; B-CYCLIN; MITOSIS; GENE; EMBRYOGENESIS; YEAST	We demonstrate that fizzy-related (fir), a conserved eukaryotic gene, negatively regulates the levers of cyclins A, B, and B3. These mitotic cyclins that bind and activate cdk1(cdc2) are rapidly degraded during exit from M and during G1. While Drosophila fizzy has previously been shown to be required for cyclin destruction during M phase, fir is required for cyclin removal during G1 when the embryonic epidermal cell proliferation stops and during G2 preceding salivary gland endoreduplication. Loss of fzr causes progression through an extra division cycle in the epidermis and inhibition of endoreduplication in the salivary gland, in addition to failure of cyclin removal. Conversely, premature fir overexpression down-regulates mitotic cyclins, inhibits mitosis, and transforms mitotic cycles into endoreduplication cycles.			Sigrist, SJ (corresponding author), UNIV BAYREUTH,DEPT GENET,D-95440 BAYREUTH,GERMANY.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Frank LH, 1996, DEVELOPMENT, V122, P1343; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SMITH AV, 1991, DEVELOPMENT, V112, P997; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WIESCHAUS E, 1983, ROUX ARCH DEVEL BIOL, V193, P296; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	53	365	369	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					671	681		10.1016/S0092-8674(00)80528-0	http://dx.doi.org/10.1016/S0092-8674(00)80528-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288747	hybrid			2022-12-24	WOS:A1997XT06600011
J	Zhang, BL; Cech, TR				Zhang, BL; Cech, TR			Peptide bond formation by in vitro selected ribozymes	NATURE			English	Article							RNA; EVOLUTION; TETRAHYMENA; CATALYSIS; INVITRO; LIGANDS; DNA	An attractive solution to the problem of the origin of protein synthesis in an evolving 'RNA world' involves catalysis by nucleic acid without assistance from proteins(1,2). Indeed, even the modem ribosome has been considered to be fundamentally an RNA, machine(3), and the large ribosomal subunit can carry out peptidyl transfer in the absence of most of its protein subunits(4). Successive cycles of in vitro selection and amplification(5-7) have been used to find RNAs that perform many biochemical reactions(8-16), including transfer of an RNA-linked amino acid io their own 5'-amino-modified terminus(15). Here we demonstrate the in vitro selection of ribozymes (196 nucleotides) that perform the same pepridyl transferase reaction as the ribosome: that is, they can join amino acids by a peptide bond. Like ribosome substrates, one amino, acid (N-blocked methionine) is esterified to the 3'(2')-O of adenosine, whereas the acceptor amino acid (phenylalanine) has a free amino group. Our best characterized ribozyme recognizes the amino-acid ester substrate by binding its adenosine moiety, and is therefore capable of utilizing Leu-and Phe- as well as Met-derived substrates. Such lack of specificity with respect to the amino acid is a feature necessary for a generalized protein-synthesizing enzyme.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								AZHAYEV AV, 1977, NUCLEIC ACIDS RES, V4, P2223, DOI 10.1093/nar/4.7.2223; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; CECH TR, 1993, RNA WORLD, P239; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAI XC, 1995, SCIENCE, V267, P237, DOI 10.1126/science.7809628; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; KRAYEVSKY AA, 1975, NUCLEIC ACIDS RES, V2, P2223, DOI 10.1093/nar/2.12.2223; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; MERCER TFB, 1972, EUR J BIOCHEM, V28, P38; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; NIERHAUS KH, 1980, BIOCHEM INT, V1, P185; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Wecker M, 1996, RNA, V2, P982; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0; Woese C, 1967, GENETIC CODE, P179	27	226	244	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					96	100		10.1038/36375	http://dx.doi.org/10.1038/36375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363898				2022-12-24	WOS:A1997YE47700060
J	Altar, CA; Cai, N; Bliven, T; Juhasz, M; Conner, JM; Acheson, AL; Lindsay, RM; Wiegand, SJ				Altar, CA; Cai, N; Bliven, T; Juhasz, M; Conner, JM; Acheson, AL; Lindsay, RM; Wiegand, SJ			Anterograde transport of brain-derived neurotrophic factor and its role in the brain	NATURE			English	Article							PARVALBUMIN-IMMUNOREACTIVE NEURONS; NERVOUS-SYSTEM; MESSENGER-RNA; BDNF; RAT; NT-3; DIFFERENTIATION; EXPRESSION; FOREBRAIN; NT-4/5	The role of neurotrophins as target-derived proteins that promote neuron survival following their retrograde transport from the terminals to the cell bodies of neurons has been firmly established in the developing peripheral nervous system. However, neurotrophins appear to have more diverse functions, particularly in the adult central nervous system. Brain-derived neurotrophic factor (BDNF), for example, produces a variety of neuromodulatory effects in the brain that are more consistent with local actions than with long-distance retrograde signalling. Here we show that BDNF is widely distributed in nerve terminals, even in brain areas such as the striatum that lack BDNF messenger RNA, and that inhibition of axonal transport or deafferentation depletes BDNF. The number of striatal neurons that contain the calcium-binding protein parvalbumin was decreased in BDNF+/- and BDNF-/- mice in direct proportion to the loss of BDNF protein, which is consistent with anterogradely supplied BDNF having a functional role in development or maintenance. Thus the anterograde transport of BDNF from neuron cell bodies to their terminals may be important for the trafficking of BDNF in the brain.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	Altar, CA (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; ALTAR CA, 1996, NEUROPROTECTIVE APPR, P160; Conner JM, 1997, J NEUROSCI, V17, P2295; CONOVER JC, 1995, NATURE, V375, P235, DOI 10.1038/375235a0; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KITA H, 1990, BRAIN RES, V536, P1, DOI 10.1016/0006-8993(90)90002-S; LAPPER SR, 1992, BRAIN RES, V580, P215, DOI 10.1016/0006-8993(92)90947-8; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; *NAT RES COUNC NAT, 1996, GUID CAR US LAB AN; Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0; SEROOGY KB, 1993, EXP NEUROL, V124, P119, DOI 10.1006/exnr.1993.1182; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WU K, 1997, MOL BRAIN RES, V43, P286; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0	28	709	725	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					856	860		10.1038/39885	http://dx.doi.org/10.1038/39885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349818				2022-12-24	WOS:A1997YC14800059
J	Ouyang, Q; Kaplan, PD; Liu, SM; Libchaber, A				Ouyang, Q; Kaplan, PD; Liu, SM; Libchaber, A			DNA solution of the maximal clique problem	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; GENE	The maximal clique problem has been solved by means of molecular biology techniques. A pool of DNA molecules corresponding to the total ensemble of six-vertex cliques was built, followed by a series of selection processes. The algorithm is highly parallel and has satisfactory fidelity. This work represents further evidence for the ability of DNA computing to solve NP-complete search problems.	ROCKEFELLER UNIV,CTR STUDIES PHYS & BIOL,NEW YORK,NY 10021	Rockefeller University	Ouyang, Q (corresponding author), NEC RES INST,4 INDEPENDENCE WAY,PRINCETON,NJ 08540, USA.		Kaplan, Peter/A-2972-2009	Kaplan, Peter/0000-0002-2292-6862				ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; CASTI J, 1997, NEW SCI, V2082, P30; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DESALLE R, 1993, EXPERIENTIA, V49, P906, DOI 10.1007/BF01952607; Eckert K A, 1991, PCR Methods Appl, V1, P17; Garey M.R., 1979, COMPUTERS INTRACTABI; Guarnieri F, 1996, SCIENCE, V273, P220, DOI 10.1126/science.273.5272.220; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAYARAMAN K, 1991, P NATL ACAD SCI USA, V88, P4084, DOI 10.1073/pnas.88.10.4084; Kaplan PD, 1997, J THEOR BIOL, V188, P333, DOI 10.1006/jtbi.1997.0475; LIPTON RJ, 1995, SCIENCE, V268, P542, DOI 10.1126/science.7725098; Paun G., 1996, Journal of Automata, Languages and Combinatorics, V1, P27; SAMBROOK J, 1987, MOL CLONING; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4	15	375	477	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					446	449		10.1126/science.278.5337.446	http://dx.doi.org/10.1126/science.278.5337.446			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334300				2022-12-24	WOS:A1997YB35500040
J	Visintin, R; Prinz, S; Amon, A				Visintin, R; Prinz, S; Amon, A			CDC20 and CDH1: A family of substrate-specific activators of APC-dependent proteolysis	SCIENCE			English	Article							B-TYPE CYCLINS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; G1 CYCLINS; MITOSIS; DROSOPHILA; YEAST; DESTRUCTION; FIZZY; DEGRADATION	Proteolysis mediated by the anaphase-promoting complex (APC) triggers chromosome segregation and exit from mitosis, yet its regulation is poorly understood. The conserved Cdc20 and Cdh1 proteins were identified as limiting, substrate-specific activators of APC-dependent proteolysis. CDC20 was required for the degradation of the APC substrate Pds1 but not for that of other APC substrates, such as Clb2 and Ase1. Conversely, cdh1 Delta mutants were impaired in the degradation of Ase1 and Clb2 but not in that of Pds1. Overexpression of either CDC20 or CDH1 was sufficient to induce APC-dependent proteolysis of the appropriate target in stages of the cell cycle in which substrates are normally stable.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute			Visintin, Rosella/J-9690-2012	Amon, Angelika/0000-0001-9837-0314; Visintin, Rosella/0000-0001-6758-9946				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SKOWYRA D, IN PRESS CELL; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; VISINTIN R, UNPUB; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	24	699	708	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					460	463		10.1126/science.278.5337.460	http://dx.doi.org/10.1126/science.278.5337.460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334304				2022-12-24	WOS:A1997YB35500044
J	Eng, CM; Schechter, C; Robinowitz, J; Fulop, G; Burgert, T; Levy, B; Zinberg, R; Desnick, RJ				Eng, CM; Schechter, C; Robinowitz, J; Fulop, G; Burgert, T; Levy, B; Zinberg, R; Desnick, RJ			Prenatal genetic carrier testing using triple disease screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TAY-SACHS-DISEASE; CYSTIC-FIBROSIS; GAUCHER DISEASE; ASHKENAZI JEWS; HUMAN GENOME; POPULATION; MUTATIONS; COMMON	Context.-Rapid progress in gene discovery has dramatically increased diagnostic capabilities for carrier screening and prenatal testing for genetic diseases. However, simultaneous prenatal carrier screening for prevalent genetic disease has not been evaluated, and patient acceptance and attitudes toward this testing strategy remain undefined. Objective.-To evaluate an educational, counseling, and carrier testing program for 3 genetic disorders: Tay-Sachs disease (TSD), type 1 Gaucher disease (GD), and cystic fibrosis (CF) that differ in detectability, severity, and availability of therapy. Design.-Potential participants received education and genetic counseling, gave informed consent, chose screening tests, and completed pre-education and posteducation questionnaires that assessed knowledge, attitudes toward genetic testing, and disease testing preferences. Setting.-Medical genetics referral center. Patients.-Volunteer sample of 2824 Ashkenazi Jewish individuals enrolled as couples who were referred for TSD testing. Intervention.-Genetic counseling, education, and ii chosen, genetic testing for any or all 3 disorders. Main Outcome Measure.-Acceptance of screening for each of the 3 disorders. Secondary outcomes include attitudes toward genetic testing and reproductive considerations. Results.-Of the 2824 individuals tested for TSD, 97% and 95% also chose testing for CF and GD, respectively. The frequency of detected carriers was 1.21 for TSD, 1:25 for CF, and 1:18 for GD. Twenty-one carrier couples were identified, counseled, and all postconception couples opted for prenatal diagnosis. Pre-education and posteducation questionnaires revealed that patients initially knew little about the diseases, but acquired disease information and increased knowledge of genetic concepts. Education and genetic counseling increased understanding and retention of genetic concepts and disease-related information, and minimized test-related anxiety. Although individuals sought screening for all 3 diseases, reproductive attitudes and decisions varied directly with disease severity and treatability. Conclusions.-These findings emphasize the importance of genetic counseling for prenatal carrier testing and may improve understanding, acceptance, and informed decision making for prenatal carrier screening for multiple genetic diseases.	CUNY MT SINAI SCH MED, DEPT PEDIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT COMMUNITY MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Eng, CM (corresponding author), CUNY MT SINAI SCH MED, DEPT HUMAN GENET, BOX 1497, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [2M01 RR00071] Funding Source: Medline; NHGRI NIH HHS [1R01 HG006440] Funding Source: Medline; NICHD NIH HHS [5P30 HD28822] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BEUTLER E, 1992, BLOOD, V79, P1662; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; Beutler E., 1995, METABOLIC MOL BASES, P2641; Brock DJH, 1996, LANCET, V347, P148, DOI 10.1016/S0140-6736(96)90340-2; CUTTING GR, 1992, AM J HUM GENET, V50, P1185; DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409; ENG CM, 1995, AM J HUM GENET, V57, P302; GRODY WW, IN PRESS AM J HUM GE; GUYER MS, 1995, P NATL ACAD SCI USA, V92, P10841, DOI 10.1073/pnas.92.24.10841; HIETALA M, 1995, AM J HUM GENET, V56, P1493; KABACK M, 1993, JAMA-J AM MED ASSOC, V270, P2307, DOI 10.1001/jama.270.19.2307; Lindeman R., 1980, INTRO BIVARIATE MULT; MASSARIK F, 1981, GENETIC DIS CONTROL, P102; McCabe ERB, 1996, JAMA-J AM MED ASSOC, V275, P548, DOI 10.1001/jama.1996.03530310054033; Morris J K, 1995, J Med Screen, V2, P22; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; ROWLEY PT, 1984, AM J HUM GENET, V36, P677; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCRIVER CR, 1995, METABOLIC MOL BASES, P2839; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; TOUCHETTE N, 1995, NAT MED, V1, P501, DOI 10.1038/nm0695-501; TRIGGSRAINE BL, 1992, AM J HUM GENET, V51, P793; TRIGGSRAINE BL, 1990, NEW ENGL J MED, V323, P6, DOI 10.1056/NEJM199007053230102; VOGEL F, 1996, HUM GENET, P559; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; Wilkinson L., 1990, SYSTAT SYSTEM STAT; IN PRESS GENETIC TES	29	61	61	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1268	1272		10.1001/jama.278.15.1268	http://dx.doi.org/10.1001/jama.278.15.1268			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333269				2022-12-24	WOS:A1997XZ70900033
J	Kushida, CA; Efron, B; Guilleminault, C				Kushida, CA; Efron, B; Guilleminault, C			A predictive morphometric model for the obstructive sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; models, anatomic; mouth; neck; body mass index	CLINICAL-FEATURES; AIRWAY; ABNORMALITIES; MORPHOLOGY	Background: Mathematical formulas have been used to clinically predict whether patients will develop the obstructive steep apnea syndrome (OSAS). However, these models do not take into account the disproportionate craniofacial anatomy that accompanies OSAS independently of obesity. Objective: To determine the accuracy of a morphometric model, which combines measurements of the oral cavity with body mass index and neck circumference, in predicting whether a patient has OSAS. Design: 6-month prospective study. Setting: University-based tertiary referral sleep clinic and research center. Participants: 300 consecutive patients evaluated for sleep disorders for the first time. Measurements: Body mass index, neck circumference, and oral cavity measurements were obtained, and a model value was calculated for each patient. Polysomnography was used to determine the number of abnormal respiratory events that occurred during sleep. Sleep apnea was defined as more than five episodes of apnea or hypopnea per hour of sleep. Results: The morphometric model had a sensitivity of 97.6% (95% Cl, 95% to 98.9%), a specificity of 100% (Cl, 92% to 100%), a positive predictive Value of 100% (Cl, 98.5% to 100%), and a negative predictive value of 88.5% (Cl, 77% to 96%). No significant discrepancies were revealed in tests of intermeasurer and test-retest reliability. Conclusions: The morphometric model provides a rapid, accurate, and reproducible method for predicting whether patients in an ambulatory setting have OSAS. The model may be clinically useful as a screening toot for OSAS rather than as a replacement for polysomnography.			Kushida, CA (corresponding author), STANFORD UNIV, SLEEP DISORDERS CLIN & RES CTR, 401 QUARRY RD, SUITE 3301-A, STANFORD, CA 94305 USA.				NIA NIH HHS [AG00164-07, AG07772] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007772] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM SLEEP DIS ASS, 1997, INT CLASS SLEEP DIS; Clemente C., 1981, ANATOMY REGIONAL ATL, V2nd ed.; CRONBACH LJ, 1972, DEPENDABILITY BEHAV, P78; CRONBACH LJ, 1990, ESSENTIALS PSYCHOL T, P195; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; DENNISON WM, 1965, PEDIATRICS, V36, P336; EFRON B, 1983, J AM STAT ASSOC, V78, P316, DOI 10.2307/2288636; Efron Bradley., 1994, INTRO BOOTSTRAP; FERGUSON KA, 1995, CHEST, V108, P375, DOI 10.1378/chest.108.2.375; Goodman R, 1970, FACE GENETIC DISORDE; HAYDEN GD, 1977, DISORDERS RESP TRACT; HOFFSTEIN V, 1992, EUR RESPIR J, V5, P377; HOFFSTEIN V, 1993, SLEEP, V16, P118; JAMIESON A, 1986, SLEEP, V9, P469, DOI 10.1093/sleep/9.4.469; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KATZ I, 1990, AM REV RESPIR DIS, V141, P1228, DOI 10.1164/ajrccm/141.5_Pt_1.1228; KEENAN SP, 1993, SLEEP, V16, pS133, DOI 10.1093/sleep/16.suppl_8.S133; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; LANIADO N, 1987, SLEEP RES, V16, P378; LOWE AA, 1986, AM J ORTHOD DENTOFAC, V90, P484, DOI 10.1016/0889-5406(86)90108-3; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MATTSON DE, 1986, STATISTICS; PARTINEN M, 1988, CHEST, V93, P1199, DOI 10.1378/chest.93.6.1199; RAUSCHER H, 1993, THORAX, V48, P275, DOI 10.1136/thx.48.3.275; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; ROJEWSKI TE, 1982, LARYNGOSCOPE, V92, P246; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strollo PJ, 1996, NEW ENGL J MED, V334, P99, DOI 10.1056/NEJM199601113340207; Swets J., 1982, EVALUATION DIAGNOSTI; VINER S, 1991, ANN INTERN MED, V115, P356, DOI 10.7326/0003-4819-115-5-356; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	31	180	197	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				581	+		10.7326/0003-4819-127-8_Part_1-199710150-00001	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341055				2022-12-24	WOS:A1997YB41900001
J	Lang, AE; Lozano, AM; Montgomery, E; Duff, J; Tasker, R; Hutchinson, W				Lang, AE; Lozano, AM; Montgomery, E; Duff, J; Tasker, R; Hutchinson, W			Posteroventral medial pallidotomy in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORE ASSESSMENT PROGRAM; VENTRAL PALLIDOTOMY; GPI PALLIDOTOMY; TRANSPLANTATION; SYMPTOMS	Background Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up. Methods Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (''off'' period) and while taking their optimal medical regimens (''on'' period). All patients were examined preoperatively, and 39 were examined at six months; 27 of the patients were also examined at one year, and 11 at two years. Results The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent). The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two yeats. The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months. Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery. The complications of surgery were generally well tolerated, and there were no significant changes in the use of medication. Conclusions In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability. Much of the benefit is sustained at two years, although some improvements, such as those on the ipsilateral side and in axial symptoms, wane within the first year. The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy. (C) 1997, Massachusetts Medical Society.	TORONTO HOSP,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; UNIV ARIZONA,COLL MED,DEPT NEUROL,TUCSON,AZ	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Arizona	Lang, AE (corresponding author), TORONTO HOSP,MOVEMENT DISORDERS CTR,DIV NEUROL,399 BATHURST ST,MP 11-306,TORONTO,ON M5T 2S8,CANADA.		Lang, Anthony/ABF-8114-2021; Lozano, Andres M/A-5058-2012	Lozano, Andres M./0000-0001-8257-3694; Lang, Anthony/0000-0003-1229-3667				Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Davis KD, 1997, NAT MED, V3, P671, DOI 10.1038/nm0697-671; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Galvez-Jimenez Nestor, 1996, Neurology, V46, pA402; GALVEZJIMENEZ N, 1996, MOVEMENT DISORD, V11, P242; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; IACONO RP, 1995, J CLIN NEUROSCI, V2, P140, DOI 10.1016/0967-5868(95)90007-1; IACONO RP, 1995, NEUROSURGERY, V36, P1118, DOI 10.1227/00006123-199506000-00008; Johansson F, 1997, J NEUROL NEUROSUR PS, V62, P125, DOI 10.1136/jnnp.62.2.125; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; LAITINEN LV, 1995, NEUROSURG CLIN N AM, V6, P105; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang A. E. T., 1989, QUANTIFICATION NEURO, P285; LANG AE, 1995, MOVEMENT DISORD, V10, P527, DOI 10.1002/mds.870100426; LANG AE, IN PRESS ADV UNDERST; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Lozano A, 1996, J NEUROSURG, V84, P194, DOI 10.3171/jns.1996.84.2.0194; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; SAINTCYR JA, 1996, MOV DISORD S1, V0011, P00161; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SUTTON JP, 1995, NEUROSURGERY, V36, P1112; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x	25	384	389	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	1997	337	15					1036	1042		10.1056/NEJM199710093371503	http://dx.doi.org/10.1056/NEJM199710093371503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ844	9321531				2022-12-24	WOS:A1997XZ84400003
J	Cowles, CR; Odorizzi, G; Payne, GS; Emr, SD				Cowles, CR; Odorizzi, G; Payne, GS; Emr, SD			The AP-3 adaptor complex is essential for cargo-selective transport to the yeast vacuole	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; GOLGI-COMPLEX; DIPEPTIDYL AMINOPEPTIDASE; PROTEIN COMPLEX; ALPHA-FACTOR; CLATHRIN; GENE; MEMBRANE; ENDOCYTOSIS; MUTANTS	Three distinct adaptor protein (AP) complexes involved in protein trafficking have been identified. AP-1 and AP-2 mediate protein sorting at the trans-Golgi network and plasma membrane, respectively, whereas the function of AP-3 has not been defined. A screen for factors specifically involved in transport of alkaline phosphatase (ALP) from the Golgi to the vacuole/lysosome has identified Apl6p and Apl5p of the yeast AP-3 complex. Deletion of each of the four AP-3 subunits results in selective mislocalization of ALP and the vacuolar t-SNARE, Vam3p (but not CPS and CPY), while deletion of AP-1 and AP-2 subunits has no effect on vacuolar protein delivery. This study, therefore, provides evidence that the AP-3 complex functions in cargo-selective protein transport from the Golgi to the vacuole/lysosome.	UNIV CALIF SAN DIEGO,SCH MED,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Odorizzi, Greg/0000-0002-1143-1098	NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689, CA 58689] Funding Source: Medline; NIGMS NIH HHS [GM32703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; COWLES CR, 1994, J CELL SCI, V107, P3449; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Feng DF, 1996, METHOD ENZYMOL, V266, P368; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; RAD MR, 1995, J CELL SCI, V108, P1605; Radisky DC, 1997, P NATL ACAD SCI USA, V94, P5662, DOI 10.1073/pnas.94.11.5662; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROBINSON JS, 1991, MOL CELL BIOL, V12, P5813; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; SPRAGUE GF, 1981, J MOL BIOL, V153, P323, DOI 10.1016/0022-2836(81)90281-3; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; Wada Y, 1997, J CELL SCI, V110, P1299; Webb GC, 1997, MOL BIOL CELL, V8, P871, DOI 10.1091/mbc.8.5.871; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	48	335	345	2	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					109	118		10.1016/S0092-8674(01)80013-1	http://dx.doi.org/10.1016/S0092-8674(01)80013-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335339	Bronze			2022-12-24	WOS:A1997XZ80900013
J	Guacci, V; Koshland, D; Strunnikov, A				Guacci, V; Koshland, D; Strunnikov, A			A direct link between sister chromatid cohesion and chromosome condensation revealed through the analysis of MCD1 in S-cerevisiae	CELL			English	Article							UBIQUITOUS PROTEIN FAMILY; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CELL-CYCLE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; GENE; DNA; MITOSIS; PROTEOLYSIS	The S. cerevisiae MCD1 (mitotic chromosome determinant) gene was identified in genetic screens for genes important for chromosome structure. MCD1 is essential for viability and homologs are found from yeast to humans. Analysis of the mcd1 mutant and cell cycle-dependent expression pattern of Mcd1p suggest that this protein functions in chromosome morphogenesis from S phase through mitosis. The mcd1 mutant is defective in sister chromatid cohesion and chromosome condensation. The physical association between Mcd1p and Smc1p, one of the SMC family of chromosomal proteins, further suggests that Mcd1p functions directly on chromosomes. These data implicate Mcd1p as a nexus between cohesion and condensation. We present a model for mitotic chromosome structure that incorporates this previously unsuspected link.	NICHHD,UNIT CHROMOSOME STRUCT & FUNCT,NIH,MOL EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Guacci, V (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES MED INST,115 W UNIV PKWY,BALTIMORE,MD 21210, USA.			Strunnikov, Alexander/0000-0002-9058-2256	Intramural NIH HHS [Z01 HD001903-11, Z99 AI999999] Funding Source: Medline; NIGMS NIH HHS [GM41718] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUMGARTNER M, 1991, CELL, V64, P761, DOI 10.1016/0092-8674(91)90505-S; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAWRENCE JB, 1988, CELL, V52, P51; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Rao P N, 1984, Symp Fundam Cancer Res, V37, P45; RATTNER JB, 1988, CHROMOSOMA, V96, P360, DOI 10.1007/BF00330702; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Rose MD., 1990, METHODS YEAST GENETI; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Saitoh S, 1997, CELL, V90, P131, DOI 10.1016/S0092-8674(00)80320-7; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; YU S, 1995, CELL STRUCT FUNCT, V20, P263, DOI 10.1247/csf.20.263	53	675	684	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					47	57		10.1016/S0092-8674(01)80008-8	http://dx.doi.org/10.1016/S0092-8674(01)80008-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335334	Bronze, Green Accepted			2022-12-24	WOS:A1997XZ80900008
J	Glinka, A; Wu, W; Onichtchouk, D; Blumenstock, C; Niehrs, C				Glinka, A; Wu, W; Onichtchouk, D; Blumenstock, C; Niehrs, C			Head induction by simultaneous repression of Bmp and Wnt signalling in Xenopus	NATURE			English	Article							HOMEOBOX GENE; SPEMANNS ORGANIZER; SIGNALING PATHWAYS; EMBRYOS; MESODERM; EXPRESSION; HOMOLOG; XWNT-8	The Spemann organizer of the amphibian embryo can be subdivided into two discrete activities, namely trunk organizer and head organizer(1). Several factors secreted from the organizer that are involved in trunk organization are thought to act by repressing Bmp signalling(2-4). With the exception of the secreted factor cerberus(5), little is known about head-organizer inducers, Here we show that co-expression of a dominant-negative Bmp receptor with inhibitors of the Wnt-signalling pathway in Xenopus leads to the induction of complete secondary axes, including a head, This induction does not require expression of the siamois marker of Nieuwkoop centre signalling, suggesting that cells are directly shifting to head-organizer fate, Furthermore, we fmd that cerberus is a potent inhibitor of Wnt signalling, Our results indicate that head-organizer activity results from the simultaneous repression of Bmp and Wnt signalling and they suggest a mechanism for region-specific induction by the organizer.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DIV MOL EMBRYOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Onichtchouk, Daria/E-1741-2012	Onichtchouk, Daria/0000-0001-6497-1445				BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; Gammill LS, 1997, DEVELOPMENT, V124, P471; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERHART J, 1991, BOD MAR LAB, P57; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Itoh K, 1995, DEVELOPMENT, V121, P3979; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; PANNESE M, 1995, DEVELOPMENT, V121, P707; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4	30	300	307	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	1997	389	6650					517	519		10.1038/39092	http://dx.doi.org/10.1038/39092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333244				2022-12-24	WOS:A1997XY90900062
J	Hilden, J				Hilden, J			Discrepant analysis - or behaviour?	LANCET			English	Editorial Material							SENSITIVITY; SPECIFICITY; BIAS				Hilden, J (corresponding author), UNIV COPENHAGEN,DEPT BIOSTAT,BLEGDAMSVEJ 3,DK-2200 COPENHAGEN N,DENMARK.							DIAMOND GA, 1986, J CHRON DIS, V39, P343, DOI 10.1016/0021-9681(86)90119-0; DIETZ K, 1985, J MATH BIOL, V22, P117; Hadgu A, 1997, STAT MED, V16, P1391, DOI 10.1002/(SICI)1097-0258(19970630)16:12<1391::AID-SIM636>3.0.CO;2-1; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HILDEN J, 1986, J CHRON DIS, V39, P853, DOI 10.1016/0021-9681(86)90087-1; KEIDING N, 1991, J R STAT SOC A STAT, V154, P371, DOI 10.2307/2983150; McGee DL, 1996, LANCET, V348, P1307, DOI 10.1016/S0140-6736(05)65781-9	7	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					902	902		10.1016/S0140-6736(05)63264-3	http://dx.doi.org/10.1016/S0140-6736(05)63264-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314866				2022-12-24	WOS:A1997XY67200006
J	tenWolde, PR; Frenkel, D				tenWolde, PR; Frenkel, D			Enhancement of protein crystal nucleation by critical density fluctuations	SCIENCE			English	Article							PHASE-BEHAVIOR; CRYSTALLIZATION; POLYMER; SYSTEM; TRANSITIONS; ENERGY; GROWTH; LATEX	Numerical simulations of homogeneous crystal nucleation with a model for globular proteins with short-range attractive interactions showed that the presence of a metastable fluid-fluid critical point drastically changes the pathway for the formation of a crystal nucleus. Close to this critical point, the free-energy barrier for crystal nucleation is strongly reduced and hence, the crystal nucleation rate increases by many orders of magnitude. Because the location of the metastable critical point can be controlled by changing the composition of the solvent, the present work suggests a systematic approach to promote protein crystallization.	FOM,INST ATOM & MOL PHYS,NL-1098 SJ AMSTERDAM,NETHERLANDS	AMOLF			Wolde, Pieter Rein Ten/U-4433-2019; Frenkel, Daan/G-2580-2014	Wolde, Pieter Rein Ten/0000-0001-9933-4016; Frenkel, Daan/0000-0002-6362-2021				Asherie N, 1996, PHYS REV LETT, V77, P4832, DOI 10.1103/PhysRevLett.77.4832; Bennett C.H., 1975, DIFFUSION SOLIDS, P73, DOI [10.1016/B978-0-12-522660-8.50007-6, DOI 10.1016/B978-0-12-522660-8.50007-6]; BERLAND CR, 1992, P NATL ACAD SCI USA, V89, P1214, DOI 10.1073/pnas.89.4.1214; Broide ML, 1996, PHYS REV E, V53, P6325, DOI 10.1103/PhysRevE.53.6325; Durbin SD, 1996, ANNU REV PHYS CHEM, V47, P171, DOI 10.1146/annurev.physchem.47.1.171; GAST AP, 1983, J COLLOID INTERF SCI, V96, P251, DOI 10.1016/0021-9797(83)90027-9; GAST AP, 1986, J COLLOID INTERF SCI, V109, P161, DOI 10.1016/0021-9797(86)90291-2; GEORGE A, 1994, ACTA CRYSTALLOGR D, V50, P361, DOI 10.1107/S0907444994001216; HAAS C, 1995, J CRYST GROWTH, V154, P126, DOI 10.1016/0022-0248(95)00135-2; HAGEN MHJ, 1994, J CHEM PHYS, V101, P4093, DOI 10.1063/1.467526; HANSEN JP, 1969, PHYS REV, V184, P151, DOI 10.1103/PhysRev.184.151; HILL TL, 1986, INTRO STAT THERMODYN, pCH15; ILETT SM, 1995, PHYS REV E, V51, P1344, DOI 10.1103/PhysRevE.51.1344; KELTON KF, 1991, SOLID STATE PHYS, V45, P75; KOSE A, 1976, J COLLOID INTERF SCI, V55, P487, DOI 10.1016/0021-9797(76)90059-X; LEKKERKERKER HNW, 1992, EUROPHYS LETT, V20, P559, DOI 10.1209/0295-5075/20/6/015; MALKIN AJ, 1993, J CRYST GROWTH, V133, P29, DOI 10.1016/0022-0248(93)90100-B; MALKIN AJ, 1992, J CRYST GROWTH, V128, P1232; MCPHERSON A, 1976, J BIOL CHEM, V251, P6300; McPherson A, 1982, PREPARATION ANAL PRO; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; Poon WCK, 1997, PHYS REV E, V55, P3762, DOI 10.1103/PhysRevE.55.3762; Poon WCK, 1995, FARADAY DISCUSS, V101, P65, DOI 10.1039/fd9950100065; RICHARDS EG, 1980, INTRO PHYSICAL PROPE; Rosenbaum D, 1996, PHYS REV LETT, V76, P150, DOI 10.1103/PhysRevLett.76.150; Rosenbaum DF, 1996, J CRYST GROWTH, V169, P752, DOI 10.1016/S0022-0248(96)00455-1; Rosenberger F, 1996, J CRYST GROWTH, V166, P40, DOI 10.1016/0022-0248(95)00921-3; SMITS C, 1990, PHASE TRANSIT, V21, P157, DOI 10.1080/01411599008206888; TENWOLDE PR, 1995, PHYS REV LETT, V75, P2714, DOI 10.1103/PhysRevLett.75.2714; tenWolde PR, 1996, J CHEM PHYS, V104, P9932, DOI 10.1063/1.471721; TORRIE GM, 1974, CHEM PHYS LETT, V28, P578, DOI 10.1016/0009-2614(74)80109-0	31	1073	1080	7	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1975	1978		10.1126/science.277.5334.1975	http://dx.doi.org/10.1126/science.277.5334.1975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302288	Green Submitted			2022-12-24	WOS:A1997XX84900038
J	Butland, BK; Strachan, DP; Lewis, S; Bynner, J; Butler, N; Britton, J				Butland, BK; Strachan, DP; Lewis, S; Bynner, J; Butler, N; Britton, J			Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ECZEMA; ATOPY; PREVALENCE; ASTHMA; CHILDREN; ALLERGY; DISEASE; SMOKING	Objective: To investigate whether changes in certain perinatal and social factors explain the increased prevalence of hay fever and eczema among British adolescents between 1974 and 1986. Design: Two prospective birth cohort studies. Setting: England, Wales, and Scotland. Subjects: 11 195 children born 3-9 March 1958 and 9387 born 5-11 April 1970. Main outcome measures: Parental reports of eczematous rashes and of hay fever or allergic rhinitis in the previous 12 months at age 16. Results: The prevalence of the conditions over the 12 month period increased between 1974 and 1986 from 3.1% to 6.4% (prevalence ratio 2.04 (95% confidence interval 1.79 to 2.32)) for eczema and from 12.0% to 23.3% (prevalence ratio 1.93 (1.82 to 2.06)) for hay fever. Both conditions were more commonly reported among children of higher birth order and those who were breast fed for longer than 1 month. Eczema was more commonly reported among girls and hay fever among boys. The prevalence of hay fever decreased sharply between social classes I and V, increased with maternal age up to the early 30s, and was lower in children whose mothers smoked during pregnancy. Neither condition varied significantly with birth weight When adjusted for these factors, the relative odds of hay fever (1986 v 1974) increased from 2.23 (2.05 to 2.43) to 2.40 (2.19 to 2.63). Similarly, the relative odds of eczema rose from 2.02 (1.73 to 2.36) to 2.14 (1.81 to 2.52). Conclusions: Taken together, changes between cohorts in sex, birth weight, birth order, maternal age, breast feeding, maternal smoking during pregnancy, and father's social dass at birth did not seem to explain any of the observed rise in the prevalence of hay fever and eczema. However, correlates of these factors which have changed over time may still underlie recent increases' in allergic disease.	UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,INT CTR CHILD STUDIES,LONDON EC1V 0HB,ENGLAND	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; City University London; University of London; University College London	Butland, BK (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Britton, John R/G-9705-2011	Butland, Barbara/0000-0001-9952-3108				ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Butler NR, 1986, BIRTH 5 STUDY HLTH B; DAVIE R, 1972, BIRTH 7 FULL STAT AP; FINN R, 1992, LANCET, V340, P1453; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; Golding J, 1986, BIRTH 5 STUDY HLTH B; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; *LUNG ASTHM INF AG, 1993, 935 ST GEORG HOSP ME; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; *REG GEN ENGL WAL, 1951, CLASS OCC; *REG GEN ENGL WAL, 1966, CLASS OCC; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496, DOI 10.1136/adc.67.4.496; SAARINEN UM, 1979, LANCET, V2, P163; *SAS I, 1989, SAS STAT US GUID VER; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P791, DOI 10.1111/j.1365-2222.1995.tb00019.x; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WILLIAMS HC, 1994, BRIT MED J, V308, P1132, DOI 10.1136/bmj.308.6937.1132	25	179	183	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 20	1997	315	7110					717	721		10.1136/bmj.315.7110.717	http://dx.doi.org/10.1136/bmj.315.7110.717			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX674	9314757	Green Published			2022-12-24	WOS:A1997XX67400023
J	Toczyski, DP; Galgoczy, DJ; Hartwell, LH				Toczyski, DP; Galgoczy, DJ; Hartwell, LH			CDC5 and CKII control adaptation to the yeast DNA damage checkpoint	CELL			English	Article							CASEIN KINASE-II; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; BUDDING YEAST; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; RAD9 CHECKPOINT; BINDING PROTEIN	A single double-stranded DNA (dsDNA) break will cause yeast cells to arrest in G2/M at the DNA damage checkpoint. If the dsDNA break cannot be repaired, cells will eventually override (that is, adapt to) this checkpoint, even though the damage that elicited the arrest is still present. Here, we report the identification of two adaptation-defective mutants that remain permanently arrested as large-budded cells when faced with an irreparable dsDNA break in a nonessential chromosome. This adaptation-defective phenotype was entirely relieved by deletion of RAD9, a gene required for the G2/M DNA damage checkpoint arrest. We show that one mutation resides in CDC5, which encodes a polo-like kinase, whereas a second, less penetrant, adaptation-defective mutant is affected at the CKB2 locus, which encodes a nonessential specificity subunit of casein kinase II.			Toczyski, DP (corresponding author), FRED HUTCHINSON CANC RES CTR, 1100 FAIRVIEW AVE N, C3-167, SEATTLE, WA 98109 USA.				NCI NIH HHS [CAO9437] Funding Source: Medline; NIGMS NIH HHS [GM-17709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017709, R01GM017709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; HARTWELL LH, 1973, GENETICS, V74, P267; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUNA RMD, 1995, NATURE, V378, P203; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; REED JC, 1994, J BIOL CHEM, V269, P18192; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	41	357	359	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1097	1106		10.1016/S0092-8674(00)80375-X	http://dx.doi.org/10.1016/S0092-8674(00)80375-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323137	Bronze			2022-12-24	WOS:A1997XX76800015
J	Kim, D; Jun, KS; Lee, SB; Kang, NG; Min, DS; Kim, YH; Ryu, SH; Suh, PG; Shin, HS				Kim, D; Jun, KS; Lee, SB; Kang, NG; Min, DS; Kim, YH; Ryu, SH; Suh, PG; Shin, HS			Phospholipase C isozymes selectively couple to specific neurotransmitter receptors	NATURE			English	Article							PHOSPHOINOSITIDE HYDROLYSIS; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; MESSENGER-RNAS; RAT-BRAIN; EPILEPSY; SEIZURES; MICE; LOCALIZATION; INTERNEURONS	A variety of extracellular signals are transduced across the cell membrane by the enzyme phosphoinositide-specific phospholipase C-beta (PLC-beta) coupled with guanine-nucleotide-binding G proteins'. There are four isoenzymes of PLC-beta, beta 1-beta 4, but their functions in vivo are not known. Here we investigate the role of PLC-beta 1 and PLC-beta 4 in the brain by generating-null mutations in mice: we found that PLC beta 1(-/-) mice developed epilepsy and PLC beta 4(-/-) mice showed ataxia. We determined the molecular basis of these phenotypes and show that PLC-beta 1 is involved in signal transduction in the cerebral cortex and hippocampus by coupling pre-dominantly to the muscarinic acetylcholine receptor, whereas PLC-beta 4 works through the metabotropic glutamate receptor in the cerebellum, illustrating how PLC-beta isoenzymes are used to generate different functions in the brain.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; INJE UNIV,INST NEUROSCI,PUSAN 614735,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Inje University			Kim, Daesoo/C-1625-2011; Suh, Pann-Ghill/F-3610-2010	Kim, Daesoo/0000-0001-9915-1463; Ryu, Sung Ho/0000-0003-0913-3048; Lee, Seong-Beom/0000-0002-2767-6188; KANG, NAE-GYU/0000-0002-3318-3873				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; BUZSAKI G, 1989, NEUROSCIENCE, V28, P527, DOI 10.1016/0306-4522(89)90002-X; CREWS FT, 1994, LIFE SCI, V55, P1993, DOI 10.1016/0024-3205(94)00379-3; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; FISHER SK, 1992, J NEUROCHEM, V58, P18, DOI 10.1111/j.1471-4159.1992.tb09273.x; FRANKEL WN, 1995, MAMM GENOME, V6, P839, DOI 10.1007/BF00292432; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHOEPP DD, 1991, EUR J PHARM-MOLEC PH, V207, P351, DOI 10.1016/0922-4106(91)90010-F; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; STAFSTROM CE, 1992, DEV BRAIN RES, V65, P227, DOI 10.1016/0165-3806(92)90184-X; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0	26	241	252	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					290	293		10.1038/38508	http://dx.doi.org/10.1038/38508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305844				2022-12-24	WOS:A1997XW77200049
J	Jost, CA; Marin, MC; Kaelin, WG				Jost, CA; Marin, MC; Kaelin, WG			p73 is a human p53-related protein that can induce apoptosis	NATURE			English	Article							P53 GENE-MUTATIONS; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; DNA-BINDING; NEUROBLASTOMA; IDENTIFICATION; DOMAIN	The protein p53 is the most frequently mutated tumour suppressor to be identified so far in human cancers(1,2). The ability of p53 to inhibit cell growth is due, at least in part, to its ability to bind to specific DNA sequences and activate the transcription of target genes such as that encoding the cell-cycle inhibitor p21(Waf1/Cip1) (ref. 3), A gene has recently been identified that is predicted to encode a protein with significant amino-acid sequence similarity to p53 (ref, 4), In particular, each of the p53 amino-acid residues implicated in direct sequence-specific DNA binding is conserved in this protein(5). This gene, called p73, maps to the short arm of chromosome 1, and is found in a region that is frequently deleted in neuroblastomas(6). Here we show that p73 can, at least when overproduced, activate the transcription of p53-responsive genes and inhibit cell growth in a p53-like manner by inducing apoptosis (programmed cell death).	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN XB, 1993, GENE DEV, V7, P2652; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLER L, 1995, CANCER RES, V55, P2910; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLEMINGTON EK, 1994, MOL CELL BIOL, V14, P3041, DOI 10.1128/MCB.14.5.3041; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; KAGHAD M, IN PRESS CELL; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; VOGAN K, 1993, CANCER RES, V53, P5269	25	870	906	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					191	194		10.1038/38298	http://dx.doi.org/10.1038/38298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296498				2022-12-24	WOS:A1997XV75700051
J	Blattler, T; Brandner, S; Raeber, AJ; Klein, MA; Voigtlander, T; Weissmann, C; Aguzzi, A				Blattler, T; Brandner, S; Raeber, AJ; Klein, MA; Voigtlander, T; Weissmann, C; Aguzzi, A			PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain	NATURE			English	Article							CREUTZFELDT-JAKOB DISEASE; CENTRAL-NERVOUS-SYSTEM; HOST PRION PROTEIN; MICE; MOUSE; PATHOGENESIS; REPLICATION; AGENT; SPREAD	Much available evidence points to a pathological isoform of the prion protein PrP being the infectious agent that causes transmissible spongiform encephalopathies, but the mechanisms controlling the neurotropism of prions are still unclear. We have previously shown that mice that do not express PrP (Prnp(o/o) mice) are resistant to infection by prions(1,2), and that if a Prnp(+/+) neurograft is introduced into such animals and these are infected intracerebrally with scrapie, the graft but not the surrounding tissue shows scrapie pathology(3). Here we show that PrP-expressing neurografts in Prnp(o/o) mice do not develop scrapie histopathology after intraperitoneal or intravenous inoculation with scrapie prions. Prion titres were undetectable in spleens of inoculated Prnp(o/o) mice, but were restored to wild-type levels upon reconstitution of the host lymphohaemopoietic system with PrP-expressing cells. Surprisingly, however, i.p. or i.v. inoculation failed to produce scrapie pathology in the neurografts of 27 out of 28 reconstituted animals, in contrast to intracerebral inoculation. We conclude that transfer of infectivity from the spleen to the central nervous system is crucially dependent on the expression of PrP in a tissue compartment that cannot be reconstituted by bone marrow transfer. Thus the requirement for the normal isoform of PrP in peripheral tissues represents a bottleneck for the spread of prions from peripheral sites to the central nervous system.	UNIV ZURICH,INST NEUROPATHOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOL BIOL,CH-8093 ZURICH,SWITZERLAND	University of Zurich; University of Zurich			Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708				Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown KL, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P159; BROWN P, 1990, NEUROLOGY, V40, P887, DOI 10.1212/WNL.40.6.887; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER HR, 1992, NATURE, V256, P577; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; FRASER H, 1978, J COMP PATHOL, V88, P563, DOI 10.1016/0021-9975(78)90010-5; Isenmann S, 1996, NEUROPATH APPL NEURO, V22, P118; KIMBERLIN RH, 1983, J NEUROL SCI, V61, P315, DOI 10.1016/0022-510X(83)90165-X; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Lasmezas CI, 1996, J VIROL, V70, P1292; OROURKE KI, 1994, J GEN VIROL, V75, P1511, DOI 10.1099/0022-1317-75-6-1511; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620	21	223	228	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					69	73		10.1038/37981	http://dx.doi.org/10.1038/37981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288968				2022-12-24	WOS:A1997XU59600046
J	Schwab, M; Lutum, AS; Seufert, W				Schwab, M; Lutum, AS; Seufert, W			Yeast Hct1 is a regulator of Clb2 cyclin proteolysis	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; G1 CYCLINS; CDC20 GENE; S-PHASE; UBIQUITIN; DEGRADATION; MITOSIS	Stage-specific proteolysis of mitotic cyclins is fundamental to eukaryotic cell cycle regulation. We found that yeast Hct1, a conserved protein of eukaryotes, is a necessary and rate-limiting component of this proteolysis pathway. In hct1 mutants, the mitotic cyclin Clb2 is highly stabilized and inappropriately induces DNA replication, while G1 cyclins and other proteolytic substrates remain short-lived. Viability of hct1 mutants depends on SIC1. This and further results suggest that inhibition of cyclin-dependent kinases may compensate for defects in cyclin proteolysis. Remarkably, elevated levels of Hct1 ectopically activate destruction box-and Cdc23-dependent degradation of Clb2 and cause phenotypic effects characteristic for a depletion of M-phase cyclins. Hct1 and the related Cdc20 may function as substrate-specific regulators of proteolysis during mitosis.			Schwab, M (corresponding author), UNIV STUTTGART,INST IND GENET,ALLMANDRING 31,D-70569 STUTTGART,GERMANY.		Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KAISER C, 1994, MEHTODS YEAST GENETI; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHWOB E, 1994, CELL, V79, P239; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	41	427	432	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					683	693		10.1016/S0092-8674(00)80529-2	http://dx.doi.org/10.1016/S0092-8674(00)80529-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288748	Bronze			2022-12-24	WOS:A1997XT06600012
J	Wood, KW; Sakowicz, R; Goldstein, LSB; Cleveland, DW				Wood, KW; Sakowicz, R; Goldstein, LSB; Cleveland, DW			CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment	CELL			English	Article							KINESIN-LIKE PROTEIN; PREDICTING COILED COILS; MITOTIC SPINDLE; DIRECTIONAL INSTABILITY; MICROTUBULE DEPOLYMERIZATION; CRYSTAL-STRUCTURE; MITOSIS; MOTILITY; POSITION; DOMAIN	Mitosis requires dynamic attachment of chromosomes to spindle microtubules. This interaction is mediated largely by kinetochores. During prometaphase, forces exerted at kinetochores, in combination with polar ejection forces, drive congression of chromosomes to the metaphase plate. A major question has been whether kinetochore-associated microtubule motors play an important role in congression. Using immunodepletion from and antibody addition to Xenopus egg extracts, we show that the kinetochore-associated kinesin-like motor protein CENP-E is essential for positioning chromosomes at the metaphase plate. We further demonstrate that CENP-E powers movement toward microtubule plus ends in vitro. These findings support a model in which CENP-E functions in congression to tether kinetochores to dynamic microtubule plus ends.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego	Wood, KW (corresponding author), UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,CELL BIOL LAB,LA JOLLA,CA 92093, USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682				BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brown KD, 1996, J CELL SCI, V109, P961; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CASSIMERIS L, 1994, J CELL SCI, V107, P285; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Duesbery NS, 1997, P NATL ACAD SCI USA, V94, P9165, DOI 10.1073/pnas.94.17.9165; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; HOWARD J, 1993, MOTILITY ASSAYS MOTO, P105; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1992, METHOD ENZYMOL, P478; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Khodjakov A, 1996, J CELL BIOL, V135, P315, DOI 10.1083/jcb.135.2.315; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matthies HJG, 1996, J CELL BIOL, V134, P455, DOI 10.1083/jcb.134.2.455; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cb.04.110188.002523; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RIEDER CL, 1982, INT REV CYTOL, V79, P1, DOI 10.1016/S0074-7696(08)61672-1; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; ROOS UP, 1976, CHROMOSOMA, V54, P363, DOI 10.1007/BF00292816; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1991, J CELL BIOL, V112, P929; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Waters JC, 1996, J CELL SCI, V109, P2823; Wilson PG, 1997, J CELL SCI, V110, P451; YAO X, 1997, IN PRESS J CELL BIOL; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	50	331	335	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					357	366		10.1016/S0092-8674(00)80419-5	http://dx.doi.org/10.1016/S0092-8674(00)80419-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363944	Bronze			2022-12-24	WOS:A1997YD94100009
J	vanWeel, C; Michels, J				vanWeel, C; Michels, J			Dying, not old age, to blame for costs of health care	LANCET			English	Article											vanWeel, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				GREENBERG I, 1997, HLTH SERV RES, V31, P723; Perls TT, 1996, ARCH INTERN MED, V156, P754, DOI 10.1001/archinte.156.7.754; RUWAARD D, 1997, VOLKSGEZONDHEID TOEK; van Noordt M, 1992, Gesundheitswesen, V54, P173; *VAND HLTH STAT NE, 1996, STAT NETH; VANWEEL C, 1996, EUR J GEN PRACT, V2, P17	6	27	27	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1159	1160		10.1016/S0140-6736(97)08312-8	http://dx.doi.org/10.1016/S0140-6736(97)08312-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343516	Green Submitted			2022-12-24	WOS:A1997YB19900044
J	Gu, JGG; MacDermott, AB				Gu, JGG; MacDermott, AB			Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses	NATURE			English	Article							SYNAPTIC TRANSMISSION; GATED CURRENTS; CHANNELS; CALCIUM; DORSAL; RAT; NICOTINE	Painful stimuli to the skin initiate action potentials in the peripheral terminals of dorsal root ganglion (DRG) neurons. These action potentials propagate to DRG central terminals in the dorsal horn of the spinal cord, evoking release of excitatory transmitters such as glutamate onto postsynaptic dorsal horn neurons. P2X receptors, a family of ligand-gated ion channels(1,2) activated by the endogenous ligand ATP, are highly expressed by DRG neurons(3-5). Immunoreactivity to P2X receptors has been identified in the dorsal horn superficial laminae associated with nociceptive DRG central terminals(5), suggesting the presence of presynaptic P2X receptors. Here we have used a DRG-dorsal horn co-culture system to show that P2X receptors are localized at presynaptic sites on DRG neurons; that activation of these receptors results in increased frequency of spontaneous glutamate release; and that activation of P2X receptors at or near presynaptic DRG nerve terminals elicits action potentials that cause evoked glutamate release. Thus activation of P2X receptors at DRG central terminals can modify sensory signal throughput, and might even initiate sensory signals at central synapses without direct peripheral input. This putative central modulation and generation of sensory signals maybe associated with physiological and pathological pain sensation, making presynaptic P2X receptors a possible target for pain therapy.	COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	Gu, JGG (corresponding author), COLUMBIA UNIV, DEPT PHYSIOL & CELLULAR BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA.							Bardoni R, 1997, J NEUROSCI, V17, P5297; BEAN BP, 1990, J NEUROSCI, V10, P11; BEHHAM CD, 1987, NATURE, V328, P275; Burnstock G, 1996, CIBA F SYMP, V198, P1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Cook SP, 1997, NATURE, V387, P505, DOI 10.1038/387505a0; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI J, 1995, J NEUROSCI, V15, P3357; Liu HT, 1997, NATURE, V386, P721, DOI 10.1038/386721a0; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MCLAREN GJ, 1994, BRIT J PHARMACOL, V111, P913, DOI 10.1111/j.1476-5381.1994.tb14825.x; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; North RA, 1996, CIBA F SYMP, V198, P91; REICHLING DB, 1991, J PHYSIOL-LONDON, V441, P199, DOI 10.1113/jphysiol.1991.sp018746; ROGERS M, 1995, BIOPHYS J, V68, P501, DOI 10.1016/S0006-3495(95)80211-0; ROY ML, 1992, J NEUROSCI, V12, P2104; SEGAL MM, 1990, J NEUROPHYSIOL, V64, P1390, DOI 10.1152/jn.1990.64.5.1390; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; WHITE TD, 1985, BRAIN RES, V334, P372, DOI 10.1016/0006-8993(85)90235-5	22	413	435	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					749	753		10.1038/39639	http://dx.doi.org/10.1038/39639			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338789				2022-12-24	WOS:A1997YA95900060
J	Howell, BW; Hawkes, R; Soriano, P; Cooper, JA				Howell, BW; Hawkes, R; Soriano, P; Cooper, JA			Neuronal position in the developing brain is regulated by mouse disabled-1	NATURE			English	Article							ABL TYROSINE KINASE; TARGETED DISRUPTION; CORTICAL-NEURONS; CEREBRAL-CORTEX; REELER MICE; CELL; MUTATION; PROTEIN; PROTOONCOGENE; MIGRATION	During mammalian brain development, immature neurons migrate radially from the neuroectoderm to defined locations, giving rise to characteristic cell layers(1,2). Here we show that targeted disruption of the mouse disabled1 (mdab1) gene(3) disturbs neuronal layering in the cerebral cortex, hippocampus and cerebellum. The gene encodes a cytoplasmic protein, mDab1 p80, which is expressed and tyrosine-phosphorylated in the developing nervous system(3). It is likely to be an adaptor protein, docking to others through its phosphotyrosine residues and protein-interacting domain(4). The mdab1 mutant phenotype is very similar to that of the reeler mouse(5-7). The product of the reeler gene, Reelin, is a secreted protein that has been proposed to act as an extracellular signpost for migrating neurons(8-10). Because mDab1 is expressed in wild-type cortical neurons, and Reelin expression is normal in mdab1 mutants, mDab1 may be part of a Reelin-regulated or parallel pathway that controls the final positioning of neurons.	UNIV CALGARY, DEPT ANAT, CALGARY, AB T2N 4N1, CANADA; UNIV CALGARY, NEUROSCI RES GRP, CALGARY, AB T2N 4N1, CANADA	University of Calgary; University of Calgary	Howell, BW (corresponding author), FRED HUTCHINSON CANC RES CTR, 1100 FAIRVIEW AVE N, SEATTLE, WA 98109 USA.		Hawkes, Richard/F-7971-2011; Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Howell, Brian/0000-0002-0204-0773				Caviness V S Jr, 1982, Brain Res, V256, P293; CAVINESS VS, 1973, J COMP NEUROL, V147, P235, DOI 10.1002/cne.901470206; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFFINET AM, 1979, ANAT EMBRYOL, V157, P205, DOI 10.1007/BF00305160; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1984, DEV BRAIN RES, V16, P263, DOI 10.1016/0165-3806(84)90031-2; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOFFARTH RM, 1995, J NEUROSCI, V15, P4838; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; LANNOO MJ, 1991, J COMP NEUROL, V310, P215, DOI 10.1002/cne.903100207; Margolis B, 1996, J LAB CLIN MED, V128, P235, DOI 10.1016/S0022-2143(96)90022-0; McConnell S K, 1992, Curr Opin Neurobiol, V2, P23, DOI 10.1016/0959-4388(92)90156-F; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; Miyata T, 1996, J COMP NEUROL, V372, P215; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; ONESHIMA H, IN PRESS NEUROSCI RE; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SMEYNE RJ, 1995, MOL CELL NEUROSCI, V6, P230, DOI 10.1006/mcne.1995.1019; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STANFIELD BB, 1979, J COMP NEUROL, V185, P393, DOI 10.1002/cne.901850302; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	30	594	607	1	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					733	737		10.1038/39607	http://dx.doi.org/10.1038/39607			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338785				2022-12-24	WOS:A1997YA95900056
J	Rittinger, K; Walker, PA; Eccleston, JF; Smerdon, SJ; Gamblin, SJ				Rittinger, K; Walker, PA; Eccleston, JF; Smerdon, SJ; Gamblin, SJ			Structure at 1.65 angstrom of RhoA and its GTPase-activating protein in complex with a transition-state analogue	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING PROTEINS; HYDROLYSIS; MECHANISM; RAC	Small G proteins of the Rho family, which includes Rho, pac and Cdc42Hs, regulate phosphorylation pathways that control a range of biological functions including cytoskeleton formation and cell proliferation(1-7). They operate as molecular switches, cycling between the biologically active GTP-bound form and the inactive GDP-bound state, Their rate of hydrolysis of GTP to GDP by virtue of their intrinsic GTPase activity is slow, but can be accelerated by up to 10(5)-fold through interaction with rhoGAP, a GTPase-activating protein that stimulates Rho-family proteins(8,9). As such, rhoGAP plays a crucial role in regulating Rho-mediated signalling pathways. Here we report the crystal structure of RhoA and rhoGAP complexed with the transition-state analogue GDP.AlF4- at 1.65 Angstrom resolution. There is a rotation of 20 degrees between the Rho and rhoGAP proteins in this complex when compared with the ground-state complex Cdc42Hs.GMPPNP/rhoGAP, in which Cdc42Hs is bound to the non-hydrolysable GTP analogue GMPPNP(10). Consequently, in the transition state complex but not in the ground state, the rhoGAP domain contributes a residue, Arg85(GAP), directly into the active site of the G protein, We propose that this residue acts to stabilize the transition state of the GTPase reaction. RhoGAP also appears to function by stabilizing several regions of RhoA that are important in signalling the hydrolysis of GTP.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Rittinger, Katrin/D-2586-2014	Rittinger, Katrin/0000-0002-7698-4435; Smerdon, Stephen/0000-0001-5688-8465				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MCCORMICK F, 1989, NATURE, V340, P678, DOI 10.1038/340678a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WITTINGHOFER A, 1993, HDB EXPT PHARM, V108, P195; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579	30	346	355	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					758	762		10.1038/39651	http://dx.doi.org/10.1038/39651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338791				2022-12-24	WOS:A1997YA95900062
J	Sheldon, M; Rice, DS; DArcangelo, G; Yoneshima, H; Nakajima, K; Mikoshiba, K; Howell, BW; Cooper, JA; Goldowitz, D; Curran, T				Sheldon, M; Rice, DS; DArcangelo, G; Yoneshima, H; Nakajima, K; Mikoshiba, K; Howell, BW; Cooper, JA; Goldowitz, D; Curran, T			Scrambler and yotari disrupt the disabled gene and produce a reeler-like phenotype in mice	NATURE			English	Article							ABL TYROSINE KINASE; LEPTIN RECEPTOR; DROSOPHILA; MOUSE; PROTEIN; ENCODES; NEURONS; DOMAIN; ORGANIZATION; EXPRESSION	Formation of the mammalian brain requires choreographed migration of neurons to generate highly ordered laminar structures such as those in the cortices of the forebrain and the cerebellum, These processes are severely disrupted by mutations in reelin(1) which cause widespread misplacement of neurons and associated ataxia in reeler mice(2,3). Reelin is a large extracellular protein secreted by pioneer neurons that coordinates cell positioning during neurodevelopment(1,4-8). Two new autosomal recessive mouse mutations, scrambler(9) and yotari(10) have been described that exhibit a phenotype identical to reeler(9-11). Here we report that scrambler and yotari arise from mutations in mdab1 (ref, 12), a mouse gene related to the Drosophila gene disabled (dab)(13). Both scrambler and yotari mice express mutated forms of mdab1 messenger RNA and little or no mDab1 protein. mDab1 is a phosphoprotein that appears to function as an intracellular adaptor in protein kinase pathways, Expression analysis indicates that mdab1 is expressed in neuronal populations exposed to Reelin. The similar phenotypes of reeler, scrambler, yotari and mdab1 null mice(14) indicate that Reelin and mDab1 function as signalling molecules that regulate cell positioning in the developing brain.	ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA; UNIV TOKYO, INST MED SCI, DEPT MOL NEUROBIOL, MINATO KU, TOKYO 108, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOL NEUROBIOL LAB, TSUKUBA, IBARAKI 305, JAPAN; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV TENNESSEE, COLL MED, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tokyo; RIKEN; Fred Hutchinson Cancer Center; University of Tennessee System; University of Tennessee Health Science Center			Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Nakajima, Kazunori/L-3396-2013; Mikoshiba, Katsuhiko/N-7943-2015	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Nakajima, Kazunori/0000-0003-1864-9425; Goldowitz, Daniel/0000-0003-4756-4017; D'Arcangelo, Gabriella/0000-0003-1575-1010; Howell, Brian/0000-0002-0204-0773				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1995, NATURE, V374, P675, DOI 10.1038/374675a0; GOLDOWITZ D, IN PRESS J NEUROSCI; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; Miyata T, 1997, J NEUROSCI, V17, P3599; Miyata T, 1996, J COMP NEUROL, V372, P215; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YONESHINA H, IN PRESS NEUROSCI RE; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	31	528	540	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					730	733		10.1038/39601	http://dx.doi.org/10.1038/39601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338784				2022-12-24	WOS:A1997YA95900055
J	Coulthard, MG; Lambert, HJ; Keir, MJ				Coulthard, MG; Lambert, HJ; Keir, MJ			Occurrence of renal scars in children after their first referral for urinary tract infection	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM, DEPT MED PHYS, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND	Newcastle University - UK	Coulthard, MG (corresponding author), ROYAL VICTORIA INFIRM, DEPT CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.			Lambert, Heather/0000-0003-4389-4078				[Anonymous], 1991, J R Coll Physicians Lond, V25, P36; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; VERNON S, 1994, LANCET, V4, P344; Vernon SJ, 1997, BMJ-BRIT MED J, V315, P905	5	58	60	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 11	1997	315	7113					918	919						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361542				2022-12-24	WOS:A1997YB07300026
J	Hines, PJ				Hines, PJ			Nota bene: Neurobiology - Unconscious odors	SCIENCE			English	Editorial Material							RECEPTORS; FAMILY											BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0	5	3	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					79	79		10.1126/science.278.5335.79	http://dx.doi.org/10.1126/science.278.5335.79			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9340759				2022-12-24	WOS:A1997XZ12400039
J	Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD				Selker, HP; Griffith, JL; Beshansky, JR; Schmid, CH; Califf, RM; DAgostino, RB; Laks, MM; Lee, KL; Maynard, C; Selvester, RH; Wagner, GS; Weaver, WD			Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: A thrombolytic predictive instrument	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-CARE-UNIT; TISSUE PLASMINOGEN-ACTIVATOR; ACUTE CARDIAC ISCHEMIA; QRS SCORING SYSTEM; RANDOMIZED TRIAL; CLINICAL-TRIAL; THERAPY; MULTICENTER; MORTALITY; STREPTOKINASE	Background: Thrombolytic therapy can be life-saving in patients with acute myocardial infarction. However, if given too late or insufficiently selectively, it may provide little benefit but still cause serious complications and incur substantial costs. Objective: To develop a thrombolytic predictive instrument for real-time use in emergency medical service settings that could 1) identify patients likely to benefit from thrombolysis and 2) facilitate the earliest possible use of this therapy. Design: Creation and validation of logistic regression-based predictive instruments based on secondary analysis of clinical data. Patients: 4911 patients who had acute myocardial infarction and ST-segment elevation on electrocardiogram; 3483 received thrombolytic therapy. Measurements: Data were obtained from 13 major clinical trials and registries and directly from medical records, including electrocardiograms obtained at presentation. Input variables include presenting clinical and electrocardiographic features; predictive models generate probabilities for acute (30-day) mortality if and if not treated with thrombolysis, 1-year mortality rates if and if not treated with thrombolysis, cardiac arrest if and if not treated with thrombolysis, thrombolysis-related intracranial hemorrhage, and thrombolysis-related major bleeding episode requiring transfusion. Together, these models constitute the thrombolytic predictive instrument. Results: The predictive models generated the following mean predictions for patients in the Thrombolytic Predictive Instrument Database: 30-day mortality rate, 7.1%; 1-year mortality rate, 10.9%; rate of cardiac arrest, 3.7%; rate of thrombolysis-related intracranial hemorrhage, 0.6%; and rate of other thrombolysis-related major bleeding episodes, 5.0%. They discriminated well between persons having and those not having the predicted outcome; areas under the receiver-operating characteristic (ROC) curve were between 0.77 and 0.84 for the five outcomes. Calibration between each instrument's predicted and observed rates was excellent. Validation of the predictive instruments for 30-day and 1-year mortality, done on a separate test dataset, yielded areas under the ROC curve of 0.76 for each. Conclusions: After the basic features of a clinical presentation are entered into a computerized electrocardiograph, the predictions of the thrombolytic predictive instrument can be printed on the electrocardiogram report. This decision aid may facilitate earlier and more appropriate use of thrombolytic therapy in patients with acute myocardial infarction.	BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; DUKE UNIV, MED CTR, DURHAM, NC 27705 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, HARBOR MED CTR, LOS ANGELES, CA 90024 USA	Boston University; Duke University; University of Washington; University of Washington Seattle; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Selker, HP (corresponding author), TUFTS UNIV, CTR CARDIOVASC HLTH SERV RES, DIV CLIN CARE RES, SCH MED, NEW ENGLAND MED CTR, BOSTON, MA 02111 USA.		Schmid, Christopher H./J-2398-2014; Maynard, Charles/N-3906-2015	Schmid, Christopher H./0000-0002-0855-5313; Maynard, Charles/0000-0002-1644-7814	AHRQ HHS [R01 HS06208] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; ANDERSON WD, 1988, AM J CARDIOL, V61, P729, DOI 10.1016/0002-9149(88)91056-9; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CAIRNS CB, 1992, J ELECTROCARDIOL, V24, P46; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CENTOR RM, 1991, MED DECIS MAKING, V11, P102, DOI 10.1177/0272989X9101100205; CHAMBERS JM, 1992, STAT MODELS S, P249; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Gunnar R M, 1990, Circulation, V82, P664; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P95; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LAROSA JH, 1992, P NAT HEART LUNG BLO; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MARDER VJ, 1988, NEW ENGL J MED, V318, P1585, DOI 10.1056/NEJM198806163182406; MAYNARD C, 1995, MED DECIS MAKING, V15, P38, DOI 10.1177/0272989X9501500107; Midgette AS, 1996, AM J CARDIOL, V78, P389, DOI 10.1016/S0002-9149(96)00325-6; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1985, MED CARE, V23, P623, DOI 10.1097/00005650-198505000-00020; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; *SAS I INC, 1989, SAS STAT US GUID VER, P1077; SCHMID CH, 1997, IN PRESS J CLIN EPID; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; SELKER HP, 1994, MED CARE, V32, P1040, DOI 10.1097/00005650-199410000-00005; SELKER HP, 1993, ANN INTERN MED, V118, P820, DOI 10.7326/0003-4819-118-10-199305150-00010; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SELKER HP, 1995, J INVEST MED, V43, P468; SELKER HP, 1989, AM J MED, V87, P491; SELKER HP, 1994, CIRCULATION, V90, P1657, DOI 10.1161/01.CIR.90.4.1657; SELKER HP, 1992, THROMBOLYTIC PREDICT, P9; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; Wall T C, 1989, N C Med J, V50, P363; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211	45	69	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1997	127	7					538	556		10.7326/0003-4819-127-7-199710010-00006	http://dx.doi.org/10.7326/0003-4819-127-7-199710010-00006			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY733	9313022				2022-12-24	WOS:A1997XY73300006
J	Ruiz, M; Karpen, JW				Ruiz, M; Karpen, JW			Single cyclic nucleotide-gated channels locked in different ligand-bound states	NATURE			English	Article							GMP-ACTIVATED CHANNEL; ROD OUTER SEGMENT; RETINAL RODS; ION CHANNELS; TIGER SALAMANDER; CONDUCTANCE; MEMBRANE; PATCHES; PROTONS; SITES	Cyclic nucleotide-gated (CNG) channels are directly activated by the binding of several ligands(1-6). For these channels as well as for other allosteric proteins, the functional effects of each ligand-binding event have been difficult to assess because ligands continuously bind and unbind at each site. Furthermore, in retinal rod photoreceptors the low cytoplasmic concentration of cyclic GMP(7) means that channels exist primarily in partially liganded states, so it is important to determine how such channels behave. Previous studies of single channels have suggested that they occasionally open to subconducting states at low cGMP(2,3,8-10), but the significance of these states and how they arise is poorly understood. Here we combine the high resolution of single-channel recording with the use of a photoaffinity analogue of cGMP(11,12) that tethers cGMP moieties covalently to their binding sites to show single retinal CNG channels can be effectively locked in four distinct ligand-bound states. Our results indicate that channels open more than they would spontaneously when two ligands are bound (similar to 1% of the maximum current), significantly more with three ligands bound (similar to 33%), and open maximally with four ligands bound. In each ligand-bound state, channels opened to two or three different conductance states, These findings place strong constraints on the activation mechanism of CNG channels.	UNIV COLORADO,SCH MED,DEPT PHYSIOL,DEPT PHYSIOL & BIOPHYS,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BROWN RL, 1993, P NATL ACAD SCI USA, V90, P5369, DOI 10.1073/pnas.90.11.5369; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HANKE W, 1988, P NATL ACAD SCI USA, V85, P94, DOI 10.1073/pnas.85.1.94; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; ILDEFONSE M, 1991, J MEMBRANE BIOL, V123, P133, DOI 10.1007/BF01998084; Karpen JW, 1996, J GEN PHYSIOL, V107, P169, DOI 10.1085/jgp.107.2.169; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; NIZZARI M, 1993, P ROY SOC B-BIOL SCI, V254, P69, DOI 10.1098/rspb.1993.0128; Picco C, 1996, J GEN PHYSIOL, V108, P265, DOI 10.1085/jgp.108.4.265; PICONES A, 1995, J PHYSIOL-LONDON, V485, P699, DOI 10.1113/jphysiol.1995.sp020763; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; TANAKA JC, 1993, BIOPHYS J, V65, P2517, DOI 10.1016/S0006-3495(93)81294-3; TAYLOR WR, 1995, J PHYSIOL-LONDON, V483, P567, DOI 10.1113/jphysiol.1995.sp020607; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZIMMERMAN AL, 1995, CURR OPIN NEUROBIOL, V5, P296, DOI 10.1016/0959-4388(95)80041-7; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	27	120	120	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					389	392		10.1038/38744	http://dx.doi.org/10.1038/38744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311781				2022-12-24	WOS:A1997XX67500054
J	Petticrew, M; Kennedy, SC				Petticrew, M; Kennedy, SC			Detecting the effects of thromboprophylaxis: the case of the rogue reviews	BRITISH MEDICAL JOURNAL			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; STANDARD HEPARIN; PERIOPERATIVE THROMBOSIS; PULMONARY-EMBOLISM; RANDOMIZED TRIALS; CLINICAL-TRIALS; PREVENTION				Petticrew, M (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Petticrew, Mark/AAY-6274-2021					ANDAZ S, 1994, PHLEBOLOGY, V9, P2, DOI 10.1177/026835559400900102; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; BORRIS LC, 1995, DRUG SAFETY, V12, P26, DOI 10.2165/00002018-199512010-00002; BORRIS LC, 1994, INT J CLIN PHARM TH, V32, P262; Campling EA, 1995, REPORT NATL CONFIDEN; CHERINGTON M, 1987, NEUROLOGY, V37, P824, DOI 10.1212/WNL.37.5.824; CLAGETT GP, 1992, CHEST S, V102, P391; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Craig P C, 1972, Trans Pa Acad Ophthalmol Otolaryngol, V25, P42; DAURES JP, 1989, REV EPIDEMIOL SANTE, V37, P363; Dirckx J H, 1979, J Dermatol Surg Oncol, V5, P191; DOYLE AC, 1928, SHERLOCK HOLMES; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; GALLUS AS, 1992, THROMB HAEMOSTASIS, V68, P238; GENT M, 1986, CHEST, V89, P396; GOLDHABER SZ, 1992, JAMA-J AM MED ASSOC, V268, P1727, DOI 10.1001/jama.268.13.1727; GREEN D, 1994, PHARMACOL REV, V46, P89; GREYER HG, 1991, SEMIN THROMB HEMOST, V17, P336; HAAS S, 1993, BLOOD COAGUL FIBRIN, V4, pS5; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; JONES DR, 1991, ANN ROY COLL SURG, V73, P219; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KEARON C, 1995, ARCH INTERN MED, V155, P366, DOI 10.1001/archinte.155.4.366; Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605; LASSEN MR, 1991, SEMIN THROMB HEMOST, V17, P284; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LOWRY JC, 1995, BRIT J ORAL MAX SURG, V33, P101, DOI 10.1016/0266-4356(95)90209-0; MALTBY JR, 1988, CAN J ANAESTH, V35, P58, DOI 10.1007/BF03010546; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; Murray DW, 1996, J BONE JOINT SURG BR, V78B, P863, DOI 10.1302/0301-620X78B6.6714; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OBRIEN BJ, 1994, CAN MED ASSOC J, V150, P1083; SIMONNEAU G, 1992, ANN FR ANESTH, V11, P354, DOI 10.1016/S0750-7658(05)80376-4; SKRABANEK P, 1990, LANCET, V335, P1446, DOI 10.1016/0140-6736(90)91460-R; *THROMB RISK FACT, 1992, BRIT MED J, V305, P567; WELLS PS, 1994, ARCH INTERN MED, V154, P67, DOI 10.1001/archinte.154.1.67	38	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					665	668		10.1136/bmj.315.7109.665	http://dx.doi.org/10.1136/bmj.315.7109.665			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310572	Green Published			2022-12-24	WOS:A1997XW69400026
J	Makgoba, MW				Makgoba, MW			Molecular basis of resistance and susceptibility to malaria	LANCET			English	Editorial Material							ADHESION; SEQUESTRATION				Makgoba, MW (corresponding author), UNIV WITWATERSRAND,DEPT MOL IMMUNOL,ZA-2000 JOHANNESBURG,SOUTH AFRICA.							BERENDT AR, 1994, PARASITOLOGY, V108, pS19, DOI 10.1017/S0031182000075685; Bunn HF, 1991, HARRISONS PRINCIPLES, P1543; FERNANDEZREYESD, 1997, HUM MOL GENET, V6, P1357; MAKGOBA MW, 1992, EUR J CLIN INVEST, V22, P443, DOI 10.1111/j.1365-2362.1992.tb01489.x; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TURNER GDH, 1994, AM J PATHOL, V145, P1057	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					678	679		10.1016/S0140-6736(05)63507-6	http://dx.doi.org/10.1016/S0140-6736(05)63507-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291898				2022-12-24	WOS:A1997XU97700004
J	Rocheleau, CE; Downs, WD; Lin, RL; Wittmann, C; Bei, YX; Cha, YH; Ali, M; Priess, JR; Mello, CC				Rocheleau, CE; Downs, WD; Lin, RL; Wittmann, C; Bei, YX; Cha, YH; Ali, M; Priess, JR; Mello, CC			Wnt signaling and an APC-related gene specify endoderm in early C-elegans embryos	CELL			English	Article							CAENORHABDITIS-ELEGANS; TISSUE POLARITY; ARMADILLO CONNECTION; CELL-INTERACTIONS; DROSOPHILA; WINGLESS; PROTEIN; ENCODES; INDUCTION; GUT	In a 4-cell stage C. elegans embryo, signaling by the P-2 blastomere induces anterior-posterior polarity in the adjacent EMS blastomere, leading to endoderm formation. We have taken genetic and reverse genetic approaches toward understanding the molecular basis for this induction. These studies have identified a set of genes with sequence similarity to genes that have been shown to be, or are implicated in, Wnt/Wingless signaling pathways in other systems. The C. elegans genes described here are related to wnt/wingless,porcupine, frizzled, beta-catenin/armadillo, and the human adenomatous polyposis coil gene, APC. We present evidence that there may be partially redundant inputs into endoderm specification and that a subset of these genes appear also to function in determining cytoskeletal polarity in certain early blastomeres.	UNIV MASSACHUSETTS, CTR CANC, DEPT CELL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; FRED HUTCHINSON CANC RES CTR, HOWARD HUGHES MED INST, SEATTLE, WA 98109 USA; UNIV WASHINGTON, DEPT ZOOL, SEATTLE, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Rocheleau, Christian/0000-0001-6738-5636				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; EDGAR LG, 1994, DEVELOPMENT, V120, P443; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GOLDSTEIN B, 1993, DEVELOPMENT, P279; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUBB D, 1993, DEVELOPMENT, P269; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; HUTTER H, 1995, DEVELOPMENT, V121, P1559; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KEMPHUES KJ, 1996, NEMATODE C ELEGANS, P335; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; SCHNABEL R, 1995, DEVELOPMENT, V121, P2219; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	54	525	554	2	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					707	716		10.1016/S0092-8674(00)80531-0	http://dx.doi.org/10.1016/S0092-8674(00)80531-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288750	Bronze			2022-12-24	WOS:A1997XT06600014
J	Atwell, S; Ultsch, M; DeVos, AM; Wells, JA				Atwell, S; Ultsch, M; DeVos, AM; Wells, JA			Structural plasticity in a remodeled protein-protein interface	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; MONOVALENT PHAGE DISPLAY; CRYSTAL-STRUCTURE; RECEPTOR; MUTAGENESIS; RESOLUTION; COMPLEX; EPITOPE; MUTANT	Remodeling of the interface between human growth hormone (hGH) and the extracellular domain of its receptor was studied by deleting a critical tryptophan residue (at position 104) in the receptor, creating a large cavity, and selecting a pentamutant of hGH by phage display that fills the cavity and largely restores binding affinity. A 2.1 Angstrom resolution x-ray structure of the mutant complex showed that the receptor cavity was filled by selected hydrophobic mutations of hGH. Large structural rearrangements occurred in the inter face at sites that were distant from the mutations. Such plasticity may be a means for protein-protein interfaces to adapt to mutations as they coevolve.	GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; University of California System; University of California San Francisco			Wells, Jim A/O-9854-2016					ATWELL S, UNPUB; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLACKSON T, UNPUB; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; VEITER IR, 1996, PROTEIN SCI, V5, P2399; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141	25	158	174	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1125	1128		10.1126/science.278.5340.1125	http://dx.doi.org/10.1126/science.278.5340.1125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353194				2022-12-24	WOS:A1997YE65200053
J	Mercurio, F; Zhu, HY; Murray, BW; Shevchenko, A; Bennett, BL; Li, JW; Young, DB; Barbosa, M; Mann, M				Mercurio, F; Zhu, HY; Murray, BW; Shevchenko, A; Bennett, BL; Li, JW; Young, DB; Barbosa, M; Mann, M			IKK-1 and IKK-2: Cytokine-activated I kappa B kinases essential for NF-kappa B activation	SCIENCE			English	Article							TRANSCRIPTION FACTORS; ALPHA PROTEOLYSIS; MASS-SPECTROMETRY; PHOSPHORYLATION; PROTEINS; UBIQUITINATION; DEGRADATION; SIGNAL; FAMILY; IDENTIFICATION	Activation of the transcription factor nuclear factor kappa B (NF-kappa B) is controlled by sequential phosphorylation, ubiquitination, and degradation of its inhibitory subunit I kappa B. A large multiprotein complex, the I kappa B kinase (IKK) signalsome, was purified from Hela cells and found to contain a cytokine-inducible I kappa B kinase activity that phosphorylates I kappa B-alpha and I kappa B-beta. Two components of the IKK signalsome, IKK-1 and IKK-2, were identified as closely related protein serine kinases containing leucine zipper and helix-loop-helix protein interaction motifs. Mutant versions of IKK-2 had pronounced effects on RelA nuclear translocation and NF-kappa B-dependent reporter activity, consistent with a critical role for the IKK kinases in the NF-kappa B signaling pathway.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	European Molecular Biology Laboratory (EMBL); Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Mercurio, F (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN AVE,SAN DIEGO,CA 92121, USA.		Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; murray, brion/0000-0003-1591-2566				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baichwal V. R., 1997, CURR BIOL, V7, P94; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, EMBO J, V13, P1842; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MAININ NL, 1997, NATURE, V385, P540; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mann M, 1996, TRENDS BIOCHEM SCI, V21, P494, DOI 10.1016/S0968-0004(96)30042-X; Manning AM, 1996, DRUG DISCOV TODAY, V1, P151, DOI 10.1016/1359-6446(96)10015-5; MERCURIO F, UNPUB; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	41	1800	1876	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					860	866		10.1126/science.278.5339.860	http://dx.doi.org/10.1126/science.278.5339.860			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346484				2022-12-24	WOS:A1997YD47900046
J	Schott, GD				Schott, GD			Bisphosphonates for pain relief in reflex sympathetic dystrophy?	LANCET			English	Editorial Material											Schott, GD (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							Adami S, 1997, ANN RHEUM DIS, V56, P201, DOI 10.1136/ard.56.3.201; Cortet B, 1997, CLIN RHEUMATOL, V16, P51, DOI 10.1007/BF02238763; DEVOGELAER JP, 1988, J BONE MINER RES  S1, V3, pSI22; Dray A, 1996, PROG BRAIN RES, V110, P85; KOZIN F, 1992, CLIN EXP RHEUMATOL, V10, P401; MAILLEFERT JF, 1995, ANN RHEUM DIS, V54, P687, DOI 10.1136/ard.54.8.687-a; OYEN WJG, 1993, PAIN, V55, P151, DOI 10.1016/0304-3959(93)90144-E; REHMAN MTA, 1992, BONE, V13, P116; SCHOTT GD, 1995, LANCET, V345, P634, DOI 10.1016/S0140-6736(95)90528-6; SELBY PL, 1994, DIABETIC MED, V11, P28, DOI 10.1111/j.1464-5491.1994.tb00225.x; Strang P, 1996, ACTA ONCOL, V35, P50, DOI 10.3109/02841869609083968; SUDECK P, 1900, ARCH KLIN CHIR, V62, P147	12	16	76	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1117	1117		10.1016/S0140-6736(05)63785-3	http://dx.doi.org/10.1016/S0140-6736(05)63785-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343496				2022-12-24	WOS:A1997YB19900005
J	PericakVance, MA; Bass, MP; Yamaoka, LH; Gaskell, PC; Scott, WK; Terwedow, HA; Menold, MM; Conneally, PM; Small, GW; Vance, JM; Saunders, AM; Roses, AD; Haines, JL				PericakVance, MA; Bass, MP; Yamaoka, LH; Gaskell, PC; Scott, WK; Terwedow, HA; Menold, MM; Conneally, PM; Small, GW; Vance, JM; Saunders, AM; Roses, AD; Haines, JL			Complete genomic screen in late-onset familial Alzheimer disease - Evidence for a new locus on chromosome 12	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFFECTED RELATIVE PAIRS; LINKAGE STRATEGIES; ALLELE; GENE; TRAITS; POLYMORPHISM; ASSOCIATION; DIAGNOSIS	Context.-Four genetic loci have been identified as contributing to Alzheimer disease (AD), including the amyloid precursor protein gene, the presenilin 1 gene, the presenilin 2 gene, and the apolipoprotein E gene, but do not account for all the genetic risk for AD. Objective.-To identify additional genetic risk factors for late-onset AD. Design.-A complete genomic screen was performed (N=280 markers). Critical values for chromosomal regional follow-up were a P value of .05 or less for affected relative pair analysis or sibpair analysis, a parametric lod score of 1.0 or greater, or both. Regional follow-up included analysis of additional markers and a second data set. Setting.-Clinic populations in the continental United States. Patients.-From a series of multiplex families affected with late-onset (greater than or equal to 60 years) AD ascertained during the last 14 years (National Insititute of Neurological Disorders and Stroke-Alzheimer's Disease and Related Disorders Association diagnostic criteria) and for which DNA has been obtained, a subset of 16 families (135 total family members, 52 of whom were patients with AD) was used for the genomic screen. A second subset of 38 families (216 total family members, 89 of whom were patients with AD) was used for the follow-up analysis. Main Outcome Measures.-Linkage analysis results generated using both genetic model-dependent (led score) and model-independent methods. Results.-Fifteen chromosomal regions warranted initial follow-up. Follow-up analyses revealed 4 regions of continued interest on chromosomes 4, 6, 12, and 20, with the strongest results observed for chromosome 12. Peak 2-point affecteds-only rod scores (n=54) were 1.3, 1.6, 2.7, and 2.2 and affected relative pairs P values (n=54) were .04, .03, .14, and .04 for D125373, D12S1057, D1251042, and D12S390, respectively. Sibpair analysis (n=54) resulted in maximum lod scores (MLSs) of 1.5, 2.6, 3.2, and 2.3 for these markers, with a peak multipoint MLS of 3.5. A priori stratification by APOEgenotype identified 27 families that had at least 1 member with AD whose genotype did not contain an APOE*4 allele. Analysis of these 27 families resulted in MLSs of 1.0, 2.4, 3.7, and 3.3 and a peak multipoint MLS of 3.9. Conclusions.-A complete genomic screen in families affected with late-onset AD identified 4 regions of interest after follow-up. Chromosome 12 gave the strongest and most consistent results with a peak multipoint MLS of 3.5, suggesting that this region contains a new susceptibility gene for AD. Additional analyses are necessary to identify the chromosome 12 susceptibility gene for AD and to follow up the regions of interest on chromosomes 4, 6, and 20.	MASSACHUSETTS GEN HOSP,MOL NEUROGENET UNIT,CHARLESTOWN,MA; INDIANA UNIV,MED CTR,DEPT MED & MOL GENET,INDIANAPOLIS,IN; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT,LOS ANGELES,CA	Harvard University; Massachusetts General Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California Los Angeles	PericakVance, MA (corresponding author), DUKE UNIV,MED CTR,MED GENET SECT,DEPT MED,BOX 3445,DURHAM,NC 27710, USA.		Haines, Jonathan/C-3374-2012; Scott, William/A-7593-2009	Haines, Jonathan/0000-0002-4351-4728; Vance, Jeffery/0000-0003-3815-8199; Scott, William/0000-0001-9336-6404	NATIONAL INSTITUTE ON AGING [U24AG021886] Funding Source: NIH RePORTER; NIA NIH HHS [U24 AG021886] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; *CAS W RES U, 1994, SAGE STAT AN GEN EP; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAUSSET J, 1986, PRESSE MED, V15, P1801; Davis S, 1996, AM J HUM GENET, V58, P867; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HERRINGTON R, 1995, NATURE, V375, P754; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOCKE PA, 1995, GENET EPIDEMIOL, V12, P83, DOI 10.1002/gepi.1370120108; MAX W, 1993, NEUROLOGY, V43, pS6; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1994, CURRENT PROTOCOLS HU; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1990, AM J HUM GENET, V46, P222; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roses A. D., 1995, American Journal of Human Genetics, V57, pA202; ROSES AD, 1997, EMERY RIMOINS PRINCI, P1807; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT WK, IN PRESS NEUROGENETI; Smalley SL, 1996, AM J HUM GENET, V58, P844; STRITTMATTER WJ, 1990, P NATL ACAD SCI USA, V90, P1971; Vance JM, 1996, AM J HUM GENET, V58, P757; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	31	302	308	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1237	1241		10.1001/jama.278.15.1237	http://dx.doi.org/10.1001/jama.278.15.1237			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333264				2022-12-24	WOS:A1997XZ70900028
J	Karason, K; Wallentin, L; Larsson, B; Sjostrom, L				Karason, K; Wallentin, L; Larsson, B; Sjostrom, L			Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSIVE PATIENTS; BLOOD-PRESSURE; ARTERIAL-HYPERTENSION; INSULIN-RESISTANCE; HEART; GEOMETRY; HYPERTROPHY; REDUCTION; YOUNG	Objectives: To investigate the consequences of longstanding obesity on left ventricular mass and structure and to examine the effects of weight loss on these variables, Design: Cross sectional survey and controlled intervention study. Setting: City of Gothenburg and surrounding areas, Sweden. Subjects: 41 obese patients treated with weight reducing gastric surgery, 31 obese patients treated conventionally, and 43 non-obese subjects. Main outcome measures: Changes in left ventricular mass and relative wall thickness. Results: Obese patients had higher blood pressure, greater left ventricular mass, and increased relative wall thickness than did matched non-obese control subjects. Obese subjects treated with gastric surgery had a substantial weight loss and a significant reduction in all variables when compared with conventionally treated obese subjects. Univariate and multivariate analysis of pooled data from the two groups of obese subjects showed that changes in relative wall thickness and left ventricular mass were more closely related to the change in weight than to the concomitant change in blood pressure. Conclusions: Structural heart abnormalities occurring in conjunction with obesity diminish after weight loss, The regression in these structural aberrations is better predicted by the weight loss than by the accompanying reduction in blood pressure. To prevent or improve abnormalities of heart structure in obese people, weight control should be the primary goal; it should be regarded as at least as important as regulating blood pressure.	SAHLGRENS UNIV HOSP,DEPT CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT MED,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital	Karason, K (corresponding author), SAHLGRENS UNIV HOSP,DEPT CARDIOL,S-41345 GOTHENBURG,SWEDEN.			Karason, Kristjan/0000-0002-2802-1191				AGABITIROSEI E, 1989, AM J HYPERTENS, V2, P70; ALEXANDE.JK, 1972, CIRCULATION, V45, P310, DOI 10.1161/01.CIR.45.2.310; ALEXANDER JK, 1962, CARDIOVASCULAR RES C, V63, P39; ALPERT MA, 1994, AM J CARDIOL, V73, P918, DOI 10.1016/0002-9149(94)90829-X; ALPERT MA, 1985, AM J CARDIOL, V55, P783, DOI 10.1016/0002-9149(85)90156-0; BYRD BF, 1989, AM HEART J, V118, P133, DOI 10.1016/0002-8703(89)90083-5; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DEVEREUX RB, 1995, J AM COLL CARDIOL, V25, P885, DOI 10.1016/0735-1097(94)00547-4; FAGARD R, 1992, EUR HEART J, V13, P1373, DOI 10.1093/oxfordjournals.eurheartj.a060069; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; HSUEH WA, 1994, ENDOCRIN METAB CLIN, V23, P405, DOI 10.1016/S0889-8529(18)30105-1; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; LAUER MS, 1992, J AM COLL CARDIOL, V19, P130, DOI 10.1016/0735-1097(92)90063-S; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; LICATA G, 1994, AM J HYPERTENS, V7, P314, DOI 10.1093/ajh/7.4.314; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MESSERLI FH, 1983, ANN INTERN MED, V99, P757, DOI 10.7326/0003-4819-99-6-757; MESSERLI FH, 1982, LANCET, V1, P1165; MESSERLI FH, 1983, AM J MED, V74, P808, DOI 10.1016/0002-9343(83)91071-9; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; SASSON Z, 1993, CIRCULATION, V88, P1431, DOI 10.1161/01.CIR.88.4.1431; SJOSTROM L, 1992, INT J OBESITY, V16, P465; VERDECCHIA P, 1995, J AM COLL CARDIOL, V25, P871, DOI 10.1016/0735-1097(94)00424-O; WILLIAMS GH, 1997, HEART DIS TXB CARDIO, P1887	28	119	120	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 11	1997	315	7113					912	916						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB073	9361540	Green Published			2022-12-24	WOS:A1997YB07300023
J	Uysal, KT; Wiesbrock, SM; Marino, MW; Hotamisligil, GS				Uysal, KT; Wiesbrock, SM; Marino, MW; Hotamisligil, GS			Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; TYROSINE KINASE-ACTIVITY; ADIPOSE-TISSUE; EXPRESSION; RECEPTOR; PHOSPHORYLATION	Obesity is highly associated with insulin resistance and is the biggest risk factor for non-insulin-dependent diabetes mellitus(1-3). The molecular basis of this common syndrome, however, is poorly understood. It has been suggested that tumour necrosis factor (TNF)-alpha is a candidate mediator of insulin resistance in obesity as it is overexpressed in the adipose tissues of rodents and humans(4-10) and it blocks the action of insulin in cultured cells and whole animals(10-14). To investigate the role of TNF-alpha in obesity and insulin resistance, we have generated obese mice with a targeted null mutation in the gene encoding TNF-alpha and those encoding the two receptors for TNF-alpha. The absence of TNF-alpha resulted in significantly improved insulin sensitivity in both diet-induced obesity and that resulting for the ob/ob model of obesity. The TNF alpha-deficient obese mice had lower levels of circulating free fatty acids, and were protected from the obesity-related reduction in the insulin receptor signalling in muscle and fat tissues, These results indicate that TNF-alpha is an important mediator of insulin resistance in obesity through its effects on several important sites of insulin action.	HARVARD UNIV,SCH PUBL HLTH,DIV BIOL SCI,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; MEM SLOAN KETTERING CANC CTR,LUDWIG INST CANC RES,NEW YORK,NY 10021	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center			Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793				BODEN G, 1997, DIABETES, V45, P3; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; COLEMAN DL, 1982, MOUSE BIOMEDICAL RES, P125; CORNELIUS P, 1989, BIOCHEM BIOPH RES CO, V165, P429, DOI 10.1016/0006-291X(89)91088-7; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Fiedorek Fred T. Jr., 1996, P604; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; OLFESKY JM, 1990, DIABETES MELLITUS, P121; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; WHITE MF, 1994, J BIOL CHEM, V269, P1	26	1743	1825	1	106	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					610	614		10.1038/39335	http://dx.doi.org/10.1038/39335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335502				2022-12-24	WOS:A1997YA00800062
J	Wang, YZ; Small, DL; Stanimirovic, DB; Morley, P; Durkin, JP				Wang, YZ; Small, DL; Stanimirovic, DB; Morley, P; Durkin, JP			AMPA receptor-mediated regulation of a G(i)-protein in cortical neurons	NATURE			English	Article							NUCLEOTIDE-BINDING-PROTEINS; METABOTROPIC GLUTAMATE-RECEPTOR; BETA-GAMMA-SUBUNITS; PERTUSSIS TOXIN; ACID; LOCALIZATION; MECHANISMS; AGONIST; KINASES	Excitatory synaptic transmission in the central nervous system is mediated primarily by the release of glutamate from presynaptic terminals onto postsynaptic channels gated by N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors(1,2). The myriad intracellular responses arising from the activation of the NMDA and AMPA receptors have previously been attributed to the flow of Ca2+ and/or Na+ through these ion channels(1-6). Here we report that the binding of the agonist AMPA. to its receptor can generate intracellular signals that are independent of Ca2+ and Na+ in rat cortical neurons, In the absence of intracellular Ca2+ and Na+, AMPA, but not NMDA, brought about changes in a guanine-nucleotide-binding protein (G alpha(il)) that inhibited pertussis toxin-mediated ADP-ribosylation of the protein in an in vitro assay, This effect was observed in intact neurons treated with AMPA as well as in isolated membranes exposed to AMPA, and was also found in MIN6 cells, which express functional AMPA receptors but have no metabotropic glutamate receptors, AMPA also inhibited forskolin-stimulated activity of adenylate cyclase in neurons, demonstrating that G(i) proteins were activated. Moreover, both G beta gamma blockage and co-precipitation experiments demonstrated that the modulation of the G(i) protein arose from the association of G alpha(il) with the glutamate receptor-1 (GluR1) subunit, These results suggest that, as well as acting as an ion channel, the APA receptor can exhibit metabotropic activity.			Wang, YZ (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,CELLULAR NEUROBIOL GRP,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.							Brauner-Osborne H, 1996, J MED CHEM, V39, P3188, DOI 10.1021/jm9602569; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Durkin JP, 1996, J NEUROCHEM, V66, P951; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GHOSH A, 1995, SCIENCE, V268, P238; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; GONOI T, 1994, J BIOL CHEM, V269, P16989; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUFF RM, 1986, J BIOL CHEM, V261, P1105; KASAHARA J, 1994, FEBS LETT, V355, P41, DOI 10.1016/0014-5793(94)01170-2; KATADA T, 1986, J BIOL CHEM, V261, P8182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLIGAN G, 1988, BIOCHEM J, V255, P1; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; Sorenson EM, 1996, J PHARMACOL EXP THER, V277, P1733; Wang YZ, 1996, EXP CELL RES, V225, P382, DOI 10.1006/excr.1996.0189; WANG YZ, 1995, J BIOL CHEM, V270, P22783, DOI 10.1074/jbc.270.39.22783; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977	23	122	125	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 2	1997	389	6650					502	504		10.1038/39062	http://dx.doi.org/10.1038/39062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XY909	9333240				2022-12-24	WOS:A1997XY90900058
J	Cummings, P; Grossman, DC; Rivara, FP; Koepsell, TD				Cummings, P; Grossman, DC; Rivara, FP; Koepsell, TD			State gun safe storage laws and child mortality due to firearms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Since 1989, several states have passed laws that make gun owners criminally liable if someone is injured because a child gains unsupervised access to a gun. These laws are controversial, and their effect on firearm-related injuries is unknown. Objective.-To determine if state laws that require safe storage of firearms are associated with a reduction in child mortality due to firearms. Design.-An ecological study of firearm mortality from 1979 through 1994. Setting.-All 50 states and the District of Columbia. Participants.-All children younger than 15 years. Main Outcome Measures.-Unintentional deaths, suicides, and homicides due to firearms. Results.-Laws that make gun owners responsible for storing firearms in a manner that makes them inaccessible to children were in effect for at least 1 year in 12 states from 1990 through 1994. Among children younger than 15 years, unintentional shooting deaths were reduced by 23% (95% confidence interval, 6%-37%) during the years covered by these laws. This estimate was based on within-state comparisons adjusted for national trends in unintentional firearm-related mortality. Gun-related homicide and suicide showed modest declines, but these were not statistically significant. Conclusions.-State safe storage laws intended to make firearms less accessible to children appear to prevent unintentional shooting deaths among children younger than 15 years.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98104; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98104; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cummings, P (corresponding author), UNIV WASHINGTON,HARBORVIEW INJURY PREVENT & RES CTR,BOX 359960,325 9TH AVE,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P207; Day NE., 1987, STATISTICAL METHODS, VII, P131; FISHER LD, 1993, BIOSTATISTICS METHOD, P389; FURJUOH SN, 1996, INJ PREV, V2, P278; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; GAYNOR PE, 1994, INTRO TIME SERIES MO, P410; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; KLECK G, 1991, POINT BLANK GUNS VIO, P51; MAGUIRE K, 1994, SOURCEBOOK CRIMINAL, P203; MAUTE ML, 1995, RUTGERS LJ, V26, P431; MCCULLAGH P, 1989, GEN LINEAR MODELS, P39; MORGENSTERN H, 1995, ANNU REV PUBL HEALTH, V16, P61, DOI 10.1146/annurev.pu.16.050195.000425; SINGH GK, 1996, MONTHLY VITAL STAT R, P55; WHITE AM, 1993, HOUS L REV, V30, P1389; World Health Organization, 1977, INT CLASS DIS	16	123	124	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1084	1086		10.1001/jama.278.13.1084	http://dx.doi.org/10.1001/jama.278.13.1084			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XX303	9315767				2022-12-24	WOS:A1997XX30300032
J	DiFiglia, M; Sapp, E; Chase, KO; Davies, SW; Bates, GP; Vonsattel, JP; Aronin, N				DiFiglia, M; Sapp, E; Chase, KO; Davies, SW; Bates, GP; Vonsattel, JP; Aronin, N			Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain	SCIENCE			English	Article							GLUTAMINE REPEATS; NEURODEGENERATIVE DISEASES; TRINUCLEOTIDE REPEAT; MUTANT HUNTINGTIN; CEREBRAL-CORTEX; EXPRESSION; EXPANSION; PATHOLOGY; VESICLES; LENGTH	The cause of neurodegeneration in Huntington's disease (HD) is unknown. Patients with HD have an expanded NH2-terminal polyglutamine region in huntingtin. An NH2-terminal fragment of mutant huntingtin was localized to neuronal intranuclear inclusions (NIIs) and dystrophic neurites (DNs) in the HD cortex and striatum, which are affected in HD, and polyglutamine length influenced the extent of huntingtin accumulation in these structures. Ubiquitin was also found in NIIs and DNs, which suggests that abnormal huntingtin is targeted for proteolysis but is resistant to removal. The aggregation of mutant huntingtin may be part of the pathogenic mechanism in HD.	UNIV LONDON UNIV COLL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, LONDON SE1 7EH, ENGLAND; UNIV MASSACHUSETTS, MED CTR, DEPT MED & CELL BIOL, WORCESTER, MA 01655 USA	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Massachusetts System; University of Massachusetts Worcester	DiFiglia, M (corresponding author), MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305	NINDS NIH HHS [NS 16367, NS 31579] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031579, P01NS016367, P50NS016367] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], ADV NEUROL; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; ARONIN N, 1991, NEUROSCIENCE, V44, P409, DOI 10.1016/0306-4522(91)90065-V; Bhide PG, 1996, J NEUROSCI, V16, P5523; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BYERS RK, 1973, NEUROLOGY, V23, P561, DOI 10.1212/WNL.23.6.561; CAMMARATA S, 1993, NEUROSCI LETT, V156, P96, DOI 10.1016/0304-3940(93)90448-T; CUDKOWICZ M, 1990, ANN NEUROL, V27, P200, DOI 10.1002/ana.410270217; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE, P1; FUNATA N, 1990, CLIN NEUROPATHOL, V9, P89; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; HALTIA M, 1984, ANN NEUROL, V15, P316, DOI 10.1002/ana.410150403; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; JACKSON M, 1995, NEUROPATH APPL NEURO, V21, P18, DOI 10.1111/j.1365-2990.1995.tb01024.x; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003	37	2185	2249	2	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					1990	1993		10.1126/science.277.5334.1990	http://dx.doi.org/10.1126/science.277.5334.1990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302293				2022-12-24	WOS:A1997XX84900043
J	Whitaker, RC; Wright, JA; Pepe, MS; Seidel, KD; Dietz, WH				Whitaker, RC; Wright, JA; Pepe, MS; Seidel, KD; Dietz, WH			Predicting obesity in young adulthood from childhood and parental obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 02-06, 1997	WASHINGTON, D.C.	Ambulatory Pediat Assoc			BODY-MASS INDEX; NUTRITION EXAMINATION SURVEYS; FOLLOW-UP; NATIONAL-HEALTH; BLOOD-PRESSURE; CHILDREN; ADOLESCENTS; OVERWEIGHT; FATNESS; WEIGHT	Background Childhood obesity increases the risk of obesity in adulthood, but how parental obesity affects the chances of a child's becoming an obese adult is unknown. We investigated the risk of obesity in young adulthood associated with both obesity in childhood and obesity in one or both parents. Methods Height and weight measurements were abstracted from the records of 854 subjects born at a health maintenance organization in Washington State between 1965 and 1971. Their parents' medical records were also reviewed. Childhood obesity was defined as a body-mass index at or above the 85th percentile for age and sex, and obesity in adulthood as a mean body-mass index at or above 27.8 for men and 27.3 for women. Results In young adulthood (defined as 21 to 29 years of age), 135 subjects (16 percent) were obese. Among those who were obese during childhood, the chance of obesity in adulthood ranged from 8 percent for 1- or 2-year-olds without obese parents to 79 percent for 10-to-14-year-olds with at least one obese parent. After adjustment for parental obesity, the odds ratios for obesity in adulthood associated with childhood obesity ranged from 1.3 (95 percent confidence interval, 0.6 to 3.0) for obesity at 1 or 2 years of age to 17.5 (7.7 to 39.5) for obesity at 15 to 17 years of age. After adjustment for the child's obesity status, the odds ratios for obesity in adulthood associated with having one obese parent ranged from 2.2 (95 percent confidence interval, 1.1 to 4.3) at 15 to 17 years of age to 3.2 (1.8 to 5.7) at 1 or 2 years of age. Conclusions Obese children under three years of age without obese parents are at low risk for obesity in adulthood, but among older children, obesity is an increasingly important predictor of adult obesity, regardless of whether the parents are obese. Parental obesity more than doubles the risk of adult obesity among both obese and nonobese children under 10 years of age. (C) 1997, Massachusetts Medical Society.	UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, BIOSTAT PROGRAM, SEATTLE, WA 98104 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	University System of Ohio; University of Cincinnati; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Tufts Medical Center	Whitaker, RC (corresponding author), CHILDRENS HOSP, MED CTR,DIV GEN & COMMUNITY PEDIAT,DEPT PEDIAT, CH-1 S, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793	NIDDK NIH HHS [P30DK46200] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; ABRAHAM S, 1960, PUBLIC HEALTH REP, V75, P263, DOI 10.2307/4590775; [Anonymous], 1985, Ann Intern Med, V103, P147; CLARKE WR, 1993, CRIT REV FOOD SCI, V33, P423, DOI 10.1080/10408399309527641; EPSTEIN LH, 1990, JAMA-J AM MED ASSOC, V264, P2519, DOI 10.1001/jama.264.19.2519; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; Frisancho AR, 1990, ANTHROPOMETRIC STAND; GARN SM, 1985, AM J DIS CHILD, V139, P181, DOI 10.1001/archpedi.1985.02140040083033; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; GUTIN B, 1990, JAMA-J AM MED ASSOC, V264, P1123, DOI 10.1001/jama.264.9.1123; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P112, DOI 10.1207/s15324796abm1203_3; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LASKARZEWSKI P, 1980, AM J EPIDEMIOL, V111, P395, DOI 10.1093/oxfordjournals.aje.a112914; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Liu K, 1996, CIRCULATION, V93, P60, DOI 10.1161/01.CIR.93.1.60; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MOLL PP, 1991, AM J HUM GENET, V49, P1243; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Perusse L, 1997, OBES RES, V5, P49, DOI 10.1002/j.1550-8528.1997.tb00283.x; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; ROBINSON TN, 1993, CRIT REV FOOD SCI, V33, P313, DOI 10.1080/10408399309527626; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; ROLLANDCACHERA MF, 1987, ANN HUM BIOL, V14, P219, DOI 10.1080/03014468700008991; ROLLANDCACHERA MF, 1982, AM J CLIN NUTR, V36, P178, DOI 10.1093/ajcn/36.1.178; RONNEMAA T, 1991, ANN MED, V23, P67, DOI 10.3109/07853899109147933; SCHAPPERT SM, 1996, DHHS PUBLICATION; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005	32	2870	2939	2	236	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					869	873		10.1056/NEJM199709253371301	http://dx.doi.org/10.1056/NEJM199709253371301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XX302	9302300	Bronze			2022-12-24	WOS:A1997XX30200001
J	Wendt, KU; Poralla, K; Schulz, GE				Wendt, KU; Poralla, K; Schulz, GE			Structure and function of a squalene cyclase	SCIENCE			English	Article							ENCODING LANOSTEROL SYNTHASE; RAT OXIDOSQUALENE CYCLASE; HOPENE CYCLASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; BACILLUS-ACIDOCALDARIUS; 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE; PARTIAL-PURIFICATION; CANDIDA-ALBICANS	The crystal structure of squalene-hopene cyclase from Alicyclobacillus acidocaldarius was determined at 2.9 angstrom resolution. The mechanism and sequence of this cyclase are closely related to those of 2,3-oxidosqualene cyclases that catalyze the cyclization step in cholesterol biosynthesis. The structure reveals a membrane protein with membrane-binding characteristics similar to those of prostaglandin-H-2 synthase, the only other reported protein of this type. The active site of the enzyme is located in a large central cavity that is of suitable size to bind squalene in its required conformation and that is lined by aromatic residues. The structure supports a mechanism in which the acid starting the reaction by protonating a carbon-carbon double bond is an aspartate that is coupled to a histidine. Numerous surface alpha helices are connected by characteristic QW-motifs (Q is glutamine and W is tryptophan) that tighten the protein structure, possibly for absorbing the reaction energy without structural damage.	UNIV FREIBURG, INST ORGAN CHEM & BIOCHEM, D-79104 FREIBURG, GERMANY; INST BIOL, D-72076 TUBINGEN, GERMANY	University of Freiburg								ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ABE I, 1994, J BIOL CHEM, V269, P802; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALLIANO G, 1992, ARCH BIOCHEM BIOPHYS, V293, P122, DOI 10.1016/0003-9861(92)90374-6; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOAR RB, 1984, J AM CHEM SOC, V106, P2476, DOI 10.1021/ja00320a064; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; CORNFORT.JW, 1965, J AM CHEM SOC, V87, P3224, DOI 10.1021/ja01092a038; ESCHENMOSER A, 1955, HELV CHIM ACTA, V38, P1890, DOI 10.1002/hlca.19550380728; Feil C, 1996, EUR J BIOCHEM, V242, P51, DOI 10.1111/j.1432-1033.1996.0051r.x; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; JOHNSON WS, 1987, J AM CHEM SOC, V109, P5852, DOI 10.1021/ja00253a048; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kaneko T, 1996, DNA Res, V3, P109; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NEUMANN S, 1986, BIOL CHEM H-S, V367, P723, DOI 10.1515/bchm3.1986.367.2.723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCHS D, 1990, EUR J BIOCHEM, V194, P75, DOI 10.1111/j.1432-1033.1990.tb19429.x; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; OURISSON G, 1992, ACCOUNTS CHEM RES, V25, P403, DOI 10.1021/ar00021a004; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; REIPEN IG, 1995, MICROBIOL-SGM, V141, P155, DOI 10.1099/00221287-141-1-155; ROESSNER CA, 1993, GENE, V127, P149, DOI 10.1016/0378-1119(93)90631-C; SECKLER B, 1986, BIOCHIM BIOPHYS ACTA, V881, P356, DOI 10.1016/0304-4165(86)90027-9; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; SIMON SA, 1977, BIOPHYS J, V19, P83, DOI 10.1016/S0006-3495(77)85570-7; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; Wendt KU, 1997, PROTEIN SCI, V6, P722; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535; ZHENG YF, 1995, J AM CHEM SOC, V117, P670, DOI 10.1021/ja00107a011	46	363	377	4	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1811	1815		10.1126/science.277.5333.1811	http://dx.doi.org/10.1126/science.277.5333.1811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295270				2022-12-24	WOS:A1997XX29800044
J	Jack, D				Jack, D			Hot shots inside the body	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					790	790		10.1016/S0140-6736(05)62583-4	http://dx.doi.org/10.1016/S0140-6736(05)62583-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298011				2022-12-24	WOS:A1997XW28200035
J	Metlay, JP; Kapoor, WN; Fine, MJ				Metlay, JP; Kapoor, WN; Fine, MJ			Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFIDENCE-INTERVALS; CLINICAL-PREDICTION; CHEST; ANTIBIOTICS; RELIABILITY; OUTPATIENTS; ADULTS	Community-acquired pneumonia is an important cause of acute respiratory symptoms (eg, cough) in the ambulatory care setting, Distinguishing pneumonia from other causes of respiratory illnesses, such as acute bronchitis and upper respiratory tract infections, has important therapeutic and prognostic implications, The reference standard for diagnosing pneumonia is chest radiography, but it is likely that many physicians rely on the patient's history and their physical examination to diagnose or exclude this disease. A review of published studies of patients suspected of having pneumonia reveals that there are no individual clinical findings, or combinations of findings, that can rule in the diagnosis of pneumonia for a patient suspected of having this illness, However, some studies have shown that the absence of any vital sign abnormalities or any abnormalities on chest auscultation substantially reduces the likelihood of pneumonia to a point where further diagnostic evaluation may be unnecessary, This article reviews the literature on the appropriate use of the history and physical examination in diagnosing community-acquired pneumonia.	MASSACHUSETTS GEN HOSP, DEPT MED, GEN INTERNAL MED UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; UNIV PITTSBURGH, DEPT MED, CTR RES HLTH CARE, DIV GEN INTERNAL MED, PITTSBURGH, PA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					BHP HRSA HHS [5 T32 PE11001-08] Funding Source: Medline	BHP HRSA HHS		Albaum MN, 1996, CHEST, V110, P343, DOI 10.1378/chest.110.2.343; Bullowa JGM, 1935, ARCH INTERN MED, V55, P558, DOI 10.1001/archinte.1935.00160220028003; CENTOR RM, 1992, MED DECIS MAKING, V12, P229, DOI 10.1177/0272989X9201200309; COCHRANE AL, 1951, LANCET, V260, P1007; DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8; EMERMAN CL, 1991, ANN EMERG MED, V20, P1215, DOI 10.1016/S0196-0644(05)81474-X; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FLETCHER CM, 1964, METHOD INFORM MED, V3, P98, DOI 10.1055/s-0038-1636275; Forgacs P, 1969, Br J Dis Chest, V63, P1, DOI 10.1016/S0007-0971(69)80039-2; Gennis P, 1989, J Emerg Med, V7, P263, DOI 10.1016/0736-4679(89)90358-2; GILBERT VE, 1989, AM REV RESPIR DIS, V140, P1012, DOI 10.1164/ajrccm/140.4.1012; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149, DOI 10.1093/oxfordjournals.epirev.a036050; Hasley PB, 1996, ARCH INTERN MED, V156, P2206, DOI 10.1001/archinte.156.19.2206; HECKERLING PS, 1986, ARCH INTERN MED, V146, P1321, DOI 10.1001/archinte.146.7.1321; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MELBYE H, 1992, Scandinavian Journal of Primary Health Care, V10, P226, DOI 10.3109/02813439209014066; Metlay J. P., 1997, JGIM, V12, P77; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; ORR PH, 1993, J FAM PRACTICE, V36, P507; OSMER JC, 1966, SOUTHERN MED J, V59, P75, DOI 10.1097/00007611-196601000-00014; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCHILLING RSF, 1955, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.4905.65; SINGAL BM, 1989, ANN EMERG MED, V18, P13, DOI 10.1016/S0196-0644(89)80304-X; SMYLLIE HC, 1965, LANCET, V2, P412; SPITERI MA, 1988, LANCET, V1, P873; THACKER RE, 1982, CHEST, V81, P672, DOI 10.1378/chest.81.6.672	33	316	327	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1440	1445		10.1001/jama.278.17.1440	http://dx.doi.org/10.1001/jama.278.17.1440			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9356004				2022-12-24	WOS:A1997YC91700032
J	Nightingale, SL				Nightingale, SL			Proposed rule on women in clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 5	1997	278	17					1394	1394						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC917	9355985				2022-12-24	WOS:A1997YC91700006
J	Ryan, TM; Ciavatta, DJ; Townes, TM				Ryan, TM; Ciavatta, DJ; Townes, TM			Knockout-transgenic mouse model of sickle cell disease	SCIENCE			English	Article							BETA-GLOBIN LOCUS; YEAST ARTIFICIAL CHROMOSOME; HEMOGLOBIN-S; DEVELOPMENTAL REGULATION; DEOXYHEMOGLOBIN-S; CRYSTAL-STRUCTURE; MICE; POLYMERIZATION; THALASSEMIA; GELATION	When transgenic mice that expressed human sickle hemoglobin were mated with mice having knockout mutations of the mouse alpha-and beta-globin genes, animals were produced that synthesized only human hemoglobin in adult red blood cells. Similar to many human patients with sickle cell disease, the mice developed a severe hemolytic anemia and extensive organ pathology. Numerous sickled erythrocytes were observed in peripheral blood. Although chronically anemic, most animals survived for 2 to 9 months and were fertile. Drug and genetic therapies can now be tested in this mouse model of sickle cell disease.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Ryan, Thomas/0000-0002-8982-0253	NCI NIH HHS [CA13148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRITTENHAM GM, 1985, BLOOD, V65, P183; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CREPEAU RH, 1978, NATURE, V274, P616, DOI 10.1038/274616a0; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; EATON WA, 1987, BLOOD, V70, P1245; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; Fabry ME, 1996, J CLIN INVEST, V98, P2450, DOI 10.1172/JCI119062; GAENSLER KML, 1993, P NATL ACAD SCI USA, V90, P11381, DOI 10.1073/pnas.90.23.11381; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; NOGUCHI CT, 1981, BLOOD, V58, P1057; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Popp RA, 1997, BLOOD, V89, P4204, DOI 10.1182/blood.V89.11.4204; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; Roberts NA, 1997, BLOOD, V89, P713, DOI 10.1182/blood.V89.2.713; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; RYAN TM, UNPUB; SERJEANT GR, 1970, BRIT J HAEMATOL, V19, P635, DOI 10.1111/j.1365-2141.1970.tb01647.x; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; Weatherall DJ, 1981, THALASSEMIA SYNDROME; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WOOD WG, 1985, NATURE, V313, P320, DOI 10.1038/313320a0; YANG BL, 1995, P NATL ACAD SCI USA, V92, P11608, DOI 10.1073/pnas.92.25.11608	34	202	211	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					873	876		10.1126/science.278.5339.873	http://dx.doi.org/10.1126/science.278.5339.873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346487				2022-12-24	WOS:A1997YD47900049
J	Caterina, MJ; Schumacher, MA; Tominaga, M; Rosen, TA; Levine, JD; Julius, D				Caterina, MJ; Schumacher, MA; Tominaga, M; Rosen, TA; Levine, JD; Julius, D			The capsaicin receptor: a heat-activated ion channel in the pain pathway	NATURE			English	Article							ROOT GANGLION-CELLS; SENSORY NEURONS; CHEMICAL-STRUCTURE; CATION CHANNEL; DROSOPHILA TRP; RUTHENIUM RED; CALCIUM-ENTRY; RAT; RESINIFERATOXIN; ACID	Capsaicin, the main pungent ingredient in 'hot' chilli peppers, elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system. We have used an expression cloning strategy based on calcium influx to Isolate a functional cDNA encoding a capsaicin receptor from sensory neurons. This receptor is a non-selective cation channel that is structurally related to members of the TRP family of ion channels. The cloned capsaicin receptor Is also activated by increases in temperature In the noxious range, suggesting that it functions as a transducer of painful thermal stimuli in vivo.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								AMANN R, 1990, N-S ARCH PHARMACOL, V341, P108; BERKLEY R, 1992, PEPPERS COOKBOOK; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1990, TRENDS PHARMACOL SCI, V11, P330; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Campbell E., 1993, CAPSAICIN STUDY PAIN, P255; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; CREM RJ, 1991, SCIENCE, V254, P1388; DEVRIES DJ, 1989, LIFE SCI, V44, P711, DOI 10.1016/0024-3205(89)90382-2; DRAY A, 1990, NEUROSCI LETT, V110, P52, DOI 10.1016/0304-3940(90)90786-9; FEIGIN AM, 1995, NEUROREPORT, V6, P2134, DOI 10.1097/00001756-199511000-00009; Fields H. L., 1987, PAIN; FORBES CA, 1988, NEUROSCI LETT S, V32, pS3; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOLZER P, 1991, PHARMACOL REV, V43, P143; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAMES IF, 1993, CAPSAICIN STUDY PAIN, P83; JANCSO G, 1977, NATURE, V270, P741, DOI 10.1038/270741a0; Kirschstein T, 1997, NEUROSCI LETT, V231, P33, DOI 10.1016/S0304-3940(97)00533-8; Kress M, 1996, NEUROSCI LETT, V211, P5, DOI 10.1016/0304-3940(96)12691-4; LIU L, 1994, P NATL ACAD SCI USA, V91, P738, DOI 10.1073/pnas.91.2.738; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Oh U, 1996, J NEUROSCI, V16, P1659; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PETERSEN M, 1993, PAIN, V54, P37, DOI 10.1016/0304-3959(93)90097-9; Reichling DB, 1997, P NATL ACAD SCI USA, V94, P7006, DOI 10.1073/pnas.94.13.7006; SATINOFF E, 1964, AM J PHYSIOL, V206, P1389, DOI 10.1152/ajplegacy.1964.206.6.1389; Scoville W.L., 1912, J AM PHARM ASSOC, V1, P453, DOI [10.1002/jps.3080010520, DOI 10.1002/JPS.3080010520]; SEGUELA P, 1993, J NEUROSCI, V13, P596; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; SZALLASI A, 1994, GEN PHARMACOL-VASC S, V25, P223, DOI 10.1016/0306-3623(94)90049-3; SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8; Szallasi A, 1996, PAIN, V68, P195, DOI 10.1016/S0304-3959(96)03202-2; SZOLCSANYI J, 1975, ARZNEIMITTEL-FORSCH, V25, P1877; SZOLCSANYI J, 1976, ARZNEIMITTEL-FORSCH, V26, P33; Szolcsanyi J., 1993, CAPSAICIN STUDY PAIN, P1; TSIEN RY, 1989, ANNU REV NEUROSCI, V12, P227, DOI 10.1146/annurev.ne.12.030189.001303; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WINTER J, 1990, BRAIN RES, V520, P131, DOI 10.1016/0006-8993(90)91698-G; WOOD JN, 1988, J NEUROSCI, V8, P3208; WOODBURY JE, 1980, J ASSOC OFF ANA CHEM, V63, P556; YEATS JC, 1992, J PHYSIOL-LONDON, V446, pP390	49	6463	6849	84	991	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					816	824		10.1038/39807	http://dx.doi.org/10.1038/39807			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349813				2022-12-24	WOS:A1997YC14800048
J	Rieckhof, GE; Casares, F; Ryoo, HD; AbuShaar, M; Mann, RS				Rieckhof, GE; Casares, F; Ryoo, HD; AbuShaar, M; Mann, RS			Nuclear translocation of extradenticle requires homothorax, which encodes an extradenticle-related homeodomain protein	CELL			English	Article							DROSOPHILA-MELANOGASTER; HOMEOBOX GENE; HOMEOTIC TRANSFORMATION; ULTRABITHORAX PROTEINS; ECTOPIC EXPRESSION; SEGMENTAL IDENTITY; BITHORAX COMPLEX; MYELOID-LEUKEMIA; DNA-BINDING; UBX GENE	We show that homothorax (hth) is required for the Hox genes to pattern the body of the fruit fly, Drosophila melanogaster, hth is necessary for the nuclear localization of an essential HOX cofactor, Extradenticle (EXD), and encodes a homeodomain protein that shares extensive identity with the product of Meis1, a murine proto-oncogene. MEIS1 is able to rescue hth mutant phenotypes and can induce the cytoplasmic-to-nuclear translocation of EXD in cell culture and Drosophila embryos. Thus, Meis1 is a murine homolog of hth. MEIS1/HTH also specifically binds to EXD with high affinity in vitro. These data suggest a novel and evolutionarily conserved mechanism for regulating HOX activity in which a direct protein-protein interaction between EXD and HTH results in EXD's nuclear translocation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOL BIOPHYS,NEW YORK,NY 10032	Columbia University			Casares, Fernando/M-5451-2019	Casares, Fernando/0000-0002-2181-3858	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058575, R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510, R01 GM058575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aspland SE, 1997, DEVELOPMENT, V124, P741; BURGLIN T, 1994, GUIDEBOOK HOMEOBOX G, P26; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHAN SK, 1996, EMBO J, V15, P2477; CHEN SK, 1997, DEVELOPMENT, V124, P2007; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; FEINSTEIN PG, 1995, GENETICS, V140, P573; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; HAMILTON BA, 1991, P NATL ACAD SCI USA, V88, P2731, DOI 10.1073/pnas.88.7.2731; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KARPEN GH, 1992, GENETICS, V132, P737; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mann RS, 1996, NATURE, V383, P630, DOI 10.1038/383630a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Paro R., 1996, EPIGENETIC MECH GENE, P507; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PATTATUCCI AM, 1991, GENETICS, V129, P443; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; PIRROTTA V, 1995, GENETICS, V141, P1439; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; RODER L, 1992, DEVELOPMENT, V115, P1017; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SUN YH, 1995, GENETICS, V141, P1075; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WIESCHAUS E, 1986, LOOKING EMBRYOS DROS, P199; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	59	377	381	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					171	183		10.1016/S0092-8674(00)80400-6	http://dx.doi.org/10.1016/S0092-8674(00)80400-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346235	hybrid			2022-12-24	WOS:A1997YC35000005
J	Troemel, ER; Kimmel, BE; Bargmann, CI				Troemel, ER; Kimmel, BE; Bargmann, CI			Reprogramming chemotaxis responses: Sensory neurons define olfactory preferences in C-elegans	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-GATED CHANNEL; GLR-1 GLUTAMATE-RECEPTOR; CHEMOSENSORY NEURONS; ENCODES; SYSTEM; CELLS; GENES	Different olfactory cues elicit distinct behaviors such as attraction, avoidance, feeding, or mating. In the nematode C. elegans, these cues are sensed by a small number of olfactory neurons, each of which expresses several different odorant receptors. The type of behavioral response elicited by an odorant could be specified by the olfactory receptor or by the olfactory neuron in which the receptor is activated. The attractive odorant diacetyl is detected by the receptor protein ODR-10, which is normally expressed in the AWA olfactory neurons. The repulsive odorant 2-nonanone is detected by the AWB olfactory neurons. Transgenic animals that express ODR-10 in AWB rather than AWA avoid diacetyl, while maintaining qualitatively normal responses to other attractive and repulsive odorants. Animals that express ODR-10 simultaneously in AWA and AWB have a defective response to diacetyl, possibly because of conflicting olfactory inputs. Thus, an animal's preference for an odor is defined by the sensory neurons that express a given odorant receptor molecule.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM NEUROSCI,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,GENET PROGRAM,DEPT ANAT,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Troemel, ER (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,PROGRAM DEV BIOL,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.			Bargmann, Cornelia/0000-0002-8484-0618	NIDCD NIH HHS [DC01393] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001393] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; Bargmann C. I., 1997, C ELEGANS, P717; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BRENNER S, 1974, GENETICS, V77, P71; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, LEARN MEMORY, V4, P179, DOI 10.1101/lm.4.2.179; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; COLBERT HA, 1997, IN PRESS J NEUROSCI; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHEL WC, 1991, J NEUROPHYSIOL, V65, P446, DOI 10.1152/jn.1991.65.3.446; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; ZECHMAN JM, 1986, J CHROMATOGR, V377, P49, DOI 10.1016/S0378-4347(00)80760-4	29	290	307	0	80	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					161	169		10.1016/S0092-8674(00)80399-2	http://dx.doi.org/10.1016/S0092-8674(00)80399-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346234	Bronze			2022-12-24	WOS:A1997YC35000004
J	Riethmacher, D; SonnenbergRiethmacher, E; Brinkmann, V; Yamaai, T; Lewin, GR; Birchmeier, C				Riethmacher, D; SonnenbergRiethmacher, E; Brinkmann, V; Yamaai, T; Lewin, GR; Birchmeier, C			Severe neuropathies in mice with targeted mutations in the ErbB3 receptor	NATURE			English	Article							NERVOUS-SYSTEM; GROWTH-FACTOR; SCHWANN-CELL; NEUREGULIN; DIFFERENTIATION; HEREGULIN; GENE; NEUROTROPHIN-3; REQUIREMENT; MYELINATION	Neuregulins and their specific receptors, members of the ErbB family of tyrosine kinases, have been implicated in the control of growth and development of Schwann cells(1-3), specialized cells that wrap around nerve axons to provide electrical insulation. Here we use gene targeting to generate mice that lack ErbB3, a high-affinity neuregulin receptor(4-6). Homozygous erbB3 mutant embryos lack Schwann-cell precursors and Schwann cells that accompany peripheral axons of sensory and motor neurons. The initial development of motor neurons and sensory neurons of dorsal root ganglia occurs as it should, but at later stages most motor neurons (79%) and sensory neurons in dorsal root ganglia (82%) undergo cell death in erbB3 mutant embryos. Degeneration of the peripheral nervous system in erbB3 mutant pups is thus much more severe than the cell death in mice that lack neurotrophins or neurotrophin receptors(7,8). We also show that ErbB3 functions in a cell-autonomous way during the development of Schwann cells, but not in the survival of sensory or motor neurons. Our results indicate that sensory and motor neurons require factors for their survival that are provided by developing Schwann cells.	MAX DELBRUCK CTR MOL MED,DEPT MED GENET,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT CELL BIOL,D-13122 BERLIN,GERMANY; MAX DELBRUCK CTR MOL MED,DEPT NEUROSCI,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Lewin, Gary R/B-8028-2011; Riethmacher, Dieter/A-6242-2010; Brinkmann, Volker/A-6015-2009; Riethmacher, Dieter/AAP-2227-2021; Riethmacher, Dieter/AAB-8690-2022	Riethmacher, Dieter/0000-0002-4206-5529; Lewin, Gary/0000-0002-2890-6352				Barinaga M, 1996, SCIENCE, V273, P1657, DOI 10.1126/science.273.5282.1657; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Davies A. M., 1995, NEURAL CELL CULTURE, P153; DONG Z, 1995, NEURON, V15, P686; ElShamy WM, 1996, NEURON, V16, P963, DOI 10.1016/S0896-6273(00)80119-1; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Griffiths IR, 1996, BIOESSAYS, V18, P789, DOI 10.1002/bies.950181005; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; KUCERA J, 1995, NEUROSCIENCE, V69, P321, DOI 10.1016/0306-4522(95)00221-4; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMKE G, 1993, GLIA, V7, P163; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MEYER D, IN PRESS DEVELOPMENT; Ockel M, 1996, DEVELOPMENT, V122, P301; ORR UA, 1993, P NATL ACAD SCI USA, V90, P1867; PAPAIOANNOU V, 1993, GENE TARGETING PRACT, P1807; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1996, J BIOL CHEM, V271, P19022; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1	30	557	568	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					725	730		10.1038/39593	http://dx.doi.org/10.1038/39593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338783				2022-12-24	WOS:A1997YA95900054
J	Mechanic, LJ; Dikman, S; CunninghamRundles, C				Mechanic, LJ; Dikman, S; CunninghamRundles, C			Granulomatous disease in common variable immunodeficiency	ANNALS OF INTERNAL MEDICINE			English	Article							HYPOGAMMAGLOBULINEMIA; FAILURE	Background: Granulomatous lesions are occasionally found in the lymphoid or solid organs of patients with common variable immunodeficiency. Objective: To examine the clinical and immunologic conditions in patients with common variable immunodeficiency who have granulomas. Design: Case series. Setting: Large tertiary care medical center. Patients: 17 hypogammaglobulinaemic patients with common variable immunodeficiency whose organ or tissue biopsy samples contained noncaseating granulomas. Measurements: Results of lymphocyte function tests. Results: Eight of 17 patients had granulomas at some point before hypogammaglobulinemia was diagnosed. Sixteen of the 17 had deficient T-cell proliferation to mitogens. Although 14 patients received standard treatment with intravenous immunoglobulin, they have had substantial illness, including frequent autoimmune disease. Conclusions: Dysregulated T-cell function or macrophage activation may have been involved in formation of granulomas and increased illness in hypogammaglobulinaemic patients with common variable immunodeficiency. Delay in recognition of antibody deficiency may have contributed to the severity of illness in these patients.	MT SINAI MED CTR, MT SINAI SCH MED, DIV CLIN IMMUNOL, NEW YORK, NY 10029 USA; MT SINAI MED CTR, MT SINAI SCH MED, DIV CLIN PATHOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA 533H] Funding Source: Medline; NCRR NIH HHS [5 M01-RR-0071] Funding Source: Medline; FDA HHS [FD-R-001162-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); FDA HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADELMAN DC, 1990, J ALLERGY CLIN IMMUN, V86, P512, DOI 10.1016/S0091-6749(05)80207-6; ASHERSON GL, 1980, DIAGNOSIS TREATMENT, P41; CRYSTAL RG, 1994, HARRISONS PRINCIPLES, P1683; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES S, 1981, J CLIN IMMUNOL, V1, P65, DOI 10.1007/BF00915478; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; GILBERT S, 1993, AM REV RESPIR DIS, V148, P483, DOI 10.1164/ajrccm/148.2.483; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; JAMES DG, 1993, SARCOIDOSIS, V10, P1; JAMES DG, 1985, SARCOIDOSIS OTHER GR, P128; LAZARUS DS, 1994, BBA-MOL BASIS DIS, V1226, P12, DOI 10.1016/0925-4439(94)90052-3; Leen C L, 1985, Sarcoidosis, V2, P91; PASTORELLI G, 1989, CLIN EXP IMMUNOL, V78, P334; SAIKI O, 1982, P NATL ACAD SCI-BIOL, V79, P6008, DOI 10.1073/pnas.79.19.6008; SNELLER MC, 1990, J IMMUNOL, V144, P3762; SPICKETT GP, 1989, IMMUNOL TODAY, V10, P192, DOI 10.1016/0167-5699(89)90323-X; STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48; World Health Organization, 1992, IMMUNODEFIC REV, P195	18	201	206	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				613	617		10.7326/0003-4819-127-8_Part_1-199710150-00005	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341059				2022-12-24	WOS:A1997YB41900005
J	Blasco, MA; Lee, HW; Hande, MP; Samper, E; Lansdorp, PM; DePinho, RA; Greider, CW				Blasco, MA; Lee, HW; Hande, MP; Samper, E; Lansdorp, PM; DePinho, RA; Greider, CW			Telomere shortening and tumor formation by mouse cells lacking telomerase RNA	CELL			English	Article							MINOR SATELLITE DNA; EMBRYO FIBROBLASTS; IMMORTAL CELLS; REPEAT ARRAYS; STEM-CELLS; SENESCENCE; LENGTH; CANCER; IDENTIFICATION; CHROMOSOMES	To examine the role of telomerase in normal and neoplastic growth, the telomerase RNA component (mTR) was deleted from the mouse germline. mTR(-/-) mice lacked detectable telomerase activity yet were viable for the six generations analyzed. Telomerase-deficient cells could be immortalized in culture, transformed by viral oncogenes, and generated tumors in nude mice following transformation. Telomeres were shown to shorten at a rate of 4.8 +/- 2.4 kb per mTR(-/-) generation. Cells from the fourth mTR(-/-) generation onward possessed chromosome ends lacking detectable telomere repeats, aneuploidy, and chromosomal abnormalities, including end-to-end fusions. These results indicate that telomerase is essential for telomere length maintenance but is not required for establishment of cell lines, oncogenic transformation, or tumor formation in mice.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; UNIV AUTONOMA MADRID,DEPT IMMUNOL & ONCOL,CTR NACL BIOTECNOL,CSIC,E-28049 MADRID,SPAIN; BRITISH COLUMBIA CANC RES CTR,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1M9,CANADA	Cold Spring Harbor Laboratory; Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); British Columbia Cancer Agency; University of British Columbia			Hande, M. Prakash/B-1645-2008; Blasco, Maria A./M-1694-2014	Hande, M. Prakash/0000-0002-4511-6256; Blasco, Maria A./0000-0002-4211-233X; Lansdorp, Peter/0000-0001-7435-1071; DePinho, Ronald/0000-0002-5625-577X; Greider, Carol/0000-0002-5494-8126	NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009383] Funding Source: NIH RePORTER; NCI NIH HHS [5P30-CA45508] Funding Source: Medline; NIA NIH HHS [R01AG09383] Funding Source: Medline; NICHD NIH HHS [R01HD348880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; AUSUBEL RM, 1993, CURRENT PROTOCOLS MO; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BEDNAREK A, 1995, CANCER RES, V55, P4566; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, ONCOGENE, V11, P893; Conzen SD, 1995, ONCOGENE, V11, P2295; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DROST JB, 1995, ENVIRON MOL MUTAGEN, V25, P48, DOI 10.1002/em.2850250609; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Harley C.B., 1990, METHOD MOL BIOL, P25; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; IKRAM Z, 1994, P NATL ACAD SCI USA, V91, P6448, DOI 10.1073/pnas.91.14.6448; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KRAEMER PM, 1996, J NATL CANCER I, V76, P703; Kyo S, 1997, CANCER RES, V57, P610; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MEEK RL, 1977, EXP CELL RES, V107, P277, DOI 10.1016/0014-4827(77)90350-0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NANDA I, 1995, CHROMOSOME RES, V3, P399, DOI 10.1007/BF00713889; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SINGER MS, 1994, SCIENCE, V266, P387; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	53	1695	1775	3	151	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					25	34		10.1016/S0092-8674(01)80006-4	http://dx.doi.org/10.1016/S0092-8674(01)80006-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335332	hybrid			2022-12-24	WOS:A1997XZ80900006
J	Denzin, LK; SantAngelo, DB; Hammond, C; Surman, MJ; Cresswell, P				Denzin, LK; SantAngelo, DB; Hammond, C; Surman, MJ; Cresswell, P			Negative regulation by HLA-DO of MHC class II-restricted antigen processing	SCIENCE			English	Article							INVARIANT CHAIN PEPTIDES; BARE LYMPHOCYTE SYNDROME; T-CELL; INTRACELLULAR-TRANSPORT; DR MOLECULES; DM; GENES; EXPRESSION; COMPARTMENTS; COMPLEX	HLA-DM is a major histocompatibility complex (MHC) class II-like molecule that facilitates antigen processing by catalyzing the exchange of invariant chain-derived peptides (CLIP) from class II molecules for antigenic peptides. HLA-DO is a second class II-like molecule that physically associates with HLA-DM in B cells. HLA-DO was shown to block HLA-DM function. Purified HLA-DM-DO complexes could not promote peptide exchange in vitro. Expression of HLA-DO in a class II+ and DM+, DO- human T cell line caused the accumulation of class II-CLIP complexes, indicating that HLA-DO blocked DM function in two and suggesting that HLA-DO is an important modulator of class II-restricted antigen processing.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University					NIAID NIH HHS [AI14579, AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014579, R01AI014579, R01AI023081, R37AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; AVVA RR, 1994, IMMUNITY, V1, P63; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; CHANG CH, 1995, INT IMMUNOL, V7, P1515, DOI 10.1093/intimm/7.9.1515; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; DENZIN LK, UNPUB; Douek DC, 1997, INT IMMUNOL, V9, P355, DOI 10.1093/intimm/9.3.355; ECKELS DD, 1984, IMMUNOGENETICS, V19, P409, DOI 10.1007/BF00364644; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND CI, UNPUB; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; LAMPSON LA, 1980, J IMMUNOL, V125, P293; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PONZONI M, 1993, INT J CANCER, V55, P817, DOI 10.1002/ijc.2910550521; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REITH W, 1995, IMMUNOL TODAY, V16, P539, DOI 10.1016/0167-5699(95)80048-4; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Robbins NF, 1996, HUM IMMUNOL, V45, P13, DOI 10.1016/0198-8859(95)00152-2; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SANTANGELO DB, UNPUB; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	47	194	195	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					106	109		10.1126/science.278.5335.106	http://dx.doi.org/10.1126/science.278.5335.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311912				2022-12-24	WOS:A1997XZ12400048
J	Gonzales, R; Steiner, JF; Sande, MA				Gonzales, R; Steiner, JF; Sande, MA			Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; COMMON-COLD; ERYTHROMYCIN; CHILDREN; COMMUNITY; CARRIAGE; BACTERIA; DISEASE; HEALTH; TRIAL	Contex.-Antibiotic use is associated with increased rates of antibiotic-resistant organisms. A previous study has shown that colds, upper respiratory tract infections, and bronchitis account for nearly one third of all antibiotic prescribing by ambulatory care physicians. How frequently antibiotics are prescribed for these conditions and for and by whom is not known. Objectives.-To measure antibiotic prescription rates and to identify predictors of antibiotic use for adults diagnosed as having colds, upper respiratory tract infections, and bronchitis in the United States. Design.-Sample survey of practicing physicians participating in the National Ambulatory Medical Care Survey, 1992. Setting.-Office-based physician practices. Subjects.-Physicians (n=1529) completing patient record forms for adult office visits (n=28787). Main Outcome Measures.-Antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis. Results.-Office visits for colds, upper respiratory tract infections, and bronchitis resulted in approximately 12 million antibiotic prescriptions, accounting for 21% of all antibiotic prescriptions to adults in 1992. A total of 51% of patients diagnosed as having colds, 52% of patients diagnosed as having upper respiratory tract infections, and 66% of patients diagnosed as having bronchitis were treated with antibiotics. Female sex (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.05-2.62) and rural practice location (OR, 2.25; 95% CI, 1.33-3.80) were associated with greater antibiotic prescription rates, whereas black race (OR, 0.44; 95% CI, 0.21-0.93) was associated with lower antibiotic prescription rates. Patient age, Hispanic ethnicity, geographic region, physician specialty, and payment sources were not associated with antibiotic prescription rates in the bivariate analysis. Multivariate logistic regression analysis identified only rural practice location (adjusted OR, 2.58; 95% CI, 1.39-4.76) to be independently associated with more frequent antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis. Conclusion.-Although antibiotics have little or no benefit for colds, upper respiratory tract infections, or bronchitis, these conditions account for a sizable proportion of total antibiotic prescriptions for adults by office-based physicians in the United States.; Overuse of antibiotics is widespread across geographical areas, medical specialties, and payment sources. Therefore, effective strategies for changing prescribing behavior for these conditions will need to be broad based.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV GEN INTERNAL MED, BOX B-180, 4200 E 9TH AVE, DENVER, CO 80262 USA.				BHP HRSA HHS [5 T32 PE10006-04] Funding Source: Medline	BHP HRSA HHS		Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; BOLDY DAR, 1990, RESP MED, V84, P377, DOI 10.1016/S0954-6111(08)80072-8; BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DEFRIESE GH, 1989, HEALTH SERV RES, V23, P931; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; *FOOD DRUG ADM, 1986, NAT DRUG COD DIR 198; FRANKS P, 1984, J FAM PRACTICE, V19, P185; HEIKKINEN T, 1995, J PEDIATR-US, V126, P313, DOI 10.1016/S0022-3476(95)70569-4; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HOWIE JGR, 1970, LANCET, V2, P1099; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; King DE, 1996, J FAM PRACTICE, V42, P601; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; Mainous AG, 1996, ARCH FAM MED, V5, P79, DOI 10.1001/archfami.5.2.79; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; Meza R A, 1994, Aust Fam Physician, V23, P1550; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; POTTHOFF RF, 1992, J AM STAT ASSOC, V87, P383, DOI 10.2307/2290269; PRAYER OL, 1996, AM MED NEWS, V39, P42; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAPPERT SM, 1994, ADV DAT VIT HLTH STA, V253; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERJEIJ TJM, 1994, BR J GEN PRACT, V44, P400; WEINER J, 1995, ANN INTERN MED, V122, P380; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P481; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, MMWR-MORBID MORTAL W, V43, P31	35	549	563	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					901	904		10.1001/jama.278.11.901	http://dx.doi.org/10.1001/jama.278.11.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302241				2022-12-24	WOS:A1997XV64000027
J	Teasdale, TW; Engberg, A				Teasdale, TW; Engberg, A			Duration of cognitive dysfunction after concussion, and cognitive dysfunction as a risk factor: a population study of young men	BRITISH MEDICAL JOURNAL			English	Article							MINOR HEAD-INJURY; SECULAR TRENDS; INTELLIGENCE; SYMPTOMS; SEQUELAE; RECOVERY	Objectives: To establish how long cognitive dysfunction lasts after concussion, and the extent to which it may be a predisposing risk factor for concussion, by examining the prevalence of cognitive dysfunction among young men who have sustained concussion. Design: Observational study. Setting: Denmark. Subjects: 1220 young men who had been admitted to hospital for concussion between the ages of 16 and 24 (identified in a national register of admissions) and who had also been cognitively tested by the Danish conscription draft board. Main outcome measure: Score on the draft board's cognitive screening test, dichotomised as dysfunctional or non-dysfunctional (20.4% of the general population of Danish men appearing before the draft board had a dysfunctional score). Results: 700 of the 1220 men had been tested after sustaining concussion; 520 had been tested before concussion. Four (50%) of the eight men who were tested less than seven days after the injury had a dysfunctional score. Among groups of the remaining 692 men who were tested at later time points after injury, the rates were only marginally raised (range 21.4% to 26.5%) above the population level. Among men tested before injury, the rate of dysfunctional scores was higher (30.4% (158/520)). Apart from suggesting cognitive dysfunction as a risk factor for concussion, this higher proportion seems to relate to the fact that they were typically injured as young adults, whereas those men who were tested after concussion had more often been injured as adolescents. The relative risk for concussion in the presence of cognitive dysfunction is estimated to be 1.57 (95% confidence interval 1.32 to 1.86). Conclusions: Cognitive dysfunction is not only a short term consequence of concussion but also a predisposing risk factor for concussion, more so for young adults than for adolescents.	ODENSE UNIV HOSP,DEPT NEUROL,DK-5000 ODENSE C,DENMARK	University of Southern Denmark; Odense University Hospital	Teasdale, TW (corresponding author), UNIV COPENHAGEN,PSYCHOL LAB,NJALSGADE 88,DK-2300 COPENHAGEN S,DENMARK.							BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Duus B R, 1991, Ugeskr Laeger, V153, P2111; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1989, MANAGEMENT HEAD INJU; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; TEASDALE TW, 1994, SCAND J PSYCHOL, V35, P328, DOI 10.1111/j.1467-9450.1994.tb00957.x; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0	19	30	30	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					569	572						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302952				2022-12-24	WOS:A1997XV71700022
J	Basso, MA; Wurtz, RH				Basso, MA; Wurtz, RH			Modulation of neuronal activity by target uncertainty	NATURE			English	Article							FRONTAL EYE FIELD; SUPERIOR COLLICULUS; VISUAL-SEARCH; ATTENTION; SELECTION; MONKEY; CORTEX	Visual scenes are composed of many elements and although we can appreciate a scene as a whole, we can only move our eyes to one element of the scene at a time. As visual scenes become more complex, the number of potential targets in the scene increases, and the uncertainty that any particular one will be selected for an eye movement also increases. How motor systems accommodate this target uncertainty remains unknown. The activities of neurons in both the cerebral cortex(1-5) and superior colliculus(6-8) are modulated by this selection process. We reasoned that activity associated with target uncertainty should be evident in the saccadic motor system at the final stages of neural processing, in the superior colliculus(9,10). By systematically changing the number of stimuli from which a selection must be made and recording from superior colliculus neurons, we found that as the target uncertainty increased,the neural activity preceding target selection decreased. These results indicate that neurons within the final common pathway for movement generation are active well in advance of the selection of a particular movement. This early activity varies with the probability that a particular movement will be selected.			Basso, MA (corresponding author), NEI,SENSORIMOTOR RES LAB,BETHESDA,MD 20892, USA.							BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GOLDBERG ME, 1972, J NEUROPHYSIOL, V35, P560, DOI 10.1152/jn.1972.35.4.560; Kustov AA, 1996, NATURE, V384, P74, DOI 10.1038/384074a0; KUSTOV AA, 1995, SOC NEUR ABSTR, V21, P665; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Miyashita N, 1996, EXP BRAIN RES, V112, P187; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHALL JD, 1995, J NEUROSCI, V15, P6905; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SPARKS DL, 1989, NEUROBIOLOGY SACCADI, V3, P213; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0	16	261	263	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					66	69		10.1038/37975	http://dx.doi.org/10.1038/37975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288967				2022-12-24	WOS:A1997XU59600045
J	Forget, F; Pierrehumbert, RT				Forget, F; Pierrehumbert, RT			Warming early Mars with carbon dioxide clouds that scatter infrared radiation	SCIENCE			English	Article							ATMOSPHERE; CLIMATE; TEMPERATURES; VENUS; WET	Geomorphic evidence that Mars was warm enough to support flowing water about 3.8 billion years ago presents a continuing enigma that cannot be explained by conventional greenhouse warming mechanisms. Model calculations show that the surface of early Mars could have been warmed through a scattering variant of the greenhouse effect, resulting from the ability of the carbon dioxide ice clouds to reflect the outgoing thermal radiation back to the surface, This process could also explain how Earth avoided an early irreversible glaciation and could extend the size of the habitable zone on extrasolar planets around stars.	UNIV CHICAGO,DEPT GEOPHYS SCI,CHICAGO,IL 60637	University of Chicago	Forget, F (corresponding author), UNIV PARIS 06,CNRS,METEOROL DYNAM LAB,BOITE POSTALE 99,4 PL JUSSIEU,F-75252 PARIS 05,FRANCE.			Pierrehumbert, Raymond/0000-0002-5887-1197				CADEIRA K, 1992, NATURE, V359, P226; EMANUEL KA, 1994, Q J ROY METEOR SOC, V120, P1111, DOI 10.1256/smsqj.51901; Fanale F.P., 1992, MARS, P1135; Forget F, 1996, J GEOPHYS RES-PLANET, V101, P16865, DOI 10.1029/96JE01077; FORGET F, 1995, J GEOPHYS RES, V100, P2119; Hansen GB, 1997, J GEOPHYS RES-PLANET, V102, P21569, DOI 10.1029/97JE01875; JENSEN EJ, 1994, GEOPHYS RES LETT, V21, P2023, DOI 10.1029/94GL01358; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KASTING JF, 1984, ICARUS, V57, P335, DOI 10.1016/0019-1035(84)90122-2; Kasting JF, 1997, SCIENCE, V276, P1213, DOI 10.1126/science.276.5316.1213; KASTING JF, 1993, ICARUS, V101, P108, DOI 10.1006/icar.1993.1010; MANABE S, 1967, J ATMOS SCI, V24, P241, DOI 10.1175/1520-0469(1967)024<0241:TEOTAW>2.0.CO;2; McKay CP, 1997, ORIGINS LIFE EVOL B, V27, P263, DOI 10.1023/A:1006500116990; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1993, ICARUS, V103, P1, DOI 10.1006/icar.1993.1055; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SAMUELSON RE, 1967, ASTROPHYS J, V147, P782, DOI 10.1086/149053; SQUYRES SW, 1994, SCIENCE, V265, P744, DOI 10.1126/science.265.5173.744; STANSBERRY JA, 1995, 27 ANN M DIV PLAN SC; STEPHENS GL, 1990, J ATMOS SCI, V47, P1742, DOI 10.1175/1520-0469(1990)047<1742:TROTMA>2.0.CO;2; TOON OB, 1989, J GEOPHYS RES-ATMOS, V94, P16287, DOI 10.1029/JD094iD13p16287; WHITMIRE DP, 1995, J GEOPHYS RES-PLANET, V100, P5457, DOI 10.1029/94JE03080; XU KM, 1989, MON WEATHER REV, V117, P1471, DOI 10.1175/1520-0493(1989)117<1471:ITTACU>2.0.CO;2	24	336	338	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1273	1276		10.1126/science.278.5341.1273	http://dx.doi.org/10.1126/science.278.5341.1273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360920				2022-12-24	WOS:A1997YG04300039
J	Middleton, J; Neil, S; Wintle, J; ClarkLewis, I; Moore, H; Lam, C; Auer, M; Hub, E; Rot, A				Middleton, J; Neil, S; Wintle, J; ClarkLewis, I; Moore, H; Lam, C; Auer, M; Hub, E; Rot, A			Transcytosis and surface presentation of IL-8 ky venular endothelial cells	CELL			English	Article							ATTRACTANT ACTIVATION PROTEIN-1; ERYTHROCYTE CHEMOKINE RECEPTOR; RED-BLOOD-CELLS; HUMAN-NEUTROPHILS; LEUKOCYTE ADHESION; HEPARAN-SULFATE; L-SELECTIN; HUMAN-SKIN; BINDING; INTERLEUKIN-8	Chemokines have been convincingly implicated in actuating inflammatory leukocyte emigration. To affect the circulating leukocytes, tissue-derived chemokines have to traverse the endothelial cells (ECs). This was thought to be accomplished by chemokine diffusion through the intercellular gaps. On the contrary, we show by electron microscopy that the prototype chemokine IL-8 is internalized by venular ECs abluminally and transcytosed to the luminal surface. Here, it is presented to the adherent leukocytes on the EC membrane, predominantly in association with the EC projections. The intact C terminus of IL-8, the molecule's ''immobilization'' domain, is required for the EC binding, transcytosis, and consequently, the in vivo proemigratory activity of IL-8, indicating that the described subcellular interactions of IL-8 with the ECs are functionally relevant.	NOVARTIS FORSCHUNGSINST, A-1235 VIENNA, AUSTRIA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z3, CANADA	Novartis; University of British Columbia				Auer, Manfred/0000-0001-8920-3522; Neil, Stuart/0000-0003-3306-5831; Rot, Antal/0000-0002-9730-6166				Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; CARVETH HJ, 1989, BIOCHEM BIOPH RES CO, V162, P387, DOI 10.1016/0006-291X(89)92009-3; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COLDITZ IG, 1990, J LEUKOCYTE BIOL, V48, P129, DOI 10.1002/jlb.48.2.129; COLDITZ IG, 1985, SURV SYN PATHOL RES, V4, P44; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DEWALD B, 1987, BIOCHEM PHARMACOL, V36, P2505, DOI 10.1016/0006-2952(87)90523-5; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; FINA L, 1990, BLOOD, V75, P2417; FURIE MB, 1995, AM J PATHOL, V146, P1287; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; KOHN S, 1992, LAB INVEST, V67, P596; Koopmann W, 1997, J BIOL CHEM, V272, P10103; LEONARD EJ, 1991, J INVEST DERMATOL, V96, P690, DOI 10.1111/1523-1747.ep12470612; LEY K, 1993, J IMMUNOL, V151, P6347; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OMOTO E, 1990, EXP CELL RES, V187, P85, DOI 10.1016/0014-4827(90)90120-Y; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PEDRESCU D, 1994, P NATL ACAD SCI USA, V91, P3014; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; ROT A, 1992, CYTOKINE, V4, P347, DOI 10.1016/1043-4666(92)90077-5; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; ROT A, 1992, BIOCH INFLAMMATION, P271; ROT A, 1993, IMMUNOLOGIST, V1, P145; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1994, CYTOKINE HDB, P419; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHUBERT C, 1989, ARCH DERMATOL RES, V281, P475, DOI 10.1007/BF00510083; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steegmaier M, 1997, J CELL SCI, V110, P687; Strieter RM, 1996, J IMMUNOL, V156, P3583; SWENSSON O, 1991, J INVEST DERMATOL, V96, P682, DOI 10.1111/1523-1747.ep12470606; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WILLIAMS EW, 1978, J MICROSC-OXFORD, V112, P319, DOI 10.1111/j.1365-2818.1978.tb00082.x; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	71	587	597	3	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 31	1997	91	3					385	395		10.1016/S0092-8674(00)80422-5	http://dx.doi.org/10.1016/S0092-8674(00)80422-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363947	Bronze			2022-12-24	WOS:A1997YD94100012
J	Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W				Caplan, LR; Mohr, JP; Kistler, JP; Koroshetz, W			Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - Not a panacea for ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NEUROL INST,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	Caplan, LR (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DEPT NEUROL,314,750 WASHINGTON ST,BOSTON,MA 02111, USA.		Mohr, J/AAO-9694-2020					Adams HP, 1996, STROKE, V27, P1711; [Anonymous], 1996, NEUROLOGY, V47, P835; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; *NAT I NEUR DIS ST, 1995, NEW ENGL J MED, V333, P1581; PESSIN MS, 1995, CEREBROVASCULAR DISEASES, P409; SLOAN MA, 1987, ARCH NEUROL-CHICAGO, V44, P748, DOI 10.1001/archneur.1987.00520190052017; YAMAGUCHI T, 1995, THROMBOLYTIC THERAPY, P111	7	147	151	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 30	1997	337	18					1309	1310						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YC920	9345084				2022-12-24	WOS:A1997YC92000012
J	Ogg, S; Paradis, S; Gottlieb, S; Patterson, GI; Lee, L; Tissenbaum, HA; Ruvkun, G				Ogg, S; Paradis, S; Gottlieb, S; Patterson, GI; Lee, L; Tissenbaum, HA; Ruvkun, G			The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C-elegans	NATURE			English	Article							DAUER LARVA DEVELOPMENT; CAENORHABDITIS-ELEGANS; ALVEOLAR RHABDOMYOSARCOMA; INTERACTING GENES; EXPRESSION; GROWTH; TRANSLOCATION; SUPPRESSES; PROTEINS; HOMOLOG	In mammals, insulin signalling regulates glucose transport together with the expression and activity of various metabolic enzymes. In the nematode Caenorhabditis elegans, a related pathway regulates metabolism, development and longevity(1,2). Wild-type animals enter the developmentally arrested dauer stage in response to high levels of a secreted pheromone(3), accumulating large amounts of fat in their intestines and hypodermis. Mutants in DAF-2 (a homologue of the mammalian insulin receptor) and AGE-1 (a homologue of the catalytic subunit of mammalian phosphatidylinositol 3-OH kinase) arrest development at the dauer stage(3), Moreover, animals bearing weak or temperature-sensitive mutations in daf-2 and age-1 can develop reproductively, but nevertheless show increased energy storage and longevity(1,2,4,5). Here we show that null mutations in daf-16 suppress the effects of mutations in daf-2 or age-1; lack of daf-16 bypasses the need for this insulin receptor-like signalling pathway. The principal role of DAF-2/AGE-1 signalling is thus to antagonize DAF-16. daf-16 is widely expressed and encodes three members of the Fork head family of transcription factors, The DAF-2 pathway acts synergistically with the pathway activated by a nematode TGF-beta-type signal, DAF-7, suggesting that DAF-16 cooperates with nematode SMAD proteins in regulating the transcription of key metabolic and developmental control genes. The probable human orthologues of DAF-16, FKHR and AFX, may also act downstream of insulin signalling and cooperate with TGF-beta effecters in mediating metabolic regulation. These genes may be dysregulated in diabetes.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DORMAN JB, 1995, GENETICS, V141, P1399; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FEDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOTTLIEB S, 1994, GENETICS, V137, P107; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; KALEBIC T, 1994, CANCER RES, V54, P5531; KAUFMANN E, 1995, J MOL BIOL, V248, P239, DOI 10.1006/jmbi.1995.0218; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NOJIMA T, 1990, VIRCHOWS ARCH A, V417, P357, DOI 10.1007/BF01605789; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; PATTERSON GI, IN PRESS GENES DEV; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle D.L., 1997, GENETIC ENV REGULATI, VII, P739; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOWELS JJ, 1992, GENETICS, V130, P105	30	1506	1554	4	177	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					994	999		10.1038/40194	http://dx.doi.org/10.1038/40194			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353126				2022-12-24	WOS:A1997YD29900062
J	Larsson, O; Barker, CJ; Sjoholm, A; Carlqvist, H; Michell, RH; Bertorello, A; Nilsson, T; Honkanen, RE; Mayr, GW; Zwiller, J; Berggren, PO				Larsson, O; Barker, CJ; Sjoholm, A; Carlqvist, H; Michell, RH; Bertorello, A; Nilsson, T; Honkanen, RE; Mayr, GW; Zwiller, J; Berggren, PO			Inhibition of phosphatases and increased Ca2+ channel activity by inositol hexakisphosphate	SCIENCE			English	Article							SERINE/THREONINE PROTEIN PHOSPHATASES; PANCREATIC BETA-CELLS; CALCIUM CHANNELS; OKADAIC ACID; 1,2,3-TRISPHOSPHATE; 1,2-BISPHOSPHATE; POLYPHOSPHATES; PURIFICATION; SPECIFICITY; ACTIVATION	Inositol hexakisphosphate (InsP(6)), the dominant inositol phosphate in insulin-secreting pancreatic beta cells, inhibited the serine-threonine protein phosphatases type 1, type 2A, and type 3 in a concentration-dependent manner. The activity of voltage-gated L-type calcium channels is increased in cells treated with inhibitors of serine-threonine protein phosphatases. Thus, the increased calcium channel activity obtained in the presence of InsP(6) might result from the inhibition of phosphatase activity. Glucose elicited a transient increase in InsP(6) concentration, which indicates that this inositol polyphosphate may modulate calcium influx over the plasma membrane and serve as a signal in the pancreatic beta cell stimulus-secretion coupling.	KAROLINSKA INST,DEPT MOL MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; ASTRA PAIN CONTROL AB,NOVUM UNIT,S-14157 HUDDINGE,SWEDEN; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV S ALABAMA,COLL MED,DEPT BIOCHEM,MOBILE,AL 36688; UNIV HAMBURG,HOSP EPPENDORF,INST PHYSIOL CHEM,D-20246 HAMBURG,GERMANY; INSERM,U338,F-67084 STRASBOURG,FRANCE	Karolinska Institutet; University of Birmingham; University of South Alabama; University of Hamburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Michell, Robert H/AAT-4974-2020	Michell, Robert H/0000-0001-9422-9858; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BARKER CJ, 1995, BIOCHEM J, V306, P557, DOI 10.1042/bj3060557; BARKER CV, UNPUB; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CARPENTER D, 1989, BIOCHEM SOC T, V17, P3, DOI 10.1042/bst0170003; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Efanov AM, 1997, P NATL ACAD SCI USA, V94, P4435, DOI 10.1073/pnas.94.9.4435; FUKADA M, 1994, J BIOL CHEM, V269, P29206; GRAF E, 1984, J BIOL CHEM, V259, P3620; HABY C, 1994, BIOCHEM J, V298, P341, DOI 10.1042/bj2980341; HAWKINS PT, 1993, BIOCHEM J, V294, P929, DOI 10.1042/bj2940929; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; Hughes P J, 1993, Curr Opin Neurobiol, V3, P383, DOI 10.1016/0959-4388(93)90132-I; Krizanova O, 1996, GEN PHYSIOL BIOPHYS, V15, P79; LARSSON O, UNPUB; LI G, 1991, J BIOL CHEM, V267, P4349; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; POYNER DR, 1993, J BIOL CHEM, V268, P1032; SJOHOLM A, 1993, BIOSCIENCE REP, V13, P349, DOI 10.1007/BF01150479; Spiers ID, 1996, CARBOHYD RES, V282, P81, DOI 10.1016/0008-6215(95)00361-4; STUART JA, 1994, BIOCHEM J, V303, P517, DOI 10.1042/bj3030517; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3161; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WALAAS SI, 1991, PHARMACOL REV, V43, P229; ZWILLER J, UNPUB	34	115	119	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					471	474		10.1126/science.278.5337.471	http://dx.doi.org/10.1126/science.278.5337.471			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334307				2022-12-24	WOS:A1997YB35500047
J	Severin, K; Lee, DH; Kennan, AJ; Ghadiri, MR				Severin, K; Lee, DH; Kennan, AJ; Ghadiri, MR			A synthetic peptide ligase	NATURE			English	Article							HELICAL COILED-COILS; GCN4 LEUCINE-ZIPPER; ELECTROSTATIC INTERACTIONS; CATALYSIS; POLYPEPTIDES; ANTIBODIES; LIGATION; DESIGN	The preparation of synthetic molecules showing the remarkable efficiencies characteristic of natural biopolymer catalysts remains a formidable challenge for chemical biology, Although significant advances have been made in the understanding of protein structure and function, the ne novo construction of such systems remains elusive(1-5). Re-engineered natural enzymes and catalytic antibodies, possessing tailored binding pockets with appropriately positioned functional groups, have been successful in catalysing a number of chemical transformations, sometimes with impressive efficiencies(6-11). But efforts to produce wholly synthetic catalytic peptides have typically resulted in compounds with questionable structural stability, let alone reactivity(1). Here we describe a 33-residue synthetic peptide, based on the coiled-coil structural motif(12-14), which efficiently catalyses the condensation of two shorter peptide fragments with high sequence-and diastereoselectivity. Depending on the substrates used, we observe rate enhancements of tenfold to 4,100-fold over the background, with catalytic efficiencies in excess of 10(4). These results augur well for the rational design of functional peptides.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute				Severin, Kay/0000-0003-2224-7234				ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; BRUICE TC, 1964, J AM CHEM SOC, V86, P738, DOI 10.1021/ja01058a044; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Corey MJ, 1996, P NATL ACAD SCI USA, V93, P11428, DOI 10.1073/pnas.93.21.11428; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DOUGLAS K T, 1992, Current Opinion in Biotechnology, V3, P370, DOI 10.1016/0958-1669(92)90165-F; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P537; JOHNSSON K, 1993, NATURE, V365, P530, DOI 10.1038/365530a0; KAISER ET, 1988, ANGEW CHEM INT EDIT, V27, P913, DOI 10.1002/anie.198809131; KEMP DS, 1993, J ORG CHEM, V58, P2216, DOI 10.1021/jo00060a043; Kirby AJ, 1996, ACTA CHEM SCAND, V50, P203, DOI 10.3891/acta.chem.scand.50-0203; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; MacBeath G, 1996, CHEM BIOL, V3, P433, DOI 10.1016/S1074-5521(96)90091-5; MARTIN RB, 1962, J AM CHEM SOC, V84, P106, DOI 10.1021/ja00860a025; MONERA OD, 1994, BIOCHEMISTRY-US, V33, P3862, DOI 10.1021/bi00179a010; Muir TW, 1996, CHEM BIOL, V3, P817, DOI 10.1016/S1074-5521(96)90067-8; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SEVERIN RS, 1997, CHEM-EUR J, V3, P1017; Smithrud DB, 1997, J AM CHEM SOC, V119, P278, DOI 10.1021/ja963167u; Tam JP, 1995, P NATL ACAD SCI USA, V92, P12485, DOI 10.1073/pnas.92.26.12485; WONG CH, 1994, ENZYMES SYNTHETIC OR; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250	31	123	125	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					706	709		10.1038/39556	http://dx.doi.org/10.1038/39556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338780				2022-12-24	WOS:A1997YA95900048
J	Gronberg, H; Isaacs, SD; Smith, JR; Carpten, JD; Bova, GS; Freije, D; Xu, JF; Meyers, DA; Collins, FS; Trent, JM; Walsh, PC; Isaacs, WB				Gronberg, H; Isaacs, SD; Smith, JR; Carpten, JD; Bova, GS; Freije, D; Xu, JF; Meyers, DA; Collins, FS; Trent, JM; Walsh, PC; Isaacs, WB			Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; PATHOLOGICAL FEATURES; RISK; RELATIVES	Context.-Approximately 9% of prostate cancer cases have been estimated to result from inheritance of mutated prostate cancer susceptibility genes. Few data exist as to whether there are clinical differences between prostate cancers that are inherited and those that occur in the general population. Objective.-To investigate phenotypic characteristics of families potentially linked to the hereditary prostate cancer 1 (HPC1) locus on chromosome 1q24-25. Design.-Retrospective case study in which clinical data were extracted from medical and pathological records. Families.-A total of 74 North American families with hereditary prostate cancer. Prostate cancer cases from the National Cancer Data Base were used as a reference population for comparison. Main Outcome Measures.-The families were divided into 2 groups: either potentially linked (33 families with 133 men with prostate cancer), and thus likely to be carrying an altered HPC1 gene, or potentially unlinked (41 families with 172 men with prostate cancer), on the basis of haplotype analysis in the region of HPC1, The age at diagnosis of prostate cancer, serum prostate-specific antigen levels, digital rectal examination status, stage, grade, primary treatment of prostate cancers, and occurrence of other cancers were compared between the groups. Results.-The mean age at diagnosis of prostate cancer for men in potentially linked families was significantly lower than for men in potentially unlinked families (63.7 vs 65.9 years, respectively, P=.01; mean age at diagnosis in the reference population was 71.6 years). Higher-grade cancers (grade 3) were more common in potentially linked families, and advanced-stage disease was found in 41% of the case patients in potentially linked families compared with 31% in both the potentially unlinked families and the reference groups (P=.03 for the tatter comparison). In the other clinical parameters, we found no significant differences between the groups, A modest excess of breast cancer and colon cancer was found in potentially linked families in comparison with potentially unlinked families, but this difference was not statistically significant. Conclusions.-Families that provide evidence for segregation of an altered HPC1 gene are characterized by multiple cases of prostate cancer that, in most respects, are indistinguishable from nonhereditary cases, However, 3 characteristics were observed: younger age at diagnosis, higher-grade tumors, and more advanced-stage disease, Our study shows that a significant fraction of hereditary prostate cancers are diagnosed in advanced stages, emphasizing the clinical importance of early detection in men potentially carrying prostate cancer susceptibility genes, These findings support the current recommendations to screen men with a positive family history of prostate cancer beginning at age 40 years.	JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD; UMEA UNIV,DEPT ONCOL,UMEA,SWEDEN	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Umea University			Smith, Jeff/C-3484-2012	Smith, Jeffrey/0000-0001-8424-910X; Bova, George/0000-0003-1639-3104	NCI NIH HHS [CA58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1993, BREAST CANCER RES TR, V28, P107, DOI 10.1007/BF00666423; ANDERSON DE, 1992, J NATL CANCER I, V84, P1114, DOI 10.1093/jnci/84.14.1114; BASTACKY SI, 1995, J UROLOGY, V153, P987, DOI 10.1016/S0022-5347(01)67619-5; BOVA GS, 1995, P AM UROL ASS, V153, pA505; Breslow N., 1987, STATISTICAL METHODS; CANNON L, 1983, INHERITANCE SUSCEPTI, P47; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CARTER BS, 1993, J UROLOGY, V150, P797, DOI 10.1016/S0022-5347(17)35617-3; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gronberg H, 1996, CANCER, V77, P138, DOI 10.1002/(SICI)1097-0142(19960101)77:1<138::AID-CNCR23>3.0.CO;2-5; ISAACS SD, 1995, J NATL CANCER I, V87, P991, DOI 10.1093/jnci/87.13.991; Keetch DW, 1996, J UROLOGY, V155, P1841, DOI 10.1016/S0022-5347(01)66024-5; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; METTLIN CJ, 1995, CANCER, V76, P1104, DOI 10.1002/1097-0142(19950915)76:6<1104::AID-CNCR2820760627>3.0.CO;2-D; OTT J, 1985, ANAL HUMAN GENETIC L, P200; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855	21	127	127	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1251	1255		10.1001/jama.278.15.1251	http://dx.doi.org/10.1001/jama.278.15.1251			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333266				2022-12-24	WOS:A1997XZ70900030
J	McGrath, MA				McGrath, MA			Planetary science - Io and the plasma torus	SCIENCE			English	Editorial Material											McGrath, MA (corresponding author), SPACE TELESCOPE SCI INST,3700 SAN MARTIN DR,BALTIMORE,MD 21218, USA.							Brown ME, 1997, SCIENCE, V278, P268, DOI 10.1126/science.278.5336.268; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; Galileo G., 1610, SIDEREUS NUNCIUS; HALL DT, IN PRESS ASTROPHYS J; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; NASH DB, 1986, SATELLITES; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; PEALE SJ, 1979, SCIENCE, V204; SCHNEIDER NM, 1989, NASA	9	3	3	3	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					237	238		10.1126/science.278.5336.237	http://dx.doi.org/10.1126/science.278.5336.237			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9340770				2022-12-24	WOS:A1997YA56400028
J	Jewitt, DC; Matthews, HE; Owen, T; Meier, R				Jewitt, DC; Matthews, HE; Owen, T; Meier, R			Measurements of C-12/C-13, N-14/N-15, and S-32/S-34 ratios in comet Hale-Bopp (C/1995 O1)	SCIENCE			English	Article							RADIO OBSERVATIONS; ISOTOPE ABUNDANCE; HALLEY; P/HALLEY; HCN	The C-12/C-13, N-14/N-15, and S-32/S-34 isotope ratios in comet Hale-Bopp (C/1995 O1) were determined through observations taken with the James Clerk Maxwell Telescope, Measurements of rare isotopes in HCN and CS revealed isotope ratios of (HCN)-C-12/(HCN)-C-13 = 111 +/- 12, (HCN)-N-14/(HCN)-N-15 = 323 +/- 46, and (CS)-S-32/(CS)-S-34 = 27 +/- 3. Within the measurement uncertainties, the isotopic ratios are consistent with solar system values. The cometary volatiles thus have an origin in the solar system and show no evidence for an interstellar component.	NATL RES COUNCIL CANADA, HERZBERG INST ASTROPHYS, DOMINION ASTROPHYS OBSERV, VICTORIA, BC V8X 4M6, CANADA; JOINT ASTRON CTR, HILO, HI 96720 USA	National Research Council Canada	Jewitt, DC (corresponding author), UNIV HAWAII, INST ASTRON, 2680 WOODLAWN DR, HONOLULU, HI 96822 USA.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1984, ASTRON ASTROPHYS, V141, P411; CAO YX, 1993, ASTRON J, V105, P1027, DOI 10.1086/116490; Chin YN, 1996, ASTRON ASTROPHYS, V305, P960; DAHMEN G, 1995, ASTRON ASTROPHYS, V295, P194; DANKS AC, 1974, ASTROPHYS J, V194, P745, DOI 10.1086/153297; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; FRERKING MA, 1980, ASTROPHYS J, V240, P65, DOI 10.1086/158207; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; KLEINE M, 1995, ASTROPHYS J, V439, P1021, DOI 10.1086/175239; KRANKOWSKY D, 1986, NATURE, V321, P326, DOI 10.1038/321326a0; LIS DC, 1997, 6566 IAU; MATTHEWS H, 1997, 6567 IAU; SCHLOERB FP, 1987, ASTRON ASTROPHYS, V187, P469; STAWIKOWSKI A, 1964, ASTROPHYS J, V140, P1280, DOI 10.1086/148023; VANYSEK V, 1991, ASTROPHYS SPACE SC L, V167, P879; VANYSEK V, 1977, COMETS ASTEROIDS MET, P499; WILSON TL, 1994, ANNU REV ASTRON ASTR, V32, P191; WYCKOFF S, 1989, ASTROPHYS J, V339, P488, DOI 10.1086/167312	20	108	108	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					90	93		10.1126/science.278.5335.90	http://dx.doi.org/10.1126/science.278.5335.90			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311932				2022-12-24	WOS:A1997XZ12400043
J	Leshner, AI				Leshner, AI			Addiction is a brain disease, and it matters	SCIENCE			English	Article							INJECTION-DRUG USERS; MOLECULAR MECHANISMS; COCAINE; ABUSE; ADAPTATIONS; BEHAVIOR; PATHWAYS; EXPOSURE; SYSTEM	Scientific advances over the past 20 years have shown that drug addiction is a chronic, relapsing disease that results from the prolonged effects of drugs on the brain. As with many other brain diseases, addiction has embedded behavioral and social-context aspects that are important parts of the disorder itself. Therefore, the most effective treatment approaches will include biological, behavioral, and social-context components. Recognizing addiction as a chronic, relapsing brain disorder characterized by compulsive drug seeking and use can impact society's overall health and social policy strategies and help diminish the health and social costs associated with drug abuse and addiction.			Leshner, AI (corresponding author), NIDA, NIH, 5600 FISHERS LANE, ROOM 10-05, ROCKVILLE, MD 20857 USA.							American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; [Anonymous], 1994, SEMIN NEUROSCI; Baxter Jr, 1996, Semin Clin Neuropsychiatry, V1, P32; Booth RE, 1996, DRUG ALCOHOL DEPEN, V42, P11, DOI 10.1016/0376-8716(96)01257-4; Childress A R, 1988, NIDA Res Monogr, V84, P25; COLON HM, 1995, AIDS EDUC PREV, V7, P195; Daley D.C., 1997, SUBSTANCE ABUSE COMP, P458; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; ICIARDI JA, 1997, J DRUG ISSUES, V27, P261; Institute of Medicine, 1996, PATHW ADD; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; LESHNER AI, 1997, HOSP PRACTICE SPECIA; MCLELLAN AT, 1997, TREATING DRUG ABUSER, P7; Melega WP, 1997, BEHAV BRAIN RES, V84, P259, DOI 10.1016/S0166-4328(97)83333-5; Nestler EJ, 1996, MOL PSYCHIATR, V1, P190; Nestler EJ, 1996, NEURON, V16, P897, DOI 10.1016/S0896-6273(00)80110-5; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; OBRIEN CP, 1975, PHARMACOL REV, V27, P533; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OBRIEN CP, 1990, ADDICT BEHAV, V15, P355, DOI 10.1016/0306-4603(90)90045-Y; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; Stephens R. C., 1993, HDB RISK AIDS INJECT, P519; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; VOLKOW ND, 1990, AM J PSYCHIAT, V147, P719; WEXLER HK, 1993, DRUG TREATMENT CRIMI, P261; Wiebel WW, 1996, J ACQ IMMUN DEF SYND, V12, P282, DOI 10.1097/00042560-199607000-00008	30	936	1013	1	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					45	47		10.1126/science.278.5335.45	http://dx.doi.org/10.1126/science.278.5335.45			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311924				2022-12-24	WOS:A1997XZ12400029
J	Ollmann, MM; Wilson, BD; Yang, YK; Kerns, JA; Chen, YR; Gantz, I; Barsh, GS				Ollmann, MM; Wilson, BD; Yang, YK; Kerns, JA; Chen, YR; Gantz, I; Barsh, GS			Antagonism of central melanocortin receptors in vitro and in vivo by Agouti-related protein	SCIENCE			English	Article							MELANOCYTE-STIMULATING-HORMONE; MOLECULAR-CLONING; HUMAN HOMOLOG; YELLOW MICE; CELL-LINE; GENE; EXPRESSION; MUTATION; IDENTIFICATION; LOCALIZATION	Expression of Agouti protein is normally limited to the skin where it affects pigmentation, but ubiquitous expression causes obesity. An expressed sequence tag was identified that encodes Agouti-related protein, whose RNA is normally expressed in the hypothalamus and whose levels were increased eightfold in ob/ob mice. Recombinant Agoutirelated protein was a potent, selective antagonist of Mc3r and Mc4r, melanocortin receptor subtypes implicated in weight regulation, Ubiquitous expression of human AGRP complementary DNA in transgenic mice caused obesity without altering pigmentation, Thus, Agouti-related protein is a neuropeptide implicated in the normal control of body weight downstream of leptin signaling.	STANFORD UNIV,SCH MED,BECKMAN CTR B271A,DEPT PEDIAT,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; UNIV MICHIGAN,SCH MED,DEPT SURG,ANN ARBOR,MI 48109	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NEI NIH HHS [EY07106] Funding Source: Medline; NIDDK NIH HHS [P30DK-34933] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KENAKIN TP, 1982, CAN J PHYSIOL PHARM, V60, P249, DOI 10.1139/y82-036; Kiefer LL, 1997, BIOCHEMISTRY-US, V36, P2084, DOI 10.1021/bi962647v; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; MICHAUD EJ, 1994, GENE DEV, V8, P1463, DOI 10.1101/gad.8.12.1463; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; OLLMANN MM, UNPUB; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; QUILLAN JM, 1995, P NATL ACAD SCI USA, V92, P2894, DOI 10.1073/pnas.92.7.2894; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; Silvers W. K., 1979, COAT COLORS MICE, P6; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; Yang YK, 1997, MOL ENDOCRINOL, V11, P274, DOI 10.1210/me.11.3.274; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	37	1479	1538	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					135	138		10.1126/science.278.5335.135	http://dx.doi.org/10.1126/science.278.5335.135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311920				2022-12-24	WOS:A1997XZ12400056
J	Bence, K; Ma, W; Kozasa, T; Huang, XY				Bence, K; Ma, W; Kozasa, T; Huang, XY			Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit	NATURE			English	Article							ACTIVATED PROTEIN-KINASE; COLI EXPRESSION SYSTEM; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ESCHERICHIA-COLI; MAP KINASE; CYTOPLASMIC DOMAIN; PURIFICATION; RECEPTOR; CELLS	Heterotrimeric guanine-nucleotide-binding regulatory proteins (G proteins) transduce signals from a wide variety of cell-surface receptors to generate physiological responses(1). Protein-tyrosine kinases are another group of critical cellular signal transducers and their malfunction often leads to cancer(2). Although activation of G-protein-coupled receptors can elicit rapid stimulation cellular protein-tyrosine phosphorylation(3), the mechanism used by G proteins to activate protein-tyrosine kinases is unclear. Here we show that the purified alpha-subunit of the G(q) class of G proteins (G alpha q) directly stimulates the activity of a purified non-receptor kinase, Bruton's tyrosine kinase (Btk)(4), whereas purified alpha-subunits from G(i1), G(0) or G(z) proteins do not, G alpha q can also activate Btk in vivo, Furthermore, in Btk-deficient cells, stimulation of another kinase, a p38 MAP kinase, by Gq-coupled receptors is blocked. Our results demonstrate that certain protein-tyrosine kinases can be direct effecters of G proteins.	CORNELL UNIV, COLL MED, DEPT PHYSIOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOYER JL, 1994, J BIOL CHEM, V269, P2814; FLINT NA, 1994, J CELL BIOCHEM, V55, P389, DOI 10.1002/jcb.240550317; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEE CW, 1994, J BIOL CHEM, V269, P25335; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PRICE DJ, 1995, BBA-MOL CELL RES, V1265, P133, DOI 10.1016/0167-4889(94)00213-X; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913	28	161	163	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					296	299		10.1038/38520	http://dx.doi.org/10.1038/38520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305846				2022-12-24	WOS:A1997XW77200051
J	Winter, MC; Welsh, MJ				Winter, MC; Welsh, MJ			Stimulation of CFTR activity by its phosphorylated R domain	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; CYSTIC-FIBROSIS; CHLORIDE CHANNEL; CL CHANNELS; ATP HYDROLYSIS; PYROPHOSPHATE; INACTIVATION	Phosphorylation controls the activity of ion channels in many tissues. In epithelia, the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is activated by phosphorylation of serine residues in its regulatory (R) domain and then gated by binding and hydrolysis of ATP by the nucleotide-binding domains(1-3). Current models propose that the unphosphorylated R domain serves as an inhibitory particle that occludes the pore(1,2,4-6), much like the inhibitory 'ball' in Shaker K+ channels(7,8); presumably, phosphorylation relieves this inhibition. Here we test this by adding an R-domain peptide to a CFTR variant in which much of the R domain had been deleted (CFTR-Delta R/S660A): in contrast to predictions, we found that adding an unphosphorylated R domain to CFTR-Delta R/S660A did not inhibit activity, whereas a phosphorylated R-domain peptide stimulated activity. To investigate how phosphorylation controls activity, we studied channel gating and found that phosphorylation of the R domain increases the rate of channel opening by enhancing the sensitivity to ATP. Our results indicate that CFTR is regulated by a new mechanism in which phosphorylation of one domain stimulates the interaction of ATP with another domain, thereby increasing activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LI C, 1996, J BIOL CHEM, V45, P28463; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; MALLER JL, 1978, P NATL ACAD SCI USA, V75, P248, DOI 10.1073/pnas.75.1.248; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Welsh M, 1995, METABOLIC MOL BASIS, V7, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	116	118	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					294	296		10.1038/38514	http://dx.doi.org/10.1038/38514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305845				2022-12-24	WOS:A1997XW77200050
J	Niki, H; Hiraga, S				Niki, H; Hiraga, S			Subcellular distribution of actively partitioning F plasmid during the cell division cycle in E-coli	CELL			English	Article							ESCHERICHIA-COLI; BACTERIAL PLASMIDS; BACILLUS-SUBTILIS; ESSENTIAL PROTEIN; ATPASE ACTIVITY; DAUGHTER CELLS; PARB PROTEIN; P1 PLASMID; CHROMOSOME; GENES	F plasmid is partitioned with fidelity to daughter cells during cell division cycle owing to two trans-acting genes, sopA and sops, and a cis-acting site, sopC. We visualized the subcellular distribution of mini-F-plasmid molecules by fluorescence in situ hybridization. Mini-F-plasmid molecules having the sopABC segment were localized at midcell in newborn cells. Replicated plasmid molecules migrated to cell positions 1/4 and 3/4 without coupling with cell elongation and were tethered to these positions until completion of cell division. In contrast, molecules of a mini F plasmid lacking the sopABC segment were distributed randomly in spaces not occupied by nucleoids. The sopABC system caused replicated plasmid molecules to be positioned and tethered at the cell quarter sites.			Niki, H (corresponding author), KUMAMOTO UNIV,SCH MED,INST MED EMBRYOL & GENET,DEPT MOL CELL BIOL,4-24-1 KUHONJI,KUMAMOTO 862,JAPAN.			Niki, Hironori/0000-0002-5391-6595				AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; ELLASSON A, 1992, MOL MICROBIOL, V6, P165; EZAKI B, 1991, J BACTERIOL, V173, P6643, DOI 10.1128/jb.173.20.6643-6646.1991; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1995, J BACTERIOL, V177, P2381, DOI 10.1128/jb.177.9.2381-2386.1995; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; Helmstetter CE, 1997, J BACTERIOL, V179, P1393, DOI 10.1128/jb.179.4.1393-1399.1997; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1991, RES MICROBIOL, V142, P189, DOI 10.1016/0923-2508(91)90029-A; HOGAN JE, 1982, PLASMID, V8, P36, DOI 10.1016/0147-619X(82)90039-7; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JAFFE A, 1985, J BACTERIOL, V163, P841; KLINE BC, 1985, PLASMID, V14, P1, DOI 10.1016/0147-619X(85)90027-7; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Miller J.H., 1972, EXPT MOL GENETICS; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; MOTALLEBIVESHAREH M, 1990, MOL MICROBIOL, V4, P1455, DOI 10.1111/j.1365-2958.1990.tb02056.x; MYSLIWIEC TH, 1991, J BACTERIOL, V173, P1911, DOI 10.1128/jb.173.6.1911-1919.1991; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; NIKI H, 1988, J BACTERIOL, V170, P5272, DOI 10.1128/jb.170.11.5272-5278.1988; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; OGURA T, 1983, CELL, V32, P351, DOI 10.1016/0092-8674(83)90454-3; SCOTT JR, 1984, MICROBIOL REV, V48, P1; WATANABE E, 1989, MOL GEN GENET, V218, P431, DOI 10.1007/BF00332406; WATANABE E, 1992, MOL GEN GENET, V234, P346, DOI 10.1007/BF00538693; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Yamanaka K, 1996, MOL GEN GENET, V250, P241	39	163	163	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					951	957		10.1016/S0092-8674(00)80359-1	http://dx.doi.org/10.1016/S0092-8674(00)80359-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298906	Bronze			2022-12-24	WOS:A1997XV56300015
J	Guo, F; Gopaul, DN; VanDuyne, GD				Guo, F; Gopaul, DN; VanDuyne, GD			Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse	NATURE			English	Article							HOLLIDAY JUNCTION; INTEGRASE FAMILY; ESCHERICHIA-COLI; PROTEIN; LOXP; BINDING; MICE; TYROSINE; HOMOLOGY; STRANDS	During site-specific DMA recombination, which brings about genetic rearrangement in processes such as viral integration and excision and chromosomal segregation, recombinase enzymes recognize specific DNA sequences and catalyse the reciprocal exchange of DNA strands between these sites. The bacteriophage recombinase Cre catalyses site-specific recombination between two 34-base-pair loxP sites. The crystal structure at 2.4 Angstrom resolution of Cre bound to aloxP substrate reveals an intermediate in the recombination reaction, fin which a Cre molecule has cleaved the substrate to form a covalent 3'-phosphotyrosine linkage with the DNA. Four recombinases and two loxP sites form a synapsed structure in which the DNA resembles models of four-way Holliday-junction intermediates. The Cre-loxP complex challenges models of site-specific recombination that require large changes in quaternary structure. Subtle allosteric changes at the carboxy termini of the Cre subunits may instead coordinate the cleavage and strand-exchange reactions.	UNIV PENN,SCH MED,JOHNSON RES FDN,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				GOPAUL, Deshmukh/0000-0003-1631-3303				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; BLAKELY GW, 1996, MOL MICROBIOL, V20, P233; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P93; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SIGAL N, 1972, J MOL BIOL, V71, P789, DOI 10.1016/S0022-2836(72)80039-1; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STERNBERG N, 1981, COLD SPRING HARB SYM, V1, P297; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tsurushita N, 1996, GENE, V172, P59, DOI 10.1016/0378-1119(96)00170-9; VanDuyne GD, 1996, J MOL BIOL, V256, P377, DOI 10.1006/jmbi.1996.0093; ZOU YR, 1994, CURR BIOL, V4, P1099, DOI 10.1016/S0960-9822(00)00248-7	50	459	518	2	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					40	46		10.1038/37925	http://dx.doi.org/10.1038/37925			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288963				2022-12-24	WOS:A1997XU59600037
J	Takizawa, PA; Sil, A; Swedlow, JR; Herskowitz, I; Vale, RD				Takizawa, PA; Sil, A; Swedlow, JR; Herskowitz, I; Vale, RD			Actin-dependent localization of an RNA encoding a cell-fate determinant in yeast	NATURE			English	Article							MESSENGER-RNA; MICROFILAMENTS; MICROTUBULES; OOCYTES; MYOSIN; ASH1P; MOVE	The cytoplasmic localization of messenger RNA creates an asymmetric distribution of proteins that specify cell fate during development in multicellular eukaryotes(1,2). The protein Ash1 is a cell-fate determinant in budding yeast which localizes preferentially to the presumptive daughter nucleus, where it inhibits mating-type switching(3'4). Here we show that Ash1 mRNA is localized to the distal tip of daughter buds in post-anaphase cells. Three-dimensional imaging reveals that Ash1 mRNA is assembled into particles that associate with the cell cortex, To achieve this localization, Ash1 mRNA must have its 3' untranslated region and the actin cytoskeleton must be intact, Ash1 mRNA is not localized correctly in the absence of a myosin (Myo4) and is mislocalized to the mother-bud neck in the absence of a regulator of the actin cytoskeleton known as Bni1. We propose that Ash1 mRNA particles are transported into the daughter bud along actin filaments and are anchored at the distal tip. Thus, as in higher eukaryotes, Saccharomyces cerevisiae employs RNA localization to generate an asymmetric distribution of proteins and hence to determine cell fate.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Swedlow, Jason/0000-0002-2198-1958				ADAMS A E M, 1991, P729; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; [Anonymous], 1997, DECONVOLUTION IMAGES; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	17	310	314	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					90	93		10.1038/38015	http://dx.doi.org/10.1038/38015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288973				2022-12-24	WOS:A1997XU59600051
J	Ash, EL; Sudmeier, JL; DeFabo, EC; Bachovchin, WW				Ash, EL; Sudmeier, JL; DeFabo, EC; Bachovchin, WW			A low-barrier hydrogen bond in the catalytic triad of serine proteases? Theory versus experiment	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; ALPHA-LYTIC PROTEASE; N-15 NMR-SPECTROSCOPY; ACTIVE-SITE; HISTIDINE; MECHANISM; ACID; CONSTANTS; COMPLEXES; TRYPSIN	Cleland and Kreevoy recently advanced the idea that a special type of hydrogen bond (H-bond), termed a low-barrier hydrogen bond (LBHB), may account for the ''missing'' transition state stabilization underlying the catalytic power of many enzymes, and Frey ef al. have proposed that the H-bond between aspartic acid 102 and histidine 57 in the catalytic triad of serine proteases is an example of a catalytically important LBHB. Experimental facts are here considered regarding the aspartic acid-histidine and cis-urocanic H-bonds that are inconsistent with fundamental tenets of the LBHB hypothesis. The inconsistencies between theory and experiment in these paradigm systems cast doubt on the existence of LBHBs, as currently defined, within enzyme active sites.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; GEORGE WASHINGTON UNIV,SCH MED,DEPT DERMATOL,WASHINGTON,DC 20037	Tufts University; George Washington University			Ash, Elissa L./AAA-5982-2021; william.bachovchin@tufts.edu/AAA-3538-2022		NIGMS NIH HHS [GM27927] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027927] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASH EL, UNPUB; BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BACHOVCHIN WW, 1994, STABLE ISOTOPE APPL, P41; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; Cassidy CS, 1997, BIOCHEMISTRY-US, V36, P4576, DOI 10.1021/bi962013o; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DAY RM, 1995, THEIS TUFTS U BOSTON; FARRJONES S, 1993, J AM CHEM SOC, V115, P6813, DOI 10.1021/ja00068a044; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FUJIWARA FY, 1974, J AM CHEM SOC, V96, P7625, DOI 10.1021/ja00832a005; FUJIWARA FY, 1974, J AM CHEM SOC, V96, P7632; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GOLUBEV NS, 1994, BIOCHEMISTRY-MOSCOW+, V59, P447; GUTHRIE JP, 1996, CHEM BIOL, V4, P259; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HORSLEY WJ, 1968, J AM CHEM SOC, V90, P3738, DOI 10.1021/ja01016a025; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P338; KETTNER CA, 1988, BIOCHEMISTRY-US, V27, P7682, DOI 10.1021/bi00420a017; LEGON AC, 1980, P ROY SOC LOND A MAT, V370, P213, DOI 10.1098/rspa.1980.0030; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; MARKLEY JL, 1996, BIOCHEMISTRY-US, V35, P1102; MARKLEY JL, 1979, BIOL APPL MAGNETIC R; MILLEN DJ, 1979, J CHEM SOC F2, V75, P592; ROBERTS JD, 1982, J AM CHEM SOC, V104, P3945, DOI 10.1021/ja00378a027; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; SAKIYAMA F, 1983, J BIOCHEM-TOKYO, V94, P1661; SANTUCCI I, 1995, THESIS FLINDERS U S; Schowen R., 1988, MECHANISTIC PRINCIPL, P119; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; Smirnov SN, 1996, J AM CHEM SOC, V118, P4094, DOI 10.1021/ja953445+; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	37	173	174	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1128	1132		10.1126/science.278.5340.1128	http://dx.doi.org/10.1126/science.278.5340.1128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353195				2022-12-24	WOS:A1997YE65200054
J	Fischer, TM; Blazis, DEJ; Priver, NA; Carew, TJ				Fischer, TM; Blazis, DEJ; Priver, NA; Carew, TJ			Metaplasticity at identified inhibitory synapses in Aplysia	NATURE			English	Article							SIPHON WITHDRAWAL REFLEX; TERM SYNAPTIC PLASTICITY; GILL-WITHDRAWAL; GAIN-CONTROL; TAIL SHOCK; SEROTONIN; SENSITIZATION; FACILITATION; DISHABITUATION; DISSOCIATION	Synaptic plasticity is an important feature of neural networks involved in the encoding of information. In the analysis of longterm potentiation and long-term depression, several examples have emerged in which this plasticity is itself modulated(1-3). This higher-order form of plasticity has been referred to as 'metaplasticity'(4), a modification of synapses reflected as a change in the ability to induce or maintain plasticity. These observations raise the question of the possible advantage of regulating the intrinsic plastic properties of a synapse. The neural circuit mediating the siphon withdrawal reflex in Aplysia provides a useful network in which to examine this question directly. Inhibitory synapses in this circuit (from L30 neurons) exhibit a variety of forms of activity-dependent short-term synaptic enhancement which contribute to dynamic gain control in the siphon withdrawal reflex(5-9). Here we report that tail shock, an extrinsic modulatory input of known behavioural relevance, induces differential metaplasticity at this synapse, attenuating its ability to exhibit short-term synaptic enhancement after presynaptic activation (augmentation and post-tetanic potentiation), while leaving intact its capacity for enhancement during activation. This attenuation of inhibition at the synaptic level seems to mediate comparable attenuation of inhibitory modulation at both network and behavioural levels.	YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520	Yale University								Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; ABRAMS TW, 1984, P NATL ACAD SCI-BIOL, V81, P7956, DOI 10.1073/pnas.81.24.7956; BLAZIS DEJ, 1993, NEURAL COMPUT, V5, P213, DOI 10.1162/neco.1993.5.2.213; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; DELANEY KR, 1994, J NEUROSCI, V14, P5885; FISCHER TM, 1995, J NEUROSCI, V15, P762; FISCHER TM, 1993, J NEUROSCI, V13, P1302; FISCHER TM, IN PRESS J NEUROPHYS; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; FITZGERALD K, 1991, J NEUROSCI, V11, P2510; FROST WN, 1988, J NEUROBIOL, V19, P297, DOI 10.1002/neu.480190402; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; HAWKINS RD, 1989, J NEUROSCI, V9, P4236; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HICKIE C, 1995, J NEUROPHYSIOL, V74, P307, DOI 10.1152/jn.1995.74.1.307; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; KANEKO S, BEHAV BRAIN RES, V45, P97; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Lieb JR, 1997, J NEUROPHYSIOL, V77, P1249, DOI 10.1152/jn.1997.77.3.1249; LIFE SCI, 1996, KANE, V60, P245; MARCUS EA, 1988, SCIENCE, V241, P210, DOI 10.1126/science.3388032; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; WALTERS ET, 1991, BIOL BULL, V180, P241, DOI 10.2307/1542394; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	27	65	65	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					860	865		10.1038/39892	http://dx.doi.org/10.1038/39892			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349819				2022-12-24	WOS:A1997YC14800060
J	Cao, A; Saba, L; Galanello, R; Rosatelli, C				Cao, A; Saba, L; Galanello, R; Rosatelli, C			Molecular diagnosis and carrier screening for beta thalassemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRADIENT GEL-ELECTROPHORESIS; LOCUS-CONTROL REGION; PRENATAL-DIAGNOSIS; ALPHA-THALASSEMIA; FETAL HEMOGLOBIN; GLOBIN GENE; DNA; MUTATIONS; TRANSCRIPTION; HETEROGENEITY	Thalassemias are common autosomal recessive disorders especially in populations of Mediterranean, Middle Eastern, and Far Eastern descent. Relatively high incidence is also observed in people of Asian Indian origin but the incidence is more limited in those of African descent. beta Thalassemias are heterogeneous at the molecular level, with more than 150 different molecular defects identified to date. Despite this heterogeneity, each at-risk population has its own spectrum of common mutations, usually from 5 to 10, a finding that simplifies mutation analysis. Homozygosity for beta thalassemias usually results in transfusion-dependent thalassemia major and, rarely, in mild non-transfusion-dependent conditions. Molecular diagnosis may be used to define genotypes associated with mild forms. Advances in carrier diagnosis using hematologic analysis followed by mutation analysis have made possible the population screening of women al childbearing age and prenatal diagnosis. This approach in combination with nondirective genetic counseling has resulted in a consistent decline of the birth of affected homozygotes in several Mediterranean at-risk populations, as well as knowledge of the risks of being a carrier. Molecular diagnosis of homozygotes and identification of carriers of beta thalassemia may lead to improved clinical management of patients with the disorder and prevention of the birth of affected homozygotes.			Cao, A (corresponding author), UNIV CAGLIARI, IST CLIN & BIOL ETA EVOLUT, VIA JENNER S-N, I-09121 CAGLIARI, ITALY.			SABA, Luisella/0000-0002-3470-3279; ROSATELLI, MARIA CRISTINA/0000-0001-6821-3190				ANGASTINIOTIS M, 1988, CYPRUS THALASSEMIA C, V23, P417; [Anonymous], 1983, Bull World Health Organ, V61, P63; BAYSAL E, 1995, HEMOGLOBIN, V19, P213, DOI 10.3109/03630269509036943; BENNANI C, 1993, BRIT J HAEMATOL, V84, P335, DOI 10.1111/j.1365-2141.1993.tb03075.x; BOLLEKENS JA, 1991, HEMATOL ONCOL CLIN N, V5, P399, DOI 10.1016/S0889-8588(18)30422-2; CAI SP, 1990, J CLIN INVEST, V85, P550, DOI 10.1172/JCI114471; CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; CAO A, 1987, Blood Reviews, V1, P169, DOI 10.1016/0268-960X(87)90032-4; CAO A, 1985, ANN NY ACAD SCI, V445, P380, DOI 10.1111/j.1749-6632.1985.tb17208.x; CAO A, 1997, CIBA F S, V197, P137; Cao A, 1990, EUR J INTERN MED, V1, P227; CHEHAB FF, 1987, BLOOD, V69, P1141; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; GALANELLO R, 1984, HEMOGLOBIN, V8, P25; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GONZALEZREDONDO JM, 1988, BLOOD, V72, P1007; GONZALEZREDONDO JM, 1989, BLOOD, V73, P1705; GRANT A, 1991, LANCET, V337, P1491; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; KANAVAKIS E, 1982, BRIT J HAEMATOL, V52, P465, DOI 10.1111/j.1365-2141.1982.tb03916.x; KATTAMIS C, 1990, BRIT J HAEMATOL, V74, P342, DOI 10.1111/j.1365-2141.1990.tb02593.x; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P209; KULOZIK AE, 1991, J CLIN INVEST, V87, P2142, DOI 10.1172/JCI115246; LIEINJO LE, 1989, AM J HUM GENET, V45, P971; LIU JZ, 1989, HEMOGLOBIN, V13, P585, DOI 10.3109/03630268908993109; LOUDIANOS G, 1990, BLOOD, V75, P526; Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MELIS MA, 1983, BLOOD, V62, P226; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; ONER R, 1990, HEMOGLOBIN, V14, P1, DOI 10.3109/03630269009002250; ORKIN SH, 1992, BLOOD, V80, P575; Poncz M, 1988, Oxf Surv Eukaryot Genes, V5, P163; PORTER JB, 1990, SEMIN HEMATOL, V27, P95; ROSATELLI C, 1984, HEMOGLOBIN, V8, P25, DOI 10.3109/03630268408996958; ROSATELLI C, 1994, HEMATOL PATHOL, V8, P25; ROSATELLI MC, 1992, AM J HUM GENET, V50, P422; ROSATELLI MC, 1992, HUM GENET, V89, P585; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; THEIN SL, 1990, AM J HUM GENET, V47, P369; THEIN SL, 1988, BRIT J HAEMATOL, V70, P225, DOI 10.1111/j.1365-2141.1988.tb02468.x; THEIN SL, 1992, BRIT J HAEMATOL, V80, P273, DOI 10.1111/j.1365-2141.1992.tb08132.x; THEIN SL, 1993, BAILLIERE CLIN HAEM, V6, P151, DOI 10.1016/S0950-3536(05)80069-1; WEATHERALL DJ, 1991, NATURE, V349, P275, DOI 10.1038/349275a0; Weatherall DJ, 1981, THALASSEMIA SYNDROME; WILKIE AOM, 1990, AM J HUM GENET, V46, P1112; WOOD WG, 1993, BAILLIERE CLIN HAEM, V6, P177, DOI 10.1016/S0950-3536(05)80070-8	52	55	59	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1273	1277		10.1001/jama.278.15.1273	http://dx.doi.org/10.1001/jama.278.15.1273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333270				2022-12-24	WOS:A1997XZ70900034
J	Falvo, MR; Clary, GJ; Taylor, RM; Chi, V; Brooks, FP; Washburn, S; Superfine, R				Falvo, MR; Clary, GJ; Taylor, RM; Chi, V; Brooks, FP; Washburn, S; Superfine, R			Bending and buckling of carbon nanotubes under large strain	NATURE			English	Article							INSTABILITIES; FLEXIBILITY; ENERGETICS	The curling of a graphitic sheet to form carbon nanotubes(1) produces a class of materials that seem to have extraordinary electrical and mechanical properties(2). In particular, the high elastic modulus of the graphite sheets means that the nanotubes might be stiffer and stronger than and other known material(3-5), with beneficial consequences for their application in composite bulk materials and as individual elements of nanometre-scale devices and sensors(6). The mechanical properties are predicted to be sensitive to details of their structure and to the presence of defects(7), which means that measurements on individual nanotubes are essential to establish these properties. Here we show that multiwalled carbon nanotubes can be bent repeatedly through large angles using the tip of an atomic force microscope, without undergoing catastrophic failure. We observe a range of responses to this high-strain deformation, which together suggest that nanotubes are remarkably flexible and resilient.	UNIV N CAROLINA,DEPT PHYS & ASTRON,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT COMP SCI,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Superfine, Richard/A-1968-2012	Superfine, Richard/0000-0002-2569-071X				AXELRAD EL, 1985, INT J NONLINEAR MECH, V20, P249, DOI 10.1016/0020-7462(85)90033-2; CHOPRA NG, 1995, NATURE, V377, P135, DOI 10.1038/377135a0; Dai HJ, 1996, NATURE, V384, P147, DOI 10.1038/384147a0; DESPRES JF, 1995, CARBON, V33, P87, DOI 10.1016/0008-6223(95)91118-Q; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; EBBESEN TW, 1992, NATURE, V358, P220, DOI 10.1038/358220a0; EBBESEN TW, 1997, CARBON NANOTUBES PRE, P225; FINCH M, 1995, SURFACE MODIFICATION, P13; FRITSCH DS, 1994, INFORMATION PROCESSI, P365; Iijima S, 1996, J CHEM PHYS, V104, P2089, DOI 10.1063/1.470966; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; JU GT, 1992, INT J SOLIDS STRUCT, V29, P1143, DOI 10.1016/0020-7683(92)90140-O; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; LIEBER C, 1997, B AM PHYS SOC, V42, P591; Lu JP, 1997, PHYS REV LETT, V79, P1297, DOI 10.1103/PhysRevLett.79.1297; PIZER SM, IN PRESS COMPUT VISI; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; RUOFF RS, 1995, CARBON, V33, P925, DOI 10.1016/0008-6223(95)00021-5; RUOFF RS, 1995, RECENT ADV CHEM PHYS, V2; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R; TAYLOR RM, 1993, NANOMANIPULATOR VIRT, P127; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Yakobson BI, 1996, PHYS REV LETT, V76, P2511, DOI 10.1103/PhysRevLett.76.2511; Yakobson BI, 1997, COMP MATER SCI, V8, P341, DOI 10.1016/S0927-0256(97)00047-5; ZHOU O, 1994, SCIENCE, V263, P1744, DOI 10.1126/science.263.5154.1744	25	1324	1402	7	398	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					582	584		10.1038/39282	http://dx.doi.org/10.1038/39282			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335495				2022-12-24	WOS:A1997YA00800053
J	Kauhanen, J; Kaplan, GA; Goldberg, DE; Salonen, JT				Kauhanen, J; Kaplan, GA; Goldberg, DE; Salonen, JT			Beer binging and mortality: results from the Kuopio ischaemic heart disease risk factor study, a prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EASTERN FINNISH MEN; ACUTE MYOCARDIAL-INFARCTION; ALCOHOL-CONSUMPTION; PHYSICAL-ACTIVITY; CORONARY; WINE; DRINKERS	Objective: To examine the association between beer binging (regular sessions of heavy beer drinking) and mortality. Design: Prospective population based study with the baseline assessment of level of alcohol intake (dose), by type of drink and drinking pattern, previous and existing diseases, socioeconomic background, occupational status, involvement in organisations during leisure time, physical activity in leisure time, body mass index, blood pressure, serum lipids and plasma fibrinogen concentration, during an average of 7.7 years' follow up of mortality. Setting: Finland. Subjects: A population sample of 1641 men who consumed beer who were aged 42, 48, 54, or 60 years at baseline. Main outcome measures: All cause mortality, cardiovascular mortality, death due to external causes, fatal myocardial infarctions. Results: The risk of death was substantially increased in men whose usual dose of beer was 6 or more bottles per session compared with men who usually consumed less than 3 bottles, after adjustment forage and total alcohol consumption (relative risk 3.01 (95% confidence interval 1.54 to 5.90) for all deaths; 7.10 (2.01 to 25.12) for external deaths; and 6.50 (2.05 to 20.61) for fatal myocardial infarction). The association changed only slightly when smoking, occupational status, previous diseases, systolic blood pressure, low density lipoprotein and high density lipoprotein cholesterol concentration, plasma fibrinogen concentration, body mass index, marital status, leisure time physical activity, and involvement in organisations were controlled for. Conclusion: The pattern of beer binging is associated with increased risk of death, independently of the total average consumption of alcoholic drinks. The relation is not explained by known behavioural, psychosocial, or biological risk factors. Death due to injuries and other external causes is overrepresented.	UNIV KUOPIO, PUBL HLTH RES INST, FIN-70211 KUOPIO, FINLAND; UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA; HUMAN POPULAT LAB, BERKELEY, CA 94704 USA	University of Eastern Finland; University of Michigan System; University of Michigan	Kauhanen, J (corresponding author), UNIV KUOPIO, DEPT PUBL HLTH & GEN PRACTICE, BOX 1627, FIN-70211 KUOPIO, FINLAND.		Kauhanen, Jussi/ABC-4064-2021; Kaplan, George/AAJ-2398-2020		NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Cox D. R., 1984, ANAL SURVIVAL DATA; Dahlstrom, 1975, MMPI HDB RES APPL, V2; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; GAZIANO JM, 1995, BRIT MED J, V311, P3, DOI 10.1136/bmj.311.6996.3a; GREENFIELD TK, 1986, INT J ADDICT, V21, P1059, DOI 10.3109/10826088609077255; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Irgens-Jensen O, 1981, SIFA STENSILSERIE, V44; ISTVAN J, 1995, INT J EPIDEMIOL, V24, P543, DOI 10.1093/ije/24.3.543; JACKSON R, 1995, LANCET, V346, P716, DOI 10.1016/S0140-6736(95)91496-X; KAPLAN GA, 1994, EPIDEMIOLOGY, V5, P495; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; *OY ALKO AB, 1995, ALC STAT YB 1994; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; SALONEN JT, 1995, CIRCULATION, V91, P645, DOI 10.1161/01.CIR.91.3.645; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Simpura J, 1987, FINNISH DRINKING HAB, V35; *WHO, 1989, INT J EPIDEMIOL S1, V18, pS38; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676	28	198	202	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 4	1997	315	7112					846	851		10.1136/bmj.315.7112.846	http://dx.doi.org/10.1136/bmj.315.7112.846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA007	9353504	Green Published, Green Submitted			2022-12-24	WOS:A1997YA00700022
J	Chuang, LSH; Ian, HI; Koh, TW; Ng, HH; Xu, GL; Li, BFL				Chuang, LSH; Ian, HI; Koh, TW; Ng, HH; Xu, GL; Li, BFL			Human DNA (cytosine-5) methyltransferase PCNA complex as a target for p21(WAF1)	SCIENCE			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR SUPPRESSION; BINDING DOMAINS; POLYMERASE-III; HISTONE H1; REPLICATION; METHYLATION	DNA-(cytosine-5) methyltransferase (MCMT) methylates newly replicated mammalian DNA, but the factors regulating this activity are unknown. Here, MCMT is shown to bind proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA replication and repair. Binding of PCNA requires amino acids 163 to 174 of MCMT, occurs in intact cells at fool of newly replicated DNA, and does not alter MCMT activity. A peptide derived from the cell cycle regulator p21(WAF1) disrupt the MCMT-PCNA interaction, which suggests that p21(WAF1) may regulate methylation by blocking access of MCMT to PCNA, MCMT and p21(WAF1) may be linked in a regulatory pathway, because the extents of their expression are inversely related in both SV40-transformed and nontransformed cells.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,CHEM CARCINOGENESIS LAB,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,BIOSCI CTR,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore			Koh, Tong-Wey/M-3774-2013; Ng, Huck Hui/A-1135-2009	Koh, Tong-Wey/0000-0001-9136-3189; 				AYI TC, 1992, CANCER RES, V52, P6423; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Carotti D, 1996, BIOCHEMISTRY-US, V35, P11660, DOI 10.1021/bi9606051; CHEN YQ, 1995, CANCER RES, V55, P4536; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lim A, 1996, EMBO J, V15, P4050, DOI 10.1002/j.1460-2075.1996.tb00778.x; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Oh HK, 1996, BIOCHEMISTRY-US, V35, P12259, DOI 10.1021/bi9603635; PETERSON SR, 1995, CANCER RES, V55, P4651; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TAN NW, 1990, BIOCHEMISTRY-US, V29, P9234, DOI 10.1021/bi00491a018; TEO AKC, UNPUB; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996	43	707	733	8	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1996	2000		10.1126/science.277.5334.1996	http://dx.doi.org/10.1126/science.277.5334.1996			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302295				2022-12-24	WOS:A1997XX84900045
J	Coyne, KJ; Qin, XX; Waite, JH				Coyne, KJ; Qin, XX; Waite, JH			Extensible collagen in mussel byssus: A natural block copolymer	SCIENCE			English	Article							DRAGLINE SILK; PROTEINS; ELASTIN; CDNA; GENE; IDENTIFICATION; EVOLUTION; SEQUENCE; THREADS; FIBROIN	To adhere to solid surfaces, marine mussels produce byssal threads, each of which is a stiff tether at one end and a shock absorber with 160 percent extensibility at the other end. The elastic extensibility of proximal byssus is extraordinary given its construction of collagen and the limited extension (less than 10 percent) of most collagenous materials. From the complementary DNA, we deduced that the primary structure of a collagenous protein (preCol-P) predominating in the extensible proximal portion of the threads encodes an unprecedented natural block copolymer with three major domain types: a central collagen domain, flanking elastic domains, and histidine-rich terminal domains. The elastic domains have sequence motifs that strongly resemble those of elastin and the amorphous glycine-rich regions of spider silk fibroins. Byssal thread extensibility may be imparted by the elastic domains of preCol-P.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware	Coyne, KJ (corresponding author), UNIV DELAWARE,COLL MARINE STUDIES,NEWARK,DE 19716, USA.			Coyne, Kathryn/0000-0001-8846-531X				BAIRATI A, 1991, FORM FUNCTION ZOOLOG, P163; Bell EC, 1996, J EXP BIOL, V199, P1005; BELL EJ, UNPUB; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; BRYAN GW, 1979, J MAR BIOL ASSOC UK, V59, P969, DOI 10.1017/S0025315400036961; COOMBS TL, 1981, AQUAT TOXICOL, V1, P291, DOI 10.1016/0166-445X(81)90023-0; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Denny M. W., 1988, BIOL MECH WAVE SWEPT; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hall, 1981, POLYM MAT, DOI 10.1007/978-1-349-10187-0_4; HINMAN MB, 1992, J BIOL CHEM, V267, P19320; HUANG X, 1991, GENOMICS, V14, P18; JOHNSON KS, 1987, MOL BIOCHEM PARASIT, V22, P89, DOI 10.1016/0166-6851(87)90072-7; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LILIUS G, 1991, EUR J BIOCHEM, V198, P499, DOI 10.1111/j.1432-1033.1991.tb16042.x; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MELNICK SC, 1958, NATURE, V181, P1483, DOI 10.1038/1811483a0; Patwary MU, 1996, J SHELLFISH RES, V15, P265; PIKKARAINEN J, 1968, EUR J BIOCHEM, V4, P555, DOI 10.1111/j.1432-1033.1968.tb00248.x; Qin X., UNPUB; QIN XX, 1995, J EXP BIOL, V198, P633; RAJU K, 1987, J BIOL CHEM, V262, P5755; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; Rudall KM, 1955, S SOC EXP BIOL, V9, P49; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; SMEATHERS JE, 1979, J MOLLUS STUD, V49, P219; SMITH MC, 1987, INORG CHEM, V26, P1965, DOI 10.1021/ic00259a030; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; THIEL BL, 1995, MRS BULL, V20, P52, DOI 10.1557/S0883769400034941; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; VITELLAROZUCCARELLO L, 1983, TISSUE CELL, V15, P547, DOI 10.1016/0040-8166(83)90006-X; Waite J.H., 1992, Results and Problems in Cell Differentiation, V19, P27; WAITE JH, 1989, BIOCHEMISTRY-US, V28, P6104, DOI 10.1021/bi00440a056; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; [No title captured]	38	209	220	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1830	1832		10.1126/science.277.5333.1830	http://dx.doi.org/10.1126/science.277.5333.1830			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295275				2022-12-24	WOS:A1997XX29800049
J	Sun, ZS; Albrecht, U; Zhuchenko, O; Bailey, J; Eichele, G; Lee, CC				Sun, ZS; Albrecht, U; Zhuchenko, O; Bailey, J; Eichele, G; Lee, CC			RIGUI, a putative mammalian ortholog of the Drosophila period gene	CELL			English	Article							CIRCADIAN BEHAVIORAL RHYTHMS; SUPRACHIASMATIC NUCLEUS; PARS TUBERALIS; MELATONIN RECEPTORS; MESSENGER-RNA; CLOCK; PROTEIN; LIGHT; RAT; ZEITGEBERS	The molecular components of mammalian circadian clocks are elusive. We have isolated a human gene termed RIGUI that encodes a bHLH/PAS protein 44% homologous to Drosophila period. The highly conserved mouse homolog (m-rigui) is expressed in a circadian pattern in the suprachiasmatic nucleus (SCN), the master regulator of circadian clocks in mammals. Circadian expression in the SCN continues in constant darkness, and a shift in the light/dark cycle evokes a proportional shift of m-rigui expression in the SCN. m-rigui transcripts also appear in a periodic pattern in Purkinje neurons, pars tuberalis, and retina, but with a timing of oscillation different from that seen in the SCN. Sequence homology and circadian patterns of expression suggest that RIGUI is a mammalian ortholog of the Drosophila period gene, raising the possibility that a regulator of circadian clocks is conserved.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; MAX PLANCK INST EXPT ENDOCRINOL,D-30625 HANNOVER,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society			Sun, Zhongsheng/AAS-4883-2020; Jansen, Heiko T./A-5770-2008; Albrecht, Urs/A-9831-2011	Sun, Zhongsheng/0000-0002-7640-5026; Jansen, Heiko T./0000-0003-0178-396X; Albrecht, Urs/0000-0002-0663-8676				Albrecht U, 1997, MOL CELLULAR METHODS, P23; ARENDT J, 1987, CHRONOBIOL INT, V4, P273, DOI 10.3109/07420528709078534; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ASCHOFF J, 1969, AEROSPACE MED, V40, P844; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DEREVIERS MM, 1989, NEUROSCI LETT, V100, P89, DOI 10.1016/0304-3940(89)90665-4; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Fraschini F, 1993, LIGHT BIOL RHYTHMS M, P121; GOTO M, 1989, J PINEAL RES, V7, P195, DOI 10.1111/j.1600-079X.1989.tb00667.x; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; IJDO JW, 1992, GENOMICS, V14, P1019, DOI 10.1016/S0888-7543(05)80125-9; KALLIONIEMI OP, 1994, GENOMICS, V20, P125, DOI 10.1006/geno.1994.1138; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KRAFT M, 1995, DIS MON, V41, P501; LEE CC, 1995, HUM MOL GENET, V4, P1373, DOI 10.1093/hmg/4.8.1373; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; NAKAZAWA K, 1991, P NATL ACAD SCI USA, V88, P7576, DOI 10.1073/pnas.88.17.7576; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; SIWICKI KK, 1992, J NEUROGENET, V8, P33, DOI 10.3109/01677069209167270; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; STANKOV B, 1991, NEUROENDOCRINOLOGY, V53, P214, DOI 10.1159/000125721; Sun Z. S., 1996, American Journal of Human Genetics, V59, pA160; SWAAB DF, 1996, HYPOTHALAMIC INTEGRA, P349; TAKAHASHI JS, 1987, BRAIN RES, V405, P199, DOI 10.1016/0006-8993(87)91010-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Teicher MH, 1997, ARCH GEN PSYCHIAT, V54, P124; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vignau J, 1993, LIGHT BIOL RHYTHMS M, P261; WEAVER DR, 1990, ENDOCRINOLOGY, V127, P2607, DOI 10.1210/endo-127-5-2607; WEHR TA, 1996, HYPOTHALAMIC INTEGRA, P321; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	47	560	584	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1003	1011		10.1016/S0092-8674(00)80366-9	http://dx.doi.org/10.1016/S0092-8674(00)80366-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323128	Bronze			2022-12-24	WOS:A1997XX76800006
J	Debanne, D; Guerineau, NC; Gahwiler, BH; Thompson, SM				Debanne, D; Guerineau, NC; Gahwiler, BH; Thompson, SM			Action-potential propagation gated by an axonal I-A-like K+ conductance in hippocampus	NATURE			English	Article							SLICE CULTURES; POTASSIUM CURRENTS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; CELLS; CA3; MECHANISM; FREQUENCY; RELEASE	Integration of membrane-potential changes is traditionally reserved for neuronal somatodendritic compartments. Axons are typically considered to transmit reliably the result of this integration, the action potential(1), to nerve terminals(2,3). By recording from pairs of pyramidal cells in hippocampal slice cultures(4-6), we show here that the propagation of action potentials to nerve terminals is impaired if presynaptic action potentials are preceded by brief or tonic hyperpolarization. Action-potential propagation fails only when the presynaptic action potential is triggered within the first 15-20 ms of a depolarizing step from hyperpolarized potentials; action-potential propagation failures are blocked when presynaptic cells are impaled with electrodes containing 4-aminopyridine, indicating that a fast-inactivating, A-type K+ conductance is involved. Propagation failed between some, but not all, of the postsynaptic cells contacted by a single presynaptic cell, suggesting that the presynaptic action potentials failed at axonal branch points. We conclude that the physiological activation of an I-A-like potassium conductance can locally block propagation of presynaptic action potentials in axons of the central nervous system, Thus axons do not always behave as simple electrical cables: their capacity to transmit action potentials is determined by a time-dependent integration of recent membrane-potential changes.	UNIV ZURICH, BRAIN RES INST, CH-8029 ZURICH, SWITZERLAND	University of Zurich			Thompson, Scott M/K-8921-2015; Debanne, Dominique/O-4673-2016	Debanne, Dominique/0000-0001-8581-5695; Guerineau, Nathalie/0000-0003-2517-4210				Bossu JL, 1996, J PHYSIOL-LONDON, V495, P367, DOI 10.1113/jphysiol.1996.sp021600; Colbert CM, 1996, J NEUROSCI, V16, P6676; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; Eccles, 2013, PHYSL SYNAPSES; FROTSCHER M, 1988, NEUROSCIENCE, V24, P541, DOI 10.1016/0306-4522(88)90348-X; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; KOCSIS JD, 1986, BRAIN RES, V383, P357, DOI 10.1016/0006-8993(86)90040-5; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LUSCHER C, 1994, J NEUROPHYSIOL, V72, P622, DOI 10.1152/jn.1994.72.2.622; MacKenzie PJ, 1996, NEURON, V16, P783, DOI 10.1016/S0896-6273(00)80098-7; PARNAS I, 1972, J NEUROPHYSIOL, V35, P903, DOI 10.1152/jn.1972.35.6.903; PARNAS I, 1976, J NEUROPHYSIOL, V39, P909, DOI 10.1152/jn.1976.39.4.909; SEGEV I, 1990, J NEUROPHYSIOL, V63, P987, DOI 10.1152/jn.1990.63.5.987; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STEPHENS GJ, 1994, J PHYSIOL-LONDON, V477, P187, DOI 10.1113/jphysiol.1994.sp020183; Storm J. F., 1994, Society for Neuroscience Abstracts, V20, P1339; STORM JF, 1990, PROG BRAIN RES, V83, P161; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Vincent P, 1996, J PHYSIOL-LONDON, V494, P183, DOI 10.1113/jphysiol.1996.sp021484; WALL PD, 1995, TRENDS NEUROSCI, V18, P99, DOI 10.1016/0166-2236(95)93883-Y	21	221	221	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					286	289		10.1038/38502	http://dx.doi.org/10.1038/38502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305843				2022-12-24	WOS:A1997XW77200048
J	Nedelec, FJ; Surrey, T; Maggs, AC; Leibler, S				Nedelec, FJ; Surrey, T; Maggs, AC; Leibler, S			Self-organization of microtubules and motors	NATURE			English	Article							CHROMOSOME SEGREGATION; KINESIN; EXTRACTS; INVITRO; FORCE	Cellular structures are established and maintained through a dynamic interplay between assembly and regulatory processes. Self-organization of molecular components provides a variety of possible spatial structures: the regulatory machinery chooses the most appropriate to express a given cellular function(1). Here we study the extent and the characteristics of self-organization using microtubules and molecular motors(2) as a model system. These components are known to participate in the formation of many cellular structures, such as the dynamic asters found in mitotic and meiotic spindles(3,4). Purified motors and microtubules have previously been observed to form asters in vitro(5). We have reproduced this result with a simple system consisting solely of multi-headed constructs of the motor protein kinesin(6) and stabilized microtubules. We show that dynamic asters can also be obtained from a homogeneous solution of tubulin and motors. By varying the relative concentrations of the components, we obtain a variety of self-organized structures. Further, by studying this process in a constrained geometry of micro-fabricated glass chambers(7), we demonstrate that the same final structure can be reached through different assembly 'pathways'.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,LAB PHYSICOCHIM THEOR,F-75231 PARIS,FRANCE	Princeton University; Princeton University; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)			Nedelec, Francois/AAC-1673-2019; Nedelec, Francois J/H-3317-2011; Surrey, Thomas/AAC-4608-2021	Nedelec, Francois/0000-0002-8141-5288; Nedelec, Francois J/0000-0002-8141-5288; Surrey, Thomas/0000-0001-9082-1870				ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BAYER E, 1990, METHOD ENZYMOL, V184, P51; BERLINER E, 1994, J BIOL CHEM, V269, P8610; DOGTEROM M, 1993, PHYS REV LETT, V70, P1347, DOI 10.1103/PhysRevLett.70.1347; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; MAYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Rodionov VI, 1997, NATURE, V386, P170, DOI 10.1038/386170a0; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926; [No title captured]	29	615	624	2	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					305	308		10.1038/38532	http://dx.doi.org/10.1038/38532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305848				2022-12-24	WOS:A1997XW77200053
J	Feuchtgruber, H; Lellouch, E; deGraauw, T; Bezard, B; Encrenaz, T; Griffin, M				Feuchtgruber, H; Lellouch, E; deGraauw, T; Bezard, B; Encrenaz, T; Griffin, M			External supply of oxygen to the atmospheres of the giant planets	NATURE			English	Article							SHORT-PERIOD COMETS; MIXING RATIOS; NEPTUNE; SATURN; RINGS; URANUS; DUST; MODEL; CO; SPECTROMETER	The atmospheres of the giant planets are reducing, being mainly composed of hydrogen, helium and methane. But the rings and icy satellites that surround these planets, together with the flux of interplanetary dust, could act as important sources of oxygen, which would be delivered to the atmospheres mainly in the form of water ice or silicate dust(1-7). Here we report the detection, by infrared spectroscopy, of gaseous H2O in the upper atmospheres of Saturn, Uranus and Neptune. The implied H2O column densities are 1.5 x 10(15), 9 x 10(13) and 3 x 10(14) molecules cm(-2) respectively, CO2 in comparable amounts was also detected in the atmospheres of Saturn and Neptune, These observations can be accounted for by external fluxes of 10(5)-10(7) H2O molecules cm(-2) s(-1) and subsequent chemical processing in the atmospheres, The presence of gaseous water and infalling dust will affect the photochemistry, energy budget and ionospheric properties of these atmospheres. Moreover, our findings may help to constrain the injection rate and possible activity of distant icy objects in the Solar System.	OBSERV PARIS,DESPA,F-92195 MEUDON,FRANCE; MAX PLANCK INST EXTRATERR PHYS,D-85748 GARCHING,GERMANY; ESA,ISO,SCI OPERAT CTR,VILLAFRANCA 28080,SPAIN; SRON,NL-9700 AV GRONINGEN,NETHERLANDS; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Max Planck Society; University of London; Queen Mary University London				Bezard, Bruno/0000-0002-5433-5661				ATNEYA SK, 1990, URANUS, P110; Atreya S. K., 1984, SATURN, P239; BISHOP J, 1992, J GEOPHYS RES-PLANET, V97, P11681, DOI 10.1029/92JE00959; BISHOP J, 1990, ICARUS, V88, P448, DOI 10.1016/0019-1035(90)90094-P; BROADFOOT AL, 1986, SCIENCE, V233, P74, DOI 10.1126/science.233.4759.74; COLWELL JE, 1992, J GEOPHYS RES-PLANET, V97, P10227, DOI 10.1029/92JE00788; COLWELL JE, 1990, GEOPHYS RES LETT, V17, P1741, DOI 10.1029/GL017i010p01741; COLWELL JE, 1990, ICARUS, V86, P530, DOI 10.1016/0019-1035(90)90232-X; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CROVISIER J, 1993, ASTEROIDS COMETS MET, P313; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; deGraauw T, 1997, ASTRON ASTROPHYS, V321, pL13; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; FERNANDEZ JA, 1985, ICARUS, V64, P308; Foryta DW, 1996, ICARUS, V123, P129, DOI 10.1006/icar.1996.0146; FOUCHET T, 1996, B AM ASTRON SOC, V28, P1129; GRUN E, 1994, ASTRON ASTROPHYS, V286, P915; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HUBBARD WB, UNPUB ICARUS; HUMES DH, 1980, J GEOPHYS RES-SPACE, V85, P5841, DOI 10.1029/JA085iA11p05841; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; Lara LM, 1996, J GEOPHYS RES-PLANET, V101, P23261, DOI 10.1029/96JE02036; LELLOUCH E, 1996, COLLISION COMET SHOE, P213; MAJEED T, 1991, PLANET SPACE SCI, V39, P1715, DOI 10.1016/0032-0633(91)90031-5; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MOSES JI, 1992, ICARUS, V99, P368, DOI 10.1016/0019-1035(92)90153-X; NOLL KS, 1990, ICARUS, V89, P168; NORTHROP TG, 1993, J GEOPHYS RES, V88, P6102; PRATHER MJ, 1978, ASTROPHYS J, V223, P1072, DOI 10.1086/156340; QUINN T, 1990, ASTROPHYS J, V355, P667, DOI 10.1086/168800; RIZK B, 1990, ICARUS, V88, P429, DOI 10.1016/0019-1035(90)90093-O; ROMANI PN, 1993, ICARUS, V106, P442, DOI 10.1006/icar.1993.1184; ROSENQVIST J, 1992, ASTROPHYS J, V392, pL99, DOI 10.1086/186435; SAMUELSON RE, 1983, J GEOPHYS RES-SPACE, V88, P8709, DOI 10.1029/JA088iA11p08709; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SMITH GR, 1983, J GEOPHYS RES-SPACE, V88, P8667, DOI 10.1029/JA088iA11p08667; STROBEL DF, 1979, ICARUS, V37, P256, DOI 10.1016/0019-1035(79)90130-1; STROBEL DF, 1990, URANUS, P65; WINKELSTEIN P, 1983, ICARUS, V54, P309, DOI 10.1016/0019-1035(83)90200-2	40	163	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					159	162		10.1038/38236	http://dx.doi.org/10.1038/38236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296492				2022-12-24	WOS:A1997XV75700041
J	Schnell, MJ; Johnson, JE; Buonocore, L; Rose, JK				Schnell, MJ; Johnson, JE; Buonocore, L; Rose, JK			Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; G-PROTEIN; RECEPTOR; EXPRESSION; GENE; GLYCOPROTEIN; FUSION; SYSTEM; ENTRY	We describe a recombinant vesicular stomatitis virus lacking its glycoprotein gene and expressing instead the HIV-1 receptor CD4 and a coreceptor, CXCR4. This virus was unable to infect normal cells but did infect, propagate on, and kill cells that were first infected with HIV-1 and therefore had the HIV membrane fusion protein on their surface. Killing of HIV-l-infected cells controlled HIV infection in a T cell line and reduced titers of infectious HIV-1 in the culture by as much as 10(4)-fold. Such a targeted virus could have therapeutic value in reducing HIV viral load. Our results also demonstrate a general strategy of targeting one virus to the envelope protein of another virus to control infection.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Schnell, Matthias/0000-0001-9040-9405	NIAID NIH HHS [AI24345, AI49235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI049235, R01AI024345, R01AI049235, R37AI024345] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Johnson JE, 1997, J VIROL, V71, P5060, DOI 10.1128/JVI.71.7.5060-5068.1997; KNIPE DM, 1977, J VIROL, V21, P1149, DOI 10.1128/JVI.21.3.1149-1158.1977; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; REED L. J., 1938, AMER JOUR HYG, V27, P493; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schuitemaker H, 1996, AIDS, V10 Suppl A, pS25, DOI 10.1097/00002030-199601001-00004; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner RR., 1996, FIELDS VIROLOGY, V1, P1121; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	34	184	206	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					849	857		10.1016/S0092-8674(00)80350-5	http://dx.doi.org/10.1016/S0092-8674(00)80350-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298897	hybrid			2022-12-24	WOS:A1997XV56300006
J	Wawryk, A; Mavromatis, C; Gold, M				Wawryk, A; Mavromatis, C; Gold, M			Electronic monitoring of vaccine cold chain in a metropolitan area	BRITISH MEDICAL JOURNAL			English	Article							STORAGE	Successful immunisation strategies depend on the provision of immunogenic vaccines and the correct manufacture and storage of those vaccines, Studies in developed and developing countries have shown that vaccines are stored inadequately and that the vaccine cold chain can be disrupted.(1 2) We measured the temperature of vaccines stored long term in a metropolitan area of a developed country using electronic data loggers to determine how long vaccines had been exposed to temperatures < 0 degrees C.	WOMENS & CHILDRENS HOSP,DEPT PAEDIAT,ADELAIDE,SA,AUSTRALIA; CHILD & YOUTH HLTH,ADELAIDE,SA 5000,AUSTRALIA	Womens & Childrens Hospital Australia								LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; MCLEAN AA, 1982, ANN INTERN MED, V97, P451, DOI 10.7326/0003-4819-97-3-451_1; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756; *WHO, 1980, EPIDEMIOL REC, V50, P385	4	16	18	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 30	1997	315	7107					518	518		10.1136/bmj.315.7107.518	http://dx.doi.org/10.1136/bmj.315.7107.518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU506	9329306	Green Published			2022-12-24	WOS:A1997XU50600018
J	Joseph, S; Weiser, B; Noller, HF				Joseph, S; Weiser, B; Noller, HF			Mapping the inside of the ribosome with an RNA helical ruler	SCIENCE			English	Article							PEPTIDYL TRANSFERASE CENTER; ESCHERICHIA-COLI RIBOSOME; SEQUENCE-SPECIFIC CLEAVAGE; ANTICODON INTERACTION SITE; P-SITE; PROTEIN-SYNTHESIS; CROSS-LINKING; 70S RIBOSOMES; 16-S RNA; 16S RNA	The structure of ribosomal RNA (rRNA) in the ribosome was probed with hydroxyl radicals generated locally from iron(II) tethered to the 5' ends of anticodon stem-loop analogs (ASLs) of transfer RNA. The ASLs, ranging in length from 4 to 33 base pairs, bound to the ribosome in a messenger RNA-dependent manner and directed cleavage to specific regions of the 16S, 23S, and 5S rRNA chains. The positions and intensities of cleavage depended on whether the ASLs were bound to the ribosomal A or P site, and on the lengths of their stems, These data predict the three-dimensional locations of the rRNA targets relative to the positions of A- and P-site transfer RNAs inside the ribosome.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, RNA, CTR MOL BIOL, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V48, P1392, DOI 10.1016/0006-291X(72)90867-4; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRIMACOMBE R, 1988, JMB, V199, P155; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; DERIEMER LH, 1981, J LABELLED COMPD RAD, V18, P1517, DOI 10.1002/jlcr.2580181017; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968; Fink DL, 1996, RNA, V2, P851; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GORNICKI P, 1984, J BIOL CHEM, V259, P493; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; HAN HY, 1994, P NATL ACAD SCI USA, V91, P4955, DOI 10.1073/pnas.91.11.4955; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; JOSEPH S, UNPUB; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LEVIEV I, 1995, NUCLEIC ACIDS RES, V23, P1512; MERRYMAN C, UNPUB; MITCHELL P, 1993, NUCLEIC ACIDS RES, V21, P887, DOI 10.1093/nar/21.4.887; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; PAULSEN H, 1983, J MOL BIOL, V167, P411, DOI 10.1016/S0022-2836(83)80342-8; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P12565, DOI 10.1021/bi00165a004; POGOZELSKI WK, 1995, J AM CHEM SOC, V117, P6428, DOI 10.1021/ja00129a002; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RINKE AJ, 1995, RNA, V1, P1018; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SANTER M, 1990, P NATL ACAD SCI USA, V87, P3700, DOI 10.1073/pnas.87.10.3700; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; SUNDARALINGAM M, 1975, P101; TAPPRICH WE, 1989, P NATL ACAD SCI USA, V86, P4927, DOI 10.1073/pnas.86.13.4927; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; TULLIUS TD, 1991, FREE RADICAL RES COM, V12-3, P521; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; VASSILENKO SK, 1981, J MOL BIOL, V152, P699, DOI 10.1016/0022-2836(81)90123-6; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5	61	76	76	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	1997	278	5340					1093	1098		10.1126/science.278.5340.1093	http://dx.doi.org/10.1126/science.278.5340.1093			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353184				2022-12-24	WOS:A1997YE65200043
J	Dixon, AK; Coulden, RA				Dixon, AK; Coulden, RA			Coronary artery calcification on computed tomography	LANCET			English	Editorial Material							CT SCANS; QUANTIFICATION				Dixon, AK (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT RADIOL,CAMBRIDGE CB2 2QQ,ENGLAND.							AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; BREEN JF, 1992, RADIOLOGY, V185, P435, DOI 10.1148/radiology.185.2.1410350; Callaway MP, 1997, BRIT J RADIOL, V70, P572, DOI 10.1259/bjr.70.834.9227248; DIXON AK, 1984, CLIN RADIOL, V35, P33, DOI 10.1016/S0009-9260(84)80228-7; ELKELES A, 1957, LANCET, V2, P714; KAUFMANN RB, 1994, RADIOLOGY, V190, P347, DOI 10.1148/radiology.190.2.8284380; MCCARTHY JH, 1974, BRIT HEART J, V36, P499; MOORE EH, 1989, RADIOLOGY, V172, P711, DOI 10.1148/radiology.172.3.2772178; Reinmuller R, 1987, DYNAMIC CARDIOVASCUL, V1, P139; Shemesh J, 1996, RADIOLOGY, V199, P665, DOI 10.1148/radiology.199.3.8637984; SHEMESH J, 1995, RADIOLOGY, V197, P779, DOI 10.1148/radiology.197.3.7480756; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	12	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1265	1265		10.1016/S0140-6736(05)62470-1	http://dx.doi.org/10.1016/S0140-6736(05)62470-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357403				2022-12-24	WOS:A1997YD68900005
J	Hudson, C; Clements, D; Friday, RV; Stott, D; Woodland, HR				Hudson, C; Clements, D; Friday, RV; Stott, D; Woodland, HR			Xsox17 alpha and -beta mediate endoderm formation in Xenopus	CELL			English	Article							IN-SITU HYBRIDIZATION; MESODERM INDUCTION; TRANSCRIPTIONAL REPRESSION; TRUNCATED ACTIVIN; GROWTH-FACTORS; EXPRESSION; LAEVIS; EMBRYOS; GENES; PROTEIN	We have isolated two Xenopus relatives of murine Sox17 expressed in gastrula presumptive endoderm. Xsox17 alpha and -beta expression can be induced in animal caps by activin, but not by FGF. Ectopic expression of these genes in animal caps induces the expression of endoderm markers; this induction is blocked by overexpression of a fusion of the Xsox17 beta HMG domain to the Drosophila Engrailed repressor domain, as is induction of endoderm markers by activin and the expression of endodermal markers in whole embryos and isolated vegetal poles. These experiments, as well as the effects of the mRNAs on embryo phenotypes, suggest that the Xsox17 genes mediate an activin-induced endoderm differentiation pathway in animal caps and are involved in normal endoderm differentiation in embryos.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick			Hudson, Clare/X-7618-2019	Hudson, Clare/0000-0003-1585-8328	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Conlon FL, 1996, DEVELOPMENT, V122, P2427; COOK JP, 1993, BIOCONJUGATE CHEM, V4, P440, DOI 10.1021/bc00024a005; DEMARTIS A, 1994, MECH DEVELOP, V47, P19, DOI 10.1016/0925-4773(94)90092-2; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fan MJ, 1997, DEVELOPMENT, V124, P2581; GAMER LW, 1995, DEV BIOL, V171, P240, DOI 10.1006/dbio.1995.1275; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Henry GL, 1996, DEVELOPMENT, V122, P1007; Horb ME, 1997, DEVELOPMENT, V124, P1689; HOSKING BM, 1995, NUCLEIC ACIDS RES, V23, P2626, DOI 10.1093/nar/23.14.2626; Islam N, 1996, TRENDS GENET, V12, P459, DOI 10.1016/0168-9525(96)99990-4; JOHN A, 1995, DEVELOPMENT, V121, P1801; JONES EA, 1993, ROUX ARCH DEV BIOL, V202, P233, DOI 10.1007/BF02427884; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KNOCHEL W, 1986, J MOL EVOL, V23, P211, DOI 10.1007/BF02115578; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; LUKYANOV SA, 1994, BIOORG KHIM+, V20, P701; Prior HM, 1996, MOL MED, V2, P405, DOI 10.1007/BF03401900; RICHARDSON JC, 1995, MECH DEVELOP, V52, P165, DOI 10.1016/0925-4773(95)00388-H; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Smith ST, 1996, DEVELOPMENT, V122, P3141; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; Weber H, 1996, DEVELOPMENT, V122, P1975; WILSON C, 1986, CELL, V47, P589, DOI 10.1016/0092-8674(86)90623-9; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2	44	304	323	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					397	405		10.1016/S0092-8674(00)80423-7	http://dx.doi.org/10.1016/S0092-8674(00)80423-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363948	Bronze			2022-12-24	WOS:A1997YD94100013
J	Lin, VSY; Motesharei, K; Dancil, KPS; Sailor, MJ; Ghadiri, MR				Lin, VSY; Motesharei, K; Dancil, KPS; Sailor, MJ; Ghadiri, MR			A porous silicon-based optical interferometric biosensor	SCIENCE			English	Article							GENE-EXPRESSION; ARRAYS; MICROARRAY; POLYMER; SURFACE	A biosensor has been developed based on induced wavelength shifts in the Fabry-Perot fringes in the visible-light reflection spectrum of appropriately derivatized thin films of porous silicon semiconductors. Binding of molecules induced changes in the refractive index of the porous silicon. The validity and sensitivity of the system are demonstrated for small organic molecules (biotin and digoxigenin), 16-nucleotide DNA oligomers, and proteins (streptavidin and antibodies) at pico- and femtomolar analyte concentrations. The sensor is also highly effective for detecting single and multilayered molecular assemblies.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Sailor, Michael J/H-9044-2017	Sailor, Michael J/0000-0002-4809-9826	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM047165] Funding Source: NIH RePORTER; NIGMS NIH HHS [2SO6 GM47165-06, GM18309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bard A. J., 1980, ELECTROCHEMICAL METH; BARNARD SM, 1991, SCIENCE, V251, P927, DOI 10.1126/science.2000492; BRECHT A, 1995, BIOSENS BIOELECTRON, V10, P923, DOI 10.1016/0956-5663(95)99230-I; BRECHT A, 1997, FRONTIERS BIOSENSORI, V2, P1; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; DOAN VV, 1992, SCIENCE, V256, P1791, DOI 10.1126/science.256.5065.1791; Ferguson JA, 1996, NAT BIOTECHNOL, V14, P1681, DOI 10.1038/nbt1296-1681; GOPEL W, 1989, SENSORS UPDATE, V1; HEMENWAY BR, 1989, APPL PHYS LETT, V55, P349, DOI 10.1063/1.101905; HICKMAN JJ, 1991, SCIENCE, V252, P688, DOI 10.1126/science.252.5006.688; Kittel C, 1986, INTRO SOLID STATE PH; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; Motohashi A, 1996, JPN J APPL PHYS 1, V35, P4253, DOI 10.1143/JJAP.35.4253; NEU DR, 1993, J PHYS CHEM-US, V97, P5713, DOI 10.1021/j100123a041; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; RIKLIN A, 1995, NATURE, V376, P672, DOI 10.1038/376672a0; Rossi B. B., 1957, OPTICS; ROWELL FJ, 1991, BIOCHEM SOC T, V19, P32, DOI 10.1042/bst0190032; SCHECHTER I, 1995, ANAL CHEM, V67, P3727, DOI 10.1021/ac00116a018; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; STIEVENARD D, 1995, APPL PHYS LETT, V67, P1570, DOI 10.1063/1.114942; Watanabe K, 1996, SENSOR ACTUAT B-CHEM, V33, P194, DOI 10.1016/0925-4005(96)80097-9	25	1137	1317	9	382	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					840	843		10.1126/science.278.5339.840	http://dx.doi.org/10.1126/science.278.5339.840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346478				2022-12-24	WOS:A1997YD47900040
J	Skinner, PJ; Koshy, BT; Cummings, CJ; Klement, IA; Helin, K; Servadio, A; Zoghbi, HY; Orr, HT				Skinner, PJ; Koshy, BT; Cummings, CJ; Klement, IA; Helin, K; Servadio, A; Zoghbi, HY; Orr, HT			Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures	NATURE			English	Article							SPINOCEREBELLAR ATAXIA; COILED BODY; TYPE-1; LOCALIZATION; ONCOPROTEIN; EXPRESSION; REPEAT; CELLS; GENE	Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative disorders caused by an expansion of a polyglutamine tract(1,2). It is characterized by ataxia, progressive motor deterioration, and loss of cerebellar Purkinje cells(1). To understand the pathogenesis of SCA1, we examined the subcellular localization of wild-type human ataxin-1 (the protein encoded by the SCA1 gene) and mutant ataxin-1 in the Purkinje cells of transgenic mice(3). We found that ataxin-1 localizes to the nuclei of cerebellar Purkinje cells, Normal ataxin-1 localizes to several nuclear structures similar to 0.5 mu m across, whereas the expanded ataxin-1 localizes to a single similar to 2-mu m structure, before the onset of ataxia. Mutant ataxin-1 localizes to a single nuclear structure in affected neurons of SCA1 patients. Similarly, COS-1 cells transfected with wild-type or mutant ataxin-1 show a similar pattern of nuclear localization; with expanded ataxin-1 occurring in larger structures that are fewer in number than those of normal ataxin-1. Colocalization studies show that mutant ataxin-1 causes a specific redistribution of the nuclear matrix-associated domain containing promyelocytic leukaemia protein(4-7). Nuclear matrix preparations demonstrate that ataxin-1 associates with the nuclear matrix in Purkinje and COS cells. We therefore propose that a critical aspect of SCA1 pathogenesis involves the disruption of a nuclear matrix-associated domain.	UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CELL & MOL BIOL PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Orr, Harry/0000-0001-6118-741X; Skinner, Pamela/0000-0003-3388-1687; Zoghbi, Huda/0000-0002-0700-3349; Helin, Kristian/0000-0003-1975-6097	Telethon [TGM06S01, 38/B] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDRADE LEC, 1993, P NATL ACAD SCI USA, V90, P1947, DOI 10.1073/pnas.90.5.1947; [Anonymous], ADV NEUROL; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; BISOTTO S, 1995, J CELL SCI, V108, P1873; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; CHAN EKL, 1994, NUCLEIC ACIDS RES, V22, P4462, DOI 10.1093/nar/22.21.4462; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Dhordain P, 1995, ONCOGENE, V11, P2689; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATILLA A, UNPUB P NATL ACAD SC; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; ROBITAILLE Y, 1995, ACTA NEUROPATHOL, V90, P572; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cb.09.110193.001405; STUURMAN N, 1992, J CELL SCI, V101, P773; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TELLEZNAGEL I, 1974, J NEUROPATH EXP NEUR, V33, P308, DOI 10.1097/00005072-197404000-00008; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZOGHBI HY, 1995, SEMIN CELL BIOL, V6, P29, DOI 10.1016/1043-4682(95)90012-8	29	470	479	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					971	974		10.1038/40153	http://dx.doi.org/10.1038/40153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353120				2022-12-24	WOS:A1997YD29900056
J	Holtz, JH; Asher, SA				Holtz, JH; Asher, SA			Polymerized colloidal crystal hydrogel films as intelligent chemical sensing materials	NATURE			English	Article							N-ISOPROPYLACRYLAMIDE; RESPONSIVE POLYMERS; PHASE-TRANSITIONS; GELS; POLY(N-ISOPROPYLACRYLAMIDE); DIFFRACTION; KINETICS; WATER; TEMPERATURE; SEPARATION	Chemical sensors' respond to the presence of a specific analyte in a variety of ways, One of the most convenient is a change in optical properties, and in particular a visually perceptible colour change. Here we report the preparation of a material that changes colour in response to a chemical signal by means of a change in diffraction (rather than absorption) properties. Our material is a crystalline colloidal array(2-12) of polymer spheres (roughly 100 nm diameter) polymerized within a hydrogel(13,14) that swells and shrinks reversibly in the presence of certain analytes (here metal ions and glucose). The crystalline colloidal array diffracts light at (visible) wavelengths determined by the lattice spacing(2-12), which gives rise to an intense colour. The hydrogel contains either a molecular-recognition group that binds the analyte selectively (crown ethers for metal ions), or a molecular-recognition agent that reacts with the analyte selectively. These recognition events cause the gel to swell owing to an increased osmotic pressure, which increases the mean separation between the colloidal spheres and so shifts the Bragg peak of the diffracted light to longer wavelengths. We anticipate that this strategy can be used to prepare 'intelligent' materials responsive to a wide range of analytes, including viruses.	UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								AASTUEN DJW, 1986, PHYS REV LETT, V57, P1733, DOI 10.1103/PhysRevLett.57.1733; ACKERSON BJ, 1981, PHYS REV LETT, V46, P123, DOI 10.1103/PhysRevLett.46.123; Asher S.A., 1986, Patent No. [US4632517A, 4632517]; Asher S.A., 1986, SPECTROSCOPY, V1, P26; ASHER SA, 1994, J AM CHEM SOC, V116, P4997, DOI 10.1021/ja00090a059; ASHER SA, 1986, Patent No. 4627689; CARLSON RJ, 1984, APPL SPECTROSC, V38, P297, DOI 10.1366/0003702844555548; CLARK NA, 1979, NATURE, V281, P57, DOI 10.1038/281057a0; DUBEY RK, 1995, TALANTA, V42, P65, DOI 10.1016/0039-9140(94)00217-G; DUSEK K, 1993, ADV POLYM SCI, V109; DUSEK K, 1993, ADV POLYM SCI, V110; FILLMORE DJ, 1979, J CHEM PHYS, V70, P1214; FLORY J, 1953, PRINCIPLES POLYM SCI; FUJISHIGE S, 1989, J PHYS CHEM-US, V93, P3311, DOI 10.1021/j100345a085; GEHRKE SH, 1986, CHEM ENG SCI, V41, P2153, DOI 10.1016/0009-2509(86)87131-7; GEHRKE SH, 1993, ADV POLYM SCI, V110, P81; GRIMSHAW PE, 1989, CHEM ENG SCI, V44, P827, DOI 10.1016/0009-2509(89)85256-X; HAKIKI A, 1994, J CHEM PHYS, V101, P9054, DOI 10.1063/1.468034; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI DOI 10.1080/10601326808051910; HILTNER PA, 1969, J PHYS CHEM-US, V73, P2386, DOI 10.1021/j100727a049; HILTNER PA, 1971, J PHYS CHEM-US, V75, P1881, DOI 10.1021/j100681a020; HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; HURD AJ, 1982, PHYS REV A, V26, P2869, DOI 10.1103/PhysRevA.26.2869; IRIE M, 1993, ADV POLYM SCI, V110, P49; IRIE M, 1993, POLYMER, V34, P4531, DOI 10.1016/0032-3861(93)90160-C; IZATT RM, 1976, J AM CHEM SOC, V98, P7626, DOI 10.1021/ja00440a029; JANATA J, 1989, PRINCIPLES CHEM SENS; KATAOKA K, 1994, MACROMOLECULES, V27, P1061, DOI 10.1021/ma00082a028; KATAOKA K, 1995, MACROMOLECULES, V28, P3336, DOI 10.1021/ma00113a038; Khokhlov AR, 1996, MACROMOLECULES, V29, P681, DOI 10.1021/ma946426d; KOPOLOW S, 1973, MACROMOLECULES, V6, P133; KRIEGER IM, 1968, J AM CHEM SOC, V90, P3114, DOI 10.1021/ja01014a025; KUBOTA K, 1990, J PHYS CHEM-US, V94, P5154, DOI 10.1021/j100375a070; LI Y, 1990, J CHEM PHYS, V92, P1365, DOI 10.1063/1.458148; MCCURLEY MF, 1994, BIOSENS BIOELECTRON, V9, P527, DOI 10.1016/0956-5663(94)90015-9; OKANO T, 1993, ADV POLYM SCI, V110, P179; OSADA Y, 1993, PROG POLYM SCI, V18, P187, DOI 10.1016/0079-6700(93)90025-8; PETERS A, 1986, MACROMOLECULES, V19, P1952, DOI 10.1021/ma00161a029; Popov A.I., 1979, COORDINATION CHEM MA; RABA J, 1995, CRIT REV ANAL CHEM, V25, P1, DOI 10.1080/10408349508050556; RUNDQUIST PA, 1989, J CHEM PHYS, V91, P4932, DOI 10.1063/1.456734; Savage M.D., 1992, AVIDIN BIOTIN CHEM H; SCHALKHAMMER T, 1995, SENSOR ACTUAT B-CHEM, V24, P166, DOI 10.1016/0925-4005(95)85036-8; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; SHEPPARD NF, 1995, SENSOR ACTUAT B-CHEM, V28, P95, DOI 10.1016/0925-4005(94)01542-P; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820; WANG KL, 1993, ADV POLYM SCI, V110, P67; Weissman JM, 1996, SCIENCE, V274, P959, DOI 10.1126/science.274.5289.959; YOKOI K, 1995, ANAL CHIM ACTA, V316, P363, DOI 10.1016/0003-2670(95)00375-A; ZEN JM, 1994, ANAL CHIM ACTA, V296, P77, DOI 10.1016/0003-2670(94)85152-2	50	1713	1789	57	1385	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 23	1997	389	6653					829	832		10.1038/39834	http://dx.doi.org/10.1038/39834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349814				2022-12-24	WOS:A1997YC14800051
J	WeverlingRijnsburger, AWE; Blauw, GJ; Lagaay, AM; Knook, DL; Meinders, AE; Westendorp, RGJ				WeverlingRijnsburger, AWE; Blauw, GJ; Lagaay, AM; Knook, DL; Meinders, AE; Westendorp, RGJ			Total cholesterol and risk of mortality in the oldest old	LANCET			English	Article							POPULATION-BASED SURVEY; SERUM-CHOLESTEROL; MYOCARDIAL-INFARCTION; FOLLOW-UP; AGED 85; PRAVASTATIN; CANCER; TRANSPLANTATION; ASSOCIATION; MORBIDITY	Background The impact of total serum cholesterol as a risk factor for cardiovascular disease decreases with age, which casts doubt on the necessity for cholesterol-lowering therapy in the elderly. We assessed the influence of total cholesterol concentrations on specific and all-cause mortality in people aged 85 years and over. Methods In 724 participants (median age 89 years), total cholesterol concentrations were measured and mortality risks calculated over 10 years of follow-up. Three categories of total cholesterol concentrations were defined <5.0 mmol/L, 5.0-6.4 mmol/L, and greater than or equal to 6.5 mmol/L. In a subgroup of 137 participants, total cholesterol was measured again after 5 years of follow-up. Mortality risks for the three categories of total cholesterol concentrations were estimated with a Cox proportional-hazards model, adjusted for age, sex, and cardiovascular risk factors. The primary causes of death were coded according to the International Classification of Diseases (ICD-9). Findings During 10 years of follow-up from Dec 1, 1986, to Oct 1, 1996, a total of 642 participants died. Each 1 mmol/L increase in total cholesterol corresponded to a 15% decrease in mortality (risk ratio 0.85 [95% CI 0.79-0.91]). This risk estimate was similar in the subgroup of participants who had stable cholesterol concentrations over a 5-year period. The main cause of death was cardiovascular disease with a similar mortality risk in the three total cholesterol categories. Mortality from cancer and infection was significantly lower among the participants in the highest total cholesterol category than in the other categories, which largely explained the lower all-cause mortality in this category. Interpretation in people older than 85 years, high total cholesterol concentrations are associated with longevity owing to lower mortality from cancer and infection. The effects of cholesterol-lowering therapy have yet to be assessed.	LEIDEN UNIV,MED CTR,DEPT CLIN EPIDEMIOL,NL-2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	WeverlingRijnsburger, AWE (corresponding author), LEIDEN UNIV,MED CTR,DEPT GEN INTERNAL MED,SECT GERONTOL & GERIATR,POB 9600,C1-R45,NL-2300 RC LEIDEN,NETHERLANDS.		Blauw, Gerard/AAW-7904-2021; Blauw, Gerard/GWD-1079-2022					*AM ASS CLIN CHEM, 1994, GER CLIN CHEM REF VA, P312; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; Corti MC, 1997, ANN INTERN MED, V126, P753, DOI 10.7326/0003-4819-126-10-199705150-00001; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; DelgadoRodriguez M, 1997, INFECT CONT HOSP EP, V18, P9; DEVRIES CL, 1993, CARDIOLOGY, V82, P89, DOI 10.1159/000175861; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; Katznelson S, 1996, TRANSPLANTATION, V61, P1469, DOI 10.1097/00007890-199605270-00010; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; KROMHOUT D, 1988, ARCH INTERN MED, V148, P1051, DOI 10.1001/archinte.148.5.1051; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; LAGAAY AM, 1992, ARCH GERONTOL GERIAT, V15, P115, DOI 10.1016/0167-4943(92)90012-S; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Netea MG, 1996, J CLIN INVEST, V97, P1366, DOI 10.1172/JCI118556; OLDHAM PD, 1962, J CHRON DIS, V15, P969, DOI 10.1016/0021-9681(62)90116-9; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; Sharp SJ, 1997, EPIDEMIOLOGY, V8, P132, DOI 10.1097/00001648-199703000-00002; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; World Health Organization, 1977, INT CLASS DIS; Zureik M, 1997, EPIDEMIOLOGY, V8, P137, DOI 10.1097/00001648-199703000-00003; 1995, LANCET, V333, P1301	27	362	377	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1119	1123		10.1016/S0140-6736(97)04430-9	http://dx.doi.org/10.1016/S0140-6736(97)04430-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343498				2022-12-24	WOS:A1997YB19900008
J	Klumpp, M; Baumeister, W; Essen, LO				Klumpp, M; Baumeister, W; Essen, LO			Structure of the substrate binding domain of the thermosome, an archaeal group II chaperonin	CELL			English	Article							T-COMPLEX POLYPEPTIDE-1; CYTOSOLIC CHAPERONIN; MOLECULAR CHAPERONE; THERMOPHILIC ARCHAEBACTERIUM; CYTOPLASMIC CHAPERONIN; EUKARYOTIC CYTOSOL; CRYSTAL-STRUCTURE; BETA-ACTIN; HEAT-SHOCK; PROTEIN	The crystal structure of the substrate binding domain of the thermosome, the archaeal group II chaperonin, has been determined at 2.3 Angstrom resolution. The core resembles the apical domain of GroEL but lacks the hydrophobic residues implied in binding of substrates to group I chaperonins. Rather, a large hydrophobic surface patch is found in a novel helix-turn-helix motif, which is characteristic of all group II chaperonins including the eukaryotic TRiC/CCT complex. Models of the holochaperonin, which are consistent with cryo electron microscopy data, suggest a dual role of this helical protrusion in substrate binding and controlling access to the central cavity independent of a GroES-like cochaperonin.	MAX PLANCK INST BIOCHEM,DEPT MOL STRUCT BIOL,D-82152 PLANEGG,GERMANY; MAX PLANCK INST BIOCHEM,DEPT MEMBRANE BIOCHEM,D-82152 PLANEGG,GERMANY	Max Planck Society; Max Planck Society			Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Klumpp, Martin/0000-0003-3373-9605				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BRUNGER AT, 1992, XPLOR VERSION 3 1; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; ELLIS J, 1992, NATURE, V358, P191, DOI 10.1038/358191a0; ELLIS RJ, 1996, ACTA CRYSTALLOGR A, V47, P392; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hegerl R, 1996, J STRUCT BIOL, V116, P30, DOI 10.1006/jsbi.1996.0006; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WALDMANN T, 1995, BIOL CHEM H-S, V376, P119, DOI 10.1515/bchm3.1995.376.2.119; WALDMANN T, 1995, FEBS LETT, V376, P67, DOI 10.1016/0014-5793(95)01248-8; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; Willison Keith R., 1996, P107, DOI 10.1016/B978-012237455-5/50006-3; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; Zahn R, 1996, P NATL ACAD SCI USA, V93, P15024, DOI 10.1073/pnas.93.26.15024	44	137	140	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					263	270		10.1016/S0092-8674(00)80408-0	http://dx.doi.org/10.1016/S0092-8674(00)80408-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346243	Bronze			2022-12-24	WOS:A1997YC35000013
J	Groux, H; OGarra, A; Bigler, M; Rouleau, M; Antonenko, S; deVries, JE; Roncarolo, MG				Groux, H; OGarra, A; Bigler, M; Rouleau, M; Antonenko, S; deVries, JE; Roncarolo, MG			A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis	NATURE			English	Article							T-HELPER-2 POPULATIONS; INTERLEUKIN-10 IL-10; MICE; PROLIFERATION; STIMULATION; EXPRESSION; CLONES; ANERGY	Induction and maintenance of peripheral tolerance are important mechanisms to maintain the balance of the immune system. In addition to the deletion of T cells and their failure to respond in certain circumstances, active suppression mediated by T cells or T-cell factors has been proposed as a mechanism for maintaining peripheral tolerance(1). However, the inability to isolate and clone regulatory T cells involved in antigen-specific inhibition of immune responses has made it difficult to understand the mechanisms underlying such active suppression. Here we show that chronic activation of both human and murine CD4(+) T cells in the presence of interleukin (IL)-10 gives rise to CD4(+) T-cell clones with low proliferative capacity, producing high levels of IL-10, low levels of IL-2 and no IL-4. These antigen-specific T-cell clones suppress the proliferation of CD4(+) T cells in response to antigen, and prevent colitis induced in SCID mice by pathogenic CD4(+)CD45RB(high) splenic T cells. Thus IL-10 drives the generation of a CD4(+) T-cell subset, designated T regulatory cells 1 (Tr1), which suppresses antigen-specific immune responses and actively downregulates a pathological immune response in vivo.	DNAX RES INST MOL & CELLULAR BIOL INC, DEPT HUMAN IMMUNOL, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Rouleau, Matthieu/D-5774-2016	Rouleau, Matthieu/0000-0002-0075-9880; O'Garra, Anne/0000-0001-9845-6134; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABRAMOWICZ D, 1993, TRANSPLANT P, V25, P312; ALLEN RD, 1993, EUR J IMMUNOL, V23, P333, DOI 10.1002/eji.1830230205; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; BLAZAR BR, 1995, BLOOD, V85, P842, DOI 10.1182/blood.V85.3.842.bloodjournal853842; Cannella B, 1996, J NEUROSCI RES, V45, P735, DOI 10.1002/(SICI)1097-4547(19960915)45:6<735::AID-JNR10>3.0.CO;2-V; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; GORCZYNSKI RM, 1994, J IMMUNOL, V152, P2011; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; HAU HS, 1996, J AUTOIMMUN, V9, P331; JENKINS MK, 1990, J IMMUNOL, V144, P16; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEE MS, 1994, J CLIN INVEST, V93, P1332, DOI 10.1172/JCI117092; MALEFYT RD, 1991, J EXP MED, V174, P915; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NISITANI S, 1995, EUR J IMMUNOL, V25, P3047, DOI 10.1002/eji.1830251110; Nossal G J, 1987, Int Rev Immunol, V2, P321, DOI 10.3109/08830188709044760; OGarra A, 1996, CHEM IMMUNOL, V63, P1; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; POWRIE F, 1993, INT IMMUNOL, V5, P1461, DOI 10.1093/intimm/5.11.1461; RENNICK D, 1995, INTERLEUKIN 10, P141; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUZUKI T, 1995, J EXP MED, V182, P477, DOI 10.1084/jem.182.2.477; Weiner HL, 1996, FASEB J, V10, pA1444; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	30	2964	3123	2	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	1997	389	6652					737	742		10.1038/39614	http://dx.doi.org/10.1038/39614			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338786				2022-12-24	WOS:A1997YA95900057
J	Kothakota, S; Azuma, T; Reinhard, C; Klippel, A; Tang, J; Chu, KT; McGarry, TJ; Kirschner, MW; Koths, K; Kwiatkowski, DJ; Williams, LT				Kothakota, S; Azuma, T; Reinhard, C; Klippel, A; Tang, J; Chu, KT; McGarry, TJ; Kirschner, MW; Koths, K; Kwiatkowski, DJ; Williams, LT			Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; ICE/CED-3 PROTEASE; ACTIN; CELLS; INHIBITION; SUBSTRATE; IDENTIFICATION; PLASMA; CED-3; MICE	The caspase-3 (CPP32, apopain, YAMA) family of cysteinyl proteases has been implicated as key mediators of apoptosis in mammalian cells, Gelsolin was identified as a substrate for caspase-3 by screening the translation products of small complementary DNA pools for sensitivity to cleavage by caspase-3. Gelsolin was cleaved in vivo in a caspase-dependent manner in cells stimulated by Fas. Caspase-cleaved gelsolin severed actin filaments in vitro in a Ca2+-independent manner, Expression of the gelsolin cleavage product in multiple cell types caused the cells to round up, detach from the plate, and undergo nuclear fragmentation. Neutrophils isolated from mice lacking gelsolin had delayed onset of both blebbing and DNA fragmentation, following apoptosis induction, compared with wild-type neutrophils. Thus, cleaved gelsolin may be one physiological effector of morphologic change during apoptosis.	CHIRON CORP,EMERYVILLE,CA 94608; BRIGHAM & WOMENS HOSP,DIV EXPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Novartis; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [P01 HL48743, R01 HL54188] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048743, R01HL054188] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Asch HL, 1996, CANCER RES, V56, P4841; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DIEFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HUCKRIEDE A, 1990, CELL MOTIL CYTOSKEL, V16, P229, DOI 10.1002/cm.970160403; Janicke RU, 1996, MOL CELL BIOL, V16, P5245; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; King RW, 1997, SCIENCE, V277, P973, DOI 10.1126/science.277.5328.973; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; KWIATKOWSKI DJ, UNPUB; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Song QZ, 1997, P NATL ACAD SCI USA, V94, P157, DOI 10.1073/pnas.94.1.157; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TAKEDA Y, 1993, INT IMMUNOL, V5, P691, DOI 10.1093/intimm/5.6.691; TANAKA M, 1995, CANCER RES, V55, P3228; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WEEDS AG, 1991, BIOCHEM SOC T, V19, P1016, DOI 10.1042/bst0191016; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	37	978	1013	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 10	1997	278	5336					294	298		10.1126/science.278.5336.294	http://dx.doi.org/10.1126/science.278.5336.294			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323209				2022-12-24	WOS:A1997YA56400046
J	Tsuneizumi, K; Nakayama, T; Kamoshida, Y; Kornberg, TB; Christian, JL; Tabata, T				Tsuneizumi, K; Nakayama, T; Kamoshida, Y; Kornberg, TB; Christian, JL; Tabata, T			Daughters against dpp modulates dpp organizing activity in Drosophila wing development	NATURE			English	Article							PATTERN; PROTEIN; MORPHOGEN; HEDGEHOG; XENOPUS; EXPRESSION; MESODERM; MOTHERS; FAMILY; GENES	The family of TGF-beta signalling molecules play inductive roles in various developmental contexts(1). One member of this family, Drosophila Decapentaplegic (Dpp)(2) serves as a morphogen that patterns both the embryo(3,1) and adult(4,5). We have now isolated a gene, Daughters against dpp (Dad), whose transcription is induced by Dpp, Dad shares weak homology with Drosophila Mad (Mothers against dpp)(6), a protein required for transduction of Dpp signals. In contrast to Mad or the activated Dpp receptor, whose overexpression hyperactivates the Dpp signalling pathway, overexpression of Dad blocks Dpp activity, Expression of Dad together with either Mad or the activated receptor rescues phenotypic defects induced by each protein alone. Dad can also antagonize the activity of a vertebrate homologue of Dpp, bone morphogenetic protein (BMP-4; ref. 7), as evidenced by induction of dorsal or neural fate following overexpression in Xenopus embryos. We conclude that the pattern-organizing mechanism governed by Dpp involves a negative-feedback circuit in which Dpp induces expression of its own antagonist, Dad, This feedback loop appears to be conserved in vertebrate development.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,TOKYO 113,JAPAN; OREGON HLTH SCI UNIV,DEPT CELL & DEV BIOL,PORTLAND,OR 97201; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of Tokyo; Oregon Health & Science University; University of California System; University of California San Francisco			Nakayama, Takuya/J-5812-2015	Nakayama, Takuya/0000-0002-5531-6710				BLITZ IL, 1995, DEVELOPMENT, V121, P993; BRAND AH, 1993, DEVELOPMENT, V118, P401; Burke R, 1996, DEVELOPMENT, V122, P2261; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; Ferguson EL, 1996, CURR OPIN GENET DEV, V6, P424, DOI 10.1016/S0959-437X(96)80063-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ito K, 1997, DEVELOPMENT, V124, P761; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAI CJ, 1995, DEVELOPMENT, V121, P2349; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MACIASSILVA M, 1997, CELL, V87, P1215; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Moon R. T., 1989, TECHNIQUE, V1, P76; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; ZECCA M, 1995, DEVELOPMENT, V121, P2265	32	346	352	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					627	631		10.1038/39362	http://dx.doi.org/10.1038/39362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335506				2022-12-24	WOS:A1997YA00800066
J	Garbe, E; LeLorier, J; Boivin, JF; Suissa, S				Garbe, E; LeLorier, J; Boivin, JF; Suissa, S			Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids	LANCET			English	Article							INTRAOCULAR-PRESSURE	Background Ocular hypertension and open-angle glaucoma are well-known side-effects of treatment with topical ophthalmic glucocorticoids. There is uncertainty about the risk of these disorders with oral glucocorticoid therapy. Methods Data from the Quebec universal health insurance programme for the elderly were used to identify 9793 patients with a new diagnosis of ocular hypertension or open-angle glaucoma, or on newly prescribed treatment for these disorders (cases). 38 325 controls were randomly selected from ophthalmology patients seen in the same month and year as the case (index date). Current use of oral glucocorticoids was defined as that within 14 days of the index date. All glucocorticoid doses were converted to the equivalent amount of hydrocortisone. The case-control analysis was done by conditional logistic regression and adjusted for age, sex, systemic hypertension, diabetes mellitus, ophthalmic glucocorticoids, glucocorticoid injections, and variables related to general health. Findings The mean ages of cases and controls were similar (74.9 [SD 6.3] vs 74.7 [6.4]). The adjusted odds ratio of ocular hypertension or open-angle glaucoma for current users of oral glucocorticoids compared with non-users was 1.41 (95% CI 1.22-1.63). There was a dose-related increase in the adjusted odds ratios for current users: 1.26 (1.01-1.56) for less than 40 mg per day of hydrocortisone, 1.37 (1.06-1.76) for patients on 40-79 mg per day, and 1.88 (1.40-2.53) for patients on 80 mg or more per day. The odds ratios also increased with the duration of treatment over the first 11 months of exposure. Interpretation The use of oral glucocorticoids increases the risk of ocular hypertension or open-angle glaucoma in elderly patients. In patients in this age-group who need long-term treatment with high doses of oral glucocorticoids, monitoring of intraocular pressure may be justified.	ROYAL VICTORIA HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ H3A 2T5,CANADA; UNIV MONTREAL,HOTEL DIEU,CTR RECH,MONTREAL,PQ H3C 3J7,CANADA; POTSDAM INST PHARMACOEPIDEMIOL & TECHNOL ASSESSME,POTSDAM,GERMANY	McGill University; Royal Victoria Hospital; McGill University; Laval University; Universite de Montreal								ABEL R, 1987, AVERYS DRUG TREATMEN, P387; ADHIKARY HP, 1982, BRIT J OPHTHALMOL, V66, P290, DOI 10.1136/bjo.66.5.290; ALFANO JE, 1963, AM J OPHTHALMOL, V56, P245, DOI 10.1016/0002-9394(63)91858-0; ARMALY MF, 1986, GLAUCOMA, P697; BECKER B, 1963, ARCH OPHTHALMOL-CHIC, V70, P500; BERNSTEIN HN, 1962, ARCH OPHTHALMOL-CHIC, V68, P742; CLARK WG, 1992, GOTHS MED PHARM, P773; DAVID DS, 1969, LANCET, V2, P149; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GODEL V, 1972, ACTA OPHTHALMOL, V50, P655; HAYNES R C JR, 1990, P1431; Hodapp EA, 1982, SECONDARY GLAUCOMAS, P258; KITAZAWA Y, 1976, AM J OPHTHALMOL, V82, P492, DOI 10.1016/0002-9394(76)90500-6; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEE PF, 1958, AM J OPHTHALMOL, V46, P328, DOI 10.1016/0002-9394(58)90256-3; LESKE MC, 1983, AM J EPIDEMIOL, V118, P166, DOI 10.1093/oxfordjournals.aje.a113626; LONG WF, 1977, AM J OPTOM PHYS OPT, V54, P248; QUIGLEY HA, 1993, NEW ENGL J MED, V328, P1097, DOI 10.1056/NEJM199304153281507; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P87; Skuta GL, 1996, GLAUCOMAS, P1177; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; STERN JJ, 1953, AM J OPHTHALMOL, V36, P389, DOI 10.1016/0002-9394(53)91389-0; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; WEINREB RN, 1981, INVEST OPHTH VIS SCI, V21, P403; *WHO, 1977, 9 REV C 1975; WILLIAMSON J, 1969, BRIT J OPHTHALMOL, V53, P361, DOI 10.1136/bjo.53.6.361	27	111	113	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					979	982		10.1016/S0140-6736(97)03392-8	http://dx.doi.org/10.1016/S0140-6736(97)03392-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329512				2022-12-24	WOS:A1997XZ71000008
J	Liem, KF; Tremml, G; Jessell, TM				Liem, KF; Tremml, G; Jessell, TM			A role for the roof plate and its resident TGF beta-related proteins in neuronal patterning in the dorsal spinal cord	CELL			English	Article							NEURAL CREST CELLS; BONE MORPHOGENETIC PROTEIN-4; FLOOR PLATE; SONIC HEDGEHOG; VERTEBRATE DEVELOPMENT; NERVOUS-SYSTEM; MOTOR-NEURONS; EXPRESSION; ACTIVIN; DIFFERENTIATION	Distinct neuronal cell types are generated at characteristic times and positions in the dorsal horn of the spinal cord. We provide evidence that the identity and pattern of generation of dorsal neurons depend initially on BMP-mediated signals that derive from the epidermal ectoderm and induce dorsal midline cells of the roof plate. Roof plate cells provide a secondary source of TGF beta-related signals that are required for the generation of distinct classes of dorsal interneurons. These inductive interactions involve both qualitative and quantitative differences in signaling by TGF beta-related factors and temporal changes in the response of neural progenitor cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOPHYS,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10021	Columbia University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN J, 1984, DEV RAT SPINAL CORD; Arkell R, 1997, DEVELOPMENT, V124, P1; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1994, FASEB J, V8, P699, DOI 10.1096/fasebj.8.10.8050668; Brown AG, 1981, ORG SPINAL CORD; CARPENTER EM, 1992, DEV BIOL, V150, P144, DOI 10.1016/0012-1606(92)90014-8; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Dudley AT, 1997, DEV DYNAM, V208, P349; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; Eichmann A, 1997, MECH DEVELOP, V65, P111, DOI 10.1016/S0925-4773(97)00063-4; EIDE AL, 1997, ANAT EMBRYOL, V197, P195; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Gale NW, 1996, ONCOGENE, V13, P1343; GURDON JB, 1994, NATURE, V225, P40; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LEBER SM, 1995, J NEUROSCI, V15, P1236; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOURY JD, 1990, DEV BIOL, V141, P243, DOI 10.1016/0012-1606(90)90380-2; MUHR J, 1997, IN PRESS NEURON; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NEWGREEN DF, 1986, INT REV CYTOL, V103, P89, DOI 10.1016/S0074-7696(08)60834-7; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PITUELLO F, 1995, P NATL ACAD SCI USA, V92, P6952, DOI 10.1073/pnas.92.15.6952; PUOPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Reilly KM, 1996, CELL, V86, P743, DOI 10.1016/S0092-8674(00)80149-X; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SELLECK MAJ, 1995, DEVELOPMENT, V121, P525; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	62	457	465	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					127	138		10.1016/S0092-8674(01)80015-5	http://dx.doi.org/10.1016/S0092-8674(01)80015-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335341	Bronze			2022-12-24	WOS:A1997XZ80900015
J	Nunn, AJ; Mulder, DW; Kamali, A; Ruberantwari, A; KengeyaKayondo, JF; Whitworth, J				Nunn, AJ; Mulder, DW; Kamali, A; Ruberantwari, A; KengeyaKayondo, JF; Whitworth, J			Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE PROGRESSION; HOMOSEXUAL MEN; AFRICAN CITY; AIDS; IMMUNODEFICIENCY; SURVIVAL; SEX; AGE; SEROCONVERSION; HEMOPHILIACS	Objective: To assess the impact of HIV-1 infection on mortality over five years in a rural Ugandan population. Design: Longitudinal cohort study followed up annually by a house to house census and medical survey. Setting: Rural population in south west Uganda. Subjects: About 10 000 people from 15 villages who were enrolled in 1989-90 or later. Main outcome measures: Number of deaths from all causes, death rates, mortality fraction attributable to HIV-1 infection. Results: Of 9777 people resident in the study area in 1989-90, 8833 (90%) had an unambiguous result on testing for HIV-1 antibody; throughout the period of follow up adult seroprevalence was about 8%. During 35 083 person years of follow up, 459 deaths occurred, 273 in seronegative subjects and 186 in seropositive subjects, corresponding to standardised death rates of 8.1 and 129.3 per 1000 person years. Standardised death rates for adults were 10.4 (95% confidence interval 9.0 to 11.8) and 114.0 (93.2 to 134.8) per 1000 person years respectively, The mortality fraction attributable to HIV-1 infection was 41% for adults and was in excess of 70% for men aged 25-44 and women aged 20-44 years. Median survival from time of enrolment was less than three years in subjects aged 55 years or more who were infected with HIV-1. Life expectancy from birth in the total population resident at any time was estimated to be 42.5 years (41.4 years in men; 43.5 years in women), which compares with 58.3 years (56.5 years in men; 60.5 years in women) in people known to be seronegative. Conclusions: These data confirm that in a rural African population HIV-1 infection is associated with high death rates and a substantial reduction in life expectancy.	UGANDA VIRUS RES INST, MED RES PROGRAMME AIDS, ENTEBBE, UGANDA; UNIV AMSTERDAM, ACAD MED CTR, INST SOCIAL MED, NL-1105 AZ AMSTERDAM, NETHERLANDS; MRC, AIDS PROGRAMME, ENTEBBE, UGANDA	Uganda Virus Research Institute; University of Amsterdam; Academic Medical Center Amsterdam	Nunn, AJ (corresponding author), UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND.			Nunn, Andrew/0000-0002-9158-4595				ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BLATT SP, 1995, J INFECT DIS, V171, P837, DOI 10.1093/infdis/171.4.837; BORGDORFF MW, 1995, GENITOURIN MED, V71, P212; BULTERYS M, 1993, AIDS, V7, P1269, DOI 10.1097/00002030-199309000-00019; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DONDERO TJ, 1994, LANCET, V343, P989, DOI 10.1016/S0140-6736(94)90120-1; Duesberg P, 1996, BRIT MED J, V312, P210; DUESBERG PH, 1995, LANCET, V346, P1371, DOI 10.1016/S0140-6736(95)92389-6; DUESBERG PH, 1995, GENETICA, V95, P51, DOI 10.1007/BF01435001; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; Low N, 1996, GENITOURIN MED, V72, P12; MANN JM, 1986, JAMA-J AM MED ASSOC, V255, P3255, DOI 10.1001/jama.255.23.3255; MARTIN JN, 1995, AM J EPIDEMIOL, V142, P1221, DOI 10.1093/oxfordjournals.aje.a117581; MELNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915, DOI 10.1001/jama.272.24.1915; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; NUNN AJ, 1994, METHOD INFORM MED, V33, P170; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; PHILLIPS AN, 1994, AIDS, V8, P831, DOI 10.1097/00002030-199406000-00017; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; Sabin CA, 1996, BMJ-BRIT MED J, V312, P207, DOI 10.1136/bmj.312.7025.207; SCHECHTER MT, 1995, J ACQ IMMUN DEF SYND, V8, P474, DOI 10.1097/00042560-199504120-00007; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014	33	99	99	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	1997	315	7111					767	771						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY911	9345167	Green Submitted, Green Published			2022-12-24	WOS:A1997XY91100016
J	Lin, K; Dorman, JB; Rodan, A; Kenyon, C				Lin, K; Dorman, JB; Rodan, A; Kenyon, C			daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans	SCIENCE			English	Article							C-ELEGANS; INTERACTING GENES; DAUER FORMATION; LONGEVITY; SEQUENCE; AGE-1; PATHWAY; HEAD	The wild-type Caenorhabditis elegans nematode ages rapidly, undergoing development, senescence, and death in less than 3 weeks. In contrast, mutants with reduced activity of the gene daf-2 a homolog of the insulin and insulin-like growth factor receptors, age more slowly than normal and live more than twice as long, These mutants are active and fully fertile and have normal metabolic rates. The life-span extension caused by daf-2 mutations requires the activity of the gene daf-16. daf-16 appears to play a unique role in life-span regulation and encodes a member of the hepatocyte nuclear factor 3 (HNF-3)/forkhead family of transcriptional regulators, In humans, insulin down-regulates the expression of certain genes by antagonizing the activity of HNF-3, raising the possibility that aspects of this regulatory system have been conserved.			Lin, K (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Rodan, Aylin/0000-0001-9202-2378	NATIONAL INSTITUTE ON AGING [R01AG011816, R37AG011816] Funding Source: NIH RePORTER; NIA NIH HHS [AG11816] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APFELD J, UNPUB; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DORMAN JB, 1995, GENETICS, V141, P1399; Finch CE, 1990, LONGEVITY SENESCENCE; Flakoll Paul, 1996, P121; FRIEDMAN DB, 1988, GENETICS, V118, P75; FROHMAN MA, 1993, METHOD ENZYMOL, V28, P341; GOTTLIEB S, 1994, GENETICS, V137, P107; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kenyon C, 1996, CELL, V84, P501, DOI 10.1016/S0092-8674(00)81024-7; KENYON C, 1997, C ELEGANS, V2, P791; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LARSEN PL, 1995, GENETICS, V139, P1567; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1996, DIABETES MELLITUS, P234; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Plasterk Ronald H.A., 1997, Cold Spring Harbor Monograph Series, V33, P97; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL, 1997, C ELEGANS, P739; Smeal T, 1997, CURR OPIN GENET DEV, V7, P281, DOI 10.1016/S0959-437X(97)80139-6; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Vanfleteren JR, 1996, J EXP ZOOL, V274, P93, DOI 10.1002/(SICI)1097-010X(19960201)274:2&lt;93::AID-JEZ2&gt;3.0.CO;2-8; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VOWELS JJ, 1992, GENETICS, V130, P105; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381	33	1188	1217	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1319	1322		10.1126/science.278.5341.1319	http://dx.doi.org/10.1126/science.278.5341.1319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9360933				2022-12-24	WOS:A1997YG04300052
J	Anderson, DM; Schneewind, O				Anderson, DM; Schneewind, O			A mRNA signal for the type III secretion of Yop proteins by Yersinia enterocolitica	SCIENCE			English	Article							TARGET-CELL CONTACT; GENETIC-ANALYSIS; TRANSPOSON TN5; EXPORT; TRANSLOCATION; MACROPHAGES; EXPRESSION; BACTERIAL; CYTOSOL; DOMAINS	Pathogenic Yersinia species have a specialized secretion system (type III) to target cytotoxic Yap proteins during infection. The signals of YopE and YopN sufficient for the secretion of translational reporter fusions were mapped to the first 15 codons, No common amino acid or peptide sequence could be identified among the secretion signals. Systematic mutagenesis of the secretion signal yielded mutants defective in Yop translation; however, no point mutants could be identified that specifically abolished secretion. Frameshift mutations that completely altered the peptide sequences of these signals also failed to prevent secretion. Thus, the signal that leads to the type III secretion of Yop proteins appears to be encoded in their messenger RNA rather than the peptide sequence.	UNIV CALIF LOS ANGELES,INST MOL BIOL,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles					NIAID NIH HHS [AI 07323] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENSON SA, 1985, ANNU REV BIOCHEM, V54, P101; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; CRICK FH, 1961, NATURE, V192, P1227, DOI 10.1038/1921227a0; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PORTNOY DA, 1981, INFECT IMMUN, V31, P775, DOI 10.1128/IAI.31.2.775-782.1981; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REISS B, 1984, EMBO J, V3, P3317, DOI 10.1002/j.1460-2075.1984.tb02297.x; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; Schesser K, 1996, J BACTERIOL, V178, P7227, DOI 10.1128/jb.178.24.7227-7233.1996; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	23	257	265	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 7	1997	278	5340					1140	1143		10.1126/science.278.5340.1140	http://dx.doi.org/10.1126/science.278.5340.1140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE652	9353199				2022-12-24	WOS:A1997YE65200058
J	Daaka, Y; Luttrell, LM; Lefkowitz, RJ				Daaka, Y; Luttrell, LM; Lefkowitz, RJ			Switching of the coupling of the beta(2)-adrenergic receptor to different G proteins by protein kinase A	NATURE			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-ADRENERGIC-RECEPTOR; MAP KINASE; BETA-2-ADRENERGIC RECEPTOR; DEPENDENT ACTIVATION; SIGNALING PATHWAYS; PERTUSSIS-TOXIN; TYROSINE-KINASE; GAMMA-SUBUNITS; FIBROBLASTS	Many of the G-grotein-coupled receptors for hormones that bind to the cell surface can signal to the interior of the cell through several different classes of G protein(1-4). Far example, although most of the actions of the prototype beta(2)-adrenergic receptor are mediated through G(s) proteins and thr cyclic-AMP-dependent protein kinase (PKA) system(5,6), beta-adrenergis receptors can also couple to G(i) proteins(1,2). Here we investigate the mechanism that controls the specificity of this coupling. We show that in HEK293 cells, stimulation of mitogen-activated protein (MAP) kinase by the beta(2)-adrenergic receptor is mediated by the beta gamma subunits of pertussis-toxin-sensitive G proteins through a pathway involving the non-receptor tyrosine kinase c-Src and the G protein Ras, Activation of this pathway by the beta(2)-adrenergic receptor requires that the receptor be phosphorylated by PKA because it is blocked by H-89, an inhibitor of PKA. Additionally, a mutant of the receptor, which lacks the sites normally phosphorylated by PKA, can activate adenylyl cyclase(5), the enzyme that generates cAMP, but not MAP kinase. Our results demonstrate that a mechanism previously shown to mediate uncoupling of the beta(2)-adrenergic receptor from G(s) and thus heterologous desensitization(7) (PKA-mediated receptor phosphorylation), also serves to 'switch' coupling of this receptor from G(s) to G(i) and initiate a new set of signalling events.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949				ABRAMSON SN, 1988, BIOCHEM PHARMACOL, V37, P4289, DOI 10.1016/0006-2952(88)90609-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; FAURE M, 1994, J BIOL CHEM, V269, P7851; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; HARWOOD SJ, 1996, BIOCHEM BIOPH RES CO, V224, P734; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krueger KM, 1997, J BIOL CHEM, V272, P5; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; STRULOVICI B, 1984, SCIENCE, V225, P837, DOI 10.1126/science.6089331; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; XIAO RP, 1995, MOL PHARMACOL, V47, P322	28	1027	1045	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					88	91		10.1038/36362	http://dx.doi.org/10.1038/36362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363896				2022-12-24	WOS:A1997YE47700058
J	Fenczik, CA; Sethi, T; Ramos, JW; Hughes, PE; Ginsberg, MH				Fenczik, CA; Sethi, T; Ramos, JW; Hughes, PE; Ginsberg, MH			Complementation of dominant suppression implicates CD98 in integrin activation	NATURE			English	Article							OUT SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; MOLECULAR-CLONING; CELL-ADHESION; RECEPTOR; PROTEINS; BINDING; EXPRESSION; MONOCYTES; SURFACE	The integrin family of adhesion receptors are involved in cell growth, migration and tumour metastasis(1). Integrins are heterodimeric proteins composed of an alpha and a beta subunit, each with a large extracellular, a single transmembrane, and a short cytoplasmic domain. The dynamic regulation of integrin affinity for ligands in response to cellular signals is central to integrin function(2). This process is energy dependent and is mediated through integrin cytoplasmic domains(3). However, the cellular machinery regulating integrin affinity remains poorly understood. Here we describe a genetic strategy to disentangle integrin signalling pathways. Dominant suppression occurs when overexpression of isolated integrin beta(1) cytoplasmic domains blocks integrin activation. Proteins involved in integrin signalling were identified by their capacity to complement dominant suppression in an expression cloning scheme. CD98, an early T-cell activation antigen that associates with functional integrins(4), was found to regulate integrin activation. Furthermore, antibody-mediated crosslinking of CD98 stimulated beta(1) integrin-dependent cell adhesion. These data indicate that CD98 is involved in regulating integrin affinity, and validate an unbiased genetic approach to analysing integrin signalling pathways.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV EDINBURGH, SCH MED, DEPT RESP MED, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Scripps Research Institute; University of Edinburgh			Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115	NCI NIH HHS [F32 CA074529-01, F32 CA074529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA074529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CHEN YP, 1994, J BIOL CHEM, V269, P18307; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HIRASAWA M, 1994, BRIT J CANCER, V70, P466, DOI 10.1038/bjc.1994.329; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INDIG FE, IN PRESS BIOCH J, V326; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MANNION BA, UNPUB FUNCTIONALLY A; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; [No title captured]	25	242	244	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					81	85		10.1038/36349	http://dx.doi.org/10.1038/36349			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363894				2022-12-24	WOS:A1997YE47700056
J	Dogterom, M; Yurke, B				Dogterom, M; Yurke, B			Measurement of the force-velocity relation for growing microtubules	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; THERMAL FLUCTUATIONS; DYNAMIC INSTABILITY; FLEXURAL RIGIDITY; VARIABLE RATES; CELL MOTILITY; MOLECULE; DEPOLYMERIZATION; DRIVEN; MOTOR	Forces generated by protein polymerization are important for various forms of cellular motility. Assembling microtubules, for instance, are believed to exert pushing forces on chromosomes during mitosis. The force that a single microtubule can generate was measured by attaching microtubules to a substrate at one end and causing them lo push against a microfabricated rigid barrier at the other end. The subsequent buckling of the microtubules was analyzed to determine both the force on each microtubule end and the growth velocity. The growth velocity decreased from 1.2 micrometers per minute at zero force to 0.2 micrometer per minute at forces of 3 to 4 piconewtons. The force-velocity relation fits well to a decaying exponential, in agreement with theoretical models, but the rate of decay is faster than predicted.	AT&T BELL LABS, LUCENT TECHNOL, MURRAY HILL, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs								[Anonymous], 1987, LINEAR AGGREGATION T; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; DOGTEROM M, UNPUB; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Elbaum M, 1996, PHYS REV LETT, V76, P4078, DOI 10.1103/PhysRevLett.76.4078; Felgner H, 1996, J CELL SCI, V109, P509; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Fygenson DK, 1997, PHYS REV E, V55, P850, DOI 10.1103/PhysRevE.55.850; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; Gittes F, 1996, BIOPHYS J, V70, P418, DOI 10.1016/S0006-3495(96)79585-1; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Hotani H, 1990, Adv Biophys, V26, P135, DOI 10.1016/0065-227X(90)90010-Q; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, NATURE, V359, P533, DOI 10.1038/359533a0; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; INOUE S, 1967, J GEN PHYSIOL, V50, P529; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; KURZ JC, 1995, BIOCHEMISTRY-US, V34, P13374, DOI 10.1021/bi00041a014; Landau LD, 1986, THEORY ELASTICITY, DOI 10.1016/C2009-0-25521-8; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; SVOBODA K, 1994, CELL, V77, P733; VENLER P, 1994, J BIOL CHEM, V169, P13353; VENLER P, 1995, J BIOL CHEM, V270, P17056; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; WATERMANSTORER CM, 1995, J CELL BIOL, V130, P1161, DOI 10.1083/jcb.130.5.1161	35	395	401	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					856	860		10.1126/science.278.5339.856	http://dx.doi.org/10.1126/science.278.5339.856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346483				2022-12-24	WOS:A1997YD47900045
J	Webb, BL; Cox, MM; Inman, RB				Webb, BL; Cox, MM; Inman, RB			Recombinational DNA repair: The RecF and RecR proteins limit the extension of RecA filaments beyond single-strand DNA gaps	CELL			English	Article							ESCHERICHIA-COLI RECF; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BINDING-PROTEIN; NUCLEOSIDE TRIPHOSPHATE; DUPLEX DNA; EXCHANGE; PURIFICATION; COMPLEXES; PATHWAY	In the presence of both the RecF and RecR proteins, RecA filament extension from a single strand gap into adjoining duplex DNA is attenuated. RecR protein alone has no effect, and RecF protein alone has a reduced activity. The RecFR complexes bind randomly, primarily to the duplex regions of the DNA, and the extension of the RecA filament is halted at the first complex encountered. A very slow lengthening of RecA filaments observed in the presence of RecFR is virtually eliminated when RecF is replaced with an RecF mutant protein that does not hydrolyze ATP. These observations are incorporated into an expanded model for the functions of RecF, RecO, and RecR proteins in the early stages of postreplication DNA repair.			Webb, BL (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725, R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07215, GM14711, GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1993, J BIOL CHEM, V268, P1424; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; Hegde SP, 1996, J BACTERIOL, V178, P184, DOI 10.1128/jb.178.1.184-190.1996; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; JAIN SK, 1994, J BIOL CHEM, V269, P20653; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kogoma T, 1997, P NATL ACAD SCI USA, V94, P3483, DOI 10.1073/pnas.94.8.3483; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kubista M, 1996, BIOLOGICAL STRUCTURE AND DYNAMICS, VOL 1, P49; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MAHDI AA, 1989, MOL GEN GENET, V216, P503, DOI 10.1007/BF00334397; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; SAWITZKE JA, 1994, J BACTERIOL, V176, P6730, DOI 10.1128/JB.176.21.6730-6737.1994; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; TSENG YC, 1994, MUTAT RES, V315, P1; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0	57	155	169	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 31	1997	91	3					347	356		10.1016/S0092-8674(00)80418-3	http://dx.doi.org/10.1016/S0092-8674(00)80418-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YD941	9363943	Bronze			2022-12-24	WOS:A1997YD94100008
J	Supp, DM; Witte, DP; Potter, SS; Brueckner, M				Supp, DM; Witte, DP; Potter, SS; Brueckner, M			Mutation of an axonemal dynein affects left right asymmetry in inversus viscerum mice	NATURE			English	Article							SITUS-INVERSUS; INSERTIONAL MUTATION; MOUSE; EXPRESSION; GENE; RAT; IDENTIFICATION; MICROTUBULES; SEQUENCES; LEGLESS	The development of characteristic visceral asymmetries along the left-right (LR) axis in an initially bilaterally symmetrical embryo is an essential feature of vertebrate patterning. The allelic mouse mutations inversus viscerum (iv)(1,2) and legless (lgl)(3,4) produce LR inversion, or situs inversus, in half of live-born homozygotes, This suggests that the iv gene product drives correct LR determination, and in its absence this process is randomized(2), These mutations provide tools for studying the development of LR-handed asymmetry and provide mouse models of human lateralization defects. At the molecular level, the normally LR asymmetric expression patterns of nodal(5) and lefty(6) are randomized in iv/iv embryos, suggesting that iv functions early in the genetic hierarchy of LR specification, Here we report the positional cloning of an axonemal dynein heavy-chain gene, left/right-dynein (lrd), that is mutated in both lgl and iv, lrd is expressed in the node of the embryo at embryonic day 7.5, consistent with its having a role in LR development(7). Our findings indicate that dynein, a microtubule-based motor, is involved in the determination of LR-handed asymmetry and provide insight into the early molecular mechanisms of this process.	YALE UNIV, SCH MED, DEPT PEDIAT CARDIOL, NEW HAVEN, CT 06520 USA; CHILDRENS HOSP RES FDN, DIV DEV BIOL, CINCINNATI, OH 45229 USA; CHILDRENS HOSP RES FDN, DIV PATHOL, CINCINNATI, OH 45229 USA	Yale University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			Supp, Dorothy/ABQ-7999-2022	Supp, Dorothy/0000-0002-2429-6630	NICHD NIH HHS [R01 HD024517] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024517] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AFZELIUS B A, 1976, Science (Washington D C), V193, P317; Afzelius BA, 1995, INT J DEV BIOL, V39, P839; Andrews KL, 1996, MOL BIOL CELL, V7, P71, DOI 10.1091/mbc.7.1.71; ASAI DJ, 1995, CELL MOTIL CYTOSKEL, V32, P129, DOI 10.1002/cm.970320212; ASAI DJ, 1994, J CELL SCI, V107, P839; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BROWN NA, 1991, CIBA F SYMP, V162, P182; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; DANOS MC, 1995, DEVELOPMENT, V121, P1467; ELISHA Z, 1995, EMBO J, V14, P5109, DOI 10.1002/j.1460-2075.1995.tb00193.x; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Jesuthasan S, 1997, CURR BIOL, V7, P31, DOI 10.1016/S0960-9822(06)00025-X; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; MCGRATH J, 1992, GENOMICS, V14, P643, DOI 10.1016/S0888-7543(05)80163-6; MCNEISH JD, 1990, J EXP ZOOL, V253, P151, DOI 10.1002/jez.1402530205; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SINGH G, 1991, GENE DEV, V5, P2245, DOI 10.1101/gad.5.12a.2245; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; TANAKA Y, 1995, J CELL SCI, V108, P1883; THEURKAUF WE, 1994, DEV BIOL, V165, P352, DOI 10.1006/dbio.1994.1258; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Vaughan KT, 1996, GENOMICS, V36, P29, DOI 10.1006/geno.1996.0422	28	422	427	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	1997	389	6654					963	966		10.1038/40140	http://dx.doi.org/10.1038/40140			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353118	Green Accepted			2022-12-24	WOS:A1997YD29900054
J	Mulley, GP				Mulley, GP			Myths of ageing	LANCET			English	Article							OLDER-PEOPLE				Mulley, GP (corresponding author), ST JAMES UNIV HOSP, ELDERLY SERV DIRECTORATE, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND.							Agate J., 1970, PRACTICE GERIATRICS; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Ebrahim S, 1996, BRIT MED J, V313, P610; Forbes A, 1996, BRIT MED J, V313, P352, DOI 10.1136/bmj.313.7053.352; MANN E, 1996, PSYCHIAT ELDERLY, P89; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MANTON KG, 1995, J GERONTOL, V50, P5104; Markowe H, 1994, Health Trends, V26, P98; *MRC, 1994, HLTH UK ELD PEOPL MR; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Starr JM, 1997, AGE AGEING, V26, P295, DOI 10.1093/ageing/26.4.295; Travers AF, 1996, BRIT MED J, V313, P482; VERHAEGHEN P, 1993, J GERONTOL, V48, pP157, DOI 10.1093/geronj/48.4.P157; WYSOCKI CJ, 1989, ANN NY ACAD SCI, V561, P12, DOI 10.1111/j.1749-6632.1989.tb20966.x; Young J, 1996, BRIT MED J, V313, P677	15	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	1997	350	9085					1160	1161		10.1016/S0140-6736(97)08296-2	http://dx.doi.org/10.1016/S0140-6736(97)08296-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343517				2022-12-24	WOS:A1997YB19900045
J	Anderson, SA; Eisenstat, DD; Shi, L; Rubenstein, JLR				Anderson, SA; Eisenstat, DD; Shi, L; Rubenstein, JLR			Interneuron migration from basal forebrain to neocortex: Dependence on Dlx genes	SCIENCE			English	Article							LATERAL GANGLIONIC EMINENCE; NEURONS; CELLS; MOUSE; IMMUNOREACTIVITY; DISPERSION; EXPRESSION; CORTEX; BRAIN; ZONE	Although previous analyses indicate that neocortical neurons originate from the cortical proliferative zone, evidence suggests that a subpopulation of neocortical interneurons originates within the subcortical telencephalon. For example, gamma-aminobutyric acid (GABA)-expressing cells migrate in vitro from the subcortical telencephalon into the neocortex. The number of GABA-expressing cells in neocortical slices is reduced by separating the neocortex from the subcortical telencephalon. Finally, mice lacking the homeodomain proteins DLX-1 and DLX-2 show no detectable cell migration from the subcortical telencephalon to the neocortex and also have few GABA-expressing cells in the neocortex.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,CTR NEUROBIOL & PSYCHIAT,NINA IRELAND LAB DEV NEUROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Eisenstat, David/AAA-4653-2020		NIMH NIH HHS [K02 MH01046, R01 MH51561] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051561, K02MH001046] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANDERSON S, UNPUB; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bhide PG, 1996, J COMP NEUROL, V374, P506; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; BUIFONE A, 1993, J NEUROSCI, V13, P3155; DEACON TW, 1994, BRAIN RES, V668, P211, DOI 10.1016/0006-8993(94)90526-6; DeCarlos JA, 1996, J NEUROSCI, V16, P6146; DEDIEGO I, 1994, EUR J NEUROSCI, V6, P983, DOI 10.1111/j.1460-9568.1994.tb00593.x; DEFELIPE J, 1993, CEREB CORTEX, V3, P273, DOI 10.1093/cercor/3.4.273; DELRIO JA, 1995, CEREB CORTEX, V5, P13, DOI 10.1093/cercor/5.1.13; DELRIO JA, 1992, J COMP NEUROL, V326, P501, DOI 10.1002/cne.903260403; Fishell G, 1997, CURR OPIN NEUROBIOL, V7, P62, DOI 10.1016/S0959-4388(97)80121-3; FISHELL G, 1993, NATURE, V362, P636, DOI 10.1038/362636a0; FISHELL G, 1995, DEVELOPMENT, V121, P803; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; LIU FC, 1992, J COMP NEUROL, V320, P304, DOI 10.1002/cne.903200304; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Metin C, 1996, J NEUROSCI, V16, P3219; Mione MC, 1997, J NEUROSCI, V17, P2018; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; PORTEUS MH, 1994, J NEUROSCI, V14, P6370; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; TAMAMAKI N, 1996, IN PRESS J NEUROSCI, V16; VANEDEN CG, 1989, J COMP NEUROL, V289, P213, DOI 10.1002/cne.902890204; WALSH C, 1993, NATURE, V362, P632, DOI 10.1038/362632a0	27	1146	1161	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					474	476		10.1126/science.278.5337.474	http://dx.doi.org/10.1126/science.278.5337.474			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334308				2022-12-24	WOS:A1997YB35500048
J	Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA				Mantyh, PW; Rogers, SD; Honore, P; Allen, BJ; Ghilardi, JR; Li, J; Daughters, RS; Lappi, DA; Wiley, RG; Simone, DA			Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor	SCIENCE			English	Article							SPINOTHALAMIC TRACT NEURONS; EXCITATORY AMINO-ACIDS; GENE-RELATED PEPTIDE; DORSAL HORN NEURONS; MEDIATED INTERNALIZATION; NEUROKININ-1 RECEPTORS; TRIGEMINAL NUCLEUS; AXONAL-TRANSPORT; SENSORY NEURONS; DOWN-REGULATION	Substance P is released in the spinal cord in response to painful stimuli, but its role in nociceptive signaling remains unclear, When a conjugate of substance P and the ribosome-inactivating protein saporin was infused into the spinal cord, it was internalized and cytotoxic to lamina I spinal cord neurons that express the substance P receptor. This treatment left responses to mild noxious stimuli unchanged, but markedly attenuated responses to highly noxious stimuli and mechanical and thermal hyperalgesia. Thus, lamina I spinal cord neurons that express the substance P receptor play a pivotal role in the transmission of highly noxious stimuli and the maintenance of hyperalgesia.	UNIV MINNESOTA, SCH DENT, DEPT PREVENT SCI, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; ADV TARGETING SYST, CARLSBAD, CA 92008 USA; VET ADM MED CTR, NEUROL SERV 147, NASHVILLE, TN 37212 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mantyh, PW (corresponding author), VET ADM MED CTR, MOL NEUROBIOL LAB 151, MINNEAPOLIS, MN 55417 USA.			Lappi, Douglas/0000-0003-4239-7387	NIMH NIH HHS [MH56368] Funding Source: Medline; NINDS NIH HHS [NS31223, NS23970] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R43MH056368, R44MH056368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023970, R37NS023970, R29NS031223] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; BENYA RV, 1994, J BIOL CHEM, V269, P11721; BOEHMER CG, 1989, PEPTIDES, V10, P1179, DOI 10.1016/0196-9781(89)90011-9; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BRIMIJOIN S, 1980, BRAIN RES, V191, P443, DOI 10.1016/0006-8993(80)91293-7; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; COX BM, 1993, HDB EXPT PHARM OPIOI, V1, P145; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DELFIACCO M, 1994, NEUROREPORT, V5, P2349, DOI 10.1097/00001756-199411000-00035; DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; DOUGHERTY PM, 1995, PAIN, V61, P411, DOI 10.1016/0304-3959(94)00222-Z; DOUGHERTY PM, 1993, BRAIN RES REV, V18, P227, DOI 10.1016/0165-0173(93)90003-I; DOUGHERTY PM, 1994, J NEUROPHYSIOL, V72, P1464, DOI 10.1152/jn.1994.72.4.1464; DOUGHERTY PM, 1991, PAIN, V47, P85, DOI 10.1016/0304-3959(91)90015-P; DUGGAN AW, 1991, NEUROSCI LETT, V122, P191, DOI 10.1016/0304-3940(91)90855-N; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HOKFELT T, 1975, BRAIN RES, V100, P235, DOI 10.1016/0006-8993(75)90481-3; Iversen LL, 1996, NATURE, V383, P759, DOI 10.1038/383759a0; IWASHITA T, 1992, BRAIN RES, V581, P59, DOI 10.1016/0006-8993(92)90344-9; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; KAR S, 1994, EUR J NEUROSCI, V6, P345, DOI 10.1111/j.1460-9568.1994.tb00277.x; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAPPI DA, 1985, BIOCHEM BIOPH RES CO, V129, P934, DOI 10.1016/0006-291X(85)91981-3; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MUNGLANI R, 1995, BRIT J ANAESTH, V75, P186, DOI 10.1093/bja/75.2.186; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAGY I, 1994, NEUROREPORT, V5, P2105, DOI 10.1097/00001756-199410270-00029; NAGY I, 1993, NEUROSCIENCE, V52, P1029, DOI 10.1016/0306-4522(93)90549-U; NICOL GD, 1992, J NEUROSCI, V12, P1917; QUARTU M, 1992, J CHEM NEUROANAT, V5, P143, DOI 10.1016/0891-0618(92)90040-W; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SALTER MW, 1991, NEUROSCIENCE, V43, P601, DOI 10.1016/0306-4522(91)90319-J; SCHAIBLE HG, 1990, BRAIN RES, V529, P214, DOI 10.1016/0006-8993(90)90830-5; Simone D A, 1992, Curr Opin Neurobiol, V2, P479, DOI 10.1016/0959-4388(92)90183-L; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; Traub RJ, 1996, PAIN, V67, P151, DOI 10.1016/0304-3959(96)03076-X; URBAN L, 1994, TRENDS NEUROSCI, V17, P432, DOI 10.1016/0166-2236(94)90018-3; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WUWONG JR, 1995, J PHARMACOL EXP THER, V274, P499; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x; YAMAMOTO T, 1993, ANESTHESIOLOGY, V79, P1042, DOI 10.1097/00000542-199311000-00023	52	498	512	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					275	279		10.1126/science.278.5336.275	http://dx.doi.org/10.1126/science.278.5336.275			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323204				2022-12-24	WOS:A1997YA56400041
J	Ingram, D; Sanders, K; Kolybaba, M; Lopez, D				Ingram, D; Sanders, K; Kolybaba, M; Lopez, D			Case-control study of phyto-oestrogens and breast cancer	LANCET			English	Article							NUTRITION EXAMINATION SURVEY; ISOFLAVONOID PHYTOESTROGENS; ALCOHOL-CONSUMPTION; NATIONAL-HEALTH; POSSIBLE ROLES; DIETARY-FAT; LIGNANS; WOMEN; EXCRETION; RISK	Background Phyto-oestrogens are a group of naturally occurring chemicals derived from plants; they have a structure similar to oestrogen, and form part of our diet. They also have potentially anticarcinogenic biological activity. We did a case-control study to assess the association between phyto-oestrogen intake (as measured by urinary excretion) and the risk of breast cancer. Methods Women with newly diagnosed early breast cancer were interviewed by means of questionnaires, and a 72 h urine collection and blood sample were taken before any treatment started. Controls were randomly selected from the electoral roll after matching for age and area of residence. 144 pairs were included for analysis. The urine samples were assayed for the isoflavonic phyto-oestrogens daidzein, genistein, and equol, and the lignans enterodiol, enterolactone, and matairesinol. Findings After adjustment for age at menarche, parity, alcohol intake, and total fat intake, high excretion of both equol and enterolactone was associated with a substantial reduction in breast-cancer risk, with significant trends through the quartiles: equol odds ratios were 1.00, 0.45 (95% CI 0.20, 1.02), 0.52 (0.23, 1.17), and 0.27 (0.10, 0.69)-trend p=0.009-and enterolactone odds ratios were 1.00, 0.91 (0.41, 1.98), 0.65 (0.29, 1.44), 0.36 (0.15, 0.86)-trend p=0.013 For most other phytoestrogens there was a reduction in risk, but it did nat reach significance. Difficulties with the genistein assay precluded analysis of that substance. Interpretation There is a substantial reduction in breast-cancer risk among women with a high intake (as measured by excretion) of phyto-oestrogens-particularly the isoflavonic phyto-oestrogen equol and the lignan enterolactone. These findings could be important in the prevention of breast cancer.	QUEEN ELIZABETH II MED CTR,UNIV DEPT SURG,PERTH,WA,AUSTRALIA	University of Western Australia			Lopez, Derrick/AAH-5046-2021	Lopez, Derrick/0000-0003-0677-0420				Adlercreutz H., 1991, Nutrition, toxicity, and cancer., P137; ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ADLERCREUTZ H, 1986, J STEROID BIOCHEM, V25, P791, DOI 10.1016/0022-4731(86)90310-9; ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; ADLERCREUTZ H, 1982, LANCET, V2, P1295; ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1993, SCAND J CLIN LAB INV, V53, P5, DOI 10.3109/00365519309090693; ADLERCREUTZ H, 1991, CLIN CHIM ACTA, V199, P263, DOI 10.1016/0009-8981(91)90120-2; ADLERCREUTZ H, 1986, ADV MASS SPECTROM, V85, P1293; ADLERERCUTZ CHT, 1995, J NUTR, V125, pS575; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AXELSON M, 1984, J ENDOCRINOL, V102, P49, DOI 10.1677/joe.0.1020049; AXELSON M, 1982, NATURE, V298, P659, DOI 10.1038/298659a0; BURGE JC, 1992, JPEN, V17, P529; DWYER JT, 1994, J AM DIET ASSOC, V94, P739, DOI 10.1016/0002-8223(94)91939-9; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; HUSE DM, 1974, AM J CLIN NUTR, V27, P771, DOI 10.1093/ajcn/27.8.771; HUTCHINS AM, 1995, J AM DIET ASSOC, V95, P545, DOI 10.1016/S0002-8223(95)00149-2; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KELLY GE, 1995, P SOC EXP BIOL MED, V208, P40, DOI 10.3181/00379727-208-43829; KELSEY JL, 1993, EPIDEMIOL REV, V15, P256, DOI 10.1093/oxfordjournals.epirev.a036112; LAMPE JW, 1994, AM J CLIN NUTR, V60, P122, DOI 10.1093/ajcn/60.1.122; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; SETCHELL KDR, 1984, AM J CLIN NUTR, V40, P569, DOI 10.1093/ajcn/40.3.569; SETCHELL KDR, 1981, LANCET, V2, P4; Setchell KDR, 1988, ROLE GUT FLORA TOXIC, P315; THOMPSON LU, 1991, NUTR CANCER, V16, P43, DOI 10.1080/01635589109514139; VANTVEER P, 1991, INT J CANCER, V47, P649, DOI 10.1002/ijc.2910470503; VANVEER P, 1989, CANCER RES, V49, P4020; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263	34	579	608	1	54	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					990	994		10.1016/S0140-6736(97)01339-1	http://dx.doi.org/10.1016/S0140-6736(97)01339-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329514				2022-12-24	WOS:A1997XZ71000010
J	Verrees, M				Verrees, M			Secondary survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1047	1047						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315747				2022-12-24	WOS:A1997XX30300002
J	Ahmed, A; Kilby, MD				Ahmed, A; Kilby, MD			Hypoxia or hyperoxia in placental insufficiency?	LANCET			English	Editorial Material							PREGNANCIES; VILLI; FORMS				Ahmed, A (corresponding author), UNIV BIRMINGHAM,DEPT OBSTET & GYNAECOL,REPROD PHYSIOL GRP,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.		Ahmed, Asif/A-7268-2010; FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Ahmed, Asif/ABE-9544-2020	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Ahmed, Asif/0000-0002-8755-8546; Goswami, Kaushal/0000-0002-7052-4358				Ahmed A, 1997, LAB INVEST, V76, P779; AHMED A, 1997, TROPHOBLAST RES, V10, P215; Burton GJ, 1996, PLACENTA, V17, P49, DOI 10.1016/S0143-4004(05)80643-5; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; LYALL F, 1977, PLACENTA, V18, P269; Macara L, 1996, PLACENTA, V17, P37, DOI 10.1016/S0143-4004(05)80642-3; PANIGEL M, 1972, ACTA ANAT, V81, P481; PARDI G, 1992, AM J OBSTET GYNECOL, V166, P699, DOI 10.1016/0002-9378(92)91700-K	9	41	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					826	827		10.1016/S0140-6736(05)62027-2	http://dx.doi.org/10.1016/S0140-6736(05)62027-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310597				2022-12-24	WOS:A1997XX40100005
J	Fischer, U; Liu, Q; Dreyfuss, G				Fischer, U; Liu, Q; Dreyfuss, G			The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; L929 MOUSE FIBROBLASTS; SMALL NUCLEAR-RNA; NUCLEOCYTOPLASMIC TRANSPORT; CAP TRIMETHYLATION; PROTEIN-BINDING; GENE FREQUENCY; M3G CAP; PATHWAY; DOMAIN	Spinal muscular atrophy (SMA) is an often fatal neuromuscular disease that has been directly linked to the protein product of the Survival of Motor Neurons (SMN) gene. The SMN protein is tightly associated with a novel protein, SIP1, and together they form a complex with several spliceosomal snRNP proteins. Here we show that the SMN-SIP1 complex is associated with spliceosomal snRNAs U1 and U5 in the cytoplasm of Xenopus oocytes. Antibodies directed against the SMN-SIP1 complex strongly interfere with the cytoplasmic assembly of the common (Sm) snRNP proteins with spliceosomal snRNAs and with the import of the snRNP complex into the nucleus. Thus, the SMN-SIP1 complex is directly involved in the biogenesis of spliceosomal snRNPs. Defects in spliceosomal snRNP biogenesis may, therefore, be the cause of SMA.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Pennsylvania			Fischer, Utz/AAT-8422-2020; Dreyfuss, Gideon/D-1218-2013; Fischer, Utz/A-4090-2016	Fischer, Utz/0000-0002-1465-6591; Dreyfuss, Gideon/0000-0001-8129-8774; Fischer, Utz/0000-0002-1465-6591				BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; FISHER DE, 1985, CELL, V42, P751, DOI 10.1016/0092-8674(85)90271-5; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Liu Q, 1996, COLD SPRING HARB SYM, V61, P689; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; Moore M., 1993, RNA WORLD, P303; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; SAUTERER RA, 1990, J BIOL CHEM, V265, P1048; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2	39	536	550	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1023	1029		10.1016/S0092-8674(00)80368-2	http://dx.doi.org/10.1016/S0092-8674(00)80368-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323130	hybrid			2022-12-24	WOS:A1997XX76800008
J	Horiuchi, H; Lippe, R; McBride, HM; Rubino, M; Woodman, P; Stenmark, H; Rybin, V; Wilm, M; Ashman, K; Mann, M; Zerial, M				Horiuchi, H; Lippe, R; McBride, HM; Rubino, M; Woodman, P; Stenmark, H; Rybin, V; Wilm, M; Ashman, K; Mann, M; Zerial, M			A novel Rab5 GDP/GTP exchange factor complexed to Rabaptin-5 links nucleotide exchange to effector recruitment and function	CELL			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; ENDOCYTIC MEMBRANE-FUSION; VACUOLAR PROTEINS; BOVINE BRAIN; YEAST; VESICLES; PATHWAY; DOCKING; CELLS	The small GTPase Rab5 plays an essential role in endocytic traffic. Rab GDP dissociation inhibitor delivers Rab5 to the membrane, where a nucleotide exchange activity allows recruitment of an effector protein, Rabaptin-5. Here we uncovered a novel 60 kDa Rab5-binding protein, Rabex-5. Rabex-5 forms a tight physical complex with Rabaptin-5, and this complex is essential for endocytic membrane fusion. Sequencing of mammalian Rabex-5 by nanoelectrospray mass spectrometry and cloning revealed striking homology to Vps9p, a yeast protein implicated in endocytic traffic. Rabex-5 displays GDP/GTP exchange activity on Rab5 upon delivery of the GTPase to the membrane. This demonstrates that a soluble exchange factor coupled to a Rab effector translocates from cytosol to the membrane, where the complex stabilizes the GTPase in the active state.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MANCHESTER,SCH BIOL SCI,DIV BIOCHEM,MANCHESTER M13 9PT,LANCS,ENGLAND; NORWEGIAN RADIUM HOSP,DEPT BIOCHEM,N-0310 OSLO,NORWAY	European Molecular Biology Laboratory (EMBL); University of Manchester; University of Oslo			McBride, Heidi M./ABD-5774-2021; Ashman, Keith/G-2328-2011; Stenmark, Harald/B-8868-2008; Mann, Matthias/A-3454-2013; McBride, Heidi M/C-1162-2008	McBride, Heidi M./0000-0003-4666-2280; Mann, Matthias/0000-0003-1292-4799; McBride, Heidi M/0000-0003-4666-2280; Wilm, Matthias/0000-0002-5461-6834; Lippe, Roger/0000-0001-5066-3070				Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1996, MOL CELL BIOL, V16, P2369; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; LI GP, 1994, J BIOL CHEM, V269, P14631; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Shevchenko A, 1997, RAPID COMMUN MASS SP, V11, P1015, DOI 10.1002/(SICI)1097-0231(19970615)11:9<1015::AID-RCM958>3.0.CO;2-H; SHEVCHENKO A, 1996, ANAL CHEM, V68, P820; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1995, METHOD ENZYMOL, V257, P243; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WOODMAN PG, 1988, EUR J BIOCHEM, V173, P101, DOI 10.1111/j.1432-1033.1988.tb13972.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	48	460	479	4	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 19	1997	90	6					1149	1159		10.1016/S0092-8674(00)80380-3	http://dx.doi.org/10.1016/S0092-8674(00)80380-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323142	Bronze			2022-12-24	WOS:A1997XX76800020
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Just one word: Plastics	SCIENCE			English	Article																		DORDICK JS, COMMUNICATION; Wang P, 1997, NAT BIOTECHNOL, V15, P789, DOI 10.1038/nbt0897-789; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1849	1849						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9324772				2022-12-24	WOS:A1997XX29800054
J	Oscherwitz, T; Peterson, J; Roger, S; Sciortino, S; Alpers, A; Royce, S; Lo, B				Oscherwitz, T; Peterson, J; Roger, S; Sciortino, S; Alpers, A; Royce, S; Lo, B			Detention of persistently nonadherent patients with tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Patients with tuberculosis (TB) who are persistently nonadherent to treatment present a public health risk. In 1993, California created a new civil detention process and allowed detention of noninfectious but persistently nonadherent patients. Objectives.-To determine (1) which patients TB controllers attempt to detain, (2) how often and where patients are detained, and (3) how many or these patients complete TB treatment. Design.-Case series with cross-sectional comparison to other adult TB patients in the study counties. Setting-Twelve California counties with the largest number of new TB cases reported in 1994. Subjects.-All patients whom TB controllers sought to detain during 1994 and 1995 because of persistent nonadherence to treatment. Data Sources.-Public health records, interviews with county TB officials, and Reports of Verified Cases of Tuberculosis to the California Tuberculosis Control Branch. Results.-Tuberculosis controllers sought the civil detention or arrest of 67 patients during the study period (1.3% of adult TB patients with the same disease sites). Forty-six percent of these patients were homeless, 81% had drug or alcohol abuse, and 28% had mental illness. Tuberculosis controllers sought civil detention of 15 patients. Fourteen patients were detained (median length of detention, 14.5 days). Tuberculosis controllers sought to arrest 62 patients during the study period. Fifty-three patients were arrested (median time in jail, 83 days). In 10 cases, both civil and criminal detention were attempted. We analyzed completion of therapy after excluding patients who were not detained or who died or moved. Overall, 41 (84%) of the remaining 49 detained patients completed therapy. Of the patients who completed therapy, only 17 were detained until treatment was completed. Compared with other TB patients in these counties, detained patients had 4 times the proportion lost to follow-up and half the proportion completing therapy within 12 months. Conclusion.-Further improvements in the care of persistently nonadherent patients may require more psychosocial services, appropriate facilities for civil detention, and detaining patients long enough to assure completion of treatment.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Health Care Services				Sciortino, Stanley/0000-0002-6191-8179	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [2 P50 MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ball C. A., 1994, YALE LAW POLICY REV, V12, P38; BAYER R, 1995, ANNU REV PUBL HEALTH, V16, P307; Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GASNER R, 1996, TB TIMES, V10, P4; Gostin Lawrence O, 1995, MD Law Rev, V54, P1; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1	8	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					843	846		10.1001/jama.278.10.843	http://dx.doi.org/10.1001/jama.278.10.843			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293993				2022-12-24	WOS:A1997XU55200040
J	Li, JM; Chory, J				Li, JM; Chory, J			A putative leucine-rich repeat receptor kinase involved in brassinosteroid signal transduction	CELL			English	Article							ARABIDOPSIS-THALIANA; PROTEIN-KINASE; CELL-SURFACE; HUMAN SPERM; TRANSMEMBRANE PROTEIN; TYROSINE KINASE; BINDING SITES; GENE; PHOSPHATASE; RESISTANCE	Brassinosteroids are a class of growth-promoting regulators that play a key role throughout plant development. Despite their importance, nothing is known of the mechanism of action of these steroid hormones. We describe the identification of 18 Arabidopsis dwarf mutants that are unable to respond to exogenously added brassinosteroid, a phenotype that might be expected for brassinosteroid signaling mutants. All 18 mutations define alleles of a single previously described gene, BRI1. We cloned BRI1 and examined its expression pattern. It encodes a ubiquitously expressed putative receptor kinase. The extracellular domain contains 25 tandem leucine-rich repeats that resemble repeats found in animal hormone receptors, plant disease resistance genes, and genes involved in unknown signaling pathways controlling plant development.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA	Salk Institute			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BarbierBrygoo H, 1997, TRENDS PLANT SCI, V2, P214, DOI 10.1016/S1360-1385(97)89546-5; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bishop GJ, 1996, PLANT CELL, V8, P959, DOI 10.1105/tpc.8.6.959; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHOI S, 1995, WEEDS WORLD, V2, P17; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hong SW, 1997, PLANT PHYSIOL, V113, P1203, DOI 10.1104/pp.113.4.1203; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KWON HB, 1986, DEV BIOL, V117, P354, DOI 10.1016/0012-1606(86)90305-2; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LEWIN DI, 1996, J NIH RES, V8, P29; Li JM, 1997, P NATL ACAD SCI USA, V94, P3554, DOI 10.1073/pnas.94.8.3554; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MENDOZA C, 1995, BIOCHEM BIOPH RES CO, V210, P518, DOI 10.1006/bbrc.1995.1690; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Nakhla AM, 1997, J BIOL CHEM, V272, P6838, DOI 10.1074/jbc.272.11.6838; Nomura T, 1997, PLANT PHYSIOL, V113, P31, DOI 10.1104/pp.113.1.31; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHULZ B, 1995, PLANT MOL BIOL MANUA; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERKNAAP E, 1996, PLANT PHYSIOL, V112, P1397; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WISTROM CA, 1993, DEV BIOL, V159, P679	61	1172	1267	6	188	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					929	938		10.1016/S0092-8674(00)80357-8	http://dx.doi.org/10.1016/S0092-8674(00)80357-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298904	Bronze			2022-12-24	WOS:A1997XV56300013
J	Mebatsion, T; Finke, S; Weiland, F; Conzelmann, KK				Mebatsion, T; Finke, S; Weiland, F; Conzelmann, KK			A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells	CELL			English	Article							RABIES VIRUS GLYCOPROTEIN; HUMAN CD4; RECEPTOR; FUSION; PARTICLES; COFACTOR; ENTRY; CCR5; RETROVIRUS; CLONING	We show that a cellular virus receptor functions in the envelope of a virus, allowing selective infection of cells displaying the receptor ligand. A G-deficient rabies virus (RV) pseudotyped with CD4- and CXCR4-derived proteins selectively infected cells expressing HIV-1 envelope protein. Envelope protein or CD4 antibodies blocked virus entry. Pseudotype virus formation was most efficient with chimeric receptor proteins possessing the cytoplasmic tail of the RV G spike protein (CXCR4-RV and CD4-RV). While CXCR4-RV was incorporated when expressed alone, CD4-RV incorporation required CXCR4-RV as a carrier protein, indicating a mechanism by which oligomeric surface proteins are sorted into the RV envelope. Viral vectors bearing virus receptors in their envelope may be useful reagents for targeting virus-infected cells in vivo.	FED RES CTR VIRUS DIS ANIM,DEPT CLIN VIROL,D-72076 TUBINGEN,GERMANY				Conzelmann, Karl-Klaus/L-7239-2013	Finke, Stefan/0000-0001-8716-2341; Conzelmann, Karl-Klaus/0000-0002-8614-3656				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Conzelmann KK, 1996, TRENDS MICROBIOL, V4, P386, DOI 10.1016/0966-842X(96)10062-7; CONZELMANN KK, 1994, J VIROL, V68, P713, DOI 10.1128/JVI.68.2.713-719.1994; CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Franci C, 1996, J IMMUNOL, V157, P5606; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P7310, DOI 10.1073/pnas.93.14.7310; Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P11366, DOI 10.1073/pnas.93.21.11366; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; SCHUBERT M, 1992, J VIROL, V66, P1579, DOI 10.1128/JVI.66.3.1579-1589.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner RR., 1996, FIELDS VIROLOGY, V1, P1121; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WIMMER E, 1994, CELLULAR RECEPTORS A; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YOUNG JAT, 1990, SCIENCE, V250, P1421, DOI 10.1126/science.2175047	39	114	122	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					841	847		10.1016/S0092-8674(00)80349-9	http://dx.doi.org/10.1016/S0092-8674(00)80349-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298896	Bronze			2022-12-24	WOS:A1997XV56300005
J	He, ZG; TessierLavigne, M				He, ZG; TessierLavigne, M			Neuropilin is a receptor for the axonal chemorepellent Semaphorin III	CELL			English	Article							GROWTH CONE GUIDANCE; NEURONAL RECOGNITION MOLECULE; CELL-SURFACE MOLECULE; CHICK NERVOUS-SYSTEM; SPINAL-CORD; C-ELEGANS; COLORECTAL-CANCER; NEURITE OUTGROWTH; VISUAL CENTERS; PROTEIN	Extending axons in the developing nervous system are guided to their targets through the coordinate actions of attractive and repulsive guidance cues. The semaphorin family of guidance cues comprises several members that can function as diffusible axonal chemorepellents. To begin to elucidate the mechanisms that mediate the repulsive actions of Collapsin-1/Semaphorin III/D (Sema III), we searched for Sema III-binding proteins in embryonic rat sensory neurons by expression cloning. We report that Sema III binds with high affinity to the transmembrane protein neuropilin, and that antibodies to neuropilin block the ability of Sema III to repel sensory axons and to induce collapse of their growth cones. These results provide evidence that neuropilin is a receptor or a component of a receptor complex that mediates the effects of Sema III on these axons.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	He, ZG (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJISAWA H, 1989, DEV BIOL, V135, P231, DOI 10.1016/0012-1606(89)90175-9; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1992, GENETICS, V132, P675; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; SNIDER WD, 1992, J NEUROSCI, V12, P3494; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	51	926	978	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					739	751		10.1016/S0092-8674(00)80534-6	http://dx.doi.org/10.1016/S0092-8674(00)80534-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288753	Bronze			2022-12-24	WOS:A1997XT06600017
J	Rivers, JK; Roof, MI				Rivers, JK; Roof, MI			Sentinel lymph-node biopsy in melanoma: is less surgery better?	LANCET			English	Editorial Material									BRITISH COLUMBIA CANC AGCY,VANCOUVER,BC V5Z 4E8,CANADA; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030	British Columbia Cancer Agency; University of Texas System; UTMD Anderson Cancer Center	Rivers, JK (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV DERMATOL,VANCOUVER,BC V5Z 4E8,CANADA.		Rivers, Jason/K-1031-2019	Rivers, Jason/0000-0002-0131-1607				Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Brady MS, 1997, ARCH DERMATOL, V133, P1014, DOI 10.1001/archderm.133.8.1014; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Piepkorn M, 1997, ARCH DERMATOL, V133, P995, DOI 10.1001/archderm.133.8.995; Ross MI, 1996, SEMIN SURG ONCOL, V12, P394, DOI 10.1002/(SICI)1098-2388(199611/12)12:6<394::AID-SSU4>3.0.CO;2-5; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010	7	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 8	1997	350	9088					1336	1337		10.1016/S0140-6736(97)22045-3	http://dx.doi.org/10.1016/S0140-6736(97)22045-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YE872	9365442				2022-12-24	WOS:A1997YE87200002
J	Hoffenberg, R; Lock, M; Tilney, N; Casabona, C; Daar, AS; Guttmann, RD; Kennedy, I; Nundy, S; RadcliffeRichards, J; Sells, RA				Hoffenberg, R; Lock, M; Tilney, N; Casabona, C; Daar, AS; Guttmann, RD; Kennedy, I; Nundy, S; RadcliffeRichards, J; Sells, RA			Should organs from patients in permanent vegetative state be used for transplantation?	LANCET			English	Article									ROYAL LIVERPOOL HOSP, RENAL TRANSPLANT UNIT, INT FORUM TRANSPLANT ETH, LIVERPOOL L7 8XP, MERSEYSIDE, ENGLAND; DEPT SOCIAL STUDIES MED, MONTREAL, PQ, CANADA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV DEUSTO, CATEDRA DERECHRO & GENOMA HUMANO, BILBAO, SPAIN; SULTAN QABOOS UNIV, COLL MED, DEPT SURG, AL KHOUD, OMAN; ROYAL VICTORIA HOSP, MONTREAL, PQ H3A 1A1, CANADA; ALL INDIA INST MED SCI, DEPT GASTROINTESTINAL SURG, NEW DELHI, INDIA	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; Harvard University; Brigham & Women's Hospital; University of Deusto; Sultan Qaboos University; McGill University; Royal Victoria Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi				Nundy, Samiran/0000-0002-1757-3919				Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; *BRIT MED ASS ETH, 1992, DISC PAP TREATM PAT; CELESIA, 1993, ANN NEUROL, V33, P386; CRAWFORD R, 1996, BRIT MED J, V313, P5; Dyer C, 1997, BRIT MED J, V314, P996; *HL, 1994, REP SEL COMM MED ETH	8	21	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1320	1321		10.1016/S0140-6736(97)02306-4	http://dx.doi.org/10.1016/S0140-6736(97)02306-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357422				2022-12-24	WOS:A1997YD68900045
J	Farmer, PB				Farmer, PB			Diesel fuel and exhaust emissions: Is there a human carcinogenic risk?	LANCET			English	Editorial Material							CARBON-BLACK; EXPOSURE; ADDUCTS; RATS; DNA				Farmer, PB (corresponding author), UNIV LEICESTER,MRC,TOXICOL UNIT,LEICESTER LE1 9HN,LEICS,ENGLAND.							HEINRICH U, 1995, INHAL TOXICOL, V7, P533, DOI 10.3109/08958379509015211; *INT AG RES CANC, 1989, IARC MON, V46, P41; IPCS (International Programme on Chemical Safety), 1996, ENV HLTH CRIT, V171; LEVY LS, 1995, INDOOR ENVIRON, V4, P254; Nielsen PS, 1996, TOXICOL LETT, V86, P27, DOI 10.1016/0378-4274(96)83963-4; Nielsen PS, 1996, CARCINOGENESIS, V17, P1021, DOI 10.1093/carcin/17.5.1021; NIKULA KJ, 1995, FUND APPL TOXICOL, V25, P80, DOI 10.1006/faat.1995.1042	7	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1118	1118		10.1016/S0140-6736(05)63786-5	http://dx.doi.org/10.1016/S0140-6736(05)63786-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343497				2022-12-24	WOS:A1997YB19900006
J	Lahita, RG				Lahita, RG			Influence of age on Henoch Schonlein purpura	LANCET			English	Editorial Material											Lahita, RG (corresponding author), COLUMBIA UNIV,ST LUKES ROOSEVELT MED CTR,DEPT RHEUMATOL,NEW YORK,NY 10019, USA.							BERTHOUX FC, 1978, NEW ENGL J MED, V298, P1034; Blanco R, 1997, ARTHRITIS RHEUM, V40, P859, DOI 10.1002/art.1780400513; Escudero A, 1996, Allergol Immunopathol (Madr), V24, P22; MERRILL J, 1994, BRIT J RHEUMATOL, V33, P586; MICHEL BA, 1992, J RHEUMATOL, V19, P721; MILLS JA, 1990, ARTHRITIS RHEUM, V33, P1114; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438	7	23	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1116	1117		10.1016/S0140-6736(05)63784-1	http://dx.doi.org/10.1016/S0140-6736(05)63784-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343495	hybrid			2022-12-24	WOS:A1997YB19900004
J	Elliot, JL; Stansberry, JA; Olkin, CB; Agner, MA; Davies, ME				Elliot, JL; Stansberry, JA; Olkin, CB; Agner, MA; Davies, ME			Triton's distorted atmosphere	SCIENCE			English	Article							STELLAR OCCULTATION; MODEL; VOYAGER-2; DYNAMICS; NEPTUNE; 28-SGR; CYCLE	A stellar-occultation light curve for Triton shows asymmetry that can be understood if Triton's middle atmosphere is distorted from spherical symmetry. Although a globally oblate model can explain the data, the inferred atmospheric flattening is so large that it could be caused only by an unrealistic internal mass distribution or highly supersonic zonal winds, Cyclostrophic winds confined to a jet near Triton's northern or southern limbs (or both) could also be responsible for the details of the light curve, but such winds are required to be slightly supersonic. Hazes and clouds in the atmosphere are unlikely to have caused the asymmetry in the fight curve.	MIT, DEPT PHYS, CAMBRIDGE, MA 02139 USA; LOWELL OBSERV, FLAGSTAFF, AZ 86001 USA; RAND CORP, SANTA MONICA, CA 90407 USA	Massachusetts Institute of Technology (MIT); RAND Corporation	Elliot, JL (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, BLDG 54-422, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.		Olkin, Catherine/AAF-5160-2019	Olkin, Catherine/0000-0002-5846-716X; Stansberry, John/0000-0003-2434-5225				Bevington PR, 1969, DATA REDUCTION ERROR; BROADFOOT AL, 1989, SCIENCE, V246, P1459, DOI 10.1126/science.246.4936.1459; DAVIES ME, 1991, J GEOPHYS RES, V96, P15; ELLIOT JL, 1977, ASTROPHYS J, V217, P661, DOI 10.1086/155612; ELLIOT JL, 1992, ASTRON J, V103, P991, DOI 10.1086/116121; ELLIOT JL, 1976, SKY TELESCOPE, V52, P23; HANSEN CJ, 1992, ICARUS, V99, P273, DOI 10.1016/0019-1035(92)90146-X; HILLIER J, 1994, ICARUS, V109, P284, DOI 10.1006/icar.1994.1094; Holton J.R., 2013, INTRO DYNAMIC METEOR; HUBBARD WB, 1988, ASTROPHYS J, V325, P490, DOI 10.1086/166019; HUBBARD WB, 1993, ASTRON ASTROPHYS, V269, P541; INGERSOLL AP, 1990, NATURE, V344, P315, DOI 10.1038/344315a0; IWMSA, COMMUNICATION; KRASNOPOLSKY VA, 1993, J GEOPHYS RES-PLANET, V98, P3065, DOI 10.1029/92JE02680; LELLOUCH E, 1986, NATURE, V324, P227, DOI 10.1038/324227a0; NICHOLSON PD, 1995, ICARUS, V113, P57, DOI 10.1006/icar.1995.1005; OLKIN CB, IN PRESS ICARUS; POLLACK JB, 1990, SCIENCE, V250, P440, DOI 10.1126/science.250.4979.440; SICARDY B, 1990, NATURE, V343, P350, DOI 10.1038/343350a0; SMITH BA, 1989, SCIENCE, V246, P1422, DOI 10.1126/science.246.4936.1422; SODERBLOM LA, 1990, SCIENCE, V250, P410, DOI 10.1126/science.250.4979.410; SPENCER JR, 1992, ICARUS, V99, P261, DOI 10.1016/0019-1035(92)90145-W; STONE EC, 1989, SCIENCE, V246, P1417, DOI 10.1126/science.246.4936.1417; Strobel DF, 1996, ICARUS, V120, P266, DOI 10.1006/icar.1996.0050; Strobel DF, 1995, SPACE SCI S, P1107; YELLE RV, 1991, ICARUS, V89, P347, DOI 10.1016/0019-1035(91)90182-S; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	27	13	13	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					436	439		10.1126/science.278.5337.436	http://dx.doi.org/10.1126/science.278.5337.436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334297				2022-12-24	WOS:A1997YB35500037
J	Murphy, GG; Glanzman, DL				Murphy, GG; Glanzman, DL			Mediation of classical conditioning in Aplysia californica by long-term potentiation of sensorimotor synapses	SCIENCE			English	Article							GILL-WITHDRAWAL REFLEX; ASPARTATE RECEPTOR ANTAGONIST; SENSORY NEURONS; PRESYNAPTIC FACILITATION; CELLULAR MECHANISM; SYNAPTIC TRANSMISSION; SENSITIZATION; INTERNEURONS; HIPPOCAMPUS; TRANSMITTER	Long-term potentiation (LTP) is considered an important neuronal mechanism of learning and memory. Currently, however, there is no direct experimental link between LTP of an identified synapse and learning. A cellular analog of classical conditioning in Aplysia was used to determine whether this form of invertebrate learning involves N-methyl-D-aspartate (NMDA)-type LTP. The NMDA receptor-antagonist DL-2-amino-5-phosphonovalerate significantly disrupted synaptic enhancement after associative training but did not disrupt synaptic enhancement after nonassociative training. Thus, classical conditioning in Aplysia appears to be mediated, in part, by LTP due to activation of NMDA-related receptors.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,INTERDEPT GRAD PROGRAM NEUROSCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH011136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS029563, R01NS029563] Funding Source: NIH RePORTER; NIMH NIH HHS [F31-MH11136] Funding Source: Medline; NINDS NIH HHS [NS29563] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; BYRNE J, 1974, J NEUROPHYSIOL, V37, P1041, DOI 10.1152/jn.1974.37.5.1041; CAREW TJ, 1984, J NEUROSCI, V4, P1217; CAREW TJ, 1981, J NEUROSCI, V1, P1426; CAREW TJ, 1983, SCIENCE, V219, P397, DOI 10.1126/science.6681571; CASTELLUCCI VF, 1974, P NATL ACAD SCI USA, V71, P5004, DOI 10.1073/pnas.71.12.5004; CLARK GA, 1994, LEARN MEMORY, V1, P243; CLEARY LJ, 1995, LEARN MEMORY, V2, P133, DOI 10.1101/lm.2.3-4.133; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1993, P NATL ACAD SCI USA, V90, P7163, DOI 10.1073/pnas.90.15.7163; DAVIS S, 1992, J NEUROSCI, V12, P21; ELIOT LS, 1994, J NEUROSCI, V14, P368; FROST WN, 1988, J NEUROBIOL, V19, P297, DOI 10.1002/neu.480190402; FROST WN, 1995, J NEUROPHYSIOL, V73, P2413, DOI 10.1152/jn.1995.73.6.2413; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1995, TRENDS NEUROSCI, V18, P30, DOI 10.1016/0166-2236(95)93947-V; GLANZMAN DL, 1994, J NEUROBIOL, V25, P666, DOI 10.1002/neu.480250608; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HAWKINS RD, 1989, J NEUROSCI, V9, P4236; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P304, DOI 10.1152/jn.1981.45.2.304; HAWKINS RD, 1981, J NEUROPHYSIOL, V45, P315, DOI 10.1152/jn.1981.45.2.315; HEBB DO, 1949, ORG BEHAVIOR; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P113, DOI 10.1098/rspb.1994.0016; LIN XY, 1994, P ROY SOC B-BIOL SCI, V255, P215, DOI 10.1098/rspb.1994.0031; Lin XY, 1997, J NEUROPHYSIOL, V77, P667, DOI 10.1152/jn.1997.77.2.667; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MACKEY SL, 1989, J NEUROSCI, V9, P4227; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Murphy G.P., UNPUB; Murphy GG, 1996, P NATL ACAD SCI USA, V93, P9931, DOI 10.1073/pnas.93.18.9931; OCORR KA, 1985, P NATL ACAD SCI USA, V82, P2548, DOI 10.1073/pnas.82.8.2548; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; TRUDEAU LE, 1993, J NEUROPHYSIOL, V70, P1221, DOI 10.1152/jn.1993.70.3.1221; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; WALTERS ET, 1983, BRAIN RES, V280, P165, DOI 10.1016/0006-8993(83)91186-1; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x	49	109	113	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 17	1997	278	5337					467	471		10.1126/science.278.5337.467	http://dx.doi.org/10.1126/science.278.5337.467			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YB355	9334306				2022-12-24	WOS:A1997YB35500046
J	Fleming, DT; McQuillan, GM; Johnson, RE; Nahmias, AJ; Aral, SO; Lee, FK; StLouis, ME				Fleming, DT; McQuillan, GM; Johnson, RE; Nahmias, AJ; Aral, SO; Lee, FK; StLouis, ME			Herpes simplex virus type 2 in the United States, 1976 TO 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUALLY-TRANSMITTED DISEASES; GENITAL HERPES; RISK-FACTORS; INFECTION; TRANSMISSION; WOMEN; SEROCONVERSION; ANTIBODIES; REACTIVATION; PREVALENCE	Background Herpes simplex virus type 2 (HSV-2) infection is usually transmitted sexually and can cause recurrent, painful genital ulcers. In neonates the infection is potentially lethal. We investigated the seroprevalence and correlates of HSV-2 infection in the United States and identified changes in HSV-2 seroprevalence since the late 1970s. Methods Serum samples and questionnaire data were collected during the National Health and Nutrition Examination Surveys (NHANES) II (1976 to 1980) and III (1988 to 1994). HSV-2 antibody was assessed with an immunodot assay specific for glycoprotein gG-2 of HSV-2. Results From 1988 to 1994, the seroprevalence of HSV-2 in persons 12 years of age or older in the United States was 21.9 percent (95 percent confidence interval, 20.2 to 23.6 percent), corresponding to 45 million infected people in the noninstitutionalized civilian population. The seroprevalence was higher among women (25.6 percent) than men (17.8 percent) and higher among blacks (45.9 percent) than whites (17.6 percent). Less than 10 percent of all those who were seropositive reported a history of genital herpes infection. In a multivariate model, the independent predictors of HSV-2 seropositivity were female sex, black race or Mexican-American ethnic background, older age, less education, poverty, cocaine use, and a greater lifetime number of sexual partners. As compared with the period from 1976 to 1980, the age-adjusted seroprevalence of HSV-2 rose 30 percent (95 percent confidence interval, 15.8 to 45.8 percent). The seroprevalence quintupled among white teenagers and doubled among whites in their twenties. Among blacks and older whites, the increases were smaller. Conclusions Since the late 1970s, the prevalence of HSV-2 infection has increased by 30 percent, and HSV-2 is now detectable in roughly one of five persons 12 years of age or older nationwide. Improvements in the prevention of HSV-2 infection are needed, particularly since genital ulcers may facilitate the transmission of the human immunodeficiency virus. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,NATL CTR HIV STD & TB PREVENT,DIV STD PREVENT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; EMORY UNIV,SCH MED,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Emory University								ANDERSON JE, 1992, SEX TRANSM DIS, V19, P320, DOI 10.1097/00007435-199211000-00004; ARAL SO, 1991, JAMA-J AM MED ASSOC, V266, P2570, DOI 10.1001/jama.266.18.2570; ARAL SO, 1994, CHLAMYDIAL INFECT, P17; Becker TM, 1996, SEX TRANSM DIS, V23, P138, DOI 10.1097/00007435-199603000-00009; Bourne N, 1996, J INFECT DIS, V173, P800, DOI 10.1093/infdis/173.4.800; *BUR CENS, 1991, CURR POP REP SER P, V60; CAMERON DW, 1989, LANCET, V2, P403; Carmack MA, 1996, J INFECT DIS, V174, P899, DOI 10.1093/infdis/174.5.899; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; *CDCP DIV STD PREV, 1996, SEX TRANSM DIS SURV, P30; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; COREY L, 1994, SEX TRANSM DIS, V21, pS38; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; ELANDTJOHNSON RC, 1980, SURVIVAL MODELS DATA, P69; ENG TR, 1997, HIDDEN EPIDEMIC CONF, P1; EZZATI T, 1993, 1992 P SURV RES METH, P339; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507, DOI 10.1093/oxfordjournals.aje.a113568; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; *I MED, 1985, DIS IMP US, V1, P280; *INT WORK GROUP VA, 1996, AIDS, V10; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P87; KASSLER WJ, 1994, AIDS, V8, P351, DOI 10.1097/00002030-199403000-00009; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; KOST K, 1992, FAM PLANN PERSPECT, V24, P244, DOI 10.2307/2135853; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LAUMANN EO, 1994, SOCIAL ORG SEXUALITY, P172; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MCDOWELL A, 1981, DHHS PUBLICATION; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MOHADJER L, 1996, NATL HLTH NUTR EXAMI, V3; MORAN JS, 1989, PUBLIC HEALTH REP, V104, P560; MOSHER WD, 1990, FAM PLANN PERSPECT, V22, P198, DOI 10.2307/2135493; MOSHER WD, 1991, FAM PLANN PERSPECT, V23, P107; NAHMIAS AJ, 1973, NEW ENGL J MED, V289, P667, DOI 10.1056/NEJM197309272891305; NAHMIAS AJ, 1996, GENITAL NEONATAL HER, P93; *NAT CTR HLTH STAT, 1994, DHHS PUBL; OBERLE MW, 1989, AM J TROP MED HYG, V41, P224, DOI 10.4269/ajtmh.1989.41.224; OLEARY A, 1995, WOMEN RISK ISSUES PR, P13; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PROBER CG, 1992, CLIN INFECT DIS, V15, P1031, DOI 10.1093/clind/15.6.1031; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; SEIDMAN SN, 1992, AM J PUBLIC HEALTH, V82, P1297, DOI 10.2105/AJPH.82.9.1297; Shah BV, 1996, SUDAAN USERS MANUAL; SONENSTEIN FL, 1989, FAM PLANN PERSPECT, V21, P152, DOI 10.2307/2135805; Stanberry L. R., 1996, GENITAL NEONATAL HER, P109; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; STRAUS SE, 1996, 36 INT C ANT AG CHEM, P178; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; Wald A, 1996, ANN INTERN MED, V124, P8, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00002; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WALD A, 1996, 36 INT C ANT AG CHEM; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; 1993, MMWR-MORBID MORTAL W, V42, P589; 1991, MMWR-MORBID MORTAL W, V39, P929	58	868	907	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1105	1111		10.1056/NEJM199710163371601	http://dx.doi.org/10.1056/NEJM199710163371601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329932	Bronze			2022-12-24	WOS:A1997YA91200001
J	Yan, SD; Fu, J; Soto, C; Chen, X; Zhu, HJ; AlMohanna, F; Collison, K; Zhu, AP; Stern, E; Saido, T; Tohyama, M; Ogawa, S; Roher, A; Stern, D				Yan, SD; Fu, J; Soto, C; Chen, X; Zhu, HJ; AlMohanna, F; Collison, K; Zhu, AP; Stern, E; Saido, T; Tohyama, M; Ogawa, S; Roher, A; Stern, D			An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease	NATURE			English	Article							PRECURSOR PROTEIN; IN-VITRO; PRESENILIN-1; ACCUMULATION; APOPTOSIS; SECRETION; NEURONS; CELLS; GENERATION; EXPRESSION	Amyloid-beta is a neurotoxic peptide which Is implicated In the pathogenesis of Alzheimer's disease. It binds an intracellular polypeptide known as ERAB, thought to be a hydroxysteroid dehydrogenase enzyme, which Is expressed in normal tissues, but is overexpressed In neurons affected In Alzheimer's disease, ERAB immunoprecipitates with amyloid-beta, and when cell cultures are exposed to amyloid-beta, ERAB inside the cell is rapidly redistributed to the plasma membrane, The toxic effect of amyloid-beta on these cells is prevented by blocking ERAB and is enhanced by overexpression of ERAB. By Interacting with intracellular amyloid-beta, ERAB may therefore contribute to the neuronal dysfunction associated with Alzheimer's disease.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG & PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT CELLULAR BIOPHYS,NEW YORK,NY 10032; NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; KING FAISAL SPECIALIST HOSP & RES CTR,RIYADH 11211,SAUDI ARABIA; OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,SUITA,OSAKA 565,JAPAN; SUN HLTH RES INST,HALDEMAN LAB ALZHEIMERS DIS RES,SUN CITY,AZ 85372	Columbia University; Columbia University; New York University; King Faisal Specialist Hospital & Research Center; Osaka University; Banner Research; Banner Health; Banner Sun Health Research Institute	Yan, SD (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Fu, Jin/A-3510-2012	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; 				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ELKHOURY J, 1996, NATURE, V382, P685; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRACKOWIAK J, 1995, BRAIN RES, V676, P225, DOI 10.1016/0006-8993(94)01465-T; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Roses AD, 1996, NAT MED, V2, P267, DOI 10.1038/nm0396-267; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/0304-3940(96)12970-0; SCHEMBRI MA, 1995, J BACTERIOL, V177, P4501, DOI 10.1128/jb.177.15.4501-4507.1995; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; TIERNARI P, 1997, P NATL ACAD SCI USA, V94, P4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Urmoneit B, 1997, LAB INVEST, V77, P157; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7784; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	48	319	354	2	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 16	1997	389	6652					689	695						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA959	9338779				2022-12-24	WOS:A1997YA95900043
J	ShattuckEidens, D; Oliphant, A; McClure, M; McBride, C; Gupte, J; Rubano, T; Pruss, D; Tavtigian, SV; Teng, DHF; Adey, N; Staebell, M; Gumpper, K; Lundstrom, R; Hulick, M; Kelly, M; Holmen, J; Lingenfelter, B; Manley, S; Fujimura, F; Luce, M; Ward, B; CannonAlbright, L; Steele, L; Offit, K; Gilewski, T; Norton, L; Brown, K; Schulz, C; Hampel, H; Schluger, A; Giulotto, E; Zoli, W; Ravaioli, A; Nevanlinna, H; Pyrhonen, S; Rowley, P; Loader, S; Osborne, MP; Daly, M; Tepler, I; Weinstein, PL; Scalia, JL; Michaelson, R; Scott, RJ; Radice, P; Pierotti, MA; Garber, JE; Isaacs, C; Peshkin, B; Lippman, ME; Dosik, MH; Caligo, MA; Greenstein, RM; Pilarski, R; Weber, B; Burgemeister, R; Frank, TS; Skolnick, MH; Thomas, A				ShattuckEidens, D; Oliphant, A; McClure, M; McBride, C; Gupte, J; Rubano, T; Pruss, D; Tavtigian, SV; Teng, DHF; Adey, N; Staebell, M; Gumpper, K; Lundstrom, R; Hulick, M; Kelly, M; Holmen, J; Lingenfelter, B; Manley, S; Fujimura, F; Luce, M; Ward, B; CannonAlbright, L; Steele, L; Offit, K; Gilewski, T; Norton, L; Brown, K; Schulz, C; Hampel, H; Schluger, A; Giulotto, E; Zoli, W; Ravaioli, A; Nevanlinna, H; Pyrhonen, S; Rowley, P; Loader, S; Osborne, MP; Daly, M; Tepler, I; Weinstein, PL; Scalia, JL; Michaelson, R; Scott, RJ; Radice, P; Pierotti, MA; Garber, JE; Isaacs, C; Peshkin, B; Lippman, ME; Dosik, MH; Caligo, MA; Greenstein, RM; Pilarski, R; Weber, B; Burgemeister, R; Frank, TS; Skolnick, MH; Thomas, A			BRCA 1 sequence analysis in women at high risk for susceptibility mutations - Risk factor analysis and implications for genetic testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER FAMILIES; PROTEIN TRUNCATION TEST; OVARIAN-CANCER; STRONG CANDIDATE; POLYMORPHISMS; FREQUENCY	Context.-A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer, However, knowledge regarding all possible mutations and the relationship between risk factors and mutations is incomplete. Objectives.-To identify BRCA1 mutations and to determine factors that best predict presence of a deleterious BRCA1 mutation in patients with breast and/or ovarian cancer. Design.-A complete sequence analysis of the BRCA1 coding sequence and flanking intronic regions was performed in 798 women in a collaborative effort involving institutions from the United States, Italy, Germany, Finland, and Switzerland. Participants.-Institutions selected 798 persons representing families (1 person for each family) thought to be at elevated a priori risk of BRCA1 mutation due to potential risk factors, such as multiple cases of breast cancer, early age of breast cancer diagnosis, and cases of ovarian cancer, No participant was from a family in which genetic markers showed linkage to the BRCA1 locus. Major Outcome Measures.-Sequence variants detected in this sample are presented along with analyses designed to determine predictive characteristics of those testing positive for BRCA1 mutations. Results.-In 102 women (12.8%), clearly deleterious mutations were detected. Fifty new genetic alterations were found including 24 deleterious mutations, 24 variants of unknown significance, and 2 rare polymorphisms. In a subset of 71 Ashkenazi Jewish women, only 2 distinct deleterious mutations were found: 185delAG in 17 cases and 5382insC in 7 cases. A bias in prior reports for mutations in exon 11 was revealed, Characteristics of a patient's specific diagnosis (unilateral or bilateral breast cancer, with or without ovarian cancer), early age at diagnosis, Ashkenazi Jewish ethnicity, and family history of cancer were positively associated with the probability of her carrying a deleterious BRCA1 mutation. Conclusions.-Using logistic regression analysis, we provide a method for evaluating the probability of a woman's carrying a deleterious BRCA1 mutation for a wide range of cases, which can be an important tool for clinicians as they incorporate genetic susceptibility testing into their medical practice.	MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA; MYRIAD GENET LABS INC, SALT LAKE CITY, UT USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY USA; UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY; OSPED GB MORGAGNI L PIERANTONE, DEPT MED ONCOL, FORLI, ITALY; IST ONCOL ROMAGNOLO, FORLI, ITALY; OSPED INFERMI RIMINI, DEPT ONCOL, RIMINI, ITALY; UNIV HELSINKI, CENT HOSP, DEPT OBSTET & GYNECOL, FIN-00290 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT ONCOL, HELSINKI, FINLAND; UNIV ROCHESTER, ROCHESTER, NY USA; STRANG CANC PREVENT CTR, NEW YORK, NY USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; BENNETT CANC CTR, STAMFORD, CT USA; CANC CTR ST BARNABAS, LIVINGSTON, NJ USA; KANTONSSPITAL, DEPT FORSCH, CH-4031 BASEL, SWITZERLAND; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; DANA FARBER CANC INST, BOSTON, MA 02115 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; N SHORE HEMATOL ONCOL ASSOCIATES PC, SETAUKET, NY USA; IST ANAT PATOL, PISA, ITALY; UNIV CONNECTICUT, HLTH SCI CTR, DIV HUMAN GENET, FARMINGTON, CT USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	Myriad Genetics, Inc; Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Memorial Sloan Kettering Cancer Center; University of Pavia; Hospital of Rimini; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Rochester; Fox Chase Cancer Center; Kantonsspital Aarau AG (KSA); University of Basel; Fondazione IRCCS Istituto Nazionale Tumori Milan; Harvard University; Dana-Farber Cancer Institute; Georgetown University; University of Connecticut; University of Pennsylvania			Radice, Paolo/O-3119-2013; Scott, Rodney J/B-2827-2013; Pilarski, Robert/E-3871-2011; Hampel, Heather/AAV-4041-2020; Pilarski, Robert/X-3256-2019; Caligo, Adelaide Maria/K-4289-2018	Radice, Paolo/0000-0001-6298-4111; Scott, Rodney J/0000-0001-7724-3404; Hampel, Heather/0000-0001-7558-9794; Caligo, Adelaide Maria/0000-0003-0589-1829; Pierotti, Marco Alessandro/0000-0002-7431-8332; GIULOTTO, ELENA/0000-0002-4705-2049; albright, lisa/0000-0003-2602-3668; Thomas, Alun/0000-0001-5650-7044	NCI NIH HHS [CA-55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM CANC SOC, 1997, CANC FACTS FIG 1997; Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Barker DF, 1996, GENET EPIDEMIOL, V13, P595; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Berman DB, 1996, AM J HUM GENET, V58, P1166; Brown MA, 1996, ONCOGENE, V12, P2507; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; Puget N, 1997, CANCER RES, V57, P828; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Serova O, 1996, AM J HUM GENET, V58, P42; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TAVTIGIAN SV, 1997, GEN MOTORS CANC RES; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	29	312	318	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1242	1250		10.1001/jama.278.15.1242	http://dx.doi.org/10.1001/jama.278.15.1242			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333265				2022-12-24	WOS:A1997XZ70900029
J	Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI				Malmberg, AB; Chen, C; Tonegawa, S; Basbaum, AI			Preserved acute pain and reduced neuropathic pain in mice lacking PKC gamma	SCIENCE			English	Article							PROTEIN-KINASE-C; RAT SPINAL-CORD; SENSORY NEURONS; DORSAL HORN; MUTANT MICE; NERVE INJURY; SUBSTANTIA GELATINOSA; JOINT INFLAMMATION; PERSISTENT PAIN; INCREASES	In normal animals, peripheral nerve injury produces a persistent, neuropathic pain state in which pain is exaggerated and can be produced by nonpainful stimuli. Here, mice that lack protein kinase C gamma (PKC gamma) displayed normal responses to acute pain stimuli, but they almost completely failed to develop a neuropathic pain syndrome after partial sciatic nerve section, and the neurochemical changes that occurred in the spinal cord after nerve injury were blunted. Also, PKC gamma was shown to be restricted to a small subset of dorsal horn neurons, thus identifying a potential biochemical target for the prevention and therapy of persistent pain.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 92143 USA; UNIV CALIF SAN FRANCISCO, WM KECK FDN CTR INTEGRAT NEUROSCI, SAN FRANCISCO, CA 92143 USA; MIT, CTR CANC RES, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Malmberg, AB (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 92143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014627, P50NS021445, P01NS021445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008377] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08377] Funding Source: Medline; NINDS NIH HHS [NS 21445, NS 14627] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbadie C, 1996, NEUROSCIENCE, V70, P201, DOI 10.1016/0306-4522(95)00343-H; ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BENNETT GJ, 1980, J COMP NEUROL, V194, P809, DOI 10.1002/cne.901940407; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CODERRE TJ, 1992, NEUROSCI LETT, V140, P181, DOI 10.1016/0304-3940(92)90097-Q; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; CODERRE TJ, 1989, J NEUROPHYSIOL, V62, P48, DOI 10.1152/jn.1989.62.1.48; Dubner R, 1994, TXB PAIN, P225; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HARGREAVES KM, 1990, AM J PHYSIOL, V258, pE235, DOI 10.1152/ajpendo.1990.258.2.E235; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUNT SP, 1992, SENSORY NEURONS DIVE, P60; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KNYIHARCSILLIK E, 1981, PROG HISTOCHEM CYTOC, V14, P1; LANGFORD LA, 1979, J COMP NEUROL, V184, P193, DOI 10.1002/cne.901840111; LIGHT AR, 1979, J COMP NEUROL, V186, P151, DOI 10.1002/cne.901860204; Lin Q, 1996, J NEUROSCI, V16, P3026; LIU HT, 1994, P NATL ACAD SCI USA, V91, P1009, DOI 10.1073/pnas.91.3.1009; Malmberg AB, 1997, J NEUROSCI, V17, P7462; MAO J, 1993, J NEUROPHYSIOL, V70, P470, DOI 10.1152/jn.1993.70.2.470; MAO JR, 1995, NEUROSCI LETT, V198, P75, DOI 10.1016/0304-3940(95)11975-3; MAO JR, 1992, BRAIN RES, V588, P144, DOI 10.1016/0006-8993(92)91354-H; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; NAHIN RL, 1994, PAIN, V58, P95, DOI 10.1016/0304-3959(94)90189-9; PALECEK J, 1994, J NEUROPHYSIOL, V71, P529, DOI 10.1152/jn.1994.71.2.529; REES H, 1995, J PHYSIOL-LONDON, V484, P437, DOI 10.1113/jphysiol.1995.sp020676; Schafer M, 1997, EUR J PHARMACOL, V323, P1, DOI 10.1016/S0014-2999(97)00057-5; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; SLUKA KA, 1993, NEUROREPORT, V5, P109, DOI 10.1097/00001756-199311180-00003; SLUKA KA, 1993, PAIN, V55, P217, DOI 10.1016/0304-3959(93)90150-N; WAKISAKA S, 1991, NEUROSCI LETT, V124, P200, DOI 10.1016/0304-3940(91)90093-9; WOOLF CJ, 1983, J COMP NEUROL, V221, P313, DOI 10.1002/cne.902210307	39	530	565	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	1997	278	5336					279	283		10.1126/science.278.5336.279	http://dx.doi.org/10.1126/science.278.5336.279			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA564	9323205				2022-12-24	WOS:A1997YA56400042
J	Imamura, T; Takase, M; Nishihara, A; Oeda, E; Hanai, J; Kawabata, M; Miyazono, K				Imamura, T; Takase, M; Nishihara, A; Oeda, E; Hanai, J; Kawabata, M; Miyazono, K			Smad6 inhibits signalling by the TGF-beta superfamily	NATURE			English	Article							MAD-RELATED PROTEIN; SIGNALING PATHWAYS; RECEPTORS	SMBD proteins(1) have been identified as signalling mediators of the TGF-beta superfamily, which is involved in a range of biological activities including cell growth, morphogenesis, development and immune responses(2,3). Smad1, Smad2, Smad3 and Smad5 are ligand-specific Smad1 and Smad5 transduce signals from bone morphogenetic proteins(4-7), and Smad2 and Smad3 mediate signalling by TGF-beta and activin(8,9), whereas Smad4 acts as a common signalling component(10). For example, Smad2 is phosphorylated by the TGF-beta type I receptor upon ligand binding, forms a heteromer with Smad4 and then translocates into the nucleus where it activates transcription(10,11). Here we report the isolation of Smad6 in the mouse. Smad6 is quite different in structure from the other SMAD proteins, and forms stable associations with type I receptors. Smad6 interferes with the phosphorylation of Smad2 and the subsequent heteromerization with Smad4, but does not inhibit the activity of Smad3, Smad6 also inhibits the phosphorylation of Smad1 that is induced by the bone morphogenetic protein type IB receptor. These data indicate that signals of the TGF-beta superfamily are regulated both positively and negatively by members of the SMAD family.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; JAPAN SOC PROMOT SCI,RES FUTURE PROGRAM,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research; Japan Society for the Promotion of Science								Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NAKAO A, IN PRESS EMBO J; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	16	840	885	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					622	626		10.1038/39355	http://dx.doi.org/10.1038/39355			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335505				2022-12-24	WOS:A1997YA00800065
J	Singleton, L; Turner, M; Haskal, R; Etkind, S; Tricarico, M; Nardell, E				Singleton, L; Turner, M; Haskal, R; Etkind, S; Tricarico, M; Nardell, E			Long-term hospitalization for tuberculosis control - Experience with a medical-psychosocial inpatient unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; HEALTH; BABY	Context.-Patients with tuberculosis (TB) who are nonadherent to therapy or have complicated medical or social problems pose a threat to public health. In some cases, hospitalization may be a necessary component of a comprehensive TB control program. Objective.-To describe experience with a new inpatient program for TB control. Design.-Retrospective review. Setting.-Eighteen-bed, secure, TB treatment unit in a state public health hospital providing a spectrum of acute and chronic care services. Patients.-Patients with known or suspected TB who were unable to be treated as outpatients and were hospitalized from 1990 through 1995. Interventions.-voluntary or involuntary hospitalization, with medical, psychosocial, and legal services. Main Outcome Measures.-Admissions, treatment completion, and disposition. Results.-A total of 166 patients with a confirmed diagnosis of TB accounted for 214 hospitalizations for TB. The mean age was 42 years, 132 (79.5%) were men, 84 (50.6%) were nonwhite, and 45 (27.1%) were foreign born. At the time of admission, 58 patients (34.5%) were homeless, 116 (69.9%) had a history of abuse of alcohol or other drugs, and 46 (31.7%) were positive for human immunodeficiency virus. The mean length of stay was 119.7 days (median, 70 days; range, 7-656 days), and was higher among homeless patients than nonhomeless patients (168.8 vs 93.4 days). Of 48 patients (28.9%) who were admitted involuntarily, 21 required long-term confinement under court order. Admission indications (not mutually exclusive) changed over 5 years: nonadherence decreased (95% to 34%), medical complexity increased (14% to 77%), short-term isolation increased (19% to 39%), and involuntary admission decreased (54% to 13%). Of 157 patients with positive cultures for Mycobacterium tuberculosis, 36 (23.1%) were resistant to at least 1 drug, including 16 who were multidrug resistant. A total of 123 patients (74.7%) were discharged to an outpatient setting to complete therapy, 40 (24.1%) required inpatient care to complete therapy, and 3 died (1 from TB) before discharge. Conclusions.-A high proportion of patients with TB who failed outpatient therapy completed treatment in a combined medical and psychosocial inpatient unit. During the 5-year study period, involuntary admissions decreased and most patients completed therapy as outpatients. In Massachusetts, this program plays an important role in protecting public health and in providing specialized medical management for patients to complete therapy in a safe and supportive environment.	MASSACHUSETTS DEPT PUBL HLTH,LEMUEL SHATTUCK HOSP,BOSTON,MA 02130	Massachusetts Department of Public Health	Singleton, L (corresponding author), MASSACHUSETTS DEPT PUBL HLTH,DEPT PUBL HLTH,DIV TB PREVENT & CONTROL,305 S ST,BOSTON,MA 02130, USA.							ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; *AM LUNG ASS S CAR, 1989, US INC EN TUB CONTR; ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; EARNEST M, 1996, TUBERCULOSIS, P927; Etkind S, 1991, Semin Respir Infect, V6, P273; ETKIND SC, 1996, TUBERCULOSIS, P945; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GUNDERSON JG, 1978, PSYCHIATRY, V41, P327, DOI 10.1080/00332747.1978.11023992; HARSCH HH, 1989, PSYCHOSOMATICS, V30, P313; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; POZIK CJ, 1993, MED CLIN N AM, V77, P1289; RUBEL AJ, 1992, PUBLIC HEALTH REP, V107, P626; SBARBARO JA, 1986, CHEST, V90, P754, DOI 10.1378/chest.90.5.754; STOUDEMIRE A, 1986, PSYCHOSOMATICS, V27, P341, DOI 10.1016/S0033-3182(86)72685-6; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; TURNER M, 1995, AM J RESP CRIT CAR 2, V151, pA554; TURNER M, 1994, AM J RESP CRIT CAR 2, V149, pA257; *US DEP HHS, 1994, IMPR PAT ADH TUB TRE; YEAGER H, 1986, CHEST, V90, P752, DOI 10.1378/chest.90.5.752	22	40	46	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					838	842		10.1001/jama.278.10.838	http://dx.doi.org/10.1001/jama.278.10.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU552	9293992				2022-12-24	WOS:A1997XU55200039
J	Meyerson, M; Counter, CM; Eaton, EN; Ellisen, LW; Steiner, P; Caddle, SD; Ziaugra, L; Beijersbergen, RL; Davidoff, MJ; Liu, QY; Bacchetti, S; Haber, DA; Weinberg, RA				Meyerson, M; Counter, CM; Eaton, EN; Ellisen, LW; Steiner, P; Caddle, SD; Ziaugra, L; Beijersbergen, RL; Davidoff, MJ; Liu, QY; Bacchetti, S; Haber, DA; Weinberg, RA			hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization	CELL			English	Article							TETRAHYMENA-TELOMERASE; EPITHELIAL-CELLS; HUMAN GENOME; HUMAN FIBROBLASTS; RNA COMPONENT; MAP; IDENTIFICATION; LYMPHOCYTES; SENESCENCE; CARCINOMA	Telomerase, the ribonucleoprotein enzyme that elongates telomeres, is repressed in normal human somatic cells but is reactivated during tumor progression. We report the cloning of a human gene, hEST2, that shares significant sequence similarity with the telomerase catalytic subunit genes of lower eukaryotes. hEST2 is expressed at high levels in primary tumors, cancer cell lines, and telomerase-positive tissues but is undetectable in telomerase-negative cell lines and differentiated telomerase-negative tissues. Moreover, the message is up-regulated concomitant with the activation of telomerase during the immortalization of cultured cells and down-regulated during in vitro cellular differentiation. Taken together, these observations suggest that the induction of hEST2 mRNA expression is required for the telomerase activation that occurs during cellular immortalization and tumor progression.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,CHARLESTOWN,MA 02129; MERCK RES LABS,DEPT HUMAN GENET,W POINT,PA 19486; MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Merck & Company; McMaster University	Meyerson, M (corresponding author), MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.		Meyerson, Matthew L/E-7123-2012; Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910; Beijersbergen, Roderick/0000-0003-0116-4130; Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R37CA058596, R01CA058596, R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58596, CA 39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avilion AA, 1996, CANCER RES, V56, P645; Balsara BR, 1997, CANCER RES, V57, P2116; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHUMAKOV IM, 1995, NATURE, V377, P175; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gollahon LS, 1996, ONCOGENE, V12, P715; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER CW, 1995, TELOMERES, P35; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Petersen I, 1997, CANCER RES, V57, P2331; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wright WE, 1996, DEV GENET, V18, P173; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Xu D, 1996, LEUKEMIA, V10, P1354; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	65	1591	1803	1	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					785	795		10.1016/S0092-8674(00)80538-3	http://dx.doi.org/10.1016/S0092-8674(00)80538-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288757	Bronze			2022-12-24	WOS:A1997XT06600021
J	Greenfield, EM; Goldberg, VM				Greenfield, EM; Goldberg, VM			Genetic determination of bone density	LANCET			English	Editorial Material							OSTEOPOROSIS; ALLELES; VIEW				Greenfield, EM (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPAED, CLEVELAND, OH 44106 USA.							BEAMER W, 1997, J BONE MINER RES, V12, P174; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; Gong YQ, 1996, AM J HUM GENET, V59, P146; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; Lewallen DG, 1995, AAOS INSTR COURS LEC, V44, P287; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; Ralston SH, 1997, SCAND J CLIN LAB INV, V57, P114; Rogers J, 1997, ANN RHEUM DIS, V56, P85, DOI 10.1136/ard.56.2.85; Vezyroglou G, 1996, J RHEUMATOL, V23, P672	9	23	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1263	1264		10.1016/S0140-6736(05)62468-3	http://dx.doi.org/10.1016/S0140-6736(05)62468-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357401				2022-12-24	WOS:A1997YD68900003
J	Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B				Pedersen, AT; Lidegaard, O; Kreiner, S; Ottesen, B			Hormone replacement therapy and risk of non-fatal stroke	LANCET			English	Article							POSTMENOPAUSAL ESTROGEN; CARDIOVASCULAR-DISEASE; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; FOLLOW-UP; WOMEN; USERS; COPENHAGEN; MORTALITY; COHORT	Background The effect of postmenopausal hormone replacement therapy (HRT) on the risk of subtypes of stroke is as yet unclear. To investigate the effect of oestrogen and combined oestrogen-progestagen therapy on the risk of nonfatal haemorrhagic and thromboembolic stroke, we carried out a case-control study. Methods From the Danish National Patient Register we identified all Danish women aged 45-64 years who had a non-fatal, first-ever cerebrovascular attack during 1990-92. Two age-matched controls were randomly selected for each case from the Danish National Person Register. Important correlates of hormone use and stroke, on which information was obtained from postal questionnaires, were controlled for by multivariate analyses based on log-linear graphical models. The analyses included data on 1422 cases classified in four subtypes of stroke (160 subarachnoid haemorrhage, 95 intracerebral haemorrhage, 846 thromboembolic infarction, 321 transient ischaemic attack) and 3171 controls. Findings After adjustment for confounding variables and correction for the trend in sales of HRT preparations, no significant associations were detected between current use of unopposed oestrogen replacement therapy and non-fatal subarachnoid haemorrhage (odds ratio 0.52 [95% CI 0.23-1.22]), intracerebral haemorrhage (0.15 [0.02-1.09]), or thromboembolic infarction (1.16 [0.86-1.58]), respectively, compared with never use. Current use of combined oestrogen-progestagen replacement therapy had no significant influence on the risk of subarachnoid haemorrhage (1.22 [0.79-1.89]), intracerebral haemorrhage (1.17 [0.64-2.13]), or thromboembolic infarction (1.17 [0.92-1.47]). A significantly increased incidence of transient ischaemic attacks among former users of HRT and among current users of unopposed oestrogen may to some extent be explained by selection-HRT users being more aware of symptoms than non-users. Interpretation Unopposed oestrogen and combined oestrogen-progestagen replacement therapy have no influence on the risk of non-fatal thromboembolic or haemorrhagic stroke in women aged 45-64 years.	UNIV COPENHAGEN, INST SOCIOL, COPENHAGEN, DENMARK; HERLEV HOSP, DEPT OBSTET & GYNAECOL, DK-2730 HERLEV, DENMARK	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Pedersen, AT (corresponding author), UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT OBSTET & GYNAECOL 537, KETTEGARDS ALLEE 30, DK-2650 HVIDOVRE, DENMARK.							[Anonymous], [No title captured]; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DARROCH JN, 1980, ANN STAT, V8, P522, DOI 10.1214/aos/1176345006; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; Falkeborn M, 1996, EPIDEMIOLOGY, V7, P67, DOI 10.1097/00001648-199601000-00012; FEINBERG WM, 1994, CIRCULATION, V89, P2950, DOI 10.1161/01.CIR.89.6.2950; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; KLEIN JP, 1995, STAT MED, V14, P1265, DOI 10.1002/sim.4780141202; LINDEGAARD O, 1993, BRIT MED J, V306, P956; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; PFEFFER RI, 1978, J CHRON DIS, V31, P389, DOI 10.1016/0021-9681(78)90003-6; ROSENBERG SH, 1980, WESTERN J MED, V133, P292; SALOMAA V, 1995, ARTERIOSCL THROM VAS, V15, P1549, DOI 10.1161/01.ATV.15.10.1549; SPEROFF L, 1996, EUR MENOPAUSE J, V3, P151; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; THOMPSON SG, 1989, J EPIDEMIOL COMMUN H, V43, P173, DOI 10.1136/jech.43.2.173; WERMUTH N, 1990, J ROY STAT SOC B MET, V52, P21; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; ZHANG XH, 1995, STROKE, V26, P1774, DOI 10.1161/01.STR.26.10.1774	33	122	122	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	1997	350	9087					1277	1283		10.1016/S0140-6736(97)06005-4	http://dx.doi.org/10.1016/S0140-6736(97)06005-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357407				2022-12-24	WOS:A1997YD68900009
J	Nelsen, SF; Ismagilov, RF; Trieber, DA				Nelsen, SF; Ismagilov, RF; Trieber, DA			Adiabatic electron transfer: Comparison of modified theory with experiment	SCIENCE			English	Article							CHARGE RECOMBINATION; DISTANCE DEPENDENCE; SOLVENT DEPENDENCE; ACCEPTOR COMPOUNDS; RADICAL-CATION; BIS(HYDRAZINE); SEPARATION; MOLECULES; COMPLEXES; BRIDGES	The radical cations of properly designed bishydrazines allow comparison of observed and calculated electron transfer rate constants. These compounds have rate constants small enough to be measured by dynamic electron spin resonance spectroscopy and show charge transfer bands corresponding to vertical excitation from the energy well for the charge occurring upon one hydrazine unit to that for the electron-transferred species. Analysis of the data for all six compounds studied indicates that the shape of the adiabatic surface on which electron transfer occurs can be obtained from the charge transfer band accurately enough to successfully predict the electron transfer rate constant and that explicit tunneling corrections are not required for these compounds.			Nelsen, SF (corresponding author), UNIV WISCONSIN,DEPT CHEM,1101 UNIV AVE,MADISON,WI 53706, USA.							Barbara PF, 1996, J PHYS CHEM-US, V100, P13148, DOI 10.1021/jp9605663; BIXON M, 1994, J AM CHEM SOC, V116, P7349, DOI 10.1021/ja00095a044; CLOSS GL, 1988, SCIENCE, V240, P440, DOI 10.1126/science.240.4851.440; CORTES J, 1994, J PHYS CHEM-US, V98, P2527, DOI 10.1021/j100061a006; CREUTZ C, 1983, PROG INORG CHEM, V30, P1, DOI 10.1002/9780470166314.ch1; CREUTZ C, 1994, J PHOTOCH PHOTOBIO A, V82, P47, DOI 10.1016/1010-6030(94)02013-2; DOORN SK, 1989, J AM CHEM SOC, V111, P1142, DOI 10.1021/ja00185a062; GOULD IR, 1994, J AM CHEM SOC, V116, P8188, DOI 10.1021/ja00097a028; GOULD IR, 1993, CHEM PHYS, V176, P439, DOI 10.1016/0301-0104(93)80253-6; Hush N. S., 1967, PROGR INORG CHEM, V8, P391, DOI [10.1002/9780470166093.CH7, DOI 10.1002/9780470166093.CH7]; HUSH NS, 1985, COORDIN CHEM REV, V64, P135, DOI 10.1016/0010-8545(85)80047-3; HUSH NS, 1985, CHEM PHYS LETT, V117, P8, DOI 10.1016/0009-2614(85)80394-8; JORTNER J, 1988, J CHEM PHYS, V88, P167, DOI 10.1063/1.454632; JORTNER J, 1975, J CHEM PHYS, V63, P4358; KROON J, 1993, J PHYS CHEM-US, V97, P5065, DOI 10.1021/j100121a036; KROON J, 1991, ANGEW CHEM INT EDIT, V30, P1358, DOI 10.1002/anie.199113581; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEYERS AB, 1996, CHEM REV, V96, P911; Nelsen SF, 1996, J AM CHEM SOC, V118, P2047, DOI 10.1021/ja952539g; Nelsen SF, 1997, J AM CHEM SOC, V119, P6863, DOI 10.1021/ja963415m; NELSEN SF, 1993, J AM CHEM SOC, V115, P12276, DOI 10.1021/ja00079a007; NELSEN SF, 1994, J AM CHEM SOC, V116, P1589, DOI 10.1021/ja00083a062; Nelsen SF, 1996, J AM CHEM SOC, V118, P6313, DOI 10.1021/ja960500l; NELSEN SF, IN PRESS J AM CHEM S; OEVERING H, 1987, J AM CHEM SOC, V109, P3258, DOI 10.1021/ja00245a014; OEVERING H, 1989, TETRAHEDRON, V45, P4751, DOI 10.1016/S0040-4020(01)85150-4; PADDONROW MN, 1988, J PHYS CHEM-US, V92, P6958, DOI 10.1021/j100335a024; Prassides K., 1991, MIXED VALENCY SYSTEM; SUTIN N, 1983, PROG INORG CHEM, V30, P441, DOI 10.1002/9780470166314.ch9; WARMAN JM, 1991, J PHYS CHEM-US, V95, P1979, DOI 10.1021/j100158a018; WASLELEWSKI MR, 1992, CHEM REV, V92, P435	31	121	121	3	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 31	1997	278	5339					846	849		10.1126/science.278.5339.846	http://dx.doi.org/10.1126/science.278.5339.846			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346480	Green Accepted			2022-12-24	WOS:A1997YD47900042
J	Luh, FY; Archer, SJ; Domaille, PJ; Smith, BO; Owen, D; Brotherton, DH; Raine, ARC; Xu, X; Brizuela, L; Brenner, SL; Laue, ED				Luh, FY; Archer, SJ; Domaille, PJ; Smith, BO; Owen, D; Brotherton, DH; Raine, ARC; Xu, X; Brizuela, L; Brenner, SL; Laue, ED			Structure of the cyclin-dependent kinase inhibitor p19(Ink4d)	NATURE			English	Article							FAMILIAL MELANOMA; LARGER PROTEINS; TUMOR; CDK4; P16(INK4); NMR; SPECTROSCOPY; ALLELES; ANKYRIN; P19	In cancer, the biochemical pathways that are dominated by the two tumour-suppressor proteins, p53 and Rb, are the most frequently disrupted. Cyclin D-dependent kinases phosphorylate Rb to control its activity and they are, in turn, specifically inhibited by the Ink4 family of cyclin-dependent kinase inhibitors (CDKIs) which cause arrest at the G1 phase of the cell cycle. Mutations in Rb, cyclin D1, its catalytic subunit Cdk4, and the CDKI p16(Ink4a), which alter the protein or its level of expression, are all strongly implicated in cancer. This suggests that the Rb 'pathway' is of particular importance(1). Here we report the structure of the p19(Ink4d) protein, determined by NMR spectroscopy(2-4). The structure indicates that most mutations to the p16(Ink4a) gene, which result in loss of function, are due to incorrectly folded and/or insoluble protein(5). We propose a model for the interaction of Ink4 proteins with D-type cyclin-Cdk4/6 complexes that might provide a basis for the design of therapeutics against cancer.	UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CTR MOL RECOGNIT, CAMBRIDGE CB2 1QW, ENGLAND; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA	University of Cambridge; DuPont			; Smith, Brian/J-1899-2015	Laue, Ernest/0000-0002-7476-4148; Smith, Brian/0000-0003-3363-4168; Luh, Frederick/0000-0001-5180-8489	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Clowes Robin T., 1995, Current Opinion in Biotechnology, V6, P81, DOI 10.1016/0958-1669(95)80013-1; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Kalus W, 1997, FEBS LETT, V401, P127, DOI 10.1016/S0014-5793(96)01465-2; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Parry D, 1996, MOL CELL BIOL, V16, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith BO, 1996, J BIOMOL NMR, V8, P360, DOI 10.1007/BF00410335; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WICK ST, 1995, ONCOGENE, V11, P2013; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YANG R, 1995, CANCER RES, V55, P2503; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734	30	89	92	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 30	1997	389	6654					999	1003		10.1038/40202	http://dx.doi.org/10.1038/40202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD299	9353127				2022-12-24	WOS:A1997YD29900063
J	Yang, DD; Kuan, CY; Whitmarsh, AJ; Rincon, M; Zheng, TS; Davis, RJ; Rakic, P; Flavell, RA				Yang, DD; Kuan, CY; Whitmarsh, AJ; Rincon, M; Zheng, TS; Davis, RJ; Rakic, P; Flavell, RA			Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene	NATURE			English	Article							EXCITATORY AMINO-ACIDS; KAINIC ACID; NERVOUS-SYSTEM; C-JUN; BRAIN-DAMAGE; KINASE; NEUROTOXICITY; GLUTAMATE; PATHWAY; SEIZURE	Excitatory amino acids induce both acute membrane depolarization and latent cellular toxicity, which often leads to apoptosis in many neurological disorders(1,2). Recent studies indicate that glutamate toxicity may involve the c-Jun amino-terminal kinase (JNK) group of mitogen-activated protein (MAP) kinases(3-5). One member of the JNK family, Jnk3, may be required for stress-induced neuronal apoptosis, as it is Selectively expressed in the nervous system(6,7). Here we report that disruption of the gene encoding Jnk3 in mice caused the mice to be resistant to the excitotoxic glutamate-receptor agonist kainic acid: they showed a reduction in seizure activity and hippocampal neuron apoptosis was prevented. Although application of kainic add imposed the same level of noxious stress, the phosphorylation of c-Jun and the transcriptional activity of the AP-1 transcription factor complex were markedly reduced in the mutant mice. These data indicate that the observed neuroprotection is due to the extinction of a Jnk3-mediated signalling, pathway, which is an important component in the pathogenesis of glutamate neurotoxicity.	YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV VERMONT, DEPT MED, IMMUNOBIOL PROGRAM, BURLINGTON, VT 05405 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont				Whitmarsh, Alan/0000-0003-1184-6610				BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BERGER M, 1983, NEUROSCI LETT, V39, P237, DOI 10.1016/0304-3940(83)90306-3; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FERKANY JW, 1984, NATURE, V308, P561, DOI 10.1038/308561a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; KASOF GM, 1995, J NEUROSCI, V15, P4238; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	30	1081	1140	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 23	1997	389	6653					865	870		10.1038/39899	http://dx.doi.org/10.1038/39899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YC148	9349820				2022-12-24	WOS:A1997YC14800061
J	Malagnac, F; Wendel, B; Goyon, C; Faugeron, G; Zickler, D; Rossignol, JL; NoyerWeidner, M; Vollmayr, P; Trautner, TA; Walter, J				Malagnac, F; Wendel, B; Goyon, C; Faugeron, G; Zickler, D; Rossignol, JL; NoyerWeidner, M; Vollmayr, P; Trautner, TA; Walter, J			A gene essential for de novo methylation and development in ascobolus reveals a novel type of eukaryotic DNA methyltransferase structure	CELL			English	Article							CYTOSINE METHYLTRANSFERASE; ARABIDOPSIS-THALIANA; HOST DEFENSE; IMMERSUS; CELLS; CDNA; EXPRESSION; TRANSFORMATION; PURIFICATION; INACTIVATION	Molecular mechanisms determining methylation patterns in eukaryotic genomes still remain unresolved. We have characterized, in Ascobolus, a gene for de novo methylation. This novel eukaryotic gene, masc1, encodes a protein that has all motifs of the catalytic domain of eukaryotic C5-DNA-methyltransferases but is unique in that it lacks a regulatory N-terminal domain. The disruption of masc1 has no effect on viability or methylation maintenance but prevents the de novo methylation of DNA repeats, which takes place after fertilization, through the methylation induced premeiotically (MIP) process. Crosses between parents harboring the masc1 disruption are arrested at an early stage of sexual reproduction, indicating that the activity of Masc1, the product of the gene, is crucial in this developmental process.	MAX PLANCK INST MOL GENET,ABT TRAUTNER,D-14195 BERLIN,GERMANY; UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,F-91405 ORSAY,FRANCE	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Malagnac, Fabienne/0000-0003-1139-7691				Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; COLOT V, 1995, GENETICS, V141, P1299; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; FAUGERON G, 1989, GENE, V76, P109, DOI 10.1016/0378-1119(89)90013-9; FAUGERON G, 1990, GENETICS, V124, P585; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; Goyon C, 1996, NUCLEIC ACIDS RES, V24, P3348, DOI 10.1093/nar/24.17.3348; Goyon C, 1996, MOL CELL BIOL, V16, P3054; GOYON C, 1994, J MOL BIOL, V240, P42, DOI 10.1006/jmbi.1994.1416; GRIFFITHS AJF, 1976, CAN J GENET CYTOL, V18, P35, DOI 10.1139/g76-005; GUNTHERT U, 1981, J BIOL CHEM, V256, P9340; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HAGEMANN AT, 1996, EPIGENETIC MECH GENE, P335; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KELLEHER JE, 1991, J MOL BIOL, V221, P431, DOI 10.1016/0022-2836(91)80064-2; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; Lei H, 1996, DEVELOPMENT, V122, P3195; Leonhardt H., 1993, DNA methylation: molecular biology and biological significance., P109; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; NOYERWEIDNER M, 1993, DNA METHYLATION MOL, P39; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2424; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; RHOUNIM L, 1994, CURR GENET, V26, P344, DOI 10.1007/BF00310499; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SMITH SS, 1994, PROG NUCLEIC ACID RE, V49, P65; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	40	110	116	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					281	290		10.1016/S0092-8674(00)80410-9	http://dx.doi.org/10.1016/S0092-8674(00)80410-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346245	Bronze			2022-12-24	WOS:A1997YC35000015
J	Skowyra, D; Craig, KL; Tyers, M; Elledge, SJ; Harper, JW				Skowyra, D; Craig, KL; Tyers, M; Elledge, SJ; Harper, JW			F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex	CELL			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; G1 CYCLINS; DEGRADATION; INHIBITOR; KINASE; PROTEOLYSIS; ACTIVATION; PATHWAY; ENCODES	We have reconstituted the ubiquitination pathway for the Cdk inhibitor Sic1 using recombinant proteins. Skp1, Cdc53, and the F-box protein Cdc4 form a complex, SCFCdc4, which functions as a Sic1 ubiquitin-ligase (E3) in combination with the ubiquitin conjugating enzyme (E2) Cdc34 and E1. Cdc4 assembled with Skp1 functions as the receptor that selectively binds phosphorylated Sic1. Grr1, an F-box protein involved in Cln destruction, forms complexes with Skp1 and Cdc53 and binds phosphorylated Cln1 and Cln2, but not Sic1. Because the constituents of the SCF complex are members of protein families, SCFCdc4 in likely to serve as the prototype for a large class of E3s formed by combinatorial interactions of related family members. SCF complexes couple protein kinase signaling pathways to the control of protein abundance.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Tyers, Michael/ABE-3194-2021	Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG-11085] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HENHOZ S, 1997, IN PRESS GENES DEV; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LI F, 1997, IN PRESS EMBO J; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VISINTIN R, 1997, IN PRESS SCIENCE; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	42	1017	1045	1	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					209	219		10.1016/S0092-8674(00)80403-1	http://dx.doi.org/10.1016/S0092-8674(00)80403-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346238	Bronze			2022-12-24	WOS:A1997YC35000008
J	Baorto, DM; Gao, ZM; Malaviya, R; Dustin, ML; vanderMerwe, A; Lublin, DM; Abraham, SN				Baorto, DM; Gao, ZM; Malaviya, R; Dustin, ML; vanderMerwe, A; Lublin, DM; Abraham, SN			Survival of FimH-expressing enterobacteria in macrophages relies on glycolipid traffic	NATURE			English	Article							URINARY-TRACT INFECTIONS; ESCHERICHIA-COLI; TYPE-1 FIMBRIAE; ADHESION; PILI; IDENTIFICATION; COLONIZATION; ENDOCYTOSIS; BACTEREMIA; ACTIVATION	Strains of Escherichia coli persist within the human gut as normal commensals, but are frequent pathogens and can cause recurrent infection(1-3). Here we show that, in contrast to E. coli subjected to opsonic interactions stimulated by the host's immune response, E. coli that bind to the macrophage surface exclusively through the bacterial lectin FimH can survive inside the cell following phagocytosis. This viability is largely due to the attenuation of intracellular free-radical release and of phagosome acidification during FimH-mediated internalization, both of which are triggered by antibody-mediated internalization. This different processing of non-opsonized bacteria is supported by morphological evidence of tight-fitting phagosomes compared with looser, antibody-mediated phagosomes. We propose that non-opsonized FimH-expressing E. coli co-opt internalization of lipid-rich microdomains following binding to the FimH receptor, the glycosylphosphatidylinositol-linked protein CD48, because (1) the sterol-binding agents filipin, nystatin and methyl beta-cyclodextrin specifically block FimH-mediated internalization; (2) CD48 and the protein caveolin both accumulate on macrophage membranes surrounding bacteria; and (3) antibodies against CD48 inhibit FimH-mediated internalization. Our findings bring the traditionally extracellular E. coli into the realm of opportunistic intracellular parasitism and suggest how opportunistic infections with FimH-expressing enterobacteria could occur in a setting deprived of opsonizing antibodies.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND	Washington University (WUSTL); Washington University (WUSTL); University of Oxford			Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BERGER KH, 1994, METHOD CELL BIOL, V45, P247; BLUEB JL, 1995, BIOCHIM BIOPHYS ACTA, V1244, P79; BRAUNER A, 1994, J INFECTION, V28, P49, DOI 10.1016/S0163-4453(94)94130-0; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; GBARAH A, 1993, INFECT IMMUN, V61, P1687, DOI 10.1128/IAI.61.5.1687-1693.1993; GOETZ MB, 1987, J INFECT DIS, V156, P229, DOI 10.1093/infdis/156.1.229; HAGBERG L, 1981, INFECT IMMUN, V31, P564, DOI 10.1128/IAI.31.2.564-570.1981; KEITH BR, 1990, INFECT IMMUN, V58, P3448, DOI 10.1128/IAI.58.10.3448-3454.1990; KEITH BR, 1986, INFECT IMMUN, V53, P693, DOI 10.1128/IAI.53.3.693-696.1986; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KISIELIUS PV, 1989, INFECT IMMUN, V57, P1656, DOI 10.1128/IAI.57.6.1656-1662.1989; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LOCK R, 1990, INFECT IMMUN, V58, P37, DOI 10.1128/IAI.58.1.37-42.1990; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MAY AK, 1993, INFECT IMMUN, V61, P1667, DOI 10.1128/IAI.61.5.1667-1673.1993; OFEK I, 1995, ANNU REV MICROBIOL, V49, P239, DOI 10.1146/annurev.mi.49.100195.001323; ORNDORFF PE, 1984, J BACTERIOL, V159, P736, DOI 10.1128/JB.159.2.736-744.1984; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; SAUKKONEN K, 1991, J EXP MED, V173, P1143, DOI 10.1084/jem.173.5.1143; SAUTER SL, 1993, J BIOL CHEM, V268, P15510; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SENECA H, 1981, J AM GERIATR SOC, V29, P359, DOI 10.1111/j.1532-5415.1981.tb01242.x; STURGILLKOSZYCK.S, 1994, SCIENCE, V263, P637; TEWARI R, 1993, J BIOL CHEM, V268, P3009; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	30	233	238	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 9	1997	389	6651					636	639		10.1038/39376	http://dx.doi.org/10.1038/39376			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YA008	9335508				2022-12-24	WOS:A1997YA00800068
J	Zeidler, M; Stewart, GE; Barraclough, CR; Bateman, DE; Bates, D; Burn, DJ; Colchester, AC; Durward, W; Fletcher, NA; Hawkins, SA; Mackenzie, JM; Will, RG				Zeidler, M; Stewart, GE; Barraclough, CR; Bateman, DE; Bates, D; Burn, DJ; Colchester, AC; Durward, W; Fletcher, NA; Hawkins, SA; Mackenzie, JM; Will, RG			New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests	LANCET			English	Article							SPONGIFORM ENCEPHALOPATHIES; DECADE 1968-1977; STRAIN VARIATION; FRANCE; TRANSMISSION; WOMAN; CJD; BSE	Background In April, 1996, ten cases of Creutzfeldt-Jakob disease (CJD) with an apparently new clinicopathological phenotype were published and it was suggested that these new variant cases (nvCJD) might be causally linked to bovine spongiform encephalopathy (BSE). There have now been 21 cases of nvCJD in the UK and one case in France. We report clinical features and diagnostic test results of the first 14 cases of nvCJD in the UK. Methods Case ascertainment of CJD was mainly by direct referral from neurologists and neuropathologists. Clinical and investigative details were obtained by interview with patients' relatives and by examination of case notes. Ten cases in this report were examined while alive. Prion protein (PrP) gene analysis was carried out with informed consent from the patient or from a relative. The diagnosis of nvCJD was established histologically. Findings Eight cases were women. Mean age at onset of symptoms was 29 (16-48) years and the median duration of illness was 14 (9-35) months. All patients had early psychiatric symptoms, most often depression, and 13 were seen by a psychiatrist early in the clinical course. Eight patients developed early sensory symptoms which were persistent and often painful. Neurological signs, including ataxia and involuntary movements, developed in all cases and towards the end of the illness, most had akinetic mutism. The electroencephalogram was abnormal in most patients but typical periodic complexes of CJD were not seen in any case. Cerebral imaging was usually normal or showed non-specific abnormalities; in two cases magnetic-resonance imaging scans showed high signal in the thalamus. Interpretation Clinical features in these cases are similar and relatively distinct from other forms of CJD, suggesting that this is a new clinical phenotype consistent with a single strain of infectious agent. There is, however, some overlap with atypical cases of sporadic CJD, and the diagnosis of nvCJD remains dependent on neuropathological confirmation.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Burn, David/ABD-6052-2021	Burn, David/0000-0001-7658-1209				ALPERS M, 1987, P451; BERMAN PH, 1988, PEDIATR NEUROSCI, V14, P42, DOI 10.1159/000120361; BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1984, ANN NEUROL, V16, P295, DOI 10.1002/ana.410160305; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; BROWN P, 1979, ANN NEUROL, V6, P438, DOI 10.1002/ana.410060511; BROWN P, 1988, NOVEL INFECTIOUS AGE, P3; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; CARABALLO-H A J, 1991, Arquivos de Neuro-Psiquiatria, V49, P218; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *DEP HLTH, 1997, CMOS UPDATE, V13, P4; DESILVA RN, IN PRESS BMJ; Deslys JP, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P465; deVillemeur TB, 1996, NEUROLOGY, V47, P690, DOI 10.1212/WNL.47.3.690; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Hornabrook R W, 1975, P N G Med J, V18, P226; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUNTER N, 1994, VET REC, V135, P400, DOI 10.1136/vr.135.17.400; KIMBERLIN RH, 1990, CAN J VET RES, V54, P30; KULCZYCKI J, 1991, EUR J EPIDEMIOL, V7, P501, DOI 10.1007/BF00143129; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MONREAL J, 1981, J NEUROL SCI, V52, P341, DOI 10.1016/0022-510X(81)90015-0; PACKER RJ, 1980, NEUROLOGY, V30, P492, DOI 10.1212/WNL.30.5.492; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; RAVERDY P, 1983, REV NEUROL, V139, P381; TRIMBLE ME, 1996, NEUROLOGY CLIN PRACT, V1, P107; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; WILL RG, 1996, PRION DIS, P119; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1996, BRIT MED J, V312, P844; ZEIDLER M, 1997, J NEUROL NEUROSUR PS, V62, P206	38	212	219	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					903	907		10.1016/S0140-6736(97)07472-2	http://dx.doi.org/10.1016/S0140-6736(97)07472-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY672	9314867				2022-12-24	WOS:A1997XY67200007
J	Zeidler, M; Johnstone, EC; Bamber, RWK; Dickens, CM; Fisher, CJ; Francis, AF; Goldbeck, R; Higgo, R; JohnsonSabine, EC; Lodge, GJ; McGarry, P; Mitchell, S; Tarlo, L; Turner, M; Ryley, P; Will, RG				Zeidler, M; Johnstone, EC; Bamber, RWK; Dickens, CM; Fisher, CJ; Francis, AF; Goldbeck, R; Higgo, R; JohnsonSabine, EC; Lodge, GJ; McGarry, P; Mitchell, S; Tarlo, L; Turner, M; Ryley, P; Will, RG			New variant Crutzfeldt-Jakob disease: psychiatric features	LANCET			English	Article							DELUSIONS	Background An apparently new variant of Creutzfeldt-Jakob disease (CJD), new variant CJD [nvCJD), was identified in the UK in 1996. There have now been 21 cases of nvCJD in the UK and one in France, Psychiatric symptoms are prominent in the initial presentation in these cases. Methods Cases of nvCJD are identified mainly by direct referral horn neurologists and neuropathologists. Detailed clinical information was obtained by review of case notes and interviewing patients' relatives. We report the psychiatric features of the first 14 cases on nvCJD in the UK. Psychiatric notes were examined in ail 13 of these cases who were seen by a psychiatrist. Results Eight cases were women. Ali 14 cases had early psychiatric features and in nine, the first symptom was psychiatric. 13 cases were seen by a psychiatrist and the majority were diagnosed as suffering from depression or depression secondary to organic disease. Two cases suffered from first-rank symptoms suggestive of psychotic illness and transient delusions and auditory or visual hallucinations occurred in the majority. Aii cases were referred to a neurologist as the illness evolved and neurological signs developed. Interpretation Psychiatric symptoms are a consistent early clinical feature in nvCJD. Analysis of the psychiatric symptoms does not suggest specific features that readily allow distinction from more common psychiatric disorders, although the occurrence of associated persistent sensory symptoms may raise the possibility of this diagnosis. Neurological signs, including ataxia, involuntary movements and cognitive impairment developed in ail cases and the evolution of increasing neurological deficits is likely to remain critical to the clinical diagnosis of nvCJD.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh				Dickens, Chris/0000-0001-6326-7544				AZORIN JM, 1993, COMPR PSYCHIAT, V34, P42, DOI 10.1016/0010-440X(93)90034-2; BERRIOS GE, 1984, BRIT J PSYCHIAT, V144, P662, DOI 10.1192/bjp.144.6.662; BROWN P, 1979, ANN NEUROL, V6, P430, DOI 10.1002/ana.410060510; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BURNS A, 1990, BRIT J PSYCHIAT, V157, P72, DOI 10.1192/bjp.157.1.72; CHAPMAN J, 1993, J NEUROL NEUROSUR PS, V56, P1109, DOI 10.1136/jnnp.56.10.1109; CUMMINGS JL, 1985, BRIT J PSYCHIAT, V146, P184, DOI 10.1192/bjp.146.2.184; ESMONDE TFG, 1994, THESIS TRINITY COLL; KESHAVAN MS, 1987, BRIT J PSYCHIAT, V151, P260, DOI 10.1192/bjp.151.2.260; MCMILLAN JF, 1984, THESIS EDINBURGH U U; *NAT CJD SURV UN D, 1995, 4 DEP EP POP SCI LON; STEVENS EM, 1979, J CLIN PSYCHIAT, V40, P445; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; WILL RG, 1984, THESIS CAMBRIDGE U U; WILL RG, 1996, PRION DIS, P119; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2	17	128	135	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 27	1997	350	9082					908	910		10.1016/S0140-6736(97)03148-6	http://dx.doi.org/10.1016/S0140-6736(97)03148-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XY672	9314868				2022-12-24	WOS:A1997XY67200008
J	McDonagh, TA; Morrison, CE; Lawrence, A; Ford, I; TunstallPedoe, H; McMurray, JJV; Dargie, HJ				McDonagh, TA; Morrison, CE; Lawrence, A; Ford, I; TunstallPedoe, H; McMurray, JJV; Dargie, HJ			Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; UNITED-STATES; PREVALENCE; HEALTH; ECHOCARDIOGRAPHY; HYPERTENSION; MORBIDITY; MORTALITY	Background In most previous epidemiological studies on the prevalence of chronic heart failure (CHF) the disorder has been defined on clinical criteria. In a cross-sectional survey of 2000 men and women aged 25-74, randomly sampled from one geographical area, we assessed left-ventricular systolic function by echocardiography. Methods 1640 (83%) of those invited took part. They completed a questionnaire on current medication, history, and symptoms of breathlessness. Blood pressure was measured and electrocardiography (ECG) and echocardiography were done. Left-ventricular ejection fraction was measurable in 1467 (89.5%) participants by the biplane Simpson's rate method. Findings The mean left-ventricular ejection fraction was 47.3%. The prevalence of definite left-ventricular systolic dysfunction (defined as a left-ventricular ejection fraction less than or equal to 30%) was 2.9% overall (43 participants); it increased with age and was higher in men than in women (4.0 vs 2.0%). The left-ventricular systolic dysfunction was symptomatic in 1.5% of participants and asymptomatic in 1.4%. 83% of participants with left-ventricular systolic dysfunction had evidence of ischaemic heart disease (IHD) from history or ECG criteria compared with 21% of those without this abnormality (p<0.001). Hypertension was also more common in those with left-ventricular systolic dysfunction (72 vs 38%, p<0.001), but there was no difference between those with and without left-ventricular systolic dysfunction in the rate of hypertension without IHD. Interpretation Left-ventricular systolic dysfunction was at least twice as common as symptomatic heart failure defined by clinical criteria. The main risk factors are IHD and hypertension in the presence of IHD; screening of such high-risk groups for left-ventricular systolic dysfunction should be considered.	UNIV GLASGOW,WESTERN INFIRM,MRC,CLIN RES INITIAT HEART FAILURE,GLASGOW G11 6NT,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,SCOTTISH MONICA PROJECT,GLASGOW G4 0SF,LANARK,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow; University of Dundee; University of Glasgow	McDonagh, TA (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT CARDIOL,GLASGOW G11 6NT,LANARK,SCOTLAND.		mcmurray, John/B-2467-2013; Ford, Ian/ABE-6145-2020	mcmurray, John/0000-0002-6317-3975; 				BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; Clarke KW, 1995, J PUBLIC HEALTH MED, V17, P459; *CONSENSUS TRIAL S, 1987, NEW ENGL J MED, V316, P1429; COSTANZO MR, 1995, CIRCULATION, V92, P3593, DOI 10.1161/01.CIR.92.12.3593; ERIKSSON H, 1989, EUR HEART J, V10, P647, DOI 10.1093/oxfordjournals.eurheartj.a059542; FLETCHER CM, 1959, BMJ-BRIT MED J, V2, P257, DOI 10.1136/bmj.2.5147.257; GARDIN JM, 1995, CIRCULATION, V91, P1739, DOI 10.1161/01.CIR.91.6.1739; GHJALI JK, 1990, ARCH INTERN MED, V150, P769; GIBSON TC, 1966, J CHRON DIS, V19, P141, DOI 10.1016/0021-9681(66)90045-2; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; KOSTIS JB, 1995, AM J HYPERTENS, V8, P909, DOI 10.1016/0895-7061(95)00156-J; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; MCKEE PA, 1971, NEW ENGL J MED, V285, P781; MCMURRAY J, 1993, EUR HEART J, V14, P1158, DOI 10.1093/eurheartj/14.9.1158; PARAMESHWAR J, 1992, BRIT J GEN PRACT, V42, P287; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROSE GA, WHO MONOGRAPH SERIES, V56; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; *SOLVD INV, 1991, NEW ENGL J MED, V325, P293; *SOLVD INV, 1992, NEW ENGL J MED, V327, P685; *TASK FORC HEART F, 1995, EUR HEART J, V16, P741; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Vasan RS, 1997, NEW ENGL J MED, V336, P1350, DOI 10.1056/NEJM199705083361903; WHEELDON NM, 1993, Q J MED, V86, P17	30	454	467	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					829	833		10.1016/S0140-6736(97)03033-X	http://dx.doi.org/10.1016/S0140-6736(97)03033-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310600				2022-12-24	WOS:A1997XX40100008
J	Lam, KP; Kuhn, R; Rajewsky, K				Lam, KP; Kuhn, R; Rajewsky, K			In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death	CELL			English	Article							CD4(+) T-CELLS; ANTIGEN RECEPTOR; HEAVY-CHAIN; RAG-1-DEFICIENT MICE; CLONAL SELECTION; IMMUNE-RESPONSE; LYMPHOCYTES-B; NP ANTIBODIES; EXPRESSION; APOPTOSIS	Gene targeting experiments have demonstrated that the expression of immunoglobulin heavy chain in the pre-B cell receptor (pBCR) and of heavy and light chains in the B cell antigen receptor (BCR) marks checkpoints in early B cell development that the cells have to pass to survive. To investigate whether the persistence of mature B cells in the peripheral immune system also depends on BCR expression, we have generated a transgenic mouse in which the BCR can be inducibly ablated through V region gene deletion. Ablation leads to rapid death of mature B lymphocytes, which is preceded by down-regulation of MHC antigens and up-regulation of CD95 (Fas) and can be delayed by constitutive bcl-2 expression.			Lam, KP (corresponding author), UNIV COLOGNE, INST GENET, WEYERTAL 121, D-50931 COLOGNE, GERMANY.		Lam, Kong-Peng/G-5374-2012; Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Lam, Kong-Peng/0000-0002-1316-4333; Rajewsky, Klaus/0000-0002-6633-6370				BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dul JL, 1996, J IMMUNOL, V157, P2969; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Gong SC, 1996, SCIENCE, V272, P411, DOI 10.1126/science.272.5260.411; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lagresle C, 1996, J EXP MED, V183, P1377, DOI 10.1084/jem.183.4.1377; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RATHMELL JC, 1995, NATURE, V376, P181, DOI 10.1038/376181a0; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SCHWARTZ RS, 1994, IMMUNOL TODAY, V15, P27, DOI 10.1016/0167-5699(94)90022-1; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TAKI S, 1993, SCIENCE, V262, P1268, DOI 10.1126/science.8235657; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; Torres RM, 1997, LAB PROTOCOLS CONDIT; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	53	913	938	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1073	1083		10.1016/S0092-8674(00)80373-6	http://dx.doi.org/10.1016/S0092-8674(00)80373-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323135	Bronze			2022-12-24	WOS:A1997XX76800013
J	Starks, CM; Back, KW; Chappell, J; Noel, JP				Starks, CM; Back, KW; Chappell, J; Noel, JP			Structural basis for cyclic terpene biosynthesis by tobacco 5-epi-aristolochene synthase	SCIENCE			English	Article							SESQUITERPENE CYCLASE; TAXADIENE SYNTHASE; TAXOL BIOSYNTHESIS; DITERPENE CYCLASE; EXPRESSION; CATALYZES; ALGORITHM; BIOLOGY; MODELS; STEP	Terpene cyclases catalyze the synthesis of cyclic terpenes with 10-, 15-, and 20-carbon acyclic isoprenoid diphosphates as substrates. Plants have been a source of these natural products by providing a homologous set of terpene synthases. The crystal structures of 5-epi-aristolochene synthase, a sesquiterpene cyclase from tobacco, alone and complexed separately with two farnesyl diphosphate analogs were analyzed. These structures reveal an unexpected enzymatic mechanism for the synthesis of the bicyclic product, 5-epi-aristolochene, and provide a basis for understanding the stereochemical selectivity displayed by other cyclases in the biosynthesis of pharmacologically important cyclic terpenes. As such, these structures provide templates for the engineering of novel terpene cyclases.	SALK INST BIOL STUDIES,STRUCT BIOL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV KENTUCKY,BIOCHEM & MOL BIOL PROGRAM,LEXINGTON,KY 40546	Salk Institute; University of California System; University of California San Diego; University of Kentucky			Noel, Joseph P/A-9459-2009		NIGMS NIH HHS [GM54029, GM07240] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054029] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULLAH MI, 1990, HETEROCYCLES, V30, P317; ALESHIN AE, 1994, J MOL BIOL, V238, P575, DOI 10.1006/jmbi.1994.1316; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BACK KC, UNPUB; BACK KW, 1994, ARCH BIOCHEM BIOPHYS, V315, P527, DOI 10.1006/abbi.1994.1533; Back KW, 1996, P NATL ACAD SCI USA, V93, P6841, DOI 10.1073/pnas.93.13.6841; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BISWAS KM, 1989, J CHEM SOC P1, V11, P1981; BORMAN S, 1996, CHEM ENG NEWS   0701, P27; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P187; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GUEDES MEM, 1982, PHYTOCHEMISTRY, V21, P2987, DOI 10.1016/0031-9422(80)85086-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; Morse MA, 1996, CANCER LETT, V104, P211, DOI 10.1016/0304-3835(96)04252-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1991, CCP4 SERC DAR LAB; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201	31	552	597	0	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1815	1820		10.1126/science.277.5333.1815	http://dx.doi.org/10.1126/science.277.5333.1815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295271				2022-12-24	WOS:A1997XX29800045
J	Wortley, PM; Fleming, PL				Wortley, PM; Fleming, PL			AIDS in women in the United States - Recent trends	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; CRACK COCAINE USE; NEW-YORK-CITY; HIV-INFECTION; RISK-FACTORS; SAN-FRANCISCO; CONDOM USE; EPIDEMIC; BEHAVIOR	Context.-The effect of the acquired immunodeficiency syndrome (AIDS) epidemic Objective.-To describe AIDS incidence trends in women. Design.-We analyzed national surveillance data on women 13 years of age and older with AIDS reported through June 1996. Data were adjusted for reporting delay, unreported risk, and the 1993 change in AIDS surveillance case definition to assess overall trends and examine trends by age group and birth cohort. Setting.-Surveillance conducted by the Centers for Disease Control and Prevention in collaboration with state and local health departments. Results.-In 1995, women accounted for 19% of AIDS cases in adults; AIDS incidence rates per 100 000 women were highest in black women (50.1), women in the Northeast (22.3), heterosexual contacts (5.5), and women living in metropolitan statistical areas with more than 1 million residents (15.9). Greatest increases in rates between 1991 and 1995 by region and mode of transmission were in the South and in heterosexual contacts. Greatest increases in AIDS incidence rates were observed in heterosexually infected women born between 1970 and 1974, ie, women who were 14 to 18 years old in 1988. Conclusions.-These trends predict continued growth of the number of AIDS cases in women, especially in those in the South and those infected heterosexually, and suggest that successive cohorts or young women may be at risk for human immunodeficiency virus infection as they reach adolescence and young adulthood. Prevention programs must reach young women before they initiate sexual activity and drug use.			Wortley, PM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HIV STD & TB PREVENT, DIV HIV AIDS PREVENT, ATLANTA, GA 30333 USA.							*A GUTTM I, 1994, SEX AM TEEN; BACCHETTI P, 1991, BIOMETRICS, V47, P947, DOI 10.2307/2532651; BATTJES RJ, 1994, AIDS, V8, P681, DOI 10.1097/00002030-199405000-00016; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; CDC, 1991, MMWR-MORBID MORTAL W, V40, P314; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P323; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; *CDCP, 1996, HIV AIDS SURV REP, P8; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P121; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DIAZ T, 1993, JAMA-J AM MED ASSOC, V269, P2845, DOI 10.1001/jama.1993.03500220031012; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Guinan M E, 1995, J Am Med Womens Assoc (1972), V50, P74; Gwinn M, 1996, CLIN OBSTET GYNECOL, V39, P292, DOI 10.1097/00003081-199606000-00005; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HEWITT M, 1989, DEFINING RURAL AREAS, P1; HSER YI, 1987, AM J DRUG ALCOHOL AB, V13, P231, DOI 10.3109/00952998709001512; HU DJ, 1994, ARCH INTERN MED, V154, P654, DOI 10.1001/archinte.154.6.654; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KARON JM, 1991, J ACQ IMMUN DEF SYND, V4, P1179; KARON JM, 1993, PROJECTIONS NUMBERS; KARON JM, 1989, MATH STATISTICAL APP, P58; KARON JM, 1993, IN PRESS J ACQUIR IM; KLEVENS RM, 1996, P 11 INT C AIDS JUL; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; MICHAEL RT, 1994, SEX AM DEFINITIVE SU, P42; MILLER K, IN PRESS FAM PLANN P; *NAT CTR HLTH STAT, 1994, BIRTHS TEEN MOMS AG; NOVICK DM, 1989, J MED VIROL, V29, P181, DOI 10.1002/jmv.1890290307; NWANYANWU OC, 1993, AM J DRUG ALCOHOL AB, V19, P399, DOI 10.3109/00952999309001630; OTTEN MW, 1994, AIDS, V8, P549, DOI 10.1097/00002030-199404000-00020; Paone D, 1995, J Am Med Womens Assoc (1972), V50, P109; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SINGH BK, 1993, INT J ADDICT, V28, P735, DOI 10.3109/10826089309062170; *US BUR CENS, 1990 1994 STAT POP E; *US BUR CENS, APR 1 90 JUL 1 94 CO; VANICHSENI S, 1993, AIDS, V7, P887, DOI 10.1097/00002030-199306000-00020; WATTERS JK, 1994, J ACQ IMMUN DEF SYND, V7, P1276; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P13; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P1	51	135	138	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					911	916		10.1001/jama.278.11.911	http://dx.doi.org/10.1001/jama.278.11.911			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302243				2022-12-24	WOS:A1997XV64000029
J	Huber, AH; Nelson, WJ; Weis, WI				Huber, AH; Nelson, WJ; Weis, WI			Three-dimensional structure of the armadillo repeat region of beta-catenin	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; CELL-ADHESION MOLECULE; E-CADHERIN; XENOPUS EMBRYOS; ALPHA-CATENIN; ANOMALOUS DIFFRACTION; NUCLEAR-LOCALIZATION; CYTOPLASMIC DOMAIN	beta-catenin is essential for cadherin-based cell adhesion and Wnt/Wingless growth factor signaling. In these roles, it binds to cadherins, Tcf-family transcription factors, and the tumor suppressor gene product Adenomatous Polyposis Coli (APC). A core region of beta-catenin, composed of 12 copies of a 42 amino acid sequence motif known as an armadillo repeat, mediates these interactions. The three-dimensional structure of a protease-resistant fragment of beta-catenin containing the armadillo repeat region has been determined. The 12 repeats form a superhelix of helices that features a long, positively charged groove. Although unrelated in sequence, the beta-catenin binding regions of cadherins, Tcfs, and APC are acidic and are proposed to interact with this groove.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hirschl D, 1996, FEBS LETT, V383, P31, DOI 10.1016/0014-5793(96)00215-3; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNIGHT S, 1989, THESIS SWEDISH U AGR; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nicholls A., 1992, GRASP GRAPHICAL REPR; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TUNNISSEN AMW, 1994, NATURE, V467, P750; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	57	554	577	1	23	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					871	882		10.1016/S0092-8674(00)80352-9	http://dx.doi.org/10.1016/S0092-8674(00)80352-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298899	Bronze			2022-12-24	WOS:A1997XV56300008
J	Aksentijevich, I; Centola, M; Deng, ZM; Sood, R; Balow, JE; Wood, G; Zaks, N; Mansfield, E; Chen, X; Eisenberg, S; Vedula, A; Shafran, N; Raben, N; Pras, E; Pras, M; Kastner, DL; Blake, T; Baxevanis, AD; Robbins, C; Krizman, D; Collins, FS; Liu, PP; Chen, XG; Shohat, M; Hamon, M; Kahan, T; Cercek, A; Rotter, JI; FischelGhodsian, N; Richards, N; Shelton, DA; Gumucio, D; Yokoyama, Y; Mangelsdorf, M; Orsborn, A; Richards, RI; Ricke, DO; Buckingham, JM; Moyzis, RK; Deaven, LL; Doggett, NA				Aksentijevich, I; Centola, M; Deng, ZM; Sood, R; Balow, JE; Wood, G; Zaks, N; Mansfield, E; Chen, X; Eisenberg, S; Vedula, A; Shafran, N; Raben, N; Pras, E; Pras, M; Kastner, DL; Blake, T; Baxevanis, AD; Robbins, C; Krizman, D; Collins, FS; Liu, PP; Chen, XG; Shohat, M; Hamon, M; Kahan, T; Cercek, A; Rotter, JI; FischelGhodsian, N; Richards, N; Shelton, DA; Gumucio, D; Yokoyama, Y; Mangelsdorf, M; Orsborn, A; Richards, RI; Ricke, DO; Buckingham, JM; Moyzis, RK; Deaven, LL; Doggett, NA			Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN SECONDARY STRUCTURE; SHORT ARM; EXPRESSION; CLONING; FINGER; IDENTIFICATION; CHROMOSOME-16; EVOLUTIONARY; AMYLOIDOSIS	Familial Mediterranean fever (FMF) is a recessively inherited disorder characterized by dramatic episodes of fever and serosal inflammation. This report describes the cloning of the gene likely to cause FMF from a 115-kb candidate interval on chromosome 16p. Three different missense mutations were identified in affected individuals, but not in normals. Haplotype and mutational analyses disclosed ancestral relationships among carrier chromosomes in populations that have been separated for centuries. The novel gene encodes a 3.7-kb transcript that is almost exclusively expressed in granulocytes. The predicted protein, pyrin, is a member of a family of nuclear factors homologous to the Ro52 autoantigen. The cloning of the FMF gene promises to shed light on the regulation of acute inflammatory responses.	NIAMSD, ARTHRIT & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; CHAIM SHEBA MED CTR, HELLER INST MED RES, DEPT MED C, IL-52621 TEL HASHOMER, ISRAEL; NHGRI, CANC GENET LAB, BETHESDA, MD 20892 USA; NHGRI, LAB GENE TRANSFER, BETHESDA, MD 20892 USA; NHGRI, GENOME TECHNOL BRANCH, BETHESDA, MD 20892 USA; CEDARS SINAI MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90048 USA; CEDARS SINAI MED CTR, DEPT MED GENET, LOS ANGELES, CA 90048 USA; BEILINSON MED CTR, DEPT MED GENET, IL-49100 PETAH TIQWA, ISRAEL; UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; ADELAIDE WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Cedars Sinai Medical Center; Cedars Sinai Medical Center; Rabin Medical Center; University of Michigan System; University of Michigan; Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Los Alamos National Laboratory			Richards, Robert/ABE-6423-2020; Hamon, Melanie/B-3501-2013; Aksentijevich, Ivona/AAF-1335-2019; Liu, Paul/A-7976-2012; Mangelsdorf, Marie E/A-2318-2013	Liu, Paul/0000-0002-6779-025X; Mangelsdorf, Marie E/0000-0002-7855-7701; Baxevanis, Andy/0000-0002-5370-0014; Hamon, Melanie/0000-0001-5078-4083; Richards, Robert Ian/0000-0002-5978-6453				AISEN PS, 1985, P NATL ACAD SCI USA, V82, P1232, DOI 10.1073/pnas.82.4.1232; AKSENTIJEVICH I, 1993, AM J HUM GENET, V53, P644; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALOW JE, 1997, IN PRESS GENOMICS; BARAKAT MH, 1988, LANCET, V2, P1280; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Dackowski WR, 1996, GENOME RES, V6, P515, DOI 10.1101/gr.6.6.515; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; DOGGETT NA, 1995, NATURE, V377, P335; FRENCH FMF, 1996, AM J HUM GENET, V59, P603; GERTZ MA, 1987, MAYO CLIN PROC, V62, P1095, DOI 10.1016/S0025-6196(12)62502-6; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; JACK LJW, 1990, J BIOL CHEM, V265, P14481; KARENKO L, 1992, J INTERN MED, V232, P365, DOI 10.1111/j.1365-2796.1992.tb00600.x; KASTNER DL, 1996, RTHRITIS ALLIED COND, P1279; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Levy EN, 1996, AM J HUM GENET, V58, P523; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PRAS E, 1994, HUM GENET, V94, P576; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; PRAS E, 1997, IN PRESS AM J MED GE; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; PTACEK LJ, 1991, CELL, V67, P1021; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook JFE, 1989, MOL CLONING LAB MANU; SHOHAT M, 1992, AM J HUM GENET, V51, P1349; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; Sood R, 1996, CYTOGENET CELL GENET, V72, P21; Sood R, 1997, GENOMICS, V42, P83, DOI 10.1006/geno.1997.4629; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; VERNET C, 1993, J MOL EVOL, V37, P600; WEATHERALL DJ, 1995, METABOLIC MOL BASES, P3417; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319	48	1137	1183	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					797	807						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288758				2022-12-24	WOS:A1997XT06600022
J	Kaghad, M; Bonnet, H; Yang, A; Creancier, L; Biscan, JC; Valent, A; Minty, A; Chalon, P; Lelias, JM; Dumont, X; Ferrara, P; McKeon, F; Caput, D				Kaghad, M; Bonnet, H; Yang, A; Creancier, L; Biscan, JC; Valent, A; Minty, A; Chalon, P; Lelias, JM; Dumont, X; Ferrara, P; McKeon, F; Caput, D			Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers	CELL			English	Article							TUMOR-SUPPRESSOR GENES; N-MYC AMPLIFICATION; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; PROTEIN; CARCINOMA; MUTATIONS; GROWTH; RETINOBLASTOMA	We describe a gene encoding p73, a protein that shares considerable homology with the tumor suppressor p53. p73 maps to 1p36, a region frequently deleted in neuroblastoma and other tumors and thought to contain multiple tumor suppressor genes. Our analysis of neuroblastoma cell lines with Ip and p73 loss of heterozygosity failed to detect coding sequence mutations in remaining p73 alleles. However, the demonstration that p73 is monoallelically expressed supports the notion that it is a candidate gene in neuroblastoma. p73 also has the potential to activate p53 target genes and to interact with p53. We propose that the disregulation of p73 contributes to tumorigenesis and that p53-related proteins operate in a network of developmental and cell cycle controls.	SANOFI RECH,F-31676 LABEGE,FRANCE; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; INST GUSTAVE ROUSSY,URA 1967 CNRS,LAB CYTOGENET & GENET ONCOL,VILLEJUIF,FRANCE	Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; AMLER LC, 1995, EUR J CANCER, V31A, P527, DOI 10.1016/0959-8049(95)00064-P; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHENG NC, 1995, ONCOGENE, V10, P291; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GENUARDI M, 1989, AM J HUM GENET, V45, P73; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huttner WB, 1997, CURR OPIN NEUROBIOL, V7, P29, DOI 10.1016/S0959-4388(97)80117-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUREYS G, 1995, EUR J CANCER, V31A, P523, DOI 10.1016/0959-8049(95)00012-8; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANIATIS T, 1992, MOL CLONING; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SOZZI G, 1988, CANCER GENET CYTOGEN, V30, P151, DOI 10.1016/0165-4608(88)90104-5; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEMESS BA, 1990, SCIENCE, V248, P76; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; YEH SH, 1994, CANCER RES, V54, P4188; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	1476	1614	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					809	819		10.1016/S0092-8674(00)80540-1	http://dx.doi.org/10.1016/S0092-8674(00)80540-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288759	Bronze			2022-12-24	WOS:A1997XT06600023
J	Paszty, C; Brion, CM; Manci, E; Witkowska, HE; Stevens, ME; Mohandas, N; Rubin, EM				Paszty, C; Brion, CM; Manci, E; Witkowska, HE; Stevens, ME; Mohandas, N; Rubin, EM			Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease	SCIENCE			English	Article							BETA-S-GLOBINS; MOUSE MODEL; HIGH EXPRESSION; ALPHA-GLOBINS; GENE; THALASSEMIA; HYPOXIA; SAD	To create mice expressing exclusively human sickle hemoglobin (HbS), transgenic mice expressing human alpha-, gamma-, and beta(s)-globin were generated and bred with knockout mice that had deletions of the murine alpha- and beta-globin genes. These sickle cell mice have the major features (irreversibly sickled red cells, anemia, multiorgan pathology) found in humans with sickle cell disease and, as such, represent a useful in vivo system to accelerate the development of improved therapies for this common genetic disease.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DEPT SUBCELLULAR STRUCT, BERKELEY, CA 94720 USA; UNIV S ALABAMA, DOCTORS HOSP, CENTRALIZED PATHOL UNIT SICKLE CELL DIS, MOBILE, AL 36604 USA; CHILDRENS HOSP OAKLAND, RES INST, OAKLAND, CA 94609 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of South Alabama; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Paszty, C (corresponding author), UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, CTR HUMAN GENOME, 1 CYCLOTRON RD, MS 74-157, BERKELEY, CA 94720 USA.				NHLBI NIH HHS [HL31579, N01-HB-07086, HL20985] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB007086] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985, R01HL031579] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAUHAN PM, 1983, PATHOL ANNU, V18, P253; CIAVATTA DJ, 1995, P NATL ACAD SCI USA, V92, P9259, DOI 10.1073/pnas.92.20.9259; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P4894, DOI 10.1073/pnas.81.15.4894; DALAND GA, 1948, J LAB CLIN MED, V33, P1082; Embury SH, 1994, SICKLE CELL DIS BASI; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12155, DOI 10.1073/pnas.89.24.12155; FABRY ME, 1995, BLOOD, V86, P2419, DOI 10.1182/blood.V86.6.2419.bloodjournal8662419; GREAVES DR, 1990, NATURE, V343, P183, DOI 10.1038/343183a0; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; PASZTY C, 1995, NAT GENET, V11, P33, DOI 10.1038/ng0995-33; Paszty C, 1997, Curr Opin Hematol, V4, P88; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; RUBIN EM, 1991, J CLIN INVEST, V87, P639, DOI 10.1172/JCI115041; RYAN TM, 1990, SCIENCE, V247, P566, DOI 10.1126/science.2154033; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TRUDEL M, 1994, BLOOD, V84, P3189; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723	21	353	357	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					876	878		10.1126/science.278.5339.876	http://dx.doi.org/10.1126/science.278.5339.876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346488	Green Submitted			2022-12-24	WOS:A1997YD47900050
J	Bandmann, O; Vaughan, J; Holmans, P; Marsden, CD; Wood, NW				Bandmann, O; Vaughan, J; Holmans, P; Marsden, CD; Wood, NW			Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease	LANCET			English	Article							POLYMERASE CHAIN-REACTION; 5'-FLANKING REGION; OXIDATIVE STRESS; GENE; POLYMORPHISM; SMOKING; SUSCEPTIBILITY; CARCINOGENS; EXPRESSION; METABOLISM	Background Epidemiological studies have identified positive family history and exposure to environmental toxins as risk factors for Parkinson's disease (PD). An inherited defect of xenobiotic metabolism could result in increased susceptibility to such toxins. We investigated the frequency of functionally relevant polymorphisms in six detoxification enzymes among patients with PD to elucidate the relation between these polymorphisms and the disease. Methods We obtained brain-tissue samples from 100 patients with apparently sporadic PD and blood samples from 100 living patients with familiar PD. For the control group, we extracted DNA from the tissue of 100 pathologically normal brains. The six enzymes analysed in these three groups were: CYP2D6, CYP2E1, NAD(P)H-menadione reductase, glutathione transferases M1 and T1, and N-acetyltransferase 2. We also investigated N-acetyltransferase 2 in 100 blood samples from patients with genetically proven Huntington's disease. We used PCR-based methods and restriction-enzyme analysis to detect polymorphisms. Findings The slow acetylator genotype for N-acetyltransferase 2 was more common in the familial PD group (69%) than in all controls (37%). Even after correction for multiple comparisons, this result remained highly significant (p=0.002) for familial PD compared with normal controls (odds ratio 3.79 [95% CI 2.08-6.90]) and compared with Huntington's disease (2.45 [1.37-4.38], p=0.004). The slow acetylator frequency for N-acetyltransferase 2 for sporadic PD was between that for Huntington's disease and familiar PD. The frequencies of all the other polymorphisms were similar in the two study groups and the normal control group. Interpretation We found an association between the slow acetylator genotype for N-acetyltransferase 2 and familial PD. Further studies are needed to investigate the biological relevance of these findings, but slow acetylation could lead to impaired ability of patients with familial PD to handle neurotoxic substances.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND; UNIV WALES COLL MED,NEUROPSYCHIAT GENET UNIT,CARDIFF CF4 4XN,S GLAM,WALES	University of London; University College London; Cardiff University			Holmans, Peter/F-4518-2015; Wood, Nicholas W/C-2505-2009	Holmans, Peter/0000-0003-0870-9412; Wood, Nicholas W/0000-0002-9500-3348; Bandmann, Oliver/0000-0003-3149-0252				ARMSTRONG M, 1993, HUM GENET, V91, P616; ARMSTRONG M, 1992, LANCET, V339, P1017, DOI 10.1016/0140-6736(92)90537-D; Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; Chen CL, 1996, PHARMACOGENETICS, V6, P187, DOI 10.1097/00008571-199604000-00005; DEXTER D, 1986, LANCET, V2, P639; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; Diederich N, 1996, ANN NEUROL, V40, P463, DOI 10.1002/ana.410400319; Gibb W., 1989, DISORDERS MOVEMENT C, P33; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P559, DOI 10.1093/oxfordjournals.jbchem.a123619; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; IGBOKWE E, 1993, E AFR MED J, V70, P807; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; LADERO JM, 1989, EUR J CLIN PHARMACOL, V37, P391, DOI 10.1007/BF00558506; LIN HJ, 1993, AM J HUM GENET, V52, P827; MARAGANORE DM, 1991, MOVEMENT DISORD, V6, P205, DOI 10.1002/mds.870060303; MONTOLIU C, 1995, J NEUROCHEM, V65, P2561; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; PAYAMI H, 1989, AM J HUM GENET, V45, P541; PETERS L, 1994, XENOBIOTICA, V24, P1013, DOI 10.3109/00498259409043298; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Rijk M. C., 1997, J NEUROL NEUROSUR PS, V62, P10, DOI DOI 10.1136/JNNP.62.1.10; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Sies H, 1988, GLUTATHIONE CONJUGAT; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SNYDER SH, 1986, NEUROLOGY, V36, P250, DOI 10.1212/WNL.36.2.250; TRAVER RD, 1992, CANCER RES, V52, P797; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WATANABE J, 1994, J BIOCHEM-TOKYO, V116, P321, DOI 10.1093/oxfordjournals.jbchem.a124526; Wood N, 1997, J NEUROL NEUROSUR PS, V62, P305, DOI 10.1136/jnnp.62.4.305	36	108	111	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1136	1139		10.1016/S0140-6736(97)03495-8	http://dx.doi.org/10.1016/S0140-6736(97)03495-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343502				2022-12-24	WOS:A1997YB19900012
J	Barr, FA; Puype, M; Vandekerckhove, J; Warren, G				Barr, FA; Puype, M; Vandekerckhove, J; Warren, G			GRASP65, a protein involved in the stacking of Golgi cisternae	CELL			English	Article							3-DIMENSIONAL ELECTRON-MICROSCOPY; CELL-FREE SYSTEM; VESICULAR TRANSPORT; NITRIC-OXIDE; APPARATUS; MEMBRANES; FRAGMENTS; NSF	NEM prevents mitotic reassembly of Golgi cisternae into stacked structures. The major target of NEM is a 65 kDa protein conserved from yeast to mammals. Antibodies to this protein and a recombinant form of it block cisternal stacking in a cell-free system, justifying its designation as a Golgi ReAssembly Stacking Protein (GRASP65). One of the two minor targets of NEM is GM130, previously implicated in the docking of transport vesicles and mitotic fragmentation of the Golgi stack. GRASP65 is complexed with GM130 and is tightly bound to Golgi membranes, even under mitotic conditions when both are heavily phosphorylated. These results link vesicle docking, stacking of Golgi cisternae, and the disruption of both of these interactions during mitosis.	FLANDERS INST BIOTECHNOL,DEPT BIOCHEM,B-9000 GHENT,BELGIUM	Flanders Institute for Biotechnology (VIB)	Barr, FA (corresponding author), IMPERIAL CANC RES FUND,CELL BIOL LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Barr, Francis/0000-0001-7518-253X				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMOS WB, 1968, J CELL BIOL, V38, P466, DOI 10.1083/jcb.38.2.466; Becker B, 1996, MICROBIOL REV, V60, P697, DOI 10.1128/MMBR.60.4.697-721.1996; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CLUETT EB, 1992, J CELL SCI, V103, P773; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRANKE WW, 1972, Z ZELLFORSCH MIK ANA, V132, P365, DOI 10.1007/BF02450714; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; GOLGI C, 1898, ARCH ITAL BIOL, V30, P60; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MOLLENHAUER HH, 1966, ANN REV PLANT PHYSIO, V17, P27, DOI 10.1146/annurev.pp.17.060166.000331; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RAMBOURG A, 1993, ANAT REC, V237, P441, DOI 10.1002/ar.1092370402; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SAPPERSTEIN SK, 1996, J CELL BIOL, V132, P765; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WHALEY WG, 1976, GOLGI APPARATUS, V2	30	337	344	2	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 17	1997	91	2					253	262		10.1016/S0092-8674(00)80407-9	http://dx.doi.org/10.1016/S0092-8674(00)80407-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346242	Bronze			2022-12-24	WOS:A1997YC35000012
J	Barcellos, LF; Thomson, G; Carrington, M; Schafer, J; Begovich, AB; Lin, P; Xu, XH; Min, BQ; Marti, D; Klitz, W				Barcellos, LF; Thomson, G; Carrington, M; Schafer, J; Begovich, AB; Lin, P; Xu, XH; Min, BQ; Marti, D; Klitz, W			Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis - Evidence of a new susceptibility locus in Caucasian and Chinese patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASIC-PROTEIN GENE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; APOLIPOPROTEIN-E; LINKAGE DISEQUILIBRIUM; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; SHANGHAI CHINESE; HLA; POLYMORPHISM; COMPLEX	Context.-Susceptibility to multiple sclerosis (MS) involves a genetically complex autoimmune component. However, except for genes in the HLA system, specific susceptibility loci are unknown or unconfirmed. Objective.-To investigate several loci spanning 3 candidate regions for a role in multiple sclerosis (MS) susceptibility in 2 ethnic groups using both single-locus and haplotype analyses. The 3 regions include HLA on chromosome 6p21.3, APOE on chromosome 19q13.2, and MBP (myelin basic protein) on chromosome 18q23. Design.-Case-control association testing. Subjects.-A total of 120 Caucasian patients with MS and 107 unrelated control individuals from California, and 32 patients and 32 unrelated control individuals from Beijing, China. All patients with MS were diagnosed as having clinically definite disease according to published criteria. Main Outcome Measures.-chi(2) Testing of loci and individual alleles and haplotypes. Haplotype frequencies were estimated with standard maximum likelihood methods. Results.-The HLA effect is due to the class II DR2 haplotype, DRB1*1501-DQA1*0102-DRB1*0602; contributions to MS susceptibility from additional DRB1-DQB1 alleles or other HLA region loci were not observed. Variation within the MBP locus on chromosome 18q23 showed no effect in MS. The distribution of haplotypes from 5 loci within the chromosome 19q13.2 region, including D19S178, D19S574, APOE, APOC2, and D19S219, differed between patient and control samples. D19S574 showed a significant effect (P=.015) in Caucasian patients with MS due to the increased frequency of a single allele (P=.002). The APOE variation, prominent in other neurological diseases, showed no influence on MS susceptibility, despite its location within the chromosome 19q13.2 region. interaction effects between DR2 and chromosome 19q13.2 or MBP in MS susceptibility were not apparent. Conclusions.-The significant chromosome 19q13.2 single-locus and multilocus haplotype associations with MS in Caucasian and Chinese patient samples indicate an effect from a nearby disease susceptibility locus. These initial observations are an encouraging step toward the description of non-HLA genetic susceptibility to MS.	UNIV CALIF BERKELEY, DEPT INTEGRAT BIOL, BERKELEY, CA 94720 USA; ROCHE MOL SYST INC, DEPT HUMAN GENET, ALAMEDA, CA USA; CHILDRENS HOSP, OAKLAND RES INST, OAKLAND, CA 94609 USA; NCI, INTRAMURAL RES SUPPORT PROGRAM, SAIC FREDERICK, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21701 USA; UNIV CALIF DAVIS, DEPT NEUROL, DAVIS, CA USA; BEIJING UNION MED COLL HOSP, DEPT NEUROL, BEIJING 100730, PEOPLES R CHINA	University of California System; University of California Berkeley; Roche Holding; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of California System; University of California Davis; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035326] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; ALLEN M, 1994, HUM IMMUNOL, V39, P41, DOI 10.1016/0198-8859(94)90099-X; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Baur M.P., 1980, HISTOCOMPATIBILITY T, P955; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; BIAN HJ, 1992, NEUROEPIDEMIOLOGY, V11, P52, DOI 10.1159/000110911; CARRINGTON M, 1994, HUM MOL GENET, V3, P218, DOI 10.1093/hmg/3.1.218; CARRINGTON M, 1994, HUM IMMUNOL, V41, P234, DOI 10.1016/0198-8859(94)90041-8; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CLERGETDARPOUX F, 1992, ANN HUM GENET, V56, P145, DOI 10.1111/j.1469-1809.1992.tb01140.x; Cohen J., 1988, STAT POWER ANAL BEHA; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; EBERS GC, 1995, NATURE, V377, P150, DOI 10.1038/377150a0; GOODKIN DE, 1991, ARCH NEUROL-CHICAGO, V48, P805, DOI 10.1001/archneur.1991.00530200041016; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HAINES JL, 1993, AM J HUM GENET, V53, P266; HASHIMOTO LL, 1993, J NEUROIMMUNOL, V44, P77, DOI 10.1016/0165-5728(93)90270-9; HILLERT J, 1994, ANN NEUROL, V36, pS15, DOI 10.1002/ana.410360706; HILTON AA, 1995, J NEUROCHEM, V65, P309; Ibsen SN, 1996, ACTA NEUROL SCAND, V93, P236; Imanish T, 1992, HLA 1991, V1, P1065; KAMBOH MI, 1995, HUM BIOL, V67, P195; KELLARWOOD HF, 1995, J NEUROIMMUNOL, V58, P183, DOI 10.1016/0165-5728(95)00015-T; KELLY MA, 1995, J CLIN PATHOL-CL MOL, V48, pM111; KELLY MA, 1995, HUM IMMUNOL, V42, P203, DOI 10.1016/0198-8859(94)00094-7; KLITZ W, 1995, AM J HUM GENET, V57, P1436; Kuokkanen S, 1996, NAT GENET, V13, P477, DOI 10.1038/ng0896-477; KURTZKE JF, 1983, MULTIPLE SCLEROSIS P, P47; LONG JC, 1995, AM J HUM GENET, V56, P799; MARTIN M, 1995, HUM MOL GENET, V4, P423, DOI 10.1093/hmg/4.3.423; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NILLESEN WM, 1992, NUCLEIC ACIDS RES, V18, P428; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAMACHANDRAN S, 1995, TISSUE ANTIGENS, V46, P140, DOI 10.1111/j.1399-0039.1995.tb02492.x; RISCH N, 1990, AM J HUM GENET, V46, P242; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RISCH N, 1987, AM J HUM GENET, V40, P1; RISCH N, 1992, AM J HUM GENET, V51, P673; ROTH MP, 1994, J NEUROIMMUNOL, V51, P93, DOI 10.1016/0165-5728(94)90133-3; ROTH MP, 1995, J NEUROIMMUNOL, V61, P117, DOI 10.1016/0165-5728(95)00078-G; ROTH MP, 1995, HUM IMMUNOL, V43, P276, DOI 10.1016/0198-8859(95)91033-T; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1993, ANN NEUROL, V33, P281, DOI 10.1002/ana.410330309; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SERJEANTSON SW, 1992, EUR J IMMUNOGENET, V19, P11, DOI 10.1111/j.1744-313X.1992.tb00043.x; SPURKLAND A, 1994, HUM IMMUNOL, V39, P299, DOI 10.1016/0198-8859(94)90273-9; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A; VANDEVYVER C, 1994, J NEUROIMMUNOL, V52, P97, DOI 10.1016/0165-5728(94)90167-8; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISS KM, 1993, GENETIC VARIATION HU, P180; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WOOD NW, 1994, J NEUROL NEUROSUR PS, V57, P1191, DOI 10.1136/jnnp.57.10.1191	57	67	69	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	1997	278	15					1256	1261		10.1001/jama.278.15.1256	http://dx.doi.org/10.1001/jama.278.15.1256			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ709	9333267				2022-12-24	WOS:A1997XZ70900031
J	Bolognia, JL; Edelson, RL				Bolognia, JL; Edelson, RL			Spread of antibiotic-resistant bacteria from acne patients to personal contacts - a problem beyond the skin?	LANCET			English	Editorial Material							STAPHYLOCOCCI; ERYTHROMYCIN; THERAPY				Bolognia, JL (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Edelson, Richard/AAD-4826-2019					CRAWFORD WW, 1979, J INVEST DERMATOL, V72, P187, DOI 10.1111/1523-1747.ep12676385; EADY EA, 1993, BRIT MED J, V306, P555, DOI 10.1136/bmj.306.6877.555; HARKAWAY KS, 1992, BRIT J DERMATOL, V126, P586; LEYDEN JJ, 1983, J AM ACAD DERMATOL, V8, P41, DOI 10.1016/S0190-9622(83)70005-8; LYEDEN JJ, 1997, J GERIATR DERMATO SA, V5, pA1; Miller YW, 1996, J ANTIMICROB CHEMOTH, V38, P829; MURRAY PR, 1994, MED MICROBIOLOGY, V176, P292	7	10	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 4	1997	350	9083					972	973		10.1016/S0140-6736(05)64063-9	http://dx.doi.org/10.1016/S0140-6736(05)64063-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XZ710	9329508				2022-12-24	WOS:A1997XZ71000004
J	Boussiotis, VA; Freeman, GJ; Berezovskaya, A; Barber, DL; Nadler, LM				Boussiotis, VA; Freeman, GJ; Berezovskaya, A; Barber, DL; Nadler, LM			Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CBL PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; SUPPRESSOR ACTIVITY; INSULIN-RECEPTOR; MAMMALIAN-CELLS	In the absence of costimulation, T cells activated through their antigen receptor become unresponsive (anergic) and do not transcribe the gene encoding interleukin-2 (IL-2) when restimulated with antigen. Anergic alloantigen-specific human T cells contained phosphorylated Cbl that coimmunoprecipitated with Fyn. The adapter protein CrkL was associated with both phosphorylated Cbl and the guanidine nucleotide-releasing factor G3G, which catalyzes guanosine triphosphate (GTP) exchange on Rap1. Active Rap1 (GTP-bound form) was present in anergic cells, Forced expression of low amounts of Rap1-GTP in Jurkat T cells recapitulated the anergic defect and blocked T cell antigen receptor (TCR)- and CD28-mediated IL-2 gene transcription. Therefore, Rap1 functions as a negative regulator of TCR-mediated IL-2 gene transcription and may be responsible for the specific defect in IL-2 production in T cell anergy.	HARVARD UNIV, SCH MED, BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; ONTARIO CANC INST, DIV CELLULAR & MOL BIOL, TORONTO, ON M5G 2M9, CANADA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Boussiotis, VA (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT ADULT ONCOL, BOSTON, MA 02115 USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54785] Funding Source: Medline; NIAID NIH HHS [AI39671, AI 35225] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BOUSSIOTIS VA, UNPUB; Brownell HL, 1996, DNA CELL BIOL, V15, P443, DOI 10.1089/dna.1996.15.443; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JONGEWARD GD, 1995, GENETICS, V139, P1553; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MIGITA K, 1995, J IMMUNOL, V155, P5083; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAHL HL, 1991, EXP HEMATOL, V19, P1038; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PIZON V, 1988, ONCOGENE, V3, P201; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, J BIOL CHEM, V268, P4488; QUILL H, 1987, J IMMUNOL, V138, P3704; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SREEDQUIST KA, 1996, J BIOL CHEM, V271, P8453; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	77	388	395	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					124	128		10.1126/science.278.5335.124	http://dx.doi.org/10.1126/science.278.5335.124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311917				2022-12-24	WOS:A1997XZ12400053
J	MacCoun, R; Reuter, P				MacCoun, R; Reuter, P			Interpreting Dutch cannabis policy: Reasoning by analogy in the legalization debate	SCIENCE			English	Article							DRUG PROHIBITION	The Dutch depenalization and subsequent de facto legalization of cannabis since 1976 is used here to highlight the strengths and limitations of reasoning by analogy as a guide for projecting the effects of relaxing drug prohibitions. While the Dutch case and other analogies have flaws, they appear to converge in suggesting that reductions in criminal penalties have limited effects on drug use-at least for marijuana-but that commercial access is associated with growth in the drug-using population.	UNIV MARYLAND,SCH PUBL AFFAIRS,COLLEGE PK,MD 20742; UNIV MARYLAND,DEPT CRIMINOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	MacCoun, R (corresponding author), UNIV CALIF BERKELEY,RICHARD & RHODA GOLDMAN SCH PUBL POLICY,BERKELEY,CA 94720, USA.		MacCoun, Robert/N-1765-2019; MacCoun, Robert/D-1702-2011	MacCoun, Robert/0000-0003-0929-4423; 				Brown Jodi M., 1996, CORRECTIONAL POPULAT; COHEN P, 1997, CANNABIS USE AMSTERD; Cohen P., 1996, CANNABIS USE STEPPIN; COHEN P, COMMUNICATION; Cook T.C., 1979, QUASIEXPERIMENTATION; DEZWART WM, 1997, KERNGEGEVENS ROKEN D; DRIESSEN FM, 1989, ALCOHOL DRUGS ANDERE, V15, P2; *DRUG ENF ADM, ILL DRUG WHOL RET PR; DUKE SB, 1993, LONGEST RUNNING WAR; *EUR MON CTR DRUG, 1996, 1995 EUR MON CTR DRU; EVERINGHAM S, UNPUB 1993 NATL HOUS; *GEN ACC OFF, 1997, TGGD977 GAO; Goldstein A., 1994, ADDICTION BIOL DRUG; Hartnoll R., 1994, MULTICITY STUDY DRUG; Jansen A.C.M., 1991, CANNABIS AMSTERDAM G; Johnston LD, 1981, MARIJUANA DECRIMINAL; Johnston LD, 1995, NATL SURVEY RESULTS; KANDEL DB, 1991, MILBANK Q, V69, P365, DOI 10.2307/3350102; Kaplan J., 1970, MARIJUANA NEW PROHIB; KLEBER HD, 1994, NEW ENGL J MED, V330, P361, DOI 10.1056/NEJM199402033300514; Kleiman M, 1992, EXCESS DRUG POLICY R; KORF DJ, 1988, TIJDSCHR ALCOHOL DRU, V14, P81; LANGEMEIJER MPS, IN PRESS ILLICIT DRU; Leuw E, 1994, PROHIBITION LEGALIZA, P23; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MACCOUN R, IN PRESS DRUG WAR LE; MACCOUN RJ, 1993, PSYCHOL BULL, V113, P497, DOI 10.1037/0033-2909.113.3.497; MACCOUN RJ, 1993, J DRUG ISSUES, V23, P615, DOI 10.1177/002204269302300404; MACCOUN RJ, 1993, PSYCHOACTIVE DRUGS H, P103; MACCOUN RJ, 1995, POLICIES STRATEGIES; MEYENFELDT LH, 1996, EUROPEAN DRUG POLICI, P97; *MIN FOR AFF MIN H, 1995, DRUGS POL NETH CONT; *MIN JUST, DUTCH DRUGS POL; MIRON JA, 1995, J ECON PERSPECT, V9, P175, DOI 10.1257/jep.9.4.175; MIRON JA, 1991, AM ECON REV, V81, P242; NADELMANN E, 1989, SCIENCE, V245, P739; *NORW MIN HLTH SOC, 1997, NEW TRENDS DRUG AB N; *OFF NAT DRUG CONT, 1997, NAT DRUG CONTR STRAT; *OFF NAT DRUG CONT, 1993, STAT LOC SPEND DRUG; RHODES W, 1995, WHAT AM USERS SPEND; SANDWIJK JP, 1995, LICIT ILLICIT DRUG U, V2; SANDWIJK JP, 1991, LICIT ILLICIT DRUG U; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; *SUBST AB MENT HLT, 1994, MED EX DAT STAT 1 B, V14; *SUBST AB MENT HLT, NAT HOUS SURV DRUG A; UCHTENHAGEN A, 1997, PROGRAMME MED PRESCR; *UN, 1981, 2 UN SURV CRIME TREN; WILSON JQ, 1991, COMMENTARY, V89, P21; Wisotsky Steven., 1992, SOC SUSPECTS WAR DRU; 1997, MMWR-MORBID MORTAL W, V45, P392	50	91	94	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					47	52		10.1126/science.278.5335.47	http://dx.doi.org/10.1126/science.278.5335.47			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XZ124	9311925				2022-12-24	WOS:A1997XZ12400030
J	Dantonel, JC; Murthy, KGK; Manley, JL; Tora, L				Dantonel, JC; Murthy, KGK; Manley, JL; Tora, L			Transcription factor TFIID recruits factor CPSF for formation of 3' end of mRNA	NATURE			English	Article							RNA-POLYMERASE-II; POLYADENYLATION SPECIFICITY FACTOR; ESTROGEN-RECEPTOR; GLOBIN GENE; ACTIVATION; TERMINATION; CLEAVAGE; SUBUNIT; COMPLEX; PROTEIN	Initiation of transcription by RNA polymerase II from a promoter region on DNA requires the assembly of several initiation factors to form a preinitiation complex, Assembly of this complex(1,2) is initiated by the binding of the transcription factor TFIID, composed of the TATA-box binding protein (TBP) and TBP-associated factors (TAF(II)s), to the promoter, We have now characterized an immunopurified TFIID complex which we unexpectedly find contains the cleavage-polyadenylation specificity factor (CPSF), one of the factors required for formation of the 3' end of messenger RNA(3,4). CPSF is brought to the preinitiation complex by TFIID, but after transcription starts, CPSF dissociates from TFIID and becomes associated with the elongating polymerase, We also show that overexpression of recombinant TBP in HeLa cells decreases polyadenylation without affecting the correct initiation of transcription of the reporter gene, This indicates that, owing to incomplete assembly of TFIID on recombinant TBP, CPSF is not brought to the promoter and therefore polyadenylation becomes less efficient. Our observations have thus revealed a link between transcription initiation and elongation by RNA polymerase II and processing of the 3' end of mRNA.	ULP,COLL FRANCE,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 STRASBOURG,FRANCE; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Columbia University			Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Besse Sylvie, 1995, Gene Expression, V4, P143; BIENROTH S, 1991, J BIOL CHEM, V266, P768; BOAM DS, 1995, J BIOL CHEM, V270, P487; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; GERARD M, 1991, J BIOL CHEM, V266, P20940; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LAVIGNE AC, 1996, J BIOL CHEM, V271, P774; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	30	249	250	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					399	402		10.1038/38763	http://dx.doi.org/10.1038/38763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311784				2022-12-24	WOS:A1997XX67500057
J	Cumming, BG; Parker, AJ				Cumming, BG; Parker, AJ			Responses of primary visual cortical neurons to binocular disparity without depth perception	NATURE			English	Article							HUMAN STEREO VISION; CORTEX; MONKEY	The identification of brain regions that are associated with the conscious perception of visual stimuli is a major goal in neuroscience(1). Here we present a test of whether the signals on neurons in cortical area V1 correspond directly to our conscious perception of binocular stereoscopic depth. Depth perception requires that image features on one retina are first matched with appropriate features on the other retina. The mechanisms that perform this matching can be examined by using random-dot stereograms(2), in which the left and right eyes view randomly positioned but binocularly correlated dots. We exploit the fact that anticorrelated random-dot stereograms (in which dots in one eye are matched geometrically to dots of the opposite contrast in the other eye) do not give rise to the perception of depth(3) because the matching process does not find a consistent solution. Anticorrelated random-dot stereograms contain binocular features that could excite neurons that have not solved the correspondence problem. We demonstrate that disparity-selective neurons in V1 signal the disparity of anticorrelated random-dot stereograms, indicating that they do not unambiguously signal stereoscopic depth. Hence single V1 neurons cannot account for the conscious perception of stereopsis, although combining the outputs of many V1 neurons could solve the matching problem. The accompanying paper(4) suggests an additional function for disparity signals from V1: they may be important for the rapid involuntary control of vergence eye movements (eye movements that bring the images on the two foveae into register).			Cumming, BG (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; GRIMSON WEL, 1981, PHILOS T ROY SOC B, V292, P217, DOI 10.1098/rstb.1981.0031; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; POGGIO GF, 1995, CEREB CORTEX, V3, P193; QIAN N, 1994, NEURAL COMPUT, V6, P390, DOI 10.1162/neco.1994.6.3.390; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2	17	310	315	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					280	283		10.1038/38487	http://dx.doi.org/10.1038/38487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305841				2022-12-24	WOS:A1997XW77200046
J	Luger, K; Mader, AW; Richmond, RK; Sargent, DF; Richmond, TJ				Luger, K; Mader, AW; Richmond, RK; Sargent, DF; Richmond, TJ			Crystal structure of the nucleosome core particle at 2.8 angstrom resolution	NATURE			English	Article							X-RAY-DIFFRACTION; CHROMATIN; DNA; TRANSCRIPTION; HISTONE; PROTEIN; MODEL; BINDING; YEAST; INTEGRATION	The X-ray crystal structure of the nucleosome cave particle of chromatin shows in atomic detail how the histone protein octamer is assembled and how 146 base pairs of DNA are organized into a superhelix around it. Both histone/histone and histone/DNA interactions depend on the histone fold domains and additional, well ordered structure elements extending from this motif. Histone amino-terminal tails pass over and between the gyres of the DNA superhelix to contact neighbouring particles. The lack of uniformity between multiple histone/DNA-binding sites causes the DNA to deviate from ideal superhelix geometry.	ETH HONGGERBERG, ETHZ, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich				SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BRUNGER A, 1992, X PLOR V3 1 MANUAL; CAMERINIOTERO RD, 1977, P NATL ACAD SCI USA, V74, P5519, DOI 10.1073/pnas.74.12.5519; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FINCH JT, 1979, FEBS P M, V51, P193; Flaus A, 1996, P NATL ACAD SCI USA, V93, P1370, DOI 10.1073/pnas.93.4.1370; FLAUS A, IN PRESS J MOL BIOL; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Harp JM, 1996, ACTA CRYSTALLOGR D, V52, P283, DOI 10.1107/S0907444995009139; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LUGER K, IN PRESS J MOL BIOL; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1989, METHOD ENZYMOL, V170, P420; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; van Holde K.E., 1988, CHROMATIN; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YANG TP, 1982, P NATL ACAD SCI-BIOL, V79, P6593, DOI 10.1073/pnas.79.21.6593	51	6531	6744	11	639	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					251	260		10.1038/38444	http://dx.doi.org/10.1038/38444			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305837				2022-12-24	WOS:A1997XW77200038
J	Gale, JE; Ashmore, JF				Gale, JE; Ashmore, JF			An intrinsic frequency limit to the cochlear amplifier	NATURE			English	Article							OUTER HAIR-CELLS; MEMBRANE CAPACITANCE; NA,K PUMP; CHANNEL; MOTILITY; TRANSITIONS	Hearing in mammals depends on a feedback process within the inner ear termed the 'cochlear amplifier'(1). The essential components of this amplifier are sensorimotor cells, the outer hair cells, which transduce motion of the basilar membrane induced by sound and generate forces to cancel the viscous damping of the cochlear partition(2,3). Outer hair cells alter the passive mechanics of the cochlea, enhancing both the sensitivity and the frequency selectivity of the auditory system. The molecular basis of the mechanism is thought to be a voltage-sensitive 'motor' protein, as yet unidentified, embedded in the basolateral membrane of the outer hair cell(4). The cochlear amplifier operates up to at least 22 kHz (ref. 5), but by measuring both the charge and mechanical movements associated with the motor(6,7) in isolated membrane patches under voltage damp, we show here that the limiting frequency at which the motor operates lies near 25 kHz. This value therefore sets an upper limit to the range of hearing in mammalian cochleas using this mechanism. The fast charge movement, arising from charge displacement within the presumed motor molecule, further suggests that the protein is more likely to be related to a transporter than to a modified ion channel.	UCL, DEPT PHYSIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	Gale, JE (corresponding author), UNIV BRISTOL, SCH MED SCI, DEPT PHYSIOL, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND.		Gale, Jonathan/AAG-6874-2019	Gale, Jonathan/0000-0003-4678-4878	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1988, Q J EXP PHYSIOL CMS, V73, P143, DOI 10.1113/expphysiol.1988.sp003114; ASHMORE JF, 1990, NEUROSCI RES       S, V12, P39; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325; Dallos P., 1996, COCHLEA, P1; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GALE JE, 1997, EUR J PHYSL, V434, P267; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; IWASA KH, 1994, J ACOUST SOC AM, V96, P2216, DOI 10.1121/1.410094; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; MACONOCHIE DJ, 1995, BIOPHYS J, V68, P483, DOI 10.1016/S0006-3495(95)80209-2; MAMMANO F, 1993, J ACOUST SOC AM, V93, P3320, DOI 10.1121/1.405716; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; SIGG D, 1994, SCIENCE, V264, P578, DOI 10.1126/science.8160016; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; VATER M, 1992, J COMP NEUROL, V318, P367, DOI 10.1002/cne.903180403; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	24	107	107	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					63	66		10.1038/37968	http://dx.doi.org/10.1038/37968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288966				2022-12-24	WOS:A1997XU59600044
J	Kuroo, M; Matsumura, Y; Aizawa, H; Kawaguchi, H; Suga, T; Utsugi, T; Ohyama, Y; Kurabayashi, M; Kaname, T; Kume, E; Iwasaki, H; Iida, A; ShirakiIida, T; Nishikawa, S; Nagai, R; Nabeshima, Y				Kuroo, M; Matsumura, Y; Aizawa, H; Kawaguchi, H; Suga, T; Utsugi, T; Ohyama, Y; Kurabayashi, M; Kaname, T; Kume, E; Iwasaki, H; Iida, A; ShirakiIida, T; Nishikawa, S; Nagai, R; Nabeshima, Y			Mutation of the mouse klotho gene leads to a syndrome resembling ageing	NATURE			English	Article							LACTASE-PHLORIZIN HYDROLASE; ELONGATION FACTOR-1-ALPHA; SUPERFAMILY; PROMOTER; MICE	A new gene, termed klotho, has been identified that is involved in the suppression of several ageing phenotypes. A defect in klotho gene expression in the mouse results in a syndrome that resembles human ageing, Including a short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema. The gene encodes a membrane protein that shares sequence similarity with the B-glucosidase enzymes. The klotho gene product may function as part of a signalling pathway that regulates ageing in vivo and morbidity In age-related diseases.	GUNMA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,MAEBASHI,GUMMA 371,JAPAN; UNIV TOKYO,FAC MED,DEPT ORTHOPAED SURG,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; TANABE SEIYAKU CO LTD,LEAD OPTIMIZAT RES LAB,TODA,SAITAMA 335,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN; KYOWA HAKKO KOGYO CO LTD,PHARMACEUT RES LABS,NAGAIZUMI,SHIZUOKA 411,JAPAN; JRDC,CREST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Gunma University; University of Tokyo; Kumamoto University; Mitsubishi Tanabe Pharma Corporation; Kyowa Kirin Ltd; Kyowa Kirin Ltd; Japan Science & Technology Agency (JST); Osaka University	Kuroo, M (corresponding author), NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV MOL GENET,4-1-1 OGAWAHIGASKI,KODAIRA,TOKYO 187,JAPAN.							Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; CHUTTANI A, 1995, HDB PHYSL, V11, P309; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; Ellis NA, 1996, NATURE, V381, P110, DOI 10.1038/381110a0; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HAUSMAN PB, 1985, HDB BIOL AGING, P414; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; KANAME T, 1993, CYTOGENET CELL GENET, V64, P195, DOI 10.1159/000133573; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KUROO M, 1995, CIRC RES, V76, P148, DOI 10.1161/01.RES.76.1.148; LANSING AI, 1959, ARTERIAL WALL, P136; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MASER EJ, 1995, HDB PHYSL, V11, P3; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P155; ROBBINS SL, 1981, BASIC PATHOLOGY, P3; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 1989, MOL CLONING; TAKEDA T, 1991, J AM GERIATR SOC, V39, P911, DOI 10.1111/j.1532-5415.1991.tb04460.x; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOLFSON L, 1992, PRINCIPLES GERIATRIC, P75; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	26	2551	2751	2	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 6	1997	390	6655					45	51		10.1038/36285	http://dx.doi.org/10.1038/36285			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YE477	9363890				2022-12-24	WOS:A1997YE47700045
J	Turner, R; Stratton, I; Horton, V; Manley, S; Zimmet, P; Mackay, IR; Shattock, M; Bottazzo, GF; Holman, R				Turner, R; Stratton, I; Horton, V; Manley, S; Zimmet, P; Mackay, IR; Shattock, M; Bottazzo, GF; Holman, R			UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes	LANCET			English	Article							ANTIBODIES; MELLITUS; RELATIVES; IDDM; DIAGNOSIS; ADULTS; ONSET; DISEASE; MARKERS	Background Autoantibodies to islet-cell cytoplasm (ICA) and glutamic acid decarboxylase (GADA) can occur in apparently typical, non-insulin dependent diabetes mellitus (type 2). We investigated whether the presence of either or both antibodies characterises a subtype of diabetes and provides better prediction of requirement for insulin therapy by 6 years' follow-up than clinical variables. Methods We measured ICA and GADA at diagnosis of diabetes in a representative population of 3672 white patients with type 2 diabetes, aged between 25 and 65 years. The phenotype was assessed by age of onset, body-mass index, percentage haemoglobin A(1c) (HbA(1c)), and islet beta-cell function. We investigated the need for insulin therapy among 1538 patients not assigned insulin and followed up for 6 years from diagnosis. Findings The proportion of patients with ICA and GADA decreased with increasing age at diagnosis (from 33 [21%] of 157 patients aged 25-65 to 66 [4%] of 1769 aged 55-65 for ICA; from 53 [34%] to 122 [7%] for GADA). Among patients younger than 35 at diagnosis, those with ICA or GADA had lower body-mass index than those without (mean 24.9 [SD 6.0] vs 31.7 [7.3] kg/m(2); p<0.0001 and had higher percentage of HbA(1c) (9.7 vs 8.7%, p<0.05). 94% of patients with ICA and 84% of those with GADA required insulin therapy by 6 years, compared with 14% of those without the antibodies (p<0.0001). Among patients older than 55 at diagnosis, the difference between those with and without antibodies in body-mass index was smaller (27.2 [5.4] vs 28.6 [4.8] kg/m(2), p<0.001); 44% of those with ICA, 34% of those with GADA, and 5% with neither antibody required insulin therapy by 6 years (p<0.0001). Among patients older than 45 years, body-mass index and HbA(1c) provided little predictive information for insulin requirement, whereas the positive predictive values of GADA (greater than or equal to 60 U/L) alone, or both GADA (greater than or equal to 20 U/L) and ICA (>5 U/L), for insulin therapy were 52% and 68%. Interpretation Among young adults with type 2 diabetes, the phenotype of those with ICA or GADA antibodies was similar to that of classic juvenile-onset insulin-dependent diabetes, and either phenotype or antibodies predicted insulin requirement. In older adults, the phenotype was closer to that of patients without antibodies and only the presence of antibodies predicted an increased likelihood of insulin requirement.	INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MONASH UNIV,DEPT BIOCHEM & MOL BIOL,CLAYTON,VIC 3168,AUSTRALIA; ST BARTHOLOMEWS & ROYAL LONDON MED SCH & DENT,DEPT IMMUNOL,LONDON,ENGLAND	Monash University; University of London; Queen Mary University London	Turner, R (corresponding author), RADCLIFFE INFIRM,DIABET RES LABS,UK PROSPECT DIBAET STUDY GRP,WOODSTOCK RD,OXFORD OX2 6HE,ENGLAND.		stratton, irene/AAZ-3627-2020; Zimmet, Paul/O-8486-2019; Mackay, Ian R/A-7228-2010	stratton, irene/0000-0003-1172-7865; Zimmet, Paul/0000-0003-0627-0776; Manley, Susan/0000-0002-8298-4511				BAEKKESKOV V, 1990, NATURE, V347, P152; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BONIFACIO E, 1995, DIABETOLOGIA, V38, P816, DOI 10.1007/s001250050358; BOTTAZZO GF, 1993, DIABETES, V42, P778; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; CHEN QY, 1993, PEDIATR RES, V34, P785, DOI 10.1203/00006450-199312000-00018; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; GLEICHMANN H, 1984, DIABETOLOGIA, V27, P90, DOI 10.1007/BF00275656; GOTTSATER A, 1995, DIABETES RES CLIN PR, V27, P133, DOI 10.1016/0168-8227(95)01026-A; GROOP L, 1988, DIABETES, V37, P99, DOI 10.2337/diabetes.37.1.99; GROOP LC, 1986, DIABETES, V35, P237, DOI 10.2337/diabetes.35.2.237; IRVINE WJ, 1977, LANCET, V1, P1025; KOBAYASHI T, 1993, DIABETES CARE, V16, P780, DOI 10.2337/diacare.16.5.780; KOBAYASHI T, 1987, DIABETES, V36, P510, DOI 10.2337/diabetes.36.4.510; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; NABARRO JDN, 1991, DIABETIC MED, V8, P59, DOI 10.1111/j.1464-5491.1991.tb01517.x; NISKANEN LK, 1995, DIABETES CARE, V18, P1557, DOI 10.2337/diacare.18.12.1557; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SANJEEVI CB, 1996, DIABETOLOGIA, V39, pS301; Seissler J, 1996, DIABETOLOGIA, V39, P1351, DOI 10.1007/s001250050582; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; *UKPDS GROUP, IN PRESS UK PROSP DI, V24; *UKPDS GROUP, 1991, DIABETOLOGIA, V34, P877; VERGE CF, 1994, DIABETOLOGIA, V37, P113; Willis JA, 1996, DIABETES RES CLIN PR, V33, P89, DOI 10.1016/0168-8227(96)01281-8; ZIMMET PZ, 1994, DIABETIC MED, V11, P299, DOI 10.1111/j.1464-5491.1994.tb00275.x; 1985, LANCET, V2, P809	30	564	612	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 1	1997	350	9087					1288	1293		10.1016/S0140-6736(97)03062-6	http://dx.doi.org/10.1016/S0140-6736(97)03062-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD689	9357409				2022-12-24	WOS:A1997YD68900011
J	Pufahl, RA; Singer, CP; Peariso, KL; Lin, SJ; Schmidt, PJ; Fahrni, CJ; Culotta, VC; PennerHahn, JE; OHalloran, TV				Pufahl, RA; Singer, CP; Peariso, KL; Lin, SJ; Schmidt, PJ; Fahrni, CJ; Culotta, VC; PennerHahn, JE; OHalloran, TV			Metal ion chaperone function of the soluble Cu(I) receptor Atx1	SCIENCE			English	Article							WILSON-DISEASE GENE; COPPER-TRANSPORTING ATPASE; MENKES DISEASE; IRON UPTAKE; CHEMISTRY; COMPLEX; MECHANISM; PROTEINS; ENCODES; BINDING	Reactive and potentially toxic cofactors such as copper ions are imported into eukaryotic cells and incorporated into target proteins by unknown mechanisms. Atx1, a prototypical copper chaperone protein from yeast, has now been shown to act as a soluble cytoplasmic copper(l) receptor that can adopt either a two-or three-coordinate metal center in the active site. Atx1 also associated directly with the Atx1-like cytosolic domains of Ccc2, a vesicular protein defined in genetic studies as a member of the copper-trafficking pathway. The unusual structure and dynamics of Atx1 suggest a copper exchange function for this protein and related domains in the Menkes and Wilson disease proteins.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; UNIV MICHIGAN, DEPT CHEM, ANN ARBOR, MI 48109 USA; JOHNS HOPKINS UNIV, DEPT ENVIRONM HLTH SCI, BALTIMORE, MD 21205 USA	Northwestern University; Northwestern University; University of Michigan System; University of Michigan; Johns Hopkins University			Penner-Hahn, James/GYD-3750-2022; O'Halloran, Thomas/ABE-6125-2021; Peariso, Katrina/AAQ-2090-2021; Peariso, Katrina/Y-1516-2019	Penner-Hahn, James/0000-0003-0314-1274; O'Halloran, Thomas/0000-0001-8732-5059; Peariso, Katrina/0000-0003-1616-8329	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, R01GM050016, R29GM038047, R37GM050016, R01GM038047] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50016, R01 GM054111, GM-38047, GM-54111] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHEESMAN BV, 1988, J AM CHEM SOC, V110, P6359, DOI 10.1021/ja00227a014; COUCOUVANIS D, 1980, INORG CHEM, V19, P2993, DOI 10.1021/ic50212a030; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DASILVA JRR, 1991, BIOL CHEM ELEMENTS, P396; Dieckmann GR, 1997, J AM CHEM SOC, V119, P6195, DOI 10.1021/ja964351i; ERIKSSON PO, 1993, J BIOMOL NMR, V3, P613; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; GITSCHLER J, COMMUNICATION; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; Hausinger RP, 1996, MECH METALLOCENTER A; Hobman JL, 1997, MET IONS BIOL SYST, V34, P527; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KOCH SA, 1984, INORG CHEM, V23, P121, DOI 10.1021/ic00170a001; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIN SJ, 1997, J BIOL CHEM, V272, P9214; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; SOLOMON EI, 1996, CHEM REV, V96, P2653; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; THORP HH, 1992, INORG CHEM, V31, P1585, DOI 10.1021/ic00035a012; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; Utschig LM, 1997, INORG CHEM, V36, P2926, DOI 10.1021/ic960571l; VALENTINE JS, 1994, BIOINORG CHEM, V1, P253; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Winge DR, 1997, J BIOL INORG CHEM, V2, P2, DOI 10.1007/s007750050100; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	582	596	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 31	1997	278	5339					853	856		10.1126/science.278.5339.853	http://dx.doi.org/10.1126/science.278.5339.853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YD479	9346482				2022-12-24	WOS:A1997YD47900044
J	Orentlicher, D				Orentlicher, D			The Supreme Court and physician-assisted suicide - Rejecting assisted suicide but embracing euthanasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TERMINALLY ILL; CANCER		INDIANA UNIV,SCH LAW,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis								Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P206; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; Cherny N I, 1994, J Palliat Care, V10, P31; ENCK RE, 1994, MED CARE TERMINALLY, P166; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; Ramani S, 1996, SOUTH MED J, V89, P1101, DOI 10.1097/00007611-199611000-00017; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311	14	100	100	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 23	1997	337	17					1236	1239		10.1056/NEJM199710233371713	http://dx.doi.org/10.1056/NEJM199710233371713			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB718	9340517				2022-12-24	WOS:A1997YB71800013
J	Resnick, NM; Marcantonio, ER				Resnick, NM; Marcantonio, ER			How should clinical care of the aged differ?	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; EFFICACY; THERAPY		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA	Harvard University; Harvard Medical School	Resnick, NM (corresponding author), BRIGHAM & WOMENS HOSP,DIV GERONTOL,75 FRANCIS ST,BOSTON,MA 02115, USA.		Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008812, P60AG008812, P01AG004390] Funding Source: NIH RePORTER; NIA NIH HHS [AG-04390, AG-08812] Funding Source: Medline; NIDDK NIH HHS [DK-49482] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDUCCI L, 1991, J AM GERIATR SOC, V39, P1113, DOI 10.1111/j.1532-5415.1991.tb02879.x; Balducci L, 1992, Oncology (Williston Park), V6, P62; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CASSEL CK, 1997, GERIATRIC MED; Fries JF, 1981, VITALITY AGING; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; KAPOOR WN, 1997, GERIATRIC MED, P757; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LIPSITZ LA, 1983, ANN INTERN MED, V99, P92, DOI 10.7326/0003-4819-99-1-92; MOKSHAGUNDAM S, 1993, J AM GERIATR SOC, V41, P1361, DOI 10.1111/j.1532-5415.1993.tb06488.x; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; RESNICK NM, 1995, LANCET, V346, P94, DOI 10.1016/S0140-6736(95)92117-6; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SIVENIUS J, 1995, BMJ-BRIT MED J, V310, P25, DOI 10.1136/bmj.310.6971.25; Tinetti ME, 1997, GERIATRIC MED, P787	16	63	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 18	1997	350	9085					1157	1158		10.1016/S0140-6736(05)63817-2	http://dx.doi.org/10.1016/S0140-6736(05)63817-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB199	9343515				2022-12-24	WOS:A1997YB19900043
J	KowenzLeutz, E; Herr, P; Niss, K; Leutz, A				KowenzLeutz, E; Herr, P; Niss, K; Leutz, A			The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation	CELL			English	Article							AVIAN LEUKEMIA VIRUSES; DNA-BINDING DOMAIN; HEMATOPOIETIC-CELLS; NF-M; MYELOID CELLS; C-MYB; TRANSCRIPTIONAL CONTROL; TRANSLOCATION PROTEIN; MOLECULAR-CLONING; PRE-B	The homeobox gene GBX2 was identified as a target gene of the v-Myb oncoprotein encoded by the avian myeloblastosis virus (AMV). GBX2 activation by c-Myb requires signal transduction emanating from the cell surface while the leukemogenic AMV v-Myb constitutively induces the GBX2 gene. Mutations in the DHA binding domain of AMV-Myb render it independent of signaling events and concomitantly abrogate the collaboration between Myb and CCAAT Enhancer Binding Proteins (C/EBP), which are involved in granulocyte differentiation. Ectopic expression of GBX2 in growth factor-dependent myeloblasts induces monocytic features and independence from exogenous cytokines, reflecting distinct features of AMV-transformed cells. Our results suggest that Myb or factors it interacts with contribute to hematopoietic lineage choice and differentiation in a signal transduction-dependent fashion.	MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BULFONE A, 1993, J NEUROSCI, V13, P3155; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; EWERT DL, 1984, J IMMUNOL, V132, P2524; FAINSOD A, 1989, FEBS LETT, V250, P381, DOI 10.1016/0014-5793(89)80760-4; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Harlow E, 1988, ANTIBODIES LAB MANUA; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KAADEN OR, 1977, MED MICROBIOL IMMUN, V163, P157, DOI 10.1007/BF02126676; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEHRL JH, 1994, CRIT REV ONCOL HEMAT, V16, P145, DOI 10.1016/1040-8428(94)90046-9; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1996, ONCOGENE, V13, P223; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MOSCOVICI C, 1982, TRANSFORMATION HEMOP, V1; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wolff L, 1997, BBA-REV CANCER, V1332, pF67, DOI 10.1016/S0304-419X(97)00006-1; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	48	87	88	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 17	1997	91	2					185	195		10.1016/S0092-8674(00)80401-8	http://dx.doi.org/10.1016/S0092-8674(00)80401-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YC350	9346236	Bronze			2022-12-24	WOS:A1997YC35000006
J	Schiodt, FV; Rochling, FA; Casey, DL; Lee, WM				Schiodt, FV; Rochling, FA; Casey, DL; Lee, WM			Acetaminophen toxicity in an urban county hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC MISADVENTURE; INDUCED HEPATOTOXICITY; MEDICAL PROGRESS; N-ACETYLCYSTEINE; LIVER; ALCOHOL; ETHANOL; FAILURE; ASSOCIATION	Background The prevalence and characteristics of acetaminophen associated liver injury in hospitalized patients are not well defined. Methods We identified patients hospitalized for excessive acetaminophen ingestion at an urban county hospital over a 40-month period (1992 to 1995) and reviewed their medical records to determine the incidence and clinical features of the ingestions and their outcomes. Results Of the 71 patients studied, 50 were classified as having taken acetaminophen during suicide attempts and 21 as having accidentally poisoned themselves while attempting to relieve pain, The suicidal patients had ingested almost twice as much acetaminophen as those in the accidental-overdose group (median, 20 vs. 12 g; P=0.009), Among the patients for whom data were available, 63 percent of those in the accidental-overdose group and 25 percent of those in the suicidal group were chronic alcohol abusers (P=0.009). The patients in the accidental-overdose group more often had severe liver necrosis (aminotransferase levels, >3500 IU per liter; 52 percent vs, 14 percent; P=0.002) and were more likely to have hepatic coma (33 percent vs. 6 percent, P=0.006). There were four deaths (19 percent) in the accidental-overdose group and one (2 percent) in the suicidal group (P=0.04). Five patients - three in the accidental-overdose group and two in the suicidal group - had ingested 4 g of acetaminophen or less. Acetaminophen ingestion accounted for 12 percent of all patients hospitalized with overdoses (71 of 589) and 40 percent of patients with acute liver failure (10 of 25) during the study period. Conclusions In an urban county hospital, patients hospitalized with acetaminophen toxicity related to accidental misuse had higher rates of morbidity and mortality than those who attempted suicide, even though the latter had taken more acetaminophen. A higher frequency of chronic alcohol abuse among the patients with accidental overdoses may be one explanation. (C) 1997, Massachusetts Medical Society.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,LIVER DIV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Altman D.G., 1991, PRACTICAL STATISTIC; BLACK M, 1984, ANNU REV MED, V35, P577, DOI 10.1146/annurev.me.35.020184.003045; BLACK M, 1986, ANN INTERN MED, V104, P427, DOI 10.7326/0003-4819-104-3-427; BROTODIHARDJO AE, 1992, MED J AUSTRALIA, V157, P382, DOI 10.5694/j.1326-5377.1992.tb137246.x; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HUGHES R D, 1991, Gut, pS86; Johnston SC, 1997, MEDICINE, V76, P185, DOI 10.1097/00005792-199705000-00004; KUMAR S, 1991, ARCH INTERN MED, V151, P1189, DOI 10.1001/archinte.151.6.1189; LEE WM, 1994, NEW ENGL J MED, V330, P584; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; LICHT H, 1980, ANN INTERN MED, V92, P511, DOI 10.7326/0003-4819-92-4-511_1; Litovitz TL, 1996, AM J EMERG MED, V14, P487, DOI 10.1016/S0735-6757(96)90160-6; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; MAKIN AJ, 1997, ACUTE LIVER FAILURE, P32; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; MUTIMER DJ, 1994, GUT, V35, P809, DOI 10.1136/gut.35.6.809; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; TAKAHASHI T, 1993, HEPATOLOGY, V17, P236, DOI 10.1016/0270-9139(93)90083-Y; VALE JA, 1995, LANCET, V346, P547, DOI 10.1016/S0140-6736(95)91385-8; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WOOTTON FT, 1990, SOUTHERN MED J, V83, P1047, DOI 10.1097/00007611-199009000-00017; Zimmerman HJ, 1995, HEPATOLOGY, V22, P1898; ZIMMERMAN HJ, 1995, HEPATOLOGY, V22, P767, DOI 10.1016/0270-9139(95)90295-3	28	296	301	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 16	1997	337	16					1112	1117		10.1056/NEJM199710163371602	http://dx.doi.org/10.1056/NEJM199710163371602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA912	9329933				2022-12-24	WOS:A1997YA91200002
J	Schwartz, SM; Siscovick, DS; Longstreth, WT; Psaty, BM; Beverly, RK; Raghunathan, TE; Lin, DY; Koepsell, TD				Schwartz, SM; Siscovick, DS; Longstreth, WT; Psaty, BM; Beverly, RK; Raghunathan, TE; Lin, DY; Koepsell, TD			Use of low-dose oral contraceptives and stroke in young women	ANNALS OF INTERNAL MEDICINE			English	Article						contraceptives, oral; cerebrovascular disorders; norgestrel; cerebrovascular hemorrhage; cerebral infarction	CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; PROGESTOGENS; MENOPAUSE; ESTROGEN; RISK	Background: Low-dose oral contraceptives are widely used, but there are limited data on the cerebrovascular risks associated with these medications. Objective: To determine whether use of low-dose oral contraceptives influences the risk for stroke. Design: Population-based case-control study. Setting: Women 18 to 44 years of age who resided in western Washington State between 1991 and 1995. Participants: Patients with ischemic stroke (n = 60). hemorrhagic stroke (n = 102), and other types of stroke (n = 11) and controls identified through random-digit dialing (n = 485). Measurements: Details about oral contraceptive use and other risk factors for stroke were obtained through in-person interviews. Results: The estimated incidences of hemorrhagic stroke and ischemic stroke were 6.4 and 4.3 per 100,000 women-years, respectively. Compared with women who had never used oral contraceptives (after adjustment for risk factors for stroke), current users of low-dose oral contraceptives had estimated odds ratios of 0.93 (95% Cl, 0.37 to 2.31) for hemorrhagic stroke and 0.89 (Cl, 0.27 to 2.94) for ischemic stroke. Compared with past users of oral contraceptives, current users had odds ratios of 1.41 (Cl, 0.67 to 2.96) for hemorrhagic stroke and 1.37 (Cl, 0.49 to 3.81) for ischemic stroke. For past users compared with never users, the odds ratios were 0.59 (Cl, 0.30 to 1.18) for hemorrhagic stroke and 0.57 (Cl, 0.25 to 1.32) for ischemic stroke. The odds ratio for hemorrhagic stroke in current users of low-dose oral contraceptives containing norgestrel or levonorgestrel was elevated (3.23 [Cl, 1.24 to 8.41]). Among patients with hemorrhagic stroke, the odds ratio for aneurysmal bleeding associated with current use of low-dose oral contraceptives containing norgestrel or levonorgestrel was 4.46 (Cl, 1.58 to 12.53). Conclusions: The overall risk for stroke and type of stroke was not increased among current users of low-dose oral contraceptives in the study population. Larger studies are needed to clarify both the relation of risk for stroke to past use of oral contraceptives and the possible association between current use of norgestrel-containing oral contraceptives and hemorrhagic stroke.	UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NICHD NIH HHS [HD-1-31-7] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1973, Lancet, V1, P1399; BOLOGNIA JL, 1989, MATURITAS, V11, P295, DOI 10.1016/0378-5122(89)90026-1; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; GANGAR KF, 1991, LANCET, V338, P839; GODSLAND IF, 1995, CONTRACEPTION, V52, P143, DOI 10.1016/0010-7824(95)00153-2; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; INMAN WHW, 1968, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5599.193; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; MANN JI, 1975, BRIT MED J, V2, P245, DOI 10.1136/bmj.2.5965.245; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; MEADE TW, 1977, LANCET, V2, P948; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PHILLIPS A, 1987, CONTRACEPTION, V36, P181, DOI 10.1016/0010-7824(87)90013-8; Poulter NR, 1996, LANCET, V348, P505; Poulter NR, 1996, LANCET, V348, P498; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; *ROYAL COLL GEN PR, 1977, LANCET, V2, P727; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; VESSEY MP, 1993, METHOD INFORM MED, V32, P222	23	93	96	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	1				596	+		10.7326/0003-4819-127-8_Part_1-199710150-00003	http://dx.doi.org/10.7326/0003-4819-127-8_Part_1-199710150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB419	9341057				2022-12-24	WOS:A1997YB41900003
J	SoderbergNaucler, C; Fish, KN; Nelson, JA				SoderbergNaucler, C; Fish, KN; Nelson, JA			Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors	CELL			English	Article							VERSUS-HOST DISEASE; GRANULOCYTE-MACROPHAGE PROGENITORS; MARROW TRANSPLANT RECIPIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; BONE-MARROW; MURINE CYTOMEGALOVIRUS; GENE-EXPRESSION; IN-VIVO; INFECTION; LYMPHOCYTES	Reactivation of human cytomegalovirus (HCMV) results in severe disease in AIDS patients and immunocompromised patients receiving blood transfusions or organ or bone marrow grafts. Although the site of HCMV latency is unknown, blood cells have been implicated as a viral reservoir. In this study, we demonstrate HCMV reactivation in vitro from seven consecutive healthy donors through allogeneic stimulation of peripheral blood mononuclear cells (PBMCs). HCMV replication was detected at 17 days poststimulation, and virus was recovered after long-term culture from a macrophage expressing dendritic cell markers. Thus, these observations demonstrate that PBMCs harbor latent HCMV, which reactivates in a myeloid lineage cell upon allogeneic stimulation.	OREGON HLTH SCI UNIV,DEPT MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University			Fish, Kenneth/AAX-3067-2020	Fish, Kenneth/0000-0003-1774-3815	NIAID NIH HHS [AI 21640] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1992, MACROPHAGE, P77; BOSTROM L, 1990, BONE MARROW TRANSPL, V5, P321; Britt W. J., 1996, FIELDS VIROLOGY, P2493; BRITT WJ, 1992, J VIROL, V66, P6747, DOI 10.1128/JVI.66.11.6747-6754.1992; BRUNING JH, 1986, TRANSPLANTATION, V41, P695, DOI 10.1097/00007890-198606000-00005; BRYTTING M, 1995, TRANSPLANTATION, V60, P961; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CHOU SW, 1986, NEW ENGL J MED, V314, P1418, DOI 10.1056/NEJM198605293142205; DOCKE WD, 1994, LANCET, V343, P238; Fish KN, 1996, J VIROL, V70, P1855, DOI 10.1128/JVI.70.3.1855-1862.1996; FISH KN, 1995, J VIROL, V69, P3737, DOI 10.1128/JVI.69.6.3737-3743.1995; FLECKENSTEIN B, 1982, GENE, V18, P39, DOI 10.1016/0378-1119(82)90054-3; GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428; GNANN JW, 1988, AM J PATHOL, V132, P239; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; HAMILTON JD, 1995, TRANSPLANTATION, V39, P290; IBANEZ CE, 1991, J VIROL, V65, P6581, DOI 10.1128/JVI.65.12.6581-6588.1991; JORDAN MC, 1982, J CLIN INVEST, V70, P762, DOI 10.1172/JCI110672; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KOFFRON AJ, 1995, SCAND J INF DIS S, V99, P612; Kondo K, 1996, P NATL ACAD SCI USA, V93, P11137, DOI 10.1073/pnas.93.20.11137; KONDO K, 1994, P NATL ACAD SCI USA, V91, P11879, DOI 10.1073/pnas.91.25.11879; LONNQVIST B, 1984, TRANSPLANTATION, V38, P465, DOI 10.1097/00007890-198411000-00004; MACIEJEWSKI JP, 1992, BLOOD, V80, P170; Mandanas RA, 1996, AM J HEMATOL, V51, P104; MATLOUBIAN M, 1993, J VIROL, V67, P7340, DOI 10.1128/JVI.67.12.7340-7349.1993; MELNICK JL, 1995, BIOESSAYS, V17, P899, DOI 10.1002/bies.950171012; Mendelson M, 1996, J GEN VIROL, V77, P3099, DOI 10.1099/0022-1317-77-12-3099; MERCER JA, 1988, J VIROL, V62, P987, DOI 10.1128/JVI.62.3.987-997.1988; MEYERS JD, 1986, AM J MED, V81, P27, DOI 10.1016/0002-9343(86)90511-5; MINTON EJ, 1994, J VIROL, V68, P4017, DOI 10.1128/JVI.68.6.4017-4021.1994; MYERSON D, 1984, HUM PATHOL, V15, P430, DOI 10.1016/S0046-8177(84)80076-3; NOVASSAGH M, 1996, BLOOD, V88, P1277; OLDING LB, 1975, J EXP MED, V141, P561, DOI 10.1084/jem.141.3.561; Pollock JL, 1997, VIROLOGY, V227, P168, DOI 10.1006/viro.1996.8303; REDDEHASE MJ, 1994, J EXP MED, V179, P185, DOI 10.1084/jem.179.1.185; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; Roizman B, 1996, FIELDS VIROLOGY, P2231; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHMADER KE, 1992, J INFECT DIS, V166, P1403, DOI 10.1093/infdis/166.6.1403; SCHRIER RD, 1990, J VIROL, V64, P3280, DOI 10.1128/JVI.64.7.3280-3288.1990; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SIMMONS P, 1990, P NATL ACAD SCI USA, V87, P1386, DOI 10.1073/pnas.87.4.1386; Sinzger C, 1996, J INFECT DIS, V173, P240, DOI 10.1093/infdis/173.1.240; SINZGER C, 1993, J INFECT DIS, V167, P1427, DOI 10.1093/infdis/167.6.1427; SODERBERG C, 1993, J VIROL, V67, P3166; Soderberg C, 1996, TRANSPLANTATION, V61, P600; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; STODDART CA, 1994, J VIROL, V68, P6243, DOI 10.1128/JVI.68.10.6243-6253.1994; TAYLORWIEDEMAN J, 1994, J VIROL, V68, P1597, DOI 10.1128/JVI.68.3.1597-1604.1994; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; TEGTMEIER GE, 1989, ARCH PATHOL LAB MED, V113, P236; TOROKSTORB B, 1992, ANN HEMATOL SA, V64, P128; vandenBerg AP, 1996, CLIN TRANSPLANT, V10, P224; VONLAER D, 1995, BLOOD, V86, P4086, DOI 10.1182/blood.V86.11.4086.bloodjournal86114086; VONLAER D, 1995, J INFECT DIS, V172, P365, DOI 10.1093/infdis/172.2.365; YAGYU K, 1993, TRANSPLANT P, V25, P1152; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903	59	530	546	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 3	1997	91	1					119	126		10.1016/S0092-8674(01)80014-3	http://dx.doi.org/10.1016/S0092-8674(01)80014-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XZ809	9335340	Bronze			2022-12-24	WOS:A1997XZ80900014
J	Nightingale, SL				Nightingale, SL			New guidance for prescription drug TV and radio advertising proposed	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	1997	278	13					1054	1054						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX303	9315751				2022-12-24	WOS:A1997XX30300006
J	Kutay, U; Bischoff, FR; Kostka, S; Kraft, R; Gorlich, D				Kutay, U; Bischoff, FR; Kostka, S; Kraft, R; Gorlich, D			Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; SEGREGATION GENE CSE1; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; CHROMOSOME SEGREGATION; HNRNP A1; RAN-GTP; RAN/TC4 HOMOLOG; YEAST; LOCALIZATION	NLS proteins are transported into the nucleus by the importin alpha/beta heterodimer. Importin alpha binds the NLS, while importin beta mediates translocation through the nuclear pore complex. After translocation, RanGTP, whose predicted concentration is high in the nucleus and low in the cytoplasm, binds importin beta and displaces importin alpha. Importin alpha must then be returned to the cytoplasm, leaving the NLS protein behind. Here, we report that the previously identified CAS protein mediates importin alpha re-export. CAS binds strongly to importin alpha only in the presence of RanGTP, forming an importin alpha/CAS/RanGTP complex. Importin alpha is released from this complex in the cytoplasm by the combined action of RanBP1 and RanGAP1. CAS binds preferentially to NLS-free importin alpha, explaining why import substrates stay in the nucleus.	UNIV HEIDELBERG, ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, ABT MOL BIOL MITOSE, D-69120 HEIDELBERG, GERMANY; ZENTRUM MOL MED, D-13122 BERLIN, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)			Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DEANE R, 1997, IN PRESS MOL CELL BI; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fridell RA, 1997, J CELL SCI, V110, P1325; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZAURRALDE E, 1997, IN PRESS EMBO J; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LENO GH, 1991, METHOD CELL BIOL, V36, P561; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; Schlenstedt G, 1996, FEBS LETT, V389, P75, DOI 10.1016/0014-5793(96)00583-2; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	72	517	528	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 19	1997	90	6					1061	1071		10.1016/S0092-8674(00)80372-4	http://dx.doi.org/10.1016/S0092-8674(00)80372-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XX768	9323134	Bronze			2022-12-24	WOS:A1997XX76800012
J	Ames, JB; Ishima, R; Tanaka, T; Gordon, JI; Stryer, L; Ikura, M				Ames, JB; Ishima, R; Tanaka, T; Gordon, JI; Stryer, L; Ikura, M			Molecular mechanics of calcium-myristoyl switches	NATURE			English	Article							RHODOPSIN KINASE; RECOVERIN; PROTEIN; BINDING; SYSTEM; RESOLUTION; TERMINUS; FAMILY	Many eukaryotic cellular and viral proteins have a covalently attached myristoyl group at the amino terminus. One such protein is recovering a calcium sensor in retinal rod cells, which controls the lifetime of photoexited rhodopsin by inhibiting rhodopsin kinase(1-6). Recoverin has a relative molecular mass of 23,000 (M-r 23K), and contains an amino-terminal myristoyl group (or related acyl group) and four EF hands(7). The binding of two Ca2+ ions to rccoverin leads to its translocation from the cytosol to the disc membraned(8,9). In the Ca2+-free state, the myristoyl group is sequestered in a deep hydrophobic box, where it is clamped by multiple residues contributed by three of the EF hands(10). We have used nuclear magnetic resonance to show that Ca2+ induces the unclamping and extrusion of the myristoyl group, enabling it to interact with a lipid bilayer membrane. The transition is also accompanied by a 45-degree rotation of the amino-terminal domain relative to the carboxy-terminal domain, and many hydrophobic residues are exposed. The conservation of the myristoyl binding site and two swivels in recoverin homologues from yeast to humans indicates that calcium-myristoyl switches are ancient devices for controlling calcium-sensitive processes.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba; Washington University (WUSTL)				Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLER MPG, 1993, NEURON, V10, P523; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	29	411	416	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					198	202		10.1038/38310	http://dx.doi.org/10.1038/38310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296500				2022-12-24	WOS:A1997XV75700053
J	Lijam, N; Paylor, R; McDonald, MP; Crawley, JN; Deng, CX; Herrup, K; Stevens, KE; Maccaferri, G; McBain, CJ; Sussman, DJ; WynshawBoris, A				Lijam, N; Paylor, R; McDonald, MP; Crawley, JN; Deng, CX; Herrup, K; Stevens, KE; Maccaferri, G; McBain, CJ; Sussman, DJ; WynshawBoris, A			Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1	CELL			English	Article							SEGMENT-POLARITY GENE; PREPULSE INHIBITION; ACOUSTIC STARTLE; SCHIZOPHRENIC-PATIENTS; INBRED STRAINS; ANIMAL-MODEL; DROSOPHILA; STIMULATION; DEFICITS; HABITUATION	Mice completely deficient for Dvl1, one of three mouse homologs of the Drosophila segment polarity gene Dishevelled, were created by gene targeting. Dv1-deficient mice are viable, fertile, and structurally normal. Surprisingly, these mice exhibited reduced social interaction, including differences in whisker trimming, deficits in nest-building, less huddling contact during home cage sleeping, and subordinate responses in a social dominance test. Sensorimotor gating was abnormal, as measured by deficits in prepulse inhibition of acoustic and tactile startle. Thus, Dv1 mutants may provide a model for aspects of several human psychiatric disorders. These results are consistent with an interpretation that common genetic mechanisms underlie abnormal social behavior and sensorimotor gating deficits and implicate Dvl1 in processes underlying complex behaviors.	NIMH,SECT BEHAV NEUROPHARMACOL,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892; NIDDK,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NICHHD,LAB CELLULAR & MOL NEUROPHYSIOL,NATL INST HLTH,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,DENVER,CO 80262; UNIV MARYLAND,SCH MED,DIV HUMAN GENET,BALTIMORE,MD 21201	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Maryland; University of Maryland Baltimore	Lijam, N (corresponding author), NATL HUMAN GENOME RES INST,LAB GENET DIS RES,BETHESDA,MD 20892, USA.		deng, chuxia/N-6713-2016; Herrup, Karl/C-5313-2014	McDonald, Michael P./0000-0002-9642-964X; Herrup, Karl/0000-0001-7786-5844	NATIONAL CANCER INSTITUTE [R01CA063929, R55CA063929] Funding Source: NIH RePORTER; NCI NIH HHS [CA63929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKSHI VP, 1994, J PHARMACOL EXP THER, V271, P787; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BRAFF D, 1978, PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; CADENHEAD KS, 1993, AM J PSYCHIAT, V150, P1862; Castellanos FX, 1996, BIOL PSYCHIAT, V39, P33, DOI 10.1016/0006-3223(95)00101-8; CIARANELLO AL, 1995, ANNU REV NEUROSCI, V18, P101, DOI 10.1146/annurev.ne.18.030195.000533; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; DAVIS M, 1982, J NEUROSCI, V2, P791; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; GEYER MA, 1993, BIOL PSYCHIAT, V34, P361, DOI 10.1016/0006-3223(93)90180-L; GRAHAM FK, 1975, PSYCHOPHYSIOLOGY, V12, P238, DOI 10.1111/j.1469-8986.1975.tb01284.x; GRANT E. C, 1963, BEHAVIOUR, V21, P246, DOI 10.1163/156853963X00185; GRILLON C, 1992, BIOL PSYCHIAT, V32, P939, DOI 10.1016/0006-3223(92)90183-Z; Hahn ME, 1996, BEHAV GENET, V26, P463, DOI 10.1007/BF02359750; HARLOW E, 1988, J HERED, V43, P77; ISON JR, 1973, PHYSIOL BEHAV, V10, P1036; JOHANSSON C, 1995, PHARMACOL BIOCHEM BE, V52, P649, DOI 10.1016/0091-3057(95)00160-X; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LIJAM N, 1996, GENOME RES, V5, P116; LINDZEY G, 1961, NATURE, V191, P474, DOI 10.1038/191474a0; LONG SY, 1972, ANIM BEHAV, V20, P10, DOI 10.1016/S0003-3472(72)80167-2; Luna L.G., 1992, HISTOPATHOLOGICAL ME; Maccaferri G, 1996, J NEUROSCI, V16, P5334; MANSBACH RS, 1988, PSYCHOPHARMACOLOGY, V94, P507, DOI 10.1007/BF00212846; MCDOWD JM, 1993, SCHIZOPHRENIA BULL, V19, P733, DOI 10.1093/schbul/19.4.733; MESSERI P, 1975, PHYSIOL BEHAV, V14, P53, DOI 10.1016/0031-9384(75)90141-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Murphy KC, 1996, J MOL NEUROSCI, V7, P147, DOI 10.1007/BF02736794; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Paylor R, 1996, BEHAV NEUROSCI, V110, P1415, DOI 10.1037/0735-7044.110.6.1415; PICKAR D, 1995, LANCET, V345, P557, DOI 10.1016/S0140-6736(95)90469-7; Pizzuti A, 1996, AM J HUM GENET, V58, P722; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; STROZIK E, 1981, LAB ANIM, V15, P309, DOI 10.1258/002367781780953040; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SWERDLOW NR, 1995, J NEUROL NEUROSUR PS, V58, P192, DOI 10.1136/jnnp.58.2.192; SWERDLOW NR, 1994, ARCH GEN PSYCHIAT, V51, P139; SWERDLOW NR, 1993, BIOL PSYCHIAT, V33, P298, DOI 10.1016/0006-3223(93)90300-3; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; WILKINSON LS, 1994, NEUROPSYCHOPHARMACOL, V10, P61, DOI 10.1038/npp.1994.8; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	51	373	393	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					895	905		10.1016/S0092-8674(00)80354-2	http://dx.doi.org/10.1016/S0092-8674(00)80354-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298901	Bronze			2022-12-24	WOS:A1997XV56300010
J	Panning, B; Dausman, J; Jaenisch, R				Panning, B; Dausman, J; Jaenisch, R			X chromosome inactivation is mediated by Xist RNA stabilization	CELL			English	Article							MOUSE DEVELOPMENT; EMBRYONIC-CELLS; GENE-EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; METHYLATION; REQUIREMENT; BLASTOCYST; NUCLEUS; PROTEIN	Low level Xist expression can be detected from both active X chromosomes (Xa) in female embryonic stem cells prior to X inactivation. After differentiation, Xist is expressed at high levels only from the inactive X chromosome (Xi). Differentiating female cells increase Xist expression from the Xi prior to silencing low level Xist expression from the Xa. The transition from low level to high level expression is regulated by the stabilization of Xist transcripts at the Xi. We suggest that these developmentally modulated changes in Xist expression are regulated by several different mechanisms: factors that stabilize Xist transcripts at the Xi, an activity that blocks this stabilization at the Xa, and a mechanism that silences low level Xist expression from the Xa.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	Panning, B (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; ANDREWS GK, 1982, DEV BIOL, V89, P111, DOI 10.1016/0012-1606(82)90299-8; BARR ML, 1959, SCIENCE, V130, P679, DOI 10.1126/science.130.3377.679; BARR ML, 1962, ACTA CYTOL, V6, P34; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURGOYNE PS, 1993, DEVELOPMENT, V117, P341; CATTANACH BM, 1975, ANNU REV GENET, V9, P1, DOI 10.1146/annurev.ge.09.120175.000245; CLEMSON CM, 1996, J CELL BIOL, V132, P1; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CRUZ YP, 1993, IN VITRO CELL DEV, V29, P671; GARDNER RL, 1971, NATURE, V231, P385, DOI 10.1038/231385a0; HENDRICH BD, 1997, NUCLEIC ACIDS RES, V13, P2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1961, NATURE, V190, P327; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MATTEI JF, 1981, HUM GENET, V56, P409, DOI 10.1007/BF00274703; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MOORE MJ, 1993, RNA WORLD, P305; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; PANNING B, 1996, GENE DEV, V10, P1191; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219	48	248	257	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					907	916		10.1016/S0092-8674(00)80355-4	http://dx.doi.org/10.1016/S0092-8674(00)80355-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298902	Bronze			2022-12-24	WOS:A1997XV56300011
